```
1
              UNITED STATES DISTRICT COURT
            FOR THE NORTHERN DISTRICT OF OHIO
 2.
                    EASTERN DIVISION
 3
       IN RE: NATIONAL
                               )
                                  MDL No. 2804
       PRESCRIPTION
                               )
 4
       OPIATE LITIGATION
                                 Case No.
 5
                               )
                                  1:17-MD-2804
                               )
 6
                               )
       THIS DOCUMENT RELATES ) Hon. Dan A.
 7
       TO ALL CASES
                              ) Polster
 8
                TUESDAY, JANUARY 8, 2019
 9
        HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
10
                 CONFIDENTIALITY REVIEW
11
                Videotaped deposition of Ginger
12
13
      Collier, held at the offices of STINSON
      LEONARD STREET LLP, 7700 Forsyth Boulevard,
14
      Suite 1000, St. Louis, Missouri, commencing
15
      at 9:10 a.m., on the above date, before
16
      Carrie A. Campbell, Registered Diplomate
17
18
      Reporterand Certified Realtime Reporter.
19
20
2.1
22
23
               GOLKOW LITIGATION SERVICES
            877.370.3377 ph | 917.591.5672 fax
24
                     deps@golkow.com
25
```

achighity Compidentiars a subjective	4
Page 2	Page 4
1 APPEARANCES:	¹ ARNOLD & PORTER
3 KELLER ROHRBACK LLP	BY: DAVID HIBEY 09:11:42
BY: GARY GOTTO	david.hibey@arnoldporter.com
4 ggotto@kellerrohrback.com GABE VERDUGO	(VIA TELECONFERENCE)
5 gverdugo@kellerrohrback.com	3 601 Massachusetts Avenue, NW
1201 Third Avenue, Suite 3200	Washington, DC 20001-3743
6 Seattle, Washington 98101	4 (202) 942-5000 Counsel for Endo Pharmaceuticals
(206) 623-1900 7 Counsel for Plaintiffs	5 Inc., and Endo Health Solutions Inc.
8	6 Inc., and Endo Health Solutions Inc.
9 BRANSTETTER STRANCH & JENNINGS, PLLC	7 VIDEOGRAPHER:
BY: TRICIA HERZFELD triciah@bsjfirm.com	JAMES ARNDT,
223 Rosa L. Parks Avenue, Suite 200	8 Golkow Litigation Services
11 Nashville, Tennessee 37203	9
(615) 254-8801 Counsel for the Tennessee Action	10
13	11
14 ARMSTRONG TEASDALE	12
BY: SARAH E. HARMON sharmon@armstrongteasdale.com	13
7700 Forsyth Boulevard, Suite 1800	14
16 St. Louis, Missouri 63105	15
(314) 621-5070 Counsel for Cardinal Health, Inc.	16
18	17
19 COVINGTON & BURLING LLP	18
BY: FREDERICK BENSON fbenson@cov.com	19
850 Tenth Street, NW	20
21 Washington, DC 20001-4956	21 22
(202) 662-6000 Counsel for McKesson Corporation	
23	23 24
24 25	25
Page 3	Page 5
Page 3	1 INDEX
Page 3	1 INDEX PAGE
Page 3	1 INDEX 2 PAGE 3 APPEARANCES 2
Page 3	1 INDEX 2 PAGE 3 APPEARANCES
Page 3	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS 2 sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 3 150 Clay Street, Suite 500 Morgantown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS 2 sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 3 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 4 (304) 284-4138 Counsel for AmerisourceBergen	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS 2 sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 3 150 Clay Street, Suite 500 Morgantown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 JONES DAY RY: LAURA JANE DURFEE	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS 2 sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 3 150 Clay Street, Suite 500 Morgantown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 10NES DAY RY: LAURA JANE DURFEE	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS 2 sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 3 150 Clay Street, Suite 500 Morgantown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 10NES DAY RY: LAURA JANE DURFEE	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS 2 sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 3 150 Clay Street, Suite 500 Morgantown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 10NES DAY RY: LAURA JANE DURFEE	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganfown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 10NES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500 Morganfown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 1 JONES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 244-4138 Counsel for AmerisourceBergen 10NES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 JONES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 JONES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 244-4138 Counsel for AmerisourceBergen 10NES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 JONES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 JONES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street. Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 1 JONES DAY BY: LAURA JANE DURFEE ldurfee@jonesday.com 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Counsel for Walmart 10 11 12 ROPES & GRAY, LLP 13 ROPES & GRAY, LLP 14 BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRAA A. LARUSSA Cassandra LaRussa@ropesgray.com 800 Boylston Street Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 10 JONES DAY PBY: LAURA JANE DURFEE Idurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas 75201 (214) 220-3939 Counsel for Walmart 10 11 ROPES & GRAY LLP BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA Cassandra. LaRussa@ropesgray.com 800 Boylston Street Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street. Suite 500. Morganlown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 10 JONES DAY BY: LAURA JANE DURFEE Idurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas 75201 (214) 220-3939 Counsel for Walmart 10 11 ROPES & GRAY LLP BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA Cassandra. LaRussa@ropesgray.com 800 Boylston Street Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street. Suite 500. Morganlown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 10 JONES DAY BY: LAURA JANE DURFEE Idurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas 5201 (214) 220-3939 Counsel for Walmart 10 11 ROPES & GRAY, LLP BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA cassandra. LaRussa@ropesgray.com Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt FOX ROTHSCHILD LLP BY: EILEEN OAKES MUSKETT EMuskett@foxrothschild.com	1 INDEX 2 PAGE 3 APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street. Suite 500. Morganlown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 10 JONES DAY BY: LAURA JANE DURFEE Idurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas 5201 (214) 220-3939 Counsel for Walmart 10 11 ROPES & GRAY, LLP BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA cassandra. LaRussa@ropesgray.com Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt FOX ROTHSCHILD LLP BY: EILEEN OAKES MUSKETT EMuskett@foxrothschild.com	INDEX
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morganiown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 5 JONES DAY 7 BY: LAURA JANE DURFEE Idurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas /5201 (214) 220-3939 Counsel for Walmart 10 11 ROPES & GRAY, LLP BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA Cassandra. LaRussa@ropesgray.com 800 Boylston Street Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt FOX ROTHSCHILD LLP BY: EILEEN OAKES MUSKETT EMuskett@foxrothschild.com	INDEX PAGE APPEARANCES
1 JACKSON KELLY 2 BY: SYLVIA WINSTON NICHOLS 3 sylvia winston@jacksonkelly.com 3 150 Clay Street. Suite 500. 4 Morganiown West Virginia 26501 4 (304) 284-4138 5 Counsel for AmerisourceBergen 7 BY: LAURA JANE DURFEE 1 durfee@jonesday.com 2727 North Harwood Street Dallas, Lexas 5201 (214) 220-3939 Counsel for Walmart 10 11 12 ROPES & GRAY LLP 14 BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA Cassandra. LaRussa@ropesgray.com 800 Boylston Street Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt 16 17 18 BY: EILEEN OAKES MUSKETT EMuskett@foxrothschild com (1A TELECONFERENCE) 1301 Atlantic Avenue, Suite 400 Atlantic City, New Jersey 08401 (609) 572-2355 Counsel for Validus Pharmaceuticals	INDEX PAGE APPEARANCES
Page 3 1 JACKSON KELLY BY: SYLVIA WINSTON NICHOLS sylvia winston@jacksonkelly.com (VIA TELECONFERENCE) 150 Clay Street, Suite 500. Morgantown, West Virginia 26501 (304) 284-4138 Counsel for AmerisourceBergen 1 JONES DAY BY: LAURA JANE DURFEE Idurfee@jonesday.com 2727 North Harwood Street Dallas, Jexas 75201 (214) 220-3939 Counsel for Walmart 10 11 ROPES & GRAY LLP BY: ANDREW O'CONNOR Andrew O'Connor@ropesgray.com CASSANDRA A. LARUSSA Cassandra. LaRussa@ropesgray.com 800 Boylston Street Boston, Massachusetts 02199-3600 (617) 951-7000 Counsel for Mallinckrodt FOX ROTHSCHILD LLP BY: EILEEN OAKES MUSKETT EMuskett@foxrothschild.com (VIA TELECONFERENCE) 1301 Atlantic Avenue, Suite 400 Atlantic City, New Jersey 08401 (609) 572-2355	1 INDEX 2 PAGE 3 APPEARANCES
1 JACKSON KELLY 2 BY: SYLVIA WINSTON NICHOLS 3 sylvia winston@jacksonkelly.com 3 150 Clay Street, Suite 500. 4 Morgantown, West Virginia 26501 4 (304) 284-4138 5 Counsel for AmerisourceBergen 7 BY: LAURA JANE DURFEE 8 Jdurfee@jonesday.com 9 2727 North Harwood Street 10 2144) 220-3939 10 Counsel for Walmart 12 ROPES & GRAY, LLP 12 BY: ANDREW O'CONNOR 13 Cassandra.LaRussa@ropesgray.com 14 ROPES & GRAY LLP 15 Boston, Massachusetts 02199-3600 16 (617) 951-7000 17 Counsel for Mallinckrodt 18 BY: FILEEN OAKES MUSKETT 19 EXECUTE FOR THE CHILD LLP 19 BY: FILEEN OAKES MUSKETT 19 TOX ROTHSCHILD LLP 20 Atlantic City, New Jersey 08401 21 (609) 572-2355 22 Counsel for Validus Pharmaceuticals	PAGE APPEARANCES

Page 6	Page 8
¹ Mallinckrodt Covidien Pharmaceuticals 136	¹ Mallinckrodt Chart of advertising 246
Collier 7 Specialty Generics Business Review, January 6, 2010, MNK-T1_0006305472	2 expenditures, 2 MNK-T1 0006714382
3	Collier 27 expenditures 240
Mallinckrodt Covidien Pharmaceuticals 145 4 Collier 8 Specialty Generics Business	4 MNK-T1 0005964790 5 Mallinckrodt "The nuances and 252
4 Collier 8 Specialty Generics Business Review, April 7, 2010. MNK-T1 0002236317	Conner 29 Comblexities of obloid
6 Mallinckrodt Specialty Generics Hobart 154	6 rotation, MNK-T1 0001553927 - MNK-T1 0001553928
6 Mallinckrodt Specialty Generics Hobart Collier 9 Business Review, February 21, 2011	7 MNK-T1 ⁻ 0001553928 8 Mallinckrodt E-mail(s), 254
MNK-T1_0002337098	8 Mallinckrodt E-mail(s) 254 Collier 30 MNK-T1_0004673096
Mallinckrodt October 11, 2011 letter from 159 9 Collier 10, Ginger Collier to Hal	
Harrison,	Mallinckrodt Mallinckrodt Fentanyl 254 Collier 31 Transdermal System, MNK-T1_0004673097
Harrison, 10 MNK-TI 0002738887 - MNK-TI=0002738888	
	12 Collier 32 MNK-T1 000925331 -
12 Coller 11 Business Review - November	MNK-T1_000925332
Cycle, MNK-T1 0007289278 - MNK-T1=0007289283	Mallinckrodt E-mail(s), 260 14 Collier 33 MNK-T1 0000660532 -
1 4	MNK-T1_0000660534
Mallinckrodt Mallinckrodt Pharmaceuticals 167 Collier 12 Specialty Generics Overview,	Mallinckrodt 2014 GCC Approved Grants 262
Intern Initiation, Ginger	Mallinckrodt 2014 GCC Approved Grants 262 16 Collier 34 (Jan '14 - Present) (updated 9.5.14). 17 MNK-T1 0000661003
15 Collier 12 Specialty Generics Overview, Intern Initiation, Ginger Collier, June 2014 MNK-T1 0000661013 - MNK-T1 0000661037 18 Mallinckrodt Covidien Pharmaceuticals Collier 13 Specialty Generics Strategic Plan 2013-2017 MNK-T1 0000607429 - MNK-T1 0000607538 20 Mallinckrodt Mallinckrodt Pharmaceuticals 187 Coller 14 Specialty Generics Strategic Plan 2014-2019 MNK-T1 0000663716 - MNK-T1 0000663788 Mallinckrodt E-mail(s) 190 Collier 15 MNK-T1 0000418885 190	17 MNK-T1 0000661003 18 Mallinckrodt E-mail(s) 264
18 Mallinckrodt Coyidien Pharmaceuticals 173	Collier 35 MNK-T1 0000558153 -
Collier 13 Specialty Generics Strategic	19 MNK-T1 0000558154 20 Mallinckrodt NACDS Meetings, April 20 - 267
MNK-TI 0000607429 -	Collier 36 23, 2013, Customer Meetings, MNK-T1 0000609142 -
Mallinckrodt Mallinckrodt Pharmaceuticals 187	MNK-T1_0000609155
22 Plan 2014-2019,	Mallinckrodt E-mail(s), 274
MNK-T1 0000663716 - MNK-T1=0000663788	23 Collier 37 MNK TNSTA05202063 - MNK TNSTA05202064
24 Mallinckrodt E-mail(s), 190	24
25 WINK-11_0000418883	Mallinckrodt E-mail(s). 277 Collier 38 MNK_TNSTA0520176
Page 7	Page 9
¹ Mallinckrodt, "Summary" Worksheet, 190	¹ Mallinckrodt SOM Steering Committee 295
Coller 16 MNK-T1_0000418886	Collier 39 Meeting Agenda 6/23/11,
	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1_0000483769 Mallinckrodt Suspicious Order Monitoring 215	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1_0000483769 Mallinckrodt Suspicious Order Monitoring 215	Collier 39 Meeting Agenda 6/23/11, MNK_TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1_0000483769 Mallinckrodt Suspicious Order Monitoring 215	Collier 39 Meeting Agenda 6/23/11, MNK_TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11,
Mallinckrodt E-mail(s), 205 Collier 17 MNK-TI 0000483766 - MNK-TI 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated 4/7/II.	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MK-T1 0000496062 Mallinckrodt E-mail(s) 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11,
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MK-T1 0000496062 Mallinckrodt E-mail(s) 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MK-T1 0000496062 Mallinckrodt E-mail(s) 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315
Mallinckrodt E-mail(s), 205 Collier 17 MNK-T1 0000483766 - MNK-T1_0000483766 - MNK-T1_0000483766 - MNK-T1_0000483766 - MNK-T1_0000483766 - MNK-T1_0000483766 - MNK-T1_0000496062 Mallinckrodt Suspicious Order Monitoring Program, Presentation for Marketing Group, March 2 201 MNK-T1_0000496098 - MNK-T1_0000496124	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11.
Mallinckrodt E-mail(s), 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated 4/7/11 MNK-T1 0000496062 Mallinckrodt E-mail(s), 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 1 2000496098 - MNK-T1 0000496098 - MNK-T1 0000496124	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681
Mallinckrodt E-mail(s), 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated 4/7/11 MNK-T1 0000496062 Mallinckrodt E-mail(s), 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 1 2000496098 - MNK-T1 0000496098 - MNK-T1 0000496124	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681 Mallinckrodt Top 150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data
Mallinckrodt E-mail(s), 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated 4/7/11 MNK-T1 0000496062 Mallinckrodt E-mail(s), 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 1 2000496098 - MNK-T1 0000496098 - MNK-T1 0000496124	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681 Mallinckrodt Top-150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined,
Mallinckrodt E-mail(s), 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated 4/7/11 MNK-T1 0000496062 Mallinckrodt E-mail(s), 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 1 2000496098 - MNK-T1 0000496098 - MNK-T1 0000496124	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Mallinckrodt State Concentration 315 Mallinckrodt State Concentration 315 Mallinckrodt State Concentration 315 Mallinckrodt Top 150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined, MNK_TNSTA05098003 - MNK_TNSTA05098012
Mallinckrodt E-mail(s), 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated 4/7/11 MNK-T1 0000496062 Mallinckrodt E-mail(s), 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 1 2000496098 - MNK-T1 0000496098 - MNK-T1 0000496124	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681 Mallinckrodt Top 150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined, MNK_TNSTA05098003 - MNK_TNSTA05098003 - MNK_TNSTA05098012 Mallinckrodt E-mail(s), 326
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MNK-T1 0000496062 Mallinckrodt E-mail(s) 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program Presentation for Marketing Group, March 21 011 MNK-T1 0000496098 - MNK-T1 0000496124 Mallinckrodt November 10, 2010 letter to 233 Collier 21 KeySource Medical, MNK-T1-0000484113 MNK-T1-0000484113 Mallinckrodt November 12, 2010 letter to 234 Collier 22 Cardinal Health and others, MNK-T1 000048414156 MALTI 000048414156 Collier 23 MNK-T1 000558202	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681 Mallinckrodt Top-150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined, MNK_TNSTA05098003 - MNK_TNSTA05098012 Mallinckrodt E-mail(s), 326 Collier 45 MNK_TNSTA05299706 - MNK_TNSTA05299707
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MNK-T1 0000496062 Mallinckrodt E-mail(s) 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program Presentation for Marketing Group, March 21 011 MNK-T1 0000496098 - MNK-T1 0000496124 Mallinckrodt November 10, 2010 letter to 233 Collier 21 KeySource Medical, MNK-T1-0000484113 MNK-T1-0000484113 Mallinckrodt November 12, 2010 letter to 234 Collier 22 Cardinal Health and others, MNK-T1 000048414156 MALTI 000048414156 Collier 23 MNK-T1 000558202	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681 Mallinckrodt Top 150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined, MNK_TNSTA05098003 - MNK_TNSTA05098012 Mallinckrodt E-mail(s), 326 Collier 45 MNK_TNSTA05299706 - MNK_TNSTA05299707 Mallinckrodt E-mail(s), 336 Collier 46 MNK_TNSTA05299707
Mallinckrodt E-mail(s) 205 Collier 17 MNK-T1 0000483766 - MNK-T1 0000483769 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MNK-T1 0000496062 Mallinckrodt E-mail(s) 221 Collier 19 MNK-T1 0000262709 Mallinckrodt Mallinckrodt Controlled 228 Collier 20 Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 2 201 MNK-T1 0000496098'- MNK-T1 0000496124 Mallinckrodt November 10, 2010 letter to 233 Collier 21 KeySource Medical, MNK-T1-0000484113 MNK-T1-0000484113 Mallinckrodt November 12, 2010 letter to 234 Collier 22 Cardinal Health and others, MNK-T1 000048414156 MNK-T1 000048414156 Collier 23 MNK-T1 000558202 Mallinckrodt E-mail(s) 239 Mallinckrodt E-mail(s) 239	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1 0007251681 Mallinckrodt Top 150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined, MNK_TNSTA05098003 - MNK_TNSTA05098012 Mallinckrodt E-mail(s), 326 Collier 45 MNK_TNSTA05299706 - MNK_TNSTA05299707 Mallinckrodt E-mail(s), 336 Collier 46 MNK-T1 0000368477 - MNK-T1 0000368480
Mallinckrodt E-mail(s) 205 Mallinckrodt Suspicious Order Monitoring 215 Mallinckrodt Suspicious Order Monitoring 215 Mollinckrodt Suspicious Order Monitoring 215 Mollinckrodt Suspicious Order Monitoring 215 Mollinckrodt E-mail(s) 221 Mallinckrodt Mallinckrodt Controlled 228 Mallinckrodt Mallinckrodt Controlled 228 Mallinckrodt Mallinckrodt Controlled 228 Mollinckrodt Mallinckrodt Controlled 228 Mollinckrodt Mallinckrodt Controlled 228 Mollinckrodt Mallinckrodt Order Monitoring Program Presentation for Marketing Group, March 2011 Mollinckrodt Mollinckrodt 221 Mallinckrodt November 10, 2010 letter to 233 Mollinckrodt November 10, 2010 letter to 233 Mollinckrodt November 12, 2010 letter to 234 Collier 22 Cardinal Health and others, Mollinckrodt E-mail(s) 236 Mallinckrodt E-mail(s) 236 Mallinckrodt E-mail(s) 239 Mallinckrodt E-mail(s) 239 Collier 24 Mollinckrodt 239 Mollinckrodt E-mail(s) 239 Mollinckrodt E-mail(s) 239	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2 distributors - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251679 Mallinckrodt State Concentration Oxy 15 & 312 Collier 42 30 - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251680 Mallinckrodt State Concentration 315 Collier 43 Hydro-Apap - Apr 2011.xlsx, 5/31/11, MNK-T1_0007251681 Mallinckrodt Top 150 Pharmacies, Oxy 30 Collier 44 mg only, 2009-2011 data combined, MNK_TNSTA05098003 - MNK_TNSTA05098012 Mallinckrodt E-mail(s), 326 Collier 45 MNK_TNSTA05299706 - MNK_TNSTA05299707 Mallinckrodt E-mail(s), 336 Collier 46 MNK-T1_0000368480 MNK-T1_0000368480 Mallinckrodt Total \$ & Units by Dist., 338 Collier 47 MNK-T1_0000273249 -
Mallinckrodt E-mail(s) 205 Mallinckrodt E-mail(s) 205 Mallinckrodt Suspicious Order Monitoring 215 Collier 18 Team Charter, Updated MNK-T1 0000496062 Mallinckrodt E-mail(s) 221 Mallinckrodt Mallinckrodt Controlled 228 Monitoring Program Presentation for Marketing Group, March 21 2011 MNK-T1 0000496098 - MNK-T1 0000496124 Mallinckrodt November 10, 2010 letter to 233 Collier 21 KeySource Medical 10 MNK-T1 0000484113 Mallinckrodt November 12, 2010 letter to 234 Collier 22 Cardinal Health and others, MNK-T1 000048414156 Mallinckrodt E-mail(s) 236 Collier 23 MNK-T1 000558202 Mallinckrodt E-mail(s) 239 Mallinckrodt E-mail(s) 239 Mallinckrodt E-mail(s) 239 Mallinckrodt E-mail(s) 242 MNK-T1 0005905205	Collier 39 Meeting Agenda 6/23/11, MNK TNSTA05296154 Mallinckrodt E-mail(s), 297 Collier 40 MNK-T1_0007251678 Mallinckrodt Customers Sourcing Oxy 15 & 297 Collier 41 30 from more than 2
Mallinckrodt E-mail(s) 205	Collier 39 Meeting Agenda 6/23/11,
Mallinckrodt E-mail(s) 205	Collier 39 Meeting Agenda 6/23/11,
Mallinckrodt E-mail(s) 205	Collier 39 Meeting Agenda 6/23/11,
Mallinckrodt E-mail(s) 205	Collier 39 Meeting Agenda 6/23/11,

	Page 10		Page 12
1	VIDEOGRAPHER: We are now on 08:47:29	1	reporter is Carrie Campbell, and she 09:12:31
2	the record. My name is James Arndt. 09:10:34	2	will now swear in the witness. 09:12:33
3	I'm a videographer for Golkow 09:10:37	3	
4	Litigation Services. 09:10:39	4	GINGER COLLIER,
5	Today's date is January 8, 09:10:39	5	of lawful age, having been first duly sworn
6	2019, and the time is 9:10 a m. 09:10:42	6	to tell the truth, the whole truth and
7	This video deposition is being 09:10:44	7	nothing but the truth, deposes and says on
8	held in St. Louis, Missouri, in the 09:10:46	8	behalf of the Plaintiffs, as follows:
9	matter of the National Prescription 09:10:47	9	09:12:39
10	Opiate Litigation for the United 09:10:49	10	DIRECT EXAMINATION 09:12:39
11	States District Court for the Northern 09:10:52	11	QUESTIONS BY MR. GOTTO: 09:12:40
12	District of Ohio, Eastern Division. 09:10:54	12	Q. Good morning, Ms. Collier. 09:12:42
13	The deponent is Ginger Collier. 09:10:56	13	A. Good morning. 09:12:43
14	Will counsel please identify 09:10:58	14	Q. How are you? 09:12:43
15	themselves. 09:10:59	15	A. Very good, thank you. 09:12:44
16	MR. GOTTO: Gary Gotto, Keller 09:11:00	16	Q. Great. 09:12:45
17	Rohrback, LLP, for the plaintiffs. 09:11:03	17	As you just heard, my name is 09:12:45
18	MR. VERDUGO: Gabe Verdugo, 09:11:07	18	Gary Gotto. I'm one of the lawyers 09:12:47
19	Keller Rohrback, LLP, also for the 09:11:07	19	representing the plaintiffs in this 09:12:49
20	plaintiffs. 09:11:09	20	litigation. 09:12:50
21	MR. BENSON: Fred Benson, 09:11:11	21	Could you please state your 09:12:52
22	Covington Burling, LLP, for McKesson 09:11:12	22	business address, please? 09:12:56
23	Corporation. 09:11:15	23	A. My business address? I do not 09:12:57
24	MS. HARMON: Sarah Harmon with 09:11:17	24	have a business address. My home address? 09:13:00
25	Armstrong Teasdale for Cardinal 09:11:17	25	Q. Sure, home address is fine. 09:13:02
	Page 11		Page 13
1	Health. 09:11:19	1	A. Okay.
2	MS. DURFEE: Laura Jane Durfee 09:11:20		09:13:07
	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20	l _	Q. Okay. And are you currently 09:13:17
2	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20	3 4	Q. Okay. And are you currently 09:13:11 employed? 09:13:11
2 3	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24	3	Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12
2 3 4	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25	3 4	Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12
2 3 4 5	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28	3 4 5	Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13
2 3 4 5	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28	3 4 5 6	Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12
2 3 4 5 6 7	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30	3 4 5 6 7	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18
2 3 4 5 6 7 8	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34	3 4 5 6 7 8	Q. Okay. And are you currently 09:13:07 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15
2 3 4 5 6 7 8	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34	3 4 5 6 7 8	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21
2 3 4 5 6 7 8 9	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35	3 4 5 6 7 8 9	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19
2 3 4 5 6 7 8 9 10	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42	3 4 5 6 7 8 9 10	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24
2 3 4 5 6 7 8 9 10 11	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43	3 4 5 6 7 8 9 10 11	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25
2 3 4 5 6 7 8 9 10 11 12 13	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42	3 4 5 6 7 8 9 10 11 12 13	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24
2 3 4 5 6 7 8 9 10 11 12 13 14	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43	3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25
2 3 4 5 6 7 8 9 10 11 12 13 14 15	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45	3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:45	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 employed? 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:49	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:30
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:45 Nichols on behalf of AmerisourceBergen 09:11:49 Drug Corporation. 09:11:49	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:30 A. Bridgewater. Sorry, we just 09:13:31
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:49 Drug Corporation. 09:11:49 Drug Corporation. 09:11:52	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:30 A. Bridgewater. Sorry, we just 09:13:31 moved from Princeton, so I'm still thinking 09:13:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:45 Nichols on behalf of AmerisourceBergen 09:11:49 Drug Corporation. 09:11:49 MS. MUSKETT: Eileen Muskett of 09:11:52 Fox Rothschild on behalf of Validus. 09:12:03	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:30 A. Bridgewater. Sorry, we just 09:13:35 Princeton. 09:13:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:45 Nichols on behalf of AmerisourceBergen 09:11:49 Drug Corporation. 09:11:49 MS. MUSKETT: Eileen Muskett of 09:12:03 MS. WINSTON: Yes, this is 09:12:20	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:31 moved from Princeton, so I'm still thinking 09:13:35 Princeton. 09:13:41 Q. Okay. Great. 09:13:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:45 Nichols on behalf of AmerisourceBergen 09:11:49 Drug Corporation. 09:11:49 MS. MUSKETT: Eileen Muskett of 09:11:52 Fox Rothschild on behalf of Validus. 09:12:03 MS. WINSTON: Yes, this is 09:12:20 Sylvia Winston. 09:12:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:30 A. Bridgewater. Sorry, we just 09:13:31 moved from Princeton, so I'm still thinking 09:13:35 Princeton. 09:13:41 Q. Okay. Great. 09:13:41 Have you ever given a 09:13:42
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MS. DURFEE: Laura Jane Durfee 09:11:20 with Jones Day for Walmart. 09:11:20 MS. LARUSSA: Cassandra 09:11:20 Larussa, Ropes & Gray, for 09:11:24 Mallinckrodt, LLC, SpecGx and Ginger 09:11:25 Collier. 09:11:28 MR. O'CONNOR: Andrew O'Connor 09:11:28 from Ropes & Gray for Mallinckrodt, 09:11:30 LLC, SpecGx and Ginger Collier. 09:11:34 VIDEOGRAPHER: Will counsel on 09:11:34 the phone please identify themselves? 09:11:35 MR. HIBEY: David Hibey of 09:11:42 Arnold & Porter on behalf of the Endo 09:11:43 defendants. 09:11:45 MS. WINSTON: Sylvia Winston 09:11:45 Nichols on behalf of AmerisourceBergen 09:11:49 Drug Corporation. 09:11:49 MS. MUSKETT: Eileen Muskett of 09:12:03 MS. WINSTON: Yes, this is 09:12:20 Sylvia Winston. 09:12:22 MS. HERZFELD: Tricia Herzfeld 09:12:25	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. And are you currently 09:13:07 Q. Okay. And are you currently 09:13:11 A. Yes, I am. 09:13:12 Q. By whom? 09:13:12 A. Hisun Pharmaceutical. 09:13:13 Q. Okay. And what's your position 09:13:15 at Hisun? 09:13:18 A. Vice president, national 09:13:19 accounts. 09:13:21 Q. Okay. And when did you join 09:13:22 Hisun? 09:13:24 A. In 2017. 09:13:25 Q. Where is Hisun located? 09:13:28 A. New Jersey. 09:13:29 Q. Where in New Jersey? 09:13:30 A. Bridgewater. Sorry, we just 09:13:31 moved from Princeton, so I'm still thinking 09:13:35 Princeton. 09:13:41 Q. Okay. Great. 09:13:41 Have you ever given a 09:13:42 deposition before? 09:13:43

	Page 14		Page 16
1	under oath in any setting? 09:13:46	1	embellishment. If that's the case, please 09:15:46
2	A. Not that I can recall. 09:13:47	2	let me know, and we'll be happy to 09:15:49
3	Q. Okay. And you understand 09:13:51	3	accommodate that as well. 09:15:50
4	you're under oath today? 09:13:52	4	Okay? 09:15:52
5	A. Yes. 09:13:53	5	A. Okay. 09:15:52
6	Q. Okay. And I'm sure your 09:13:54	6	Q. Are you taking any medications 09:15:53
7	counsel has given you a preview of how 09:13:55	7	that could impair your memory or ability to 09:15:54
8	depositions proceed generally, but I'll just 09:13:59	8	testify accurately here today? 09:15:57
9	give you a few ground rules. 09:14:01	9	A. No. 09:15:58
10	I will do my best not to talk 09:14:03	10	Q. Great. 09:16:00
11	over you, and if you could reciprocate that, 09:14:06	11	And you're represented by 09:16:00
12	that'll make for the court reporter to be 09:14:10	12	counsel here today, correct? 09:16:03
13	able to take down a good, clean transcript so 09:14:11	13	A. Yes, I am. 09:16:05
14	folks can understand what we're saying here 09:14:14	14	Q. And are you paying your counsel 09:16:05
15	today if they ever choose to look at it down 09:14:16	15	for today's representation? 09:16:08
16	the road. 09:14:19	16	A. No, I am not. 09:16:09
17	I will try to make my questions 09:14:19	17	Q. Okay. Do you know who is 09:16:10
18	as clear as I can. If they're in any way 09:14:21	18	paying them? 09:16:12
19	unclear to you, please let me know, and I'll 09:14:26	19	A. I assume Mallinckrodt. 09:16:12
20	try to clarify them. 09:14:29	20	Q. Okay. Let's go ahead and 09:16:14
21	If you you know, if you 09:14:30	21	mark 09:16:22
22	answer a question, I'll assume you understand 09:14:30	22	(Mallinckrodt-Collier Exhibit 1 09:16:22
23	it and thought it was reasonably clear to 09:14:32	23	marked for identification.) 09:16:29 OUESTIONS BY MR. GOTTO: 09:16:29
24	you. 09:14:35 Is that fair? 09:14:35	24	
25	Is that fair? 09:14:35	25	Q. We've marked as Exhibit 1 the 09:16:41
	Page 15		Page 17
1	A. Yes. 09:14:35	1	notice we served for today's deposition. 09:16:47
2	O If you made 11 00 1426		
1	Q. If you need a break at any 09:14:36	2	Have you seen this document 09:16:52
3	point, just let me know, and we'll find a 09:14:39	3	before? 09:16:52
3 4	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42		before? 09:16:52 A. Yes, I did. 09:16:52
	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44	3	before? 09:16:52 A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53
4	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46	3 4	before? 09:16:52 A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54
4 5	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47	3 4 5	before? 09:16:52 A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54
4 5 6	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53	3 4 5 6	before? 09:16:52 A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55
4 5 6 7 8	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56	3 4 5 6 7	before? 09:16:52 A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56
4 5 6 7 8	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59	3 4 5 6 7 8	before? 09:16:52 A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56 your deposition in this matter? 09:16:58
4 5 6 7 8	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00	3 4 5 6 7 8 9 10	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. Okay. When did you first O9:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59
4 5 6 7 8 9 10 11	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07	3 4 5 6 7 8 9 10 11	before? A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56 your deposition in this matter? 09:16:58 A. About two months ago. 09:16:59 Q. Did you undertake personally 09:17:05
4 5 6 7 8 9 10 11 12	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14	3 4 5 6 7 8 9 10 11 12 13	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. O9:16:55 Decome aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08
4 5 6 7 8 9 10 11 12 13	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16	3 4 5 6 7 8 9 10 11 12 13	before? A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56 your deposition in this matter? 09:16:58 A. About two months ago. 09:16:59 Q. Did you undertake personally 09:17:05 any effort to locate documents that would be 09:17:08 responsive to the document request that's 09:17:15
4 5 6 7 8 9 10 11 12 13 14 15	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18	3 4 5 6 7 8 9 10 11 12 13 14	before? A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56 your deposition in this matter? 09:16:58 A. About two months ago. 09:16:59 Q. Did you undertake personally 09:17:05 any effort to locate documents that would be 09:17:08 responsive to the document request that's 09:17:15 included in the deposition notice? 09:17:17
4 5 6 7 8 9 10 11 12 13 14 15 16	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20	3 4 5 6 7 8 9 10 11 12 13 14 15 16	before? A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56 your deposition in this matter? 09:16:58 A. About two months ago. 09:16:59 Q. Did you undertake personally 09:17:05 any effort to locate documents that would be 09:17:08 responsive to the document request that's 09:17:15 included in the deposition notice? 09:17:17 A. No, I don't recall having any 09:17:18
4 5 6 7 8 9 10 11 12 13 14 15 16	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23	3 4 5 6 7 8 9 10 11 12 13 14 15 16	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. Okay. When did you first O9:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:17 A. No, I don't recall having any O9:17:21
4 5 6 7 8 9 10 11 12 13 14 15 16 17	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. Okay. When did you first O9:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:17 A. No, I don't recall having any O9:17:21 left Mallinckrodt. O9:17:23
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:29	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. O9:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:15 included in the deposition notice? O9:17:17 A. No, I don't recall having any O9:17:21 left Mallinckrodt. O9:17:23 Q. Okay. And when did you leave O9:17:24
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:31	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	before? A. Yes, I did. 09:16:52 Q. Okay. And when do you recall 09:16:53 seeing it for the first time? 09:16:54 A. Yesterday. 09:16:54 Q. Okay. When did you first 09:16:55 become aware that there was a request to take 09:16:56 your deposition in this matter? 09:16:58 A. About two months ago. 09:16:59 Q. Did you undertake personally 09:17:05 any effort to locate documents that would be 09:17:08 responsive to the document request that's 09:17:15 included in the deposition notice? 09:17:17 A. No, I don't recall having any 09:17:18 documents in my possession. I retired when I 09:17:21 left Mallinckrodt. 09:17:23 Q. Okay. And when did you leave 09:17:24 Mallinckrodt? 09:17:25
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:31 expected. 09:15:35	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. Okay. When did you first O9:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:17 A. No, I don't recall having any O9:17:21 left Mallinckrodt. O9:17:23 Q. Okay. And when did you leave O9:17:24 Mallinckrodt? O9:17:25 A. February of 2015. O9:17:25
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:31 expected. 09:15:35 In the course of the day you 09:15:35	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. O9:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:15 included in the deposition notice? O9:17:17 A. No, I don't recall having any O9:17:21 left Mallinckrodt. O9:17:23 Q. Okay. And when did you leave O9:17:25 A. February of 2015. O9:17:25 Q. Okay. And at that point did O9:17:27
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:31 expected. 09:15:35 In the course of the day you 09:15:35 may find that an answer that you gave 09:15:37	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. O8:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:17 A. No, I don't recall having any O9:17:18 documents in my possession. I retired when I O9:17:21 left Mallinckrodt. O9:17:25 A. February of 2015. Okay. And at that point did O9:17:27 you take with you any of your any files O9:17:30
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:31 expected. 09:15:35 In the course of the day you 09:15:35 may find that an answer that you gave 09:15:39	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. Okay. When did you first O9:16:55 become aware that there was a request to take O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:17 A. No, I don't recall having any O9:17:21 left Mallinckrodt. O9:17:23 Q. Okay. And when did you leave O9:17:25 A. February of 2015. O9:17:27 you take with you any of your any files O9:17:30 that you had maintained while you were at O9:17:33
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	point, just let me know, and we'll find a 09:14:39 convenient breaking spot. We will take 09:14:42 regular breaks, approximately every hour or 09:14:44 so, in any event. 09:14:46 The court reporter is here, of 09:14:47 course, making a transcript. We also have 09:14:53 this on video. There are various purposes in 09:14:56 the litigation that your testimony could be 09:14:59 used for in the future. And if you have 09:15:00 any any questions regarding procedure at 09:15:07 all today, just feel free to let me know at 09:15:14 any point. 09:15:16 Today is not a memory test. 09:15:18 Many of the events we're going to be talking 09:15:20 about happened several years ago, and I 09:15:23 understand that, you know, your memory may 09:15:25 not be as clear on certain things as on 09:15:31 expected. 09:15:35 In the course of the day you 09:15:35 may find that an answer that you gave 09:15:37	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	before? A. Yes, I did. O9:16:52 Q. Okay. And when do you recall O9:16:53 seeing it for the first time? O9:16:54 A. Yesterday. O8:16:55 become aware that there was a request to take O9:16:56 your deposition in this matter? O9:16:58 A. About two months ago. O9:16:59 Q. Did you undertake personally O9:17:05 any effort to locate documents that would be O9:17:08 responsive to the document request that's O9:17:17 A. No, I don't recall having any O9:17:18 documents in my possession. I retired when I O9:17:21 left Mallinckrodt. O9:17:25 A. February of 2015. Okay. And at that point did O9:17:27 you take with you any of your any files O9:17:30

	D 10	Т	D 20
	Page 18		Page 20
1	A. No. 09:17:35	1	ask if there are documents that 09:19:22
2	Q. Okay. Any computer records, 09:17:36	2	pertain to Ms. Collier's 09:19:23
3	laptop, anything of that nature? 09:17:38	3	Mallinckrodt-issued phone account, 09:19:26
4	A. No. 09:17:39	4	text messages, et cetera, that those 09:19:28
5	Q. Okay. Did you while you 09:17:40	5	be produced. 09:19:30
6	were at Mallinckrodt, did you maintain 09:17:46	6	MR. O'CONNOR: I understand the 09:19:30
7	personally any files and when I say 09:17:48	7	request. 09:19:31
8	"personally," I mean independent of your 09:17:51	8	MR. GOTTO: Thank you. 09:19:32
9	place of work. 09:17:52	9	QUESTIONS BY MR. GOTTO: 09:19:32
10	Did you maintain any files that 09:17:53	10	Q. Okay. Ms. Collier, I'd like to 09:19:35
11	pertained to your work at Mallinckrodt? 09:17:55	11	know what you did to prepare for today's 09:19:38
12	A. No, there were occasions when I 09:17:57	12	deposition. I don't want you to divulge the 09:19:40
13	would do work from home on my computer, but I $09:18:01$	13	communications you had with any of your 09:19:43
14	would transfer it to my work computer and 09:18:03	14	counsel in giving me that description, but 09:19:47
15	send it to myself in e-mail or transfer it to 09:18:05	15	perhaps you can tell me generally what you 09:19:50
16	my work computer via USB hub. 09:18:07	16	did to prepare. 09:19:52
17	Q. Okay. Great. 09:18:12	17	A. I had two meetings with general 09:19:52
18	Did you ever use while you 09:18:12	18	counsel, one in October and another one just 09:19:55
19	were at Mallinckrodt, did you use any 09:18:13	19	yesterday. 09:19:58
20	personal e-mail accounts to communicate with 09:18:15	20	Q. Okay. And who was present at 09:19:59
21	respect to professional activities? 09:18:19	21	those meetings? 09:20:01
22	A. No. 09:18:20	22	A. Bill was the first meeting. I 09:20:02
23	Q. Did you use your phone to send 09:18:21	23	don't remember his last name. And Andrew 09:20:05
24	text messages that pertained to Mallinckrodt 09:18:28	24	O'Connor and Cassandra were at the second 09:20:07
25	business while you were at Mallinckrodt? 09:18:30	25	meeting yesterday. 09:20:11
	•		
	Page 19		Page 21
1	A. I had a Mallinckrodt phone at 09:18:32	1	Q. And Bill is an attorney? 09:20:11
1 2	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35	1 2	Q. And Bill is an attorney? 09:20:11A. Yes. 09:20:12
	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37		 Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13
2	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38	2	 Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16
2 3	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38	2	 Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16
2 3 4	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38	2 3 4	 Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19
2 3 4 5	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38	2 3 4 5	 Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16
2 3 4 5 6	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40	2 3 4 5	 Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19
2 3 4 5 6 7	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42	2 3 4 5 6 7	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20
2 3 4 5 6 7 8	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44	2 3 4 5 6 7 8	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24
2 3 4 5 6 7 8	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50	2 3 4 5 6 7 8	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22
2 3 4 5 6 7 8 9	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49	2 3 4 5 6 7 8 9	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24
2 3 4 5 6 7 8 9 10	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50	2 3 4 5 6 7 8 9 10	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31
2 3 4 5 6 7 8 9 10 11	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53	2 3 4 5 6 7 8 9 10 11	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33
2 3 4 5 6 7 8 9 10 11 12 13	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53	2 3 4 5 6 7 8 9 10 11 12 13	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35
2 3 4 5 6 7 8 9 10 11 12 13	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55	2 3 4 5 6 7 8 9 10 11 12 13	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37 A. I don't have any to review. 09:20:39 Q. Okay. Have you spoken with 09:20:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57 records from that account; is that right? 09:18:58	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37 A. I don't have any to review. 09:20:39 Q. Okay. Have you spoken with 09:20:41 anyone who has given testimony in this 09:20:42
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57 records from that account; is that right? 09:18:58 A. No, I do not. 09:19:00	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:39 Q. Okay. Have you spoken with 09:20:41 anyone who has given testimony in this 09:20:48
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I had a Mallinckrodt phone at 09:18:32 the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57 records from that account; is that right? 09:18:58 A. No, I do not. 09:19:00 Q. Okay. Do you know who at 09:19:01	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37 A. I don't have any to review. 09:20:39 Q. Okay. Have you spoken with 09:20:41 anyone who has given testimony in this 09:20:42 litigation with respect to the litigation? 09:20:48 A. No, I have not. 09:20:49
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57 records from that account; is that right? 09:18:58 A. No, I do not. 09:19:00 Q. Okay. Do you know who at 09:19:01 Mallinckrodt would have any records that 09:19:08	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37 A. I don't have any to review. 09:20:39 Q. Okay. Have you spoken with 09:20:41 anyone who has given testimony in this 09:20:42 litigation with respect to the litigation? 09:20:48 A. No, I have not. 09:20:49 Q. Okay. Have you reviewed any 09:20:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57 records from that account; is that right? 09:18:58 A. No, I do not. 09:19:00 Q. Okay. Do you know who at 09:19:01 Mallinckrodt would have any records that 09:19:08 exist today with respect to your 09:19:12	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37 A. I don't have any to review. 09:20:39 Q. Okay. Have you spoken with 09:20:41 anyone who has given testimony in this 09:20:42 litigation with respect to the litigation? 09:20:48 A. No, I have not. 09:20:49 Q. Okay. Have you reviewed any 09:20:51 transcripts of any depositions or any other 09:20:52
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the time, so I may have. 09:18:35 Q. Okay. When you say "a 09:18:37 Mallinckrodt phone," what do you mean by 09:18:38 that? 09:18:38 A. A company-issued phone that I 09:18:40 returned. It was company property. 09:18:42 Q. Okay. Do you know who the 09:18:44 cellular carrier was on that for that 09:18:46 phone? 09:18:49 A. Possibly AT&T, I think is who 09:18:50 was doing it. 09:18:53 Q. Okay. It was an account that 09:18:53 Mallinckrodt handled, though, paid for, et 09:18:55 cetera? 09:18:56 A. Correct. 09:18:56 Q. Okay. So you don't have any 09:18:57 records from that account; is that right? 09:18:58 A. No, I do not. 09:19:00 Q. Okay. Do you know who at 09:19:01 Mallinckrodt would have any records that 09:19:08 exist today with respect to your 09:19:12 Mallinckrodt-issued phone account? 09:19:14	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. And Bill is an attorney? 09:20:11 A. Yes. 09:20:12 Q. Okay. A Ropes & Gray lawyer 09:20:13 or 09:20:16 A. He's at Ropes & Gray, yes. 09:20:16 Q. Okay. Great. 09:20:19 Approximately how long did each 09:20:20 one of those meetings last? 09:20:21 A. The first one was about six 09:20:22 hours, and yesterday was seven and a half. 09:20:24 Q. Okay. Independent of the 09:20:31 meetings with counsel, did you do anything 09:20:33 else to prepare for today's deposition? 09:20:35 A. No, sir. 09:20:37 Q. Didn't review any documents? 09:20:37 A. I don't have any to review. 09:20:39 Q. Okay. Have you spoken with 09:20:41 anyone who has given testimony in this 09:20:42 litigation with respect to the litigation? 09:20:48 A. No, I have not. 09:20:49 Q. Okay. Have you reviewed any 09:20:51 transcripts of any depositions or any other 09:20:52 proceedings 09:20:55

	5 1		2
	Page 22		Page 24
1	pertaining to this litigation? 09:20:58	1	· · · · · · · · · · · · · · · · · · ·
2	A. (Witness shakes head.) 09:21:00	2	A. Not in preparation for the 09:22:30
3	Q. In your meetings with counsel, 09:21:01	3	deposition, no. 09:22:31
4	did you review any documents? 09:21:07	4	Q. Okay. Have you reviewed the 09:22:33
5	A. Yes, I did. 09:21:09	5	any of the complaints on file in this 09:22:38
6	Q. Okay. Did any of those 09:21:10	6	litigation? 09:22:41
7	documents refresh your recollection in any 09:21:11	7	A. No, I knew that there was a 09:22:42
8	regard? 09:21:14	8	lawsuit. I was aware there was a lawsuit, 09:22:45
9	A. On some issues, yes. 09:21:14	9	but I haven't reviewed any of the materials. 09:22:46
10	Q. What issues can you recall your 09:21:16	10	Q. Okay. When did you first 09:22:49
11	recollection being refreshed on? 09:21:18	11	become aware that this litigation was 09:22:50
12	A. Some memos that were sent in 09:21:21	12	pending? 09:22:52
13	e-mail. 09:21:26	13	A. I can't remember. And I can't 09:22:53
14	Q. In terms of subject matter of 09:21:26	14	remember how I found out either. 09:22:57
15	the nature of the issues that you were 09:21:28	15	Q. Okay. Do you have an 09:22:59
16	refreshed on, do you have a recollection of 09:21:29	16	understanding of the nature of the claims 09:23:03
17	what those were? 09:21:31	17	that are asserted in the litigation? 09:23:05
18	MR. O'CONNOR: Objection. I'm 09:21:32	18	A. Yes, I do. 09:23:07
19	going to instruct the witness not to 09:21:33	19	Q. And what's that understanding? 09:23:08
20	answer to the extent this is getting 09:21:34	20	A. My understanding is that 09:23:09
21	into attorney-client communications 09:21:36	21	federal facilities and counties and states 09:23:13
22	and work product. 09:21:38	22	are suing to because they believe there is 09:23:16
23	MR. GOTTO: Well, I think if 09:21:39	23	lack of diligence or something on behalf of 09:23:24
24	they refreshed her recollection, we're 09:21:41	24	the companies and that they want to sue on 09:23:28
25	entitled to know the subject matter on 09:21:45	25	behalf of the counties for cost, for opioid 09:23:32
	Page 23		Page 25
1	which they refreshed her recollection, 09:21:46	1	abuse. 09:23:37
2	which is 09:21:48	2	Q. Do you have any personal 09:23:38
3	MR. O'CONNOR: You can answer 09:21:48	3	opinion as to the merits of any of those 09:23:40
4	at a very high level. 09:21:49	4	claims? 09:23:43
5	THE WITNESS: Sure. Specific 09:21:50	5	A. Yes, I do. 09:23:44
6	customer meetings or specific customer 09:21:52	6	Q. What are those opinions? 09:23:46
7	communication. 09:21:54	7	A. I think they're probably 09:23:48
8	QUESTIONS BY MR. GOTTO: 09:21:55	8	overreaching and misguided. 09:23:53
9	Q. Okay. Do you remember what 09:21:55	9	Q. Okay. What do you base that 09:23:55
10	customers? 09:21:57	10	on? 09:23:57
11	A. Yes, I do. 09:21:57	11	A. My knowledge of the industry. 09:23:57
12	Q. Which were they? 09:21:59	12	And I don't have explicit knowledge about 09:24:00
13		1	abuse and how abuse occurs, but it's 09:24:02
	A. KeySource and Masters were 09:22:00	13	
14	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05	13	basically on my knowledge of the industry and 09:24:05
	A. KeySource and Masters were 09:22:00		
14	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05	14	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10
14 15	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09	14 15	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19
14 15 16	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10	14 15 16	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21
14 15 16 17	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12	14 15 16 17	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22
14 15 16 17 18	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12 So the two the two meetings 09:22:14	14 15 16 17 18	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22 Q. Are you being reimbursed for 09:24:23
14 15 16 17 18 19	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12	14 15 16 17 18 19	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22
14 15 16 17 18 19	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12 So the two the two meetings 09:22:14 you had with counsel were personal meetings, 09:22:17 not telephonic; is that right? 09:22:19	14 15 16 17 18 19	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22 Q. Are you being reimbursed for 09:24:23
14 15 16 17 18 19 20 21	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12 So the two the two meetings 09:22:14 you had with counsel were personal meetings, 09:22:17 not telephonic; is that right? 09:22:19 A. They were personal. 09:22:21	14 15 16 17 18 19 20 21	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22 Q. Are you being reimbursed for 09:24:23 any of your expenses? 09:24:25 A. For my \$12 parking today, I 09:24:26 assume, yes. 09:24:28
14 15 16 17 18 19 20 21 22	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12 So the two the two meetings 09:22:14 you had with counsel were personal meetings, 09:22:17 not telephonic; is that right? 09:22:19 A. They were personal. 09:22:21 Q. Okay. And did you have any 09:22:22	14 15 16 17 18 19 20 21	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22 Q. Are you being reimbursed for 09:24:23 any of your expenses? 09:24:25 A. For my \$12 parking today, I 09:24:26 assume, yes. 09:24:28 Q. Okay. Travel expense or hotel 09:24:29
14 15 16 17 18 19 20 21 22 23	A. KeySource and Masters were 09:22:00 mentioned in them. 09:22:05 Q. Okay. Well, we'll be looking 09:22:05 at some documents today on each of those 09:22:07 A. Okay. 09:22:09 Q and we can get into that in 09:22:10 some more detail at that point. 09:22:12 So the two the two meetings 09:22:14 you had with counsel were personal meetings, 09:22:17 not telephonic; is that right? 09:22:19 A. They were personal. 09:22:21	14 15 16 17 18 19 20 21 22 23	basically on my knowledge of the industry and 09:24:05 some of the assertions that have been made. 09:24:07 Q. Okay. Are you being 09:24:10 compensated in any way for your testimony 09:24:19 here today? 09:24:21 A. No, I'm not. 09:24:22 Q. Are you being reimbursed for 09:24:23 any of your expenses? 09:24:25 A. For my \$12 parking today, I 09:24:26 assume, yes. 09:24:28

	Page 26	Т	Page 28
1	A. I live here, so there's no 09:24:34	1	A. No. 09:26:48
2	expense involved. 09:24:36	2	Q. Did you take any courses 09:26:49
3	Q. Okay. Great. 09:24:37	3	related to pharmaceuticals more generally? 09:26:53
4	I'd like to ask you just a 09:24:38	4	A. No. 09:26:57
5	little bit about your background. 09:24:43	5	Q. When you were pursuing your 09:26:57
6	Could you describe generally 09:24:44	6	bachelor's or master's degrees, did you have 09:27:02
7	your post-high school education? 09:24:45	7	an intent to pursue a career in the 09:27:06
8	A. Yes. I have a master's 09:24:46	8	pharmaceutical industry? 09:27:10
9	yeah, a master's in business administration, 09:24:48	9	A. I was already in the 09:27:10
10	a bachelor's in management, and those are my 09:24:53	10	pharmaceutical industry. I just was pursuing 09:27:12
11	two levels of education. 09:24:58	11	my degree to round out my education and to be 09:27:15
12	Q. Okay. And from what 09:25:00	12	a better manager. 09:27:18
13	institutions did you receive those degrees? 09:25:02	13	Q. Okay. Well, then let's go 09:27:20
14	A. University of Phoenix in 09:25:04	14	back. Tell me when you first became involved 09:27:21
15	Fountain Valley, California. 09:25:07	15	in any position in the pharmaceutical 09:27:23
16	Q. And approximately when did you 09:25:08	16	industry. 09:27:25
17	receive your degrees? 09:25:09	17	A. That was all the way back to 09:27:25
18	A. It's been a while. 23 years 09:25:11	18	1975. I worked in a drugstore. From the 09:27:29
19	ago I received my bachelor's, and 20 years 09:25:17	19	drugstore, I worked for a drug wholesaler, 09:27:34
20	ago I received my master's. 09:25:21	20	and from the drug wholesaler, I went to work 09:27:36
21	Q. Okay. Great. 09:25:23	21	for a pharmaceutical company. 09:27:38
22	Beyond your bachelor's and 09:25:24	22	And so I stayed in the 09:27:39
23	master's programs, have you received any 09:25:29	23	pharmaceutical company, went back to work for 09:27:40
24	other or participated in any other formal 09:25:37	24	a drug wholesaler, then worked for another 09:27:42
25	post-high school courses of study? 09:25:40	25	pharmaceutical company. 09:27:47
	Page 27		Daga 20
	Page 27		Page 29
1	A. Well, I've attended other 09:25:42	1	Q. Okay. So fair to say that when 09:27:48
2	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46	2	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51
2	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50	2	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52
2 3 4	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53	2 3 4	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56
2 3 4 5	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56	2 3 4 5	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical industry? 09:27:57
2 3 4 5 6	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59	2 3 4 5	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59
2 3 4 5 6 7	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02	2 3 4 5 6 7	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02
2 3 4 5 6 7 8	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05	2 3 4 5 6 7 8	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03
2 3 4 5 6 7 8	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08	2 3 4 5 6 7 8	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07
2 3 4 5 6 7 8 9	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10	2 3 4 5 6 7 8 9	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08
2 3 4 5 6 7 8 9 10	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11	2 3 4 5 6 7 8 9 10	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09
2 3 4 5 6 7 8 9 10 11 12	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:11	2 3 4 5 6 7 8 9 10 11	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10
2 3 4 5 6 7 8 9 10 11 12 13	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:13	2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11
2 3 4 5 6 7 8 9 10 11 12 13	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18	2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11
2 3 4 5 6 7 8 9 10 11 12 13 14	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 Q. Okay. And I'm sorry, you may 09:26:22	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:16 Q. And what position did you have? 09:28:20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 have already told me this, but what was your 09:26:28	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:16 Q. And what position did you have? 09:28:20 A. Product manager and national 09:28:22
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 have already told me this, but what was your 09:26:28 undergraduate major? 09:26:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:16 Q. And what position did you have? 09:28:20 A. Product manager and national 09:28:22 account manager. 09:28:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 Q. Okay. And I'm sorry, you may 09:26:28 undergraduate major? 09:26:30 A. Bachelor of arts in management. 09:26:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:20 A. Product manager and national 09:28:22 account manager. 09:28:24 Q. Okay. So product manager, what 09:28:25
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 A. No. 09:26:22 have already told me this, but what was your 09:26:28 undergraduate major? 09:26:30 A. Bachelor of arts in management. 09:26:31 Q. Okay. In either your 09:26:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:26 A. Product manager and national 09:28:22 account manager. 09:28:24 Q. Okay. So product manager, what 09:28:25 does that mean in the pharmaceutical 09:28:28
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:11 Okay. Do you hold any 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 Q. Okay. And I'm sorry, you may 09:26:22 have already told me this, but what was your 09:26:28 undergraduate major? 09:26:31 Q. Okay. In either your 09:26:35 undergraduate or master's degree programs, 09:26:37	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:20 A. Product manager and national 09:28:22 account manager. 09:28:24 Q. Okay. So product manager, what 09:28:25 does that mean in the pharmaceutical 09:28:28 industry? 09:28:30
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Well, I've attended other 09:25:42 sessions on management and, you know, 09:25:46 certification programs, but it's more 09:25:50 continuing education for management and 09:25:53 brushing up on skill sets, like that. 09:25:56 Q. Okay. So apart from the 09:25:59 bachelor's and master's programs, are those 09:26:02 the were there any other times when you 09:26:05 were considered yourself to be a full- or 09:26:08 part-time student 09:26:10 A. No. 09:26:11 Q post-high school? 09:26:13 professional licenses or certifications? 09:26:18 A. No, I do not. 09:26:19 Q. Have you at any time? 09:26:20 A. No. 09:26:22 A. No. 09:26:22 have already told me this, but what was your 09:26:28 undergraduate major? 09:26:30 A. Bachelor of arts in management. 09:26:31 Q. Okay. In either your 09:26:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. So fair to say that when 09:27:48 you were pursuing your bachelor's and 09:27:51 master's degrees, you were anticipating 09:27:52 future employment in the pharmaceutical 09:27:56 industry? 09:27:57 A. I was anticipating staying in 09:27:59 the pharmaceutical industry. 09:28:02 Q. Okay. So were you continued 09:28:03 were you employed while you were pursuing 09:28:07 your degrees? 09:28:08 A. Yes, I was. 09:28:09 Q. I see. Okay. Okay. Thank 09:28:10 you. 09:28:11 So by whom were you employed at 09:28:11 that time? 09:28:15 A. When I finished my degree, I 09:28:15 was employed with Schein Pharmaceutical. 09:28:26 A. Product manager and national 09:28:22 account manager. 09:28:24 Q. Okay. So product manager, what 09:28:25 does that mean in the pharmaceutical 09:28:25

	ighty confidencial - Subject to		
	Page 30		Page 32
1	product management means forecasting, pricing 09:28:34	1	1
2	strategy, working with the national account 09:28:43	2	responsible for regulatory compliance? 09:30:54
3	managers on customer strategy. 09:28:45	3	A. I don't know that. It's not 09:30:56
4	Q. And when you said it's a little 09:28:46	4	anyone I interacted with or remember 09:30:59
5	different in generics, did you mean that you 09:28:51	5	interacting with. 09:31:02
6	were in a branded manufacturer at the time? 09:28:52	6	Q. Okay. You were aware, though, 09:31:03
7	A. No, I was always with the 09:28:57	7	that the narcotics that Schein was 09:31:04
8	generic side. 09:28:59	8	distributing were scheduled under the 09:31:06
9	Q. Okay. Okay. Including at 09:29:00	9	Controlled Substances Act? 09:31:10
10	Mallinckrodt? 09:29:01	10	A. That, I don't know. 09:31:10
11	A. Correct. 09:29:02	11	Q. Okay. You know it now, but you 09:31:12
12	At Elan, I did one branded 09:29:03	12	don't know if you were aware of it then? 09:31:15
13	product that was nonpromoted, and so there 09:29:06	13	A. Correct. 09:31:17
14	was one brand product in my background. 09:29:09	14	Q. Okay. Did you stay at Schein 09:31:18
15	Q. Okay. And so you indicated you 09:29:12	15	after you got your master's degree? 09:31:24
16	were both a product manager and a national 09:29:15	16	A. Yes, I did. 09:31:26
17	account manager. 09:29:16	17	Q. And for how long? 09:31:26
18	What is a national account 09:29:17	18	A. For a brief period. And I got 09:31:27
19	manager responsible for, typically, in the 09:29:20	19	promoted during that time and moved into the 09:31:30
20	generic industry? 09:29:22	20	home office. That's when I became a product 09:31:33
21	A. A national account manager 09:29:22	21	manager, right after graduation, and I worked 09:31:36
22	works with key accounts, largest accounts, 09:29:24	22	there for a brief period. 09:31:38
23	national accounts, and negotiates contracts, 09:29:27	23	Then they were acquired by 09:31:41
24	works on behalf of the customer to ensure 09:29:30	24	Watson, and then I stayed with Watson for a 09:31:43
25	that they're getting all that they need taken 09:29:33	25	brief period and left there. 09:31:46
	Page 31		Page 33
1	care of, and it also they also would 09:29:34		_
+			O Olyany And dyning the named 00.21.47
1 2	•	1	Q. Okay. And during the period 09:31:47
2	negotiate pricing and determine who the 09:29:38	2	you were at Watson, did you continue to be a 09:31:48
3	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41	2	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51
3 4	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44	2 3 4	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51
3 4 5	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49	2 3 4 5	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52
3 4 5 6	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54	2 3 4 5 6	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54
3 4 5 6 7	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58	2 3 4 5 6 7	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55
3 4 5 6 7 8	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04	2 3 4 5 6 7 8	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01
3 4 5 6 7 8	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06	2 3 4 5 6 7 8	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04
3 4 5 6 7 8 9	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09	2 3 4 5 6 7 8 9	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06
3 4 5 6 7 8 9 10	negotiate pricing and determine who the 09:29:38 incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10	2 3 4 5 6 7 8 9 10	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09
3 4 5 6 7 8 9 10 11	negotiate pricing and determine who the 109:29:38 incumbent competitor is and try and displace 109:29:41 the incumbent competitor. 109:29:44 Q. Okay. So in your career in the 109:29:49 pharmaceutical industry, when did you when 109:29:54 were you first in a position that involved 109:29:58 responsibilities with respect to 109:30:04 pharmaceuticals that were scheduled under the 109:30:06 Controlled Substances Act? 109:30:09 A. When I was working at Schein 109:30:10 Pharmaceutical, we sold some narcotics, and I 109:30:14	2 3 4 5 6 7 8 9 10 11	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11
3 4 5 6 7 8 9 10 11 12	negotiate pricing and determine who the 109:29:38 incumbent competitor is and try and displace 109:29:41 the incumbent competitor. 109:29:44 Q. Okay. So in your career in the 109:29:49 pharmaceutical industry, when did you when 109:29:54 were you first in a position that involved 109:29:58 responsibilities with respect to 109:30:04 pharmaceuticals that were scheduled under the 109:30:06 Controlled Substances Act? 109:30:09 A. When I was working at Schein 109:30:10 Pharmaceutical, we sold some narcotics, and I 109:30:14 was product manager for them and sold them as 109:30:16	2 3 4 5 6 7 8 9 10 11 12 13	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13
3 4 5 6 7 8 9 10 11 12 13	negotiate pricing and determine who the 109:29:38 incumbent competitor is and try and displace 109:29:41 the incumbent competitor. 109:29:44 Q. Okay. So in your career in the 109:29:49 pharmaceutical industry, when did you when 109:29:54 were you first in a position that involved 109:29:58 responsibilities with respect to 109:30:04 pharmaceuticals that were scheduled under the 109:30:06 Controlled Substances Act? 109:30:09 A. When I was working at Schein 109:30:10 Pharmaceutical, we sold some narcotics, and I 109:30:14 was product manager for them and sold them as 109:30:16 a national account manager. 109:30:17	2 3 4 5 6 7 8 9 10 11 12 13	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15
3 4 5 6 7 8 9 10 11 12 13 14	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19	2 3 4 5 6 7 8 9 10 11 12 13 14	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18
3 4 5 6 7 8 9 10 11 12 13 14 15 16	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:19
3 4 5 6 7 8 9 10 11 12 13 14 15 16	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:29 business. 09:32:22
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30 occasion to become familiar with any aspect 09:30:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25 product manager position? 09:32:28
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30 occasion to become familiar with any aspect 09:30:36 of the regulatory requirements imposed under 09:30:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25 product manager position? 09:32:28 A. It was any products that they 09:32:29
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30 occasion to become familiar with any aspect 09:30:32 of the regulatory requirements imposed under 09:30:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25 product manager position? 09:32:29 were not promoting for generics and that 09:32:32
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30 occasion to become familiar with any aspect 09:30:32 of the regulatory requirements imposed under 09:30:36 the Controlled Substances Act while you were 09:30:40 at Schein? 09:30:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25 product manager position? 09:32:29 were not promoting for generics and that 09:32:32 became genericized, I would help them figure 09:32:37
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30 occasion to become familiar with any aspect 09:30:32 of the regulatory requirements imposed under 09:30:36 the Controlled Substances Act while you were 09:30:40 at Schein? 09:30:42 A. No. 09:30:43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25 product manager position? 09:32:29 were not promoting for generics and that 09:32:32 became genericized, I would help them figure 09:32:37 out a strategy. 09:32:40
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	negotiate pricing and determine who the incumbent competitor is and try and displace 09:29:41 the incumbent competitor. 09:29:44 Q. Okay. So in your career in the 09:29:49 pharmaceutical industry, when did you when 09:29:54 were you first in a position that involved 09:29:58 responsibilities with respect to 09:30:04 pharmaceuticals that were scheduled under the 09:30:06 Controlled Substances Act? 09:30:09 A. When I was working at Schein 09:30:10 Pharmaceutical, we sold some narcotics, and I 09:30:14 was product manager for them and sold them as 09:30:16 a national account manager. 09:30:17 Q. Okay. So when did you start at 09:30:19 Schein? 09:30:20 A. I believe it was 1980, early 09:30:21 1980s. 09:30:29 Q. Okay. And did you have 09:30:30 occasion to become familiar with any aspect 09:30:32 of the regulatory requirements imposed under 09:30:36 the Controlled Substances Act while you were 09:30:40 at Schein? 09:30:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	you were at Watson, did you continue to be a 09:31:48 product manager? 09:31:51 A. Yes. 09:31:51 Q. Okay. And when you left 09:31:52 Watson, where did you go from there? 09:31:54 A. I went to Baxter oh, 09:31:55 actually, excuse me, I went to Elan for a 09:32:01 very brief period, only six months or seven 09:32:04 months. I went to Elan; they were a business 09:32:06 partner of Watson. I went to work for them 09:32:09 in a specialty position, in product 09:32:11 management, basically, but it was more 09:32:13 working with their business partners. So I 09:32:15 didn't manage the products, per se, but I 09:32:18 worked with them on that side of the 09:32:22 Q. And so what was the nature of 09:32:22 your responsibilities in this specialty 09:32:25 product manager position? 09:32:29 were not promoting for generics and that 09:32:32 became genericized, I would help them figure 09:32:37

	Page 34		Page 36
1	is I worked with did the analytics on 09:32:43	1	Q. Great. Thank you. 09:34:35
2	business partners to make sure that Elan was 09:32:46	2	You indicated Baxter sold 09:34:38
3	correctly getting the amount owed to them in 09:32:48	3	injectables. What type of medication? 09:34:40
4	the alliance, because we had profit share 09:32:53	4	A. Anesthesia products primarily, 09:34:43
5	arrangements, and so I had to review. 09:32:55	5	and things used in the operating room or 09:34:47
6	Because as a in a generic sector, if 09:32:57	6	surgical procedures. 09:34:50
7	you've doing this a little while, you realize 09:32:59	7	Q. Okay. 09:34:52
8	it's very complicated in the pricing. So I 09:33:01	8	A. Post and preop. 09:34:52
9	had to help them analyze the pricing and make 09:33:03	9	Q. Okay. So these were not 09:34:53
10	sure that they the rebates, discounts and 09:33:05	10	Controlled Substances Act scheduled 09:34:55
11	allowances were being calculated properly. 09:33:07	11	materials, correct? 09:34:56
12	Q. And after you left Elan, where 09:33:13	12	A. We had some schedule drugs, but 09:34:57
13	did you go? 09:33:15	13	I'm not sure which fell under the purview of 09:35:03
14	A. I went to Baxter. 09:33:16	14	the Controlled Substances Act. 09:35:06
15	Q. Okay. And what was your 09:33:17	15	Q. Okay. So while you were at 09:35:07
16	position at Baxter? 09:33:18	16	Baxter, did you have occasion to become 09:35:08
17	A. Director of marketing. 09:33:19	17	familiar with any of the regulatory 09:35:10
18	Q. How long were you at Baxter? 09:33:21	18	requirements imposed by the Controlled 09:35:13
19	A. I was at Baxter two years. 09:33:25	19	Substances Act? 09:35:15
20	Q. What was your reason for 09:33:26	20	A. No. 09:35:15
21	leaving Elan and joining Baxter? 09:33:28	21	Q. Okay. And you were at Baxter 09:35:16
22	A. Elan terminated my position. 09:33:30	22	for a couple of years; is that what you 09:35:19
23	Q. And do you know the reason for 09:33:32	23	indicated? 09:35:21
24	that? 09:33:33	24	A. Yes. 09:35:21
25	A. They were moving the 09:33:34	25	Q. Okay. And where did you go 09:35:21
		_	
	Page 35		Page 37
1	Page 35 facilities. They were selling off the entire 09:33:36	1	Page 37 from Baxter? 09:35:22
1 2	_	1 2	
	facilities. They were selling off the entire 09:33:36		from Baxter? 09:35:22
2	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38	2	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24
2	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40	2	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29
2 3 4	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43	2 3 4	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33
2 3 4 5	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46	2 3 4 5	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34
2 3 4 5 6	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46	2 3 4 5	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35
2 3 4 5 6	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52	2 3 4 5 6 7	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36
2 3 4 5 6 7 8	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54	2 3 4 5 6 7 8	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45
2 3 4 5 6 7 8	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56	2 3 4 5 6 7 8	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45
2 3 4 5 6 7 8 9	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:59 customers on the contracts. The NAMs would 09:33:59	2 3 4 5 6 7 8 9	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46
2 3 4 5 6 7 8 9 10	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02	2 3 4 5 6 7 8 9 10	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49
2 3 4 5 6 7 8 9 10 11	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04	2 3 4 5 6 7 8 9 10 11	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52
2 3 4 5 6 7 8 9 10 11 12 13	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:59 come up with contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06	2 3 4 5 6 7 8 9 10 11 12 13	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:53
2 3 4 5 6 7 8 9 10 11 12 13	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09	2 3 4 5 6 7 8 9 10 11 12 13 14	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55
2 3 4 5 6 7 8 9 10 11 12 13 14	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09 company. 09:34:12	2 3 4 5 6 7 8 9 10 11 12 13 14	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:35:58
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:12 And my team was responsible for 09:34:12	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:35:58 contracts, bring in new products, help the 09:36:02
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:12 And my team was responsible for 09:34:12 forecasting any programs that we had to 09:34:14	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:58 contracts, bring in new products, help the 09:36:02 team. Because it was different than the way 09:36:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09 company. 09:34:12 And my team was responsible for 09:34:14 ensure the compliance to the contracts, and 09:34:18	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	from Baxter? A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:35:58 contracts, bring in new products, help the 09:36:02 team. Because it was different than the way 09:36:10 McKesson operated because they're a little 09:36:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:12 And my team was responsible for 09:34:12 forecasting any programs that we had to 09:34:14	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:36:02 team. Because it was different than the way 09:36:10 McKesson operated because they're a little 09:36:13 more independent, and then worked with them 09:36:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09 company. 09:34:12 And my team was responsible for 09:34:14 ensure the compliance to the contracts, and 09:34:18	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	from Baxter? A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:35:58 contracts, bring in new products, help the 09:36:02 team. Because it was different than the way 09:36:10 McKesson operated because they're a little 09:36:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09 company. 09:34:12 And my team was responsible for 09:34:14 ensure the compliance to the contracts, and 09:34:18 then forecasting and pricing. 09:34:22	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:36:02 team. Because it was different than the way 09:36:10 McKesson operated because they're a little 09:36:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09 company. 09:34:12 And my team was responsible for 09:34:14 ensure the compliance to the contracts, and 09:34:18 then forecasting any programs that we had to 09:34:22 Q. Okay. And you used the acronym 09:34:26 NAMs. Is that national account manager? 09:34:29 A. National account manager, I'm 09:34:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	from Baxter? 09:35:22 A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:55 work with various vendors to negotiate 09:36:02 team. Because it was different than the way 09:36:10 McKesson operated because they're a little 09:36:13 more independent, and then worked with them 09:36:15 on understanding how contracts work and 09:36:17 contract administration and chargebacks and 09:36:20 everything else. 09:36:22
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	facilities. They were selling off the entire 09:33:36 facility, and everybody was let go. 09:33:38 Q. Okay. So you went to Baxter 09:33:40 and you were director of marketing? 09:33:43 A. Correct. 09:33:46 Q. So tell me generally what your 09:33:46 responsibilities were as director of 09:33:48 marketing at Baxter. 09:33:50 A. Again, it was a generic 09:33:52 division of Baxter. It sold we sold 09:33:54 injectables, and so it was working with 09:33:56 customers on the contracts. The NAMs would 09:33:59 come up with contracts, and I would review 09:34:02 the contracts and adjust any terms and 09:34:04 conditions that I didn't think that we could 09:34:06 honor or that were too costly for the 09:34:09 company. 09:34:12 And my team was responsible for 09:34:12 forecasting any programs that we had to 09:34:14 ensure the compliance to the contracts, and 09:34:18 then forecasting and pricing. 09:34:22 Q. Okay. And you used the acronym 09:34:26 NAMs. Is that national account manager? 09:34:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	from Baxter? A. I went to Baxter, then I moved 09:35:24 to Virginia, and I went to work for McKesson 09:35:29 medical/surgical. 09:35:33 Q. And what was your reason for 09:35:34 leaving Baxter and going to McKesson? 09:35:35 A. My husband retired, and I got 09:35:36 an opportunity at McKesson med/surg. 09:35:39 Q. And what position did you have 09:35:43 at McKesson? 09:35:45 A. Director of marketing. 09:35:45 Q. Okay. Were your 09:35:46 responsibilities at McKesson similar to the 09:35:49 responsibilities you had at Baxter? 09:35:52 A. No, McKesson's different. They 09:35:53 work with the vendors, so my job there was to 09:35:58 contracts, bring in new products, help the 09:36:02 team. Because it was different than the way 09:36:10 McKesson operated because they're a little 09:36:13 more independent, and then worked with them 09:36:17 contract administration and chargebacks and 09:36:20

	Page 38		Page 40
1	team work on their programs to improve what 09:36:25	1	***************************************
2	they were doing in Virginia. 09:36:27	2	Q. Okay. 09:38:20
3	Q. Okay. You've used the term 09:36:29	3	A. That I remember. 09:38:20
4	"chargebacks" a couple of times. 09:36:31	4	Q. Okay. So approximately, just 09:38:21
5	What do you mean by chargeback? 09:36:32	5	so we have some dates and I realize you 09:38:23
6	A. Well, in the industry, in order 09:36:33	6	know, they don't have to be precise. 09:38:25
7	to sell to everybody at a certain price 09:36:35	7	Approximately when you were at Baxter and 09:38:27
8	everybody has different prices based on 09:36:39	8	then at McKesson? 09:38:29
9	different terms that they have and what value 09:36:42	9	A. I was at McKesson from 1997 09:38:31
10	they can bring to the company, so you 09:36:44	10	wait a minute 2007, excuse me, 2007 to 09:38:36
11	negotiate with them on pricing. 09:36:45	11	2000 let me back up. I have to work 09:38:43
12	So CVS and Rite Aid might have 09:36:47	12	backwards. I'm sorry. 09:38:47
13	two different prices. Well, McKesson's not 09:36:50	13	Do you happen to have my 09:38:48
14	going to know what that pricing they're 09:36:53	14	résumé? Because that would help. 09:38:50
15	not going to sell we're not going to sell 09:36:55	15	Q. I have your your offer 09:38:52
16	to McKesson at that. We have to have a 09:36:57	16	letter from Mallinckrodt. 09:38:54
17	threshold. So wholesale acquisition cost is 09:36:59	17	A. Yes. 09:38:57
18	that threshold. So everybody buys at one 09:37:01	18	Q. And I believe it's in 2009, if 09:38:57
19	price for which we can administer contracts. 09:37:04	19	that helps. 09:38:59
20	After that, if we sell to CVS 09:37:07	20	A. Right. I started at 09:38:59
21	for a certain price, then McKesson might 09:37:10	21	Mallinckrodt in 2009, and I was with 09:39:01
22	have paid \$20, but the contract price that 09:37:12	22	GeneraMedix from 2004. That's it. So I was 09:39:03
23	they sell it to CVS for might be 7.50, so 09:37:14	23	with McKesson from 2002 to 2004, and with 09:39:06
24	they have to issue a chargeback. They charge 09:37:18	24	Baxter about 2000 to 2002. 09:39:15
25	us back for the difference between the list 09:37:21	25	Q. Okay. Great. 09:39:19
	Page 39		Page 41
1	price of WAC, we call it, and the contract 09:37:22	1	And so when you left McKesson, 09:39:20
2	price. 09:37:25	2	you went where? 09:39:23
3	Q. Okay. And when you were using 09:37:25	3	A. To GeneraMedix. 09:39:24
4	the pronoun "us" in that setting, "charge us 09:37:27	4	Q. And what position did you hold 09:39:27
5	back," "us" is the manufacturer? 09:37:32	5	there? 09:39:31
6	A. Yes, sir. 09:37:33	1 ~	
7		6	A. Vice president of marketing. 09:39:31
	Q. Okay. And McKesson was not a 09:37:34	7	Q. And just describe generally 09:39:33
8	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37		Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41
8 9	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that correct? 09:37:38	7	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43
9	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that correct? 09:37:38 A. Correct. 09:37:38	7 8 9 10	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44
9 10 11	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38	7 8 9 10 11	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44
9 10 11 12	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43	7 8 9 10 11 12	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46
9 10 11 12 13	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55	7 8 9 10 11 12 13	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47
9 10 11 12 13	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47	7 8 9 10 11 12 13	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51
9 10 11 12 13 14 15	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49	7 8 9 10 11 12 13 14 15	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53
9 10 11 12 13 14 15 16	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were working through getting that system set up. 09:37:51	7 8 9 10 11 12 13 14 15	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57
9 10 11 12 13 14 15 16 17	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57	7 8 9 10 11 12 13 14 15 16	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01
9 10 11 12 13 14 15 16 17	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01	7 8 9 10 11 12 13 14 15 16 17	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05
9 10 11 12 13 14 15 16 17 18	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02	7 8 9 10 11 12 13 14 15 16 17 18	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07
9 10 11 12 13 14 15 16 17 18 19	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02 Q. And during your time at 09:33:06	7 8 9 10 11 12 13 14 15 16 17 18 19	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07 GeneraMedix? 09:40:12
9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02 Q. And during your time at 09:38:10 McKesson, did you have occasion to become 09:38:10	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07 GeneraMedix? 09:40:12 A. Five years. 09:40:13
9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02 Q. And during your time at 09:38:06 McKesson, did you have occasion to become 09:38:10 familiar with any of the regulatory 09:38:13	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07 GeneraMedix? 09:40:12 A. Five years. 09:40:13 Q. Okay. Until you went to 09:40:14
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02 Q. And during your time at 09:38:16 familiar with any of the regulatory 09:38:13 requirements under the Controlled Substances 09:38:15	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07 GeneraMedix? 09:40:12 A. Five years. 09:40:13 Q. Okay. Until you went to 09:40:14 Mallinckrodt? 09:40:17
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02 Q. And during your time at 09:38:10 familiar with any of the regulatory 09:38:13 requirements under the Controlled Substances 09:38:15 Act? 09:38:16	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07 GeneraMedix? 09:40:12 A. Five years. 09:40:13 Q. Okay. Until you went to 09:40:14 Mallinckrodt? 09:40:17 A. Correct. 09:40:17
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. And McKesson was not a 09:37:34 manufacturer when you were there; is that 09:37:37 correct? 09:37:38 A. Correct. 09:37:38 Q. Okay. They were a distributor? 09:37:38 A. However, McKesson had to issue 09:37:43 chargebacks, so we had to set up the system 09:37:55 so that when the vendors needed to get their 09:37:47 money back, we could do that. So we were 09:37:49 working through getting that system set up. 09:37:51 Q. Okay. How long were you at 09:37:57 McKesson? 09:38:01 A. I think I was there two years. 09:38:02 Q. And during your time at 09:38:16 familiar with any of the regulatory 09:38:13 requirements under the Controlled Substances 09:38:15	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And just describe generally 09:39:33 what your responsibilities were at 09:39:41 GeneraMedix. 09:39:43 A. GeneraMedix was a startup 09:39:44 company. It was an injectable company 09:39:44 started by the president former president 09:39:46 of Baxter, and so I was helping him set 09:39:47 strategy for the company, what products would 09:39:51 we want to bring in, what customers would we 09:39:53 work with, and, again, reviewing contracts, 09:39:57 setting strategy, pricing, and then mostly 09:40:01 managing the portfolio. 09:40:05 Q. Okay. And how long were you at 09:40:07 GeneraMedix? 09:40:12 A. Five years. 09:40:13 Q. Okay. Until you went to 09:40:14 Mallinckrodt? 09:40:17

1	Page 42		Page 44
1	leaving McKesson and joining GeneraMedix? 09:40:20	1	
2	A. Because the former president of 09:40:21	2	A. Correct. 09:42:40
3	Baxter called me and asked me if I would be 09:40:23	3	Q. How long did you stay at 09:42:40
4	interested with working with him, and it was 09:40:27	4	Mallinckrodt? 09:42:44
5	a startup company, so I had options available 09:40:28	5	A. Five years. 09:42:44
6	to me, which was desirable. 09:40:31	6	Q. Okay. And I say 09:42:46
7	Q. Okay. During your time at 09:40:32	7	"Mallinckrodt." I see that the letterhead 09:42:49
8	GeneraMedix, did you have occasion to become 09:40:34	8	actually says "Covidien." In 2009, was there 09:42:50
9	familiar with any of the regulatory 09:40:36	9	a distinction in your mind between 09:42:53
10	requirements under the Controlled Substances 09:40:37	10	Mallinckrodt and Covidien? 09:42:55
11	Act? 09:40:38	11	A. No. Covidien owned 09:42:56
12	A. No, we didn't sell any 09:40:38	12	Mallinckrodt, and we kept the Mallinckrodt 09:43:00
13	controlled substances. 09:40:40	13	name on the product. 09:43:02
14	Q. Okay. And in 2009, you left 09:40:42	14	Q. Okay. During your period at 09:43:03
15	GeneraMedix and joined Mallinckrodt, correct? 09:40:46	15	Mallinckrodt, did your compensation change? 09:43:10
16	A. Correct. 09:40:48	16	A. Yes, it did. 09:43:12
17	Q. What was your reason for making 09:40:48 that move? 09:40:49	17	Q. And can you describe for me 09:43:13
18	***************************************	18	approximately how the manners in which it 09:43:15
19	A. GeneraMedix sold as a startup, 09:40:50	19	changed? 09:43:18
20	that's what we do, and so they sold the 09:40:53 company. I'm from St. Louis, so I got the 09:40:55	20	A. Well, I got an increase when I 09:43:18
21		21	became a senior director of marketing. 09:43:21
22	opportunity to move home and work with 09:40:57 Mallinckrodt with my former boss. 09:40:59	22	They Mallinckrodt reviewed all the 09:43:23
23	Q. Okay. Great. 09:41:01	23	employees and corrected salaries for those 09:43:25 that were started at a lower base, and I got 09:43:29
25	(Mallinckrodt-Collier Exhibit 2 09:41:35	24	that were started at a lower base, and I got 09:43:29 moved to be called a senior director. And my 09:43:32
25	(Manifickfout-Confer Exhibit 2 09.41.55	25	moved to be called a semor director. And my 09.43.32
	Page 43		Page 45
1	marked for identification.) 09:41:36	1	salary eventually, when I left, was 203,000 a 09:43:35
2	QUESTIONS BY MR. GOTTO: 09:41:36	2	year. 09:43:39
3	Q. Ms. Collier, we've marked as 09:41:37	3	Q. Okay. When did you become a 09:43:40
4	Exhibit 2 what I believe is a copy of your 09:41:38	4	senior director? 09:43:42
5	offer letter from Mallinckrodt. It's a 09:41:45	5	A. That had to be probably in 09:43:43
6	multipage document that begins at 09:41:47	6	2010, 2011 time frame. 09:43:47
7	MNK-T1_0007277843. 09:41:51	7	Q. Were you a corporate officer? 09:43:49
8	If you could take a moment and 09:41:55	8	A. No, I was not. 09:43:53
9	look through that document and tell me if you 09:41:56	9	Q. Were you at any time a member 09:43:54
10	recognize it. 09:42:01	10	of any committees at Mallinckrodt for any 09:44:01
11	A. Yes, I recognize this. 09:42:01	11	period of time? 09:44:13
12	Q. Okay. And this was your offer 09:42:06	12	MR. O'CONNOR: Object to form. 09:44:13
13	letter when you joined Mallinckrodt? 09:42:07	13	THE WITNESS: Probably they 09:44:15
14	A. Yes. 09:42:08	14	had a lot of committees, so I guess I 09:44:16
15	Q. Okay. This indicates your 09:42:09	15	would need to understand what 09:44:18
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	16	specifically you're looking for. 09:44:19
16	starting salary was an annual salary of 09:42:20		OTTEGETORIG DATA OF COURSE
16 17	\$ when you began. 09:42:23	17	QUESTIONS BY MR. GOTTO: 09:44:20
16 17 18	when you began. 09:42:23 Is that consistent with your 09:42:25	18	Q. Sure. Sure. 09:44:20
16 17 18 19	when you began. 09:42:23 Is that consistent with your 09:42:25 recollection? 09:42:26	18 19	Q. Sure. Sure. 09:44:20 Any formal committee that met 09:44:21
16 17 18 19 20	when you began. 09:42:23 Is that consistent with your 09:42:25 recollection? 09:42:26 A. Yes. 09:42:26	18 19 20	Q. Sure. Sure. 09:44:20 Any formal committee that met 09:44:21 on a regular schedule with agendas, 09:44:28
16 17 18 19 20 21	when you began. 09:42:23 Is that consistent with your 09:42:25 recollection? 09:42:26 A. Yes. 09:42:26 Q. Okay. And you were also 09:42:27	18 19 20 21	Q. Sure. Sure. 09:44:20 Any formal committee that met 09:44:21 on a regular schedule with agendas, 09:44:28 maintained minutes, that sort of thing? 09:44:30
16 17 18 19 20 21	when you began. 09:42:23 Is that consistent with your 09:42:25 recollection? 09:42:26 A. Yes. 09:42:26 Q. Okay. And you were also 09:42:27 eligible to participate in an annual 09:42:30	18 19 20 21 22	Q. Sure. Sure. 09:44:20 Any formal committee that met 09:44:21 on a regular schedule with agendas, 09:44:28 maintained minutes, that sort of thing? 09:44:30 A. Most of them were informal 09:44:33
16 17 18 19 20 21 22 23	when you began. 09:42:23 Is that consistent with your 09:42:25 recollection? 09:42:26 A. Yes. 09:42:26 Q. Okay. And you were also 09:42:27 eligible to participate in an annual 09:42:30 incentive plan, correct? 09:42:33	18 19 20 21 22 23	Q. Sure. Sure. 09:44:20 Any formal committee that met 09:44:21 on a regular schedule with agendas, 09:44:28 maintained minutes, that sort of thing? 09:44:30 A. Most of them were informal 09:44:33 committees, and I don't remember them having 09:44:35
16 17 18 19 20 21	when you began. 09:42:23 Is that consistent with your 09:42:25 recollection? 09:42:26 A. Yes. 09:42:26 Q. Okay. And you were also 09:42:27 eligible to participate in an annual 09:42:30	18 19 20 21 22	Q. Sure. Sure. 09:44:20 Any formal committee that met 09:44:21 on a regular schedule with agendas, 09:44:28 maintained minutes, that sort of thing? 09:44:30 A. Most of them were informal 09:44:33

		_	
	Page 46		Page 48
1	been in that effect, but there were 09:44:46	1	8
2	committees. 09:44:48	2	chargeback in certain instances. 09:46:49
3	I remember being on the 09:44:49	3	Q. Okay. And did you have an 09:46:51
4	committee, for example, we were doing 09:44:51	4	understanding as to the interplay between 09:46:54
5	serialization. It's a new regulation that's 09:44:56	5	chargebacks and the suspicious order 09:47:00
6	come up, and so they asked me to be part of 09:44:59	6	monitoring program? 09:47:03
7	that from a customer representative 09:45:01	7	MR. O'CONNOR: Object to form. 09:47:03
8	perspective. 09:45:03	8	THE WITNESS: Yes. 09:47:05
9	So I didn't participate in all 09:45:03	9	QUESTIONS BY MR. GOTTO: 09:47:06
10	the meetings, even when I was on committees, 09:45:05	10	Q. And what was that? 09:47:07
11	because I was very busy, and so I asked only 09:45:08 to be included when it was absolutely 09:45:10	11	A. What was I'm sorry, please 09:47:08 explain your question. 09:47:12
12	,	12	1 2 1
13		13	Q. Sure. 09:47:13 You mentioned in terms of 09:47:13
	Q. Okay. Do you recall being on 09:45:13 any committees, formal or informal, that had 09:45:15		part of the information you provided to the 09:47:16
15 16	any responsibilities with respect to 09:45:19	15	
	* *		3 1
17	compliance with any requirements under the 09:45:23 Controlled Substances Act? 09:45:26	17	to the chargeback process, and so my question 09:47:21 was what your understanding was of the 09:47:24
19	A. I was on an SOM committee, 09:45:26	19	interplay between the chargeback process and 09:47:26
20	which was about the development of the 09:45:30	20	the SOM process. 09:47:28
21	suspicious order monitoring, as a peripheral 09:45:33	21	MR. O'CONNOR: Same objection. 09:47:30
22	partner on that. 09:45:38	22	THE WITNESS: I honestly don't 09:47:30
23	Q. And what do you mean by that? 09:45:39	23	know, because I would explain to them 09:47:32
24	A. It means that I offered advice 09:45:41	24	how it worked and what we could 09:47:34
25	on customer reporting, customer information, 09:45:44	25	possibly information we could pull, 09:47:36
	on easienter reporting, easienter information,		possiony information we could pun, 67.17.50
	Page 47		Page 49
1	but I was not part of the establishment of 09:45:48	1	and then it was up to the SOM team to 09:47:38
1 2	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52	1 2	
	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55		and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42
2	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57	2	and then it was up to the SOM team to 09:47:38 decide how to use that data and what to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43
2 3	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58	2	and then it was up to the SOM team to 09:47:38 decide how to use that data and what to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43
2 3 4	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59	2 3 4	and then it was up to the SOM team to 09:47:38 decide how to use that data and what to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45
2 3 4 5	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05	2 3 4 5	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46
2 3 4 5 6	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08	2 3 4 5	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51
2 3 4 5 6 7 8	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09	2 3 4 5 6 7 8	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52
2 3 4 5 6 7 8 9	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11	2 3 4 5 6 7 8 9	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54
2 3 4 5 6 7 8 9 10	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13	2 3 4 5 6 7 8 9 10	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57
2 3 4 5 6 7 8 9 10 11 12	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14	2 3 4 5 6 7 8 9 10 11	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58
2 3 4 5 6 7 8 9 10 11 12 13	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16	2 3 4 5 6 7 8 9 10 11 12 13	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00
2 3 4 5 6 7 8 9 10 11 12 13 14	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18	2 3 4 5 6 7 8 9 10 11 12 13	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20	2 3 4 5 6 7 8 9 10 11 12 13 14	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06 Medical had a problem with the DEA, and one 09:48:10 of my employees was able to I don't want 09:48:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:24 A. Well, we would get IMS data, 09:46:24	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24 A. Well, we would get IMS data, 09:46:24 which is industry reporting, so we could pull 09:46:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:45 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:16 system, or hacked, I don't know how you say 09:48:20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24 A. Well, we would get IMS data, 09:46:24 which is industry reporting, so we could pull 09:46:29 industry reporting data in certain formats. 09:46:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06 Medical had a problem with the DEA, and one 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:20 it, but she figured out a way to get into the 09:48:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24 A. Well, we would get IMS data, 09:46:24 which is industry reporting, so we could pull 09:46:29 industry reporting data in certain formats. 09:46:31 I understood how the chargeback 09:46:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06 Medical had a problem with the DEA, and one 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:20 it, but she figured out a way to get into the 09:48:21 contract admin system and pull reports and 09:48:26
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24 A. Well, we would get IMS data, 09:46:24 which is industry reporting, so we could pull 09:46:29 industry reporting data in certain formats. 09:46:31 I understood how the chargeback 09:46:35 process worked. Not necessarily had 09:46:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06 Medical had a problem with the DEA, and one 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:20 it, but she figured out a way to get into the 09:48:21 contract admin system and pull reports and 09:48:26 look for specific very specific data 09:48:27
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24 A. Well, we would get IMS data, 09:46:24 which is industry reporting, so we could pull 09:46:29 industry reporting data in certain formats. 09:46:31 I understood how the chargeback 09:46:35 process worked. Not necessarily had 09:46:38 responsibility for the chargebacks, but I 09:46:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 that information with respect to the 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06 Medical had a problem with the DEA, and one 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:20 it, but she figured out a way to get into the 09:48:21 contract admin system and pull reports and 09:48:26 look for specific very specific data 09:48:27 related to Sunrise. 09:48:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	but I was not part of the establishment of 09:45:48 rules, policies, things of that nature. 09:45:52 Q. Okay. And do you recall 09:45:55 approximately when you were on that 09:45:57 committee? 09:45:58 A. Probably 2012 or 2013. 09:45:59 Q. Okay. For approximately what 09:46:05 period of time, if you recall? 09:46:08 A. I don't recall. 09:46:09 Q. Okay. Did you attend meetings 09:46:11 of that committee? 09:46:13 A. Yes. 09:46:14 Q. Okay. And you indicated you 09:46:16 offered advice on customer reporting and 09:46:18 customer information. 09:46:20 What sort of advice can you 09:46:21 recall offering? 09:46:24 A. Well, we would get IMS data, 09:46:24 which is industry reporting, so we could pull 09:46:29 industry reporting data in certain formats. 09:46:31 I understood how the chargeback 09:46:35 process worked. Not necessarily had 09:46:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and then it was up to the SOM team to 09:47:38 decide how to use that data and what 09:47:40 to look at. 09:47:42 QUESTIONS BY MR. GOTTO: 09:47:43 Q. Okay. And so did you provide 09:47:45 chargeback process pursuant to a request you 09:47:46 received from the committee? 09:47:51 A. No, actually some of that was 09:47:52 volunteered earlier on. 09:47:54 Q. Okay. And what was your 09:47:57 reasoning for volunteering that information 09:47:58 to the SOM committee? 09:48:00 A. Because during the Sunrise 09:48:01 Medical there were rumors that Sunrise 09:48:06 Medical had a problem with the DEA, and one 09:48:10 of my employees was able to I don't want 09:48:11 to say it's a backdoor, but she got into the 09:48:20 it, but she figured out a way to get into the 09:48:21 contract admin system and pull reports and 09:48:26 look for specific very specific data 09:48:27

	5 1		
	Page 50		Page 52
1	we do this on a regular basis, what 09:48:40	1	A. Yes. 09:50:08
2	information you get, how do we pull 09:48:42	2	Q. Okay. And what can you recall 09:50:10
3	information. 09:48:44	3	about her raising that with you? 09:50:13
4	And so we provided them 09:48:44	4	A. She said, well, I can pull 09:50:14
5	guidance because we certainly couldn't do it 09:48:46	5	their chargeback data, but we wouldn't know 09:50:17
6	ourselves on a regular basis. It was just 09:48:48	6	what to look for because chargeback data is 09:50:20
7	too much data. 09:48:51	7	voluminous. There's so much information, 09:50:25
8	Q. And so which employee was it 09:48:51	8	unless you're looking specifically for 09:50:26
9	who got this Sunrise data? 09:48:53	9	something at a specific point in time, you're 09:50:27
10	A. Kate Neely. Kate Muhlenkamp at 09:48:55	10	not going to be able to tease it out. 09:50:30
11	the time. 09:49:02	11	So she told me this, that she 09:50:33
12	Q. Okay. That's the same person, 09:49:02	12	could get that, but we didn't know what to 09:50:37
13	Kate Neely? 09:49:03	13	look for. So we decided to look for specific 09:50:39
14	A. Yes. 09:49:06	14	words and query the system for that. 09:50:43
15	Q. Okay. Great. 09:49:07	15	Q. Okay. What types of words did 09:50:45
16	So Ms. Neely you used the 09:49:09	16	you look for? 09:50:47
17	word "hacked." I'm sure you didn't mean to 09:49:12	17	A. "Doctor" or "MD." 09:50:47
18	suggest she did anything improper? 09:49:15	18	Q. Okay. And why did you choose 09:50:49
19	A. Not illegal, but, yeah, just 09:49:16	19	those words to look for? 09:50:55 A. Because from what we were 09:50:56
20	outside company norms. 09:49:18	20	
21	Q. Okay. So the information that 09:49:20 she obtained was information that 09:49:22	21	reading, it sounded as if Sunrise Medical was 09:50:58
22		22	in trouble for selling to doctors in Florida. 09:51:01
23	Mallinckrodt maintained internally, correct? 09:49:24	23	And if that's a problem, then we need to 09:51:08 understand that and why. 09:51:10
25	A. It was yes, it was in the 09:49:26 system. 09:49:27	25	•
25	system. 09:49:27	23	Q. Okay. And when you say 09:51:11
	Page 51		Page 53
1	Q. And do you know how she 09:49:28	1	"reading," do you mean in press accounts? 09:51:13
2	well, did you instruct her to attempt to 09:49:32	2	A. Yes. I don't remember exactly 09:51:15
3	access that information? 09:49:37	3	where the information came from, but I do 09:51:17
4	MR. O'CONNOR: Object to form. 09:49:38	4	remember seeing that they were in trouble for 09:51:19
4 5	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39		that. 09:51:21
	MR. O'CONNOR: Object to form. 09:49:38	4	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22
5	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40	4 5	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32
5	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40	4 5 6	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34
5 6 7	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43	4 5 6 7 8	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35
5 6 7 8 9	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44	4 5 6 7 8 9	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37
5 6 7 8 9 10	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45	4 5 6 7 8 9 10	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39
5 6 7 8 9 10 11 12	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47	4 5 6 7 8 9 10 11	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44
5 6 7 8 9 10 11 12 13	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51	4 5 6 7 8 9 10 11 12 13	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45
5 6 7 8 9 10 11 12 13	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53	4 5 6 7 8 9 10 11 12 13 14	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48
5 6 7 8 9 10 11 12 13 14 15	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 Q. Do you know go ahead. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 MR. O'CONNOR: Objection. 09:49:53	4 5 6 7 8 9 10 11 12 13 14 15	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50
5 6 7 8 9 10 11 12 13 14 15	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 MR. O'CONNOR: Objection. 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54	4 5 6 7 8 9 10 11 12 13 14 15 16	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56
5 6 7 8 9 10 11 12 13 14 15 16	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 Q. Do you know go ahead. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55	4 5 6 7 8 9 10 11 12 13 14 15 16	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58
5 6 7 8 9 10 11 12 13 14 15 16 17	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 Q. Do you know go ahead. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 MR. O'CONNOR: Objection. 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00
5 6 7 8 9 10 11 12 13 14 15 16 17 18	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:43 A. Yes. 09:49:44 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 A. Yes. 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 MR. O'CONNOR: Objection. 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57 QUESTIONS BY MR. GOTTO: 09:49:58	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 Q. Do you know go ahead. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57 QUESTIONS BY MR. GOTTO: 09:49:58 Q. Okay. 09:49:58	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04 get, but there's standard forms that are 09:52:07
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:39 Q. Do you know go ahead. 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 MR. O'CONNOR: Objection. 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57 QUESTIONS BY MR. GOTTO: 09:49:58 Q. Okay. 09:49:58 A what she did because it was 09:49:59	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04 get, but there's standard forms that are 09:52:09
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 Q. Do you know go ahead. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:51 A. She may have told me 09:49:53 MR. O'CONNOR: Objection. 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57 QUESTIONS BY MR. GOTTO: 09:49:58 A what she did because it was 09:49:59 over my head. 09:50:00	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04 get, but there's standard forms that are 09:52:07 transferred back and forth between the 09:52:09 wholesaler/distributor and the vendor. And 09:52:11
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:53 A. She may have told me 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57 QUESTIONS BY MR. GOTTO: 09:49:58 A what she did because it was 09:49:59 over my head. 09:50:00 Q. Okay. Did she before 09:50:01	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04 get, but there's standard forms that are 09:52:07 transferred back and forth between the 09:52:11 so from what I've seen, it contains the 09:52:14
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:53 A. She may have told me 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:55 Q. Okay. 09:49:58 A what she did because it was 09:49:59 over my head. 09:50:00 Q. Okay. Did she before 09:50:01 seeking to access the information, did she 09:50:04	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04 get, but there's standard forms that are 09:52:09 wholesaler/distributor and the vendor. And 09:52:11 so from what I've seen, it contains the 09:52:16
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. O'CONNOR: Object to form. 09:49:38 THE WITNESS: No. 09:49:39 QUESTIONS BY MR. GOTTO: 09:49:40 A. No, I did not instruct her. 09:49:40 Q. Okay. Was it her idea? 09:49:43 A. Yes. 09:49:44 Q. Okay. Do you know how she 09:49:45 how she came to believe that that information 09:49:47 might be accessible in some fashion? 09:49:53 A. She may have told me 09:49:53 THE WITNESS: Oh, I'm sorry. 09:49:54 She may have told me, and I 09:49:55 would not remember 09:49:57 QUESTIONS BY MR. GOTTO: 09:49:58 A what she did because it was 09:49:59 over my head. 09:50:00 Q. Okay. Did she before 09:50:01	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that. 09:51:21 Q. Okay. Do you recall how the 09:51:22 Sunrise issues with the DEA first came to 09:51:32 your attention? 09:51:34 MR. O'CONNOR: Object to form. 09:51:35 THE WITNESS: I believe they 09:51:37 came from Victor Borelli, one of our 09:51:39 national account managers. 09:51:44 QUESTIONS BY MR. GOTTO: 09:51:45 Q. Okay. So the chargeback data 09:51:48 that Ms. Muhlenkamp was able to access, 09:51:50 what's the nature of the information that's 09:51:56 contained there? 09:51:58 A. From what I know, because it's 09:52:00 limited in the amount of information that I 09:52:04 get, but there's standard forms that are 09:52:07 transferred back and forth between the 09:52:11 so from what I've seen, it contains the 09:52:14

	Page 54		Page 56
1	address to which it was shipped, the state, 09:52:30	1	
2	you know, obviously, in the address, and the 09:52:33	2	with any suspicious order monitoring program? 09:54:20
3	quantity that they purchased and the amount 09:52:34	3	A. I was not 09:54:23
4	of the debit memo that they're requesting. 09:52:35	4	MR. O'CONNOR: Object to form. 09:54:23
5	So if there were ten units, then the 09:52:40	5	THE WITNESS: I was not aware 09:54:24
6	chargeback amount was \$10 per unit, then it's 09:52:43	6	of that. 09:54:25
7	a hundred dollars. 09:52:45	7	QUESTIONS BY MR. GOTTO: 09:54:25
8	Q. Okay. And again, the "they" in 09:52:46	8	Q. Do you know if there came to be 09:54:29
9	this context would be the distributor that 09:52:48	9	a time when Mallinckrodt regularly used 09:54:33
10	was 09:52:49	10	chargeback data as part of its suspicious 09:54:36
11	A. And the wholesaler, yes. 09:52:49	11	order monitoring? 09:54:40
12	Q. Okay. And so it would be data 09:52:51	12	A. I was not aware of what 09:54:40
13	that would show so Mallinckrodt let me 09:52:53	13	information was used by the SOM team. 09:54:42
14	back up. Strike that. 09:52:55	14	Q. Okay. At any time? 09:54:44
15	So Mallinckrodt's customer in 09:52:56	15	A. Right. 09:54:45
16	this setting is a distributor or a 09:52:57	16	Q. Okay. Including when you were 09:54:47
17	wholesaler, correct? 09:52:59	17	on the committee that you were describing 09:54:48
18	A. Correct. 09:53:00	18	earlier? 09:54:49
19	Q. And then the chargeback data 09:53:00	19	A. Right. They did ask me for 09:54:50
20	would have information regarding whom the 09:53:03	20	information, but I didn't know if they 09:54:52
21	ultimate customer of that wholesaler or 09:53:07	21	after that, I gave them guidance, but I don't 09:54:55
22	distributor was, correct? 09:53:10	22	know if they used it and I don't they 09:54:57
23	MR. O'CONNOR: Objection. 09:53:11	23	would ask me sometimes for information, but I 09:54:59
24	MS. DURFEE: Objection. 09:53:13	24	don't know what they were using to make 09:55:02
25	THE WITNESS: I want to be 09:53:14	25	decisions. 09:55:05
	Page 55		Page 57
1	clear: You don't always know who the 09:53:15	1	Q. Okay. 09:55:06
2	ultimate customer is, so it would 09:53:18	2	A. If that makes sense. 09:55:06
3	contain information about who 09:53:20	3	Q. Okay. Back on to your offer 09:55:08
4	purchased that particular product on 09:53:23	4	letter, Exhibit 2. You described how your 09:55:12
5	that date. 09:53:25	_	
		5	salary changed over time while you were at 09:55:17
6	QUESTIONS BY MR. GOTTO: 09:53:25	6	Mallinckrodt. 09:55:19
6 7	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26		Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20
	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28	6	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25
7	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30	6 7	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27
7 8	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31	6 7 8	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25
7 8 9	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34	6 7 8 9	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27
7 8 9 10	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37	6 7 8 9	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34
7 8 9 10 11	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39	6 7 8 9 10 11	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35
7 8 9 10 11	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37	6 7 8 9 10 11 12	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34
7 8 9 10 11 12	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39	6 7 8 9 10 11 12	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35
7 8 9 10 11 12 13	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41	6 7 8 9 10 11 12 13	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37
7 8 9 10 11 12 13 14	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:41	6 7 8 9 10 11 12 13 14	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38
7 8 9 10 11 12 13 14 15	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:41 Q. Okay. And I think we'll look 09:53:42	6 7 8 9 10 11 12 13 14 15	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39
7 8 9 10 11 12 13 14 15 16	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:41 Q. Okay. And I think we'll look 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49	6 7 8 9 10 11 12 13 14 15 16	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44
7 8 9 10 11 12 13 14 15 16 17	QUESTIONS BY MR. GOTTO: 09:53:25 Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49 Do you have a recollection of 09:53:53	6 7 8 9 10 11 12 13 14 15 16 17	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44
7 8 9 10 11 12 13 14 15 16 17 18	QUESTIONS BY MR. GOTTO: Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49 Do you have a recollection of 09:53:53 the approximate time frame when 09:53:56	6 7 8 9 10 11 12 13 14 15 16 17 18	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44 the company performance, but there were other 09:55:46
7 8 9 10 11 12 13 14 15 16 17 18 19 20	QUESTIONS BY MR. GOTTO: Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:41 Q. Okay. And I think we'll look 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49 Do you have a recollection of 09:53:53 the approximate time frame when 09:53:56 Ms. Muhlenkamp accessed this information? 09:53:59	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44 the company performance, but there were other 09:55:46 metrics for 09:55:48
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	QUESTIONS BY MR. GOTTO: Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49 Do you have a recollection of 09:53:56 Ms. Muhlenkamp accessed this information? 09:53:59 A. I believe it was around 2010. 09:54:01	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44 the company performance, but there were other 09:55:46 metrics for 09:55:48 Q. Okay. What were the metrics 09:55:50
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	QUESTIONS BY MR. GOTTO: Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 QUESTIONS BY MR. GOTTO: 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49 Do you have a recollection of 09:53:53 the approximate time frame when 09:53:59 A. I believe it was around 2010. 09:54:01 It was probably in the first half of 2010. 09:54:03	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44 the company performance, but there were other 09:55:46 metrics for 09:55:48 Q. Okay. What were the metrics 09:55:50 that came into play in determining your 09:55:51
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. GOTTO: Q. Okay. So strike the word 09:53:26 "ultimate" from my question. 09:53:28 The chargeback information 09:53:30 would include information regarding the 09:53:31 identity of the of the customer of 09:53:34 Mallinckrodt's customer, correct? 09:53:37 MS. DURFEE: Objection. Form. 09:53:39 THE WITNESS: Yes. 09:53:41 Q. Okay. And I think we'll look 09:53:42 at some documents in a bit regarding Sunrise. 09:53:49 Do you have a recollection of 09:53:53 the approximate time frame when 09:53:56 Ms. Muhlenkamp accessed this information? 09:53:59 A. I believe it was around 2010. 09:54:01 It was probably in the first half of 2010. 09:54:06	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Mallinckrodt. 09:55:19 Did the bonus structure change 09:55:20 over time at all as well? 09:55:25 A. My bonus percentage remained 09:55:27 the same, and it fluctuated. 09:55:29 Q. The dollar amount fluctuated? 09:55:32 A. Correct. 09:55:34 Q. Okay. And what were the 09:55:35 A. Well, can I correct? 09:55:37 Q. Please. 09:55:38 A. Okay. The dollar amount 09:55:39 fluctuated depending on the overall company 09:55:41 performance. And there was a percentage of 09:55:44 the company performance, but there were other 09:55:46 metrics for 09:55:48 Q. Okay. What were the metrics 09:55:50 that came into play in determining your 09:55:51 bonus? 09:55:54

	5 1		4
	Page 58		Page 60
1	developed good programs that worked well for 09:56:07	1	y y
2	the customer; allocation process, if we 09:56:09	2	MR. O'CONNOR: Object to form. 09:59:31
3	developed processes that worked well for the 09:56:11	3	THE WITNESS: Yes. Yes, it is. 09:59:32
4	customers and for Mallinckrodt. 09:56:13	4	QUESTIONS BY MR. GOTTO: 09:59:34
5	Q. Okay. Were total sales an 09:56:16	5	Q. Okay. And so when you joined 09:59:34
6	element of the bonus determination? 09:56:22	6	as director of marketing, did the individuals 09:59:37
7	A. Yes. 09:56:24	7	that are listed in the far right column, 09:59:41
8	Q. Okay. And during your six or 09:56:25	8	beginning with Kate Muhlenkamp and the names 09:59:43
9	so years at Mallinckrodt, apart from the 09:56:33	9	under hers, report to you? 09:59:46
10	annual incentive plan and the long-term 09:56:36	10	A. Yes, they did. 09:59:48
11	incentive plan, were there any other bonus 09:56:38	11	Q. Okay. And you reported to 09:59:49
12	programs that you were eligible to 09:56:41	12	Mr. Gunning; is that right? 09:59:52
13	participate in? 09:56:42	13	A. Yes, I did. 09:59:53
14	A. I received stock options and 09:56:43	14	Q. Okay. When you started as 09:59:54
15	stock grants, but they were not related to 09:56:46	15	director of marketing at Mallinckrodt, did 09:59:59
16	the team's performance. 09:56:50	16	anyone else report to you other than the 10:00:00
17	Q. Okay. And what was the basis 09:56:52	17	individuals who are identified in this org 10:00:03
18	for the stock grants that you received, or 09:56:53	18	chart? 10:00:06
19	options? 09:56:57	19	A. I cannot remember because the 10:00:06
20	A. Honestly, I could never figure 09:56:57	20	team changed considerably over time, but I 10:00:10
21	that out. 09:57:00	21	can't remember at the time when I started if 10:00:14
22	Q. Okay. Okay. You can set that 09:57:01	22	it was the same team. 10:00:15
23	aside. 09:57:06	23	Q. Okay. Tell me what you can 10:00:17
24	A. Okay. 09:57:06	24	recall about the team changing under team 10:00:19
25	(Mallinckrodt-Collier Exhibit 3 09:57:14	25	in terms of people who reported to you, 10:00:22
23	(Manifickrout-Confer Exhibit 3 09.57.14	23	in terms of people who reported to you, 10.00.22
	Page 59		Page 61
1	marked for identification.) 09:57:14	1	directly or indirectly, how that changed over 10:00:24
2	QUESTIONS BY MR. GOTTO: 09:57:14	2	time, any particular personnel changes. 10:00:27
3	Q. Ms. Collier, we have marked as 09:57:37	3	And again, I realize it's a 10:00:29
4	Exhibit 3 three pages from your personnel 09:57:38	4	several-year period and there were probably 10:00:32
5	file beginning at MNK-T1_0007277883. 09:57:44	5	multiple changes, so I'm not expecting a 10:00:34
6	The first page appears to be a 09:57:51	6	complete and comprehensive list, but whatever 10:00:36
7	job description with respect to the director 09:57:54	7	comes to your mind in terms of changes in the 10:00:39
8	of marketing position for specialty generics. 09:57:57	8	team over time, if you could describe those. 10:00:41
9	Second page is blank, and the third page is 09:58:00	9	A. Okay. 10:00:43
10	an organizational chart. 09:58:03	10	MR. O'CONNOR: Object to form. 10:00:43
11	Would you take a moment and 09:58:05	11	THE WITNESS: Kate ended up 10:00:43
12	look, and let me know if you recognize those 09:58:06	12	leaving the company, and she was the 10:00:47
13	documents. 09:58:10	13	product manager. At one point she had 10:00:48
1		l	another employee, Lisa Lundergan, 10:00:50
14	A. I remember this. 09:58:10	14	
14 15	A. I remember this. 09:58:10	14	reporting to her, who is now Lisa 10:00:54
	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47		reporting to her, who is now Lisa 10:00:54 Cardetti. 10:00:56
15 16	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04	15	Cardetti. 10:00:56
15 16 17	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06	15 16 17	Cardetti. 10:00:56 We added analytical people to 10:00:57
15 16 17 18	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09	15 16 17 18	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04
15 16 17 18 19	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09 marketing position is indicated as open. I 09:59:15	15 16 17 18 19	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04 Margie and moved their products to 10:01:12
15 16 17 18 19 20	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09 marketing position is indicated as open. I 09:59:15 take it this was before you joined the 09:59:18	15 16 17 18 19 20	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04 Margie and moved their products to 10:01:12 other people. 10:01:16
15 16 17 18 19 20 21	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09 marketing position is indicated as open. I 09:59:15 take it this was before you joined the 09:59:18 company. 09:59:20	15 16 17 18 19 20 21	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04 Margie and moved their products to 10:01:12 other people. 10:01:16 QUESTIONS BY MR. GOTTO: 10:01:17
15 16 17 18 19 20 21	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09 marketing position is indicated as open. I 09:59:15 take it this was before you joined the 09:59:18 company. 09:59:20 Can you otherwise review the 09:59:21	15 16 17 18 19 20 21	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04 Margie and moved their products to 10:01:12 other people. 10:01:16 QUESTIONS BY MR. GOTTO: 10:01:17 Q. What was the reason for those 10:01:18
15 16 17 18 19 20 21 22 23	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09 marketing position is indicated as open. I 09:59:15 take it this was before you joined the 09:59:18 company. 09:59:20 Can you otherwise review the 09:59:21 chart and tell me if this is consistent with 09:59:24	15 16 17 18 19 20 21 22 23	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04 Margie and moved their products to 10:01:12 other people. 10:01:16 QUESTIONS BY MR. GOTTO: 10:01:17 Q. What was the reason for those 10:01:18 terminations? 10:01:20
15 16 17 18 19 20 21 22	A. I remember this. 09:58:10 Q. Okay. If we could just start 09:58:47 on the third page on the organizational 09:59:04 chart. 09:59:06 On this chart, the director of 09:59:09 marketing position is indicated as open. I 09:59:15 take it this was before you joined the 09:59:18 company. 09:59:20 Can you otherwise review the 09:59:21	15 16 17 18 19 20 21	Cardetti. 10:00:56 We added analytical people to 10:00:57 the team, and I terminated Penny and 10:01:04 Margie and moved their products to 10:01:12 other people. 10:01:16 QUESTIONS BY MR. GOTTO: 10:01:17 Q. What was the reason for those 10:01:18

	Page 62		Page 64
1	Ms. Muhlenkamp left Mallinckrodt? 10:01:25	1	general opinion of her job performance? 10:03:26
2	A. It was probably 2012 or 2013. 10:01:27	2	A. She was an excellent employee 10:03:28
3	Q. Okay. And did someone else 10:01:33	3	and very, very bright. 10:03:30
4	take her position after she left? 10:01:34	4	Q. Okay. And judging from this 10:03:32
5	A. Yes. Lisa Cardetti. 10:01:37	5	org chart, she had been at Mallinckrodt 10:03:35
6	Q. Okay. So and Ms. Cardetti 10:01:39	6	before you joined, correct? 10:03:37
7	had previously reported to Ms. Muhlenkamp? 10:01:41	7	A. Yes. 10:03:38
8	A. Correct. 10:01:44	8	Q. Do you know how long she had 10:03:38
9	Q. Okay. Do you recall what the 10:01:45	9	been there? 10:03:40
10	reasons were for Ms. Muhlenkamp or at 10:01:47	10	A. No. 10:03:40
11	least what your understanding was as for the 10:01:50	11	Q. Okay. And I take it 10:03:40
12	reasons for her leaving? 10:01:52	12	Ms. Cardetti joined Mallinckrodt sometime 10:03:47
13	MR. O'CONNOR: Object to form. 10:01:52	13	after you did, judging from her absence on 10:03:50
14	THE WITNESS: The reason she 10:01:53	14	this org chart; is that right? 10:03:52
15	told us is that she wanted to move up 10:01:56	15	A. No, she was working in another 10:03:54
16	in an organization, and she left for a 10:01:59	16	department. 10:03:56
17	better opportunity. 10:02:02	17	Q. Okay. 10:03:57
18	QUESTIONS BY MR. GOTTO: 10:02:03	18	A. And we brought her over for 10:03:57
19	Q. Okay. Did you perform any 10:02:03	19	analytics. 10:03:59
20	periodic evaluation or review of the job 10:02:09	20	Q. Okay. And then she took 10:04:00
21	performance of the individuals that reported 10:02:12	21	Ms. Muhlenkamp's position when Ms. Muhlenkamp 10:04:02
22	to you? 10:02:14	22	left. 10:04:05
23	A. Yes, I did. 10:02:18	23	And did she stay in that 10:04:05
24	Q. And you indicated that you 10:02:19	24	position for the balance of your tenure at 10:04:07
25	terminated some individuals from being 10:02:21	25	Mallinckrodt? 10:04:09
	Page 63		Page 65
1	ineffective. 10:02:22	1	A. No, she went into a national 10:04:10
2	Apart from them, do you recall 10:02:23	2	account manager role. 10:04:12
3	any other situations in which you felt that 10:02:24	3	Q. Okay. And who took that 10:04:13
4	the job performance of any of the individuals 10:02:30	4	position, her position, under you at that 10:04:16
5	the jee periormance of any of the marriagens 10.02.00		
	that reported to you was unsatisfactory? 10:02:33		
	that reported to you was unsatisfactory? 10:02:33 A. I can't recall that because 10:02:37	5	point? 10:04:19
6	A. I can't recall that because 10:02:37		point? 10:04:19 A. We had hired another product 10:04:19
6 7	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44	5	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22
6 7 8	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46	5 6 7	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25
6 7	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47	5 6 7 8	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28
6 7 8 9	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49	5 6 7 8 9	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29
6 7 8 9 10 11	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52	5 6 7 8 9 10	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32
6 7 8 9 10 11	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52	5 6 7 8 9 10 11	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33
6 7 8 9 10 11 12	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54	5 6 7 8 9 10 11 12 13	point? 10:04:19 A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38
6 7 8 9 10 11 12 13 14	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57	5 6 7 8 9 10 11 12 13	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43
6 7 8 9 10 11 12 13 14 15	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00	5 6 7 8 9 10 11 12 13 14 15	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43
6 7 8 9 10 11 12 13 14 15	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04	5 6 7 8 9 10 11 12 13 14 15	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45
6 7 8 9 10 11 12 13 14 15 16	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06	5 6 7 8 9 10 11 12 13 14 15 16	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47
6 7 8 9 10 11 12 13 14 15 16 17	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10	5 6 7 8 9 10 11 12 13 14 15 16 17 18	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51
6 7 8 9 10 11 12 13 14 15 16 17 18	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10 level of support. 10:03:12	5 6 7 8 9 10 11 12 13 14 15 16 17 18	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:51
6 7 8 9 10 11 12 13 14 15 16 17 18	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10 level of support. 10:03:12 Q. Okay. Any other examples that 10:03:14	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:51 A. I don't recall when he came on 10:04:53
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10 level of support. 10:03:12 Q. Okay. Any other examples that 10:03:17	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:53 board. I'm sorry, I barely remember my own 10:04:59
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:10 level of support. 10:03:12 Q. Okay. Any other examples that 10:03:14 come to your mind of individuals who you felt 10:03:17 their job performance was unsatisfactory? 10:03:19	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:51 A. I don't recall when he came on 10:04:59 dates, let alone all the employees. 10:05:01
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10 level of support. 10:03:12 Q. Okay. Any other examples that 10:03:14 come to your mind of individuals who you felt 10:03:17 their job performance was unsatisfactory? 10:03:19 A. No. 10:03:22	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:51 A. I don't recall when he came on 10:04:53 board. I'm sorry, I barely remember my own 10:04:59 dates, let alone all the employees. 10:05:03
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10 level of support. 10:03:12 Q. Okay. Any other examples that 10:03:14 come to your mind of individuals who you felt 10:03:17 their job performance was unsatisfactory? 10:03:19 A. No. 10:03:22 Q. Okay. How about 10:03:23	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	point? A. We had hired another product 10:04:19 manager, Jennifer Block, to work for us at 10:04:22 the time. And so Jennifer was also another 10:04:25 product manager that worked during that 10:04:28 period, so we just realigned the products. 10:04:29 Q. Okay. And approximately when 10:04:32 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:51 A. I don't recall when he came on 10:04:53 board. I'm sorry, I barely remember my own 10:04:59 dates, let alone all the employees. 10:05:01 Q. I understand. 10:05:03 What position did he hold? 10:05:04
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I can't recall that because 10:02:37 this is an incomplete list. 10:02:44 Oh, yes, actually, I do 10:02:46 remember one. Thomas Brown. 10:02:47 Q. Okay. What can you recall 10:02:49 about that? 10:02:52 A. Thomas Brown was hired as the 10:02:52 communications support to work for with us 10:02:54 on trade shows and the programs that I said 10:02:57 that we developed for customers, and just 10:03:00 take some of the pressure off the product 10:03:04 managers for any materials, any support that 10:03:06 he could provide, and he did not provide that 10:03:10 level of support. 10:03:12 Q. Okay. Any other examples that 10:03:14 come to your mind of individuals who you felt 10:03:17 their job performance was unsatisfactory? 10:03:19 A. No. 10:03:22	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	point? A. We had hired another product manager, Jennifer Block, to work for us at the time. And so Jennifer was also another product manager that worked during that period, so we just realigned the products. Q. Okay. And approximately when 10:04:29 did Ms. Cardetti leave your team? 10:04:33 A. Probably 2014 2015. 10:04:38 Q. Okay. 10:04:43 A. 2014, 2015, sometime there. 10:04:43 Q. Okay. Did there come to be a 10:04:45 time when Mr. Vorderstrasse was on your team? 10:04:47 A. Yes. 10:04:51 Q. When was that? 10:04:51 A. I don't recall when he came on 10:04:59 dates, let alone all the employees. 10:05:03

	igning contractional castees ex	_	droner contractsoration nevica
	Page 66		Page 68
1	analytical team, and he helped because he 10:05:09	1	
2	was a big data mining person, so he could do 10:05:13	2	reporting to you throughout your time, 10:07:26
3	that. He also helped with business 10:05:17	3	correct? 10:07:27
4	development, which meant deciding what 10:05:20	4	A. Correct. 10:07:27
5	products to go pursue if we wanted to 10:05:23	5	Q. And did each of them have 10:07:28
6	continue our pipeline growth. 10:05:25	6	responsibility for discrete products? 10:07:32
7	Q. Okay. So 10:05:25	7	A. Yes. 10:07:34
8	A. And he also launched a drug for 10:05:27	8	Q. Okay. And so did 10:07:36
9	us, so 10:05:29	9	Mr. Vorderstrasse, for example, have 10:07:39
10	Q. Okay. What drug was that? 10:05:30	10	responsibility for discrete products? 10:07:41
11	A. Methylphenidate. It's a 10:05:31	11	A. Yes, he did. 10:07:42
12	Concerta. 10:05:34	12	Q. Okay. Now, when you came to 10:07:44
13	Q. Okay. So looking back at the 10:05:35	13	Mallinckrodt well, let's look at page 1 10:07:52
14	org chart, this part of Exhibit 3, 10:05:38	14	of the first page, rather, of Exhibit 3, 10:07:56
15	Ms. Muhlenkamp is identified as a product 10:05:43	15	which the top-half of the page has eight 10:07:59
16	manager, as is Marock Montgomery? 10:05:45	16	numbered items which appear to be a 10:08:05
17	A. It's actually Marc. 10:05:51	17	description of the role and responsibility of 10:08:08
18	Q. Marc? 10:05:51	18	the of the director of marketing for 10:08:10
19	A. That's a typo. 10:05:52	19	specialty generics. So I'd like to go 10:08:13
20	Q. Okay. How were how were 10:05:58	20	through those with you and understand if, in 10:08:15
21	the how did their responsibilities differ? 10:06:00	21	fact, those were your roles and 10:08:20
22	A. They each had different 10:06:03	22	responsibilities and what you did in these 10:08:22
23	products that they were responsible for. 10:06:05	23	regards. 10:08:24
24	Q. Okay. And what products do you 10:06:06	24	Let me begin by asking what 10:08:24
25	recall Ms. Muhlenkamp being responsible for? 10:06:10	25	specialty generics, what did you understand 10:08:32
	recan ivis. ividinenkamp being responsible for.		specialty generics, what did you understand 10.00.52
	Page 67		Page 69
1	A. Oxycodone, oxy APAP. Marc had 10:06:11	1	that phrase to means? 10:08:34
2	hydrocodone at the time. We had mixed salts, 10:06:17	2	A. It means different things to 10:08:35
3	and I know Marc was responsible for that, but 10:06:26	3	different people. At Mallinckrodt they meant 10:08:36
4	I don't remember exactly how the products 10:06:30	4	that it was just a niche, that not everyone 10:08:39
5	lined up after that. 10:06:31	5	can produce and sell in a certain area. 10:08:42
6	Q. Okay. And then you indicated 10:06:33	6	Q. Okay. Did Mallinckrodt 10:08:43
7	Mr. Vorderstrasse had particular 10:06:39	7	manufacture other generic drugs that it did 10:08:46
8	responsibility for analytics. 10:06:42	8	not categorize as specialty generics? 10:08:49
9	Was there any similar division 10:06:43	9	A. No, because they use that as an 10:08:51
10	of responsibilities before he joined the 10:06:45	10	umbrella comment. 10:08:57
11	team, where one of the product managers had a 10:06:48	11	Q. Okay. So specialty generics, 10:08:57
12	particular responsibility for analytics? 10:06:51	12	in the Mallinckrodt setting, anyway, meant 10:08:58
13	MR. O'CONNOR: Object to form. 10:06:53	13	all generics that Mallinckrodt was 10:09:00
14	THE WITNESS: That is a very 10:06:54	14	manufacturing? 10:09:01
15	broad question because they each 10:06:56	15	A. Correct. 10:09:01
16	everyone on the team has to do some 10:07:00	16	Q. Okay. So I take it when you 10:09:05
17	form of analytics, so I'm not sure 10:07:05	17	became director of marketing, you needed to 10:09:09
18	what you're asking for. 10:07:07	18	become familiar with Mallinckrodt's product 10:09:12
19	QUESTIONS BY MR. GOTTO: 10:07:08	19	line in the generic area, correct? 10:09:14
20	Q. Okay. I was just trying to 10:07:08	20	A. Correct. 10:09:16
21	understand if the nature of the let me ask 10:07:10	21	Q. And so what did you do to 10:09:16
22	the question this way. 10:07:11	22	become familiar with what Mallinckrodt 10:09:17
23	Throughout your time as 10:07:12	23	manufactured and sold, the generics that they 10:09:21
			manufactured and sold? 10:09:24
24	director of marketing at Mallinckrodt, was it 10.07.13	24	manufactured and sold:
	director of marketing at Mallinckrodt, was it 10:07:13 the case that you had one or more product 10:07:16	24	
24 25	the case that you had one or more product 10:07:16	25	A. Met with the product managers 10:09:25

	Page 70		Page 72
1	to understand their products, looked at IMS 10:09:27	1	A. So I can't say if I understood 10:11:30
2	data to understand the sales, the 10:09:30	2	any of that or not. 10:11:32
3	competitors. I sat with different team 10:09:34	3	Q. Okay. So when you say you were 10:11:32
4	members in different parts of the 10:09:36	4	already familiar with, for example, the 222 10:11:34
5	organization, such as logistics, to 10:09:38	5	form, that was from prior employment you were 10:11:36
6	understand how products were being shipped, 10:09:41	6	familiar with that? 10:11:37
7	and did a tour of our warehouse not 10:09:43	7	A. Correct. 10:11:38
8	warehouse manufacturing site up in Hobart 10:09:47	8	Q. Okay. Although in your prior 10:11:39
9	at one point. 10:09:49	9	employment I think you had indicated you had 10:11:43
10	Q. Okay. Before we get into the 10:09:50	10	little 10:11:45
11	individual items listed in paragraphs 1 to 8 10:09:59	11	A. At Schein, I did. 10:11:45
12	here, when you joined Mallinckrodt, were 10:10:03	12	Q. I'm sorry? 10:11:46
13	there aspects of the director of marketing 10:10:05	13	A. At Schein Pharmaceutical. 10:11:48
14	job that you were taking that you felt were 10:10:11	14	Q. Okay. So going back to your 10:11:48
15	different from the responsibilities you had 10:10:17	15	time at Schein, you developed that 10:11:50
16	had at prior employers? 10:10:20	16	familiarity? 10:11:52
17	MR. O'CONNOR: Object to form. 10:10:23	17	A. Uh-huh. 10:11:52
18	THE WITNESS: Not really. The 10:10:23	18	Q. Was there any training that you 10:11:53
19	responsibilities are similar across 10:10:28	19	received at Mallinckrodt with respect to 10:11:58
20	any company. They were the same type 10:10:30	20	the any requirements under the Controlled 10:12:02
21	of job. 10:10:35	21	Substances Act? 10:12:04
22	QUESTIONS BY MR. GOTTO: 10:10:35	22	A. Not that I recall. 10:12:04
23	Q. Okay. Now, Mallinckrodt 10:10:36	23	Q. Okay. And you indicated a 10:12:07
24	obviously was engaged in the manufacture and 10:10:40	24	little earlier that go ahead. 10:12:09
25	sale of a variety of scheduled 10:10:43	25	A. Well, I'm sorry. Are you 10:12:10
	sale of a variety of self-dated		The weight into your roller to
	Page 71		Page 73
1	Page 71 pharmaceuticals under the Controlled 10:10:47	1	referring to when I was being hired? 10:12:12
1 2	_	1 2	_
	pharmaceuticals under the Controlled 10:10:47		referring to when I was being hired? 10:12:12
2	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48	2	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15
2 3	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49	2	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17
2 3 4	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49	2 3 4	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21
2 3 4 5	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51	2 3 4 5	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22
2 3 4 5 6	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53	2 3 4 5 6	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24
2 3 4 5 6	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54	2 3 4 5 6 7	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29
2 3 4 5 6 7 8	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57	2 3 4 5 6 7 8	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31
2 3 4 5 6 7 8	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00	2 3 4 5 6 7 8	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35
2 3 4 5 6 7 8 9	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined 10:11:03	2 3 4 5 6 7 8 9	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37
2 3 4 5 6 7 8 9 10	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined Mallinckrodt? 10:11:04	2 3 4 5 6 7 8 9 10	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40
2 3 4 5 6 7 8 9 10 11	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined 10:11:03 Mallinckrodt? 10:11:04 MR. O'CONNOR: Object to form. 10:11:04	2 3 4 5 6 7 8 9 10 11	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44
2 3 4 5 6 7 8 9 10 11 12 13	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined 10:11:03 Mallinckrodt? 10:11:04 MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06	2 3 4 5 6 7 8 9 10 11 12 13	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44 through Karen Harper giving sessions to the 10:12:46
2 3 4 5 6 7 8 9 10 11 12 13	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined Mallinckrodt? 10:11:04 MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:08	2 3 4 5 6 7 8 9 10 11 12 13	referring to when I was being hired? 10:12:12 Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44 through Karen Harper giving sessions to the 10:12:46 team about what it is and not what the Act 10:12:50
2 3 4 5 6 7 8 9 10 11 12 13 14	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined 10:11:03 Mallinckrodt? 10:11:04 MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:08 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:13	2 3 4 5 6 7 8 9 10 11 12 13 14	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44 through Karen Harper giving sessions to the 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined 10:11:03 Mallinckrodt? 10:11:04 MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:108 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:13 expect to get it like any other drug 10:11:14	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the Controlled Substances Act when you joined Mallinckrodt? MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:108 ordered using a 222 form. Customers 10:11:13 expect to get it like any other drug 10:11:16	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44 through Karen Harper giving sessions to the 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	pharmaceuticals under the Controlled 10:10:47 Substances Act, correct? 10:10:48 A. Correct. 10:10:49 Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the 10:11:00 Controlled Substances Act when you joined 10:11:03 Mallinckrodt? 10:11:04 MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:08 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:13 expect to get it like any other drug 10:11:16 that I was already familiar with. 10:11:18	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44 through Karen Harper giving sessions to the 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the Controlled Substances Act when you joined MR. O'CONNOR: Object to form. 10:11:04 MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:10 couldn't just place an order and 10:11:11 expect to get it like any other drug 10:11:16 that I was already familiar with. 10:11:18 I'm not familiar with the 10:11:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06 participate in various types of continuing 10:13:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any 10:10:54 effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the Controlled Substances Act when you joined Mallinckrodt? MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:108 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:12 expect to get it like any other drug 10:11:18 I'm not familiar with the 10:11:21 regulations of the Controlled 10:11:23	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06 participate in various types of continuing 10:13:07 education programs over the years. 10:13:09
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different from your prior experience, correct? A. Yes. Q. And did you undertake any effort to become familiar with any of the Controlled Substances Act when you joined Mallinckrodt? MR. O'CONNOR: Object to form. THE WITNESS: My familiarity THE WITNESS: My familiarity THE WITNESS: My familiarity ordered using a 222 form. Customers to get it like any other drug product. So there were some things that I was already familiar with the I'm not familiar with the I0:11:24 regulations of the Controlled Substances Act, so I have no idea of I0:11:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:44 through Karen Harper giving sessions to the 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06 participate in various types of continuing 10:13:07 education programs over the years. 10:13:09 Did any of those programs 10:13:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different 10:10:49 from your prior experience, correct? A. Yes. Q. And did you undertake any effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the Controlled Substances Act when you joined MR. O'CONNOR: Object to form. MR. O'CONNOR: Object to form. MR. O'CONNOR: My familiarity THE WITNESS: My familiarity THE WITNESS: My familiarity ordered using a 222 form. Customers 10:11:08 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:13 expect to get it like any other drug product. So there were some things 10:11:18 I'm not familiar with the 10:11:21 regulations of the Controlled 10:11:23 Substances Act, so I have no idea of 10:11:26 them. I'm not a specialist in that. 10:11:28	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06 participate in various types of continuing 10:13:07 education programs over the years. 10:13:09 Did any of those programs 10:13:11 address in any way requirements under the 10:13:14
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different 10:10:49 from your prior experience, correct? 10:10:51 A. Yes. 10:10:53 Q. And did you undertake any effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the Controlled Substances Act when you joined Mallinckrodt? MR. O'CONNOR: Object to form. 10:11:04 THE WITNESS: My familiarity 10:11:06 ran to that I knew things had to be 10:11:108 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:13 expect to get it like any other drug product. So there were some things 10:11:18 I'm not familiar with the 10:11:21 regulations of the Controlled 10:11:23 Substances Act, so I have no idea of 10:11:28 QUESTIONS BY MR. GOTTO: 10:10:49 10:10:57 10:10:57 10:10:57 10:10:57 10:11:00 10:11:00 10:11:00 10:11:00 10:11:00 10:11:01 10:11:00 10:11:21 10:11:11 10:11:12 10:11:23 10:11:24	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06 participate in various types of continuing 10:13:07 education programs over the years. 10:13:11 address in any way requirements under the 10:13:14 Controlled Substances Act? 10:13:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	pharmaceuticals under the Controlled Substances Act, correct? A. Correct. Q. And that was somewhat different 10:10:49 from your prior experience, correct? A. Yes. Q. And did you undertake any effort to become familiar with any of the 10:10:57 regulatory requirements imposed by the Controlled Substances Act when you joined MR. O'CONNOR: Object to form. MR. O'CONNOR: Object to form. MR. O'CONNOR: My familiarity THE WITNESS: My familiarity THE WITNESS: My familiarity ordered using a 222 form. Customers 10:11:08 ordered using a 222 form. Customers 10:11:11 couldn't just place an order and 10:11:13 expect to get it like any other drug product. So there were some things 10:11:18 I'm not familiar with the 10:11:21 regulations of the Controlled 10:11:23 Substances Act, so I have no idea of 10:11:26 them. I'm not a specialist in that. 10:11:28	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	referring to when I was being hired? Q. Well, let's start with that, 10:12:15 and then you can tell me also in the future 10:12:17 whether you received any such training. 10:12:21 A. Okay. When I was hired, I did 10:12:22 not receive any training specific to here's 10:12:24 the Controlled Substances Act, here's what it 10:12:29 is. I had familiarity with it as far as like 10:12:31 222 forms and that you can't just be shipping 10:12:35 product anywhere to anybody. 10:12:37 The I gained additional 10:12:40 knowledge while I worked at Mallinckrodt 10:12:46 team about what it is and not what the Act 10:12:50 is in particular, but what we should be doing 10:12:53 from our end. 10:12:57 Q. Okay. You had indicated a 10:12:59 little earlier today in terms of your general 10:13:04 education that you had occasion to 10:13:06 participate in various types of continuing 10:13:07 education programs over the years. 10:13:09 Did any of those programs 10:13:11 address in any way requirements under the 10:13:14

		_	
	Page 74		Page 76
1	Q. Okay. But Ms. Harper conducted 10:13:20	1	A. July 29, 2009. 10:31:43
2	programs from time to time, I take it, at 10:13:24	2	Q. Okay. Okay. Well, let's look 10:31:47
3	Mallinckrodt that addressed certain aspects 10:13:26 of the Controlled Substances Act? 10:13:28	3	at Exhibit 3 for a moment under the heading 10:31:48
4		5	of director of marketing, specialty generics. 10:31:50 Item Number 1 is "oversee the 10:31:53
5	A. From how it impacted the 10:13:29		
6	commercial aspect of the business and what we 10:13:32 needed to do, yes. 10:13:34	7	management of generic products by developing 10:31:56 financially sound business plans." 10:31:58
7 8	7,3	8	Tell me what well, first of 10:32:01
	MR. GOTTO: Okay. All right. 10:13:37 Well, why don't we take a break. 10:13:37		
9	•	9	all, during your time as director of 10:32:09 marketing, did you develop business plans for 10:32:10
10	We've been going for about an hour. 10:13:40 VIDEOGRAPHER: We are going off 10:13:41	10	the generic products? 10:32:12
12	the record at 10:13 a m. 10:13:42	12	A. Yes, I did. 10:32:13
13	(Off the record at 10:13 a m.) 10:13:44	13	Q. Were there separate plans for 10:32:14
14	VIDEOGRAPHER: We are back on 10:30:20	14	different products, or how did that work? 10:32:15
15	the record at 10:30 a m. 10:30:22	15	A. Each product had a separate 10:32:18
16	QUESTIONS BY MR. GOTTO: 10:30:23	16	plan, separate market share, because each had 10:32:20
17	Q. Welcome back, Ms. Collier. 10:30:27	17	different competitors. 10:32:22
18	A. Thank you. 10:30:28	18	Q. Okay. And so the components of 10:32:24
19	Q. Before the break, we had marked 10:30:28	19	the business plan for a generic product would 10:32:26
20	as Exhibit 3 a document that included the job 10:30:31	20	consist of what? 10:32:30
21	description director of marketing. I'd like 10:30:36	21	A. It would consist of reviewing 10:32:31
22	to go through some of those items in some 10:30:39	22	historical sales, what sales projections 10:32:33
23	more detail. 10:30:41	23	there are, what new products we anticipated 10:32:35
24	Before I do, who had been your 10:30:42	24	to launch, any additional customer programs 10:32:38
25	predecessor at Mallinckrodt as director of 10:30:46	25	we intended to implement, any problems we had 10:32:40
	production in 11.11.11.11.11.11.11.11.11.11.11.11.11.		To the same of the
	Daga 75		Page 77
	Page 75		Page //
1	marketing; do you know? 10:30:49	1	within the past year regarding such thing as 10:32:43
1 2	_	1 2	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45
	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51		within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49
2	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54	2 3 4	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52
2 3	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54	2	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54
2 3 4	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56	2 3 4	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57
2 3 4 5	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01	2 3 4 5	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58
2 3 4 5 6	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03	2 3 4 5 6	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02
2 3 4 5 6 7 8	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07	2 3 4 5 6 7 8	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05
2 3 4 5 6 7 8 9	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09	2 3 4 5 6 7 8 9	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07
2 3 4 5 6 7 8 9 10	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11	2 3 4 5 6 7 8 9 10	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08
2 3 4 5 6 7 8 9 10 11	marketing; do you know? 10:30:49 A. Jeff Burd. 10:30:50 Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11	2 3 4 5 6 7 8 9 10 11 12	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12
2 3 4 5 6 7 8 9 10 11 12 13	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15	2 3 4 5 6 7 8 9 10 11 12 13	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:17 requesting quota from the DEA from time to 10:33:17
2 3 4 5 6 7 8 9 10 11 12 13 14	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:18	2 3 4 5 6 7 8 9 10 11 12 13	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:17 time? 10:33:20
2 3 4 5 6 7 8 9 10 11 12 13 14 15	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:18 transition? 10:31:21	2 3 4 5 6 7 8 9 10 11 12 13 14	within the past year regarding such thing as quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:17 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:50 Mallinekrodt? 10:30:54 A. Yes, he did. Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:18 transition? 10:31:21 A. Most of his files were I 10:31:22	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:18 transition? 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23 we picked up new business, and the customers 10:33:26
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:27	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	within the past year regarding such thing as quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:28
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:26 probably weren't going to be relevant to me 10:31:27 because it was old data. 10:31:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	within the past year regarding such thing as quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:26 probably weren't going to be relevant to me 10:31:27 because it was old data. 10:31:29 But I mostly got my information 10:31:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:28 new business that we secured from a 10:33:31
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:54 A. Yes, he did. Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of information from him to you? A. No, he was gone before I was 10:31:07 A. No, he was gone before I was 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:27 because it was old data. 10:31:31 from working with the product managers in 10:31:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	within the past year regarding such thing as 10:32:43 quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we 10:32:49 address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:28 new business that we secured from a 10:33:31 switch the quota from the competitor to us. 10:33:33
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:18 transition? 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:26 probably weren't going to be relevant to me 10:31:27 because it was old data. 10:31:33 from working with the product managers in 10:31:33 what the process had been about product 10:31:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	within the past year regarding such thing as quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:29 competitor, and therefore the DEA would 10:33:31 switch the quota from the competitor to us. 10:33:33 I'm not sure of the process or 10:33:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:54 A. Yes, he did. Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in terms of any meetings or transfer of information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? A. No, he was gone before I was information from him to you? It is a local to the first transition? It is a local transition from him to you? It is a local transition from him to you? It is a local transition from him to you in first transition? It is a local transition from him to you? It is a local transition from him to you in formation from him to you? It is a local transition from him to you in formation from him to you? It is a local transition from him to you in formation from him to you? It is a local transition from him to you in formation from from him to you? It is a local transition from him to you in formation from him to you? It is a local transition from him to you in formation from him to you in formation from him to you? It is a local transition from him to you in formation from him to you in forma	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	within the past year regarding such thing as quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:29 competitor, and therefore the DEA would 10:33:31 switch the quota from the competitor to us. 10:33:33 I'm not sure of the process or 10:33:35 how the request was made. I just was 10:33:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	marketing; do you know? A. Jeff Burd. Q. And did Mr. Burd leave 10:30:51 Mallinckrodt? 10:30:54 A. Yes, he did. 10:30:54 Q. And did you was there any 10:30:56 sort of transition from Mr. Burd to you in 10:31:01 terms of any meetings or transfer of 10:31:03 information from him to you? 10:31:07 A. No, he was gone before I was 10:31:09 hired. 10:31:11 Q. Okay. Did you have access to 10:31:11 any materials that he had prepared to assist 10:31:15 the incoming director of marketing in 10:31:18 transition? 10:31:21 A. Most of his files were I 10:31:22 don't remember seeing any of his files. They 10:31:26 probably weren't going to be relevant to me 10:31:27 because it was old data. 10:31:33 from working with the product managers in 10:31:33 what the process had been about product 10:31:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	within the past year regarding such thing as quota allocation, inventory management 10:32:45 issues, manufacturing issues, and how do we address those going forward. 10:32:52 Q. Okay. When you say "quota 10:32:54 allocation," what do you mean by that? 10:32:57 A. The DEA allots quota based on 10:32:58 some criteria, and we may not get everything 10:33:02 we need to supply our customers throughout 10:33:05 the year. 10:33:07 Q. Okay. And do you were you 10:33:08 involved in the process of applying for or 10:33:12 requesting quota from the DEA from time to 10:33:17 time? 10:33:20 A. The only aspect that I was 10:33:20 involved in is occasionally they would ask if 10:33:23 we picked up new business, and the customers 10:33:26 had to provide a letter saying that it was 10:33:29 competitor, and therefore the DEA would 10:33:31 switch the quota from the competitor to us. 10:33:33 I'm not sure of the process or 10:33:35

	5 1		4
	Page 78		Page 80
1	that information from you regarding the 10:33:43	1	A. Yes. The exception in 10:35:41
2	customer? 10:33:45	2	oxycodone is that we had a 5 milligram and 10:35:44
3	A. Karen Harper. 10:33:45	3	not everyone had that. Not all competitors 10:35:46
4	Q. And so in formulating the 10:33:47	4	had it, so that would call out for something 10:35:49
5	business plans for the different products, 10:33:56	5	different. 10:35:51
6	one of the one of the issues you had to 10:33:58	6	Q. So you had a separate business 10:35:51
7	deal with was quota allocation, correct? 10:34:03	7	plan on the 5 milligram? 10:35:53
8	A. Correct. 10:34:05	8	A. Right. A separate projection 10:35:54
9	Q. And so the DEA quota, did you 10:34:06	9	of market share percentage, because obviously 10:35:56
10	have an understanding as to how that quota 10:34:09	10	there were fewer competitors. 10:35:58
11	was granted in terms of its applicability to 10:34:13	11	Q. Okay. But in terms of the 10:36:00
12	various of the products? 10:34:21	12	quota from the DEA, your understanding was 10:36:02
13	MR. O'CONNOR: Object to form. 10:34:23	13	there was a single quota that Mallinckrodt 10:36:05
14	THE WITNESS: The only thing I 10:34:24	14	had for oxycodone in whatever dosage and 10:36:07
15	was aware of is that they would give 10:34:27	15	strength it chose to manufacture and sell, 10:36:10
16	quota based on historical sales. I 10:34:28	16	correct? 10:36:12
17	have no idea how that was derived or 10:34:30	17	A. Correct. 10:36:13
18	who set that quota or how Mallinckrodt 10:34:33	18	MR. O'CONNOR: Object to form. 10:36:13
19	played a role in that. 10:34:36	19	THE WITNESS: Correct. 10:36:14
20	QUESTIONS BY MR. GOTTO: 10:34:37	20	QUESTIONS BY MR. GOTTO: 10:36:15
21	Q. Okay. And so the quota, did 10:34:38	21	Q. Okay. So, for example, 10:36:22
22	you understand it to be to be applicable 10:34:39	22	oxycodone 15 milligram versus 30 milligram, 10:36:23
23	to each particular molecule of controlled 10:34:42	23	were there separate business plans for those 10:36:27
24	substance? 10:34:45	24	two dosages? 10:36:29
25	A. Correct. 10:34:45	25	A. I don't recall doing separate 10:36:30
	Page 79		Page 81
1	Q. And did you understand did 10:34:46	1	business plans for them. 10:36:32
2	you have an understanding as to whether there 10:34:49	2	Q. Okay. When you when you 10:36:33
3	was quota for a particular dosage of that 10:34:51	3	started at Mallinckrodt, did you review the 10:36:41
4	molecule? 10:34:54	4	then existing business plans for the various 10:36:46
5	MR. O'CONNOR: Object to form. 10:34:55	5	products that were within the specialty 10:36:49
6	THE WITNESS: No. 10:34:56	6	generics umbrella? 10:36:51
7	QUESTIONS BY MR. GOTTO: 10:34:57	7	A. When I started, they did not 10:36:52
8	Q. Okay. You didn't have an 10:34:58	8	have a formal business plan. They continued 10:36:55
9	understanding one way or the other on that? 10:35:00	9	doing what they were doing as far as product 10:36:58
10	A. I'm sorry, no, I do not believe 10:35:01	10	forecasting and pricing and customer 10:37:02
11	that it was per molecule. 10:35:03	11	strategy. 10:37:04
12	Q. Okay. 10:35:05	12	Q. Okay. So Exhibit 3, when 10:37:05
13	A. It was just to the molecule, 10:35:05	13	there's a reference to developing financially 10:37:07
14	•	14	sound business plans, was that a new 10:37:10
1	not to the dosage form or the strength. 10:35:08	1	initiative for the director of marketing when 10:37:14
15	not to the dosage form or the strength. 10:35:08 Q. Okay. And so in terms of 10:35:11	15	
	Q. Okay. And so in terms of 10:35:11	15 16	_
15	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13		you joined compared to what Mallinckrodt had 10:37:17
15 16	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15	16	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18
15 16 17 18	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18	16 17 18	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19
15 16 17 18 19	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22	16 17 18 19	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20
15 16 17 18 19 20	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22 A. Not typically. Typically you 10:35:23	16 17 18 19 20	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20 formal level to it. 10:37:22
15 16 17 18 19 20 21	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22 A. Not typically. Typically you 10:35:23 would have it just for the molecule itself. 10:35:26	16 17 18 19 20 21	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20 formal level to it. 10:37:22 Q. Okay. Item Number 2, "direct 10:37:23
15 16 17 18 19 20 21 22	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22 A. Not typically. Typically you 10:35:23 would have it just for the molecule itself. 10:35:26 Q. Okay. So, for example, with 10:35:28	16 17 18 19 20 21 22	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20 formal level to it. 10:37:22 Q. Okay. Item Number 2, "direct 10:37:23 and lead the creation and development of 10:37:30
15 16 17 18 19 20 21	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22 A. Not typically. Typically you 10:35:23 would have it just for the molecule itself. 10:35:26 Q. Okay. So, for example, with 10:35:28 oxycodone, when you when you joined 10:35:35	16 17 18 19 20 21 22 23	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20 formal level to it. 10:37:22 Q. Okay. Item Number 2, "direct 10:37:23 and lead the creation and development of 10:37:30 marketing plans, promotional literature, 10:37:32
15 16 17 18 19 20 21 22 23 24	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22 A. Not typically. Typically you 10:35:23 would have it just for the molecule itself. 10:35:26 Q. Okay. So, for example, with 10:35:28 oxycodone, when you when you joined 10:35:35 Mallinckrodt, would you have a single 10:35:38	16 17 18 19 20 21 22	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20 formal level to it. 10:37:22 Q. Okay. Item Number 2, "direct 10:37:23 and lead the creation and development of 10:37:30 marketing plans, promotional literature, 10:37:32 product messages/identity and product-related 10:37:35
15 16 17 18 19 20 21 22 23	Q. Okay. And so in terms of 10:35:11 formulating business plans for the different 10:35:13 products, did you have a different business 10:35:15 plan for different dosage and strength of the 10:35:18 same molecule? 10:35:22 A. Not typically. Typically you 10:35:23 would have it just for the molecule itself. 10:35:26 Q. Okay. So, for example, with 10:35:28 oxycodone, when you when you joined 10:35:35	16 17 18 19 20 21 22 23 24	you joined compared to what Mallinckrodt had 10:37:17 done historically? 10:37:18 A. I think that was the 10:37:19 expectation; it's just that I brought a 10:37:20 formal level to it. 10:37:22 Q. Okay. Item Number 2, "direct 10:37:23 and lead the creation and development of 10:37:30 marketing plans, promotional literature, 10:37:32

	D 02	_	B 04
	Page 82		Page 84
1	Does that accurately describe 10:37:41	1	you to implement to attempt to increase 10:39:48
2	an aspect of your responsibilities while you 10:37:45	2	market share on a given product? 10:39:51
3	were director of marketing? 10:37:49	3	A. Well, one of the biggest things 10:39:53
4	A. It's a little vague, but, yes. 10:37:52	4	you would do is differentiate yourself as a 10:39:55
5	Q. Okay. Well, let's break it 10:37:55	5	company, provide better customer service, be 10:39:57
6	down a little bit. 10:37:56	6	responsive to customer needs. Communication 10:40:00
7	First of all, it makes 10:37:57	7	is the biggest, letting them know what's 10:40:02
8	reference to marketing plans. Tell me what 10:37:59	8	going on if there's a product issue, new 10:40:05
9	you understand it to mean what you 10:38:03	9	entrants coming, you know, advising them of 10:40:08
10	understand a marketing plan to mean in this 10:38:05	10	what's going on. So just providing good 10:40:11
11	context. 10:38:07	11	customer service is the bottom line. 10:40:14
12	A. A marketing plan would be 10:38:08	12	Q. Okay. So when you say 10:40:16
13	developing the pricing strategy, what target 10:38:09	13	communicating, letting them know "if there's 10:40:26
14	customers we wanted, what market share, who 10:38:12	14	a product issue," are there types of product 10:40:28
15	were the competitors and who would we 10:38:15	15	issues you can recall arising during your 10:40:31
16	displace in selling product if we wanted to 10:38:17	16	time at Mallinckrodt that you communicated 10:40:34
17	gain share. 10:38:20	17	with customers on? 10:40:36
18	Q. Okay. So in terms of gaining 10:38:21	18	MR. O'CONNOR: Object to form. 10:40:38
19	market share, since it's you're in a 10:38:24	19	THE WITNESS: Sure. There's 10:40:39
20	generic industry here, what techniques were 10:38:31	20	always problems with supply. Either 10:40:40
21	available to you as a marketing director to 10:38:34	21	there's a manufacturing issue, it's 10:40:42
22	develop strategies for gaining market share 10:38:39	22	delayed, a raw material issue. 10:40:44
23	with respect to a particular product? 10:38:41	23	Advising them on anything that you can 10:40:47
24	MR. O'CONNOR: Object to form. 10:38:44	24	see might be a long term versus a 10:40:49
25	THE WITNESS: I'm not sure what 10:38:45	25	short term and when you can supply the 10:40:52
	Page 83		Page 85
1	you mean by "techniques." It would be 10:38:46	1	product again. 10:40:54
1 -	you incan by techniques. It would be 10.36.40		
2			
2	evaluating the market, so I'm going to 10:38:49	2	QUESTIONS BY MR. GOTTO: 10:40:55
3	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51	2	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55
3 4	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54	2 3 4	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04
3 4 5	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55	2 3 4 5	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08
3 4 5 6	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55	2 3 4 5	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11
3 4 5 6 7	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56	2 3 4 5 6 7	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13
3 4 5 6 7 8	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58	2 3 4 5 6 7 8	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14
3 4 5 6 7 8	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00	2 3 4 5 6 7 8	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18
3 4 5 6 7 8 9	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02	2 3 4 5 6 7 8 9	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20
3 4 5 6 7 8 9 10	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05	2 3 4 5 6 7 8 9 10	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23
3 4 5 6 7 8 9 10 11	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08	2 3 4 5 6 7 8 9 10 11	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24
3 4 5 6 7 8 9 10 11 12 13	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12	2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28
3 4 5 6 7 8 9 10 11 12 13	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14	2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question on, you know, techniques to increase market on, you know, techniques to increase market share, competing on price being one, excellent customer service of the type you described being another. Are there other approaches of marketing to try to increase market share with respect to a given product? A. Sure. There's the customers participating in their incentive programs 10:41:28 10:41:28 10:41:30
3 4 5 6 7 8 9 10 11 12 13 14 15	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15	2 3 4 5 6 7 8 9 10 11 12 13 14	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:33
3 4 5 6 7 8 9 10 11 12 13 14 15 16	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:16	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:33 is one. So it still goes back to price, 10:41:35
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:33 is one. So it still goes back to price, 10:41:35 because you're still going to price them 10:41:38
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:35 because you're still going to price them 10:41:38 appropriately for the market. 10:41:40
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	QUESTIONS BY MR. GOTTO: 10:40:55 Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, 10:41:08 excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing 10:41:18 to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:33 is one. So it still goes back to price, 10:41:35 because you're still going to price them 10:41:38 appropriately for the market. 10:41:40 And just again, just 10:41:44
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31 many years at this it would seem to be one 10:39:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:35 because you're still going to price them 10:41:40 And just again, just 10:41:44 differentiating yourself as the vendor, as 10:41:48
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31 many years at this it would seem to be one 10:39:32 of the things you can do is develop 10:39:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:33 is one. So it still goes back to price, 10:41:35 because you're still going to price them 10:41:38 appropriately for the market. 10:41:40 And just again, just 10:41:48 the manufacturer. Providing consistency of 10:41:51
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31 many years at this it would seem to be one 10:39:32 of the things you can do is develop 10:39:36 strategies to compete on price, correct? 10:39:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:33 is one. So it still goes back to price, 10:41:35 because you're still going to price them 10:41:38 appropriately for the market. 10:41:40 And just again, just 10:41:44 differentiating yourself as the vendor, as 10:41:51 supply is really important to customers so 10:41:55
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31 many years at this it would seem to be one 10:39:32 of the things you can do is develop 10:39:36 strategies to compete on price, correct? 10:39:38 A. Correct. 10:39:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:35 because you're still going to price them And just again, just 10:41:44 differentiating yourself as the vendor, as 10:41:55 that they don't have to have the pharmacies 10:41:55
3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31 many years at this it would seem to be one 10:39:32 of the things you can do is develop 10:39:36 strategies to compete on price, correct? 10:39:41 Q. Okay. Apart from competing on 10:39:41	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:11 described being another. 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:20 to a given product? 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so 10:41:28 participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:35 because you're still going to price them 10:41:40 And just again, just 10:41:44 differentiating yourself as the vendor, as 10:41:51 supply is really important to customers so 10:41:55 that they don't have to have the pharmacies 10:42:01
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	evaluating the market, so I'm going to 10:38:49 answer just what I'm thinking you 10:38:51 might mean. 10:38:54 QUESTIONS BY MR. GOTTO: 10:38:55 Q. Okay. 10:38:55 A. It would be evaluating the 10:38:56 market, see who the competitors are, who 10:38:58 might be entering based on market 10:39:00 intelligence provided by the national account 10:39:02 managers or anything we read online from the 10:39:05 FDA site. So evaluating who might be 10:39:08 potential threats and who make take our 10:39:12 business, and if we wanted to retain the 10:39:14 business or let it go. 10:39:15 Q. Okay. So in general, generic 10:39:16 pharmaceuticals, to expand market share I 10:39:25 mean, I'm not in the business, so I'm 10:39:29 obviously asking you as someone who has spent 10:39:31 many years at this it would seem to be one 10:39:32 of the things you can do is develop 10:39:36 strategies to compete on price, correct? 10:39:38 A. Correct. 10:39:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. GOTTO: Q. Okay. So back to my question 10:40:55 on, you know, techniques to increase market 10:41:04 share, competing on price being one, excellent customer service of the type you 10:41:13 Are there other approaches 10:41:14 available to you as a director of marketing to try to increase market share with respect 10:41:23 A. Sure. There's the customers 10:41:24 have incentive programs in place, and so participating in their incentive programs 10:41:30 that help them achieve their corporate goals 10:41:35 because you're still going to price them And just again, just 10:41:44 differentiating yourself as the vendor, as 10:41:55 that they don't have to have the pharmacies 10:41:55

	Page 86		Page 88
1	Q. Okay. When you joined 10:42:04	1	cycles. But I don't remember a 10:44:20
	Mallinckrodt, what was your understanding as 10:42:07	2	specific instance where we said, oh, 10:44:21
3	to Mallinckrodt's market share with respect 10:42:12	3	we really want to go after this 10:44:23
4	to its various generic products? 10:42:17	4	product, and we're going to cut 10:44:25
5	MR. O'CONNOR: Object to form. 10:42:19	5	everybody out of the market. 10:44:26
6	THE WITNESS: Mallinckrodt had 10:42:20	6	QUESTIONS BY MR. GOTTO: 10:44:27
7	strong market share on some products. 10:42:24	7	Q. Okay. What are examples of 10:44:27
8	We're trailing on other products. 10:42:27	8	products you can recall shedding because of 10:44:29
9	QUESTIONS BY MR. GOTTO: 10:42:28	9	nonprofitability? 10:44:32
10	Q. Okay. When you first joined, 10:42:29	10	A. There was methylphenidate, one 10:44:33
	were there any products that you can 10:42:30	11	of the methylphenidates, it wasn't making any 10:44:37
12	recall as to which you can recall any 10:42:32	12	money. It was a difficult product to make, 10:44:40
13	particular effort to increase market share? 10:42:37	13	and so we were losing money on it, and we 10:44:42
14	A. Well, frankly, when you launch 10:42:38	14	decided not to sell it anymore. 10:44:45
15	a product, you obviously want to get some 10:42:45	15	Q. Okay. Any others? 10:44:47
16	market share. I don't remember particular 10:42:47	16	A. None that I can recall, but I 10:44:48
17	strategies where we wanted to gain more 10:42:52	17	know we did terminate several products, but I 10:44:51
18	share, because in some instances the more 10:42:53	18	can't remember the names of them at this 10:44:54
19	share we gained, the more the price came down 10:42:55	19	point. 10:44:56
20	and we actually got diminished returns. So 10:42:57	20	Q. Okay. What product launches 10:44:56
21	there were instances when I remember that we 10:43:01	21	can you recall during your period at 10:44:58
22	would say we would surrender share because 10:43:03	22	Mallinckrodt? 10:44:59
23	somebody else entered. 10:43:05	23	A. We launched fentanyl lozenge, 10:45:00
24	But as far as gaining share, 10:43:06	24	fentanyl patch and methylphenidate ER, the 10:45:06
25	there might be cases that we did it for a 10:43:08	25	generic for Concerta. 10:45:09
	Page 87		Page 89
	-8		1 age of
1	particular customer because we wanted a full 10:43:10	1	Q. From in terms of your 10:45:11
1 2		1 2	
2	particular customer because we wanted a full 10:43:10		Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21
2	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18	2	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19
2 3 4 5	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19	2	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25
2 3 4 5 6	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22	2 3 4	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30
2 3 4 5 6 7	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27	2 3 4 5	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33
2 3 4 5 6 7	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34	2 3 4 5	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37
2 3 4 5 6 7	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37	2 3 4 5 6 7	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38
2 3 4 5 6 7 8 9	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43	2 3 4 5 6 7 8 9	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41
2 3 4 5 6 7 8 9 10	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46	2 3 4 5 6 7 8 9 10	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44
2 3 4 5 6 7 8 9 10 11	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46	2 3 4 5 6 7 8 9 10 11	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:46
2 3 4 5 6 7 8 9 10 11 12	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47	2 3 4 5 6 7 8 9 10 11 12 13	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49
2 3 4 5 6 7 8 9 10 11 12 13	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49	2 3 4 5 6 7 8 9 10 11 12 13	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:52
2 3 4 5 6 7 8 9 10 11 12 13 14	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:54	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:54 with pricing adjustments in order to 10:43:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:49 a fentanyl lozenge launch? 10:45:57 was a little bit easier; there was limited 10:45:58
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:57 achieve our objectives, and we 10:44:00	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:54 with pricing adjustments in order to 10:43:57 achieve our objectives, and we 10:44:00 actually shed products because they 10:44:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:57 achieve our objectives, and we 10:44:00 actually shed products because they 10:44:03 were not profitable. So I remember 10:44:05	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03 machinery. So we knew we would be taking it 10:46:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:57 achieve our objectives, and we 10:44:00 actually shed products because they 10:44:03 were not profitable. So I remember 10:44:05 culling out products instead of 10:44:09	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:52 A. We would look at that one 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03 machinery. So we knew we would be taking it 10:46:06 from I believe it was Teva at the time. 10:46:08
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:54 with pricing adjustments in order to 10:43:57 achieve our objectives, and we 10:44:00 actually shed products because they 10:44:03 were not profitable. So I remember 10:44:05 culling out products instead of 10:44:09 looking to gain share. 10:44:11	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03 machinery. So we knew we would be taking it 10:46:06 from I believe it was Teva at the time. 10:46:08 So we were going to be taking a product away 10:46:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:54 with pricing adjustments in order to 10:43:57 achieve our objectives, and we 10:44:03 were not profitable. So I remember 10:44:05 culling out products instead of 10:44:09 looking to gain share. 10:44:11 I don't remember specifically 10:44:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03 machinery. So we knew we would be taking it 10:46:06 from I believe it was Teva at the time. 10:46:08 So we were going to be taking a product away 10:46:10 from Teva, and so we knew we were strong in a 10:46:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:57 achieve our objectives, and we 10:44:00 actually shed products because they 10:44:03 were not profitable. So I remember 10:44:05 culling out products instead of 10:44:09 looking to gain share. 10:44:11 I don't remember specifically 10:44:13 anything along that line, but that's 10:44:14	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:52 A. We would look at that one 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03 machinery. So we knew we would be taking it 10:46:08 So we were going to be taking a product away 10:46:10 from Teva, and so we knew we were strong in a 10:46:11 particular customer, so we'd better we 10:46:14
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	particular customer because we wanted a full 10:43:10 line with that customer, but other than that, 10:43:12 that wasn't our target, other than launching 10:43:16 products. 10:43:18 Q. Okay. So putting aside product 10:43:19 launches for a moment, during your time at 10:43:22 Mallinckrodt, as a general matter, is it your 10:43:27 recollection that in terms of market share, 10:43:34 again, apart from launching new products, the 10:43:37 emphasis was on maintaining existing market 10:43:43 share? 10:43:46 MR. O'CONNOR: Object to form. 10:43:46 THE WITNESS: Our emphasis was 10:43:47 more on sales margin and maintaining 10:43:49 margin, so we did more things in line 10:43:54 with pricing adjustments in order to 10:43:57 achieve our objectives, and we 10:44:03 were not profitable. So I remember 10:44:05 culling out products instead of 10:44:09 looking to gain share. 10:44:11 I don't remember specifically 10:44:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. From in terms of your 10:45:11 position as director of marketing, what were 10:45:19 your responsibilities associated with a 10:45:21 product launch? 10:45:23 A. To establish the market base 10:45:25 that we were going to target, who what 10:45:30 customers did we want to pursue, what 10:45:33 incentives were involved, what would be the 10:45:37 margin be if we targeted those customers, and 10:45:38 who would we take the market share from. 10:45:41 Q. And so how did you go about 10:45:44 performing the analysis pertinent to those 10:45:46 types of issues with respect to, for example, 10:45:49 a fentanyl lozenge launch? 10:45:52 A. We would look at that one 10:45:57 was a little bit easier; there was limited 10:45:58 competition. It's a really difficult product 10:46:00 to make; very few companies have the 10:46:03 machinery. So we knew we would be taking it 10:46:06 from I believe it was Teva at the time. 10:46:08 So we were going to be taking a product away 10:46:10 from Teva, and so we knew we were strong in a 10:46:11

	Page 90		Page 92
1	and what their contract said about what we'd 10:46:21	1	So the challenge we had with 10:48:31
2	have to offer, so we would determine pricing 10:46:24	2	messaging on fentanyl patch is that we 10:48:32
3	based on that. And we knew what share we 10:46:26	3	couldn't say anything about we had a good 10:48:34
4	needed to hit and did that with a couple of 10:46:30	4	tear factor, too, or that we had anything 10:48:36
5	customers. 10:46:34	5	that was better about our product, the size 10:48:39
6	Q. Okay. How about the fentanyl 10:46:35	6	of it. And that's the one thing. Once they 10:48:41
7	patch? 10:46:38	7	did see the size of ours, because it was a 10:48:43
8	A. The fentanyl patch was a little 10:46:39	8	little bit smaller, they liked that because a 10:48:46
9	bit different in that Mylan had a good 10:46:42	9	patient didn't want it to be as obvious. And 10:48:48 easy to tear off, you know, after they're 10:48:53
10	product out there. They had the customers 10:46:46 liked it. It's because, again, it's 10:46:49	10	easy to tear off, you know, after they're 10:48:53 done using it for three days. 10:48:55
11	that one's a little bit differentiated than 10:46:51	11	So the only that was one 10:48:56
13	taking the tablet because it's got a tear 10:46:54	13	campaign that we did advertising, to show 10:48:59
14	factor. So Mylan's product was 10:46:56	14	that the size of our patch was relatively 10:49:02
15	well-received, so it was a little bit 10:46:59	15	
16	difficult because pharmacists knew the 10:47:01	16	small. And it had the strength on the patch 10:49:04 itself so the patients could tell. And it 10:49:07
17	patients liked that. 10:47:04	17	was color-coded so it made it easier. So we 10:49:10
18	So we struggled to find our 10:47:05	18	did some trade journal advertising in that 10:49:13
19	share and our footing on that at first, but 10:47:08	19	case so pharmacies could see why it was a 10:49:15
20	we had a good product also. So once patients 10:47:09	20	good product. 10:49:18
21	started using our product, they liked it and 10:47:12	21	Q. Okay. And when you say "we" 10:49:18
22	they were they stayed on it. 10:47:14	22	did that, that was Mallinckrodt advertising? 10:49:23
23	Q. Okay. So as director of 10:47:15	23	A. Yes. Yes. 10:49:26
24	marketing, what steps can you recall taking 10:47:19	24	Q. Were there similar or strike 10:49:26
25	to deal with for example, in the fentanyl 10:47:24	25	"similar." 10:49:35
	Daga ()1		Daga 02
	Page 91		Page 93
1	patch example, to deal with the fact Mylan 10:47:30	1	Were there other messaging 10:49:36
2	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33	2	Were there other messaging 10:49:36 initiatives with respect to other generic 10:49:40
2	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36	2	Were there other messaging 10:49:36 initiatives with respect to other generic 10:49:40 products that you can recall during your 10:49:43
2 3 4	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38	2 3 4	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your period as director of marketing? 10:49:47
2 3 4 5	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39	2 3 4 5	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49
2 3 4 5 6	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42	2 3 4 5	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50
2 3 4 5 6 7	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45	2 3 4 5 6 7	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53
2 3 4 5 6 7 8	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47	2 3 4 5 6 7 8	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57
2 3 4 5 6 7 8	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49	2 3 4 5 6 7 8	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59
2 3 4 5 6 7 8 9	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52	2 3 4 5 6 7 8 9	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04
2 3 4 5 6 7 8 9 10	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55	2 3 4 5 6 7 8 9 10	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any 10:50:04
2 3 4 5 6 7 8 9	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57	2 3 4 5 6 7 8 9	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any messaging initiatives that you can recall? 10:50:07
2 3 4 5 6 7 8 9 10 11	patch example, to deal with the fact Mylan 10:47:30 already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00	2 3 4 5 6 7 8 9 10 11	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any 10:50:07 A. I know we did some advertising. 10:50:10
2 3 4 5 6 7 8 9 10 11 12 13	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:48:00 their catalogs and they list it on their 10:48:00	2 3 4 5 6 7 8 9 10 11 12 13	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any 10:50:04 messaging initiatives that you can recall? 10:50:07 A. I know we did some advertising. 10:50:10
2 3 4 5 6 7 8 9 10 11 12 13 14	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:48:00 their catalogs and they list it on their 10:48:00	2 3 4 5 6 7 8 9 10 11 12 13	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the existing product line, were there any 10:50:04 messaging initiatives that you can recall? 10:50:07 A. I know we did some advertising. 10:50:10 We changed some of our labeling, so we 10:50:13
2 3 4 5 6 7 8 9 10 11 12 13 14	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:57 They don't really like the wholesalers 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05	2 3 4 5 6 7 8 9 10 11 12 13 14	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any messaging initiatives that you can recall? 10:50:07 A. I know we did some advertising. 10:50:10 We changed some of our labeling, so we 10:50:13 announced that the labels had changed so the 10:50:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:07	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Were there other messaging 10:49:36 initiatives with respect to other generic products that you can recall during your 10:49:43 period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any 10:50:07 A. I know we did some advertising. 10:50:10 We changed some of our labeling, so we 10:50:13 announced that the labels had changed so the 10:50:15 customers could see that. 10:50:19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:07 to get our share on that at first. 10:48:11	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? A. Sure. We made a product announcement in trade journals, goes to pharmacists, to announce that we had fentanyl lozenge. And fentanyl patch was the same, Okay. And how about with the Q. Okay. And how about with the existing product line, were there any messaging initiatives that you can recall? A. I know we did some advertising. I o:50:10 We changed some of our labeling, so we announced that the labels had changed so the I o:50:15 customers could see that. I o:50:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:57 they don't really like the wholesalers 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:07 to get our share on that at first. 10:48:11 Q. And when you say "message" in 10:48:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? A. Sure. We made a product announcement in trade journals, goes to pharmacists, to announce that we had fentanyl lozenge. And fentanyl patch was the same, Q. Okay. And how about with the existing product line, were there any messaging initiatives that you can recall? A. I know we did some advertising. I objected We changed some of our labeling, so we I objected I don't remember any other I objected I other sequence I objected I object
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:07 to get our share on that at first. 10:48:11 Q. And when you say "message" in 10:48:13 that setting, what do you mean by that? 10:48:16	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? 10:49:47 A. Sure. We made a product 10:49:49 announcement in trade journals, goes to pharmacists, to announce that we had fentanyl 10:49:50 pharmacists, to announce that we had fentanyl 10:49:53 lozenge. And fentanyl patch was the same, 10:49:57 and methylphenidate ER was the same. 10:49:59 Q. Okay. And how about with the 10:50:04 existing product line, were there any 10:50:04 messaging initiatives that you can recall? 10:50:07 A. I know we did some advertising. 10:50:10 We changed some of our labeling, so we 10:50:13 announced that the labels had changed so the 10:50:15 customers could see that. 10:50:21 advertising that we did around our core 10:50:22 products. 10:50:25
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:11 Q. And when you say "message" in 10:48:13 that setting, what do you mean by that? 10:48:16 A. You can't tell you can't say 10:48:16	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? A. Sure. We made a product announcement in trade journals, goes to pharmacists, to announce that we had fentanyl lozenge. And fentanyl patch was the same, and methylphenidate ER was the same. Q. Okay. And how about with the existing product line, were there any messaging initiatives that you can recall? A. I know we did some advertising. We changed some of our labeling, so we announced that the labels had changed so the I 0:50:15 customers could see that. I don't remember any other I don't remember any other I do:50:25 Q. Okay. All right. Back on I 0:50:25
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:07 to get our share on that at first. 10:48:11 Q. And when you say "message" in 10:48:13 that setting, what do you mean by that? 10:48:16 A. You can't tell you can't say 10:48:16 that we have a better tear factor or we have 10:48:18	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? A. Sure. We made a product announcement in trade journals, goes to pharmacists, to announce that we had fentanyl lozenge. And fentanyl patch was the same, Q. Okay. And how about with the existing product line, were there any messaging initiatives that you can recall? A. I know we did some advertising. We changed some of our labeling, so we I the control of the customers could see that. I don't remember any other I don't remember any other Q. Okay. All right. Back on I 0:50:25 Item 2 on Exhibit 3, there's reference to, I 0:50:30
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the 10:47:52 pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:07 to get our share on that at first. 10:48:11 Q. And when you say "message" in 10:48:13 that setting, what do you mean by that? 10:48:16 A. You can't tell you can't say 10:48:16 that we have a better tear factor or we have 10:48:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? A. Sure. We made a product announcement in trade journals, goes to pharmacists, to announce that we had fentanyl lozenge. And fentanyl patch was the same, Q. Okay. And how about with the existing product line, were there any messaging initiatives that you can recall? A. I know we did some advertising. We changed some of our labeling, so we locitoria announced that the labels had changed so the I don't remember any other I don't remember any other locitoria
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	patch example, to deal with the fact Mylan already had a well-received product and 10:47:33 Mallinckrodt would be a new entrant into that 10:47:36 market? 10:47:38 A. We would pursue other customers 10:47:39 that were more about price and they weren't 10:47:42 as concerned about customer patient 10:47:45 feedback. So that's part of it. 10:47:47 So and then we also pursued 10:47:49 customers that we knew could work with the pharmacies in messaging, I guess, to them. 10:47:55 They don't really like the wholesalers 10:47:57 don't message. They list the product in 10:48:00 their catalogs and they list it on their 10:48:02 website so they don't send a message behind 10:48:05 it. So it was kind of a challenge, frankly, 10:48:07 to get our share on that at first. 10:48:11 Q. And when you say "message" in 10:48:13 that setting, what do you mean by that? 10:48:16 A. You can't tell you can't say 10:48:16 that we have a better tear factor or we have 10:48:21 They're equivalent. The FDA declared them 10:48:24	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Were there other messaging initiatives with respect to other generic products that you can recall during your period as director of marketing? A. Sure. We made a product announcement in trade journals, goes to pharmacists, to announce that we had fentanyl lozenge. And fentanyl patch was the same, and methylphenidate ER was the same. Q. Okay. And how about with the existing product line, were there any messaging initiatives that you can recall? A. I know we did some advertising. We changed some of our labeling, so we announced that the labels had changed so the I 0:50:15 customers could see that. I don't remember any other I 0:50:22 products. Q. Okay. All right. Back on J0:50:35 Item 2 on Exhibit 3, there's reference to, J0:50:36 development of marketing plans" and then J0:50:36

	Page 94	Τ	Page 96
1	something that was part of your 10:50:42	1	competitor. You had to show that you 10:52:46
1 2	responsibilities? 10:50:44	2	know, we showed the hand and showed how small 10:52:51
3	A. Yes. 10:50:46	3	it was next to somebody's hand. 10:52:53
4	Q. So tell me what sorts of 10:50:47	4	Our fentanyl lozenge, I know we 10:52:54
5	promotional literature you oversaw. 10:50:49	5	advertise. I think that in the trade 10:52:58
6	A. The advertising for the product 10:50:50	6	journals we would simply show that we had the 10:53:01
7	launch products in the trade journals. We 10:50:54	7	four sizes, strengths, and just the color of 10:53:03
8	developed several programs to better connect 10:50:57	8	the packaging because that helped, because 10:53:09
9	with the customers, so we had advertising - 10:50:59	9	the pharmacists could quickly identify which 10:53:10
10	or not advertising, but we send information 10:51:02	10	strength they were pulling from the shelf if 10:53:12
11	out to the customers. If there was a product 10:51:06	11	they were taking care of a patient and 10:53:14
12	change or a product announcement, we would 10:51:12	12	filling a prescription. 10:53:14
13	send information to the customers. 10:51:14	13	And methylphenidate, just to 10:53:19
14	So my team oversaw that and 10:51:15	14	announce that it was available. 10:53:21
15	messaged the message about the product's now 10:51:18	15	Q. Okay. Item Number 4 on 10:53:23
16	available, here's the wholesaler order entry 10:51:20	16	Exhibit 3 is "identify new product/growth 10:53:34
17	numbers to the wholesalers. You know, here's 10:51:24	17	areas, including new dosage forms of existing 10:53:37
18	all the information we have. If we have 10:51:27	18	products, preparing the necessary analyses to 10:53:40
19	to fill out a form that tells them everything 10:51:29	19	support same, which includes working with R&D 10:53:43
20	from what the list price is to the packaging 10:51:31	20	on potential product line extensions and 10:53:46
21	weights, dimensions, so we'd it's not 10:51:33	21	working with new product group and business 10:53:48
22	really promotional material, but we had to 10:51:36	22	development to develop strategies and tactics 10:53:51
23	send all that material, too. 10:51:37	23	resulting in additions to Mallinckrodt's 10:53:53
24	Q. Okay. In terms of material you 10:51:39	24	product portfolio." 10:53:57
25	would think of as promotional material, 10:51:42	25	Does Item 4 describe an aspect 10:53:59
	,		1
	Page 95		Page 97
1	approximately was that a regular process 10:51:47	1	of what you understood to be your 10:54:06
1 2	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51	1 2	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08
2 3	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54	2	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09
2 3 4	approximately was that a regular process 10:51:47 or was that an occasional process when there was, say, a new development with respect to a 10:51:54 product? 10:51:56	2 3 4	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10
2 3 4 5	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57	2 3 4 5	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11
2 3 4 5	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00	2 3 4 5 6	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14
2 3 4 5 6 7	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03	2 3 4 5 6 7	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17
2 3 4 5 6 7 8	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05	2 3 4 5 6 7 8	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22
2 3 4 5 6 7 8	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08	2 3 4 5 6 7 8	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23
2 3 4 5 6 7 8 9	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14	2 3 4 5 6 7 8 9	of what you understood to be your 10:54:06 responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28
2 3 4 5 6 7 8 9 10	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19	2 3 4 5 6 7 8 9 10	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30
2 3 4 5 6 7 8 9 10 11	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24	2 3 4 5 6 7 8 9 10 11	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32
2 3 4 5 6 7 8 9 10 11 12 13	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25	2 3 4 5 6 7 8 9 10 11 12 13	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33
2 3 4 5 6 7 8 9 10 11 12 13 14	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26	2 3 4 5 6 7 8 9 10 11 12 13	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:36
2 3 4 5 6 7 8 9 10 11 12 13 14 15	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28	2 3 4 5 6 7 8 9 10 11 12 13 14	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:29 of. 10:52:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:49 would be involved in those discussions with 10:54:49
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:29 of. 10:52:30 A. That was what I was just 10:52:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:29 of. 10:52:30 A. That was what I was just 10:52:31 explaining about trying to get across a 10:52:34	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51 we want a patent challenge versus not. So 10:54:53
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:30 A. That was what I was just 10:52:31 explaining about trying to get across a 10:52:34 message to the pharmacists that our product 10:52:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51 we want a patent challenge versus not. So 10:54:53 there was many things like that. 10:54:56
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:30 A. That was what I was just 10:52:31 explaining about trying to get across a 10:52:34 message to the pharmacists that our product 10:52:35 was available, that you know, you couldn't 10:52:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51 we want a patent challenge versus not. So 10:54:53 there was many things like that. 10:54:56 And then there were other 10:54:58
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:31 explaining about trying to get across a 10:52:34 message to the pharmacists that our product 10:52:35 was available, that you know, you couldn't 10:52:36 talk about we had a smaller size; you could 10:52:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:36 We looked at other products 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51 we want a patent challenge versus not. So 10:54:53 there was many things like that. 10:54:58 products that were in the pipeline portfolio 10:55:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:30 A. That was what I was just 10:52:31 explaining about trying to get across a 10:52:35 message to the pharmacists that our product 10:52:35 was available, that you know, you couldn't 10:52:36 talk about we had a smaller size; you could show, basically. You had to we couldn't 10:52:41	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:36 We looked at other products 10:54:39 like methylphenidate ER; should we continue 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51 we want a patent challenge versus not. So 10:54:53 there was many things like that. 10:54:56 And then there were other 10:54:58 products that were in the pipeline portfolio 10:55:01 when I started, and we killed some of those, 10:55:05
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	approximately was that a regular process 10:51:47 or was that an occasional process when there 10:51:51 was, say, a new development with respect to a 10:51:54 product? 10:51:56 A. It was an occasional process. 10:51:57 As products go, the only thing we really did 10:52:00 was announce when products were available, 10:52:03 again, if there was some change to a product. 10:52:05 Q. The next item under heading 2 10:52:08 is product messages/identity. I guess it's 10:52:14 creation and development of product 10:52:19 messages/identities. 10:52:24 Is that something that you 10:52:25 viewed as part of your responsibility as 10:52:26 director of marketing? 10:52:28 A. Yes. 10:52:29 Q. And tell me what that consisted 10:52:31 explaining about trying to get across a 10:52:34 message to the pharmacists that our product 10:52:35 was available, that you know, you couldn't 10:52:36 talk about we had a smaller size; you could 10:52:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	of what you understood to be your responsibilities as director of marketing? 10:54:08 A. Yes, it does. 10:54:09 Q. And tell me what you did to go 10:54:10 about identifying new product and growth 10:54:11 areas in the matter described in Item 4 here. 10:54:14 A. The easiest path we had for new 10:54:17 products would be to do line extensions. For 10:54:22 example, oxycodone had 5, 10, 15, 20 and 10:54:23 30 milligrams. We did not have the 10 or the 10:54:28 30 milligram to launch those. 10:54:30 We looked at solutions. If we 10:54:32 had the finished dosage form in an oral 10:54:33 solid, can we launch it in a solution form. 10:54:36 We looked at other products 10:54:39 like methylphenidate ER; should we continue 10:54:40 filing for a patent challenge. And if so, I 10:54:44 would be involved in those discussions with 10:54:49 legal about what would be the implications if 10:54:51 we want a patent challenge versus not. So 10:54:53 there was many things like that. 10:54:58 products that were in the pipeline portfolio 10:55:01

	5 1		4
	Page 98		Page 100
1	because the market would dwindle before we 10:55:09	1	8
2	even got to market, so there wasn't anything 10:55:12	2	hydrocodone. It moved from a Schedule III to 10:57:28
3	of value there. 10:55:14	3	a Schedule II. 10:57:30
4	Q. Okay. And so were there any 10:55:16	4	Q. Okay. Item 8 is "work closely 10:57:31
5	new products you can recall during your time 10:55:17	5	with sales to ensure business plans are met." 10:57:43
6	at Mallinckrodt that were developed where 10:55:20	6	Was that part of your 10:57:46
7	the where the impetus for that development 10:55:26	7	responsibility as director of marketing? 10:57:48
8	came from the marketing department? 10:55:28	8	A. Yes. 10:57:49
9	A. None that they took on that I 10:55:30	9	Q. And so who did you work with in 10:57:50
10	can remember. 10:55:40	10	the sales department to ensure business plans 10:57:53
11	Q. Okay. And so in terms of the 10:55:40	11	are met? 10:57:55
12	new products, it was marketing 10:55:41	12	A. Primarily I worked with John 10:57:57
13	department's involvement was essentially 10:55:44	13	Adams in the beginning, and then John left, 10:57:58
14	responding to ideas that came out of other 10:55:49	14	and then I worked with Jane Williams. 10:58:00
15	other parts of the company? 10:55:50	15	Q. Okay. Do you recall when 10:58:03
16	A. Right. 10:55:51	16	Mr. Adams left? 10:58:04
17	Q. Okay. Item Number 5. And I 10:55:53	17	A. Not really. I think it was 10:58:05
18	won't read the whole paragraph, but at the 10:56:08	18	around 2011 or 2012. 10:58:08
19	toward the end it talks about compliance with 10:56:11	19	Q. Okay. And in terms of working 10:58:10
20	associated product-related dimensions as far 10:56:16	20	with those individuals, what was describe 10:58:12
21	as working with the regulatory and legal 10:56:19	21	for me the types of things you would interact 10:58:15
22	departments. 10:56:23	22	with them on. 10:58:18
23	Who did you work with who 10:56:23	23	A. Marketing would interact with 10:58:19
24	did the folks in the marketing department 10:56:24	24	sales on a regular basis. Sales would be 10:58:23
25	under you, as part of your team, work with in 10:56:27	25	would bring customer requests to us such as 10:58:28
	Page 99		Page 101
1	the regulatory and legal departments to 10:56:30	1	the customer wants this incentive, they want 10:58:33
2	ensure compliance as it's described in this 10:56:32	2	this pricing, here's the contract. So I 10:58:35
3	paragraph? 10:56:35	3	constantly worked with them on the contract 10:58:39
4	A. Primarily oh. 10:56:36	4	terms, incentives that the customers were 10:58:43
5	MR. O'CONNOR: Object to form. 10:56:36	5	receiving, any value that the customer got, 10:58:45
6	THE WITNESS: Primarily we 10:56:37	6	because we did the analytics in my team on 10:58:47
7	worked with Stu Kim on regulatory and 10:56:39	7	what the real net margin was for that 10:58:49
8	Don Lohman on compliance. 10:56:43	8	particular customer, those product mix or 10:58:52
9	QUESTIONS BY MR. GOTTO: 10:56:45	9	whatever was in the mix with that. And then 10:58:54
10	Q. Okay. And when you say "on 10:56:45	10	we also worked with them on forecasting. 10:58:58
11	regulatory" in this setting, what do you 10:56:48	11	Q. Okay. In terms of contract 10:59:02
12	mean? What sorts of things did you work on? 10:56:51	12	terms, pricing, et cetera, incentives and the 10:59:04
13	A. Again, I'll go back to the 10:56:53	13	like, who made the ultimate decision on 10:59:08
14	methylphenidate ER. Stu Kim was working on a 10:56:55	14	whether to offer a particular term or 10:59:13
15	strategy on some of the products, like how we 10:56:59	15	incentive to a customer? 10:59:15
16	would respond to the FDA on some of our 10:57:03	16	A. If we were in conflict, if I 10:59:17
17	filings. Methylphenidate ER, should we 10:57:05	17	was in conflict with the vice president of 10:59:20
1		18	sales, it would roll up to our president of 10:59:21
18	continue filing a paragraph IV challenge. 10:57:09	1	
18	continue filing a paragraph IV challenge. 10:57:09 Even though other people were ahead of us, 10:57:10	19	generics. 10:59:25
	Even though other people were ahead of us, 10:57:10 should we continue doing that. What value 10:57:12	19 20	generics. 10:59:25 Q. Okay. And that was? 10:59:25
19	Even though other people were ahead of us, 10:57:10		-
19 20	Even though other people were ahead of us, 10:57:10 should we continue doing that. What value 10:57:12	20	Q. Okay. And that was? 10:59:25
19 20 21	Even though other people were ahead of us, 10:57:10 should we continue doing that. What value 10:57:12 would it bring to the company if we won. And 10:57:13	20 21	Q. Okay. And that was? 10:59:25 A. Mike Gunning at one time and 10:59:26
19 20 21 22	Even though other people were ahead of us, 10:57:10 should we continue doing that. What value 10:57:12 would it bring to the company if we won. And 10:57:13 so because it's an expense, obviously, to 10:57:15 hire external lawyers to do that, so was it 10:57:18 worth it to hire them to do that. 10:57:20	20 21 22	Q. Okay. And that was? 10:59:25 A. Mike Gunning at one time and 10:59:26 then David Silver for an interim and then 10:59:29 Walt Kaczmarek. 10:59:35 Q. Do you recall that occurring 10:59:38
19 20 21 22 23	Even though other people were ahead of us, 10:57:10 should we continue doing that. What value 10:57:12 would it bring to the company if we won. And 10:57:13 so because it's an expense, obviously, to 10:57:15 hire external lawyers to do that, so was it 10:57:18	20 21 22 23	Q. Okay. And that was? 10:59:25 A. Mike Gunning at one time and 10:59:26 then David Silver for an interim and then 10:59:29 Walt Kaczmarek. 10:59:35

2 A. Yes. 10.5940 2 O. Okay. When can you recall that 10.5941 3 occurring? 10.5942 4 A. There were several instances 10.5943 5 when we would not give an incentive, and then 10.5945 6 sales would push back. And either 1 would 10.5952 7 refer to the contract and they would comply 10.5958 8 with the contract and they would comply 10.5958 10 disagreement about what we should do as far 11.00.50 10 as should we offer an incentive, then that 11.00.00 11 unuld rull up to our boxs. And I do remember 11.00.13 12 time with Jane Williams. 11.00.19 13 to secure their business away from a 11.00.21 14 ocception and by offering latt, we would 11.00.20 15 to secure their business away from a 11.00.20 16 a. It was - we were looking at a 11.00.19 17 smaller customer that wanted a price in order 11.00.20 18 to secure their business away from a 11.00.25 19 competitor, and by offering latt, we would 11.00.26 10 have to offer a really big customer that same 11.00.31 21 discount, which would devalue the entire 11.00.35 22 product line. 11.00.35 23 Q. I see. 11.00.35 24 Do you recall what the product 11.00.36 25 line was? 11.00.40 3 Q. And with whom can you recall 11.00.50 4 A. No. I just remember the 11.00.57 2 moment. 11.00.40 3 Q. Okay. Did you personally 11.00.41 4 interact with any of the national account 11.00.47 5 managers? 11.00.49 6 A. Yes, I did. 11.00.40 7 Q. And with whom can you recall what the product 11.00.51 2 Q. Okay. And what was the -what 11.00.55 3 all of them at some point. 11.00.57 3 with them on? 11.00.59 4 A. A would generally interact with 11.00.50 5 contract terms, the incentives, the customer 11.00.57 12 deserve ir incentive, Season of toing 11.00.51 13 descrut, for other product 11.00.50 14 ocception of the devalue the entire 11.00.57 15 with them on? 11.00.40 16 A. I small cell me that a customer wasnt to be part 11.00.51 16 A. I small cell me that a customer wasnt at 10.014 17 definitions of the decument of 11.00.50 18 distance the contract of the decument of the contract of the decument of the contract of				
2 2 2 2 2 2 2 3 3 3		Page 102		Page 104
3 cocurring? 10.59-42 4 A. There were several instances 10.59-43 5 when we would not give an incentive, and then 10.59-45 6 sales would push back. And either would 10.59-52 7 refer to the contract and they would comply 10.59-52 8 with the contract, or if we came to a 11-00.05 3 disagreement about what we should do as far 11.00.05 3 as should we offer an incentive, then that 11.00.09 12 would roll up to our boss. And 10 remember 11.00.15 12 that happening with a particular customer one 11.00.15 13 time with Jane Williams. 11.00.16 13 time with Jane Williams. 11.00.16 15 cocasion? 11.00.19 15 cocasion? 11.00.19 15 cocasion? 11.00.19 15 cocasion? 11.00.19 15 cocasion? 11.00.24 15 cocasion? 11.00.24 15 cocasion? 11.00.25 15 cocasion? 11.00.35 15 cocasion? 11.00.36 15 cocasion? 11.0	1		1	2 2
4 A. There were several instances 10.5943 5 when we would not give an incentive, and then 10.5946 5 sales would push back. And either I would 10.5952 7 refer to the contract and they would comply 10.5958 8 with the contract and they would comply 10.5958 8 with the contract and they would comply 10.5958 8 with the contract and they would comply 10.5958 8 with the contract, or if we came to a 11.00.01 11.00.01 10 disagreement about what we should do as far 11.00.01 11.00.16 12.00 1	2		2	-
5 when we would not give an incentive, and then 10.59±46 6 sales would push back. And either 1 would 10.59±52 7 refer to the contract and they would comply 10.59±58 8 with the contract and they would comply 10.59±58 8 with the contract, or if we came to a 11.00±0 9 disagreement about what we should do as far 11.00±0 11 would roll up to our boss. And 1 do remember 11.00±11 12 that happening with a particular customer one 11.00±13 13 time with Jane Williams. 11.00±16 14 Q. And who was what was that 11.00±16 15 occasion? 11.00±19 16 so contractive their business away from a 11.00±24 17 smaller customer that wanted a price in order 11.00±25 18 discount, which would devalue the entire 11.00±35 19 discount, which would devalue the entire 11.00±35 21 discount, which would acqual the their 11.00±35 22 product line. 11.00±35 23 Q. I see. 11.00±35 24 Do you recall what the product 11.00±36 25 line was? 11.00±40 26 a. No. I just remember the 11.00±37 27 moment. 11.00±40 28 managers? 11.00±9 29 A. A. Su, I just remember the 11.00±54 21 with the on? 11.00±59 22 with the contract and the value 11.00±54 23 q. O kay, Did you personally 11.00±40 24 managers? 11.00±9 25 market research on what theyve done, So 11.01±0 26 market research on what theyve done, So 11.01±0 27 market research on what theyve done, So 11.01±0 28 market research on what theyve done, So 11.01±0 29 market research on what theyve done, So 11.01±0 20 deserve it' or "they dont," based on doing 11.01±0 21 deserve it' or "they dont," based on doing 11.01±0 22 market research on what theyve done, So 11.01±10 24 would own to one. 11.00±17 25 they don't reach their goal." 11.01±16 26 deserve it' or "they don't," based on doing 11.01±0 27 market research on what theyve done, So 11.01±10 28 market research on what theyve done, So 11.01±10 29 market research on what theyve done, So 11.01±10 20 dese	3	•	3	
6 sales would push back. And cither I would 10:59:52 7 refer to the contract and they would comply 10:59:58 7 refer to the contract, or if we came to a 11:00:01 3 disagreement about what we should do as far 11:00:05 11:00:18 11:01:48 11:01:48 11:01:48 11:01:48 11:01:48 11:01:49 11:01:48 11:01:49 11:01:50	4		4	7 11
7 refer to the contract, and they would comply 10-05-58 8 with the contract, or if we came to a 11-00-01 9 disagreement about what we should do as far 11-00-059 10 as should we offer an incentive, then that 11-00-099 11 would roll up to our boss. And I do remember 11-00-11 12 that happening with a particular customer one 11-00-11 13 time with Jane Williams. 11-00-16 14 Q. And who waswhat was that 11-00-19 15 occasion? 11-00-19 15 occasion? 11-00-19 16 A. It was we were looking at a 11-00-19 17 smaller customer that wanted a price in order 11-00-20 18 to secure their business away from a 11-00-20 19 to secure their business away from a 11-00-20 10 to secure their business away from a 11-00-20 10 have to offer a really big incustomer that same 11-00-31 12 discount, which would devalue the entire 11-00-35 12 Q. Jee. 11-00-35 13 discount, which would devalue the entire 11-00-35 14 A. No. I just remember the 11-00-36 15 Day ou recall what the product 11-00-36 15 A. No. I just remember the 11-00-37 16 A. No. I just remember the 11-00-37 17 and interacting? 11-00-40 18 A. No. I just remember the 11-00-37 19 analogenser? 11-00-40 10 A. No. I just remember the 11-00-37 11-00-40 3 Q. Okay. Did you personally 11-00-40 18 interacting? 11-00-40 19 A. I would generally internet with 11-00-53 10 all of them at some point. 11-00-59 10 A. A. Yes. Victor would eampaign on 11-02-20 11-00-20 11-00-20 12 20 See, 11-00-30 11-00-30 3 3 3 3 3 11-00-30 3 3 3 3 11-00-30 3 3 3 3 3 11-00-30 3 3 3 3 3 11-00-30 3 3 3 3 3 11-00-30 3 3 3 3 3 11-00-30 3 3 3 3 3 12 3 4 3 3 3 3 3 13 4 3 3 3 3 3 14 4 3 3 3 3 3 15 5 3 3	5	_	5	•
8 with the contract, or if we came to a	6	_	6	Mr. Borelli had some difficulties in your 11:01:43
9 disagreement about what we should do as far 11:00:05	7	* * *	7	<u>^</u>
10	8		8	•
12 would roll up to our boss. And I do remember 11:00:14 12 that happening with a particular customer one 11:00:15 12 11:00:16 13 time with Jane Williams. 11:00:16 12:00:16 13 concasion? 11:00:19 12:00 13 concasion? 11:00:19 15 A. Yes. Victor would campaign on 11:01:51 11:01:50 1	9		9	-
22	10		10	with that. 11:01:49
11	11	•	11	QUESTIONS BY MR. GOTTO: 11:01:49
14 Q. And who was what was that 11:00:18 15 occasion? 11:00:19 15 15 15 A. It was we were looking at a 11:00:19 17 18 18 18 19 19 19 19 19	12	that happening with a particular customer one 11:00:13	12	Q. Okay. Can you recall the 11:01:50
15 occasion? 11:00:19 16 A. It was we were looking at a 11:00:19 17 smaller customer that wanted a price in order 11:00:20 18 to secure their business away from a 11:00:24 19 competitor, and by offering that, we would 11:00:26 20 have to offer a really big customer that same 11:00:31 21 discount, which would devalue the entire 11:00:35 22 product line. 11:00:35 23 Q. I see. 11:00:35 24 Do you recall what the product 11:00:36 25 line was? 11:00:36 26 line was? 11:00:36 27 moment. 11:00:40 28 moment. 11:00:40 3 Q. Okay. Did you personally 11:00:41 4 interact with any of the national account 11:00:49 5 A. Yes, I did. 11:00:49 6 A. Yes, I did. 11:00:59 10 all of them at some point. 11:00:53 10 all of them at some point. 11:00:55 11 with them on? 11:00:59 12 were the types of issues you would interact il:10:07 13 admin team would go back to the 11:00:05 14 A. A gain, it would go back to the 11:00:05 15 contract terms, the incentives, the customer oftentimes to gain 11:02:02 16 business or to give incentitives, and I would 11:02:02 18 do analytics around it because I'm a numbers 11:02:11 19 person. So I would say, no, we don't want to 11:02:13 20 do that. And he and I had business 11:02:15 22 challenges. We did not see the business the 11:02:15 23 challenges. We did not see the business the 11:02:15 24 may by our recall what the product 11:00:36 25 line was? 11:00:36 26 mement. 11:00:36 27 moment. 11:00:40 28 mement. 11:00:40 29 A. Yes, I did. 11:00:49 20 A. Yes, I did. 11:00:49 21 THE WITNESS: Victor 11:02:30 22 sometimes Victor said, okay, he he 11:02:33 23 sometimes Victor said, okay, he he 11:02:33 24 wouldn't pursue it anymore. It just 11:02:40 25 depended on the situation and how 11:02:43 26 the word of the sait and the word of the situation and how 11:02:43 27 the With them on? 11:00:59 28 A. I would generally interact with 11:00:50 29 A. I would generally interact with 11:00:50 30 A. A. I would generally interact with 11:00:50 31 with them on? 11:00:50 32 contract terms, the incentives, the custom	13	time with Jane Williams. 11:00:16	13	circumstances that gave rise to those 11:01:51
16	14	Q. And who was what was that 11:00:18	14	difficulties? 11:01:53
17	15	occasion? 11:00:19	15	A. Yes. Victor would campaign on 11:01:53
18 to secure their business away from a 11:00:24 12:0 competitor, and by offering that, we would 11:00:26 12:0 have to offer a really big customer that same 11:00:31 20 do that. And he and I had business 11:02:15 21 22 23 Q. I see. 11:00:35 24 Do you recall what the product 11:00:36 25 25 line was? 11:00:36 25 25 line was? 11:00:36 25 26 27 27 28 29 29 29 20 20 20 20 20	16	A. It was we were looking at a 11:00:19	16	behalf of the customer oftentimes to gain 11:02:02
19 competitor, and by offering that, we would 11:00:26 20 have to offer a really big customer that same 11:00:31 21 discount, which would devalue the entire 11:00:33 22 product line. 11:00:35 23 Q. I see. 11:00:35 24 Do you recall what the product 11:00:36 25 line was? 11:00:36 25 line was? 11:00:36 25 line was? 11:00:36 25 line was? 11:00:36 26 line was? 11:00:36 27 line was? 11:00:37 28 moment. 11:00:40 29 29 moment. 11:00:40 21 sometimes they escalated, and 11:02:33 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 21 sometimes they escalated, and 11:02:36 line was 11:00:40 22 sometimes victor said, okay, he he 11:02:36 line was 11:00:40 23 strongly he felt about it. 11:02:46 line was 11:00:40 24 line was	17	-	17	business or to give incentives, and I would 11:02:07
20	18	to secure their business away from a 11:00:24	18	do analytics around it because I'm a numbers 11:02:11
21 discount, which would devalue the entire 11:00:35 22 product line. 11:00:35 23 Q. I see. 11:00:35 24 Do you recall what the product 11:00:36 24 interact with any of the national account 11:00:40 3 sometimes they escalated, and 11:02:33 3 Q. Okay. Did you personally 11:00:41 3 sometimes they escalated, and 11:02:36 4 wouldn't pursue it anymore. It just 11:02:46 4 wouldn't pursue it anymore. It just 11:02:45 4 wouldn't pursue it anymore.	19	competitor, and by offering that, we would 11:00:26	19	person. So I would say, no, we don't want to 11:02:13
22 product line. 11:00:35 22 same way. 11:02:20	20	have to offer a really big customer that same 11:00:31	20	do that. And he and I had business 11:02:15
Q. I see. 11:00:35 23 Q. Okay. Do you recall how those 11:02:21	21	discount, which would devalue the entire 11:00:33	21	challenges. We did not see the business the 11:02:17
24 Do you recall what the product 11:00:36 25 line was? 11:00:36 25 mR. O'CONNOR: Object to form. 11:02:29	22	product line. 11:00:35	22	same way. 11:02:20
Page 103	23	Q. I see. 11:00:35	23	Q. Okay. Do you recall how those 11:02:21
Page 103 1 A. No. I just remember the 11:00:37 2 moment. 11:00:40 2 sometimes they escalated, and 11:02:33 3 Q. Okay. Did you personally 11:00:41 4 interact with any of the national account 11:00:47 5 managers? 11:00:49 6 A. Yes, I did. 11:00:49 7 Q. And with whom can you recall 11:00:50 8 interacting? 11:00:52 9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would come to me. 11:01:27 24 would come to me. 11:01:27 25 sometimes they escalated, and 11:02:33 26 sometimes Nive scalated, and 11:02:33 3 sometimes Victor said, okay, he he 11:02:36 4 wouldn't pursue it anymore. It just 11:02:48 4 wouldn't pursue it anymore. It just 11:02:49 4 wouldn't pursue it anymore. It just 11:02:40 4 wouldn't pursue it anymore. It just 11:02:45 4 wouldn't pursue it anymore. It just 11:02:48 6 Q. Do you recall anyone at the 11:02:45 4 would interact with anyor. It just 11:02:48 6 Q. Do you recall anyone at the 11:02:48 8 Q. Do you recal anyone at the 11:02:48 8 Q. Do you recal anyone at t	24	Do you recall what the product 11:00:36	24	issues were resolved from time to time? 11:02:24
1 A. No. I just remember the 11:00:37 2 moment. 11:00:40 3 Q. Okay. Did you personally 11:00:41 4 interact with any of the national account 11:00:47 5 managers? 11:00:49 6 A. Yes, I did. 11:00:49 7 Q. And with whom can you recall 11:00:50 8 interacting? 11:00:52 9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:59 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:03 15 contract terms, the incentives, the customer 11:01:07 16 carned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:17 20 And so I would appen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 21 deserve it" or "they don't," based on doing 11:01:24 24 would come to me. 11:01:27 21 distance interact with her very much, if at all? 11:03:17 22 market research on what they've done. So 11:01:24 24 would come to me. 11:01:27 24 done interact with any of the national account 11:00:41 25 sometimes they escalated, and 11:02:33 26 sometimes they escalated, and 11:02:36 4 interact with any of the national account 11:02:40 4 wouldn't pursue it anymore. It just 11:02:40 4 wouldn't pursue it anymore. It just 11:02:40 4 wouldn't pursue it anymore. It just 11:02:40 5 depended on the situation and how 11:02:43 5 strongly he felt about it. 11:02:45 6 Q. Do you recall anyone at the 11:02:45 6 Q. Do you recall anyone at the 11:02:45 11 the situation and how 11:02:45 11 the situation and how 11:02:45 12 depended on the situation and how 11:02:45 12 (Q. Do you recall anyone at the 11:02:45 11 the situation and how 11:02:45 12 deferted that Mr. Borelli would say 11:02:50 11:02:54 12 deferted that Mr. Borelli would as a sale? 11:02:59 13 THE WITNESS: I don't recall 11:02:59 14 that. 11:03:03 15 QUESTIONS BY MR. GOTTO: 11:03:03 16 deserve it" or "they don't," based o	25	line was? 11:00:36	25	MR. O'CONNOR: Object to form. 11:02:29
1		Page 103		Page 105
2 moment. 11:00:40 2 sometimes they escalated, and 11:02:33 3 Q. Okay. Did you personally 11:00:47 4 interact with any of the national account 11:00:47 5 managers? 11:00:49 5 depended on the situation and how 11:02:43 6 A. Yes, I did. 11:00:49 6 strongly he felt about it. 11:02:45 7 Q. And with whom can you recall 11:00:50 8 interacting? 11:00:52 9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 12 with them on? 11:00:59 13 with them on? 11:00:59 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:10 18 customer wants this payment and it's not 11:01:10 19 they didn't reach their goal." 11:01:17 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:24 2 would come to me. 11:01:27 24 sometimes they escalated, and 11:02:36 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 7 QUESTIONS BY MR. GOTTO: 11:02:46 8 Q. Do you recall anyone at the 11:02:46 2 wouldn't pursue it anymore. It just 11:02:40 4 strongly he felt about it. 11:02:45 11:02:45 2 QUESTIONS BY MR. GOTTO: 11:02:45 2 Into the situation and how 11:02:43 strongly he felt about it. 11:02:45 2 PUESTIONS BY MR. GOTTO: 11:03:03 2 PUESTIONS BY MR. GOTTO: 11:03:03 2 PUESTIONS BY MR. GOTTO: 11:03:03 PUESTIONS BY MR. GOTTO: 11:03:14 PUESTIONS BY MR. GOTTO: 11:03:15 PUESTIONS BY MR. G	1	_	1	
3		71. 110. I just remember the 11.00.57	T	THE WITNESS: Victor 11:02:30
wouldn't pursue it anymore. It just 11:02:40	2			
5 managers? 11:00:49 6 A. Yes, I did. 11:00:49 7 Q. And with whom can you recall 11:00:50 8 interacting? 11:00:52 9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would happen on occasion. The NAMs 11:01:27 24 would come to me. 11:01:27 25 depended on the situation and how 11:02:43 26 strongly he felt about it. 11:02:45 27 QUESTIONS BY MR. GOTTO: 11:02:46 28 oronpany ever communicating to you anything to 11:02:59 29 the effect that Mr. Borelli would say 11:02:54 20 anything to make a sale? 11:02:58 20 MR. O'CONNOR: Object to form. 11:02:59 21 that WiTNESS: I don't recall 11:03:03 22 deserve it" or "they don't," based on doing 11:01:20 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 24 occasional how it. 11:02:45 25 depended on the situation and how 11:02:45 26 strongly he felt about it. 11:02:46 27 QUESTIONS BY MR. GOTTO: 11:02:46 28 don don't in:02:46 29 company ever communicating to you anything to 11:02:59 20 defect that Mr. Borelli anyone at the 11:02:48 20 don't recall anyone at the 11:02:46 21:02:48 22 don don't in:02:45 23 don't recall anyone at the 11:02:48 24 unything to make a sale? 11:02:59 24 anything to make a sale? 11:02:59 25 danything to make a sale? 11:02:59 26 don't recall anyone at the 11:02:49 27 don't recall anyone at the 11:02:49 28 don't anything to make a sale? 11:02:59 29 don't recall anyone at the 11:02:49 20 don't precall any		moment. 11:00:40	2	sometimes they escalated, and 11:02:33
6 A. Yes, I did. 11:00:49 7 Q. And with whom can you recall 11:00:50 8 interacting? 11:00:52 9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:27 23 that would come to me. 11:01:27 24 would come to me. 11:01:27 25 interacting? 11:00:59 26 strongly he felt about it. 11:02:45 27 QUESTIONS BY MR. GOTTO: 11:02:46 28 Q. Do you recall anyone at the 11:02:48 29 A. I would say interact with 11:02:48 29 company ever communicating to you anything to 11:02:48 20 Loc you recall anyone at the 11:02:48 20 Do you recall anyone at the 11:02:48 21 defect that Mr. Borelli would say 11:02:59 21 the effect that Mr. Borelli would say 11:02:59 22 MR. O'CONNOR: Object to form. 11:02:59 23 THE WITNESS: I don't recall 11:03:03 24 that. 11:03:03 25 QUESTIONS BY MR. GOTTO: 11:03:03 26 Stowart from time to time? 11:03:04 27 What she did. 11:03:15 28 WR. GOTTO: 11:03:15 29 UESTIONS BY MR. GOTTO: 11:03:15 20 QUESTIONS BY MR. GOTTO: 11:03:15 21 deserve it" or "they don't," based on doing 11:01:20 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:16 23 Q. Okay. Then I guess you didn't 11:03:16 24 interact with her very much, if at all? 11:03:17	3	moment. 11:00:40 Q. Okay. Did you personally 11:00:41	2	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36
7 Q. And with whom can you recall 11:00:50 7 QUESTIONS BY MR. GOTTO: 11:02:46 8 interacting? 11:00:52 8 Q. Do you recall anyone at the 11:02:48 9 A. I would generally interact with 11:00:53 9 company ever communicating to you anything to 11:02:50 10 all of them at some point. 11:00:54 10 the effect that Mr. Borelli would say 11:02:58 11 Q. Okay. And what was the what 11:00:57 12 MR. O'CONNOR: Object to form. 11:02:58 12 were the types of issues you would interact 11:00:57 12 MR. O'CONNOR: Object to form. 11:02:59 13 with them on? 11:00:59 13 THE WITNESS: I don't recall 11:03:01 14 A. Again, it would go back to the 11:01:00 14 that. 11:03:03 15 contract terms, the incentives, the customer 11:01:03 15 Q. Okay. Did you interact with 11:03:03 16 earned their incentive. Because the contract 11:01:01 17 Ms. Stewart from time to time? 11:03:03	3 4	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47	2 3 4	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40
8 interacting? 11:00:52 9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:07 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 they didn't reach their goal." 11:01:16 19 And so I would say, "yes, they 11:01:17 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would come to me. 11:01:27 24 would come to me. 11:01:27 25 company ever communicating to you anything to 11:02:59 26 company ever communicating to you anything to 11:02:50 27 the effect that Mr. Borelli would say 11:02:54 28 dompany ever communicating to you anything to 11:02:50 29 company ever communicating to you anything to 11:02:50 20 the effect that Mr. Borelli would say 11:02:54 21 the effect that Mr. Borelli would say 11:02:54 21 the effect that Mr. Borelli would say 11:02:54 21 the effect that Mr. Borelli would say 11:02:54 22 market research on what they interact with 11:00:57 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 25 company ever communicating to you anything to 11:02:50 26 company ever communicating to you anything to 11:02:54 27 anything to make a sale? 11:02:58 28 dompany ever communicating to you anything to 11:02:54 30 contract tens, the incentives, the customer anything to file effect that Mr. Borelli would say 11:02:54 31:00:59 31:00:59 31:00:59 32 dompany ever communicating to you anything to 11:02:59 31:00:59 31:00:59 31:00:59 32 dompany ever communicating to you anything to 11:02:59 31:00:59 31:00:59 31:00:59 32 dompany ever communicating to you anything to 11:02:59 31:00:59 31:00:59 32 dompany ever communicating to you anything to 11:02:59 31:00:59 31:00:59 32 do	3 4 5	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49	2 3 4 5	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43
9 A. I would generally interact with 11:00:53 10 all of them at some point. 11:00:54 11 Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:17 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would come to me. 11:01:27 24 would come to me. 11:01:27 25 company ever communicating to you anything to 11:02:50 10 the effect that Mr. Borelli would say 11:02:54 11 anything to make a sale? 11:02:58 12 MR. O'CONNOR: Object to form. 11:02:59 13 THE WITNESS: I don't recall 11:03:01 14 that. 11:03:03 15 QUESTIONS BY MR. GOTTO: 11:03:03 16 Q. Okay. Did you interact with 11:03:03 17 Ms. Stewart from time to time? 11:03:04 18 MR. O'CONNOR: Object to form. 11:03:11 19 they didn't reach their goal." 11:01:16 19 THE WITNESS: I know the name, 11:03:11 20 but I don't remember who she is or 11:03:14 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49	2 3 4 5	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45
all of them at some point. 11:00:54 1 Q. Okay. And what was the what 11:00:55 1 anything to make a sale? 11:02:58 1 were the types of issues you would interact 11:00:57 1 anything to make a sale? 11:02:59 1 MR. O'CONNOR: Object to form. 11:02:59 1 THE WITNESS: I don't recall 11:03:01 1 that. 11:03:03 1 that. 11:03:03 1 Output Description of the problem	3 4 5 6 7	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50	2 3 4 5 6 7	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46
Q. Okay. And what was the what 11:00:55 12 were the types of issues you would interact 11:00:57 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 10 And so I would say, "yes, they 11:01:17 11 deserve it" or "they don't," based on doing 11:01:20 21 market research on what they've done. So 11:01:21 22 would come to me. 11:01:27 23 that would happen on occasion. The NAMs 11:01:27 24 would come to me. 11:03:17 25 MR. O'CONNOR: Object to form. 11:02:59 16 MR. O'CONNOR: Object to form. 11:03:03 17 MS. Stewart from time to time? 11:03:04 18 MR. O'CONNOR: Object to form. 11:03:11 29 MR. O'CONNOR: Object to form. 11:03:11 20 MR. O'CONNOR: Object to form. 11:03:03 21 What she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 Q. Okay. Then I guess you didn't 11:03:16 24 would come to me. 11:01:27 25 Interact with her very much, if at all? 11:03:17	3 4 5 6 7 8	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52	2 3 4 5 6 7 8	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48
were the types of issues you would interact 11:00:57 12 MR. O'CONNOR: Object to form. 11:02:59 13 with them on? 11:00:59 14 A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would happen on occasion. The NAMs 11:01:27 24 would come to me. 11:03:17 25 MR. O'CONNOR: Object to form. 11:03:03 26 Q. Okay. Did you interact with 11:03:03 27 Ms. Stewart from time to time? 11:03:04 28 MR. O'CONNOR: Object to form. 11:03:11 29 Dut I don't remember who she is or 11:03:14 20 What she did. 11:03:15 21 What she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 Q. Okay. Then I guess you didn't 11:03:16 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8	Moment. 11:00:40 Q. Okay. Did you personally 11:00:41 Interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 Interacting? 11:00:52 A. I would generally interact with 11:00:53	2 3 4 5 6 7 8	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50
with them on? 11:00:59 13 THE WITNESS: I don't recall 11:03:01 14 A. Again, it would go back to the 11:01:00 14 that. 11:03:03 15 contract terms, the incentives, the customer 11:01:03 15 QUESTIONS BY MR. GOTTO: 11:03:03 16 earned their incentive. Because the contract 11:01:07 16 Q. Okay. Did you interact with 11:03:03 17 admin team would come to me and say, "This 11:01:10 17 Ms. Stewart from time to time? 11:03:04 18 customer wants this payment and it's not 11:01:12 18 MR. O'CONNOR: Object to form. 11:03:11 19 they didn't reach their goal." 11:01:16 19 THE WITNESS: I know the name, 11:03:11 19 they didn't reach their goal." 11:01:17 20 but I don't remember who she is or 11:03:14 11:03:15 11:03:15 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54	2 3 4 5 6 7 8 9	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54
A. Again, it would go back to the 11:01:00 15 contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would happen on occasion. The NAMs 11:01:27 24 would come to me. 11:01:27 25 QUESTIONS BY MR. GOTTO: 11:03:03 16 Q. Okay. Did you interact with 11:03:03 17 Ms. Stewart from time to time? 11:03:04 18 MR. O'CONNOR: Object to form. 11:03:11 20 but I don't remember who she is or 11:03:14 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 QUESTIONS BY MR. GOTTO: 11:03:16 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55	2 3 4 5 6 7 8 9 10	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58
contract terms, the incentives, the customer 11:01:03 16 earned their incentive. Because the contract 11:01:07 17 admin team would come to me and say, "This 11:01:10 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would happen on occasion. The NAMs 11:01:27 24 would come to me. 11:01:27 25 QUESTIONS BY MR. GOTTO: 11:03:03 16 Q. Okay. Did you interact with 11:03:03 17 Ms. Stewart from time to time? 11:03:04 18 MR. O'CONNOR: Object to form. 11:03:11 20 but I don't remember who she is or 11:03:14 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 QUESTIONS BY MR. GOTTO: 11:03:16 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57	2 3 4 5 6 7 8 9 10 11	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59
earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 16 Q. Okay. Did you interact with 11:03:03 17 Ms. Stewart from time to time? 11:03:04 18 customer wants this payment and it's not 11:01:12 19 they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 16 Q. Okay. Did you interact with 11:03:03 17 Ms. Stewart from time to time? 11:03:04 18 MR. O'CONNOR: Object to form. 11:03:11 29 THE WITNESS: I know the name, 11:03:11 20 but I don't remember who she is or 11:03:14 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 that would happen on occasion. The NAMs 11:01:24 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59	2 3 4 5 6 7 8 9 10 11 12 13	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01
admin team would come to me and say, "This 11:01:10 17 Ms. Stewart from time to time? 11:03:04 18 customer wants this payment and it's not 11:01:12 18 MR. O'CONNOR: Object to form. 11:03:11 19 they didn't reach their goal." 11:01:16 19 THE WITNESS: I know the name, 11:03:11 20 And so I would say, "yes, they 11:01:17 20 but I don't remember who she is or 11:03:14 21 deserve it" or "they don't," based on doing 11:01:20 21 what she did. 11:03:15 22 market research on what they've done. So 11:01:21 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 that would happen on occasion. The NAMs 11:01:24 23 Q. Okay. Then I guess you didn't 11:03:16 24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00	2 3 4 5 6 7 8 9 10 11 12 13	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03
customer wants this payment and it's not 11:01:12 18 MR. O'CONNOR: Object to form. 11:03:11 19 they didn't reach their goal." 11:01:16 19 THE WITNESS: I know the name, 11:03:11 20 And so I would say, "yes, they 11:01:17 20 but I don't remember who she is or 11:03:14 21 deserve it" or "they don't," based on doing 11:01:20 21 what she did. 11:03:15 22 market research on what they've done. So 11:01:21 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14	Moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03	2 3 4 5 6 7 8 9 10 11 12 13 14	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03
they didn't reach their goal." 11:01:16 20 And so I would say, "yes, they 11:01:17 21 deserve it" or "they don't," based on doing 11:01:20 22 market research on what they've done. So 11:01:21 23 that would happen on occasion. The NAMs 11:01:24 24 would come to me. 19 THE WITNESS: I know the name, 11:03:11 20 but I don't remember who she is or 11:03:14 21 what she did. 11:03:15 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 Q. Okay. Then I guess you didn't 11:03:16 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:03 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07	2 3 4 5 6 7 8 9 10 11 12 13 14 15	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Q. Okay. Did you interact with 11:03:03
And so I would say, "yes, they 11:01:17 20 but I don't remember who she is or 11:03:14 21 deserve it" or "they don't," based on doing 11:01:20 21 what she did. 11:03:15 22 market research on what they've done. So 11:01:21 22 QUESTIONS BY MR. GOTTO: 11:03:15 23 that would happen on occasion. The NAMs 11:01:24 23 Q. Okay. Then I guess you didn't 11:03:16 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14 15 16	moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Q. Okay. Did you interact with 11:03:03 Ms. Stewart from time to time? 11:03:04
deserve it" or "they don't," based on doing 11:01:20 21 what she did. 11:03:15 market research on what they've done. So 11:01:21 22 QUESTIONS BY MR. GOTTO: 11:03:15 that would happen on occasion. The NAMs 11:01:24 23 Q. Okay. Then I guess you didn't 11:03:16 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 customer wants this payment and it's not 11:01:12	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Q. Okay. Did you interact with 11:03:03 Ms. Stewart from time to time? 11:03:01
market research on what they've done. So 11:01:21 22 QUESTIONS BY MR. GOTTO: 11:03:15 that would happen on occasion. The NAMs 11:01:24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:03 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 customer wants this payment and it's not 11:01:12 they didn't reach their goal." 11:01:16	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Q. Okay. Did you interact with 11:03:03 Ms. Stewart from time to time? 11:03:04 MR. O'CONNOR: Object to form. 11:03:11 THE WITNESS: I know the name, 11:03:11
that would happen on occasion. The NAMs 11:01:24 23 Q. Okay. Then I guess you didn't 11:03:16 24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	moment. 11:00:40 Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 customer wants this payment and it's not 11:01:12 they didn't reach their goal." 11:01:16 And so I would say, "yes, they 11:01:17	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Q. Okay. Did you interact with 11:03:03 Ms. Stewart from time to time? 11:03:01 THE WITNESS: I know the name, 11:03:11 but I don't remember who she is or 11:03:14
24 would come to me. 11:01:27 24 interact with her very much, if at all? 11:03:17	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 customer wants this payment and it's not 11:01:12 they didn't reach their goal." 11:01:16 And so I would say, "yes, they 11:01:17 deserve it" or "they don't," based on doing 11:01:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Q. Okay. Did you interact with 11:03:03 Ms. Stewart from time to time? 11:03:01 THE WITNESS: I know the name, 11:03:11 but I don't remember who she is or 11:03:14 what she did. 11:03:15
	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Moment. Q. Okay. Did you personally 11:00:41 interact with any of the national account 11:00:47 managers? 11:00:49 A. Yes, I did. 11:00:49 Q. And with whom can you recall 11:00:50 interacting? 11:00:52 A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 customer wants this payment and it's not 11:01:12 they didn't reach their goal." 11:01:16 And so I would say, "yes, they 11:01:17 deserve it" or "they don't," based on doing 11:01:20 market research on what they've done. So 11:01:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Ms. Stewart from time to time? 11:03:04 MR. O'CONNOR: Object to form. 11:03:11 THE WITNESS: I know the name, 11:03:11 but I don't remember who she is or 11:03:14 what she did. 11:03:15 QUESTIONS BY MR. GOTTO: 11:03:15
	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Moment. Q. Okay. Did you personally interact with any of the national account managers? A. Yes, I did. Q. And with whom can you recall interacting? A. I would generally interact with 11:00:50 interacting? A. I would generally interact with 11:00:53 all of them at some point. 11:00:54 Q. Okay. And what was the what 11:00:55 were the types of issues you would interact 11:00:57 with them on? 11:00:59 A. Again, it would go back to the 11:01:00 contract terms, the incentives, the customer 11:01:03 earned their incentive. Because the contract 11:01:07 admin team would come to me and say, "This 11:01:10 customer wants this payment and it's not 11:01:12 they didn't reach their goal." 11:01:16 And so I would say, "yes, they 11:01:17 deserve it" or "they don't," based on doing 11:01:20 market research on what they've done. So 11:01:21 that would happen on occasion. The NAMs 11:01:24	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Ms. Stewart from time to time? 11:03:04 MR. O'CONNOR: Object to form. 11:03:11 THE WITNESS: I know the name, 11:03:11 but I don't remember who she is or 11:03:14 what she did. 11:03:15 QUESTIONS BY MR. GOTTO: 11:03:15 Q. Okay. Then I guess you didn't 11:03:16
	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Moment. Q. Okay. Did you personally I1:00:41 interact with any of the national account I1:00:47 managers? I1:00:49 A. Yes, I did. I1:00:49 Q. And with whom can you recall I1:00:50 interacting? I1:00:52 A. I would generally interact with I1:00:53 all of them at some point. I1:00:54 Q. Okay. And what was the what I1:00:55 were the types of issues you would interact I1:00:57 with them on? I1:00:59 A. Again, it would go back to the I1:01:00 contract terms, the incentives, the customer I1:01:03 earned their incentive. Because the contract I1:01:07 admin team would come to me and say, "This I1:01:10 customer wants this payment and it's not I1:01:12 they didn't reach their goal." I1:01:16 And so I would say, "yes, they I1:01:17 deserve it" or "they don't," based on doing I1:01:20 market research on what they've done. So I1:01:21 that would come to me. I1:01:27	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	sometimes they escalated, and 11:02:33 sometimes Victor said, okay, he he 11:02:36 wouldn't pursue it anymore. It just 11:02:40 depended on the situation and how 11:02:43 strongly he felt about it. 11:02:45 QUESTIONS BY MR. GOTTO: 11:02:46 Q. Do you recall anyone at the 11:02:48 company ever communicating to you anything to 11:02:50 the effect that Mr. Borelli would say 11:02:54 anything to make a sale? 11:02:58 MR. O'CONNOR: Object to form. 11:02:59 THE WITNESS: I don't recall 11:03:01 that. 11:03:03 QUESTIONS BY MR. GOTTO: 11:03:03 Ms. Stewart from time to time? 11:03:04 MR. O'CONNOR: Object to form. 11:03:11 THE WITNESS: I know the name, 11:03:11 but I don't remember who she is or 11:03:14 what she did. 11:03:15 QUESTIONS BY MR. GOTTO: 11:03:15 Q. Okay. Then I guess you didn't 11:03:16 interact with her very much, if at all? 11:03:17

		т —	
	Page 106		Page 108
1	Q. Okay. How about Mr. Rausch? 11:03:21	1	Mallinckrodt so this this chart that 11:06:07
2	A. Jim? 11:03:23	2	we're looking at from January 2010, this is 11:06:08
3	Q. Uh-huh. 11:03:23	3	about six months after you joined the 11:06:11
4	A. Rausch? Yes. 11:03:24	4	company, correct? 11:06:13
5	Q. Okay. In what context did you 11:03:26	5	A. Right. 11:06:13
6	interact with him? 11:03:29	6	Q. And so when you joined the 11:06:14
7	A. Occasionally orders would be 11:03:29	7	company, were you aware of the existence of a 11:06:16
8	held up and because we were allocating, or 11:03:31	8	suspicious order monitoring program at the 11:06:23
9	a customer issue might come up, and they 11:03:34	9	company at that time? 11:06:25
10	would contact my department. 11:03:36	10	MR. O'CONNOR: Object to form. 11:06:26
11	Q. Okay. 11:03:38	11	THE WITNESS: I don't 11:06:27
12	A. Or he's in customer service, so 11:03:41	12	understand what you mean was I aware 11:06:29
13	the customer service team would contact my 11:03:44	13	of a suspicious order monitoring 11:06:31
14	department or me personally. 11:03:47	14	program. 11:06:32
15	(Mallinckrodt-Collier Exhibit 4 11:04:12	15	Oh, in 2010, did I know that 11:06:34
16	marked for identification.) 11:04:12	16	they had one? 11:06:35 QUESTIONS BY MR. GOTTO: 11:06:36
17	QUESTIONS BY MR. GOTTO: 11:04:12 Q. Okay. Let's mark another 11:04:12	17	
18		18	
19	document here. 11:04:13 We've marked as Exhibit 4 a 11:04:14	19	into early 2010. 11:06:39 A. Yes, I was aware that there was 11:06:41
20	document bearing Bates MNK-T1_0004887323, and 11:04:30	20	A. Yes, I was aware that there was 11:06:41 a compliance team. 11:06:42
22	it's a two-page document. One page is blank, 11:04:40	22	•
23	indicating that it was produced in native 11:04:44	23	Q. Okay. And who was involved in 11:06:45 the compliance team? 11:06:47
24	format. The second page is another 11:04:45	24	A. I remember Don Harper I 11:06:47
25	organizational chart relating to specialty 11:04:50	25	mean, Don Lohman, Karen Harper, and then 11:06:53
	organizational chart relating to specially 1110 1150	23	inean, Bon Lonnian, Raten Harper, and then 11.00.55
	Page 107		Page 109
1	generic marketing goals and responsibilities 11:04:59	1	those were the only two I interacted with. 11:06:54
2	as of 1/12/2010. 11:04:55	2	Q. Okay. So you knew there was a 11:06:57
3	Take a moment to look at this 11:05:00	3	compliance team. 11:06:59
4	chart and tell me if that if this chart is 11:05:02	4	Did you 11:07:00
5	consistent with your recollection of those 11:05:05		
1	•	5	A. Right. 11:07:01
6	roles and responsibilities at this time. 11:05:07	6	Q. Did you have any understanding 11:07:02
6 7	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09		Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03
	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10	6	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07
7 8 9	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17	6	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09
7 8	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19	6 7 8	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11
7 8 9 10 11	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22	6 7 8 9	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15
7 8 9 10 11	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22	6 7 8 9 10 11 12	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17
7 8 9 10 11 12 13	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22	6 7 8 9 10 11 12	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20
7 8 9 10 11 12 13	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25	6 7 8 9 10 11 12 13	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22
7 8 9 10 11 12 13 14 15	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25	6 7 8 9 10 11 12 13 14	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23
7 8 9 10 11 12 13 14 15	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26	6 7 8 9 10 11 12 13 14 15	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29
7 8 9 10 11 12 13 14 15 16	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28	6 7 8 9 10 11 12 13 14 15 16	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33
7 8 9 10 11 12 13 14 15 16 17	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29	6 7 8 9 10 11 12 13 14 15 16 17	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35
7 8 9 10 11 12 13 14 15 16 17 18	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29 various products listed under each of the 11:05:37	6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37
7 8 9 10 11 12 13 14 15 16 17 18 19	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29 various products listed under each of the 11:05:40	6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37 more than their usual amount; did we know 11:07:39
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:37 product managers, and to the best of your 11:05:40 recollection, is that allocation of products 11:05:45	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37 more than their usual amount; did we know 11:07:39 why. Did we just win a contract award where 11:07:43
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	roles and responsibilities at this time. A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29 various products listed under each of the 11:05:37 product managers, and to the best of your 11:05:40 recollection, is that allocation of products 11:05:49	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37 more than their usual amount; did we know 11:07:39 why. Did we just win a contract award where 11:07:43 we took the business from a competitor. Is 11:07:46
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	roles and responsibilities at this time. A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29 various products listed under each of the 11:05:40 recollection, is that allocation of products 11:05:45 among those product managers as of January 11:05:49 2010 accurate? 11:05:51	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37 more than their usual amount; did we know 11:07:39 why. Did we just win a contract award where 11:07:43 we took the business from a competitor. Is 11:07:46 the customer buying an inventory for the end 11:07:49
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	roles and responsibilities at this time. 11:05:07 A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29 various products listed under each of the 11:05:37 product managers, and to the best of your 11:05:40 recollection, is that allocation of products 11:05:45 among those product managers as of January 11:05:49 2010 accurate? 11:05:51 A. Yes. 11:05:52	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37 more than their usual amount; did we know 11:07:39 why. Did we just win a contract award where 11:07:46 the customer buying an inventory for the end 11:07:49 of the year. Sometimes they'd do that for 11:07:52
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	roles and responsibilities at this time. A. Yes. 11:05:09 Q. Okay. And I think you've 11:05:10 already indicated Lisa Lundergan, that's 11:05:17 she changed her name to Cardetti at some 11:05:19 point? 11:05:22 A. Correct. 11:05:22 Q. Okay. And at this point she 11:05:22 was an associate. 11:05:25 Did she report to 11:05:25 Ms. Muhlenkamp at this point? 11:05:26 A. Yes. 11:05:28 Q. Okay. And so for there are 11:05:29 various products listed under each of the 11:05:40 recollection, is that allocation of products 11:05:45 among those product managers as of January 11:05:49 2010 accurate? 11:05:51	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Did you have any understanding 11:07:02 of how the suspicious order monitoring 11:07:03 process worked at Mallinckrodt at that time? 11:07:07 A. No. I just knew they would 11:07:09 call on occasion about high orders. 11:07:11 Q. Okay. Were you familiar with 11:07:15 the term "peculiar order" at that time? 11:07:17 A. I don't remember them calling 11:07:20 it that. 11:07:22 Q. Okay. When you say they would 11:07:23 call from time to time with high orders, what 11:07:29 do you recall them calling and asking about? 11:07:33 A. On occasion they would call my 11:07:35 department and say that a customer ordered 11:07:37 more than their usual amount; did we know 11:07:39 why. Did we just win a contract award where 11:07:43 we took the business from a competitor. Is 11:07:46 the customer buying an inventory for the end 11:07:49

	Page 110		Page 112
1	kinds of questions. 11:07:58	1	help us find out more information." 11:09:41
2	Q. Okay. And would they ask that 11:07:59	2	QUESTIONS BY MR. GOTTO: 11:09:43
3	directly of you or would they ask that of the 11:08:01	3	Q. Okay. So apart from just the 11:09:43
4	product managers? 11:08:04	4	size of the order, what other sorts of issues 11:09:45
5	A. They would sometimes ask it of 11:08:06	5	can you recall them flagging an order about? 11:09:47
6	the product managers, and then if the product 11:08:08	6	A. Frequency. The customer 11:09:50
7	managers didn't know, they'd ask me, and I'd 11:08:10	7	ordered more than most of the customers 11:09:52
8	work with the NAMs to find out what was going 11:08:12	8	order once a week, or even some of the small 11:09:55
9	on. 11:08:15	9	guys once a month, and they might have 11:09:59
10	Q. Okay. Can you remember 11:08:15	10	ordered more often than usual and did we know 11:10:00
11	specific examples where you worked with one 11:08:15	11	why. 11:10:03
12	or more of the national account managers 11:08:18	12	Q. Okay. And when you would 11:10:03
13	responding to an inquiry you had received in 11:08:20	13	receive such an inquiry, would it come 11:10:06
14	this regard? 11:08:22	14	through an e-mail typically? 11:10:09
15	A. Not a specific example, no. 11:08:22	15	A. Yes. 11:10:10
16	Q. Okay. But you recall that it 11:08:24	16	Q. Okay. So to the extent you 11:10:11
17	did happen? 11:08:25	17	received you personally received any such 11:10:14
18	A. Yes. 11:08:26	18	inquiries, they would be reflected in to 11:10:16
19	Q. And do you recall the 11:08:26	19	the best of your knowledge, they'd be 11:10:18
20	approximate frequency with which that would 11:08:28	20	reflected in your e-mails, correct? 11:10:20
21	happen? 11:08:30	21	MR. O'CONNOR: Object to form. 11:10:21
22	A. I don't remember it being very 11:08:30	22	THE WITNESS: Yes. There may 11:10:21
23	frequent. It did happen. I don't remember 11:08:34	23	have been phone calls, but I don't 11:10:25
24	the frequency. 11:08:36	24	recall, you know, if it was phone call 11:10:28
25	Q. Okay. Do you recall any of the 11:08:37	25	or e-mail only. 11:10:29
	B 111		D 110
	Page 111		Page 113
1	feedback you received from the national 11:08:41	1	QUESTIONS BY MR. GOTTO: 11:10:30
2	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43	2	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30
2 3	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43 involved in responding to an inquiry in this 11:08:48	2	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31
2 3 4	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49	2 3 4	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33
2 3 4 5	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43 involved in responding to an inquiry in this 11:08:48 regard? 11:08:49 A. No. The national account 11:08:50	2 3 4 5	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36
2 3 4 5 6	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43 involved in responding to an inquiry in this 11:08:48 regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55	2 3 4 5 6	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37
2 3 4 5 6 7	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43 involved in responding to an inquiry in this 11:08:48 regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57	2 3 4 5 6 7	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37
2 3 4 5 6 7 8	feedback you received from the national 11:08:41 account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00	2 3 4 5 6 7 8	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39
2 3 4 5 6 7 8	feedback you received from the national account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03	2 3 4 5 6 7 8	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41
2 3 4 5 6 7 8 9	feedback you received from the national account managers when you were personally 11:08:43 involved in responding to an inquiry in this 11:08:48 regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04	2 3 4 5 6 7 8 9	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41
2 3 4 5 6 7 8 9 10	feedback you received from the national account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07	2 3 4 5 6 7 8 9 10	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44
2 3 4 5 6 7 8 9 10 11	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09	2 3 4 5 6 7 8 9 10 11	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:0:50
2 3 4 5 6 7 8 9 10 11 12 13	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10	2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54
2 3 4 5 6 7 8 9 10 11 12 13	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:14	2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56
2 3 4 5 6 7 8 9 10 11 12 13 14 15	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:15	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59
2 3 4 5 6 7 8 9 10 11 12 13 14 15	feedback you received from the national account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:14 A. Karen Harper's office. 11:09:15 Q. Okay. And am I understanding 11:09:17	2 3 4 5 6 7 8 9 10 11 12 13 14 15	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03
2 3 4 5 6 7 8 9 10 11 12 13 14 15	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23	2 3 4 5 6 7 8 9 10 11 12 13 14 15	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:06 A. For example, if you had a small 11:11:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	feedback you received from the national account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:14 A. Karen Harper's office. 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:26 the reasons for this increased size in order? 11:09:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:06 A. For example, if you had a small 11:11:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:30 MR. O'CONNOR: Object to form. 11:09:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:07 distributor that ordered 30 percent of the 11:11:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	feedback you received from the national account managers when you were personally 11:08:43 involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:14 A. Karen Harper's office. 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:26 the reasons for this increased size in order? 11:09:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:06 A. For example, if you had a small 11:11:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:14 A. Karen Harper's office. 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:30 MR. O'CONNOR: Object to form. 11:09:33 THE WITNESS: It could be for 11:09:33 any number of reasons that they 11:09:37	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. And when you inquired 11:10:30 and so when you personally received an 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:07 distributor that ordered 30 percent of the 11:11:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:30 MR. O'CONNOR: Object to form. 11:09:33 THE WITNESS: It could be for 11:09:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:07 distributor that ordered 30 percent of the 11:11:10 total market value, that's a concern. 11:11:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	feedback you received from the national account managers when you were personally involved in responding to an inquiry in this regard? 11:08:49 A. No. The national account 11:08:50 managers obviously wouldn't be happy if an 11:08:55 order was cut off, but I don't even remember 11:08:57 the outcomes because I was not involved in 11:09:00 the decision about whether I would just 11:09:03 report the information, and I was not 11:09:04 responsible for the outcome of shipping or 11:09:07 not shipping. 11:09:09 Q. Okay. Do you recall from whom 11:09:10 the inquiry would come? 11:09:14 A. Karen Harper's office. 11:09:15 Q. Okay. And am I understanding 11:09:17 you correctly that generally the inquiry 11:09:20 would be along the lines that we've received 11:09:23 a large order and we're trying to ascertain 11:09:30 MR. O'CONNOR: Object to form. 11:09:33 THE WITNESS: It could be for 11:09:33 any number of reasons that they 11:09:37	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. GOTTO: 11:10:30 Q. Okay. And when you inquired 11:10:31 inquiry, you indicated you would inquire of 11:10:33 the national account managers, correct? 11:10:36 A. Yes. 11:10:37 Q. Did you take any other steps 11:10:37 other than inquiring of the national account 11:10:39 managers? 11:10:41 A. Yes. We would look at the 11:10:41 customer historical volume on overall and 11:10:44 find out if they did indeed award us a new 11:10:50 product, if we got a new contract with them. 11:10:54 If they were in fair share for the market, if 11:10:56 they were oversized share for the market, if 11:10:59 that would be a concern. 11:11:02 Q. What does that mean, "fair 11:11:03 share" versus "oversized share"? 11:11:06 A. For example, if you had a small 11:11:10 total market value, that's a concern. 11:11:11 Q. Okay. And when you responded 11:11:13 back to Ms. Harper's department to respond to 11:11:23

	D 114	_	D 116
	Page 114		Page 116
1	MR. O'CONNOR: Object to form. 11:11:29	1	you recall other circumstances in which you 11:14:04
2	THE WITNESS: Possibly. 11:11:29	2	were aware that Ms. Muhlenkamp was conducting 11:14:06
3	QUESTIONS BY MR. GOTTO: 11:11:30	3	any review of a potentially suspicious order? 11:14:11
4	Q. In what other forms might you 11:11:30	4	A. No, I don't recall that. You'd 11:14:15
5	have responded? 11:11:33	5	have to ask Kate. 11:14:18
6	A. Phone call. 11:11:34	6	Q. Okay. How about 11:14:19
7	Q. Do you recall if there was any 11:11:34	7	Mr. Montgomery? 11:14:23
8	requirement in place at Mallinckrodt at the 11:11:40	8	A. I doubt that he would be 11:14:24
9	time that a response to any such inquiry from 11:11:42	9	involved. He was not strong on analytics. 11:14:26
10	Ms. Harper's department be in writing? 11:11:46	10	Q. Okay. And how about Ms. Myers? 11:14:29
11	A. I don't recall that. 11:11:49	11	A. No. 11:14:34
12	Q. Do you know if any order as to 11:11:51	12	Q. Or Ms. Lundergan? 11:14:36
13	which you personally received an inquiry from 11:12:00	13	A. I'm not sure about Lisa either. 11:14:39
14	Ms. Harper's department was ultimately 11:12:02	14	Q. Okay. So in so when the 11:14:44
15	determined to be a suspicious order and 11:12:05	15	compliance department had a question 11:15:01
16	reported to the DEA? 11:12:07	16	regarding a potentially suspicious order, was 11:15:02
17	A. Honestly, I never got that 11:12:08	17	there a procedure in place at Mallinckrodt 11:15:06
18	information, so I wouldn't know. 11:12:11	18	under which they would refer that question to 11:15:16
19	Q. Okay. Do you know if the 11:12:14	19	any particular person in the marketing 11:15:19
20	product managers who reported to you received 11:12:22	20	department? 11:15:22
21	inquiries from Ms. Harper's department with 11:12:27	21	MR. O'CONNOR: Object to form. 11:15:22
22	respect to potentially suspicious orders? 11:12:31	22	THE WITNESS: I'm not sure what 11:15:23
23	A. I don't know that for a fact. 11:12:34	23	you're asking. Could you rephrase the 11:15:24
24	Q. Okay. Do you recall any 11:12:37 situation or occasion in which 11:12:45	24	question? 11:15:26
25	situation or occasion in which 11:12:45	25	
	D 116	_	
	Page 115		Page 117
1	Ms. Muhlenkamp, for example, informed you 11:12:47	1	Page 117 QUESTIONS BY MR. GOTTO: 11:15:26
1 2	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51	1 2	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26
	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56		QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27
2	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58	2	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31
2	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59	2 3	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35
2 3 4	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02	2 3 4	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38
2 3 4 5	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12	2 3 4 5	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40
2 3 4 5 6 7 8	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14	2 3 4 5 6 7 8	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43
2 3 4 5 6 7 8	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14	2 3 4 5 6 7 8	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45
2 3 4 5 6 7 8 9	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15	2 3 4 5 6 7 8 9	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the marketing department was the appropriate 11:15:48
2 3 4 5 6 7 8 9 10	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18	2 3 4 5 6 7 8 9 10	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the marketing department was the appropriate 11:15:48 person to refer that question to? 11:15:49
2 3 4 5 6 7 8 9 10 11	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24	2 3 4 5 6 7 8 9 10 11	QUESTIONS BY MR. GOTTO: 11:15:26 Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:48 person to refer that question to? 11:15:51
2 3 4 5 6 7 8 9 10 11 12 13	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:26	2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:49 MR. O'CONNOR: Object to form. 11:15:51 THE WITNESS: I'm not sure a 11:15:51
2 3 4 5 6 7 8 9 10 11 12 13	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:24 with respect to potentially suspicious 11:13:26 orders? 11:13:29	2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:49 MR. O'CONNOR: Object to form. 11:15:51 THE WITNESS: I'm not sure a 11:15:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:26 orders? 11:13:29 A. I don't recall ever having that 11:13:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:49 MR. O'CONNOR: Object to form. 11:15:51 THE WITNESS: I'm not sure a 11:15:57 be able to tell you that if she had a 11:16:00
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance I1:15:27 department had a question regarding whether an order was a suspicious order and they I1:15:35 wanted to refer that to the marketing department for further information, was there I1:15:40 a procedure in place at Mallinckrodt whereby I1:15:43 they would know what person at the in the I1:15:45 marketing department was the appropriate I1:15:48 person to refer that question to? MR. O'CONNOR: Object to form. I1:15:51 THE WITNESS: I'm not sure a I1:15:57 be able to tell you that if she had a I1:16:00 process in which she followed, but I'm I1:16:02
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:24 with respect to potentially suspicious 11:13:24 with respect to potentially suspicious 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:49 MR. O'CONNOR: Object to form. 11:15:51 THE WITNESS: I'm not sure a 11:15:57 be able to tell you that if she had a 11:16:00 process in which she followed, but I'm 11:16:03
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	QUESTIONS BY MR. GOTTO: Q. Sure. 11:15:26 If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing 11:15:38 department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:49 MR. O'CONNOR: Object to form. 11:15:51 THE WITNESS: I'm not sure a 11:15:57 be able to tell you that if she had a 11:16:00 process in which she followed, but I'm 11:16:03 was taught to my team. 11:16:05
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39 Ms. Muhlenkamp in particular, do you recall 11:13:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance I1:15:27 department had a question regarding whether an order was a suspicious order and they I1:15:35 wanted to refer that to the marketing department for further information, was there I1:15:40 a procedure in place at Mallinckrodt whereby I1:15:43 they would know what person at the in the I1:15:45 marketing department was the appropriate I1:15:49 MR. O'CONNOR: Object to form. I1:15:51 THE WITNESS: I'm not sure a I1:15:57 be able to tell you that if she had a I1:16:00 process in which she followed, but I'm I1:16:03 was taught to my team. I1:16:05 QUESTIONS BY MR. GOTTO: 11:16:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:24 with respect to potentially suspicious 11:13:24 with respect to potentially suspicious 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39 Ms. Muhlenkamp in particular, do you recall 11:13:42 being aware at any point of any well, 11:13:44	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance I1:15:27 department had a question regarding whether an order was a suspicious order and they I1:15:35 wanted to refer that to the marketing department for further information, was there a procedure in place at Mallinckrodt whereby they would know what person at the in the marketing department was the appropriate MR. O'CONNOR: Object to form. THE WITNESS: I'm not sure a I1:15:51 THE WITNESS: I'm not sure a I1:16:00 process in which she followed, but I'm 11:16:03 was taught to my team. Q. Okay. So in terms of within 11:16:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:26 orders? 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39 Ms. Muhlenkamp in particular, do you recall 11:13:42 being aware at any point of any well, 11:13:44 strike that. 11:13:48	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance 11:15:27 department had a question regarding whether 11:15:31 an order was a suspicious order and they 11:15:35 wanted to refer that to the marketing department for further information, was there 11:15:40 a procedure in place at Mallinckrodt whereby 11:15:43 they would know what person at the in the 11:15:45 marketing department was the appropriate 11:15:49 MR. O'CONNOR: Object to form. 11:15:51 THE WITNESS: I'm not sure a 11:15:51 procedure, per se. Karen Harper might 11:16:00 process in which she followed, but I'm 11:16:03 was taught to my team. Q. Okay. So in terms of within 11:16:06 the marketing department, from your 11:16:08
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:26 orders? 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39 Ms. Muhlenkamp in particular, do you recall 11:13:42 being aware at any point of any well, 11:13:44 strike that. 11:13:48 You've already testified with 11:13:48	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance I1:15:27 department had a question regarding whether an order was a suspicious order and they I1:15:35 wanted to refer that to the marketing department for further information, was there I1:15:40 a procedure in place at Mallinckrodt whereby I1:15:43 they would know what person at the in the marketing department was the appropriate I1:15:48 person to refer that question to? I1:15:49 MR. O'CONNOR: Object to form. I1:15:51 THE WITNESS: I'm not sure a I1:15:51 procedure, per se. Karen Harper might I1:16:00 process in which she followed, but I'm I1:16:03 was taught to my team. I1:16:05 QUESTIONS BY MR. GOTTO: Q. Okay. So in terms of within I1:16:08 standpoint, there wasn't any formal procedure I1:16:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:24 with respect to potentially suspicious 11:13:24 with respect to potentially suspicious 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39 Ms. Muhlenkamp in particular, do you recall 11:13:42 being aware at any point of any well, 11:13:44 strike that. 11:13:48 You've already testified with 11:13:48 regard to activities Ms. Muhlenkamp took when 11:13:51	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance I1:15:27 department had a question regarding whether I1:15:31 an order was a suspicious order and they I1:15:35 wanted to refer that to the marketing department for further information, was there I1:15:40 a procedure in place at Mallinckrodt whereby I1:15:43 they would know what person at the in the I1:15:45 marketing department was the appropriate MR. O'CONNOR: Object to form. I1:15:49 MR. O'CONNOR: Object to form. I1:15:51 THE WITNESS: I'm not sure a I1:15:57 be able to tell you that if she had a I1:16:00 process in which she followed, but I'm I1:16:03 was taught to my team. I1:16:05 QUESTIONS BY MR. GOTTO: Q. Okay. So in terms of within I1:16:08 standpoint, there wasn't any formal procedure I1:16:11 in place that stated that inquiries from the I1:16:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Ms. Muhlenkamp, for example, informed you 11:12:47 that she had received an inquiry from 11:12:51 Ms. Harper's department with respect to a 11:12:56 potentially suspicious order? 11:12:58 A. I don't remember any of that. 11:12:59 Q. Okay. Did you perform periodic 11:13:02 evaluations of the performance of the product 11:13:12 managers who reported to you? 11:13:14 A. Yes, I did. 11:13:14 Q. And so did that evaluation 11:13:15 include in any regard their activities in 11:13:18 responding to inquiries they had received 11:13:24 with respect to potentially suspicious 11:13:26 orders? 11:13:29 A. I don't recall ever having that 11:13:29 in anybody's review. It would be more around 11:13:33 forecasting accuracy. 11:13:37 Q. Okay. With respect to 11:13:39 Ms. Muhlenkamp in particular, do you recall 11:13:42 being aware at any point of any well, 11:13:44 strike that. 11:13:48 You've already testified with 11:13:48	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	QUESTIONS BY MR. GOTTO: Q. Sure. If someone in the compliance I1:15:27 department had a question regarding whether an order was a suspicious order and they I1:15:35 wanted to refer that to the marketing department for further information, was there I1:15:40 a procedure in place at Mallinckrodt whereby a procedure in place at Mallinckrodt whereby I1:15:43 they would know what person at the in the I1:15:45 marketing department was the appropriate I1:15:49 MR. O'CONNOR: Object to form. I1:15:51 THE WITNESS: I'm not sure a I1:15:51 procedure, per se. Karen Harper might I1:15:57 be able to tell you that if she had a I1:16:00 process in which she followed, but I'm I1:16:03 was taught to my team. I1:16:05 QUESTIONS BY MR. GOTTO: Q. Okay. So in terms of within I1:16:08 standpoint, there wasn't any formal procedure I1:16:11

	5 110	D 400
	Page 118	Page 120
1 to the marketing department should be har		expectation that they would inform you of 11:18:29
2 by person A, person B, person C, anything		their receipt of an inquiry from the 11:18:31
3 like that; is that fair? 11:16:		compliance department with respect to a 11:18:33
4 MR. O'CONNOR: Objection.	11:16:36	Francisco Franci
5 THE WITNESS: I would say		A. I didn't have that expectation. 11:18:36
	11:16:38	,
7 managed which products, so they migh		expect them to answer the question. They 11:18:44
8 go to that specific product manager.	11:16:42	,,,,,,,,,,,
	.6:44	11 2
where you're going with this because	11:16:50	knew they knew how to supply the correct 11:18:48
it it wasn't a formal policy that	1:16:52	information. So it was not my expectation 11:18:50
12 I'm aware of. Karen might have had	11:16:54	they would provide it to me. 11:18:52
something in place, but I don't 1	1:16:57	Q. Okay. And so there was no 11:18:54
remember us ever being educated on	11:16:58	is it fair to say that there was no 11:18:56
something about this is exactly how	11:17:00	requirement in place within the marketing 11:18:59
16 you handle it. 11:17:0)1	department that a product manager report to 11:19:01
17 QUESTIONS BY MR. GOTTO:	11:17:02	you when they received a an inquiry from 11:19:05
18 Q. Okay. And so when you say	11:17:02	the compliance department as to a potentially 11:19:09
19 "they" knew who handled which products,	you 11:17:07 1:	
20 mean the compliance department knew wh	hich 11:17:09 2	•
21 which product manager handled which pro		_
22 is that fair? 11:17:14		•
23 A. Correct. 11:17:14	4 2:	
24 Q. Okay. And certain inquiries	11:17:15	
25 you became involved in personally.	11:17:24	
, ,		
	Page 119	Page 121
1 Are you aware of any inquiries		In terms of the particular 11:19:36
2 that were referred to anyone in the marke	et 11:17:30	products that are set forth on Exhibit 4, 11:19:39
 that were referred to anyone in the marke department marketing department, you 	t 11:17:30 :: know, 11:17:32	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45
 that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious 	t 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54
 that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you 	t 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in?	t 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they	know, 11:17:30 know, 11:17:32 11:17:36 11:17:39 11:17:41	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in?	t 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4	know, 11:17:30 know, 11:17:32 11:17:36 11:17:39 11:17:41 11:17:43 1:45	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4 A. They may have made other	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware.	know, 11:17:30 know, 11:17:32 11:17:36 11:17:39 11:17:41 11:17:43 1:45	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4 A. They may have made other	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 10 A. They may have made other inquiries and I would not be aware.	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 Q. Okay. Was it your expectation	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries.	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 10 A. They may have made other inquiries and I would not be aware. 12 Q. Okay. Was it your expectation 13 that if a product manager received an inquiries from the compliance department with res	t 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13 A. No, he got promoted to senior 11:20:14
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 Q. Okay. 11:17:4 Inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries from the compliance department with resists to a potentially suspicious order that the	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:00	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18 manager was did he still report to you 11:20:20
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:07 A. The product managers were	tt 11:17:30	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18 manager was did he still report to you 11:20:20 A. Yes, he did. 11:20:22
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:07 A. The product managers were generally good about informing me of thi	tt 11:17:30 know, 11:17:32 11:17:36 11:17:39 11:17:41 11:17:43 1:45 17 11:17:47 11:17:49 11:17:53 11:17:56 11:18:00 11:18:02 11:18:02 11:18:07 11:18:07 11:18:07 11:18:14	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:20 A. Yes, he did. 11:20:22 Q. Okay. Were there other senior 11:20:23
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:0' A. The product managers were generally good about informing me of thi going on with their products, so I may have known, but they may not have always adventiced.	tt 11:17:30 know, 11:17:32 11:17:36 11:17:39 11:17:41 11:17:43 1:45 17 11:17:47 11:17:49 11:17:53 11:17:56 11:18:00 11:18:02 11:18:02 11:18:07 11:18:07 11:18:07 11:18:07 11:18:14	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18 manager was did he still report to you 11:20:20 A. Yes, he did. 11:20:22 Q. Okay. Were there other senior 11:20:23 product managers? 11:20:28
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:0 A. The product managers were generally good about informing me of thi going on with their products, so I may ha known, but they may not have always adv	th 11:17:30 know, 11:17:32 in the state of t	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18 manager was did he still report to you 11:20:20 A. Yes, he did. 11:20:22 Q. Okay. Were there other senior 11:20:23 product managers? 11:20:28 A. No, he was the only one at the 11:20:29
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:0' A. The product managers were generally good about informing me of thi going on with their products, so I may hat known, but they may not have always advance. Q. Sure. 11:18:2'	th 11:17:30 know, 11:17:32 in the state of t	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18 manager was did he still report to you 11:20:20 A. Yes, he did. 11:20:22 Q. Okay. Were there other senior 11:20:23 product managers? 11:20:28 A. No, he was the only one at the 11:20:29 time. 11:20:31
that were referred to anyone in the marke department marketing department, you inquiries regarding potentially suspicious orders, other than the inquiries that you personally became involved in? A. I'm not aware unless they involved me. 11:17:4 Q. Okay. 11:17:4 A. They may have made other inquiries and I would not be aware. Q. Okay. Was it your expectation that if a product manager received an inquiries to a potentially suspicious order that the product manager would inform you of that inquiry? 11:18:0 A. The product managers were generally good about informing me of thi going on with their products, so I may ha known, but they may not have always adva me. If they didn't tell me, I don't know. Q. Sure. 11:18:2	tt 11:17:30 know, 11:17:32 t 11:17:36 t 11:17:39 t 11:17:41 t 11:17:43 t:45 t 7 t 11:17:47 t 11:17:49 t 11:17:53 t 11:17:56 t 11:18:00 t 11:18:02 t 11:18:05 t 11:18:07 t 11:18:07 t 11:18:11 t 11:18:14 t 11:18:19 t 11:18:	products that are set forth on Exhibit 4, 11:19:39 when Ms. Muhlenkamp left, did Lisa 11:19:45 Lundergan/Cardetti Cardetti, is it? 11:19:54 A. Yes. 11:19:57 Q. Thank you. 11:19:57 Did she assume responsibility 11:19:57 for those products? 11:19:58 A. Actually, they I split them 11:19:59 out between Lisa, Marc, and hired a new 11:20:01 product manager, Jennifer Block. 11:20:05 Q. Okay. All right. And 11:20:06 Mr. Montgomery, was he a product manager 11:20:09 through your tenure at Mallinckrodt? 11:20:13 A. No, he got promoted to senior 11:20:14 product manager while I was there. 11:20:16 Q. Okay. And so senior product 11:20:18 manager was did he still report to you 11:20:20 A. Yes, he did. 11:20:22 Q. Okay. Were there other senior 11:20:23 product managers? 11:20:28 A. No, he was the only one at the 11:20:29 time. 11:20:31 Q. Okay. And who took his spot as 11:20:31

Page 122				
2 Q. Okay. The particular products 1120:38 3 discover? 3 discover? 1123:01 1123:01 4		_		
3 discover? 11:23:01	1		1	-
4 A. It was higher in Florida, but 11:23:01	2		2	
5 Mr. Longenecker when he took Mr. Montgomery's 11:20:48	3	<u> </u>	3	
6 Desition? 11:20:52	4		4	
7 A. No, those were taken over by 11:20:52 7 was greater dispensing down there. 11:23:13 8 Jemnifer Block.	5		5	
B Jennifer Block	6	-	6	We had no causal understanding of why there 11:23:08
9	7	A. No, those were taken over by 11:20:52	7	was greater dispensing down there. 11:23:13
10	8	Jennifer Block. 11:20:57	8	Q. Okay. When you say "we," do 11:23:14
12 Jake took over Lisa's products and some of 11:21:01 12 Nate's. So it was mixed on who was managing 11:21:09 12:31 12:31 13 what 11:21:09 12:31 13 what 11:21:09 14 15 Nate of Line of Line of Circumstances that have come to be 11:22:05 11:22:05 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 12:35 13:36	9	Q. Okay. 11:20:57	9	you mean Mallinckrodt? 11:23:17
12 Kate's So it was mixed on who was managing 11:21:04 12 2.04 13 2.05 14 2.05 15 15 15 15 15 15 15	10	A. And Lisa Lundergan left, so 11:20:58	10	A. Yeah. 11:23:17
1.21.108	11	Jake took over Lisa's products and some of 11:21:01	11	Q. Okay. 11:23:17
14	12	Kate's. So it was mixed on who was managing 11:21:04	12	A. Yeah. 11:23:17
15 Lisa Lundergan left, I thought did I 11:21:14 15 something that you were did anyone else at 11:23:27 16 misunderstand? I thought she had taken 11:21:17 16 Mallinckrodt ask you to undertake this 11:23:34 11:23:35 18 yeah 11:21:22 18 MR. O'CONNOR: Object to form. 11:23:35 11:23:35 13:23 12:23 18 MR. O'CONNOR: Object to form. 11:23:36 Neely in part of the looking into 11:23:39 11	13	what. 11:21:08	13	Q. So this effort of looking into 11:23:18
1.23.35	14	Q. And I'm sorry, when you say 11:21:09	14	Florida distribution in particular, was this 11:23:25
17	15	Lisa Lundergan left, I thought did I 11:21:14	15	something that you were did anyone else at 11:23:27
18 yeah —	16	misunderstand? I thought she had taken 11:21:17	16	Mallinckrodt ask you to undertake this 11:23:34
19	17	A. She had gotten a NAM position, 11:21:19	17	inquiry? 11:23:35
20	18	yeah 11:21:22	18	MR. O'CONNOR: Object to form. 11:23:35
21 Sorry. 11:21:26 22 Surrise Medical. We said, "They're 11:23:43 22 Q. Okay. Great. Okay. You can 11:21:27 23 set that document aside. 11:21:27 24 When you joined Mallinckrodt in 11:21:29 25 mid-2009, did you have any awareness at that 11:21:54 25 mid-2009, did you have any awareness at that 11:21:54 25 said it was physician prescribing down 11:23:55 2 time of circumstances that have come to be 11:22:05 1 there. So we were trying to 11:23:55 26 known as the opioid epidemic in this country 11:22:13 3 MR. O'CONNOR: Object to form. 11:22:13 3 MR. O'CONNOR: Object to form. 11:22:13 4 Q. Okay. And when you said "they 11:23:55 3 QUESTIONS BY MR. GOTTO: 11:23:55 3 QUESTIONS BY MR. GOTTO: 11:23:55 3 A Yeah, I'm sorry. 11:23:57 3 A Yeah, I'm sorry. 11:23:59 3 A Yeah, I'm sorry. 11:23:59 3 A Yeah, I'm sorry. 11:24:04 3 product that Mallinckrodt had originally 11:24:04 3 product that Mallinckrodt had originally 11:24:04 3 product that Mallinckrodt had originally 11:24:14 3 on what was going on. 11:22:33 13 THE WITNESS: That I remember, 11:24:15 11:24:20 12:243 14 Q. Okay. What kind of background 11:22:37 14 Q. Okay. What kind of background 11:22:37 14 Q. Okay. What kind of background 11:22:37 14 Mallinckrodt see about 11:22:39 15 Mallinckrodt specifically. 11:24:20	19	Q. Okay. 11:21:23	19	THE WITNESS: No. It was Kate 11:23:36
22 Q. Okay. Great. Okay. You can 11:21:26 23 set that document aside. 11:21:27 24 When you joined Mallinckrodt in 11:21:29 25 mid-2009, did you have any awareness at that 11:21:54 26 mid-2009, did you have any awareness at that 11:21:54 27 Page 123 28 time of circumstances that have come to be 11:22:05 29 known as the opioid epidemic in this country? 11:22:11 30 MR. O'CONNOR: Object to form. 11:22:13 41 THE WITNESS: I was not aware 11:22:13 42 O, Okay. Mhen did you become 11:22:17 43 or what was going on. 11:22:23 44 Probably in 2010 when I started 11:22:33 45 the nstarted doing a little bit of background 11:22:37 46 Q. Okay. What kind of background 11:22:33 47 A Just looked to see about 11:22:39 48 Q. Okay. What kind of background 11:22:37 49 priling were being dispensed in the state of 11:22:48 40 Q. Okay. And what you said "they 11:24:12 41 MR. O'CONNOR: Object to form. 11:22:12 42 we don't know about," because they 11:23:51 43 what else is going into Florida that 11:23:49 44 we don't know about," because they 11:23:52 45 said it was physician prescribing down 11:23:52 46 there. So we were trying to 11:23:54 4	20	A when she left my department. 11:21:23	20	Neely in part of the looking into 11:23:39
23 set that document aside. 11:21:27 24 When you joined Mallinckrodt in 11:21:29 25 mid-2009, did you have any awareness at that 11:21:54 26 mid-2009, did you have any awareness at that 11:21:54 27 time of circumstances that have come to be 11:22:05 28 known as the opioid epidemic in this country? 11:22:11 3	21	Sorry. 11:21:26	21	Sunrise Medical. We said, "They're 11:23:43
When you joined Mallinckrodt in 11:21:29 24 we don't know about," because they 11:23:51 25 mid-2009, did you have any awareness at that 11:21:54 25 said it was physician prescribing down 11:23:52 11:23:55 11:23:55 26 known as the opioid epidemic in this country? 11:22:11 27 28 MR. O'CONNOR: Object to form. 11:22:13 3 QUESTIONS BY MR. GOTTO: 11:23:55 3 QUESTIONS BY MR. GOTTO: 11:23:55 3 QUESTIONS BY MR. GOTTO: 11:23:55 3 QUESTIONS BY MR. GOTTO: 11:23:57 3 QUESTIONS BY MR. GOTTO: 11:23:59 3 QUESTIONS BY MR. GOTTO: 11:24:02 3 Doking into distribution in Florida of 11:24:04 3 Dokay. What kind of background 11:22:31 3 QUESTIONS BY MR. GOTTO: 11:24:13 3 QUESTIONS BY MR. GOTTO: 11:24:13 3 QUESTIONS BY MR. GOTTO: 11:24:13 3 QUESTIONS BY MR. GOTTO: 11:24:14 3 QUESTIONS BY MR. GOTTO: 11:24:15 3 QUESTIONS BY MR. GOTTO: 11:24:15 3 QUESTIONS BY MR. GOTTO: 11:24:15 3 QUESTIONS BY MR. GOTTO: 11:24:20 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with 11:24:25 3 Dokay. And what did you do with	22	Q. Okay. Great. Okay. You can 11:21:26	22	selling into the state of Florida. 11:23:46
Page 123	23	set that document aside. 11:21:27	23	What else is going into Florida that 11:23:49
Page 123	24	When you joined Mallinckrodt in 11:21:29	24	we don't know about," because they 11:23:51
1 time of circumstances that have come to be 11:22:05 1 there. So we were trying to 11:23:54 2 known as the opioid epidemic in this country? 11:22:13 2 understand that. 11:23:55 3 MR. O'CONNOR: Object to form. 11:22:13 4 Q. Okay. And when you said "they 11:23:55 11:23:55 4 THE WITNESS: I was not aware 11:22:17 6 11:22:19 6 Q. Okay. And when you said "they 11:23:55 11:23:55 5 of the opioid epidemic, as they call 11:22:19 6 A. Yeah, I'm sorry. 11:23:59 11:23:59 7 QUESTIONS BY MR. GOTTO: 11:22:20 11:22:20 8 Q. Okay. When did you become 11:22:21 9 11:24:02 10 koking into distribution in Florida of 11:24:02 11:24:09 11:24:09 11:24:09 11:24:09 11:24:09 11:24:11 12:24:13 12 12 12 12:40 11:24:13 12 12:40 11:24:13 12 12:4:13 11:24:13 12:4:13 11:24:13 12:4:13 12:4:13 11:24:13 12:4:13 11:24:13 12:4:13 12:4:13 11:24:13 11:24:13 12:4:13 12:4:13	25	mid-2009, did you have any awareness at that 11:21:54	25	said it was physician prescribing down 11:23:52
1 time of circumstances that have come to be 11:22:05 1 there. So we were trying to 11:23:54 2 known as the opioid epidemic in this country? 11:22:13 2 understand that. 11:23:55 3 MR. O'CONNOR: Object to form. 11:22:13 4 Q. Okay. And when you said "they 11:23:55 11:23:55 4 THE WITNESS: I was not aware 11:22:17 6 11:22:19 6 Q. Okay. And when you said "they 11:23:55 11:23:55 5 of the opioid epidemic, as they call 11:22:19 6 A. Yeah, I'm sorry. 11:23:59 11:23:59 7 QUESTIONS BY MR. GOTTO: 11:22:20 11:22:20 8 Q. Okay. When did you become 11:22:21 9 11:24:02 10 koking into distribution in Florida of 11:24:02 11:24:09 11:24:09 11:24:09 11:24:09 11:24:09 11:24:11 12:24:13 12 12 12 12:40 11:24:13 12 12:40 11:24:13 12 12:4:13 11:24:13 12:4:13 11:24:13 12:4:13 12:4:13 11:24:13 12:4:13 11:24:13 12:4:13 12:4:13 11:24:13 11:24:13 12:4:13 12:4:13		Page 123		Page 125
2 known as the opioid epidemic in this country? 11:22:11 2 understand that. 11:23:55	1		1	
MR. O'CONNOR: Object to form.				
4 THE WITNESS: I was not aware 11:22:13 5 of the opioid epidemic, as they call 11:22:17 6 it today, no. 11:22:19 7 QUESTIONS BY MR. GOTTO: 11:22:20 8 Q. Okay. When did you become 11:22:21 9 aware of that, do you think? 11:22:22 10 A. Probably in 2010 when I started 11:22:23 11 hearing about Sunrise and then started - 11:22:38 12 then started doing a little bit of background 11:22:31 13 on what was going on. 11:22:33 14 Q. Okay. What kind of background 11:22:37 15 did you do? 11:22:39 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:47 19 Q. Okay. And when you said "they 11:23:55 18 said," these are press accounts you were 11:23:57 19 A. Yeah, I'm sorry. 11:24:02 10 blooking into distribution in Florida of 11:24:04 11:22:23 10 manufactured, or were you looking more 11:24:11 11 generally at the entire industry? 11:24:13 12 THE WITNESS: That I remember, 11:24:14 13 THE WITNESS: That I remember, 11:24:15 14 I think we were looking at 11:24:17 15 Mallinekrodt specifically. 11:24:20 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:43 19 Florida. 11:22:47 20 Q. Okay. And how did you go about 11:22:47 21 doing that? 11:22:48 22 A. Pulling IMS data and looking at 11:22:48 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 25 the country, and the percent of pills that 11:22:54 26 doubt a remarkable are press accounts you were 11:23:57 27 Q. Okay. And when you said "they lize as aid," these are press accounts you were 11:23:57 27 Q. Okay. And when you said "they lize as aid," these are press accounts you were 11:24:02 28 looking into distribution in Florida of 11:24:09 29 manufactured, or were you looking more 11:24:09 20 manufactured, or were you looking more 11:24:11 21 generally at the entire industry? 11:24:13 21 the were looking at 11:24:17 22 Q. Okay		* *		
5 of the opioid epidemic, as they call 11:22:17 11:22:19 5 said," these are press accounts you were 11:23:57 11:23:57 6 it today, no. 11:22:19 11:22:19 6 A. Yeah, I'm sorry. 11:23:59 11:24:02 8 Q. Okay. When did you become 11:22:21 9 aware of that, do you think? 11:22:22 12:22:22 9 looking into distribution in Florida of 11:24:04 11:24:09 10 A. Probably in 2010 when I started 11:22:23 10 manufactured, or were you looking more 11:24:11 11:24:13 11 hearing about Sunrise and then started 11:22:33 11 generally at the entire industry? 11:24:13 11:24:13 12 MR. O'CONNOR: Object to form. 11:24:13 11:24:14 MR. O'CONNOR: Object to form. 11:24:15 13 THE WITNESS: That I remember, 11:24:15 11:24:17 14 A. Just looked to see about 11:22:39 15 Mallinckrodt specifically. 11:24:20 16 A. Just looked to see about 11:22:47 16 QUESTIONS BY MR. GOTTO: 11:24:22 17 Q. Okay. And what did you do with 11:22:24 17 Q. Okay. And what did you do with 11:24:25 19 Florida. 11:22:48		3		`
6 it today, no. 11:22:19 7 QUESTIONS BY MR. GOTTO: 11:22:20 8 Q. Okay. When did you become 11:22:21 9 aware of that, do you think? 11:22:22 10 A. Probably in 2010 when I started 11:22:23 11 hearing about Sunrise and then started 11:22:28 12 then started doing a little bit of background 11:22:31 13 on what was going on. 11:22:33 14 Q. Okay. What kind of background 11:22:31 15 did you do? 11:22:39 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:47 19 Florida. 11:22:48 20 Q. Okay. And how did you go about 11:22:48 21 doing that? 11:22:48 22 A. Pulling IMS data and looking at 11:22:53 24 the country, and the percent of pills that 11:22:54 25 MR. Harper, or do you remember who in 11:24:35 26 A. Yeah, I'm sorry. 11:23:59 27 Q. Okay. And so so were you 11:24:02 28 looking into distribution in Florida of 11:24:09 29 manufactured, or were you looking more 11:24:09 21 manufactured, or were you looking more 11:24:11 22 MR. O'CONNOR: Object to form. 11:24:13 24 It think we were looking at 11:24:13 25 Mallinckrodt specifically. 11:24:20 26 Q. Okay. And what did you do with 11:24:22 27 Florida. 11:22:47 28 developed it? 11:24:28 29 A. Turned it over to the 11:24:29 20 Okay. And was it to 11:24:31 21 the entire industry? 11:24:13 22 Q. Okay. And was it to 11:24:22 23 Ms. Harper, or do you remember who in 11:24:35 24 the country, and the percent of pills that 11:22:54 25 particular 11:24:37				
7 QUESTIONS BY MR. GOTTO: 11:22:20 7 Q. Okay. And so so were you 11:24:02 8 Q. Okay. When did you become 11:22:21 8 looking into distribution in Florida of 11:24:04 9 aware of that, do you think? 11:22:22 9 product that Mallinckrodt had originally 11:24:09 10 A. Probably in 2010 when I started 11:22:23 10 manufactured, or were you looking more 11:24:11 11 hearing about Sunrise and then started 11:22:28 11 generally at the entire industry? 11:24:13 12 then started doing a little bit of background 11:22:33 12 MR. O'CONNOR: Object to form. 11:24:14 13 on what was going on. 11:22:33 13 THE WITNESS: That I remember, 11:24:15 14 Q. Okay. What kind of background 11:22:37 14 It hink we were looking at 11:24:17 15 did you do? 11:22:39 15 Mallinckrodt specifically. 11:24:20 16 A. Just looked to see about 11:22:39 16 QUESTIONS BY MR. GOTTO: 11:24:22 17 Florida, the state of Florida, and how many 11:22:43 17 Q. Okay. And what did you do with 11:24:22 19 Florida. 11:22:48 20 A. Turned it over to the 11:24:31				
8 Q. Okay. When did you become 11:22:21 9 aware of that, do you think? 11:22:22 10 A. Probably in 2010 when I started 11:22:23 11 hearing about Sunrise and then started 11:22:28 12 then started doing a little bit of background 11:22:31 13 on what was going on. 11:22:33 14 Q. Okay. What kind of background 11:22:37 15 did you do? 11:22:39 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:47 19 Florida. 11:22:47 20 Q. Okay. And how did you go about 11:22:47 21 doing that? 11:22:48 22 A. Pulling IMS data and looking at 11:22:54 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 8 looking into distribution in Florida of 11:24:04 9 product that Mallinckrodt had originally 11:24:09 11:24:09 11:24:11 12 manufactured, or were you looking more 11:24:11 12 generally at the entire industry? 11:24:13 12 MR. O'CONNOR: Object to form. 11:24:13 13 THE WITNESS: That I remember, 11:24:15 14 I think we were looking at 11:24:17 15 Mallinckrodt had originally 11:24:09 16 MR. O'CONNOR: Object to form. 11:24:13 17 MR. O'CONNOR: Object to form. 11:24:14 18 I think we were looking at 11:24:17 19 Mallinckrodt had originally 11:24:09 10 MR. O'CONNOR: Object to form. 11:24:13 11:24:15 11 generally at the entire industry? 11:24:13 12 MR. O'CONNOR: Object to form. 11:24:13 13 THE WITNESS: That I remember, 11:24:15 14 I think we were looking at 11:24:17 15 Mallinckrodt had originally 11:24:09 16 Q. Okay. And what did you do with 11:24:20 17 Q. Okay. And what did you do with 11:24:22 18 that information after you		•		•
9 aware of that, do you think? 11:22:22 9 product that Mallinckrodt had originally 11:24:09 10 A. Probably in 2010 when I started 11:22:23 10 manufactured, or were you looking more 11:24:11 11 hearing about Sunrise and then started 11:22:28 11 generally at the entire industry? 11:24:13 12 then started doing a little bit of background 11:22:31 12 MR. O'CONNOR: Object to form. 11:24:14 13 on what was going on. 11:22:33 13 THE WITNESS: That I remember, 11:24:15 14 Q. Okay. What kind of background 11:22:37 14 I think we were looking at 11:24:17 15 did you do? 11:22:39 15 Mallinckrodt specifically. 11:24:20 16 A. Just looked to see about 11:22:39 16 QUESTIONS BY MR. GOTTO: 11:24:22 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:43 18 that information after you after you 11:24:25 19 Florida. 11:22:47 19 developed it? 11:24:28 20 Q. Okay. And how did you go about 11:22:47 20 A. Turned it over to the 11:24:29 21 doing that? 11:22:48 21 compliance team. 11:24:31 22 A. Pulling IMS data and looking at 11:22:53 23 Ms. Harper, or do you remember who in 11:24:35 24 the country, and the percent of pills that 11:22:54 24 particular 11:24:37				
A. Probably in 2010 when I started 11:22:23		•		TOOKING IIIO GIBGIOGGOII III I IOIIGG OI 11.27.07
hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 THE WITNESS: That I remember, 11:24:15 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:47 Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48 A. Pulling IMS data and looking at 11:22:48 the country, and the percent of pills that 11:22:54 the country, and the percent of pills that 11:22:54 la generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 MR. O'CONNOR: Object to form. 11:24:15 It think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 Q. Okay. And what did you do with 11:24:22 la that information after you after you 11:24:25 developed it? 11:24:28 Q. Okay. And was it to 11:24:31 Q. Okay. And was it to 11:24:31 A. Pulling IMS data and looking at 11:22:48 A. Pulling IMS data and looking at 11:22:54	_	aware or mar do von mink/	1 9	product that Mallinckrodt had originally 11.24.09
then started doing a little bit of background 11:22:31 12 then started doing a little bit of background 11:22:31 13 on what was going on. 11:22:33 12 MR. O'CONNOR: Object to form. 11:24:14 13 on what was going on. 11:22:33 14 I think we were looking at 11:24:17 15 did you do? 11:22:39 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:43 19 Florida. 11:22:47 12 MR. O'CONNOR: Object to form. 11:24:14 13 THE WITNESS: That I remember, 11:24:17 14 I think we were looking at 11:24:17 15 Mallinckrodt specifically. 11:24:20 16 QUESTIONS BY MR. GOTTO: 11:24:22 17 Q. Okay. And what did you do with 11:24:22 18 that information after you after you 11:24:25 19 developed it? 11:24:28 20 A. Turned it over to the 11:24:29 21 doing that? 11:22:48 22 A. Pulling IMS data and looking at 11:22:48 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 24 particular 11:24:37	1.0	•		
on what was going on. 11:22:33 12 Q. Okay. What kind of background 11:22:37 13 THE WITNESS: That I remember, 11:24:15 14 I think we were looking at 11:24:17 15 did you do? 11:22:39 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:43 19 Florida. 11:22:47 10 Q. Okay. And what did you do with 11:24:22 11 think we were looking at 11:24:20 12 QUESTIONS BY MR. GOTTO: 11:24:22 13 that information after you after you 11:24:25 14 I think we were looking at 11:24:20 15 Mallinckrodt specifically. 11:24:20 16 QUESTIONS BY MR. GOTTO: 11:24:22 18 that information after you after you 11:24:25 19 developed it? 11:24:28 20 A. Turned it over to the 11:24:31 21 compliance team. 11:24:31 22 Q. Okay. And was it to 11:24:32 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 24 particular 11:24:37		A. Probably in 2010 when I started 11:22:23	10	manufactured, or were you looking more 11:24:11
Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48 A. Pulling IMS data and looking at 11:22:48 A. Pulling IMS data and looking at 11:22:53 the population of Florida versus the rest of 11:22:53 the country, and the percent of pills that 11:22:54 La I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 La QUESTIONS BY MR. GOTTO: 11:24:22 La QUESTIONS BY MR. GOTTO: 11:24:22 A. A. Turned it over to the 11:24:25 La Q. Okay. And what did you do with 11:24:25 La Q. Okay. And was it to 11:24:31 La VI think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 La Q. Okay. And what did you do with 11:24:25 La VI think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 La Q. Okay. And what did you do with 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you after you 11:24:25 La VI the information after you after you after you 11:24:25 La VI the information after you after you 11:24:25 La VI the information after you after you after you 11:24:25 La VI the information after you -	11	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28	10 11	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13
15 did you do? 11:22:39 15 Mallinckrodt specifically. 11:24:20 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:43 19 Florida. 11:22:47 10 Q. Okay. And what did you do with 11:24:22 11 that information after you after you 11:24:25 12 developed it? 13:24:28 14 doing that? 15 Mallinckrodt specifically. 16 QUESTIONS BY MR. GOTTO: 11:24:22 18 that information after you after you 11:24:25 19 developed it? 11:24:28 20 A. Turned it over to the 11:24:29 21 doing that? 22 A. Pulling IMS data and looking at 11:22:48 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 25 Ms. Harper, or do you remember who in 11:24:35 26 A. Just looked to see about 11:24:20 27 Q. Okay. And what did you do with 11:24:25 28 developed it? 29 Cokay. And was it to 11:24:31 20 Q. Okay. And was it to 11:24:35 21 developed it? 22 Q. Okay. And was it to 11:24:35 23 Ms. Harper, or do you remember who in 11:24:35 24 particular 11:24:37	11 12	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31	10 11 12	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14
A. Just looked to see about 11:22:39 16 A. Just looked to see about 11:22:39 17 Florida, the state of Florida, and how many 11:22:41 18 pills were being dispensed in the state of 11:22:43 19 Florida. 11:22:47 20 Q. Okay. And how did you go about 11:22:47 21 doing that? 11:22:48 22 A. Pulling IMS data and looking at 11:22:48 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 16 QUESTIONS BY MR. GOTTO: 11:24:22 17 Q. Okay. And what did you do with 11:24:22 18 that information after you after you 11:24:25 19 developed it? 11:24:28 20 A. Turned it over to the 11:24:31 21 compliance team. 11:24:31 22 Q. Okay. And was it to 11:24:32 23 Ms. Harper, or do you remember who in 11:24:35 24 particular 11:24:37	11 12 13	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33	10 11 12 13	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15
Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:24:25 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:24:25 pills that information after you after you 11:24:25 pills that information after you afte	11 12 13 14	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37	10 11 12 13 14	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17
pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills were being dispensed in the state of 11:22:43 pills that information after you after you 11:24:28 pulling IMS data and how did you go about 11:22:47 pills that information after you after you 11:24:28 pulling IMS data and how did you go about 11:22:47 pulling IMS data and looking at 11:22:48 pills that information after you after you 11:24:28 pulling it information after you	11 12 13 14 15	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39	10 11 12 13 14 15	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20
19 Florida. 11:22:47 19 developed it? 11:24:28 20 Q. Okay. And how did you go about 11:22:47 20 A. Turned it over to the 11:24:29 21 doing that? 11:22:48 21 compliance team. 11:24:31 22 A. Pulling IMS data and looking at 11:22:48 22 Q. Okay. And was it to 11:24:32 23 the population of Florida versus the rest of 11:22:53 23 Ms. Harper, or do you remember who in 11:24:35 24 the country, and the percent of pills that 11:22:54 24 particular 11:24:37	11 12 13 14 15	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39	10 11 12 13 14 15	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22
Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48 2 A. Pulling IMS data and looking at 11:22:48 A. Pulling IMS data and looking at 11:22:48 the population of Florida versus the rest of 11:22:53 the population of Florida versus the rest of 11:22:54 A. Turned it over to the 11:24:29 Q. Okay. And was it to 11:24:31 A. Harper, or do you remember who in 11:24:35 A. Harper, or do you remember who in 11:24:35 A. Harper, or do you remember who in 11:24:35 A. Harper, or do you remember who in 11:24:35	11 12 13 14 15 16	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41	10 11 12 13 14 15 16	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22
21 doing that? 11:22:48 22 A. Pulling IMS data and looking at 11:22:48 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 21 compliance team. 11:24:31 22 Q. Okay. And was it to 11:24:32 23 Ms. Harper, or do you remember who in 11:24:35 24 particular 11:24:37	11 12 13 14 15 16 17	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43	10 11 12 13 14 15 16 17	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25
A. Pulling IMS data and looking at 11:22:48 23 the population of Florida versus the rest of 11:22:53 24 the country, and the percent of pills that 11:22:54 25 Q. Okay. And was it to 11:24:32 26 Ms. Harper, or do you remember who in 11:24:35 27 Pulling IMS data and looking at 11:22:54 28 Pulling IMS data and looking at 11:22:54	11 12 13 14 15 16 17 18	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47	10 11 12 13 14 15 16 17 18	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 developed it? 11:24:28
the population of Florida versus the rest of 11:22:53 23 Ms. Harper, or do you remember who in 11:24:35 the country, and the percent of pills that 11:22:54 24 particular 11:24:37	11 12 13 14 15 16 17 18 19 20	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47 Q. Okay. And how did you go about 11:22:47	10 11 12 13 14 15 16 17 18 19	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 developed it? 11:24:28 A. Turned it over to the 11:24:29
24 the country, and the percent of pills that 11:22:54 24 particular 11:24:37	11 12 13 14 15 16 17 18 19 20 21	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47 Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48	10 11 12 13 14 15 16 17 18 19 20 21	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 developed it? 11:24:28 A. Turned it over to the 11:24:29 compliance team. 11:24:31
	11 12 13 14 15 16 17 18 19 20 21 22	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47 Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48 A. Pulling IMS data and looking at 11:22:48	10 11 12 13 14 15 16 17 18 19 20 21	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 developed it? 11:24:28 A. Turned it over to the 11:24:29 compliance team. 11:24:31 Q. Okay. And was it to 11:24:32
	111 12 13 14 15 16 17 18 19 20 21 22 23	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47 Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48 A. Pulling IMS data and looking at 11:22:53	10 11 12 13 14 15 16 17 18 19 20 21 22 23	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 developed it? 11:24:28 A. Turned it over to the 11:24:29 compliance team. 11:24:31 Q. Okay. And was it to 11:24:32 Ms. Harper, or do you remember who in 11:24:35
	111 12 13 14 15 16 17 18 19 20 21 22 23 24	A. Probably in 2010 when I started 11:22:23 hearing about Sunrise and then started 11:22:28 then started doing a little bit of background 11:22:31 on what was going on. 11:22:33 Q. Okay. What kind of background 11:22:37 did you do? 11:22:39 A. Just looked to see about 11:22:39 Florida, the state of Florida, and how many 11:22:41 pills were being dispensed in the state of 11:22:43 Florida. 11:22:47 Q. Okay. And how did you go about 11:22:47 doing that? 11:22:48 A. Pulling IMS data and looking at 11:22:53 the country, and the percent of pills that 11:22:54	10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	manufactured, or were you looking more 11:24:11 generally at the entire industry? 11:24:13 MR. O'CONNOR: Object to form. 11:24:14 THE WITNESS: That I remember, 11:24:15 I think we were looking at 11:24:17 Mallinckrodt specifically. 11:24:20 QUESTIONS BY MR. GOTTO: 11:24:22 Q. Okay. And what did you do with 11:24:22 that information after you after you 11:24:25 developed it? 11:24:28 A. Turned it over to the 11:24:29 compliance team. 11:24:31 Q. Okay. And was it to 11:24:32 Ms. Harper, or do you remember who in 11:24:35 particular 11:24:37

	Page 126		Page 128
1	Q. Okay. Do you remember the 11:24:38	1	happened, or is that what you projected 11:26:53
2	format in which you turned it over? 11:24:39	2	and 11:26:56
3	A. In a spreadsheet. 11:24:41	3	A. It's what actually happened. 11:26:56
4	Q. Okay. And did you receive back 11:24:44	4	Q. Okay. And do you know what 11:26:57
5	from the compliance department any requests 11:24:49	5	caused that to happen, for the sales to be 11:27:02
6	for follow-up information or analysis? 11:24:51	6	lower? 11:27:05
7	A. Not that I recollect. I 11:24:54	7	MR. O'CONNOR: Object to form. 11:27:06
8	believe another department started running 11:24:59	8	THE WITNESS: I'm not exactly 11:27:07
9	reports. 11:25:01	9	sure, but we projected that some 11:27:10
10	Q. Okay. Do you know which other 11:25:02	10	customers would not be able to ship 11:27:12
11	department? 11:25:04	11	into the state of Florida and 11:27:14
12	A. David Silver's department. 11:25:04	12	estimated their sales. 11:27:16
13	So we didn't pull any data. No 11:25:07	13	QUESTIONS BY MR. GOTTO: 11:27:17
14	one I don't recollect anybody asking me 11:25:09	14	Q. Okay. And mechanically, how 11:27:17
15	for more data. 11:25:11	15	did you go about estimating what the 11:27:23
16	Q. Okay. And in terms of when you 11:25:13	16	consequences would be of certain customers 11:27:26
17	pulled this data, this was in the 2010 time 11:25:16	17	not being able to ship into Florida? 11:27:28
18	frame? 11:25:19	18	A. We would look at what the 11:27:31
19	A. Correct. 11:25:19	19	customer's historical sales were. And there 11:27:33
20	Q. And it was triggered by the 11:25:20	20	were certain distribution centers that we 11:27:36
21	Sunrise DEA issues you became aware of? 11:25:23	21	shipped to, so we could tell which the 11:27:38
22	A. Uh-huh. 11:25:25	22	wholesaler distributor centers they went to, 11:27:40
23	Q. Do you know if as a result of 11:25:27	23	and so we would know that that distributor 11:27:43
24	the compilation of that data there were any 11:25:35	24	was not going to be able to ship in that 11:27:44
25	changes in Mallinckrodt's approach to the 11:25:40	25	area. And if we had that business, we knew 11:27:47
	D 127		Page 120
	Page 127		Page 129
1	sale of any of the opioid products? 11:25:47	1	that we lost that business. It may have been 11:27:48
1 2	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49	1 2	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50
	sale of any of the opioid products? 11:25:47		that we lost that business. It may have been 11:27:48
2	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50	2	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50
2	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49	2	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57
2 3 4	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59	2 3 4	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44
2 3 4 5	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55	2 3 4 5	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57
2 3 4 5 6	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59	2 3 4 5 6	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44
2 3 4 5 6 7	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05	2 3 4 5 6	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44
2 3 4 5 6 7 8	sale of any of the opioid products? 11:25:47 MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01	2 3 4 5 6 7 8	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44
2 3 4 5 6 7 8	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07	2 3 4 5 6 7 8	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48
2 3 4 5 6 7 8 9	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08	2 3 4 5 6 7 8 9	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53
2 3 4 5 6 7 8 9 10	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11	2 3 4 5 6 7 8 9 10	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58
2 3 4 5 6 7 8 9 10 11	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20	2 3 4 5 6 7 8 9 10 11 12	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03
2 3 4 5 6 7 8 9 10 11 12 13	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22	2 3 4 5 6 7 8 9 10 11 12 13	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06
2 3 4 5 6 7 8 9 10 11 12 13	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29	2 3 4 5 6 7 8 9 10 11 12 13	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07
2 3 4 5 6 7 8 9 10 11 12 13 14	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22	2 3 4 5 6 7 8 9 10 11 12 13 14	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33 which you compiled this information about the 11:26:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33 which you compiled this information about the 11:26:39 Florida sales? 11:26:41	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11 Q. Do you recognize that document? 11:30:27
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33 which you compiled this information about the 11:26:39 Florida sales? 11:26:41 MR. O'CONNOR: Object to form. 11:26:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11 Q. Do you recognize that document? 11:30:27 A. I don't remember it, but I 11:30:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33 which you compiled this information about the 11:26:39 Florida sales? 11:26:41 MR. O'CONNOR: Object to form. 11:26:42 THE WITNESS: Yes. 11:26:43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11 Q. Do you recognize that document? 11:30:27 A. I don't remember it, but I 11:30:32
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33 which you compiled this information about the 11:26:39 Florida sales? 11:26:41 MR. O'CONNOR: Object to form. 11:26:42 THE WITNESS: Yes. 11:26:43 QUESTIONS BY MR. GOTTO: 11:26:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11 Q. Do you recognize that document? 11:30:27 A. I don't remember it, but I 11:30:32 recognize it. 11:30:32 Q. Okay. 11:30:33
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	sale of any of the opioid products? MR. O'CONNOR: Object to form. 11:25:49 THE WITNESS: I don't. 11:25:49 QUESTIONS BY MR. GOTTO: 11:25:50 Q. Did you have occasion well, 11:25:55 strike that. 11:25:59 Part of your job responsibility 11:25:59 was preparing forecasts and reviewing sales 11:26:01 results, et cetera, right, on a regular 11:26:05 basis; is that fair? 11:26:07 A. Correct. 11:26:07 Q. So after you compiled the data 11:26:08 in 2010, as you prepared sales forecasts or 11:26:11 reviewed sales results going forward, did you 11:26:20 make any effort to evaluate whether the sales 11:26:22 patterns going forward were different in any 11:26:29 way from what had predated the period during 11:26:33 which you compiled this information about the 11:26:39 Florida sales? 11:26:41 MR. O'CONNOR: Object to form. 11:26:42 THE WITNESS: Yes. 11:26:43 QUESTIONS BY MR. GOTTO: 11:26:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that we lost that business. It may have been 11:27:48 picked up by a competitor in a region, but we 11:27:50 knew that it would not be our business 11:27:54 because we were aligned with a particular 11:27:56 customer. 11:27:57 (Mallinckrodt-Collier Exhibit 5 11:28:44 marked for identification.) 11:28:44 QUESTIONS BY MR. GOTTO: 11:28:44 Q. We've marked as Exhibit 5 a 11:28:45 document that was produced in native format 11:28:47 under MNK-T1_0004881300. 11:28:48 And the document is a strategic 11:28:53 business update for Covidien Pharmaceuticals 11:28:58 Specialty Generics dated December 2, 2009. 11:29:03 Could you take a moment and 11:29:06 look through that document and tell me if you 11:29:07 recognize it? 11:29:10 A. Okay. 11:29:11 Q. Do you recognize that document? 11:30:27 A. I don't remember it, but I 11:30:29 recognize it. 11:30:32 Q. Okay. 11:30:33 A. You know, the business review. 11:30:33

		T -	P 122
	Page 130		Page 132
1	materials that are contained in this 11:30:43	1	type prior to the time you joined 11:32:51
2	document? 11:30:44	2	Mallinckrodt? 11:32:53
3	A. Yes. 11:30:44	3	A. I would have no knowledge of 11:32:53 that. 11:32:54
5	Q. Which ones? 11:30:45	4 5	Q. Okay. On slide 7, it says "VIP 11:32:54
	A. My team might have actually 11:30:45	6	update" at the top. 11:33:12
7	pulled information on the business, the units, and all the financials and, on 11:30:53	7	What does VIP mean in this 11:33:16
8		8	context? 11:33:17
9	slide 12, the pipeline 11:31:02 Q. Okay. 11:31:05	9	A. Volume incentive plan or 11:33:18
10	Q. Okay. 11:31:05 A in REMS. 11:31:06	10	program. 11:33:20
11	Q. What are REMS? 11:31:07	11	Q. And what is that? 11:33:20
12	A. Risk evaluation and mitigation 11:31:09	12	A. That is an incentive plan put 11:33:20
13	strategy. They're put in place for 11:31:13	13	in place for customers to reach certain 11:33:22
14	particular products so that it requires an 11:31:16	14	volume hurdles on dollars and so that they 11:33:24
15	additional patient insert and more 11:31:18	15	can be paid a rebate in addition. And they 11:33:29
16	monitoring. 11:31:22	16	pass that along to the pharmacies, oftentimes 11:33:33
17	Q. Okay. So it's a regulatory 11:31:22	17	either a portion or all of it, on to the 11:33:35
18	requirement? 11:31:23	18	pharmacies for complying with their programs. 11:33:37
19	A. Yes. 11:31:24	19	Q. Okay. Is this separate from 11:33:40
20	Q. Okay. So turning to the slides 11:31:24	20	the chargeback program that you discussed 11:33:41
21	1 and 2, on slide 2, it refers to meeting 11:31:31	21	earlier? 11:33:44
22	participants, yourself and three other 11:31:38	22	A. Yes, it is. 11:33:44
23	Covidien/Mallinckrodt folks, and then four 11:31:41	23	Q. Okay. And so slide 7 is 11:33:45
24	AmerisourceBergen folks, correct? 11:31:47	24	showing us the volume-based rebate. Is that 11:33:48
25	A. Correct. 11:31:49	25	the VIP rebate? 11:33:51
	Page 131		Page 133
1	Q. Was this a regular type of 11:31:49	1	A. Correct. 11:33:53
2	meeting that was held between Mallinckrodt 11:31:55	2	Q. Okay. And so 11:33:53
3	and AmerisourceBergen? 11:31:58	3	AmerisourceBergen, from April of '09 through 11:33:57
4	MR. O'CONNOR: Object to form. 11:32:00	4	October of '09, had total sales of a little 11:34:03
5	THE WITNESS: I would not say 11:32:01	5	bit more than 29 million, correct? 11:34:06
6	it was regular. It was not regular. 11:32:02	6	A. Correct. 11:34:07
7	QUESTIONS BY MR. GOTTO: 11:32:05	7	Q. And then the numbers below the 11:34:08
8	Q. Okay. Do you recall if there 11:32:06	8	table, what do those numbers indicate? 11:34:10
9	was any particular reason for this this 11:32:09	9	A. Those numbers are the volume 11:34:14
10	meeting and this strategic business update to 11:32:10	10	that if they reached to the right is the 11:34:18
11	be prepared? 11:32:13 A. No, I don't. I don't. 11:32:13	11	amount of the rebate that they would receive, 11:34:20 AmerisourceBergen 11:34:23
13	A. No, 1 don't. 1 don't. 11:32:13 Q. Okay. Do you recall 11:32:15	13	Q. Okay. 11:34:24
14	participating in similar strategic meetings 11:32:18	14	A for reaching those dollar 11:34:24
15	with other customers of Mallinckrodt from 11:32:25	15	amounts. 11:34:28
16	time to time? 11:32:28	16	Q. Okay. So if Amerisource 11:34:28
17	MR. O'CONNOR: Object to form. 11:32:28	17	since AmerisourceBergen had 29 million and 11:34:31
18	THE WITNESS: I don't recall 11:32:29	18	change during this period, am I reading this 11:34:34
19	any specific meetings, no. 11:32:30	19	correctly they would have received 5 percent 11:34:36
1 - 7	QUESTIONS BY MR. GOTTO: 11:32:31	20	of 17.6 million and then 7 percent of the 11:34:38
20	QUEDITORD DI MIK. UUTTU. 11:32:31	20	•
20	O Okay Do you recall if I 11.22.22	21	difference between 17.6 well I guess 15 11.24.42
21	Q. Okay. Do you recall if I 11:32:32	21	difference between 17.6 well, I guess 15 11:34:43 million more on top of that 17.76 to 32.6 11:34:46
21 22	realize this this is from December of '09, 11:32:41	22	million more on top of that 17.76, to 32.6, 11:34:46
21 22 23	realize this this is from December of '09, 11:32:41 which was your first year at Mallinckrodt. 11:32:44	22	million more on top of that 17.76, to 32.6, 11:34:46 and then 8 percent well, they didn't get 11:34:52
21 22	realize this this is from December of '09, 11:32:41	22 23 24	million more on top of that 17.76, to 32.6, 11:34:46

	Page 134		Page 136
1	5 percent of the first 17.6 and 7 percent of 11:34:55	1	that document aside. 11:37:15
2	the balance; is that correct? 11:34:58	2	MR. GOTTO: Actually, before we 11:37:47
3	A. No, they would have gotten 11:34:58	3	get into this, maybe it would be a 11:37:48
4	7 percent of the entire sale. 11:35:00	4	good time to take a break. So why 11:37:51
5	Q. I see. 11:35:01	5	don't we go off the record. 11:37:52
6	So it ratchets it up for the 11:35:02	6	VIDEOGRAPHER: We're going off 11:37:54
7	entire thing if you reach the the next 11:35:03	7	the record at 11:19 a m. {sic}. 11:37:55
8	tier? 11:35:06	8	(Off the record at 11:37 a m.) 11:37:58
9	A. Correct. 11:35:07	9	VIDEOGRAPHER: We are back on 11:52:26
10	Q. Okay. And was that volume 11:35:08	10	the record at 11:52 a m. 11:52:36
11	were those volume thresholds, were those six 11:35:16	11	(Mallinckrodt-Collier Exhibits 11:52:37
12	months? One year? How were they set out? 11:35:20	12	6 and 7 marked for identification.) 11:52:38
13	A. One year. 11:35:23	13	QUESTIONS BY MR. GOTTO: 11:52:38
14	Q. Okay. So here we have six 11:35:24	14	Q. Ms. Collier, we've marked as 11:52:45
15	one, two, three, four, five these are 11:35:32	15	Exhibits 6 and 7 an e-mail and attachment 11:52:47
16	seven months, actually, of results that we're 11:35:32	16	from 2009. 11:52:57
17	seen on this chart, correct, from April 11:35:36	17	Exhibit 6 is Bates 11:52:57
18	through October? 11:35:37	18	MNK-T1_0006305472, and Exhibit 7 is a 11:53:00
19	A. Correct. 11:35:38	19	document that was produced in native format 11:53:05
20	Q. So if AmerisourceBergen had 11:35:38	20	under MNK-T1_0006305473. 11:53:07
21	additional sales over the remaining five 11:35:43	21	Would you take a moment to look 11:53:13
22	months, their rebate would be determined 11:35:46	22	at those materials and tell me if you 11:53:16
23	based on the table the figures below the 11:35:49	23	recognize them. 11:53:18
24	table, ultimately, correct? 11:35:52	24	Do you recognize those 11:56:59
25	A. Correct. 11:35:53	25	materials? 11:57:00
	Page 135		Page 137
	Page 133	1	
1	_	1	_
1 2	Q. Okay. On slide 9, there's 11:35:54	1 2	A. Yes, I do. 11:57:00
2	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12	2	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02
2 3	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14	2	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04
2 3 4	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16	2 3 4	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10
2 3 4 5	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16	2 3 4 5	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13
2 3 4 5 6	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19	2 3 4 5 6	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14
2 3 4 5	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25	2 3 4 5	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14
2 3 4 5 6 7 8	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28	2 3 4 5 6 7 8	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17
2 3 4 5 6 7 8	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31	2 3 4 5 6 7 8	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22
2 3 4 5 6 7 8 9	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33	2 3 4 5 6 7 8 9	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23
2 3 4 5 6 7 8	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37	2 3 4 5 6 7 8	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29
2 3 4 5 6 7 8 9 10 11	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42	2 3 4 5 6 7 8 9 10	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42	2 3 4 5 6 7 8 9 10 11 12 13	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40
2 3 4 5 6 7 8 9 10 11	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:44	2 3 4 5 6 7 8 9 10 11	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:44 to the customer, and the blue line represents 11:36:46	2 3 4 5 6 7 8 9 10 11 12 13	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. Okay. 11:57:44
2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:49	2 3 4 5 6 7 8 9 10 11 12 13 14	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:52	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:47
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:49 customer. So even though we declined in 11:36:52 sales, they had enough inventory to cover it 11:36:54	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:50
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:52 sales, they had enough inventory to cover it 11:36:54 during that period to ship to their customers 11:36:56	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:50 asterisk explains how modified gross is 11:57:53
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:52 sales, they had enough inventory to cover it 11:36:54 during that period to ship to their customers 11:36:56 with a slight dip. 11:36:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:50 asterisk explains how modified gross is 11:57:53 determined. 11:57:56
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:49 customer. So even though we declined in 11:36:52 sales, they had enough inventory to cover it 11:36:54 during that period to ship to their customers 11:36:56 with a slight dip. 11:36:59 Q. Okay. 11:37:00	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:50 asterisk explains how modified gross is 11:57:53 determined. 11:57:56 Is that a metric that had been 11:57:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:49 customer. So even though we declined in 11:36:52 sales, they had enough inventory to cover it 11:36:54 during that period to ship to their customers 11:36:56 with a slight dip. 11:36:59 Q. Okay. 11:37:00 A. That's my understanding. I 11:37:00	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes, I do. Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:47 modified gross with an asterisk, and then the 11:57:50 asterisk explains how modified gross is 11:57:53 determined. 11:57:56 Is that a metric that had been 11:57:57 used at Mallinckrodt at the time that you 11:58:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:52 sales, they had enough inventory to cover it 11:36:54 during that period to ship to their customers 11:36:56 with a slight dip. 11:36:59 Q. Okay. 11:37:00 mean, AmerisourceBergen, it's their data, so 11:37:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes, I do. 11:57:00 Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:50 asterisk explains how modified gross is 11:57:53 determined. 11:57:56 Is that a metric that had been 11:57:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. On slide 9, there's 11:35:54 reference to scorecard service levels. 11:36:12 What does "scorecard" mean in 11:36:14 this setting? 11:36:16 A. This would be on 11:36:16 AmerisourceBergen-driven grading of how 11:36:19 Mallinckrodt delivered product over time: if 11:36:25 we delivered on time, didn't deliver at all, 11:36:28 how did we perform. 11:36:31 Q. Okay. So on the table, there's 11:36:33 COV, raw service level and PRO raw service 11:36:37 level. 11:36:42 What are those showing us? 11:36:42 A. Covidien means what we shipped 11:36:44 to the customer, and the blue line represents 11:36:46 what ABC was allowed to ship to their 11:36:52 sales, they had enough inventory to cover it 11:36:54 during that period to ship to their customers 11:36:56 with a slight dip. 11:36:59 Q. Okay. 11:37:00 mean, AmerisourceBergen, it's their data, so 11:37:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes, I do. Q. Okay. And it appears that the 11:57:02 attachment is the beginnings of the business 11:57:04 review that you referred to in your 11/20/09 11:57:10 e-mail, correct? 11:57:13 A. Correct. 11:57:14 Q. Okay. So did you compile the 11:57:14 information that's included in Exhibit 7? 11:57:17 A. My team did, yes. 11:57:22 Q. Okay. If you would turn to 11:57:23 slide 5 in Exhibit 7, there's a term 11:57:29 "Covidien modified gross" with an asterisk. 11:57:36 It's slide 5 it would be. I believe 11:57:40 you're looking at 6. 11:57:43 A. Oh, I'm looking at 6. Okay. 11:57:44 Q. There you go. 11:57:46 There's a reference to Covidien 11:57:50 asterisk explains how modified gross is 11:57:53 determined. 11:57:56 Is that a metric that had been 11:57:57 used at Mallinckrodt at the time that you 11:58:01 joined, modified gross? 11:58:05

		_	
	Page 138		Page 140
1	metric was used? 11:58:12	1	The second secon
2	A. Because if we used WAC sales, 11:58:13	2	Q. Okay. On slide 6, under the 12:00:08
3	that would greatly increase the value of the 11:58:15	3	pie chart there's a reference to four key 12:00:14
4	products without having actual value. 11:58:18	4	product families represent 82 percent of 12:00:16
5	Q. Okay. 11:58:21	5	total modified gross sales. 12:00:19
6	A. So it would it would inflate 11:58:21	6	Do you see that? 12:00:20
7	the value of the product. 11:58:24	7	A. Correct. 12:00:21
8	Q. Okay. And when you say "WAC 11:58:25	8	Q. And do you recall that being 12:00:21
9	sales," you mean if you were not calculating 11:58:26	9	the case back in fiscal '09? 12:00:24
10	in the chargebacks? 11:58:28	10	A. Yes. 12:00:27
11	A. Correct. 11:58:30	11	Q. And do you recall if that 12:00:27
12	Q. Okay. And what's in the 11:58:30	12	metric changed over time in terms of those 12:00:37
13	footnote there's a reference to wholesaler 11:58:32	13	four product families and the percentage 12:00:40
14	differentials. 11:58:34	14	total modified gross sales that they 12:00:43
15	What is that? 11:58:35	15	represented? 12:00:45
16	A. Correct. We sometimes would 11:58:36	16	A. Yes, it changed significantly. 12:00:45
17	give a rebate or a discount on a given 11:58:39	17	Q. And how did it change? 12:00:47
18	product, for example, if we wanted to not 11:58:42	18	A. We launched new products which 12:00:48
19	deflate the total market. And so we would 11:58:45	19	contributed to the modified gross, and that 12:00:52
20	offer the customer one price, but we would 11:58:49	20	changed because one of the products we 12:00:55
21	give them a discount oh, excuse me, 11:58:51	21	launched, methylphenidate ER, was a sizeable 12:00:58
22	differentials is different. 11:58:56	22	product, so that made all these numbers look 12:01:02
23	Differentials is that, for 11:58:57	23	smaller, and some of our smaller products 12:01:05
24	example, we would price a particular 11:58:59	24	contributed, so we had a bigger contribution 12:01:07
25	customer, a chain store, higher and then give 11:59:02	25	from other products. 12:01:09
	customer, a chain store, nigher and then give 11.57.02		from other products.
	Page 139		Page 141
			<u> </u>
1	them a rebate or discount down to the actual 11:59:06	1	Q. Okay. All right. If you would 12:01:10
1 2	them a rebate or discount down to the actual 11:59:06 contract price because we didn't want the 11:59:08	1 2	
			Q. Okay. All right. If you would 12:01:10
2	contract price because we didn't want the 11:59:08	2	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23
2 3	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11	2	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38
2 3 4	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12	2 3 4	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40
2 3 4 5	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13	2 3 4 5	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43
2 3 4 5 6	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16	2 3 4 5 6	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45
2 3 4 5 6	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20	2 3 4 5 6 7	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47
2 3 4 5 6 7 8	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25	2 3 4 5 6 7 8	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49
2 3 4 5 6 7 8	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26	2 3 4 5 6 7 8	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53
2 3 4 5 6 7 8 9	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27	2 3 4 5 6 7 8 9	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55
2 3 4 5 6 7 8 9 10	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28	2 3 4 5 6 7 8 9 10	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00
2 3 4 5 6 7 8 9 10 11	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30	2 3 4 5 6 7 8 9 10 11	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55
2 3 4 5 6 7 8 9 10 11 12 13	contract price because we didn't want the 11:59:08 wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33	2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:05
2 3 4 5 6 7 8 9 10 11 12 13	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:05 Do you see that? 12:02:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:41	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:05 Do you see that? 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10 A. Anytime that we get a contract 12:02:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46 A. You've challenged the patent 11:59:47	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:05 Do you see that? 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10 A. Anytime that we get a contract 12:02:11 with a customer, we ask them for how many 12:02:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46 A. You've challenged the patent 11:59:47 that the brand has and say that you should be 11:59:49	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10 A. Anytime that we get a contract 12:02:11 with a customer, we ask them for how many 12:02:13 units they'll sell. And then we set our 12:02:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46 A. You've challenged the patent 11:59:47 that the brand has and say that you should be 11:59:49 able to launch before they before the 11:59:51	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10 A. Anytime that we get a contract 12:02:11 with a customer, we ask them for how many 12:02:13 units they'll sell. And then we set our 12:02:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46 A. You've challenged the patent 11:59:47 that the brand has and say that you should be 11:59:51 patent expires. And so that's what 11:59:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10 A. Anytime that we get a contract 12:02:11 with a customer, we ask them for how many 12:02:13 units they'll sell. And then we set our 12:02:15 pricing and incentives based on what they say 12:02:17 they're going to sell, and they may not come 12:02:19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46 A. You've challenged the patent 11:59:47 that the brand has and say that you should be 11:59:51 patent expires. And so that's what 11:59:55 Mallinckrodt had done, and so they negotiated 11:59:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	contract price because we didn't want the wholesaler to be able to see their actual 11:59:11 contract price. 11:59:12 Q. Okay. And then to get to 11:59:13 modified gross, you're also backing out the 11:59:16 oxycodone ER, fentanyl lozenge and fentanyl 11:59:20 patch. 11:59:25 What's the reason for taking 11:59:26 those out? 11:59:27 A. Because we hadn't launched them 11:59:27 yet, so we were looking forward and saying 11:59:28 that we don't include those the oxy ER was 11:59:30 discontinued. We had it for a period of time 11:59:33 before I arrived at the company. Part of a 11:59:34 paragraph IV filing against the branded 11:59:39 product, so we had exclusivity for a period. 11:59:41 Q. What do you mean when you say 11:59:44 "a paragraph IV filing"? 11:59:46 A. You've challenged the patent 11:59:47 that the brand has and say that you should be 11:59:51 patent expires. And so that's what 11:59:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. All right. If you would 12:01:10 turn back to slide 38, under the assumptions 12:01:23 under the table, one of the assumptions is 12:01:38 market growth rate 7 percent. 12:01:40 Do you recall what the basis 12:01:43 was for that assumption? 12:01:45 A. That would be historical 12:01:47 trends, what you see in historical trends, 12:01:49 that it was the market had been growing 12:01:51 over time. 12:01:53 Q. The next bullet item says, 12:01:55 "COV" I assume that's Covidien or 12:02:00 Mallinckrodt "will increase compliance at 12:02:02 McKesson." 12:02:06 A. Yes. 12:02:06 Q. What does that phrase mean, 12:02:06 "increase compliance" in this setting? 12:02:10 A. Anytime that we get a contract 12:02:11 with a customer, we ask them for how many 12:02:13 units they'll sell. And then we set our 12:02:15 pricing and incentives based on what they say 12:02:17 they're going to sell, and they may not come 12:02:19

1 value for the value that they said they were 12-02-24 2 2 2 3 at the plant and everything, so we expect 12-02-28 3 at the plant and everything, so we expect 12-02-28 3 at the plant and everything, so we expect 12-02-28 5 2 2 4 4 4 4 4 4 4 4				
2 going to deliver, and that drives production 12-02-28 2 2-02-28		Page 142		
3	1	• •	1	· · · · · · · · · · · · · · · · · · ·
4 them to buy as much as they said they were 12-02-30 5 going to. 12-02-33 6	2	•	2	•
5 going to. 12:02:33	3		3	•
And in this particular case, 12:02:33 Mexicsson was not buying what they said they 12:02:35 Mexicsson was not buying what they all diety 12:02:35 Mould in this certing means compliance with what their 12:02:48 Joy as the word "compliance" in 12:02:38 A. Ourcet. 12:04:44 A. No, it's what they said they 12:02:47 Company, and we would gain their business. 12:02:51 And they said, for example, that we can sell 12:02:53 have been buying 90,000 instead of a hundred 12:02:53 this total was an issue, and get them to buy 12:03:04 why are you not buying at the level you said 12:03:04 why there was an issue, and get them to buy 12:03:15 The compliance with what they 12:03:16 Why there was an issue, and get them to buy 12:03:16 Why there was an issue, and get them to buy 12:03:16 Why there was an issue word 12:03:16 Why there was an issue word 12:03:16 Why there was an issue why would be buying? 12:03:16 Why there was an issue word buying to 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word be buying? 12:03:16 Why there was an issue word the word 12:03:16 Why there was an issue word the word 12:03:16 Why there was an issue word the word 12:03:16 Why there was an issue word the word 12:03:16 Why there was an issue word the word 12:03:16 Why there was an issue word 12:03:16 Why the word 12:03	4		4	•
7	5		5	-
8 would. 12:02:38 9 Q. So the word "compliance" in 12:02:38 9 Q. Do you see that? 12:04:44 12:04:44 12:04:44 12:04:44 12:04:44 12:04:45 12:04:46 12:04:46 12:04:46 12:04:46 12:04:45 12:	6		6	•
9 Q. So the word "compliance" in 12:02:38 12:04:44 10 15:05:38 12:04:44 12:04:44 13:06:07 12:04:45 13:06:07 12:04:45 14:07 14:				
10 this setting means compliance with what their 12:02:42 12 A. No. it's what they said they 12:02:47 13 could — what they were buying from another 12:02:49 14 company, and we would gain their business 12:02:51 14 needed at the times, so we think that we'll 12:04:45 12 A. That means that we were not 12:04:47 13 able to supply our customers with what they 12:04:47 14 needed at the times, so we think that we'll 12:04:55 15 pick up that business in the coming year. 12:04:55 16 And they said, for example, that we can set 12:02:56 17 part business in the coming year. 12:04:55 17 performance, the bullet item says, "12:05:16 12:05:16 18 Walgreens business." 12:05:16 12:05:26 17 part business in the coming year. 12:05:16 18 Walgreens business." 12:05:16 18 Walgreens business." 12:05:18 19 Do you recall lift that occurred; 12:05:51 19 Do you recall lift that occurred; 12:05:18 19 Do you, lift that occurred; 12:05:18 19 Do you, lift t				•
11 sales or purchasing forecast had been? 12:02:44 12 A. No, it's what they said they 12:02:47 13 2004 and what they were buying from another 12:02:49 14 2:04:45 15 2:04:45 2:04:45 15 2:04:45 2:04:45 16 2:04:45 2:04:45 17 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 17 2:04:45 18 2:04:55 18 2:04:55 18 2:04:55 18 2:04:55 18 2:04:55 18 2:04:55 18 2:04:55 18 2:04:55 18 2:04:55		*		
12		•		•
13 could what they were buying from another 12:02:49 13 able to supply our customers with what they 12:04:47 12:04:50 13 And they said, for example, that we can set 12:02:51 15 and they said, for example, that we can set 12:02:56 17 have been buying 90,000 instead of a hundred 12:02:56 17 have been buying 90,000 instead of a hundred 12:02:56 18 thousand, or whatever the variance is 12:03:01 18 thousand, or whatever the variance is 12:03:01 19 And so we needed to ask them, 12:03:02 19 Do you recall if that occurred? 12:05:16 19 And so we needed to ask them, 12:03:06 12:03:06 12:03:06 12:03:09 12:03:12 13 this level they said they would. 12:03:12 12:03:09 12:03:12 13 this level they said they would. 12:03:13 12:03:14 13 had forecast they would be buying? 12:03:21 14 A. What they told us they had been 12:03:22 15 compliance with what they 12:03:23 16 Do you recall if that occurred? 12:05:18 12:05:29 12:05:19 12:05:29 12:05:19 12:05:29		· -		
14 company, and we would gain their business. 12:02:51 15 And they said, for example, that we can sell 12:02:55 16 a hundred thousand tablets, and they might 12:02:56 17 have been buying 90,000 instead of a hundred 12:02:58 18 thousand, or whatever the variance is. 12:03:01 19 And so we needed to ask them, 12:03:02 20 "why are you not buying at the level you said 12:03:04 21 you would," and try and drive and find out 12:03:04 22 why there was an issue, and get them to buy 12:03:09 22 at the level they said they would. 12:03:12 23 at the level they said they would. 12:03:13 24 Q. Okay. Tm just trying to 12:03:13 25 understand the meaning of the word 12:03:15 26 Teophilance" in this setting. 12:03:16 27 "compliance" in this setting. 12:03:16 28 Losompliance with what they 12:03:17 3 had forecast they would be buying? 12:03:21 4 A. What they told us they had been 12:03:22 5 purchasing from the competitor. So it could 12:03:24 6 Competitor, so we needed to find out why. 12:03:31 10 like a contractual term. Ir's just a term, 12:03:34 11 with is sidd you were going to buy; we want 12:03:41 12 were not, and if they could not meet the 12:03:48 15 original number that they provided. 12:03:46 16 Q. Okay. If you turn to the next 12:03:36 17 vere not, and if they could not meet the 12:03:46 18 vere not, and if they could not meet the 12:03:46 19 vere not, and if they could not meet the 12:03:46 10 Q. Okay. If you turn to the next 12:03:56 10 Q. Okay. If you turn to the next 12:03:66 10 Q. Okay. If you turn to the next 12:03:66 10 Q. Okay. If you turn to the next 12:03:66 10 Q. Okay. If you turn to the next 12:03:66 10 Q. Okay. If you turn to the next 12:03:66 10 Q. Okay. If you turn to the next 12:03:66 10 Q. Okay. If you turn to the next 1		• • • • • • • • • • • • • • • • • • • •		
15 And they said, for example, that we can sell 12:02:53 12:04:52 12:04:55 14 12:04:55 14 14 14 15 15 15 15				
16 a hundred thousand tablets, and they might 12:02:56 17 have been buying 90,000 instead of a hundred 12:02:58 18 thousand, or whatever the variance is 12:03:01 19 And so we needed to ask them, 12:03:02 19 Do you recall if that occurred? 12:05:18 12:05:18 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 12:05:29 19 19 19 19 19 19 19				
17				
18 thousand, or whatever the variance is. 12:03:01 18 Malgreens business." 12:05:16 19 And so we needed to ask them, 12:03:04 20 "why are you not buying at the level you said 12:03:06 21 you would," and try and drive and find out 12:03:09 22 why there was an issue, and get them to buy 12:03:09 22 why there was an issue, and get them to buy 12:03:09 23 at the level they said they would. 12:03:12 23 24 Q. Okay. I'm just trying to 12:03:13 25 understand the meaning of the word 12:03:15 25 understand the meaning of the word 12:03:16 20 understand the meaning of the word 12:03:16 20 understand the meaning of the word 12:03:17 21 compliance" in this setting. 12:03:16 22 understand they not be buying? 12:03:17 22 documents aside. 12:05:35 20 understand they not be buying? 12:03:21 22 documents aside. 12:05:35 20 understand they not be buying? 12:03:24 25 understand they not be buying? 12:03:21 25 understand they would be buying? 12:03:21 26 documents aside. 12:05:35 documents aside. 12:05:35 documents aside. 12:05:35 20 understand they not be understand they not said you were going to buy; we ward 12:03:48 various of they could not meet the 12:03:46 12:04:08 20 various of these products had a market growth at the provided 12:04:08 20 various of these products had a market growth at 12:04:12 21 various of these products had a market growth at 12:04:12 22 various of these products had a market growth at 12:04:12 23 Q. Okay. And would that be - 12:04:12 24 various of these products had a market growth at 12:04:13 25 26 27 28 27 29 29 29 29 20 20 20 20				•
19				• •
20		,		
21 you would," and try and drive and find out 12:03:06 22 why there was an issue, and get them to buy 12:03:09 23 at the level they said they would. 12:03:13 24 Q. Okay. I'm just trying to 12:03:13 24 A. If it's a particular product or 12:05:25 25:29 25 understand the meaning of the word 12:03:15 25 if it's in general. 12:05:31 26 If it's a particular product or 12:05:31 20 If it's in general. 12:05:31 20 If it's in general. 12:05:31 20 If it's in general. 12:05:33 20 If it's in general. 12:05:3				•
22 why there was an issue, and get them to buy 12:03:09 22 sure what this is referring to. 12:05:27 23 at the level they said they would. 12:03:12 23 Q. Okay. 12:05:29 24 Q. Okay. I'm just trying to 12:03:15 25 understand the meaning of the word 12:03:15 25 if it's in general. 12:05:31 26 27 20:05:29 27 20:05:29 28 29 29 29 29 29 29				e e
23 at the level they said they would. 12:03:12 23 Q. Okay. 12:05:29				
24 Q. Okay. I'm just trying to 12:03:13 24 A. If it's a particular product or 12:05:29 25 if it's in general. 12:05:31 26 27 27 28 27 29 29 29 29 29 29 29				_
Page 143 Compliance In this setting 12:03:16 Is compliance with what they 12:03:17 Is compliance with what they 12:03:21 Is compliance with what they 12:03:22 Is compliance with what they 12:03:22 Is compliance with what they 12:03:24 Is compliance with what they 12:03:34 It was a reason compliance is not 12:03:34 It was a reason compliance is not 12:03:34 It was a reason compliance is not 12:03:34 It was a reason compliance with what 12:03:34 It was a reason compliance with what 12:03:34 It was a reason compliance with what 12:03:34 It were not, and if they could not meet the 12:03:46 It was a reason compliance with what 12:03:46 It was a reason compliance with what 12:03:46 It was a reason compliance with what 12:03:34 It were not, and if they could not meet the 12:03:46 It was a reason compliance with what 12:03:46 It was a reason compliance with what 12:03:41 It were not, and if they could not meet the 12:03:46 It was a reason compliance with what 12:03:48 It was a reason compliance with what 12:0		•		•
Page 143 1 "compliance" in this setting. 12:03:16 2 Is compliance with what they 12:03:17 3 had forecast they would be buying? 12:03:21 4 A. What they told us they had been 12:03:22 5 purchasing from the competitor. So it could 12:03:24 6 be that either their demand had dropped off, 12:03:26 7 even though they switched from the other 12:03:28 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason — compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:34 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:56 17 Q. Okay. If you turn to the next 12:03:56 18 assumptions, there's a — market growth rate 12:04:02 19 historical data? 12:04:08 20 Q. Okay. And would that be — 12:04:12 21 various of these products had a market growth 12:04:13 22 A. Correct. 12:04:11 23 Q. Okay. And is this a document 12:10:22 24 various of these products had a market growth 12:04:13 25 documents aside. 12:05:35 26 documents aside. 12:06:02 27 (Mallinckrodt-Collier Exhibit 8 12:06:02 28 documents aside. 12:06:03 29 (Mallinckrodt-Collier Exhibit 8 12:06:02 20 Okey've marked as Exhibit 8 a 12:06:03 21 document produced in native format under 12:06:23 24 document produced in native format under 12:06:23 25 Q. Owey marked as Exhibit 8 a 12:06:03 26 Q. We've marked as Exhibit 8 a 12:06:03 27 document produced in native format under 12:06:25 28 Bates MNK-T1_0002236317, and it's a 12:06:25 29 PowerPoint deck that's — first slide 12:06:39 21 indicates Covidien Pharmaceuticals Specialty 12:06:43 22 Could you take a look and tell 12:06:49 23 Q. Okay. If you turn to the next 12:03:46 24 A. Okay. 12:06:25 25 Q. Do you recognize that document? 12:10:10 26 A. Yes, I do. 12:10:10 27 Q. And what is it? 12:10:10 28 A. It is our business review 12:10:11 2				
1 "compliance" in this setting. 12:03:16 2 Is compliance with what they 12:03:17 3 had forecast they would be buying? 12:03:21 4 A. What they told us they had been 12:03:22 4 Mallinckrodt-Collier Exhibit 8 12:06:02 4 Mallinckrodt-Collier Exhibit 8 12:06:03 5 purchasing from the competitor. So it could 12:03:24 5 QUESTIONS BY MR. GOTTO: 12:06:03 6 be that either their demand had dropped off, 12:03:26 7 even though they switched from the other 12:03:28 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 12 were not, and if they could not meet the 12:03:46 12 Could you take a look and tell 12:06:49 12 Could you take a look and tell 12:06:49 12 Could you take a look and tell 12:06:51 12 Could you take a look and tell 12:06:49 12 Could you take a look and tell 12:06:51 12 Could you take a look and tell 12:06:51 12 Could you take a look and tell 12:06:49 12 Could you take a look and tell 12:06:49 12 Could you take a look and tell 12:06:49 12 Could you take a look and tell 12:06:51 13 Could you take a look and tell 12:06:51 14 A. Okay. 12:06:52 15 Okay. If you turn to the next 12:03:36 15 Q. Do you recognize that document? 12:10:08 16 A. Yes, I do. 12:10:10 17 Various of these products had a market growth 12:04:08 17 Q. And what is it? 12:10:11 19 12:10:13 12:10:12 12:10:13 12:10:21 12:10:12 12:10:12 12:10:12 12:10:12 12:10:13 12:10:21 12:10:21 12:10:21 12:10:22 12:10:21 12:10:21 12:10:22 12:10:21 12:10:21 12:10:22 12:10:21 12:10:22 12:10:21 12:10:22 12:10:21 12:10:22 12:10:21 12:10:22 12:10:22 12:10:22 12:10:21 12:10:22 12:10:21 12:10:22	23	understand the meaning of the word 12.03.13	23	11 it's in general. 12.05.51
2 Is compliance with what they 12:03:17 2 documents aside. 12:05:35 3 had forecast they would be buying? 12:03:21 4 A. What they told us they had been 12:03:22 4 A. What they told us they had been 12:03:24 5 purchasing from the competitor. So it could 12:03:24 6 be that either their demand had dropped off, 12:03:26 7 even though they switched from the other 12:03:28 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:48 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 15 Q. Okay. If you turn to the next 12:04:06 15 percent here. 12:04:06 17 Q. And what is it? 12:10:10 17 18 this is in the produced in the produced in native format under 12:06:23 12:06:23 12:06:28 12:06:28 12:06:29 12:06:29 12:06:29 12:06:29 12:06:29 12:06:29 12:06:29 12:06:29 12:06:29 12:06:29 12:06:39 10:06:29 12:06:39 10:06:29 12:06:49 12:06:49 12:06:49 12:06:49 12:06:49 12:06:51 12:06:49 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:51 12:06:52 12:06:52 12:06:51 12:06:51 12:06:52 12:06:5		Page 143		Page 145
3 had forecast they would be buying? 12:03:21 4 A. What they told us they had been 12:03:22 5 purchasing from the competitor. So it could 12:03:24 6 be that either their demand had dropped off, 12:03:26 7 even though they switched from the other 12:03:28 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:34 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:56 16 Q. We've marked as Exhibit 8 a 12:06:03 17 document produced in native format under 12:06:25 18 Bates MNK-T1_0002236317, and it's a 12:06:28 19 PowerPoint deck that's first slide 12:06:39 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:34 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:46 16 Q. Okay. If you turn to the next 12:03:40 17 document produced in native format under 12:06:25 18 Bates MNK-T1_0002236317, and it's a 12:06:28 19 PowerPoint deck that's first slide 12:06:39 10 indicates Covidien Pharmaceuticals Specialty 12:06:43 11 Generics Business Review, April 7, 2010. 12:06:45 12 Could you take a look and tell 12:06:49 13 me if you recognize that document? 12:10:10 14 A. Okay. 12:06:51 15 Q. Do you recognize that document? 12:10:10 16 A. Yes, I do. 12:10:09 17 Q. And what is it? 12:10:10 18 A. It is our business review 12:10:11 19 document explaining the generic and our 12:10:13 19 budget and forecast for the year. 12:10:17 19 Q. And did you participate in the 12:10:18 10 preparation of this document? 12:10:20 11 A. Yes, I did. 12:10:21 12 Q. Okay. And is this a document 12:10:22	1	"compliance" in this setting 12.03.16	1	O Okay Okay Wa aan sat thosa 12:05:22
4 A. What they told us they had been 12:03:22 5 purchasing from the competitor. So it could 12:03:24 6 be that either their demand had dropped off, 12:03:26 7 even though they switched from the other 12:03:28 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:03:50 18 assumptions, there's a market growth rate 12:04:02 19 is 15 percent here. 12:04:06 20 Okay. And would that also be based on 12:04:08 21 A. Correct. 12:04:11 22 A. Correct. 12:04:11 23 Q. Okay. And would that be 12:04:12 24 various of these products had a market growth 12:04:13 24 marked for identification.) 12:06:03 25 QUESTIONS BY MR. GOTTO: 12:06:03 26 Q. We've marked as Exhibit 8 a 12:06:23 26 document produced in native format under 12:06:25 3 document produced in native format under 12:06:25 4 document produced in native format under 12:06:25 5 DeverPoint deck that's first slide 12:06:49 5 DeverPoint deck that's first slide 12:06:49 5 DeverPoint deck th	1	•	-	
5 purchasing from the competitor. So it could 12:03:24 5 QUESTIONS BY MR. GOTTO: 12:06:03 12:06:03 6 be that either their demand had dropped off, 21:03:26 6 Q. We've marked as Exhibit 8 a 12:06:23 12:06:25 7 even though they switched from the other 21:03:28 12:03:28 6 Q. We've marked as Exhibit 8 a 12:06:23 12:06:25 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 12:03:31 9 PowerPoint deck that's first slide 12:06:39 12:06:28 10 like a contractual term. It's just a term, 12:03:34 12:03:38 10 like a contractual term. It's just a term, 12:03:34 12:03:34 11 Generics Business Review, April 7, 2010. 12:06:45 12:06:49 12 what you said you were going to buy; we want 12:03:41 12:03:46 12 Could you take a look and tell 12:06:49 12:06:49 13 were not, and if they could not meet the 12:03:46 12:03:48 15 Q. Do you recognize that document? 12:10:08 12:06:51 14 were not, and if they could not meet the 12:03:56 16 A. Yes, I do. 12:10:09 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 16 A. Yes, I do. 12:10:10 A. It is our business review 12:10:11 18 assumptions, there's a market growth rate 12:04:09 12:04:08 20 A. Correct. 12:04:11	2	Is compliance with what they 12:03:17		documents aside. 12:05:35
6 be that either their demand had dropped off, 12:03:26 7 even though they switched from the other 12:03:28 8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 18 assumptions, there's a market growth rate 12:04:06 19 is 15 percent here. 12:04:06 20 We've marked as Exhibit 8 a 12:06:23 4 document produced in native format under 12:06:25 4 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:49 10 indicates Covidien Pharmaceuticals Specialty 12:06:43 11 Generics Business Review, April 7, 2010. 12:06:45 12 Could you take a look and tell 12:06:49 13 me if you recognize that document? 12:10:08 14 A. Okay. 12:06:52 15 Q. Do you recognize that document? 12:10:09 16 A. Yes, I do. 12:10:09 17 glide, slide 30 I'm sorry, 39, under the 12:03:56 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 20 Would that also be based on 12:04:08 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 23 Q. Okay. And would that be 12:04:12 24 various of these products had a market growth 12:04:13 24 various of these products had a market growth 12:04:13		Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21	2	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02
7 even though they switched from the other 8 competitor, so we needed to find out why. 12:03:28 7 document produced in native format under 12:06:25 12:06:25 8 competitor, so we needed to find out why. 12:03:29 8 Bates MNK-T1_0002236317, and it's a 12:06:28 9 And if it was a reason compliance is not 12:03:31 12:03:34 10 like a contractual term. It's just a term, 12:03:34 10 like a contractual term. It's just a term, 12:03:34 11 divided that's first slide 12:06:49 12:06:43 11 this is what you committed to. So this is 12:03:38 12:03:34 12 Generics Business Review, April 7, 2010. 12:06:45 12:06:45 12 wat you to buy that much. And find out why they 12:03:41 12:03:43 13 me if you recognize that document? 12:06:52 15 original number that they provided. 12:03:46 12:03:48 14 A. Okay. 12:06:52 15 original number that they provided. 12:03:50 15 Q. Do you recognize that document? 12:10:08 16 Q. Okay. If you turn to the next 12:03:50 16 A. Yes, I do. 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:04:06 12:04:06 18 assumptions, there's a market growth rate 12:04:08 12:04:06 20 Would that also be based on 12:04:08 20 Would that also be based on 12:04:08 20 Q. And did you participate in the 12:10:18 21 Q. Okay.	3 4	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22	2 3 4	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03
8 competitor, so we needed to find out why. 12:03:29 9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 18 assumptions, there's a market growth rate 12:04:02 19 is 15 percent here. 12:04:08 20 Would that also be based on 12:04:08 21 A. Correct. 12:04:11 22 A. Correct. 12:04:11 24 various of these products had a market growth 12:04:13 24 various of these products had a market growth 12:04:13 25 A. Yes, I did. 12:10:21 26 Okay. And is this a document 12:10:22 27 A. Okay. And is this a document 12:10:22	3 4	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24	2 3 4 5	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03
9 And if it was a reason compliance is not 12:03:31 10 like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 18 assumptions, there's a market growth rate 12:04:02 19 is 15 percent here. 12:04:06 10 indicates Covidien Pharmaceuticals Specialty 12:06:43 11 dividing Pharmaceuticals Specialty 12:06:43 12 Could you take a look and tell 12:06:49 13 me if you recognize that document? 12:06:51 14 A. Okay. 12:06:52 15 Q. Do you recognize that document? 12:10:08 16 A. Yes, I do. 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 21 A. Correct. 12:04:11 22 A. Correct. 12:04:11 23 Q. Okay. And would that be 12:04:12 24 various of these products had a market growth 12:04:13 24 Various of these products had a market growth 12:04:13	3 4 5 6	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26	2 3 4 5	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23
like a contractual term. It's just a term, 12:03:34 11 this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:04:02 18 assumptions, there's a market growth rate 12:04:02 19 is 15 percent here. 12:04:06 20 Would that also be based on 12:04:08 21 A. Correct. 12:04:11 22 A. Correct. 12:04:11 23 Q. Okay. And would that be 12:04:12 24 various of these products had a market growth 12:04:13 26 indicates Covidien Pharmaceuticals Specialty 12:06:43 10 indicates Covidien Pharmaceuticals Specialty 12:06:43 11 Generics Business Review, April 7, 2010. 12:06:45 12 Could you take a look and tell 12:06:49 12 Deould you take a look and tell 12:06:49 13 me if you recognize that document? 12:10:08 14 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 15 Q. And what is it? 12:10:09 16 A. Yes, I do. 12:10:10 18 A. It is our business review 12:10:11 19 document explaining the generic and our 12:10:13 20 budget and forecast for the year. 12:10:17 21 Q. And did you participate in the 12:10:18 22 preparation of this document? 12:10:20 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13	3 4 5 6 7	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28	2 3 4 5 6 7	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25
this is what you committed to. So this is 12:03:38 12 what you said you were going to buy; we want 12:03:41 13 you to buy that much. And find out why they 12:03:43 14 were not, and if they could not meet the 12:03:46 15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 18 assumptions, there's a market growth rate 12:04:02 19 is 15 percent here. 12:04:06 20 Would that also be based on 12:04:08 21 Q. Okay. And would that be 12:04:11 22 A. Correct. 12:04:11 23 Q. Okay. And would that be 12:04:12 24 various of these products had a market growth 12:04:13 11 Generics Business Review, April 7, 2010. 12:06:45 12 Could you take a look and tell 12:06:49 13 me if you recognize that document? 12:06:51 4 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 16 A. Yes, I do. 12:10:09 17 Q. And what is it? 12:10:10 18 A. It is our business review 12:10:11 20 budget and forecast for the year. 12:10:13 21 Q. And did you participate in the 12:10:18 22 preparation of this document? 12:10:20 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29	2 3 4 5 6 7 8	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28
12 what you said you were going to buy; we want 12:03:41 12 Could you take a look and tell 12:06:49 13 you to buy that much. And find out why they 12:03:43 13 me if you recognize that document? 12:06:51 14 were not, and if they could not meet the 12:03:46 14 A. Okay. 12:06:52 15 original number that they provided. 12:03:48 15 Q. Do you recognize that document? 12:10:08 16 Q. Okay. If you turn to the next 12:03:50 16 A. Yes, I do. 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 17 Q. And what is it? 12:10:10 18 assumptions, there's a market growth rate 12:04:02 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 20 budget and forecast for the year. 12:10:17 21 historical data? 12:04:09 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 22 preparation of this document? 12:10:21 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31	2 3 4 5 6 7 8	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39
13 you to buy that much. And find out why they 12:03:43 13 me if you recognize that document? 12:06:51 14 were not, and if they could not meet the 12:03:46 14 A. Okay. 12:06:52 15 original number that they provided. 12:03:48 15 Q. Do you recognize that document? 12:10:08 16 Q. Okay. If you turn to the next 12:03:50 16 A. Yes, I do. 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 17 Q. And what is it? 12:10:10 18 assumptions, there's a market growth rate 12:04:02 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 20 budget and forecast for the year. 12:10:17 21 A. Correct. 12:04:11 22 preparation of this document? 12:10:21 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13	3 4 5 6 7 8 9	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34	2 3 4 5 6 7 8 9	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43
14 were not, and if they could not meet the 12:03:46 14 A. Okay. 12:06:52 15 original number that they provided. 12:03:48 15 Q. Do you recognize that document? 12:10:08 16 Q. Okay. If you turn to the next 12:03:50 16 A. Yes, I do. 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 17 Q. And what is it? 12:10:10 18 assumptions, there's a market growth rate 12:04:02 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 20 budget and forecast for the year. 12:10:17 21 historical data? 12:04:09 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 22 preparation of this document? 12:10:20 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38	2 3 4 5 6 7 8 9 10	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45
15 original number that they provided. 12:03:48 16 Q. Okay. If you turn to the next 12:03:50 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 18 assumptions, there's a market growth rate 12:04:02 19 is 15 percent here. 12:04:06 20 Would that also be based on 12:04:08 21 historical data? 12:04:09 22 A. Correct. 12:04:11 23 Q. Do you recognize that document? 12:10:09 16 A. Yes, I do. 12:10:09 17 Q. And what is it? 12:10:10 18 A. It is our business review 12:10:11 19 document explaining the generic and our 12:10:13 20 budget and forecast for the year. 12:10:17 21 Q. And did you participate in the 12:10:18 22 preparation of this document? 12:10:20 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 26 Q. Do you recognize that document? 12:10:09 27 Q. And what is it? 12:10:10 28 A. It is our business review 12:10:11 29 budget and forecast for the year. 12:10:17 21 Q. And did you participate in the 12:10:18 22 preparation of this document? 12:10:21 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 29 Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41	2 3 4 5 6 7 8 9 10 11	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49
16 Q. Okay. If you turn to the next 12:03:50 16 A. Yes, I do. 12:10:09 17 slide, slide 30 I'm sorry, 39, under the 12:03:56 17 Q. And what is it? 12:10:10 18 assumptions, there's a market growth rate 12:04:02 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 20 budget and forecast for the year. 12:10:17 21 historical data? 12:04:09 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 22 preparation of this document? 12:10:20 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43	2 3 4 5 6 7 8 9 10 11 12 13	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51
17 slide, slide 30 I'm sorry, 39, under the 12:03:56 17 Q. And what is it? 12:10:10 18 assumptions, there's a market growth rate 12:04:02 18 A. It is our business review 12:10:11 19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 20 budget and forecast for the year. 12:10:17 21 historical data? 12:04:09 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 22 preparation of this document? 12:10:20 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46	2 3 4 5 6 7 8 9 10 11 12 13	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52
assumptions, there's a market growth rate 12:04:02 yellow is 15 percent here. 12:04:06 Would that also be based on 12:04:08 12:04:09 A. Correct. 12:04:11 22	3 4 5 6 7 8 9 10 11 12 13 14	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 01:03:48	2 3 4 5 6 7 8 9 10 11 12 13 14	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08
19 is 15 percent here. 12:04:06 19 document explaining the generic and our 12:10:13 20 Would that also be based on 12:04:08 20 budget and forecast for the year. 12:10:17 21 historical data? 12:04:09 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 22 preparation of this document? 12:10:20 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:50	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09
Would that also be based on 12:04:08 12:04:09 21 A. Correct. 12:04:11 22 Q. And did you participate in the 12:10:18 23 Q. Okay. And would that be 12:04:12 24 various of these products had a market growth 12:04:13 20 budget and forecast for the year. 12:10:17 21 Q. And did you participate in the 12:10:18 22 preparation of this document? 12:10:20 23 A. Yes, I did. 12:10:21 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:48 Q. Okay. If you turn to the next 12:03:56 slide, slide 30 I'm sorry, 39, under the 12:03:56	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10
21 historical data? 12:04:09 21 Q. And did you participate in the 12:10:18 22 A. Correct. 12:04:11 22 preparation of this document? 12:10:20 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:50 slide, slide 30 I'm sorry, 39, under the 12:03:56 assumptions, there's a market growth rate 12:04:02	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11
22 A. Correct. 12:04:11 22 preparation of this document? 12:10:20 23 Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:46 Q. Okay. If you turn to the next 12:03:50 slide, slide 30 I'm sorry, 39, under the 12:03:56 assumptions, there's a market growth rate 12:04:02 is 15 percent here. 12:04:06	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11 document explaining the generic and our 12:10:13
Q. Okay. And would that be 12:04:12 23 A. Yes, I did. 12:10:21 24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:48 Q. Okay. If you turn to the next 12:03:56 assumptions, there's a market growth rate 12:04:02 is 15 percent here. 12:04:08	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11 document explaining the generic and our 12:10:13 budget and forecast for the year. 12:10:17
24 various of these products had a market growth 12:04:13 24 Q. Okay. And is this a document 12:10:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:48 Q. Okay. If you turn to the next 12:03:50 slide, slide 30 I'm sorry, 39, under the 12:03:56 assumptions, there's a market growth rate 12:04:02 is 15 percent here. 12:04:08 historical data? 12:04:09	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11 document explaining the generic and our 12:10:13 budget and forecast for the year. 12:10:17 Q. And did you participate in the 12:10:18
	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:46 Q. Okay. If you turn to the next 12:03:50 slide, slide 30 I'm sorry, 39, under the 12:03:56 assumptions, there's a market growth rate 12:04:02 is 15 percent here. 12:04:06 Would that also be based on 12:04:08 historical data? 12:04:09 A. Correct. 12:04:11	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11 document explaining the generic and our 12:10:13 budget and forecast for the year. 12:10:17 Q. And did you participate in the 12:10:18 preparation of this document? 12:10:20
that job would propare on all alliant outsits.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:46 Q. Okay. If you turn to the next 12:03:50 slide, slide 30 I'm sorry, 39, under the 12:03:56 assumptions, there's a market growth rate 12:04:02 is 15 percent here. 12:04:08 historical data? 12:04:09 A. Correct. 12:04:11 Q. Okay. And would that be 12:04:12	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11 document explaining the generic and our 12:10:13 budget and forecast for the year. 12:10:17 Q. And did you participate in the 12:10:18 preparation of this document? 12:10:20 A. Yes, I did. 12:10:21
	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Is compliance with what they 12:03:17 had forecast they would be buying? 12:03:21 A. What they told us they had been 12:03:22 purchasing from the competitor. So it could 12:03:24 be that either their demand had dropped off, 12:03:26 even though they switched from the other 12:03:28 competitor, so we needed to find out why. 12:03:29 And if it was a reason compliance is not 12:03:31 like a contractual term. It's just a term, 12:03:34 this is what you committed to. So this is 12:03:38 what you said you were going to buy; we want 12:03:41 you to buy that much. And find out why they 12:03:43 were not, and if they could not meet the 12:03:46 original number that they provided. 12:03:48 Q. Okay. If you turn to the next 12:03:50 slide, slide 30 I'm sorry, 39, under the 12:03:56 assumptions, there's a market growth rate 12:04:02 is 15 percent here. 12:04:08 historical data? 12:04:09 A. Correct. 12:04:11 Q. Okay. And would that be 12:04:12 various of these products had a market growth 12:04:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	documents aside. 12:05:35 (Mallinckrodt-Collier Exhibit 8 12:06:02 marked for identification.) 12:06:03 QUESTIONS BY MR. GOTTO: 12:06:03 Q. We've marked as Exhibit 8 a 12:06:23 document produced in native format under 12:06:25 Bates MNK-T1_0002236317, and it's a 12:06:28 PowerPoint deck that's first slide 12:06:39 indicates Covidien Pharmaceuticals Specialty 12:06:43 Generics Business Review, April 7, 2010. 12:06:45 Could you take a look and tell 12:06:49 me if you recognize that document? 12:06:51 A. Okay. 12:06:52 Q. Do you recognize that document? 12:10:08 A. Yes, I do. 12:10:09 Q. And what is it? 12:10:10 A. It is our business review 12:10:11 document explaining the generic and our 12:10:13 budget and forecast for the year. 12:10:17 Q. And did you participate in the 12:10:18 preparation of this document? 12:10:21 Q. Okay. And is this a document 12:10:22

	Page 146		Page 148
1	A. Yes. It changed over time, 12:10:27	1	obtaining sufficient raw materials. 12:12:28
2	but, yes, something similar. 12:10:29	2	It's about our ability to manufacture 12:12:30
3	Q. If you turn to slide 4, it 12:10:32	3	the raw material, that it's a 12:12:32
4	indicates Fiscal Year 2010 Specialty Generics 12:10:44	4	difficult process and sometimes they 12:12:34
5	Objectives. First one is "rebuild customer 12:10:48	5	had failures. And so we couldn't get 12:12:36
6	confidence." 12:10:51	6	enough product, API, up to Hobart in 12:12:38
7	Do you recall why the objective 12:10:53	7	order to manufacture the finished 12:12:42
8	was to rebuild customer confidence at this 12:10:57	8	dosage form. 12:12:45
9	time? 12:10:59	9	QUESTIONS BY MR. GOTTO: 12:12:45
10	A. Because we had supply issues. 12:10:59	10	Q. Okay. So it's Mallinckrodt 12:12:45
11	Q. And what were those supply 12:11:01	11	manufacture of the raw materials for Hobart 12:12:46
12	issues? 12:11:03	12	that was the issue? 12:12:49
13	A. We had they were various, 12:11:03	13	A. Correct. 12:12:49
14	but some of it was having problems out of our 12:11:06	14	Q. I see. Okay. 12:12:50
15	API site, active pharmaceutical ingredients, 12:11:09	15	And do you know if the if 12:12:50
16	which are the raw materials, their inability 12:11:12	16	the manufacturing level or if the target 12:12:53
17	to supply enough product to the manufacturing 12:11:14	17	manufacturing level in 2009 was a higher 12:12:56
18	site in Hobart. Or Hobart had issues 12:11:18	18	level than the company had historically 12:12:58
19	supplying product. They couldn't produce to 12:11:18	19	engaged in? 12:13:01
20	the commitment the forecast, so they 12:11:23	20	MR. O'CONNOR: Object to form. 12:13:01
21	sometimes would not have inventory readily 12:11:27	21	THE WITNESS: I don't know 12:13:02
22	available when we needed it. 12:11:29	22	that. 12:13:02
23	Q. Okay. And so was that a 12:11:32	23	QUESTIONS BY MR. GOTTO: 12:13:02
24	problem that existed at the time you joined 12:11:35	24	Q. On slide 4, second bullet item 12:13:05
25	Mallinckrodt? 12:11:37	25	is "control price erosion." 12:13:08
	D 145		P 140
	Page 147		Page 149
1	A. Yes, it was. 12:11:38	1	Do you see that? 12:13:10
2	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38	2	Do you see that? 12:13:10 A. Correct. 12:13:11
2 3	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39	2	Do you see that? 12:13:10 A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11
2 3 4	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42	2 3 4	Do you see that? 12:13:10 A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13
2 3 4 5	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43	2 3 4 5	Do you see that? 12:13:10 A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16
2 3 4 5 6	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47	2 3 4 5	Do you see that? 12:13:10 A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19
2 3 4 5 6 7	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50	2 3 4 5 6 7	Do you see that? A. Correct. 12:13:10 A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21
2 3 4 5 6 7 8	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51	2 3 4 5 6 7 8	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24
2 3 4 5 6 7 8	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52	2 3 4 5 6 7 8	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27
2 3 4 5 6 7 8 9	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53	2 3 4 5 6 7 8 9	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31
2 3 4 5 6 7 8 9 10	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55	2 3 4 5 6 7 8 9 10	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32
2 3 4 5 6 7 8 9 10 11	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58	2 3 4 5 6 7 8 9 10 11	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:35
2 3 4 5 6 7 8 9 10 11 12 13	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00	2 3 4 5 6 7 8 9 10 11 12 13	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:38
2 3 4 5 6 7 8 9 10 11 12 13	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02	2 3 4 5 6 7 8 9 10 11 12 13	Do you see that? A. Correct. Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:38 A. Yes. 12:13:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05	2 3 4 5 6 7 8 9 10 11 12 13 14	Do you see that? A. Correct. Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:38 A. Yes. 12:13:39 Q. And do you know what was 12:13:40
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 12:12:07	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Do you see that? 12:13:10 A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:38 A. Yes. 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:42
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 12:12:07 of the problem was some difficulty in 12:12:10	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:38 A. Yes. 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes, it was. 12:11:38 Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 12:12:10 obtaining sufficient raw materials. 12:12:15	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46 general, that is just additional competitors, 12:13:48
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply 12:11:39 problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:47 so I don't know when 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 12:12:10 obtaining sufficient raw materials. 12:12:15 Do you know if in 2009 the 12:12:17	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46 general, that is just additional competitors, people 12:13:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply problems historically? A. I don't know for sure before 12:11:42 A. I don't know for sure before my time, 12:11:43 me, but it obviously happened before my time, 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 00 obtaining sufficient raw materials. 12:12:15 Do you know if in 2009 the 12:12:17 Mallinckrodt was seeking to obtain raw 12:12:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46 general, that is just additional competitors, people 12:13:51 taking business from each other, trying to 12:13:53
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply problems historically? A. I don't know for sure before 12:11:42 A. I don't know for sure before my time, 12:11:47 so I don't know when Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 0 obtaining sufficient raw materials. 12:12:17 Mallinckrodt was seeking to obtain raw 12:12:21 materials at a greater level than it had 12:12:23	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46 general, that is just additional competitors, 12:13:48 fierce competition among competitors, people 12:13:51 taking business from each other, trying to 12:13:53 gain share. Or companies taking business, 12:13:55
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 12:12:10 obtaining sufficient raw materials. Do you know if in 2009 the 12:12:17 Mallinckrodt was seeking to obtain raw 12:12:23 historically? 12:12:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:42 A. In the generic industry in 12:13:48 fierce competition among competitors, people 12:13:51 taking business from each other, trying to 12:13:55 not people. 12:13:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply problems historically? A. I don't know for sure before 12:11:42 A. I don't know for sure before my time, 12:11:43 me, but it obviously happened before my time, 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 00 obtaining sufficient raw materials. 12:12:15 Do you know if in 2009 the 12:12:17 Mallinckrodt was seeking to obtain raw 12:12:23 historically? 12:12:26 MR. O'CONNOR: Objection. 12:12:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46 general, that is just additional competitors, 12:13:48 fierce competition among competitors, people 12:13:51 taking business from each other, trying to 12:13:55 not people. 12:13:57 Q. Okay. Turn if you would to 12:13:58
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply problems historically? 12:11:42 A. I don't know for sure before 12:11:43 me, but it obviously happened before my time, 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 12:12:10 obtaining sufficient raw materials. 12:12:15 Do you know if in 2009 the 12:12:17 Mallinckrodt was seeking to obtain raw 12:12:23 historically? 12:12:26 MR. O'CONNOR: Objection. 12:12:26 Form. 12:12:27	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:38 A. Yes. 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:42 A. In the generic industry in 12:13:46 general, that is just additional competitors, 12:13:51 taking business from each other, trying to 12:13:53 gain share. Or companies taking business, 12:13:55 not people. 12:13:57 Q. Okay. Turn if you would to 12:13:58 slide 51, which is a pie chart showing the 12:14:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes, it was. Q. Okay. Do you know if the 12:11:38 company had experienced similar supply problems historically? A. I don't know for sure before 12:11:42 A. I don't know for sure before my time, 12:11:43 me, but it obviously happened before my time, 12:11:50 Q. Sure. 12:11:51 A how the frequency. 12:11:52 Q. Okay. In terms of the problems 12:11:53 that were experienced in fiscal '09, do you 12:11:55 know if it was the result of an increase in 12:11:58 demand for the products? 12:12:00 A. In 2009, I'm not sure what the 12:12:02 problem was. 12:12:05 Q. Okay. And you indicated part 00 obtaining sufficient raw materials. 12:12:15 Do you know if in 2009 the 12:12:17 Mallinckrodt was seeking to obtain raw 12:12:23 historically? 12:12:26 MR. O'CONNOR: Objection. 12:12:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Do you see that? A. Correct. 12:13:11 Q. And what's that referring to? 12:13:11 A. That means that we do not want 12:13:13 to have our products erode in the 12:13:16 marketplace, so we balance our market share 12:13:19 against the additional prices that we need to 12:13:21 price concessions we need to give or 12:13:24 incentives we need to give in order to gain 12:13:27 that additional business. 12:13:31 Q. Okay. Was price erosion a 12:13:32 problem at the time that you were 12:13:35 particularly focused on addressing? 12:13:39 Q. And do you know what was 12:13:40 causing that problem in fiscal '09? 12:13:46 general, that is just additional competitors, 12:13:48 fierce competition among competitors, people 12:13:51 taking business from each other, trying to 12:13:55 not people. 12:13:57 Q. Okay. Turn if you would to 12:13:58

	Page 150		Page 152
1	One of the items in the pie 12:14:15	1	A. Some of them are general 12:16:24
2	chart is seminars, meetings, conferences. 12:14:20	2	national conventions, so that was just 12:16:27
3	Do you see that? 12:14:22	3	standard industry attendance. So it was 12:16:30
4	A. Yes. 12:14:23	4	expected that we would attend those, but 12:16:32
5	Q. What types of seminars, 12:14:23	5	ultimately that would be decided by the 12:16:35
6	meetings, conferences would Mallinckrodt 12:14:24	6	president of the team. 12:16:36
7	participate in that gave rise to this 12:14:29	7	Q. Okay. Take a look at slide 54, 12:16:38
8	expense? 12:14:33	8	if you would, please. There's a reference to 12:16:48
9	A. We would attend conferences or 12:14:33	9	unapproved products deletions unapproved 12:16:56
10	trade shows with sometimes with the 12:14:35	10	products deletion. 12:17:01
11	executives, so the buyers from the 12:14:40	11	Do you know what that's 12:17:03
12	warehousing chains, the wholesalers or their 12:14:43	12	referring to? 12:17:04
13	executives. And sometimes we would attend 12:14:47	13	A. Yes. At one point products 12:17:04
14	like a there's a hospital pharmacy buyer 12:14:49	14	that were before the I don't know the 12:17:06
15	meeting, so we would attend a buyer meeting 12:14:52	15	regulation or the ruling, but before generics 12:17:11
16	to talk to the pharmacy buyers to find out 12:14:54	16	had proved that they were safe and effective, 12:17:14
17	what they're doing as far as their trends and 12:14:56	17	these products were already in the market so 12:17:18
18	going forward. 12:14:59	18	they didn't have to go through that process. 12:17:20
19	And some were educational, some 12:15:01	19	And so they were grandfathered, and you could 12:17:21
20	were like, for example, the Wholesale 12:15:06	20	sell grandfathered products. 12:17:24
21	Distributor Manufacturer Association, HDMA at 12:15:08	21	And Mallinckrodt was selling 12:17:26
22	the time, we would attend that to find out 12:15:11	22	these products long ago, and so we were 12:17:28
23	industry trends like on the REMS regulations 12:15:14	23	excluded. So but we were going to have to 12:17:32
24	or what was going on with other regulations 12:15:17	24	discontinue them because the government 12:17:34
25	with serialization. And that often would be 12:15:18	25	wanted everyone the FDA wanted everyone to 12:17:35
	Page 151		Page 153
	E		
1	somebody on my team to get an education 12:15:20	1	issue a new FDA I mean an ANDA to prove 12:17:37
1 2	somebody on my team to get an education 12:15:20 around some of this. 12:15:22	1 2	issue a new FDA I mean an ANDA to prove 12:17:37 that they were safe and effective. 12:17:42
			•
2	around some of this. 12:15:22	2	that they were safe and effective. 12:17:42
2	around some of this. 12:15:22 Q. Okay. And so down below I see 12:15:23	2	that they were safe and effective. 12:17:42 Q. Okay. And on the right-hand 12:17:44
2 3 4	around some of this. 12:15:22 Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 12:15:28	2 3 4	that they were safe and effective. 12:17:42 Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47
2 3 4 5	around some of this. 12:15:22 Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. 12:15:30	2 3 4 5	that they were safe and effective. 12:17:42 Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50
2 3 4 5 6	around some of this. 12:15:22 Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 12:15:28 exhibits. 12:15:30 Is that a different type of 12:15:30	2 3 4 5	that they were safe and effective. 12:17:42 Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50
2 3 4 5 6 7	around some of this. 12:15:22 Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 12:15:28 exhibits. 12:15:30 Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37	2 3 4 5 6 7	that they were safe and effective. 12:17:42 Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03
2 3 4 5 6 7 8	around some of this. 12:15:22 Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. 12:15:30 Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39	2 3 4 5 6 7 8	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:17:42
2 3 4 5 6 7 8	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. 12:15:30 Is that a different type of 12:15:30 event from what you've just described? A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:24	2 3 4 5 6 7 8	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09
2 3 4 5 6 7 8 9	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 12:15:28 exhibits. 12:15:30 Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47	2 3 4 5 6 7 8 9	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12
2 3 4 5 6 7 8 9 10	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 21:15:28 exhibits. Is that a different type of 12:15:30 event from what you've just described? A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53	2 3 4 5 6 7 8 9 10 11 12 13	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12
2 3 4 5 6 7 8 9 10 11 12 13	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. 12:15:30 Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57	2 3 4 5 6 7 8 9 10 11 12 13	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13
2 3 4 5 6 7 8 9 10 11 12 13 14	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. Is that a different type of 12:15:30 event from what you've just described? A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00	2 3 4 5 6 7 8 9 10 11 12 13 14 15	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 21:15:28 exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. Is that a different type of 12:15:30 event from what you've just described? A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02 A. That often was the sales leader 12:16:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02 A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:07	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:20 customers didn't understand how the products 12:18:22
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 21:15:28 exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:10	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02 A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:10 then for educational purposes, I would decide 12:16:12	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24 just giving them information on and I 12:18:28
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02 A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:10 then for educational purposes, I would decide 12:16:12 who on my team should go to learn a little 12:16:14	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24 just giving them information on and I 12:18:28 don't know that we used it, so I'll start 12:18:31
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 12:15:28 exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02 A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:10 then for educational purposes, I would decide 12:16:12 who on my team should go to learn a little 12:16:14 bit more about a category or an area. 12:16:17	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:17 showed everything from how because our 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24 just giving them information on and I 12:18:28 don't know that we used it, so I'll start 12:18:31 that off. But it was intended to show them 12:18:33
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 21:15:28 exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:07 customer meetings they would attend. And 12:16:10 then for educational purposes, I would decide 12:16:12 who on my team should go to learn a little 12:16:14 bit more about a category or an area. 12:16:17 Q. And how about the conventions 12:16:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:17 showed everything from how because our 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24 just giving them information on and I 12:18:31 that off. But it was intended to show them 12:18:33 how the product goes from raw opium into a 12:18:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and exhibits. 12:15:30 Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? 12:16:02 A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:10 then for educational purposes, I would decide 12:16:12 who on my team should go to learn a little 12:16:14 bit more about a category or an area. 12:16:17 Q. And how about the conventions 12:16:20 and exhibits? Who would decide what which 12:16:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:17 showed everything from how because our 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24 just giving them information on and I 12:18:31 that off. But it was intended to show them 12:18:33 how the product goes from raw opium into a 12:18:35 finished dosage tablet. 12:18:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	around some of this. Q. Okay. And so down below I see 12:15:23 COND, which I assume is conventions and 21:15:28 exhibits. Is that a different type of 12:15:30 event from what you've just described? 12:15:32 A. Correct. That would include 12:15:35 the conventions, you know, attending some of 12:15:37 the educational shows to learn, but also the 12:15:39 cost of the exhibits when we had to display. 12:15:44 Q. Okay. Who made the 12:15:47 determination as to what seminars and 12:15:53 meetings Mallinckrodt would participate in 12:15:57 that give rise to the expenses that are shown 12:16:00 on this slide? A. That often was the sales leader 12:16:04 would decide which sales meeting which 12:16:07 customer meetings they would attend. And 12:16:10 then for educational purposes, I would decide 12:16:12 who on my team should go to learn a little 12:16:14 bit more about a category or an area. 12:16:17 Q. And how about the conventions 12:16:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that they were safe and effective. Q. Okay. And on the right-hand 12:17:44 column there's identity of the products that 12:17:47 fall under this category, correct? 12:17:50 A. Correct. 12:17:50 Q. Okay. Turn, if you would, to 12:17:51 slide 59. 12:18:01 A. (Witness complies.) 12:18:03 Q. Improve Customer Confidence. 12:18:03 The second bullet item is "narcotic story." 12:18:09 Do you see that? 12:18:12 A. Yes. 12:18:12 Q. What does that refer to? 12:18:13 A. That was an active 12:18:14 pharmaceutical ingredient initiative. It 12:18:17 showed everything from how because our 12:18:20 customers didn't understand how the products 12:18:22 were actually made from raw opium, so it was 12:18:24 just giving them information on and I 12:18:31 that off. But it was intended to show them 12:18:33 how the product goes from raw opium into a 12:18:35

	5 1		
	Page 154		Page 156
1	under the heading "Improve Customer 12:18:46	1	
2	Confidence," was there a belief that there 12:18:48	2	A. Yes, I did. 12:22:42
3	was some failure of customer confidence with 12:18:53	3	Q. Okay. If you turn to slide 2, 12:22:44
4	respect to Mallinckrodt's manufacturing 12:18:55	4	you'll see it's an org chart, and this the 12:22:48
5	process, or what gave rise to that being 12:18:58	5	spot that previously had been occupied by 12:22:52
6	something that you'd address to deal with 12:19:01	6	Ms. Muhlenkamp is identified as vacant. 12:22:55
7	customer confidence? 12:19:03	7	So is that consistent with your 12:22:58
8	A. Supply. It was a supply issue. 12:19:05	8	recollection, by February 2011 Ms. Muhlenkamp 12:23:00
9	And to explain to them and it went all the 12:19:07	9	had left? 12:23:04
10	way back to India where we secured the opium, 12:19:10	10	A. Yes. 12:23:04
11	and then we had our manufacturing in 12:19:13	11	Q. And ultimately ultimately, 12:23:05
12	St. Louis and in Hobart. So just to explain 12:19:14	12	who took that spot? 12:23:10
13	to them that we are thoroughly knowledged in 12:19:19	13	A. Jennifer Bullerdick, and then I 12:23:11
14	the process of converting it from raw 12:19:21	14	hired Jake Longenecker from the API site. 12:23:14
15	material to finished dosage form. 12:19:23	15	Q. Okay. Great. 12:23:26
16	Q. Okay. You can set that 12:19:26	16	On slide 3, Ranking of Generic 12:23:26
17	document aside. 12:19:30	17	Companies, Covidien/Mallinckrodt is indicated 12:23:35
18	A. Okay. 12:19:56	18	MAT September 2010 rank. 12:23:38
19	(Mallinckrodt-Collier Exhibit 9 12:19:56	19	What is MAT? 12:23:41
20	marked for identification.) 12:19:57	20	A. Moving annual total. 12:23:42
21	QUESTIONS BY MR. GOTTO: 12:19:57	21	Q. Okay. And scripts are 12:23:44
22	Q. We've marked as document as 12:20:05	22	prescriptions; is that right? 12:23:47
23	Exhibit 9 a document produced in native 12:20:09	23	A. Correct. 12:23:47
24	format under Bates MNK-T1_0002237098. 12:20:11	24	Q. Okay. And share of generics, 12:23:49
25	Would you take a moment to take 12:20:19	25	do you know how that's calculated? 12:23:51
	Page 155		Page 157
1	a look at that document, please? 12:20:20	1	A. It's the total number of 12:23:53
2	A. Okay. 12:20:20	2	prescriptions. For example, on Teva, it 12:23:57
3	Q. Do you recognize that document? 12:22:03	3	would be their number of prescriptions by the 12:23:59
4	A. Yes, I do. 12:22:04	4	total number that were provided in the 12:24:01
5	Q. And what is it? 12:22:04	5	Wolters Kluwer study. 12:24:03
6	A. It is a business review that 12:22:05	6	Q. Okay. So it's not a dollar 12:24:04
7	was presented to our manufacturing site in 12:22:11	7	determination? 12:24:06
8	Hobart. 12:22:12	8	A. No. 12:24:06
9	Q. Okay. Was that a regular 12:22:13	9	Q. It's a number of prescriptions 12:24:06
10	process, to present a business review to 12:22:16	10	determination? 12:24:08
11	Hobart? 12:22:18	11	A. Correct. 12:24:08
	1100ait: 12.22.16		
12	A. No, it was not. 12:22:18	12	Q. Okay. And again so here the 12:24:08
		12 13	Q. Okay. And again so here the 12:24:08 company is identified Covidien/Mallinckrodt, 12:24:13
12	A. No, it was not. 12:22:18		•
12 13	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19	13	company is identified Covidien/Mallinckrodt, 12:24:13
12 13 14	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21	13 14	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16
12 13 14 15	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23	13 14 15	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18
12 13 14 15 16	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26	13 14 15 16	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19
12 13 14 15 16	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26 were doing and why we came up with our 12:22:28	13 14 15 16 17	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19 Q. Okay. 12:24:20
12 13 14 15 16 17	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26 were doing and why we came up with our 12:22:28 forecast numbers. 12:22:30	13 14 15 16 17 18	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19 Q. Okay. 12:24:20 A. Not for the generics. 12:24:22
12 13 14 15 16 17 18	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26 were doing and why we came up with our 12:22:28 forecast numbers. 12:22:30 Q. Okay. And so who made this 12:22:31	13 14 15 16 17 18	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19 Q. Okay. 12:24:20 A. Not for the generics. 12:24:22 Q. Yeah. 12:24:24
12 13 14 15 16 17 18 19	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26 were doing and why we came up with our 12:22:28 forecast numbers. 12:22:30 Q. Okay. And so who made this 12:22:31 presentation? 12:22:33	13 14 15 16 17 18 19	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19 Q. Okay. 12:24:20 A. Not for the generics. 12:24:22 Q. Yeah. 12:24:24 Was that the case with branded 12:24:24
12 13 14 15 16 17 18 19 20 21	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26 were doing and why we came up with our 12:22:28 forecast numbers. 12:22:30 Q. Okay. And so who made this 12:22:31 presentation? 12:22:33 A. My team. 12:22:33	13 14 15 16 17 18 19 20 21	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19 Q. Okay. 12:24:20 A. Not for the generics. 12:24:22 Q. Yeah. 12:24:24 Was that the case with branded 12:24:24 product, that there was 12:24:25
12 13 14 15 16 17 18 19 20 21 22	A. No, it was not. 12:22:18 Q. Was there a reason this 12:22:19 particular presentation was made when it was? 12:22:21 A. To help them understand why 12:22:23 consistent supply was important in what they 12:22:26 were doing and why we came up with our 12:22:28 forecast numbers. 12:22:30 Q. Okay. And so who made this 12:22:31 presentation? 12:22:33 A. My team. 12:22:33 Q. And you participated in that? 12:22:35	13 14 15 16 17 18 19 20 21	company is identified Covidien/Mallinckrodt, 12:24:13 but there was no separate product line that 12:24:16 was Covidien versus Mallinckrodt, correct? 12:24:18 A. Correct. 12:24:19 Q. Okay. 12:24:20 A. Not for the generics. 12:24:22 Q. Yeah. 12:24:24 Was that the case with branded 12:24:24 product, that there was 12:24:25 A. I don't know. 12:24:26

	D 150	T	D 160
1	Page 158 underscore, the generic core business." 12:24:50	1	Page 160 QUESTIONS BY MR. GOTTO: 12:27:07
2	So the reference here to the 12:24:53	2	Q. We've marked as Exhibit 10 a 12:27:28
3	generic core business, what would that be 12:24:56	3	single-page or two-page document, sorry, 12:27:31
4	referring to? 12:24:58	4	beginning at Bates MNK-T1 0002738887. It 12:27:37
	A. Our portfolio products. And so 12:24:58	5	appears to be a letter that you sent out 12:27:43
5			October 11, 2011. 12:27:47
6	_	6	
7	additional share or increase prices or 12:25:06 maintain the current business of customers. 12:25:12		Please take a look and tell me 12:27:48
8		8	if you recognize it. 12:27:50
9	Q. Okay. Okay. And turn to 12:25:16	9	A. Okay. 12:27:51
10	slide 12, please. 12:25:18	10	Q. Do you recognize that letter? 12:28:27
11	A. Yes. 12:25:19	11	A. Yes, I do. 12:28:30
12	Q. Slide 12, one of the fiscal 12:25:19	12	Q. And do you recall sending this 12:28:31
13	year '11 objectives is "reinforce 12:25:23	13	letter out in October of 2011? 12:28:34
14	Covidien/Mallinckrodt as pain management 12:25:28	14	A. I don't recall the date, but, 12:28:36
15	experts." 12:25:30	15	yes, it's on the letter, so I assume that's 12:28:39
16	Do you see that? 12:25:30	16	it. 12:28:42
17	A. Yes. 12:25:30	17	Q. Okay. Did you send a series of 12:28:42
18	Q. And what steps were taken to 12:25:31	18	similar letters out to other customers? 12:28:44
19	reinforce Covidien/Mallinckrodt as pain 12:25:33	19	A. Yes. 12:28:45
20	management experts? 12:25:37	20	Q. Okay. And this letter, the 12:28:46
21	A. I can only remember having 12:25:38	21	first paragraph says, "Mallinckrodt, LLC, 12:28:47
22	discussions with Karen about customers that 12:25:39	22	continues to experience supply challenges 12:28:51
23	were trying to set up their own warehouse, 12:25:43	23	related to our oxycodone immediate release 12:28:54
24	and she could help them do that. 12:25:46	24	tablets in 15-milligram and 30-milligram 12:28:57
25	I don't think anything came to 12:25:49	25	strengths. The supply issue is driven by 12:28:59
	Page 159		D 1/1
	1 agc 139		Page 161
1	fruition of this, but I don't remember for 12:25:50	1	unexpected quota shortfalls from the US Drug 12:29:03
1 2		1 2	
	fruition of this, but I don't remember for 12:25:50		unexpected quota shortfalls from the US Drug 12:29:03
2	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52	2	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06
2 3	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54	2	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07
2 3 4	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55	2 3 4	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09
2 3 4 5	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57	2 3 4 5	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11
2 3 4 5 6	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57	2 3 4 5	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12
2 3 4 5 6 7	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58	2 3 4 5 6 7	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13
2 3 4 5 6 7 8	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05	2 3 4 5 6 7 8	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14
2 3 4 5 6 7 8	fruition of this, but I don't remember for 12:25:50 sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09	2 3 4 5 6 7 8	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18
2 3 4 5 6 7 8 9	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14	2 3 4 5 6 7 8 9	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21
2 3 4 5 6 7 8 9 10	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17	2 3 4 5 6 7 8 9 10	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31
2 3 4 5 6 7 8 9 10 11	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14	2 3 4 5 6 7 8 9 10 11	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36
2 3 4 5 6 7 8 9 10 11 12 13	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17	2 3 4 5 6 7 8 9 10 11 12 13	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31
2 3 4 5 6 7 8 9 10 11 12 13	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20	2 3 4 5 6 7 8 9 10 11 12 13	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36
2 3 4 5 6 7 8 9 10 11 12 13 14 15	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25	2 3 4 5 6 7 8 9 10 11 12 13 14	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29 A. Well, it would be the expertise 12:26:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29 A. Well, it would be the expertise 12:26:30 that Karen offered in the compliance because 12:26:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45 reasons for those quota shortfalls? 12:29:49
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:30 that Karen offered in the compliance because 12:26:31 she could in the past they had helped 12:26:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45 reasons for those quota shortfalls? 12:29:49 MR. O'CONNOR: Object to form. 12:29:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29 A. Well, it would be the expertise 12:26:30 that Karen offered in the compliance because 12:26:31 she could in the past they had helped 12:26:35 other people with DEA inspections, how do you 12:26:37	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45 reasons for those quota shortfalls? 12:29:49 MR. O'CONNOR: Object to form. 12:29:51 THE WITNESS: No, I don't 12:29:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29 A. Well, it would be the expertise 12:26:30 that Karen offered in the compliance because 12:26:31 she could in the past they had helped 12:26:35 other people with DEA inspections, how do you 12:26:37 work with the DEA and things like that. 12:26:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45 reasons for those quota shortfalls? 12:29:49 MR. O'CONNOR: Object to form. 12:29:51 THE WITNESS: No, I don't 12:29:51 recall why, because I did not interact 12:29:54
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29 A. Well, it would be the expertise 12:26:30 that Karen offered in the compliance because 12:26:35 other people with DEA inspections, how do you 12:26:37 work with the DEA and things like that. 12:26:42 Q. Okay. All right. You can set 12:26:43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45 reasons for those quota shortfalls? 12:29:49 MR. O'CONNOR: Object to form. 12:29:51 THE WITNESS: No, I don't 12:29:54 with the DEA. 12:29:55
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	fruition of this, but I don't remember for sure. I don't remember developing any 12:25:52 materials around this particular program. 12:25:54 Q. Okay. When you say "Karen," is 12:25:55 that Karen Harper? 12:25:57 A. Karen Harper. 12:25:57 Q. So in terms of pain management, 12:25:58 I mean, that would your recollection is 12:26:05 to that meant storing and warehousing 12:26:09 product? 12:26:13 A. That's our portfolio of 12:26:13 products, is pain management, so schedule 12:26:14 drugs would be another name. 12:26:17 Q. But the expertise that is being 12:26:20 reinforced here, what expertise is that, as 12:26:25 best you can recall? 12:26:29 A. Well, it would be the expertise 12:26:30 that Karen offered in the compliance because 12:26:31 she could in the past they had helped 12:26:35 other people with DEA inspections, how do you 12:26:37 work with the DEA and things like that. 12:26:42 Q. Okay. All right. You can set 12:26:43 that document aside. 12:26:50	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	unexpected quota shortfalls from the US Drug 12:29:03 Enforcement Administration, with no firm 12:29:06 answer at this point as to when that 12:29:07 situation will improve." 12:29:09 Do you recall that circumstance 12:29:11 back in 2011? 12:29:12 A. Yes, I do. 12:29:13 Q. So you had testified earlier 12:29:14 back in 2009 there were some supply issues 12:29:18 relating to some manufacturing constraints or 12:29:21 difficulties, correct? 12:29:26 In 2011, now there's supply 12:29:28 issues resulting from quota shortfalls. Do 12:29:31 you know what cause or well, strike that. 12:29:36 There's a reference here to 12:29:39 unexpected quota shortfalls. Did you ever 12:29:41 come to have an understanding as to the 12:29:45 reasons for those quota shortfalls? 12:29:49 MR. O'CONNOR: Object to form. 12:29:51 THE WITNESS: No, I don't 12:29:51 recall why, because I did not interact 12:29:54 with the DEA. 12:29:55 QUESTIONS BY MR. GOTTO: 12:29:56

			_
	Page 162		Page 164
1	what do you mean by that exactly? 12:30:03	1	A. I don't recall any specific 12:32:12
2	A. My understanding was at the 12:30:04	2	situations, but I'm sure I did. 12:32:14
3	time Mallinckrodt expected to have additional 12:30:06	3	Q. Did you were there any 12:32:16
4	quota, or enough quota to meet their annual 12:30:09	4	modifications made to the proposed 12:32:18
5	needs. And we did not receive that approval 12:30:13	5	allocations as a result of any feedback 12:32:22
6	from the DEA, and so we didn't have enough 12:30:18	6	received from customers? 12:32:25
7	inventory to allow that. 12:30:21	7	A. No. 12:32:26
8	I honestly don't even know if 12:30:23	8	Q. Okay. You can set that aside. 12:32:31
9	it was an API or finished dosage form quotas. 12:30:24	9	A. Not that I'm aware of. 12:32:32
10	Q. Okay. And do you know if 12:30:28	10	Q. Okay. And is that something 12:32:33
11	the if the quota that Mallinckrodt 12:30:29	11	that would have been a decision you would 12:32:34
12	received for the year was less than prior 12:30:32	12	have been involved in? 12:32:37
13	year quota, or do you have any understanding 12:30:37	13	A. Yes. 12:32:38
14	of that at all? 12:30:39	14	Q. Okay. You can set that aside. 12:32:39
15	A. I don't remember. 12:30:40	15	(Mallinckrodt-Collier Exhibit 12:32:49
16	Q. In the third paragraph you say, 12:30:42	16	11 marked for identification.) 12:32:50
17	"You were one of our valued partners, and it 12:30:50	17	QUESTIONS BY MR. GOTTO: 12:32:50
18	is our goal to meet as much of your demand as 12:30:52	18	Q. We've marked as Exhibit 12 12:33:11
19	possible. The impact this supply reduction 12:30:55	19	{sic} a multipage document beginning at Bates 12:33:14
20	could have on your business is well 12:30:58	20	MNK-T1_0007289278. Appears to be minutes and 12:33:16
21	understood. We have developed a supply plan, 12:31:00	21	action item from a November 23, 2011 business 12:33:23
22	attached, to maximize the amount of oxycodone 12:31:03	22	review meeting. 12:33:30 MR. O'CONNOR: Just for 12:33:31
23	we can ship to you in the coming months that 12:31:05	23	MR. O'CONNOR: Just for 12:33:31 clarity, this is marked 11. 12:33:32
24	are helping you to meet the needs of your 12:31:08 customers and their patients," correct? 12:31:10	24	MR. GOTTO: Is it 11? Oh, 12:33:36
25	customers and their patients, correct: 12.31.10	25	WIK. GOTTO: 18 It 11: Oil, 12.33.30
	Page 163		Page 165
1	A. Correct. 12:31:12	1	that's because I was looking at 12 12:33:38
2	Q. How did you go about developing 12:31:12	1 2	
		2	over here that we hadn't used yet. 12:33:39
3	the supply plan and allocating the available 12:31:14	3	Thank you. 12:33:41
4	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21	3 4	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41
4 5	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23	3 4 5	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42
4 5 6	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27	3 4 5 6	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42
4 5 6 7	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29	3 4 5 6 7	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43
4 5 6 7 8	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31	3 4 5 6 7 8	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45
4 5 6 7 8	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33	3 4 5 6 7 8	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. A. Page 3. 12:35:51
4 5 6 7 8 9	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35	3 4 5 6 7 8 9	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52
4 5 6 7 8 9 10	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39	3 4 5 6 7 8 9 10	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53
4 5 6 7 8 9 10 11	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43	3 4 5 6 7 8 9 10 11 12	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:54
4 5 6 7 8 9 10	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46	3 4 5 6 7 8 9 10	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:55 A. Yes, I do. 12:35:55
4 5 6 7 8 9 10 11 12 13	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48	3 4 5 6 7 8 9 10 11 12 13	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:54
4 5 6 7 8 9 10 11 12 13 14	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48	3 4 5 6 7 8 9 10 11 12 13	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:55 A. Yes, I do. 12:35:55 Q. And what is it? 12:35:57 A. This is from our sales and 12:35:58
4 5 6 7 8 9 10 11 12 13 14	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49	3 4 5 6 7 8 9 10 11 12 13 14	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:55 A. Yes, I do. 12:35:55 Q. And what is it? 12:35:57 A. This is from our sales and 12:35:58
4 5 6 7 8 9 10 11 12 13 14 15 16	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:55 A. Yes, I do. 12:35:55 Q. And what is it? 12:35:57 A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01
4 5 6 7 8 9 10 11 12 13 14 15 16	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:55 A. Yes, I do. 12:35:55 Q. And what is it? 12:35:57 A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01 have with the leaders of each business unit 12:36:03
4 5 6 7 8 9 10 11 12 13 14 15 16 17	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53 responses from various customers to this and 12:31:59	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Thank you. 12:33:41 MR. O'CONNOR: No problem. 12:33:41 QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. 12:35:51 Q. Yes, page 3, please. 12:35:52 First of all, do you recognize 12:35:53 what this document is? 12:35:55 A. Yes, I do. 12:35:55 Q. And what is it? 12:35:57 A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01 have with the leaders of each business unit 12:36:03 and manufacturing. 12:36:06
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53 responses from various customers to this and 12:31:59 other similar letters that went out at this 12:32:01	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Thank you. MR. O'CONNOR: No problem. QUESTIONS BY MR. GOTTO: 12:33:42 Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. A. Page 3. Q. Yes, page 3, please. First of all, do you recognize 12:35:53 what this document is? A. Yes, I do. 12:35:55 Q. And what is it? A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01 have with the leaders of each business unit 12:36:03 and manufacturing. Q. Okay. So turn to the third 12:36:08
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53 responses from various customers to this and 12:31:59 other similar letters that went out at this 12:32:01 time? 12:32:03	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Thank you. MR. O'CONNOR: No problem. QUESTIONS BY MR. GOTTO: Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. A. Page 3. Q. Yes, page 3, please. First of all, do you recognize 12:35:53 what this document is? A. Yes, I do. Q. And what is it? A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01 have with the leaders of each business unit 12:36:03 and manufacturing. Q. Okay. So turn to the third 12:36:08 page, please, and the table in the middle of 12:36:09
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53 responses from various customers to this and 12:31:59 other similar letters that went out at this 12:32:01 time? 12:32:03 A. I recall many customers were 12:32:05	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Thank you. MR. O'CONNOR: No problem. QUESTIONS BY MR. GOTTO: Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. A. Page 3. Q. Yes, page 3, please. First of all, do you recognize 12:35:52 First of all, do you recognize 12:35:53 what this document is? A. Yes, I do. Q. And what is it? A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01 have with the leaders of each business unit 12:36:03 and manufacturing. Q. Okay. So turn to the third 12:36:08 page, please, and the table in the middle of 12:36:09 the page, the second line that begins with 12:36:14
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53 responses from various customers to this and 12:31:59 other similar letters that went out at this 12:32:01 time? 12:32:03 A. I recall many customers were 12:32:05 not happy about receiving this kind of 12:32:07	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Thank you. MR. O'CONNOR: No problem. QUESTIONS BY MR. GOTTO: Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. A. Page 3. Q. Yes, page 3, please. First of all, do you recognize 12:35:52 First of all, do you recognize 12:35:53 what this document is? A. Yes, I do. 12:35:55 Q. And what is it? A. This is from our sales and 12:35:58 operations planning meeting that we would 12:36:01 have with the leaders of each business unit 12:36:03 and manufacturing. Q. Okay. So turn to the third 12:36:08 page, please, and the table in the middle of 12:36:09 the page, the second line that begins with 12:36:14 "oxymorphone/oxycodone constraint." 12:36:19
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the supply plan and allocating the available 12:31:14 quota among the existing customers? 12:31:21 A. First, we evaluated who had 12:31:23 intercontractual obligation of failure to 12:31:27 supply, which is a penalty for not supplying, 12:31:29 so that could be very costly, so they were 12:31:31 prioritized. Other customers that had more 12:31:33 of our portfolio in their line were 12:31:35 prioritized over others. If it was a 12:31:39 customer that we knew we could supply their 12:31:43 full amount, we'd try and take care of them. 12:31:46 But it was based on primarily 12:31:48 the failure to supply and the impact it'd 12:31:49 have on our business. 12:31:52 Q. Do you recall receiving 12:31:53 responses from various customers to this and 12:31:59 other similar letters that went out at this 12:32:01 time? 12:32:03 A. I recall many customers were 12:32:05 not happy about receiving this kind of 12:32:07 information. 12:32:09	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Thank you. MR. O'CONNOR: No problem. QUESTIONS BY MR. GOTTO: Q. If you could take a moment and 12:33:42 look at that document, Ms. Collier. I just 12:33:43 have a question for you on the third page. 12:33:45 A. Page 3. Q. Yes, page 3, please. I2:35:51 Q. Yes, page 3, please. First of all, do you recognize 12:35:53 what this document is? A. Yes, I do. Q. And what is it? A. This is from our sales and 12:35:58 operations planning meeting that we would have with the leaders of each business unit 12:36:03 and manufacturing. Q. Okay. So turn to the third 12:36:08 page, please, and the table in the middle of 12:36:09 the page, the second line that begins with 12:36:14 "oxymorphone/oxycodone constraint." 12:36:19 Do you see that? 12:36:21

	Page 166		Page 168
1	production at the expense of oxycodone for 12:36:25	1	that and tell me if you recognize that 12:38:45
2	generics." 12:36:27	2	document. 12:38:46
3	Do you know why that decision 12:36:28	3	A. (Witness nods head.) 12:38:46
4	was made? 12:36:30	4	Q. Do you recognize that document? 12:39:57
5	A. The St. Louis plant I 12:36:31	5	A. Yes, I do. 12:39:58
6	believe this was an incidence where the 12:36:34	6	Q. And what is it? 12:39:58
7	St. Louis plant was having a hard time 12:36:36	7	A. It is to work with interns to 12:39:59
8	manufacturing enough materials on a 12:36:38	8	explain to them who Mallinckrodt is, what our 12:40:04
9	consistent basis due to the complexity, and I 12:36:41	9	product looks like, our product line looks 12:40:06
10	think that they we were reducing the 12:36:43	10	like, and educate them a little bit about the 12:40:08
11	amount of oxycodone we were producing because 12:36:46	11	industry. 12:40:10
12	we lost some sales, and so they had to make a 12:36:48	12	Q. Okay. And did you prepare this 12:40:10
13	decision: Should they make more oxymorphone 12:36:50	13	document? 12:40:12
14	and at the expense of oxycodone for our 12:36:53	14	A. I was one of the people. My 12:40:13
15	business. 12:36:56	15	team did it. 12:40:14
16	Q. Okay. And then the next 12:36:57	16	Q. Okay. If you would turn to 12:40:15
17	paragraph in that in that box on the table 12:37:00	17	slide 4, which is Mallinckrodt Generics 12:40:22
18	says, "Need to know impact of further 12:37:03	18	Business Overview, our key products in order 12:40:33
19	oxycodone reduction for the generics business 12:37:05	19	of sales value, and then it lists a series of 12:40:36
20	in order to manage demand to the appropriate 12:37:07	20	products. 12:40:40
21	levels." 12:37:09	21	Best of your recollection, is 12:40:41
22	Do you see that? 12:37:10	22	this an accurate depiction of the key 12:40:43
23	A. Oh, I see, in that same 12:37:11	23	products Mallinckrodt generics offered in 12:40:46
24	okay. "Need to know" the further yes. 12:37:16	24	fiscal 2014? 12:40:49
25	Q. And my question is: The 12:37:18	25	A. Yes. 12:40:50
	Page 167		Page 169
1	reference to manage demand to appropriate 12:37:20	1	Q. Okay. And turn, if you would, 12:40:51
2	levels, how would you what steps would 12:37:22	2	to slide 17. 12:40:56
3	as marketing director, what steps would you 12:37:25	3	A. (Witness complies.) 12:41:07
4	take to try to manage demand to appropriate 12:37:28	4	Q. Products driving net sales. It 12:41:11
5	levels? 12:37:30	5	says, "FY '14 net sales LE." 12:41:14
6	A. We could slow down shipping 12:37:30	6	What does the LE refer to in 12:41:17
7	some orders to customers. We could ask 12:37:32	7	this setting? 12:41:19
8	customers, do not load inventory. We could 12:37:35	8	A. Latest estimate. 12:41:19
9	not have as much safety stock. So there were 12:37:38	9	Q. Okay. And FY '13 net sales, 12:41:20
10	a lot of things we could do to reduce the 12:37:41	10	those are actuals, I take it? 12:41:24
11	amount of inventory that was required for the 12:37:43	11	A. Correct. It's an overlay, so 12:41:25
12	year. 12:37:45	12	it's hard to see. 12:41:27
13	Q. Okay. And that you'd view 12:37:46	13	Q. Okay. And to the best of your 12:41:29
14	those steps as managing demand? 12:37:48	14	knowledge, the data depicted on this pie 12:41:33
15	A. Yes. 12:37:51	15	chart for fiscal '13 and '14 is accurate? 12:41:36
16	Q. Okay. You can set that aside. 12:37:51	16	A. Yes. 12:41:39
17	(Mallinckrodt-Collier Exhibit 12:38:05	17	Q. Okay. And turn, if you would, 12:41:41
18	12 marked for identification.) 12:38:06	18	to slide 20. 12:41:51
19	QUESTIONS BY MR. GOTTO: 12:38:06	19	A. (Witness complies.) 12:41:53
20	Q. Ms. Collier, we have now marked 12:38:26	20	Q. And it's current market model, 12:41:57
21	E 1 11 10 1 1 11 12 10 27	21	revised market model. And under current 12:42:02
	as Exhibit 12 a document, a multipage 12:38:27		
22	document, beginning at Bates 12:38:30	22	market model it says, "Products are pushed 12:42:03
22	document, beginning at Bates 12:38:30 MNK-T1_0000661013. It appears to be an 12:38:33	22	market model it says, "Products are pushed 12:42:03 out to customers through pricing and 12:42:05
	document, beginning at Bates 12:38:30 MNK-T1_0000661013. It appears to be an 12:38:33 intern initiation prepared in June of 2014. 12:38:39		out to customers through pricing and 12:42:05 incentive programs." 12:42:06
23	document, beginning at Bates 12:38:30 MNK-T1_0000661013. It appears to be an 12:38:33	23	out to customers through pricing and 12:42:05

	5 1		
	Page 170		Page 172
1	model, "Customers add products through 12:42:10	1	need to address their issues first." 12:43:49
2	pricing incentive programs and preferred 12:42:11	2	So that's what we were doing, 12:43:51
3	service." 12:42:13	3	was changing the way the company 12:43:52
4	Could you elaborate on the 12:42:14	4	looked at the customers. 12:43:56
5	distinction that's being drawn there and what 12:42:17	5	QUESTIONS BY MR. GOTTO: 12:43:57
6	steps were taken at Mallinckrodt to move from 12:42:20	6	Q. Okay. Turn to slide 22, if you 12:43:57
7	current model to revised model? 12:42:23	7	would. There's a reference to customer 12:44:05
8	MR. O'CONNOR: Object to form. 12:42:25	8	connectivity initiative, which sounds like it 12:44:09
9	THE WITNESS: Sure. Sure. 12:42:26	9	may be part of what you were just talking 12:44:11
10	Previously we had the product, 12:42:29	10	about. 12:44:12
11	we launched it. We went and talked to 12:42:32	11	A. Exactly. 12:44:12
12	customers and said, "Okay, you've got 12:42:33	12	Q. If you could just describe to 12:44:13
13	Mylan product, you've got Teva 12:42:36	13	me what's meant by a customer connectivity 12:44:14
14	product, and we'd like you to switch 12:42:39	14	initiative. 12:44:16
15	to our product." 12:42:40	15	A. That's exactly what it was. It 12:44:16
16	And what we decided that we 12:42:40	16	was to get our internal groups to understand 12:44:18
17	needed to do was put the customer at 12:42:41	17	who the important customers were. So we 12:44:21
18	the center of our focus. 12:42:43	18	taught them, like, these are the customers 12:44:23
19	So our drug wholesalers, 12:42:44	19	driving the value for the business, and 12:44:24
20	warehousing chains and distributors, 12:42:46	20	that's who's really paying your paycheck. 12:44:27
21	mostly the drug wholesalers and the 12:42:47	21	And then we empowered them to 12:44:30
22	warehousing chains, they had formed a 12:42:50	22	make their own decisions to resolve issues. 12:44:33
23	consortium, so we had to align better 12:42:51	23	So if there was a chargeback issue and they 12:44:36
24	with them and meet their needs rather 12:42:55	24	thought that the customer was entitled to 12:44:38
25	than us going to them and asking them 12:42:56	25	that chargeback but we deducted it for some 12:44:39
	Page 171		Page 173
1	to meet our needs. 12:42:58	1	reason, they were now saying that they could 12:44:43
2	So we came up with initiatives 12:43:00	2	resolve that issue themselves. 12:44:44
3	to focus more on providing better 12:43:01	3	And we actually surveyed 12:44:46
4	customer service than we had in the 12:43:05	4	customers on what was important to them, and 12:44:47
5	past, better communication about 12:43:05	5	that's how we came up with what we needed to 12:44:51
6	1 '		
	supply issues. And that's what this 12:43:07	6	do. 12:44:53
7	was about, was how do we communicate 12:43:11	7	do. 12:44:53 MR. GOTTO: Okay. You can put 12:44:53
7 8			
	was about, was how do we communicate 12:43:11	7	MR. GOTTO: Okay. You can put 12:44:53
8	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13	7 8	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55
8	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15	7 8 9	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55
8 9 10	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15	7 8 9 10	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58
8 9 10 11	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18	7 8 9 10 11	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59
8 9 10 11	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20	7 8 9 10 11 12	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:00
8 9 10 11 12	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24	7 8 9 10 11 12 13	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:00 (Off the record at 12:44 p m.) 12:45:01
8 9 10 11 12 13	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25	7 8 9 10 11 12 13	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:01 VIDEOGRAPHER: We are back on 13:26:47
8 9 10 11 12 13 14 15	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27	7 8 9 10 11 12 13 14 15	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:00 (Off the record at 12:44 p m.) 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43
8 9 10 11 12 13 14 15	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29	7 8 9 10 11 12 13 14 15	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:01 (Off the record at 12:44 p m.) 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44
8 9 10 11 12 13 14 15 16 17	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29 We had we informed people in 12:43:31	7 8 9 10 11 12 13 14 15 16	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44 13 marked for identification.) 13:33:45
8 9 10 11 12 13 14 15 16 17	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29 We had we informed people in 12:43:31 contract admin, "If this particular 12:43:34	7 8 9 10 11 12 13 14 15 16 17	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:00 (Off the record at 12:44 p m.) 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44 13 marked for identification.) 13:33:45 QUESTIONS BY MR. GOTTO: 13:33:45
8 9 10 11 12 13 14 15 16 17 18	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29 We had we informed people in 12:43:31 contract admin, "If this particular 12:43:34 customer calls, make sure you answer 12:43:35	7 8 9 10 11 12 13 14 15 16 17 18	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:01 (Off the record at 12:44 p m.) 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44 13 marked for identification.) 13:33:45 QUESTIONS BY MR. GOTTO: 13:33:46
8 9 10 11 12 13 14 15 16 17 18 19 20	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29 We had we informed people in 12:43:31 contract admin, "If this particular 12:43:34 customer calls, make sure you answer 12:43:35 their call and address their issues. 12:43:37	7 8 9 10 11 12 13 14 15 16 17 18 19	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44 13 marked for identification.) 13:33:45 QUESTIONS BY MR. GOTTO: 13:33:45 Q. Welcome back, Ms. Collier. 13:33:46 A. Thank you. 13:33:48
8 9 10 11 12 13 14 15 16 17 18 19 20 21	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29 We had we informed people in 12:43:31 contract admin, "If this particular 12:43:34 customer calls, make sure you answer 12:43:35 their call and address their issues. 12:43:40	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:00 (Off the record at 12:44 p m.) 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44 13 marked for identification.) 13:33:45 QUESTIONS BY MR. GOTTO: 13:33:46 A. Thank you. 13:33:48 Q. We've marked as Exhibit 13 a 13:33:48
8 9 10 11 12 13 14 15 16 17 18 19 20 21	was about, was how do we communicate 12:43:11 better than what we've been doing in 12:43:13 the past. 12:43:15 Because they had for 12:43:15 example, a huge customer might call in 12:43:18 and ask about where their order is. 12:43:20 They might get a voicemail because 12:43:24 they got bounced around on the phone 12:43:25 call for several people, so we gave 12:43:27 them dedicated people to work with. 12:43:29 We had we informed people in 12:43:31 contract admin, "If this particular 12:43:34 customer calls, make sure you answer 12:43:37 They're a priority. Don't think that 12:43:40 everybody in your basket is as 12:43:41	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MR. GOTTO: Okay. You can put 12:44:53 that aside. 12:44:55 Why don't we take our lunch 12:44:55 break. 12:44:58 VIDEOGRAPHER: We are going off 12:44:59 the record at 12:44 p m. 12:45:00 (Off the record at 12:44 p m.) 12:45:01 VIDEOGRAPHER: We are back on 13:26:47 the record at 1:33 p m. 13:33:43 (Mallinckrodt-Collier Exhibit 13:33:44 13 marked for identification.) 13:33:45 QUESTIONS BY MR. GOTTO: 13:33:45 Q. Welcome back, Ms. Collier. 13:33:46 A. Thank you. 13:33:48 Q. We've marked as Exhibit 13 a 13:33:51

			- 1=c
	Page 174		Page 176
1	questions for you on it. 13:34:09		though, what sorts of things would you do 13:36:41
2	If you could just look at it 13:34:10		to to as it says, "Growing more 13:36:44
3	just briefly to confirm that or ascertain 13:34:11	_	profitable product families through a 13:36:46
4	if you're familiar with it. 13:34:15		compliance initiative"? 13:36:48
5	A. Yes, I'm familiar with it. 13:34:37	5	A. That means so, for example, 13:36:49
6	Q. And what is it? 13:34:38		if one of the drug wholesalers was not 13:36:51
7	A. It is a STRAT plan, a strategic 13:34:39	_	purchasing the volume that we thought they 13:36:55
8	plan, about how our sales will project in the 13:34:44		would, we would, again, work with them, find 13:36:56
9	future. 13:34:48		out why they weren't purchasing, were they 13:36:59
10	Q. Okay. And did you participate 13:34:48		buying from somebody else, too, because they 13:37:01
11	in the preparation of this? 13:34:50		could do that. They didn't have a commitment 13:37:03
12	A. Yes, I did. 13:34:52	12 i	in their contract to buy any certain volumes. 13:37:06
13	Q. Okay. If you would turn to 13:34:53	13	And because we didn't have a 13:37:09
14	slide 20. And this is an industry trends 13:34:56		commitment from them that we would change 13:37:09
15	retail slide. 13:35:07		your pricing, the only thing we could do was 13:37:11
16	And the bottom two bullet 13:35:08	16 8	ask them specifically why were they were not 13:37:13
17	items, one says, "Our focus here will 13:35:12	17 1	buying. 13:37:16
18	continue to diminish as C-IIs become less of 13:35:15	18	And if they were buying off of 13:37:16
19	an opportunity." 13:35:18	19 8	another program because somebody was offering 13:37:17
20	Do you know what's meant by 13:35:22	20 8	at a lower price or if it was something 13:37:19
21	that? 13:35:24	21 1	that pharmacist's preference, anything 13:37:22
22	A. I'm not clear what this meant 13:35:24	22]	like that, then we would try and uncover that 13:37:23
23	in the context, no. 13:35:26	23 8	and find out what we needed to do differently 13:37:25
24	Q. Okay. How about the next 13:35:27	24 8	at our company in order to ensure that 13:37:27
25	bullet, "Need to implement SOM monitoring for 13:35:28	25 t	they're buying our product. 13:37:29
	D 175		Page 177
			Page I / /
	Page 175		_
1	HB/APAP for this class of customers in 13:35:31	1	Q. Okay. Turn to slide 54, 13:37:31
2	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34	2 1	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38
2 3	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36	² 1	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55
2 3 4	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38	2] 3 4	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57
2 3 4 5	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39	2 1 3 4 5 5	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58
2 3 4 5 6	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43	2] 3 4 5 §	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58
2 3 4 5 6 7	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45	2] 3 4 5 s 6	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00
2 3 4 5 6 7 8	HB/APAP for this class of customers in 13:35:31 addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46	2 J 3 4 5 9 6 7 8 §	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02
2 3 4 5 6 7 8	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55	2] 3 4 5 9	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04
2 3 4 5 6 7 8 9	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05	2 1 3 4 5 5 6 7 8 8 9 1	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04
2 3 4 5 6 7 8 9 10	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09	2 1 3 4 5 5 6 7 8 8 9 1	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06
2 3 4 5 6 7 8 9 10 11	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11	2 J 3 4 5 S 6 7 8 S 9 I 10 11 12	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07
2 3 4 5 6 7 8 9 10 11 12 13	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13	2 J 3 4 5 S 6 7 8 S 9 J 10 11 12 13]	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10
2 3 4 5 6 7 8 9 10 11 12 13	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16	2 J 3 4 5 s 6 7 8 s 9 1 10 11 12 13] 14 [Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17	2 J 3 4 5 s 6 7 8 s 9 J 10 11 12 13] 14 [15]	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:15
2 3 4 5 6 7 8 9 10 11 12 13 14 15	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20	2	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:15 Do you see that? 13:38:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:20 A. That would be, again, ensuring 13:36:21	2	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:15 Do you see that? 13:38:16 A. Yes. 13:38:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15	HB/APAP for this class of customers in addition to the wholesalers." 13:35:34 Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24	2	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:16 A. Yes. 13:38:16 Q. And what's the basis for that, 13:38:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:26	2 J 3 4 5 S 6 7 8 S 9 I 10 11 12 13 J 14 I 15 I 16 17 18 19 I	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:16 A. Yes. 13:38:16 Q. And what's the basis for that, 13:38:16 that Mallinckrodt is recognized as a leader 13:38:19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:26 level. And then we would worry more about 13:36:28	2 J 3 4 5 S 6 7 8 S 9 I 10 11 12 13 J 14 I 15 I 16 17 18 19 I	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:16 A. Yes. 13:38:16 Q. And what's the basis for that, 13:38:16 that Mallinckrodt is recognized as a leader 13:38:19 in narcotics? 13:38:20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:28 the profitable products than the less 13:36:31	2	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:16 A. Yes. 13:38:16 Q. And what's the basis for that, 13:38:19 tin narcotics? 13:38:20 A. Partly due to our market share. 13:38:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:26 level. And then we would worry more about 13:36:31 profitable ones, because before we were just 13:36:32	2	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:16 A. Yes. 13:38:16 Q. And what's the basis for that, 13:38:19 in narcotics? 13:38:20 A. Partly due to our market share. 13:38:21 It was a 150-year-old company that started 13:38:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:28 the profitable products than the less 13:36:31 profitable ones, because before we were just 13:36:32 kind of focusing on everything. We needed to 13:36:35	2 J 3 4 5 S 6 7 8 S 9 I 10 11 12 13 I 14 I 15 I 16 17 18 19 I 20 I 21 23 G	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:26 level. And then we would worry more about 13:36:31 profitable ones, because before we were just 13:36:32	2 J 3 4 5 S 6 7 8 S 9 I 10 11 12 13 I 14 I 15 I 16 17 18 19 I 20 I 21 23 G	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38 Under Strengths, the first 13:37:55 A. It must be the wrong page, I'm 13:37:57 sorry. 13:37:58 Q. I'm sorry, it's slide 54. 13:37:58 A. I was on 64. Even with my 13:38:00 glasses I'm having a hard time reading those 13:38:02 numbers. 13:38:04 Q. These are a little tiny. 13:38:04 A. Yes, they are. Thank you. 13:38:06 Q. Okay. So the SWOT analysis for 13:38:07 Mallinckrodt, under Strengths, the first 13:38:10 bullet item is, "Recognized as leader in 13:38:11 narcotics." 13:38:16 A. Yes. 13:38:16 Q. And what's the basis for that, 13:38:19 in narcotics? 13:38:20 A. Partly due to our market share. 13:38:21 It was a 150-year-old company that started 13:38:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	HB/APAP for this class of customers in addition to the wholesalers." Do you know what's meant there? 13:35:36 A. Hydrocodone APAP was going from 13:35:38 a Schedule III to a Schedule II, so that 13:35:39 means it was included in the suspicious order 13:35:43 monitoring program. 13:35:45 Q. Okay. All right. If you'd 13:35:46 turn to slide 28, please. This is a slide 13:35:55 entitled "Customer Initiatives." 13:36:05 Toward the middle of the slide, 13:36:09 there's a reference to "compliance 13:36:11 initiatives based on growing more profitable 13:36:13 product families." 13:36:16 What would be examples of 13:36:17 compliance initiatives? 13:36:20 A. That would be, again, ensuring 13:36:21 that the customers, when they gave us the 13:36:24 volume, that they were buying at that volume 13:36:28 the profitable products than the less 13:36:31 profitable ones, because before we were just 13:36:32 kind of focusing on everything. We needed to 13:36:35	2	Q. Okay. Turn to slide 54, 13:37:31 please. This is the SWOT analysis. 13:37:38

	D 170	Т	D 100
1	Page 178 dosage form, so they also sold tablets and 13:38:35	1	Page 180 Q. Okay. Turn to slide 95, 13:40:30
2	everything. 13:38:37	2	please. If it's easier, it's the Bates 13:40:46
3	And anytime you're vertically 13:38:38	3	number ends in 523 in the lower right-hand 13:40:47
4	integrated like that in the industry, that's 13:38:40	4	corner. 13:40:52
5	really widely appreciated because there 13:38:42	5	A. Perfect. Thank you. 13:40:52
	should be some consistency of supply behind 13:38:44	6	Q. This slide is on promotional 13:40:53
6			*
7		7	positioning. 13:40:57
8	Q. Okay. Under Strengths, the 13:38:47	8	What's meant by that phrase, 13:40:57
9	bottom bullet item says, "Lobbyists engaged 13:38:52	9	"promotional positioning"? 13:41:01
10	in legislation." 13:38:54	10	A. It means how are we different 13:41:02
11	Do you recall at this time if 13:38:57	11	than Mylan, Teva and other competitors at 13:41:04
12	there were any particular legislative 13:38:58	12	that time. 13:41:07
13	initiatives that lobbyists were engaged in? 13:39:00	13	Q. Okay. And the second main 13:41:07
14	A. I can't remember the specific 13:39:03	14	bullet item says, "Primary focus is 13:41:12
15	initiative. I remember working with one of 13:39:09	15	Mallinckrodt is a leader in pain management." 13:41:14
16	our lobbyists at that time. We were at a 13:39:12	16	Do you see that? 13:41:17
17	meeting in Washington, DC, and I can't 13:39:16	17	A. Yes. 13:41:17
18	remember specifically what that was around. 13:39:18	18	Q. And under that, the bullet item 13:41:17
19	It might have had to do with REMS, because of 13:39:19	19	is "committed to education." 13:41:19
20	the cost of REMS. 13:39:22	20	What's that referring to, 13:41:21
21	Q. Under Weaknesses there's 13:39:23	21	"committed to education"? 13:41:24
22	"prolonged supply issues," and that's 13:39:25	22	A. At one time there and I'm 13:41:25
23	something we've touched on here today, 13:39:28	23	and I'm sorry if I misstate this, but I 13:41:29
24	correct? 13:39:29	24	believe that there was a program intended to 13:41:31
25	A. Correct. 13:39:30	25	educate about pain management, and there were 13:41:34
			r F F
	Page 179		Page 181
1	Q. And it appears that that 13:39:30	1	alternative therapies such as medication and 13:41:38
2	. 1, 1 11 12.20.22		1' 1'1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	continued to be a problem up till the time 13:39:32	2	things like that. 13:41:41
3	this document was prepared, correct? 13:39:36	3	And I'm not sure we never 13:41:42
3 4	* *		
	this document was prepared, correct? 13:39:36	3	And I'm not sure we never 13:41:42
4	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37	3 4	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45
4 5	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37	3 4 5	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48
4 5 6	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42	3 4 5 6	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50
4 5 6 7	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45	3 4 5 6 7	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51
4 5 6 7 8	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47	3 4 5 6 7 8	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57
4 5 6 7 8	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47	3 4 5 6 7 8	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58
4 5 6 7 8 9	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48	3 4 5 6 7 8 9	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00
4 5 6 7 8 9 10	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53	3 4 5 6 7 8 9 10	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01
4 5 6 7 8 9 10 11	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54	3 4 5 6 7 8 9 10 11 12	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02
4 5 6 7 8 9 10 11 12	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58	3 4 5 6 7 8 9 10 11 12 13	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05
4 5 6 7 8 9 10 11 12 13 14	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00	3 4 5 6 7 8 9 10 11 12 13	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05
4 5 6 7 8 9 10 11 12 13 14 15 16	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02	3 4 5 6 7 8 9 10 11 12 13 14 15 16	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08
4 5 6 7 8 9 10 11 12 13 14 15 16	this document was prepared, correct? 13:39:36 A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02 impact the overall value of our 13:40:04	3 4 5 6 7 8 9 10 11 12 13 14 15 16	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10
4 5 6 7 8 9 10 11 12 13 14 15 16 17	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:42 Why was pill mill legislation." 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:04 portfolio. 13:40:06	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:42 Why was pill mill legislation." 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02 impact the overall value of our 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:06	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02 impact the overall value of our 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:06 Q. Okay. Do you know if there was 13:40:08	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16 so it was probably around that. 13:42:19
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:04 portfolio. 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:08 specific pending or proposed legislation 13:40:15	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16 so it was probably around that. 13:42:19 Q. Okay. And the next bullet 13:42:22
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:37 item is "pill mill legislation." 13:39:42 Why was pill mill legislation a 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02 impact the overall value of our 13:40:04 portfolio. 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:06 Q. Okay. Do you know if there was 13:40:08 specific pending or proposed legislation 13:40:15 related to pill mills at this time that was 13:40:20	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16 so it was probably around that. 13:42:22 item, "Sponsor CE article in drug topics." 13:42:25
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:42 Why was pill mill legislation." 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02 impact the overall value of our 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:06 Q. Okay. Do you know if there was 13:40:20 of particular interest? 13:40:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16 so it was probably around that. 13:42:19 Q. Okay. And the next bullet 13:42:22 item, "Sponsor CE article in drug topics." 13:42:25 Do you know what that article 13:42:28
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:42 Why was pill mill legislation." 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. 13:39:47 THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:04 portfolio. QUESTIONS BY MR. GOTTO: 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:06 Q. Okay. Do you know if there was 13:40:08 specific pending or proposed legislation 13:40:20 of particular interest? 13:40:22 A. I really don't remember what 13:40:23	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16 so it was probably around that. 13:42:19 Q. Okay. And the next bullet 13:42:22 item, "Sponsor CE article in drug topics." 13:42:25 Do you know what that article 13:42:28 pertained to? 13:42:29
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	this document was prepared, correct? A. Correct. 13:39:37 Q. Under Threats, first bullet 13:39:42 Why was pill mill legislation." 13:39:45 threat? 13:39:47 MR. O'CONNOR: Objection. THE WITNESS: It wouldn't be 13:39:48 considered a threat. It would mean 13:39:51 a threat would be anything that would 13:39:53 adjust our business, so we had to 13:39:54 consider it. So I wouldn't say it's a 13:39:58 threat, per se, that it's a reduction 13:40:00 in our business, so it's going to 13:40:02 impact the overall value of our 13:40:06 QUESTIONS BY MR. GOTTO: 13:40:06 Q. Okay. Do you know if there was 13:40:20 of particular interest? 13:40:22	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And I'm not sure we never 13:41:42 launched that program. But I'm not sure what 13:41:45 it means in this context, what all we 13:41:48 intended to do. 13:41:50 Q. Okay. Two bullet items below 13:41:51 that, there's a bullet item "education about 13:41:57 the proper use of medication and therapeutic 13:41:58 category." 13:42:00 Do you see that? 13:42:01 A. Yes. 13:42:01 Q. Any more insight into education 13:42:02 in that context? 13:42:05 A. Well, and it seems that we did 13:42:05 run a CE article, continuing education 13:42:08 article, about proper use, and I do know that 13:42:10 we looked at proper disposal of products, 13:42:13 especially with the launch of fentanyl patch, 13:42:16 so it was probably around that. 13:42:19 Q. Okay. And the next bullet 13:42:22 item, "Sponsor CE article in drug topics." 13:42:25 Do you know what that article 13:42:28

	Page 182		Page 184
1	topic. 13:42:32	1	A. We would do a direct mail on 13:44:45
2	Q. Okay. Next bullet item says, 13:42:33	2	new products and tell them what product is 13:44:47
3	"Our primary vehicles for getting out our 13:42:36	3	now available. For example, I earlier I 13:44:49
4	messages will be direct mail, Pharm/alert and 13:42:39	4	spoke to that we had fentanyl patch, fentanyl 13:44:51
5	PDQ." 13:42:43	5	lozenge and methylphenidate, so we would give 13:44:51
6	Direct mail in this setting, 13:42:44	6	them information if the product's available 13:44:56
7	what is that referring to? 13:42:46	7	so that they were aware. Because they may 13:44:59
8	A. That would be send it out 13:42:48	8	have been continuing to order even though 13:45:02
9	send information out there's two levels: 13:42:51	9	we might have gotten the award on a contract, 13:45:04
10	One is our buyers, our customers, which are 13:42:53	10	they may have continued to order from the 13:45:06
11	the warehousing chains, wholesalers and 13:42:55	11	competitor, not knowing that we were now 13:45:08
12	distributors, or send something out to the 13:42:59	12	available. 13:45:10
13	retail pharmacies, which is downstream a 13:43:01	13	Q. Okay. What is PDQ? 13:45:12
14	little bit further. And so we so 13:43:04	14	A. PDQ is a pharm like 13:45:22
15	Pharm/alert goes to retail pharmacies. They 13:43:07	15	Pharm/alert or any other mail. It's a 13:45:24
16	can't sell them to hospital pharmacies, so 13:43:11	16	collection of pieces from different 13:45:26
17	the pharmacists get information that way. 13:43:12	17	manufacturers, and it comes in a big mailing 13:45:28
18	Q. When you said "they can't sell 13:43:16	18	packet, you know, like some of the junk mail 13:45:30
19	to hospital pharmacies," who is the "they" 13:43:39	19	you get, and so the pharmacists receive that. 13:45:32
20	you're referring to there? 13:43:41	20	And they get a whole packet of information 13:45:34 about new products and whatever other 13:45:36
21	Maybe I just didn't understand 13:43:45 your answer. You were talking in terms of a 13:43:46	21	about new products and whatever other 13:45:36 information that other companies might want 13:45:40
23	direct mail to pharmacies. 13:43:47	23	to put out. 13:45:43
24	A. It can go to hospital 13:43:50	24	Q. Okay. The next bullet item 13:45:43
25	pharmacies, hospital pharmacists. 13:43:53	25	says, "Other vehicles will be webinars, our 13:45:44
23	pharmacies, nospital pharmacists.	23	says, Other vehicles will be webliars, our 13.43.44
	Page 183		Page 185
	1 450 103		_
1	Q. Okay. 13:43:55	1	website and e-mails." 13:45:48
1 2	Q. Okay. 13:43:55A. So we did sell to pharmacies 13:43:55	1 2	website and e-mails." 13:45:48 What types of webinars were 13:45:49
	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58		website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51
2 3 4	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59	2 3 4	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52
2 3 4 5	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02	2 3 4 5	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56
2 3 4 5 6	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03	2 3 4 5	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01
2 3 4 5 6 7	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03	2 3 4 5 6 7	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02
2 3 4 5 6 7 8	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04	2 3 4 5 6 7 8	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03
2 3 4 5 6 7 8	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12	2 3 4 5 6 7 8	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04
2 3 4 5 6 7 8 9	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19	2 3 4 5 6 7 8 9	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07
2 3 4 5 6 7 8 9 10	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21	2 3 4 5 6 7 8 9 10	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10
2 3 4 5 6 7 8 9 10 11	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21	2 3 4 5 6 7 8 9 10 11	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21	2 3 4 5 6 7 8 9 10 11 12 13	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23	2 3 4 5 6 7 8 9 10 11 12 13	website and e-mails." 13:45:48 What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:23	2 3 4 5 6 7 8 9 10 11 12 13 14 15	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:23	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:23 Q. Who decided what was going to 13:44:24 get sent out to whom? 13:44:25	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:23 Q. Who decided what was going to 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27 out of my department, and usually instructed 13:44:28	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36 boards, question mark, topics, value, 13:46:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27 out of my department, and usually instructed 13:44:28 by me and with approval of the president of 13:44:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36 boards, question mark, topics, value, 13:46:39 potential participants." 13:46:42
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27 out of my department, and usually instructed 13:44:28 by me and with approval of the president of 13:44:32 the division. 13:44:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36 boards, question mark, topics, value, 13:46:42 Do you recall if Mallinckrodt 13:46:43
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27 out of my department, and usually instructed 13:44:28 by me and with approval of the president of 13:44:32 the division. 13:44:35 Q. Okay. And so in terms of 13:44:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36 boards, question mark, topics, value, 13:46:49 potential participants." 13:46:42 Do you recall if Mallinckrodt 13:46:43 became involved in any advisory boards? 13:46:48
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:23 Q. Who decided what was going to 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27 out of my department, and usually instructed 13:44:28 by me and with approval of the president of 13:44:32 the division. 13:44:35 Q. Okay. And so in terms of 13:44:35 direct mail to retail pharmacy or to hospital 13:44:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36 boards, question mark, topics, value, 13:46:49 potential participants." 13:46:42 Do you recall if Mallinckrodt 13:46:43 became involved in any advisory boards? 13:46:48 A. No, we did not. 13:46:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. 13:43:55 A. So we did sell to pharmacies 13:43:55 through the wholesalers. 13:43:58 Q. Okay. And so direct mail could 13:43:59 go to retail pharmacies and hospital 13:44:02 pharmacies? 13:44:03 A. Correct. 13:44:03 Q. Okay. And how often well, 13:44:04 who was in charge of any kind of direct mail 13:44:12 program that you engaged in from time to 13:44:19 time? 13:44:21 MR. O'CONNOR: Object to form. 13:44:21 THE WITNESS: In charge of and 13:44:21 actually 13:44:23 QUESTIONS BY MR. GOTTO: 13:44:24 get sent out to whom? 13:44:25 A. Well, that would be generated 13:44:27 out of my department, and usually instructed 13:44:28 by me and with approval of the president of 13:44:32 the division. 13:44:35 Q. Okay. And so in terms of 13:44:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	website and e-mails." What types of webinars were 13:45:49 conducted? 13:45:51 A. I don't remember what webinars 13:45:52 we may or may have even done them, if we 13:45:56 did them at all. 13:46:01 Q. Who would have coordinated 13:46:02 webinar activity? 13:46:03 A. That would have been within 13:46:04 promotion within the promotional group, 13:46:07 which was in my team. 13:46:10 Q. Okay. But you don't recall if 13:46:10 that actually was done? 13:46:12 A. No, I don't recall that. 13:46:12 Q. Turn to slide 97, please, two 13:46:14 after the one you're on. It's a slide about 13:46:27 other promotional activities. 13:46:34 And there's a bullet, "advisory 13:46:36 boards, question mark, topics, value, 13:46:43 potential participants." 13:46:43 became involved in any advisory boards? 13:46:48 A. No, we did not. 13:46:51

	<u> </u>		
	Page 186		Page 188
1	didn't come together? 13:46:56	1	document? 13:51:03
2	A. It was a decision not to do it. 13:46:57	2	A. Yes, I am. 13:51:03
3	Q. Do you know why? 13:46:59	3	Q. And what is it? 13:51:04
4	A. My input was that there were 13:47:00	4	A. It's a strategic plan developed 13:51:05
5	challenges in trying to decide who would be 13:47:04	5	by the generics group, generics marketing 13:51:07
6	on the board and what would even be the topic 13:47:06	6	group, for periods 2014 to 2019. 13:51:10
7	that we wanted to discuss. We couldn't 13:47:10	7	Q. Okay. And did you participate 13:51:12
8	perceive it to be something that we were 13:47:11	8	in the preparation of this document? 13:51:13
9	having the customers do to give the customers 13:47:13	9	A. Yes, I did. 13:51:15
10	a day out of the office. 13:47:16	10	Q. Okay. If you would turn to 13:51:16
11	It needed to be something that 13:47:17	11	slide 8, please. The Bates number ends in 13:51:18
12	was constructive for the company. We 13:47:18	12	723. 13:51:25
13	couldn't come up with what would be value for 13:47:20	13	A. (Witness complies.) 13:51:28
14	the company. 13:47:22	14	Q. This is a trends slide, and the 13:51:29
15	Q. And if you turn to the next 13:47:23	15	bottom half, there's a bullet item talking 13:51:35
16	slide, slide 98, it's Generic Business 13:47:35	16	about "abuse-deterrent legislation." 13:51:37
17	Expenses, and the first line, which says, 13:47:45	17	Do you see that? 13:51:40
18	"Product Manager Collier." And there's some 13:47:47	18	A. Yes. 13:51:40
19	prior year, fiscal '12 and fiscal '13 13:47:52	19	Q. What was abuse-deterrent 13:51:41
20	figures, which show a significant increase in 13:47:56	20	legislation as used in this slide? 13:51:44
21	fiscal year '13 budget versus the prior 13:47:58	21	A. There was consideration by 13:51:46
22	years. 13:48:00	22	several states to have products that if there 13:51:47
23	Do you know what the reason for 13:48:00	23	was an abuse-deterrent product available, 13:51:49
24	that is? 13:48:02	24	that they would give preference to that drug 13:51:53
25	A. I think this was with the 13:48:03	25	over other nonabuse-deterrent drugs. 13:51:57
	Page 187		Page 189
1	launch this may have been that we were 13:48:05	1	Q. Okay. And the very last bullet 13:51:59
2	preparing for the launch of one, I had 13:48:10	2	item on this slide says, "Mallinckrodt and 13:52:00
3	more people on my staff to do more analytics, 13:48:12	3	GPHA are opposed to this." 13:52:03
4	and this may have had to do something with 13:48:15	4	Is that the abuse-deterrent 13:52:06
5	the launch of methylphenidate, that we needed 13:48:18		is that the abuse-deterrent 13.32.00
	the launen of methylphemate, that we needed 13.10.10	5	legislation that Mallinckrodt was opposed to? 13:52:09
6	to increase the staffing prior to launch, and 13:48:21	6	
6 7	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24		legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11
	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27	6	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09
7	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27	6 7	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15
7 8	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38	6 7 8	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15
7 8 9	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10	6 7 8 9	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15
7 8 9 10	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10	6 7 8 9	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16
7 8 9 10 11 12	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10	6 7 8 9 10 11 12	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21
7 8 9 10 11 12 13	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18	6 7 8 9 10 11 12 13	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21
7 8 9 10 11 12 13 14 15	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21	6 7 8 9 10 11 12 13 14	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23
7 8 9 10 11 12 13 14 15	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28	6 7 8 9 10 11 12 13 14 15	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25
7 8 9 10 11 12 13 14 15 16	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30	6 7 8 9 10 11 12 13 14 15 16	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28
7 8 9 10 11 12 13 14 15 16 17	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35	6 7 8 9 10 11 12 13 14 15 16 17	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28
7 8 9 10 11 12 13 14 15 16 17 18	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37	6 7 8 9 10 11 12 13 14 15 16 17 18	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28 would turn to the Bates Bates number 768 13:52:31
7 8 9 10 11 12 13 14 15 16 17 18 19	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37 A. Okay. 13:49:37	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:31 at the end, toward the back of the document. 13:52:35
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37 A. Okay. 13:49:37 Q. But if you can look through it 13:49:37	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28 would turn to the Bates Bates number 768 13:52:31 at the end, toward the back of the document. 13:52:35 It's slide 53. It's the SWOT analysis. 13:52:38
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37 A. Okay. 13:49:37 Q. But if you can look through it 13:49:39 briefly just to familiarize yourself and 13:49:39	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28 would turn to the Bates Bates number 768 13:52:31 at the end, toward the back of the document. 13:52:35 It's slide 53. It's the SWOT analysis. 13:52:38 And this is similar to the SWOT 13:52:50
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37 Q. But if you can look through it 13:49:37 briefly just to familiarize yourself and 13:49:39 confirm that you are familiar with it. 13:49:41	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28 would turn to the Bates Bates number 768 13:52:31 at the end, toward the back of the document. 13:52:35 It's slide 53. It's the SWOT analysis. 13:52:50 analysis we looked at in the prior exhibit. 13:52:52
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37 Q. But if you can look through it 13:49:37 briefly just to familiarize yourself and 13:49:39 confirm that you are familiar with it. 13:49:41 A. Okay. 13:49:43	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28 would turn to the Bates Bates number 768 13:52:31 at the end, toward the back of the document. 13:52:35 It's slide 53. It's the SWOT analysis. 13:52:38 And this is similar to the SWOT 13:52:50 analysis we looked at in the prior exhibit. 13:52:52 Under Threats, though, I had a 13:52:54
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	to increase the staffing prior to launch, and 13:48:21 just better analytics around all of our sales 13:48:24 numbers. 13:48:27 Q. Okay. You can set that aside. 13:48:27 A. Okay. 13:48:38 (Mallinckrodt-Collier Exhibit 13:49:10 14 marked for identification.) 13:49:10 QUESTIONS BY MR. GOTTO: 13:49:10 Q. Ms. Collier, Exhibit 14 is a 13:49:18 multipage document beginning at Bates 13:49:21 MNK-T1_0000663716. Appears to be a strategic 13:49:28 plan for the years 2014 through '19. Again, 13:49:30 I just have a couple of questions for you on 13:49:35 the document. 13:49:37 Q. But if you can look through it 13:49:37 briefly just to familiarize yourself and 13:49:39 confirm that you are familiar with it. 13:49:41	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	legislation that Mallinckrodt was opposed to? 13:52:09 MR. O'CONNOR: Object to form. 13:52:09 THE WITNESS: Yes, I would 13:52:11 assume based where it's placed in the 13:52:12 slide, yes. 13:52:15 QUESTIONS BY MR. GOTTO: 13:52:15 Q. And do you know why 13:52:15 Mallinckrodt was opposed to abuse-deterrent 13:52:16 legislation? 13:52:21 A. No, but I I could speculate, 13:52:21 but I would think that it would be better 13:52:23 placed with the lobbyists that were working 13:52:25 on the program. 13:52:28 Q. Okay. All right. And if you 13:52:28 would turn to the Bates Bates number 768 13:52:31 at the end, toward the back of the document. 13:52:35 It's slide 53. It's the SWOT analysis. 13:52:50 analysis we looked at in the prior exhibit. 13:52:52

	Page 190		Page 192
1	attempts by government to restrict access in 13:53:00	1	they'll sell to the customer. They 13:56:17
2	an effort to reduce abuse or misuse which 13:53:02	2	may not know that that particular 13:56:18
3	affects pain patients." 13:53:06	3	customer is buying from other 13:56:19
4	Do you know what continued 13:53:07	4	distributors or wholesalers. 13:56:21
5	attempts by the government are being referred 13:53:11	5	So because of the issue in 13:56:22
6	to in that bullet item? 13:53:14	6	Florida, we looked at Florida and 13:56:24
7	A. Yes. It would have been 13:53:16	7	pulled those customers that we thought 13:56:27
8	switching for here, for example, 13:53:20	8	were possibly buying from other 13:56:29
9	hydrocodone APAP to a C-II to restrict access 13:53:22	9	distributors. 13:56:33
10	so patients were getting fewer pills. So we 13:53:26	10	QUESTIONS BY MR. GOTTO: 13:56:34
11	would have to accommodate the new request by 13:53:28	11	Q. Okay. So is this the work 13:56:34
12	the government, and what would that mean in 13:53:31	12	product that you were referring to earlier 13:56:37
13	our total volume. 13:53:33	13	today when you talked about analysis that you 13:56:39
14	Q. Okay. And that was a threat to 13:53:35	14	and Ms. Muhlenkamp did after the Sunrise 13:56:41
15	Mallinckrodt for what reason? 13:53:36	15	issues surfaced? 13:56:46
16	A. It just would be a reduction in 13:53:38	16	A. Correct. 13:56:47
17	our overall volume of units and sales, 13:53:40	17	Q. Okay. So the attachment 13:56:48
18	obviously. 13:53:44	18	just to be sure I understand the what's 13:56:52
19	Q. Okay. You can set that aside. 13:53:44	19	depicted here. Customer name the customer 13:56:57
20	(Mallinckrodt-Collier Exhibits 13:54:19	20	in the context of Exhibit 16 is 13:57:00
21	15 and 16 marked for identification.) 13:54:20	21	Mallinckrodt's customer's customer, correct? 13:57:03
22	QUESTIONS BY MR. GOTTO: 13:54:20	22	MR. O'CONNOR: Object to form. 13:57:07
23	Q. We've marked as Exhibit 15 a 13:54:53	23	THE WITNESS: Well, I want to 13:57:08
24	single-page e-mail bearing Bates 13:54:57	24	be clear I'm not sure, because what 13:57:11
25	MNK-T1_0000418885, and as Exhibit 16 what I 13:55:00	25	could happen is one of our customers 13:57:12
	Page 191		Page 193
1	believe is one of the attachments to that 13:55:08	1	could sell to another pharmacy, and 13:57:14
2	e-mail, a multipage document that was 13:55:12	2	that pharmacy, in turn, sold to other 13:57:16
3	produced in native form under Bates 13:55:17	3	pharmacies. So it's never really 13:57:19
4	MNK-T1 0000418886. 13:55:21	4	clear unless we get chargeback data 13:57:21
5	Take a look at those documents, 13:55:25	5	back on where it went. 13:57:26
	if you would, and tell me if you recognize 13:55:29		QUESTIONS BY MR. GOTTO: 13:57:27
6	, ,	6	
			•
8	A. Yes, I do recognize them. 13:55:32	8	that's listed on Exhibit 16 the entity that 13:57:29 would be identified as a customer in the 13:57:32
9	Q. And what are they? 13:55:38	9	
10	A. This is a sales report that was 13:55:39	10	chargeback report that Mallinckrodt 13:57:34 maintained? 13:57:37
11	pulled to indicate if some of our customers 13:55:44	11	
12	were buying from more than one distributor, 13:55:48 because we did not typically look at that. 13:55:49	12	A. Correct. 13:57:37
	pecause we did not typically look at that 13.55.49	13	Q. Okay. And that may be the 13:57:38 direct customer of Mallinckrodt's customer or 13:57:45
13	**		direct customer of Mallinckrodt's customer or 13:57:45
14	We just would get chargebacks from individual 13:55:52	14	
14 15	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55	15	may be an indirect customer of Mallinckrodt's 13:57:48
14 15 16	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57	15 16	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51
14 15 16 17	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59	15 16 17	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52
14 15 16 17 18	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01	15 16 17 18	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52
14 15 16 17 18	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01 you, whether they were buying from other 13:56:03	15 16 17 18 19	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52 QUESTIONS BY MR. GOTTO: 13:57:53
14 15 16 17 18 19	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01 you, whether they were buying from other 13:56:03 distributors? 13:56:04	15 16 17 18 19 20	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52 QUESTIONS BY MR. GOTTO: 13:57:53 Q. And this report is for the 13:58:04
14 15 16 17 18 19 20 21	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01 you, whether they were buying from other 13:56:03 distributors? 13:56:04 MR. O'CONNOR: Object to form. 13:56:05	15 16 17 18 19 20 21	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52 QUESTIONS BY MR. GOTTO: 13:57:53 Q. And this report is for the 13:58:04 September 2010 time period; is that correct? 13:58:07
14 15 16 17 18 19 20 21 22	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01 you, whether they were buying from other 13:56:03 distributors? 13:56:04 MR. O'CONNOR: Object to form. 13:56:05 THE WITNESS: It was my thought 13:56:06	15 16 17 18 19 20 21 22	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52 QUESTIONS BY MR. GOTTO: 13:57:53 Q. And this report is for the 13:58:04 September 2010 time period; is that correct? 13:58:07 A. Yes. It appears to be. 13:58:09
14 15 16 17 18 19 20 21 22 23	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01 you, whether they were buying from other 13:56:03 distributors? 13:56:04 MR. O'CONNOR: Object to form. 13:56:05 THE WITNESS: It was my thought 13:56:06 that our distributors may not know 13:56:10	15 16 17 18 19 20 21 22 23	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52 QUESTIONS BY MR. GOTTO: 13:57:53 Q. And this report is for the 13:58:04 September 2010 time period; is that correct? 13:58:07 A. Yes. It appears to be. 13:58:09 Q. Is this the first time that you 13:58:15
14 15 16 17 18 19 20 21 22	We just would get chargebacks from individual 13:55:52 wholesalers or distributors and never looked 13:55:55 across the channel to see if they were 13:55:57 possibly buying from other distributors. 13:55:59 Q. And why was that of interest to 13:56:01 you, whether they were buying from other 13:56:03 distributors? 13:56:04 MR. O'CONNOR: Object to form. 13:56:05 THE WITNESS: It was my thought 13:56:06	15 16 17 18 19 20 21 22	may be an indirect customer of Mallinckrodt's 13:57:48 customer; is that fair? 13:57:51 MR. O'CONNOR: Object to form. 13:57:52 THE WITNESS: Correct. 13:57:52 QUESTIONS BY MR. GOTTO: 13:57:53 Q. And this report is for the 13:58:04 September 2010 time period; is that correct? 13:58:07 A. Yes. It appears to be. 13:58:09

	3 1		
	Page 194		Page 196
1	A. Yes. 13:58:37	1	,
2	Q. Okay. 13:58:38	2	was buying from six distributors, correct? 14:00:19
3	A. That I remember it is. 13:58:38	3	A. Yes. 14:00:22
4	Q. Okay. Did you engage in this 13:58:40	4	Q. How did you ascertain how many 14:00:23
5	data gathering process again in the future? 13:58:44	5	different distributors a customer was buying 14:00:26
6	MR. O'CONNOR: Object to form. 13:58:47	6	from? 14:00:30
7	THE WITNESS: Not that I 13:58:48	7	A. Kate Neely, Kate Muhlenkamp, 14:00:30
8	recall. 13:58:51	8	pulled this, and I'm not sure exactly, but 14:00:36
9	QUESTIONS BY MR. GOTTO: 13:58:51	9	I'm sure in a query you can develop this and 14:00:38
10	Q. Okay. So according to 13:58:52	10	then have what distributor or wholesaler 14:00:41
11	Exhibit 15, your cover e-mail, you sent this 13:58:56	11	issued the chargeback. So she would be able 14:00:46
12	to Mr. Becker, Mr. Borelli and Ms. Williams, 13:58:58	12	to ascertain from that. 14:00:48
13	correct? 13:59:04	13	Q. So the number of distributors 14:00:50
14	A. Correct. 13:59:04	14	here so, for example, Tru-Valu Drugs 14:00:57
15	Q. And did you have further 13:59:05	15	buying from six different distributors, are 14:01:01
16	discussions with them regarding the data or 13:59:06	16	those six different Mallinckrodt 14:01:03
17	any further evaluation of this data? 13:59:09	17	distributors? 14:01:06
18	MR. O'CONNOR: Object to form. 13:59:13	18	A. Correct. 14:01:06
19	THE WITNESS: Yes, we did. 13:59:13	19	Q. Okay. So it's possible they 14:01:08
20	QUESTIONS BY MR. GOTTO: 13:59:14	20	could have been buying from other parties as 14:01:11
21	Q. What can you recall? 13:59:14A. I recall having a discussion 13:59:15	21	well, correct? 14:01:13 A. Correct. 14:01:13
	-		
23	with them that they needed to talk to their 13:59:18 distributors and wholesalers and advise them 13:59:20	23	Q. Okay. Is there what would 14:01:14 be a business reason why a party identified 14:01:31
25	that these might be problem customers and 13:59:23	25	as a customer on this list would buy from 14:01:35
23	that these might be problem customers and 13.39.23	23	as a customer on this list would buy from 14.01.33
	Page 195		Page 197
1	that we would no longer issue chargebacks 13:59:26	1	1
2	or pay them chargebacks for these customers 13:59:28	2	A. I'm not sure why they would do 14:01:40
3	if they continued selling to them. 13:59:30	3	that. I don't know if you need me to 14:01:45
4	Q. Okay. And so would that be the 13:59:32	4	speculate, but I'm not sure that I know why 14:01:50
5	case as to any of your customers' customers 13:59:36	5	each individual customer did that. 14:01:53
6	if they were buying from multiple 13:59:38	6	Q. Okay. When you gathered this 14:01:57
7	distributors, you would not pay chargebacks 13:59:40	7	information, was it surprising to you to 14:02:01
8	to your to Mallinckrodt's distributor? 13:59:42	8	learn how many distributors these customers 14:02:04
9	MR. O'CONNOR: Object to form. 13:59:44	9	were buying from? 14:02:08
10	THE WITNESS: No, it was 13:59:45	10	MR. O'CONNOR: Object to form. 14:02:09
11	specific to these customers that we 13:59:48	11	THE WITNESS: Yes. 14:02:10
12	identified, and that was all. 13:59:50	12	QUESTIONS BY MR. GOTTO: 14:02:11
13	QUESTIONS BY MR. GOTTO: 13:59:52	13	Q. Would your expectation have 14:02:12
14	Q. Okay. 13:59:52	14	been that they would have been buying from 14:02:13
15	A. I don't know if anybody else 13:59:52 took action later. 13:59:55	15	just one distributor? 14:02:16 A. Yes. 14:02:18
16		16	
17	Q. Okay. But the rationale was 13:59:57	17	Q. And in the month of September, 14:02:18
18	because they were buying from multiple 13:59:58 distributors, Mallinckrodt wouldn't pay 14:00:00	18	if I'm reading this correctly, it's 14:02:32
	chargebacks to the distributor who was buying 14:00:03		approximately a million and a half dollars of 14:02:35 gross sales to these various customers; is 14:02:38
20	from Mallinckrodt, correct? 14:00:05	20	gross sales to these various customers; is 14:02:38 that correct? 14:02:40
21		21	A. Yes. 14:02:40
23	A. Correct. 14:00:06 MR. O'CONNOR: Object to form. 14:00:06	23	Q. Do you have any estimate of the 14:02:41
24	MIK. O COMMOK. Object to 101111. 14:00:00	43	· · · · · · · · · · · · · · · · · · ·
44	OUESTIONS BY MP COTTO: 14.00.04	2/	nercentage of sales of Mallingkroat product 14.02.51
	QUESTIONS BY MR. GOTTO: 14:00:06 O Okay And the second entry on 14:00:13	24	percentage of sales of Mallinckrodt product 14:02:51 in September of 2010 that went to the state 14:02:56
25	QUESTIONS BY MR. GOTTO: 14:00:06 Q. Okay. And the second entry on 14:00:13	24 25	percentage of sales of Mallinckrodt product 14:02:51 in September of 2010 that went to the state 14:02:56

2 of Florida, what percentage of those sales 14-02:59 2 are reflected on Exhibit 167 14-03:00 3 MR. O'CONNOR: Object to form 14-03:05 4 THE WITNESS: I don't know 14-03:06 5 QUESTIONS BY MR. GOTTO: 14-03:08 7 ascertain that? 14-03:10 9 A. I'm sure that we knew 14-03:11 9 somewhere, but I didn't know for a fact based 14-03:13 12 Q. Do you know if the chargeback 14-03:16 13 database that Mallinckrodt maintained would 14-03:27 14 MR. O'CONNOR: Object to form 14-03:31 15 THE WITNESS: Could you repeat 14-03:35 16 Wears of the distributors 14-03:36 17 Oy Question about the 14-03:36 18 Dy ow know if the chargeback 14-03:36 19 MR. O'CONNOR: Object to form 14-03:35 20 Q. Yeah. 14-03:36 21 Exhibit 16 sales reflect, do you know if the 14-03:36 22 chargeback data that Mallinckrodt maintained 14-03:36 23 Dy My question about the 14-03:36 24 Chargeback data that Mallinckrodt maintained 14-03:36 25 MR. O'CONNOR: Object to form. 14-03:51 26 Dy ow know if the sevential that we were looking for. 14-05:42 27 Exhibit 16 sales reflect, do you know if the 14-03:36 28 Dy ow know if the sevential 14-03:36 29 MR. O'CONNOR: Object to form. 14-03:51 21 Exhibit 16 sales reflect, do you know if the 14-03:35 22 obsections of the sevential 14-03:36 23 OW CONNOR: Object to form. 14-03:51 24 answer to that question? 14-03:35 25 OW Low on wifthaths - if 14-04:30 26 Dy ou know if thaths - if 14-04:30 27 analysis was ever conducted with respect to 14-05:52 28 the question? 14-03:36 29 MR. O'CONNOR: Object to form. 14-03:31 30 OW Low on in interval was been 14-05:32 31 OW Low on indicated 14-03:36 32 OW Low on indicated 14-03:36 33 OW Low on indicated 14-04:30 34 OW Low on indicated 14-04:30 35 OW Low on indicated 14-04:30 36 OW Low on indicated 14-04:30 37 OW Low on indicated 14-04:30 38 OW Low on indicated 14-04:30 39 OW Low on indicated 14-04:30 40 OW Low on indicate		5 1		4
2 are reflected on Exhibit 16? 14-03-02 MR. O'CONNOR: Object to form. 14-03-05 UESTIONS BY MR. GOTTO: 14-03-06 Q. Was any effort made to 14-03-10 14-03-06 A. I'm sure that we knew 14-03-11 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 somewhere, but I didn't know for a fact based 14-03-13 states listed in the rew. Will, I know there 14-05-18 states listed in the rew. Will, I know there 14-05-18 states listed in the rew. Will, I know there 14-05-19 all states or if there were loaking for. 14-05-22 the guestion? 14-03-35		_		Page 200
MR. O'CONNOR: Object to form. 14-03-05		, ,		
4 THE WITNESS: I don't know. 14:03:06 5 QUESTIONS BY MR. GOTTO: 14:03:06 6 Q. Was any effort made to 14:03:08 7 ascertain that? 14:03:10 8 A. I'm sure that we knew 14:03:11 9 somewhere, but I didn't know for a fact based 14:03:11 10 on this. 14:03:14 11 Q. Do you know if the chargeback 14:03:15 12 database that Mallinckrodt maintained would 14:03:27 13 have been a source for that information? 14:03:30 14 MR. O'CONNOR: Object to form. 14:03:31 15 THE WITNESS: Could you repeat 14:03:32 16 the question? 14:03:35 17 QUESTIONS BY MR. GOTTO: 14:03:35 18 Q. Yeah. 14:03:36 19 My question about the 14:03:36 19 Exhibit 16 sales reflect, do you know if the 14:03:42 20 chargeback data that Mallinckrodt maintained 14:03:43 21 Could have been queried to ascertain the 14:03:43 22 chargeback data that Mallinckrodt maintained 14:03:43 23 QUESTIONS BY MR. GOTTO: 14:03:51 24 A. To my knowledge, this was the 14:05:52 25 MR. O'CONNOR: Object to form. 14:03:53 3 QUESTIONS BY MR. GOTTO: 14:03:53 4 Q. No and I think you indicated 14:04:04 5 Do you know indicated 14:04:04 6 Borelli and Ms. Williams about this data, 14:04:17 8 know what you had discovered. 14:04:27 10 Paper Joy on know if thats - if 14:04:24 10 that information would otherwise have been 14:04:24 10 that information would otherwise have been 14:04:24 10 that information would otherwise have been 14:04:42 10 that information would otherwise have been 14:04:43 12 Q. Do you know if thats - if 14:04:43 14 Do you know if thats - if 14:04:43 15 Q. In other words, would they have 14:04:43 16 Mallinckrodt distributors 14:04:43 17 of the idea was to let the distributors 14:04:43 18 Mallinckrodt distributors 14:04:44 19 MR. O'CONNOR: Same objection. 14:04:43 10 M				
5 QUESTIONS BY MR. GOTTO: 14-03:06		-		· ·
6 Q. Was any effort made to 14:03:08 7 ascertain that? 14:03:10 10 on this. 14:03:10 11 Q. Do you know if the chargeback 14:03:13 12 on on this. 14:03:14 13 bave been a source for that information? 14:03:30 14 MR. O'CONNOR: Object to form. 14:03:31 15 THE WITNESS: Could you repeat 14:03:32 16 the question? 14:03:35 17 QUESTIONS BY MR. GOTTO: 14:03:35 18 Q. Yeah. 14:03:36 19 percentage of sales into Horida that these 14:03:36 20 percentage of sales into Horida that these 14:03:37 21 Exhibit 16 sales reflect, do you know if the 14:03:42 22 chargeback data that Mallinckrodt maintained 14:03:42 23 could have been queried to ascertain the 14:03:48 24 answer to that question? 14:03:55 25 MR. O'CONNOR: Object to form. 14:03:51 26 Do you know if the 14:03:65 27 Page 199 28 THE WITNESS: I would assume 14:03:52 29 so, because we did it here. 14:03:53 30 QUESTIONS BY MR. GOTTO: 14:04:33 31 ARN O'CONNOR: Object to form. 14:04:33 32 QUESTIONS BY MR. GOTTO: 14:04:33 33 MR. O'CONNOR: Object to form. 14:04:33 34 QUESTIONS BY MR. GOTTO: 14:04:33 35 MR. O'CONNOR: Object to form. 14:04:34 36 band any independent way of ascertaining which 14:04:34 37 OUESTIONS BY MR. GOTTO: 14:04:33 38 QUESTIONS BY MR. GOTTO: 14:04:42 39 Do you know if that shorts in 14:04:24 30 Could have been queried to ascertain the 14:04:04:06 31 Arrival of the idea was to let the distributors 14:04:27 31 available to Mallinckrodf sitsributor 14:04:33 32 MR. O'CONNOR: Object to form. 14:04:33 33 MR. O'CONNOR: Object to form. 14:04:34 44 had any independent way of ascertaining which 14:04:36 54 Q. Do you know if that she if 14:04:42 55 Q. In other words, would they have 14:04:43 56 Mallinckrodf sitsributors? 14:04:42 57 Q. Okay. And I think you've 14:04:43 58 Mallinckrodf sitsributors? 14:04:42 59 Q. Okay. And I think you've 14:04:43 50 A. This is the entire list. 14:06:03 51 THE WITNESS: I wouldn't know 14:04:43 52 Q. Okay. And I think you've 14:04:43 53 A. This is the entire list. 14:06:03 54 A. This is the entire list. 14:06:05 55 Percentage of sits problem				
7 ascertain that?				
8 A. I'm sure that we knew 14:03:11 9 satures 14:05:11 9 states 14:05:11 10 on this. 14:05:14 11 10 on this. 14:05:14 12 12 14:05:15 14:05:16 14:05:15 12 12 13 have been a source for that information? 14:03:27 13 have been a source for that information? 14:03:27 14:03:30 13 have been a source for that information? 14:03:27 14:03:35 15 THE WITNESS: Could you repeat 14:03:32 15 16 the question? 14:03:35 17 14:03:35 17 14:03:35 17 14:03:36 18 19 My question about the 14:03:36 19 MR. O'CONNOR: Object to form. 14:03:51 18 Do you know — is it your 14:05:42 18 Do you know — is it your 14:05:42 18 Do you know — is it your 14:05:52 19 MR. O'CONNOR: Object to form. 14:03:51 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:55 18 Do you know — is it your 14:05:54 18 Do you know — is it your 14:05:55 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it your 14:05:52 18 Do you know — is it		· · · · · · · · · · · · · · · · · · ·		*
9 somewhere, but I didn't know for a fact based 14:03:15 10 10 10 11.0 12.0 13.0 13.0 14:03:16 12 12 13 13 13 13 13 13				
10				
12 database that Mallinckrodt maintained would 14:03:16 12:03 have been a source for that information? 14:03:30 14 MR. O'CONNOR: Object to form. 14:03:31 15 THE WITNESS: Could you repeat 14:03:32 15 THE WITNESS: Could you repeat 14:03:32 15 THE WITNESS: Could you repeat 14:03:32 16 the question? 14:03:36 17 QUESTIONS BY MR. GOTTO: 14:03:35 17 QUESTIONS BY MR. GOTTO: 14:03:35 18 Q. Yeah. 14:03:36 19 My question about the 14:03:36 19 MR. O'CONNOR: Object to form. 14:03:42 19 MR. O'CONNOR: Object to form. 14:03:51 14:05:42 19 MR. O'CONNOR: Object to form. 14:03:53 18 MR. O'CONNOR: Object to form. 14:03:52 18 MR. O'CONNOR: Object to form. 14:04:36 19 Do you know if that's - if 14:04:20 19 Do you know if that's - if 14:04:22 11 available to Mallinckrodt's distributor 14:04:33 14:04:14 19 MR. O'CONNOR: Object to form. 14:04:33 19 MR. O'CONNOR: Object to form. 14:04:30 19 Do you know if that's - if 14:04:24 10 that information would otherwise have been 14:04:34 18 MR. O'CONNOR: Object to form. 14:04:33 19 MR. O'CONNOR: Object to form. 14:04:34 19 MR. O'CONNOR: Sme objection. 14:04:47 19 MR. O'CO			-	
12				•
13				
14				• •
15				* * * * * * * * * * * * * * * * * * * *
16	14		14	
17		· · ·		
18	16	_	16	_
19				•
20 percentage of sales into Florida that these 14:03:37 20 a list of all of the parties identified as 14:05:48 21 chargeback data that Mallinckrodt maintained 14:03:42 22 chargeback data that Mallinckrodt maintained 14:03:48 23 could have been queried to ascertain the 14:03:48 24 answer to that question? 14:03:51 25 MR. O'CONNOR: Object to form. 14:03:51 25 MR. O'CONNOR: Object to form. 14:03:52 25 MR. O'CONNOR: Object to form. 14:03:52 26 MR. O'CONNOR: Object to form. 14:03:53 27 MR. O'CONNOR: Object to form. 14:03:53 28 MR. O'CONNOR: Object to form. 14:03:55 29 MR. O'CONNOR: Object to form. 14:03:55 29 MR. O'CONNOR: Object to form. 14:04:06 30 MR. O'CONNOR: Object to form. 14:04:06 30 MR. O'CONNOR: Object to form. 14:04:07 30 MR. O'CONNOR: Object to form. 14:04:30 12 customers? 14:06:07 30 MR. O'CONNOR: Object to form. 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:40 16 MR. O'CONNOR: Same objection. 14:04:43 17 of their customers were buying from other 14:04:35 18 MR. O'CONNOR: Same objection. 14:04:43 18 MR. O'CONNOR: Same objection. 14:04:47 19 MR. O'CONNOR: Same objection. 14:04:47 23 Q. Okay. And I think you're 14:04:47 24 already testified you performed this analysis 14:04:45 24 already testified you performed this analysis 14:04:45 14:05:48 14:05:59 14:06:54 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:03 14:06:04 14:06:05 14:06:05 14:06:06 14:06:06 14:06:06 14:06:07 14:06:				
21 Exhibit 16 sales reflect, do you know if the 14:03:42 22 22 23 24 24 24 25 25 25 25 24 25 25		* *		_
22 chargeback data that Mallinckrodt maintained 14:03:44 23 could have been queried to ascertain the 14:03:48 24 answer to that question? 14:03:51 25 bought from multiple distributors? 14:05:59 14:05:59 MR. O'CONNOR: Object to form. 14:03:51 25 list. 14:06:03 Page 2 1 THE WITNESS: I would assume 14:03:52 1 Q. Okay. 14:06:03 Page 2 2 Q. Okay. 14:06:03 Q. For all states? 14:06:05 A. And I want to be clear, too. 14:06:05 A. And I want to be clear, too. 14:06:05 A. And I want to be clear, too. 14:06:05 A. And I want to be clear, too. 14:06:05 A. And I want to be clear, too. 14:06:06 Sorelli and Ms. Williams about this data, 14:04:14 14:04:04 14:04:04 14:04:04 14:04:05 14:06:05 A. And I want to be clear, too. 14:06:07 14:06:08 14:06:09 14:06:09 14:06:10		•		•
23 could have been queried to ascertain the 14:03:48 answer to that question? 14:03:51 24 A. To my knowledge, this was the 14:06:01 25 MR. O'CONNOR: Object to form. 14:03:51 25 list. 14:06:03 Page 2 1 THE WITNESS: I would assume 14:03:52 2 so, because we did it here. 14:03:53 2 2 so, because we did it here. 14:03:53 2 2 A. This is the entire list. 14:06:04 3 QUESTIONS BY MR. GOTTO: 14:04:06 6 Borelli and Ms. Williams about this data, 14:04:14 part of the idea was to let the distributors 14:04:17 part of the idea was to let the distributors 14:04:24 po Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:30 11 A. That's when the query was 14:06:12 11 available to Mallinckrodt's distributor 14:04:34 QUESTIONS BY MR. GOTTO: 14:04:34 15 MR. O'CONNOR: Object to form. 14:04:34 16 had any independent way of ascertaining which 14:04:40 17 A. But 14:06:35 16 Mallinckrodt distributors? 14:04:41 18 MR. O'CONNOR: Same objection. 14:04:42 19 MR. O'CONNOR: Same objection. 14:04:43 19 MR. O'CONNOR: Same objection. 14:04:45 11 What their systems could do. 14:04:45 21 What their systems could do. 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45		·		
24 answer to that question? 14:03:51		_		•
Page 199		•		-
Page 199 1 THE WITNESS: I would assume 14:03:52 2 so, because we did it here. 14:03:53 3 QUESTIONS BY MR. GOTTO: 14:03:55 4 Q. And I think you indicated 14:04:00 5 earlier that when you spoke to Mr. Becker and 14:04:06 6 Borelli and Ms. Williams about this data, 14:04:14 7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:27 11 available to Mallinckrodt's distributor 14:04:33 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:34 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 17 of their customers were buying from other 14:04:40 18 MR. O'CONNOR: Same objection. 14:04:42 19 MR. O'CONNOR: Same objection. 14:04:43 20 WESTIONS BY MR. GOTTO: 14:04:45 21 What their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 24 COKay. Do you have an 14:06:01 25 THE WITNESS: I wouldn't know 14:04:33 26 Do you 14:06:33 27 Okay. No you have an 14:06:12 28 UNderstanding of what the reference to 14:06:12 29 UND you have an 14:06:12 20 UND you have an 14:06:12 20 UND you have an 14:06:12 21 What their systems could do. 14:04:43 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:44		·		
THE WITNESS: I would assume	25	MR. O CONNOR: Object to form. 14.05.31	25	list. 14.00.03
2 so, because we did it here. 14:03:53 3 QUESTIONS BY MR. GOTTO: 14:03:55 4 Q. And I think you indicated 14:04:00 5 earlier that when you spoke to Mr. Becker and 14:04:06 6 Borelli and Ms. Williams about this data, 14:04:14 7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:30 11 available to Mallinckrodt's distributor 14:04:33 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:34 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 20 THE WITNESS: I wouldn't know 14:04:43 21 What their systems could do. 14:04:47 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 24 A. This is the entire list. 14:06:05 4 A. And I want to be clear, too. 14:06:07 5 It says September 2010. I don't know the 14:06:01 6 time frame on this. 14:06:12 9 Chay. Do you have an 14:06:12 14:06:12 14:06:12 15 Q. Okay. Do you have an 14:06:12 16 time frame on this. 14:06:12 18 understanding of what the reference to 14:06:12 19 Latine frame on this. 14:06:12 10 that information would otherwise have been 14:04:27 11 A. That's when the query was 14:06:22 12 pulled for the September in 2010. She 14:06:24 13 does not have a specific date on here. We 14:06:33 14 QUESTIONS BY MR. GOTTO: 14:04:43 15 Q. Do you 14:06:33 16 A. But 14:06:36 17 A. But 14:06:36 18 Q. Go ahead. 14:06:12 19 A. Okay. It was run on 14:06:36 11/19/2010, but she doesn't even say there if 14:06:34 21 time frame, sorry. 14:06:44 22 time frame, sorry. 14:06:44 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55		_		Page 201
3 QUESTIONS BY MR. GOTTO: 14:03:55 4 Q. And I think you indicated 14:04:00 5 earlier that when you spoke to Mr. Becker and 14:04:06 6 Borelli and Ms. Williams about this data, 14:04:14 7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 8 understanding of what the reference to 14:06:12 9 Do you know if that's if 14:04:24 9 September 2010. I don't know the 14:06:12 14:06:16 9 September 2010. I don't know the 14:06:12 14:06:16 14:06:16 14:06:16 14:06:16 14:06:21 14:06:21 14:06:21 14:06:21 14:06:21 14:06:21 14:06:22 14:06:21 14:06:22 14:06:23 14:06:23 14:06:24 15 Q. In other words, would they have 14:04:34 15 Q. In other words, would they have 14:04:36 16 had any independent way of ascertaining which 14:04:36 17 A. But 14:06:35 14:06:36 14:06:36 14:06:36 14:06:44 19 MR. O'CONNOR: Same objection. 14:04:45 19 MR. O'CONNOR: Same objection. 14:04:45 20 QUESTIONS BY MR. GOTTO: 14:04:47 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45 24 data if the sales that are reflected on 14:06:45	1		1	•
4 Q. And I think you indicated 14:04:00 5 carlier that when you spoke to Mr. Becker and 14:04:06 6 Borelli and Ms. Williams about this data, 14:04:14 7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:30 11 available to Mallinckrodt's distributor 14:04:33 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:34 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:40 17 MR. O'CONNOR: Same objection. 14:04:41 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 20 UESTIONS BY MR. GOTTO: 14:04:43 21 what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 24 already testified you performed this analysis 14:04:55 4 A. And I want to be clear, too. 14:06:07 5 It says September 2010. I don't know the 14:06:06 14:06:07 14:06:07 14:06:07 14:06:01 14:06:12 15 Usuderstanding of what the reference to 14:06:12 16 understanding of what the reference to 14:06:12 18 understanding of what the reference to 14:06:12 19 September 2010 in the title of the document 14:06:14 10 means? 14:06:21 11 A. That's when the query was 14:06:22 12 pulled for the September in 2010. She 14:06:22 13 does not have a specific date on here. We 14:06:33 14 normally would have documented that 14:06:36 15 Q. Do you 14:06:33 16 Q. Do you 14:06:33 17 A. But 14:06:35 18 Q. Go ahead. 14:06:36 19 A. Okay. It was run on 14:06:36 20 I1/19/2010, but she doesn't even say there if 14:06:41 21 what their systems could do. 14:04:47 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 4 A. And I want to be clear, to in the title of the document 14:06:10 14:06:12 14 A. That's when the query was 14:06:24 15 Do you 14:06:36 16 Q. Do you 14:06:33 17 A. But 14:06:36 18 Q. Go ahead. 14:06:36 19 A. Ok				
5 Earlier that when you spoke to Mr. Becker and 14:04:06 6 Borelli and Ms. Williams about this data, 14:04:14 7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:27 11 available to Mallinckrodt's distributor 14:04:33 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:34 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 10 MR. O'CONNOR: Same objection. 14:04:42 10 that information would otherwise have been 14:04:30 14:06:21 12 pulled for the September in 2010. She 14:06:22 13 does not have a specific date on here. We 14:06:23 14 normally would have documented that 14:06:35 15 Name of the idea was to let the distributor 14:04:34 16 time frame on this. 14:06:12 20 September 2010 in the title of the document 14:06:16 3 September 2010 in the title of the document 14:06:21 4 A. That's when the query was 14:06:22 5 pulled for the September in 2010. She 14:06:22 10 means? 14:06:21 11 A. That's when the query was 14:06:22 12 pulled for the September in 2010. She 14:06:24 14 normally would have documented that 14:06:35 14 20 Do you 14:06:33 15 Q. Do you 14:06:35 16 Q. Do you 14:06:35 17 A. But 14:06:35 18 Q. Go ahead. 14:06:36 19 A. Okay. It was run on 14:06:36 11/19/2010, but she doesn't even say there if 14:06:34 14 14:06:24 25 Q. Okay. And I think you've 14:04:47 26 Q. Okay. So you don't know if the 14:06:44 27 Q. Okay. So you don't know if the 14:06:45 14 14:06:24 28 It says September 2010 in the title of the document 14:06:10 15				
6 Borelli and Ms. Williams about this data, 14:04:14 7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:27 11 available to Mallinckrodt's distributor 14:04:30 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:34 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:40 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 20 THE WITNESS: I wouldn't know 14:04:43 21 what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 24 already testified you performed this analysis 14:04:55 24 time frame on this. 14:06:12 7 Q. Okay. Do you have an 14:06:12 8 understanding of what the reference to 14:06:16 14:06:12 7 Q. Okay. Do you have an 14:06:12 8 understanding of what the reference to 14:06:16 14:06:12 7 Q. Okay. Do you have an 14:06:12 8 understanding of what the reference to 14:06:12 14:06:12 9 September 2010 in the title of the document 14:06:14 14:06:21 11 A. That's when the query was 14:06:22 12 pulled for the September in 2010. She 14:06:24 13 does not have a specific date on here. We 14:06:24 14:06:25 15 somewhere. 14:06:33 16 Q. Do you 14:06:33 17 A. But 14:06:35 18 Q. Go ahead. 14:06:36 19 A. Okay. It was run on 14:06:36 20 11/19/2010, but she doesn't even say there if 14:06:31 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45		· ·		
7 part of the idea was to let the distributors 14:04:17 8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:27 11 available to Mallinckrodt's distributor 14:04:30 11 available to Mallinckrodt's distributor 14:04:33 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:34 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 17 of their customers were buying from other 14:04:40 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 20 THE WITNESS: I wouldn't know 14:04:45 21 what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45		• •		•
8 know what you had discovered. 14:04:20 9 Do you know if that's if 14:04:24 10 that information would otherwise have been 14:04:27 11 available to Mallinckrodt's distributor 14:04:30 12 customers? 14:04:33 13 MR. O'CONNOR: Object to form. 14:04:33 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 17 of their customers were buying from other 14:04:41 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 20 THE WITNESS: I wouldn't know 14:04:43 21 What their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 24 already testified you performed this analysis 14:04:55 8 understanding of what the reference to 14:06:16 9 September 2010 in the title of the document 14:06:21 10 means? 14:06:21 11 A. That's when the query was 14:06:22 12 pulled for the September in 2010. She 14:06:24 13 does not have a specific date on here. We 14:06:24 14:06:25 15 Q. In other words, would they have 14:04:34 15 somewhere. 14:06:33 16 Q. Do you 14:06:35 17 A. But 14:06:35 18 Q. Go ahead. 14:06:36 19 A. Okay. It was run on 14:06:36 11/19/2010, but she doesn't even say there if 14:06:31 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				
9 Do you know if that's if 14:04:24				
10 that information would otherwise have been 14:04:27 10 means? 14:06:21 11 available to Mallinckrodt's distributor 14:04:30 11 A. That's when the query was 14:06:22 12 customers? 14:04:33 12 pulled for the September in 2010. She 14:06:24 13 MR. O'CONNOR: Object to form. 14:04:33 13 does not have a specific date on here. We 14:06:2 14 QUESTIONS BY MR. GOTTO: 14:04:34 14 normally would have documented that 14:06:3 15 Q. In other words, would they have 14:04:34 15 somewhere. 14:06:33 16 had any independent way of ascertaining which 14:04:36 16 Q. Do you 14:06:33 17 of their customers were buying from other 14:04:40 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 MR. O'CONNOR: Same objection. 14:04:42 19 A. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:45 20 11/19/2010, but she doesn't even say there if 14:06:34 21 what their systems could do. 14:04:47		•		
11 available to Mallinckrodt's distributor 14:04:30 11 A. That's when the query was 14:06:22 12 customers? 14:04:33 12 pulled for the September in 2010. She 14:06:24 13 MR. O'CONNOR: Object to form. 14:04:33 13 does not have a specific date on here. We 14:06:2 14 QUESTIONS BY MR. GOTTO: 14:04:34 14 normally would have documented that 14:06:3 15 Q. In other words, would they have 14:04:34 15 somewhere. 14:06:33 16 had any independent way of ascertaining which 14:04:36 16 Q. Do you 14:06:33 17 of their customers were buying from other 14:04:40 14:04:40 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 MR. O'CONNOR: Same objection. 14:04:42 19 A. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:43 20 11/19/2010, but she doesn't even say there if 14:06:3 21 what their systems could do. 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47		•		-
12 customers? 14:04:33 MR. O'CONNOR: Object to form. 14:04:33 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 17 of their customers were buying from other 14:04:40 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 20 THE WITNESS: I wouldn't know 14:04:43 21 what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 12 pulled for the September in 2010. She 14:06:24 14 does not have a specific date on here. We 14:06:24 15 somewhere. 14:06:33 16 Q. Do you 14:06:33 17 A. But 14:06:35 18 Q. Go ahead. 14:06:36 20 11/19/2010, but she doesn't even say there if 14:06:31 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55				
13 MR. O'CONNOR: Object to form. 14:04:33 14 QUESTIONS BY MR. GOTTO: 14:04:34 15 Q. In other words, would they have 14:04:34 16 had any independent way of ascertaining which 14:04:36 17 of their customers were buying from other 14:04:40 18 Mallinckrodt distributors? 14:04:41 19 MR. O'CONNOR: Same objection. 14:04:42 10 THE WITNESS: I wouldn't know 14:04:43 21 what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 13 does not have a specific date on here. We 14:06:26 14:06:33 15 Q. Do you 14:06:33 16 Q. Do you 14:06:35 17 A. But 14:06:36 19 A. Okay. It was run on 14:06:36 20 11/19/2010, but she doesn't even say there if 14:06:36 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. So you don't know if the 14:06:45				
14 QUESTIONS BY MR. GOTTO: 14:04:34 14 normally would have documented that 14:06:33 15 Q. In other words, would they have 14:04:34 15 somewhere. 14:06:33 16 had any independent way of ascertaining which 14:04:36 16 Q. Do you 14:06:33 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 MR. O'CONNOR: Same objection. 14:04:42 19 A. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:43 20 11/19/2010, but she doesn't even say there if 14:06:31 21 what their systems could do. 14:04:45 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				
15 Q. In other words, would they have 14:04:34 15 somewhere. 14:06:33 16 had any independent way of ascertaining which 14:04:36 16 Q. Do you 14:06:33 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 MR. O'CONNOR: Same objection. 14:04:42 19 A. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:43 20 11/19/2010, but she doesn't even say there if 14:06:36 21 what their systems could do. 14:04:45 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				-
16 had any independent way of ascertaining which 14:04:36 14:04:36 16 Q. Do you 14:06:33 17 of their customers were buying from other 14:04:40 14:04:40 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 M. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:43 20 11/19/2010, but she doesn't even say there if 14:06:3 21 what their systems could do. 14:04:45 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				•
17 of their customers were buying from other 14:04:40 17 A. But 14:06:35 18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 MR. O'CONNOR: Same objection. 14:04:42 19 A. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:43 20 11/19/2010, but she doesn't even say there if 14:06:3 21 what their systems could do. 14:04:45 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45		· · · · · · · · · · · · · · · · · · ·		
18 Mallinckrodt distributors? 14:04:41 18 Q. Go ahead. 14:06:36 19 MR. O'CONNOR: Same objection. 14:04:42 19 A. Okay. It was run on 14:06:36 20 THE WITNESS: I wouldn't know 14:04:43 20 11/19/2010, but she doesn't even say there if 14:06:36 21 what their systems could do. 14:04:45 21 it's just one month or I don't know the 14:06:41 22 QUESTIONS BY MR. GOTTO: 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47 23 Q. Okay. So you don't know if the 14:06:44 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				•
19 MR. O'CONNOR: Same objection. 14:04:42 20 THE WITNESS: I wouldn't know 14:04:43 21 what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 19 A. Okay. It was run on 14:06:36 20 11/19/2010, but she doesn't even say there if 14:06:36 21 it's just one month or I don't know the 14:06:41 22 time frame, sorry. 14:06:43 23 Q. Okay. So you don't know if the 14:06:44 24 data if the sales that are reflected on 14:06:45				
THE WITNESS: I wouldn't know 14:04:43 what their systems could do. 14:04:45 QUESTIONS BY MR. GOTTO: 14:04:47 Q. Okay. And I think you've 14:04:47 already testified you performed this analysis 14:04:55 THE WITNESS: I wouldn't know 14:04:43 120 11/19/2010, but she doesn't even say there if 14:06:31 21 it's just one month or I don't know the 14:06:41 22 time frame, sorry. 14:06:43 Q. Okay. So you don't know if the 14:06:44 24 data if the sales that are reflected on 14:06:45				~
what their systems could do. 14:04:45 22 QUESTIONS BY MR. GOTTO: 14:04:47 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 21 it's just one month or I don't know the 14:06:41 22 time frame, sorry. 14:06:43 23 Q. Okay. So you don't know if the 14:06:44 24 data if the sales that are reflected on 14:06:45				•
22 QUESTIONS BY MR. GOTTO: 14:04:47 22 time frame, sorry. 14:06:43 23 Q. Okay. And I think you've 14:04:47 24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				•
Q. Okay. And I think you've 14:04:47 Already testified you performed this analysis 14:04:55 Q. Okay. So you don't know if the 14:06:44 Add already testified you performed this analysis 14:04:55				
24 already testified you performed this analysis 14:04:55 24 data if the sales that are reflected on 14:06:45				•
		· · · · · · · · · · · · · · · · · · ·		
		J		To obtained in September 2010 of at

	B 404	_	D 004
1	Page 202 some other point? 14:06:52	1	Page 204 A. It's the percent of the total 14:08:38
2	A. Right. 14:06:53	2	units. And so she had to divide where 14:08:43
3	Q. Presumably it would have 14:06:54	3	where was the units, who was the average, who 14:08:48
	included September 2010, but it might have 14:06:56	4	was the median, the most frequent number, and 14:08:51
4	•		*
5	extended beyond that? 14:06:59	5	so the total dispensed units. 14:08:54
6	A. Correct. 14:07:00	6	Q. Okay. So it's a comparison. 14:08:57
7	Q. You just don't know? 14:07:00	7	So, for example, West Coast 14:08:58
8	A. Correct. 14:07:02	8	Pharmacy on the first page, 499.7 percent is 14:09:00
9	Q. Okay. And so if it's the case 14:07:03	9	a comparison of the 173,900 to the 34,800 for 14:09:05
10	that Exhibit 16 reflects all of the customers 14:07:11	10	David's Pharmacy? 14:09:11
11	buying from multiple Mallinckrodt 14:07:16	11	A. Yes, that would be the 14:09:13
12	distributors for whatever time period is 14:07:18	12	they're 499 percent to the average purchaser. 14:09:17
13	applicable here, it would appear to be the 14:07:20	13	Q. Okay. Thank you. 14:09:20
14	case that that phenomenon of customers buying 14:07:23	14	At the time of the preparation 14:09:43
15	from multiple distributors was highly 14:07:28	15	of the analysis or the compilation that's 14:09:44
16	concentrated, if not exclusive, to the state 14:07:32	16	reflected on Exhibit 16, did you make any 14:09:50
17	of Florida. 14:07:34	17	attempt to evaluate the magnitude of sales 14:09:53
18	It was at least highly 14:07:35	18	from Mallinckrodt to any of the particular 14:10:03
19	concentrated in Florida, correct? 14:07:37	19	distributors who whose customers, direct 14:10:06
20	MR. O'CONNOR: Object to form. 14:07:38	20	or indirect, are reflected on Exhibit 16? 14:10:11
21	THE WITNESS: This would 14:07:39	21	A. I do remember knowledge of 14:10:14
22	reflect only those customers or 14:07:40	22	that there were certain distributors or 14:10:19
23	pharmacies that were issued a 14:07:42	23	wholesalers in the list. 14:10:21
24	chargeback as part of a contract. 14:07:43	24	Q. And whom do you recall being in 14:10:23
25	So I cannot speak to that, 14:07:45	25	that category? 14:10:25
	<u> </u>		
	Page 203		Page 205
1	because I don't know who purchased the 14:07:47	1	A. I remember Smith Drug was one 14:10:25
2	product at this price from the 14:07:49	2	of them. 14:10:28
3	wholesaler or at some other on 14:07:50	3	Q. Okay. Do you remember if there 14:10:29
4	other various contracts or various 14:07:54	4	was any particular analysis of KeySource? 14:10:32
5	pharmacy names. So it could be 14:07:56	5	MR. O'CONNOR: Object to form. 14:10:39
6	misleading if I tell you yes. 14:07:58	6	THE WITNESS: I don't. 14:10:40
7	QUESTIONS BY MR. GOTTO: 14:08:00	7	QUESTIONS BY MR. GOTTO: 14:10:41
8	Q. Okay. But certainly among the 14:08:00	8	Q. Okay. And how about Sunrise? 14:10:41
9	universe of customers whose purchases gave 14:08:03	9	MR. O'CONNOR: Object to form. 14:10:42
10	rise to a chargeback claim that a distributor 14:08:05	10	THE WITNESS: I don't remember 14:10:44
11	made to Mallinckrodt, it's the case that this 14:08:08	11	that either. 14:10:44
12	phenomenon of purchases from multiple 14:08:11	12	At that time I'm not sure if 14:10:45
13	distributors was heavily concentrated in 14:08:13	13	they were still in our sales, because 14:10:46
14	Florida? 14:08:15	14	I'm not sure when the DEA took 14:10:49
15	MR. O'CONNOR: Object to form. 14:08:15	15	enforcement action on them. 14:10:52
16	THE WITNESS: It appears so, 14:08:16	16	QUESTIONS BY MR. GOTTO: 14:10:54
17	yes. 14:08:20	17	Q. Okay. You can set those aside. 14:10:54
18	QUESTIONS BY MR. GOTTO: 14:08:20	18	(Mallinckrodt-Collier Exhibit 14:11:26
19	Q. And on page 3, the David's 14:08:21	19	17 marked for identification.) 14:11:26
20	Pharmacy line is highlighted. 14:08:25	20	QUESTIONS BY MR. GOTTO: 14:11:26
21	Do you have any idea why that 14:08:26	21	Q. We have marked as Exhibit 17 a 14:11:26
22	is? Is it because it's the average? 14:08:28	22	multipage e-mail thread beginning at 14:11:30
23	A. Correct. 14:08:30	23	MNK-T1_0000483766, and it's an e-mail 14:11:33
24	Q. And that percent to average 14:08:31	24	exchange from June of 2010 concerning 14:11:41
25	column, what is that reflecting? 14:08:35	25	oxycodone sales in Florida. 14:11:45

Take a moment to look at those 14:11-57 2 und — those e-mails. Let me know after 14:11-53 3 you've reviewed them. 14:11-53 3 A. Yes, she did. 14:15-07 3 MR. O'CONNOR: Object to form. 14:15-15 5 Q. Do you recognize those e-mails? 14:12-56 6 A. Yes, 1 do. 14:12-58 7 Q. Okay. So turning to the 14:13-00 6 e-mails — 1 just would like to understand who 14:15-15 7 Q. Do you recognize those e-mails? 14:13-08 6 e-mail — 1 just would like to understand who 14:15-15 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp 14:13-21 1 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp 14:13-22 1 MR. Mohlenkamp on June 18th, e-mail from her 14:13-08 7 MR. Mohlenkamp 14:15-24 1 MR. Mohlenkamp 14:15-25 1 MR. Mohlenka				
2		Page 206		Page 208
3 you've reviewed them. 14:11:53 4 A. Okay. 14:11:55 5 Q. Do you recognize those o-mails? 14:12:56 5 Q. Do you recognize those o-mails? 14:12:56 6 A. Yes, I do. 14:12:58 7 Q. Okay. So turning to the 14:13:00 8 carliest in time in the thread, from 14:13:00 14:13:00 15 carliest in time in the thread, from 14:13:00 16 carliest in time in the thread, from 14:13:00 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time on June 18th, e-mail from the 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:08 16 carliest in time in the thread, from 14:13:21 17 carliest of the pose on to mention that 14:13:34 18 carliest distributor license suspensions 14:13:34 18 carlies				
4				
5				5
6		•		
Q. Okay. So turning to the 14:13:00 9 earliest in time in the thread, from 14:13:03 9 Ms. Midhlenkamp on June 18th. e-mail from the 14:13:08 14:13:13 13 talks about Harvard Drug's license being 14:13:21 13 sunrise wholesaler's DEA license was 14:13:30 13 sunrise wholesaler's DEA license was 14:13:30 14:13:34 14 suspended. She then goes on to mention that 14:13:26 15 And then she says, "The two 14:13:34 15 Sunrise wholesaler's DEA license was 14:13:30 15 And then she says, "The two 14:13:34 15 Molesaler distributor license suspensions 14:13:34 15 Covidien's exceedines lase in the state of 14:13:42 17 No. Malesaler distributor license suspensions 14:13:38 16 Covidien's exceedines lase in the state of 14:13:42 17 No. Malesaler distributor license suspensions 14:13:38 17 A. Correct, national account 14:15:29 No. Malesaler distributor license suspensions 14:13:38 17 A. Correct, national account 14:15:29 No. Malesaler distributor license suspensions 14:13:39 No. Malesaler distributor license suspensions 14:13:34 16 No. Malesaler distributor license suspensions 14:13:39 No. Malesaler distributor license suspensions 14:13:34 No. Malesaler distributor l				· · · · · · · · · · · · · · · · · · ·
8 earliest in time in the thread, from 14:13:03 9 Ms. Mubhenkamp on June 18th, e-mail from her 14:13:08 10 to a number of people and copying you, she 14:13:13 11 talks about Harvard Drug's license being 14:13:21 12 suspended. She then goes on to mention that 14:13:26 13 Surrise wholesaler's DFA license was 14:13:30 14 suspended. She then goes on to mention that 14:13:26 15 And then she says, "The two 14:13:34 16 wholesaler distributor license suspensions 14:13:34 17 led us to do a more in-depth analysis of 14:13:35 18 Covidien's oxycodone sales in the state of 14:13:42 19 Florida. We specifically focused on doctors 14:13:42 20 offices and pain clinics." 14:13:43 21 offices and pain clinics." 14:13:43 22 we discussed this morning - 14:13:53 23 A. Yes, it is. 14:13:54 24 Q where she queried the 14:13:54 25 chargeback database? 14:13:57 26 the Smith, KeySource and McKesson Onestop are 14:14:15 27 next, with only 3 percent to their total 14:14:19 28 sales coming from doctors' offices and pain 14:14:19 29 license of the morning - 14:14:15 30 sales coming from doctors' offices and pain 14:14:19 31 the distribution of oxycodone in Florida, and 14:14:27 32 investigators, paren, will be working closely 14:14:27 33 the distribution of oxycodone in Florida, and 14:14:27 34 the distribution of oxycodone in Florida, and 14:14:27 35 we will keep you apprised of further 14:14:43 36 the distribution of oxycodone in Florida, and 14:14:27 37 You then - you responded to 14:14:43 38 the distribution of oxycodone in Florida, and 14:14:42 39 You may want to send this to Karen Harper, 14:14:44 40 You may want to send this to Karen Harper, 14:14:46 41 Correct? 14:14:49 42 Correct? 14:14:49 43 Correct 14:14:49 44 Correct? 14:14:49 45 Correct? 14:14:49 46 Correct? 14:14:49 47 Correct? 14:14:49 48				•
9 Ms. Muhlenkamp on June 18th, e-mail from her 14:13:08 10 to a number of people and copying you, she				
10		*		
11 talks about Harvard Drug's license being 14:13:21 12 2 Correct 14:15:24	9	•	9	
12 Suspended. She then goes on to mention that 14:13:26 12 Correct? 14:15:24	10			
13 Sumrise wholesaler's DEA license was 14:13:34 14 14:15:25 14:15:25 15 And then she says, "The two 14:13:34 15 A. National account manager. 14:15:29 14:15:29 14:15:39	11		11	
14 suspended.	12	•	12	
15	13		13	
16		•		· · · · · · · · · · · · · · · · · · ·
17	15	•	15	
18		*		
19 Florida. We specifically focused on doctors 14:13:49 20 offices and pain clinics." 14:13:49 21 And is that the initiative that 14:13:51 22 we discussed this morning 14:13:53 22 Q. Also a national account 14:15:38 23 A. Yes, it is. 14:13:54 24 Q where she queried the 14:13:57 25 chargeback database? 14:13:57 25 Q. And Rich McKendrick? 14:15:39 25 Chargeback database? 14:13:58 25 Q. And Rich McKendrick? 14:15:49 26 A. Yes, he was for government 14:15:43 27 A. Yes, he was for government 14:15:43 28 29 A. Yes, he was for government 14:15:43 29 A. Yes, he was for government 14:15:43 29 A. Yes, he was for government 14:15:43 20 A. Yes, he was for government 14:15:43 20 A. Yes, he was for government 14:15:43 20 A. Yes, he was for government 14:15:43 21 A. Yes, he was for government 14:15:44 21 21 21 21 21 21 21				
20 offices and pain clinics." 14:13:49 20 Sanders? 14:15:37 21 And is that the initiative that 14:13:51 22 we discussed this morning 14:13:53 22 Q. Also a national account 14:15:38 23 Manager? 14:15:39 24 Q where she queried the 14:13:57 25 Q. And Rich McKendrick? 14:15:39 25 chargeback database? 14:13:57 25 Q. And Rich McKendrick? 14:15:39 26 Q. And Rich McKendrick? 14:15:40 27 Q. And Rich McKendrick? 14:15:40 28 A. Yes, he was for government 14:15:43 28 29 A. Yes, he was for government 14:15:43 29 20 And Alex McGregor? 14:15:45 20 And Alex McGregor? 14:15:49 21 A. Yes, he was for government 14:15:45 21 A. Yes, he was for government 14:15:45 21 A. Yes, he was for government 14:15:43 21 A. Yes, he was for government 14:15:45 22 A. National accounts. 14:15:49 23 A. Robert Lesnak? 14:15:49 24 A. National accounts. 14:15:49 25 A. Robert Lesnak? 14:15:59 25 A. Robert Lesnak? 14:15:59 25 A. Robert Lesnak? 14:15:59 25 A. Robert Lesnak?	18	•		-
21				
22		-		
23 A. Yes, it is. 14:13:54 24 Q where she queried the 14:13:57 25 chargeback database? 14:13:57 26 page 207 27 A. Yes. 14:13:58 28 Q. Okay. She says, "It appears 14:13:59 39 that Harvard and Sunrise were the dominant 14:14:04 4 players in this market, with over 50 percent 14:14:08 5 of their total sales coming from this market. 14:14:08 6 HD Smith, KeySource and McKesson Onestop are 14:14:17 7 next, with only 3 percent to their total 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:27 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:32 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:44 16 happenings, period." 14:14:41 17 You then - you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:49 20 too." 14:14:48 21 Correct? 14:14:49 22 A. Yes, 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 A. Yes, for hospital accounts. 14:15:39 25 Q. And Rich McKendrick? 14:15:40 A. Yes, he was for government 14:15:45 4 A. National account manager for 14:15:45 4 A. National accounts manager for 14:15:45 5 hospital accounts. 14:15:45 6 Q. Okay. And on the cc line, who 14:15:50 7 was Robert Lesnak! ed the hospital 14:15:53 8 nistitutional sales team and addiction 14:15:53 10 treatment team. He's a sales leader. 14:15:59 11 treatment team. He's a sales leader. 14:15:59 12 Ms. Muhlenkamp discussed the results of her 14:16:19 13 work before she sent the e-mail out, did you 14:16:19 14:16:19 15 to? 14:16:19 16 A. Yes, I would have been 14:16:19 17 included in the conversation. I don't think 14:16:2 18 intertucted her, but I think I was included 14:16:2 19 included in the conversation to copy everyone. 14:16:2 20 Q. Okay. And what was the reason 14:16:2 21 for providing this information to the 14:16:33 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 A. Yes. 14:16:33 25 A. To apprise them that there				
24 Q where she queried the 14:13:54 24 A. Yes, for hospital accounts. 14:15:39 25 Chargeback database? 14:13:57 25 Q. And Rich McKendrick? 14:15:40 14:15:43 27 Q. Okay. She says, "It appears 14:13:58 14:15:45 28 Q. Okay. She says, "It appears 14:13:59 28 Q. Okay. She says, "It appears 14:14:06 49 Dayers in this market, with over 50 percent 14:14:06 49 Dayers in this market, with over 50 percent 14:14:06 40 Dayers in this market, with over 50 percent 14:14:06 41:15:47 40 Dayers in this market, with over 50 percent 14:14:06 41:15:47 40 Dayers in this market, with over 50 percent 14:14:06 41:15:47 41:15:47 41:15:47 41:15:47 41:15:47 41:15:47 41:15:47 41:15:47 41:15:49 41:15:49 41:15:49 41:15:49 41:15:49 41:15:49 41:15:49 41:15:49 41:15:49 41:15:49 41:15:59 41:15				
Page 207				-
Page 207 1 A. Yes. 14:13:58 2 Q. Okay. She says, "It appears 14:13:59 3 that Harvard and Sunrise were the dominant 14:14:04 4 players in this market, with over 50 percent 14:14:06 5 of their total sales coming from this market. 14:14:08 6 HD Smith, KeySource and McKesson Onestop are 14:14:11 7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:34 14 the distribution of oxycodone in Florida, and 14:14:34 15 twe will keep you apprised of further 14:14:37 16 happenings, period." 14:14:44 17 You may want to send this to Karen Harper, 14:14:44 18 that e-mail by saying, "It was excellent. 14:14:49 19 You may want to send this to Karen Harper, 14:14:49 20 Correct? 14:14:49 21 Correct? 14:14:49 22 A. Yes. 14:16:33 24 sent her e-mail, her June 18th e-mail, had 14:14:58 26 A. National accounts. 14:15:45 3 A. National account manager for 14:15:47 4 A. National accounts. 14:15:49 4 A. National account manager for 14:15:47 5 hospital accounts. 14:15:49 4 A. National account manager for 14:15:47 5 hospital accounts. 14:15:49 4 A. National account manager for 14:15:47 5 hospital accounts. 14:15:49 4 A. National account manager for 14:15:47 5 hospital accounts. 14:15:49 4 A. National account manager for 14:15:47 5 hospital accounts. 14:15:49 4 A. National account manager for 14:15:47 5 hospital accounts. 14:15:49 4 A. National account manager for 14:15:49 4 A. National accounts. 14:16:19 5 hospital accounts. 14:16:19 5 hospital accounts. 14:16:19 4 A. National account manager for 14:15:47 5 hospital accounts. 14:16:19 5 hospital accounts. 14:16:19 6 Q. Okay. And on the cc line, who 14:15:54 6 A. Robert Lesnak led the hospital treatment team. He's a sales leader. 14:16:15 7 was Robert Lesnak? 14:16:19 7 was Robert Lesnak? 14:16:19 8 A. Robert Lesnak?				_
1 A. Yes. 14:13:58 2 Q. Okay. She says, "It appears 14:13:59 3 that Harvard and Sunrise were the dominant 14:14:04 4 players in this market, with over 50 percent 14:14:06 5 of their total sales coming from this market. 14:14:15 7 next, with only 3 percent to their total 14:14:17 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:34 14 the distribution of oxycodone in Florida, and 14:14:37 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:44 17 You may want to send this to Karen Harper, 14:14:46 18 that e-mail by saying, "It was excellent. 14:14:49 20 too." 14:14:49 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:55 25 days And Alex McGregor? 14:15:45 4 A. National account manager for 14:15:47 5 of A. National accounts and idex moral accounts. 14:15:49 5 hospital accounts. 14:15:49 6 Q. Okay. And on the cc line, who 14:15:50 7 was Robert Lesnak led the hospital 14:15:53 8 ales coming from doctors' offices and pain 14:14:17 8 A. Robert Lesnak led the hospital 14:15:59 10 treatment team. He's a sales leader. 14:15:59 11 printing accounts. 14:16:15:47 12 mext, with only 3 percent to their total 14:14:17 13 with the DEA regarding their investigation of 14:14:22 14	25	chargeback database? 14:13:5/	25	Q. And Rich McKendrick? 14:13:40
2 Q. Okay. She says, "It appears 14:13:59 3 that Harvard and Sunrise were the dominant 14:14:04 4 players in this market, with over 50 percent 14:14:06 5 of their total sales coming from this market. 14:14:08 6 HD Smith, KeySource and McKesson Onestop are 14:14:11 7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:34 14 the distribution of oxycodone in Florida, and 14:14:34 15 twe will keep you apprised of further 14:14:34 16 happenings, period." 14:14:41 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:49 20 Q. Okay. And Alex McGregor? 14:15:45 4 A. National account manager for 14:15:47 5 hospital accounts. 14:16:15:47 5 hospital accounts. 14:16:15:47 6 Q. Okay. And on the cc line, who 14:15:59 7 was Robert Lesnak? 14:15:59 8 A. Robert Lesnak led the hospital 14:15:59 9 institutional sales team and addiction 14:15:59 10 treatment team. He's a sales leader. 14:15:59 11 Q. And so when you and 14:16:03 12 work before she sent the e-mail out, did you 14:16:19 15 to? 14:16:19 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:29 18 I instructed her, but I think I was included 14:16:29 19 in the conversation to copy everyone. 14:16:23 20 Q. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 22 A. To apprise them that there was 14:16:33 23 A. To apprise them that there was 14:16:33 24 a problem with accounts and to be aware of 14:16:		Page 207		Page 209
3 that Harvard and Sunrise were the dominant 14:14:04 4 players in this market, with over 50 percent 14:14:06 5 of their total sales coming from this market. 14:14:08 6 HD Smith, KeySource and McKesson Onestop are 14:14:11 7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:34 14 the distribution of oxycodone in Florida, and 14:14:34 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:43 17 You then you responded to 14:14:44 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 Correct? 14:14:49 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 ales coming from this market. 14:14:08 26 A. National account manager for 14:15:45 27 A. National account manager for 14:15:49 28 A. National account manager for 14:15:49 29 A. National account manager for 14:15:49 20 Cokay. And on the cc line, who 14:15:50 20 Was Robert Lesnak! Park 14:15:50 20 Was Robert Lesnak led the hospital 14:15:50 21 Was Robert Lesnak led the hospital 14:15:50 20 Okay. And so when you and 14:16:03 21 Ms. Muhlenkamp discussed the results of her 14:1 22 Ms. Muhlenkamp discussed the results of her 14:1 23 work before she sent the e-mail out, did you 14:16:01 24 instructed her, but I think I was included 14:16:19 25 included in the conversation to copy everyone. 14:16:19 26 A. Yes. 14:16:49 27 Okay. And what was the re	1	A. Yes. 14:13:58	1	A. Yes, he was for government 14:15:43
4 players in this market, with over 50 percent 14:14:06 5 of their total sales coming from this market. 14:14:08 6 HD Smith, KeySource and McKesson Onestop are 14:14:11 7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:32 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:44 17 You may want to send this to Karen Harper, 14:14:44 18 that e-mail by saying, "It was excellent. 14:14:48 19 You may want to send this to Karen Harper, 14:14:49 20 Q. Okay. And on the cc line, who 14:15:50 21 was Robert Lesnak? 14:15:50 21 was Robert Lesnak? 14:15:50 22 M. Robert Lesnak led the hospital 14:15:53 23 Q. And so when you and 14:16:03 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 mexity to the introduction of 14:14:41 26 hospital accounts. 14:15:49 27 hospital accounts. 14:15:49 28 A. National account manager for 14:15:49 29 hospital accounts. 14:16:19 20 Q. Okay. And on the cc line, who 14:15:50 20 Q. Okay. And on the cc line, who 14:15:50 21 was Robert Lesnak? 14:16:19 20 Q. And so when you and 14:16:03 21 institutional sales team and addiction 14:15:50 21 Whith the DEA regarding their investigation of 14:14:22 22 A. Yes. 14:14:43 23 Q. And so before Ms. Muhlenkamp 14:14:40 24 A. National account manager for 14:15:49 25 A. Robert Lesnak? 14:15:49 26 Q. Okay. And on the cc line, who 14:15:50 27 was Robert Lesnak? 14:16:19 28 A. Robert Lesnak? 14:16:19 29 institutional sales team and addiction 14:15:50 29 institutional sales team and addiction 14:16:19 29 work before she sent the e-mail out, did you 14:16:19 20 Q. Okay. How the information 14:16:19 21 included in the conversation. I don't think 14:16:29 22 in the conversation to copy everyone. 14:16:	2	Q. Okay. She says, "It appears 14:13:59	2	accounts. 14:15:45
5 of their total sales coming from this market. 14:14:08 6 HD Smith, KeySource and McKesson Onestop are 14:14:11 7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:27 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:32 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:37 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 10 Correct? 14:14:49 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 hospital accounts. 14:15:49 26 Q. Okay. And on the cc line, who 14:15:50 27 was Robert Lesnak? 14:15:50 28 A. Robert Lesnak? 14:15:52 28 A. Robert Lesnak? 14:16:19 29 institutional sales team and addiction 14:15:53 29 institutional sales team and addiction 14:16:19 20 treatment team. He's a sales leader. 14:16:03 21 Q. And so when you and 14:16:03 22 Ms. Muhlenkamp discussed the results of her 14:16:19 23 To work before she sent the e-mail out, did you 14:16:19 24 instruct her who to forward the information 14:16:19 25 To? 14:16:19 26 A. Yes. I would have been 14:16:19 27 included in the conversation. I don't think 14:16:29 28 in the conversation to copy everyone. 14:16:29 29 in the conversation to the 14:16:29 20 Q. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 A. To apprise them that there was 14:16:33 26 A. To apprise them that there was 14:16:33	3	that Harvard and Sunrise were the dominant 14:14:04	3	Q. And Alex McGregor? 14:15:45
6 HD Smith, KeySource and McKesson Onestop are 14:14:11 7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:28 13 with the DEA regarding their investigation of 14:14:32 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:43 17 You then you responded to 14:14:44 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:49 20 Q. Okay. And on the cc line, who 14:15:50 21 was Robert Lesnak? 14:15:52 22 A. Yes. 14:14:49 23 Q. Okay. And on the cc line, who 14:15:50 24 A. Robert Lesnak? 14:15:52 25 was Robert Lesnak? 14:15:52 26 A. Robert Lesnak? 14:15:52 27 was Robert Lesnak? 14:15:52 28 A. Robert Lesnak? 14:15:53 29 institutional sales team and addiction 14:15:55 20 was Robert Lesnak? 14:15:52 20 A. Robert Lesnak? 14:15:52 21 was Robert Lesnak? 14:15:52 28 A. Robert Lesnak? 14:15:53 29 institutional sales team and addiction 14:15:55 20 A. Robert Lesnak? 14:16:15:10 20 A. Robert Lesnak? 14:16:19 21 Correal Harper, 14:14:42 21 Ms. Muhlenkamp discussed the results of her 14:16:03 22 A. Yes. I would have been 14:16:19 23 A. Yes. 14:14:49 24 Inistructed her, but I think I was included 14:16:29 25 A. Yes. 14:14:49 26 Q. Okay. And what was the reason 14:16:29 27 Inistructed her, but I think I was included 14:16:29 28 A. Yes. 14:14:49 29 Q. Okay. And what was the reason 14:16:33 29 A. To apprise them that there was 14:16:33 20 A. To apprise them that there was 14:16:33 21 A. To apprise them that there was 14:16:33 21 A. To apprise them that there was 14:16:33 22 A. Bokay. And what was the reason 14:16:33 23 A. To apprise them that there was 14:16:33 24 a problem with accounts and to be aware of 14:16:16	4	players in this market, with over 50 percent 14:14:06	4	A. National account manager for 14:15:47
7 next, with only 3 percent to their total 14:14:15 8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:32 14 the distribution of oxycodone in Florida, and 14:14:34 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:44 17 You then you responded to 14:14:44 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 10 You may want to send this to Karen Harper, 14:14:49 11 To Correct? 14:14:49 12 A. Yes. 14:14:49 13 Was Robert Lesnak? 14:15:52 14 A. Robert Lesnak? 14:15:53 14:15:52 15 A. Robert Lesnak? 14:15:53 14:15:53 15 Was Robert Lesnak? 14:15:53 14:15:53 15 Was Robert Lesnak? 14:15:53 14:15:53 15 Was Robert Lesnak? 14:15:53 16 A. Robert Lesnak? 14:15:53 16 Teatment team. He's a sales leader. 14:15:54 17 Was Muhlenkamp discussed the results of her 14:16:13 18 Mishnehamp discussed the results of her 14:16:19 19 A. Yes. I would have been 14:16:19 10 treatment team. He's a sales leader. 14:15:59 11 Q. And so when you and 14:16:03 12 Ms. Muhlenkamp discussed the results of her 14:16:03 13 work before she sent the e-mail out, did you 14:16:03 14:16:19 15 to? 14:16:19 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:29 18 I instructed her, but I think I was included 14:16:29 19 in the conversation to copy everyone. 14:16:29 20 O. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 22 A. Yes. 14:16:33 23 Q. And so before Ms. Muhlenkamp 14:14:58 24 a problem with accounts and to be aware of 14:16:	5	of their total sales coming from this market. 14:14:08	5	hospital accounts. 14:15:49
8 sales coming from doctors' offices and pain 14:14:17 9 clinics." 14:14:19 10 She goes on to say, "Karen 14:14:20 11 Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:28 14 the distribution of oxycodone in Florida, and 14:14:34 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:37 17 You then you responded to 14:14:44 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:49 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 A. Robert Lesnak led the hospital 14:15:53 26 institutional sales team and addiction 14:15:56 27 treatment team. He's a sales leader. 14:15:59 28 institutional sales team and addiction 14:16:03 29 institutional sales team and addiction 14:16:03 20 treatment team. He's a sales leader. 14:16:03 21 Ms. Muhlenkamp discussed the results of her 14:16 22 Ms. Muhlenkamp discussed the results of her 14:16 23 A. Yes. I would have been 14:16:19 24 instruct her who to forward the information 14:16:19 25 to? 14:16:19 26 A. Yes. I would have been 14:16:19 27 included in the conversation. I don't think 14:16:22 28 Q. Okay. And what was included 14:16:22 29 Q. Okay. And what was the reason 14:16:23 20 Q. Okay. And what was the reason 14:16:33 21 A. To apprise them that there was 14:16:33 22 A. To apprise them that there was 14:16:33	6	HD Smith, KeySource and McKesson Onestop are 14:14:11	6	Q. Okay. And on the cc line, who 14:15:50
9 clinics." 14:14:19 9 institutional sales team and addiction 14:15:56 10 She goes on to say, "Karen 14:14:20 10 treatment team. He's a sales leader. 14:15:59 11 Harper and team, parens, internal Covidien 14:14:27 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:28 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:37 16 happenings, period." 14:14:41 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 19 You may want to send this to Karen Harper, 14:14:48 10 Q. And so before Ms. Muhlenkamp 14:14:50 10 treatment team. He's a sales leader. 14:15:59 11 Q. And so when you and 14:16:03 1	7	next, with only 3 percent to their total 14:14:15	7	was Robert Lesnak? 14:15:52
10 She goes on to say, "Karen 14:14:20 10 treatment team. He's a sales leader. 14:15:59 11 Harper and team, parens, internal Covidien 14:14:22 11 Q. And so when you and 14:16:03 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:28 13 work before she sent the e-mail out, did you 14:16:19 14:16:19 15 to? 14:16:19 16 happenings, period." 14:14:37 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:22 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 19 in the conversation to copy everyone. 14:16:29 10 too." 14:14:49 10 for providing this information to the 14:16:23 14:16:33 14:16:29 15:16:17 16:17	8	-	8	A. Robert Lesnak led the hospital 14:15:53
Harper and team, parens, internal Covidien 14:14:22 12 investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:28 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:37 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:48 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 11 Q. And so when you and 14:16:03 12 Ms. Muhlenkamp discussed the results of her 14:16 13 work before she sent the e-mail out, did you 14:16:19 14 instruct her who to forward the information 14:16:19 15 to? 14:16:19 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:22 18 I instructed her, but I think I was included 14:16:22 20 Q. Okay. And what was the reason 14:16:23 21 for providing this information to the 14:16:33 22 national account managers? 14:16:33 23 A. To apprise them that there was 14:16:33 24 a problem with accounts and to be aware of 14:16:	9	clinics." 14:14:19	9	institutional sales team and addiction 14:15:56
investigators, paren, will be working closely 14:14:27 13 with the DEA regarding their investigation of 14:14:28 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:37 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:49 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 12 Ms. Muhlenkamp discussed the results of her 14:16 13 work before she sent the e-mail out, did you 14:16 14 instruct her who to forward the information 14:16:19 15 to? 14:16:19 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:22 18 I instructed her, but I think I was included 14:16:24 19 in the conversation to copy everyone. 14:16:27 20 Q. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 22 A. To apprise them that there was 14:16:33 23 A. To apprise them that there was 14:16:33	10	-	10	
with the DEA regarding their investigation of 14:14:28 14 the distribution of oxycodone in Florida, and 14:14:32 15 we will keep you apprised of further 14:14:34 16 happenings, period." 14:14:37 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:48 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 13 work before she sent the e-mail out, did you 14:16:19 14 instruct her who to forward the information 14:16:19 15 to? 14:16:19 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:22 18 I instructed her, but I think I was included 14:16:24 19 in the conversation to copy everyone. 14:16:25 20 Q. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 22 A. Yes. 14:14:49 23 A. To apprise them that there was 14:16:33 24 sent her e-mail, her June 18th e-mail, had 14:14:58 24 a problem with accounts and to be aware of 14:16:	11		11	•
the distribution of oxycodone in Florida, and 14:14:32 twe will keep you apprised of further 14:14:34 that e-mail by saying, "It was excellent. 14:14:44 You may want to send this to Karen Harper, 14:14:46 too." 14:14:48 Correct? 14:14:49 A. Yes. 1 would have been 14:16:29 A. Yes. 1 instructed her, but I think I was included 14:16:29 Q. Okay. And what was the reason 14:16:29 A. Yes. 14:14:49 A. Yes. 14:16:19 A. Yes. 14:16:29 A. Y	12		12	-
we will keep you apprised of further 14:14:34 happenings, period." 14:14:37 You then you responded to 14:14:41 that e-mail by saying, "It was excellent. 14:14:44 You may want to send this to Karen Harper, 14:14:46 to? 14:16:19 A. Yes. I would have been 14:16:19 included in the conversation. I don't think 14:16:22 in the conversation to copy everyone. 14:16:22 too." 14:14:48 Correct? 14:14:49 A. Yes. And what was the reason 14:16:29 A. Yes. 14:14:49 21 for providing this information to the 14:16:33 Q. And so before Ms. Muhlenkamp 14:14:50 A. Yes. I would have been 14:16:19 To provide in the conversation. I don't think 14:16:29 In the conversation to copy everyone. 14:16:29 A. Yes. 14:14:49 A. Yes. I would have been 14:16:29 In the conversation to copy everyone. 14:16:29 A. Yes. 14:14:49 A. Yes. And what was the reason 14:16:33 A. To apprise them that there was 14:16:33 A. To apprise them that there was 14:16:33	13		13	•
16 happenings, period." 14:14:37 16 A. Yes. I would have been 14:16:19 17 You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:48 20 Q. Okay. And what was the reason 14:16:29 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 16 A. Yes. I would have been 14:16:19 17 included in the conversation. I don't think 14:16:29 18 I instructed her, but I think I was included 14:16:29 19 in the conversation to copy everyone. 14:16:27 20 Q. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 22 national account managers? 14:16:33 23 A. To apprise them that there was 14:16:33	14	-		
You then you responded to 14:14:41 18 that e-mail by saying, "It was excellent. 14:14:44 19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:48 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 17 included in the conversation. I don't think 14:16:22 18 I instructed her, but I think I was included 14:16:22 20 Q. Okay. And what was the reason 14:16:22 21 for providing this information to the 14:16:33 23 A. To apprise them that there was 14:16:33 24 a problem with accounts and to be aware of 14:16:	15		15	
that e-mail by saying, "It was excellent. 14:14:44 You may want to send this to Karen Harper, 14:14:46 too." 14:14:48 Correct? 14:14:49 A. Yes. 14:14:49 Q. Okay. And what was the reason 14:16:29 A. Yes. 14:14:49 Q. Okay. And what was the reason 14:16:33 A. To apprise them that there was 14:16:33 A. To apprise them that there was 14:16:33 a problem with accounts and to be aware of 14:16:				
19 You may want to send this to Karen Harper, 14:14:46 20 too." 14:14:48 21 Correct? 14:14:49 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 19 in the conversation to copy everyone. 14:16:27 20 Q. Okay. And what was the reason 14:16:29 21 for providing this information to the 14:16:33 22 national account managers? 14:16:33 23 A. To apprise them that there was 14:16:33 24 a problem with accounts and to be aware of 14:16:				
20 too." 14:14:48 20 Q. Okay. And what was the reason 14:16:2 21 Correct? 14:14:49 21 for providing this information to the 14:16:29 22 A. Yes. 14:14:49 22 national account managers? 14:16:33 23 Q. And so before Ms. Muhlenkamp 14:14:50 23 A. To apprise them that there was 14:16:33 24 sent her e-mail, her June 18th e-mail, had 14:14:58 24 a problem with accounts and to be aware of 14:16	18		18	
Correct? 14:14:49 21 for providing this information to the 14:16:29 22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 for providing this information to the 14:16:29 26 national account managers? 14:16:33 27 A. To apprise them that there was 14:16:33 28 a problem with accounts and to be aware of 14:16:33				**
22 A. Yes. 14:14:49 23 Q. And so before Ms. Muhlenkamp 14:14:50 24 sent her e-mail, her June 18th e-mail, had 14:14:58 25 national account managers? 14:16:33 26 A. To apprise them that there was 14:16:33 27 a problem with accounts and to be aware of 14:16:33				
Q. And so before Ms. Muhlenkamp 14:14:50 23 A. To apprise them that there was 14:16:33 24 sent her e-mail, her June 18th e-mail, had 14:14:58 24 a problem with accounts and to be aware of 14:16:33				•
24 sent her e-mail, her June 18th e-mail, had 14:14:58 24 a problem with accounts and to be aware of 14:16				_
A A				**
25 she discussed with you the results of the 14:15:00 25 who might be targeted next and who they 14:16	25	she discussed with you the results of the 14:15:00	25	who might be targeted next and who they 14:16:38

1 should be watching: if there was any issue 14:16:44 2 going on with the account, that they should 14:16:46 2 a making those site visits? 14:18:35 3 be aware of it. 14:16:49 4 Q. Okay. And so the analysis that 14:16:49 5 Ms. Muhlenkamp did here regarding doctors' 14:16:56 7 analysis from the multi-distributor analysis 14:16:58 7 analysis from the multi-distributor analysis 14:16:58 7 analysis 7 the WITNESS Yes. 14:17:01 9 MR. O'CONNOR. Object to form. 14:17:02 10 QLESTIONS BY MR. GOTTO: 14:17:01 14:17:0		B 210		D 212
2 going on with the account, that they should 4:16:46 4:16:49 4 Q. Okay. And so the analysis that 4:16:49 5 Ms. Muhlenkamp did here regarding doctors' 14:16:59 5 doffices and pain clinics, that's a separate 14:16:55 7 analysis from the multi-distributor analysis 14:16:58 8 we looked at a few minutes ago, correct? 14:17:05 14:17:05 14:18:41 14:18:42 15 Ms. Muhlenkamp that she send her e-mail to 14:17:10		Page 210	,	Page 212
3				
4 Q. Okay. And so the analysis that 14:16:49 5 Ms. Muhlenkamp did here regarding doctors 14:16:52 5 familiar with them, so I was curious as to 14:18:48 7 7 7 7 7 7 7 7 7				-
5 Ms. Muhlenkamp did here regarding doctors 14:16-52 6 offices and pain clinics, that's a separate 14:16-58 7 analysis from the multi-distributor analysis 14:16-58 8 we looked at a few minutes ago, correct? 14:17-01 14:18-32 10 THE WITNESS; Yes. 14:17-03 11 QUESTIONS BY MR. GOTTO: 14:17-04 12 2 Q. And you then suggested to 14:17:11 13 Ms. Muhlenkamp that she send here-mail to 14:17:14 14 Karen Harper. 14:17-16 15 What was your reason for that? 14:17:16 16 A. I think Karen Harper, as the 14:17:18 16 MR. O'CONNOR: Object to form. 14:19-07 14:19-08 14:19-19 15 What was your reason for that? 14:17:16 16 A. I think Karen Harper, as the 14:17:18 16 What was your was of what we uncovered in ease she 14:17:25 17 18 the compliance team, that she needed to be 14:17:25 18 gets questions herself, that she could be 14:17:32 18 good. You're driving down the price 14:19:10 14:19:20 14:19:20 14:19:20 14:19:24 18 19:24 19:25				
6 offices and pain climics, that's a separate 14:16:58 7 analysis from the multi-distributor analysis 14:16:58 8 we looked at a few minutes ago, correct? 14:17:01 9 MR. O'CONNOR: Object to form. 14:17:02 10 QUESTIONS BY MR. GOTTO: 14:17:04 11 QUESTIONS BY MR. GOTTO: 14:17:04 12 Q. And you then suggested to 14:17:11 13 Ms. Mahlenkamp that she send here e-mail to 14:17:16 15 What was your reason for that? 14:17:16 16 A. I think Karen Harper, as the 14:17:16 17 lead of the suspicious order monitoring or 14:17:21 18 the compliance team, that she needed to be 14:17:22 19 fully aware of what we uncovered in case she 14:17:25 10 gets questions herself, that she could be 14:17:29 11 fully informed. 14:17:37 12 Q. So at this time you had been at 14:17:33 12 Mallinckrodt about mine or ten about 10 or 14:17:34 13 Ms. Harper at all? 14:17:37 14 A. Correct. 14:17:38 15 Q. In what context? 14:17:37 16 A. Correct 14:17:45 17 Q. In what context? 14:17:45 18 Ms. Mahlenkamp's e-mail, had you dealt with 14:17:45 19 A. Correct 14:18:10 10 A. Masters Pug and Masters 14:18:10 11 was doing site visits to a couple of 14:18:00 12 was doing site visits to a couple of 14:18:00 13 visits. 14:18:10 14 A. Masters Pug and Masters 14:18:17 15 Q. Okay. Where can you remember 14:18:10 14 was doing site visits to a couple of 14:18:06 15 Q. Okay. And about when did those 14:18:20 16 Q. Okay. And about when did those 14:18:20 17 lead of the suspicious order 14:18:10 18 what they were about and how they did 14:18:43 19 A. Masters Pug and Masters 14:18:18 19 A. Masters Yes. 14:18:18 10 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:30 22 Q. Okay. And about when did those 14:18:20 23 visits occur, if you can recall? 14:18:30 24 Q. Okay. And about when did those 14:18:20 25 view re about and driving sales to 14:20:18 26 doing calls out and driving sales to 14:20:18 27 and that is not how I normally saw it; that 14:19:51 28 doing calls out and driving sales to 14:20:18 29 Q. Okay. And shout when did those 1		· · · · · · · · · · · · · · · · · · ·		*
2				
8 we looked at a few minutes ago, correct?				· · · · · · · · · · · · · · · · · · ·
MR. O'C'ONNOR: Object to form. 14:17:02		· · · · · · · · · · · · · · · · · · ·		
10		S ·		
14:17:04 14:17:05 14:17:06 14:17:06 14:17:06 14:17:16 15 14:17:06 16:17:17 16:17		•		•
12				
13 Ms. Muhlenkamp that she send her e-mail to 14:17:14 14 Karen Harper. 14:17:16 14 Karen Harper. 14:17:16 15 Ms. twas your reason for that? 14:17:18 15 Ms. twas your reason for that? 14:17:18 16 Lead of the suspicious order monitoring or 14:17:21 17 Lead of the suspicious order monitoring or 14:17:25 18 the compliance team, that she needed to be 14:17:25 18 the compliance team, that she needed to be 14:17:25 19 fully warer of what we uncovered in case she 14:17:25 19 fully warer of what we uncovered in case she 14:17:25 19 sound business practice, that's not 14:19:18 14:19:18 14:19:19 14:19:19 14:19:19 14:19:19 14:19:19 14:19:20 14:19:22 15 milly aware of what we uncovered in case she 14:17:25 19 sound business practice, that's not 14:19:18 14:19:20 14:19:20 14:19:20 14:19:20 14:19:20 14:19:22 15 milly aware of what we uncovered in case she 14:17:33 14:19:23 14:19:23 14:19:24 14:19:25 14:19:18 14:19:25 14:19:25 14:19:25 14:19:26 14:19:26 14:19:26 14:19:26 14:19:26 14:19:26 14:19:26 14:19:26 14:19:26 14:19:26 14:19:28 14:19:28 14:19:28 14:19:29 14:1				_
14 Karen Harper. 14:17:16 15 What was your reason for that? 14:17:16 16 A. I think Karen Harper, as the 14:17:18 16 A. I think Karen Harper, as the 14:17:18 17 lead of the suspicious order monitoring or 14:17:21 18 the compliance team, that she needed to be 14:17:22 18 the compliance team, that she needed to be 14:17:22 18 the compliance team, that she needed to be 14:17:22 18 the compliance team, that she needed to be 14:17:29 18 the compliance team, that she needed to be 14:17:29 18 the compliance team, that she needed to be 14:17:29 18 the compliance team, that she needed to be 14:17:29 20 gets questions herself, that she could be 14:17:29 20 gets questions herself, that she could be 14:17:39 21 months, correct? 14:17:38 22 23 Mallinekrodt about nine or ten about 10 or 14:17:34 24 the wholesalers that actually provide 14:19:26 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:28 41:19:29 41:19:				• •
15	13	<u>*</u>		· ·
16	14	•		•
17 lead of the suspicious order monitoring or 14:17:21				•
18	16	•		·
19	17	•		
20 gets questions herself, that she could be 14:17:29 21 fully informed.	18	•		
21	19	•	19	-
22 Q. So at this time you had been at 14:17:33 22 3 Mallinckrodt about nine or ten about 10 or 14:17:34 23 24 the wholesalers that actually provide 14:19:26 25 A. Correct. 14:17:38 25 25 were undermining the marketplace, and so they 14:19:28 were undermining the marketplace, and so they 14:19:28 were undermining the marketplace. And 14:19:31	20		20	
23 Mallinckrodt about nine or ten about 10 or 14:17:34 23 the wholesalers that actually provide 14:19:26 24 11 months, correct? 14:17:37 24 25 a value in a marketplace, and so they 14:19:28 were undermining the marketplace. And 14:19:31	21	fully informed. 14:17:32	21	of your own business because you're 14:19:22
24 11 months, correct? 14:17:37 25 A. Correct. 14:17:38 Page 211 1 Q. Had you as of the time of 14:17:39 2 Ms. Muhlenkamp's e-mail, had you dealt with 14:17:42 3 Ms. Harper at all? 14:17:45 4 A. Yes, I had. 14:17:45 5 Q. In what context? 14:17:47 6 A. Conversations and some 14:17:48 7 educational materials around suspicious order 14:17:53 8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 Qo. Are those in Cincinnati? 14:18:18 16 A. Masters Drug and Masters 14:18:17 18 Q. Are those in Cincinnati? 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33 24 a value in a marketplace, and so they 14:19:28 were undermining the marketplace. And 14:19:31 Page 213 14:19:33 2 On my tour to Masters, I do 14:19:33 remember that was a little bit taken 14:19:38 aback about their sales practice. 14:19:41 That's not something I had normally 14:19:42 seen in the pharmaceutical industry. 14:19:42 seen in the pharmaceutical industry. 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:51 14 Q. Okay. Where can you remember 14:18:00 15 QUESTIONS BY MR. GOTTO: 14:19:55 16 A. Masters Drug and Masters 14:18:10 17 For two dollars a bottle from this company, 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10 ask them what they needed. 14:20:13 they typically would call the customer and 14:20:15 and shouting out deals, and Key Source. 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 Site visits coccur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33	22	Q. So at this time you had been at 14:17:33	22	selling to them, they're underselling 14:19:24
Page 211	23	Mallinckrodt about nine or ten about 10 or 14:17:34	23	the wholesalers that actually provide 14:19:26
Page 211 1 Q. Had you as of the time of 14:17:39 2 Ms. Muhlenkamp's e-mail, had you dealt with 14:17:42 3 Ms. Harper at all? 14:17:45 4 A. Yes, I had. 14:17:45 5 Q. In what context? 14:17:47 6 A. Conversations and some 14:17:48 7 educational materials around suspicious order 14:17:58 8 monitoring because I was not as familiar with 14:17:58 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:10 13 visits. 14:18:11 14 Q. Okay. Where can you remember 14:18:10 15 Q. Okay. Where can you remember 14:18:10 16 A. Masters Drug and Masters 14:18:17 17 Wholesale and KeySource. 14:18:18 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:19 20 Q. Okay. And about when did those 14:18:29 21 site visits occur, if you can recall? 14:18:30 22 Q. Okay. 14:18:33 24 Q. Okay. 14:18:33 25 On my tour to Masters, I do 14:19:33 26 On my tour to Masters, I do 14:19:36 27 That's not something I had normally 14:19:41 28 aback about their sales practice. 14:19:41 29 that not something I had normally 14:19:42 20 Seen in the pharmaceutical industry. 14:19:44 21 Facts not something I had normally 14:19:42 22 And that they were selling on price 14:19:45 23 and shouting out deals, and that was 14:19:49 24 Q. Okay. Where can you remember 14:18:06 25 A. They had someone at the front 14:19:58 26 would say, "Now we're selling acetaminophen 14:20:00 27 A. They had someone at the front 14:20:00 28 they typically would call the customer and 14:20:10 29 ask them what they needed. 14:20:13 20 ask them what they needed. 14:20:13 21 in my tenure 14:18:30 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:33 24 Q. Huh. 14:20:20	24	11 months, correct? 14:17:37	24	a value in a marketplace, and so they 14:19:28
1	25	A. Correct. 14:17:38	25	were undermining the marketplace. And 14:19:31
1		Page 211		Page 213
2 Ms. Muhlenkamp's e-mail, had you dealt with 14:17:42 3 Ms. Harper at all? 14:17:45 4 A. Yes, I had. 14:17:45 5 Q. In what context? 14:17:47 6 A. Conversations and some 14:17:48 7 educational materials around suspicious order 14:17:53 8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:10 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:12 17 Wholesale and KeySource. 14:18:17 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:30 22 A. I can't. It was fairly early 14:18:30 23 remember that was a little bit taken 14:19:38 24 A. On my tour to Masters, I do 14:19:36 25 remember that was a little bit taken 14:19:38 26 aback about their sales practice. 14:19:41 26 A. Ochay. Sabout their sales practice. 14:19:41 27 That's not something I had normally 14:19:42 28 aback about their sales practice. 14:19:41 29 Conversations and some 14:17:48 29 That's not something I had normally 14:19:42 20 And that they were selling on price and shouting out deals, and that was 14:19:47 29 Very shocking to me. 14:19:49 20 Okay. And when you say 14:19:51 21 west of Sabout when you say 14:19:51 22 A. They had someone at the front 14:19:58 23 and shouting out deals, and that is not how I normally sow it their sales practice. 14:19:44 29 A. Hat is 10 20 Okay. And about when did those 14:18:29 21 This one was that they were 14:20:14 22 A. I can't. It was fairly early 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Huh. 14:20:20	1	_	1	_
3 Ms. Harper at all? 14:17:45 3 remember that was a little bit taken 14:19:38 4 A. Yes, I had. 14:17:45 4 aback about their sales practice. 14:19:41 5 Q. In what context? 14:17:47 5 That's not something I had normally 14:19:42 6 A. Conversations and some 14:17:53 6 seen in the pharmaceutical industry. 14:19:44 7 educational materials around suspicious order 14:17:53 8 and that they were selling on price 14:19:45 8 monitoring because I was not as familiar with 14:17:56 8 and shouting out deals, and that was 14:19:47 9 it as I needed to be. 14:17:58 9 very shocking to me. 14:19:47 10 And I went with her to she 14:18:00 10 QUESTIONS BY MR. GOTTO: 14:19:51 11 was doing site visits to a couple of 14:18:06 11 Q. Okay. And when you say 14:19:55 12 facilities, and I went with her to site 14:18:08 12 "selling on price and shouting out deals," 14:19:55 12 going for site visits? 14:18:10 14 4 4 <t< td=""><td>2</td><td></td><td>2</td><td></td></t<>	2		2	
4 A. Yes, I had. 14:17:45 5 Q. In what context? 14:17:47 6 A. Conversations and some 14:17:48 7 educational materials around suspicious order 14:17:53 8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 A. Masters Drug and Masters 14:18:17 16 A. Masters Drug and Masters 14:18:18 17 Wholesale and KeySource. 14:18:18 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:30 24 Q. Okay. Huh. 14:20:20 4 aback about their sales practice. 14:19:41 5 That's not something I had normally 14:19:42 6 seen in the pharmaceutical industry. 14:19:44 7 That's not something I had normally 14:19:42 8 esen in the pharmaceutical industry. 14:19:44 7 And that they were selling on price 14:19:45 8 and shouting out deals, and that was 14:19:47 9 very shocking to me. 14:19:49 9 very shocking to me. 14:19:51 14:19:49 10 Q. Okay. And when you say 14:19:51 11 Q. Okay. And when you say 14:19:51 12 "selling on price and shouting out deals," 14:19:55 13 what in what sort of setting do you mean 14:19:55 14 that? 14:19:57 15 A. They had someone at the front 14:19:58 15 A. They had someone at the front 14:19:58 16 would say, "Now we're selling acetaminophen 14:20:00 17 Wholesale and KeySource. 14:18:18 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 24 Q. Huh. 14:20:20	3		3	•
5 Q. In what context? 14:17:47 6 A. Conversations and some 14:17:48 7 educational materials around suspicious order 14:17:53 8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:10 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 A. Masters Drug and Masters 14:18:14 16 A. Masters Drug and Masters 14:18:17 17 Wholesale and KeySource. 14:18:18 18 Q. Are those in Cincinnati? 14:18:20 19 Q. Okay. And about when did those 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:20 22 A. I can't. It was fairly early 14:18:30 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33 25 That's not something I had normally 14:19:42 26 seen in the pharmaceutical industry. 14:19:44 27 And that they were selling on price 14:19:49 28 and shouting out deals, and that was 14:19:47 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 21 and shouting out deals, and that was 14:19:47 21 very shocking to me. 14:19:49 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 20 Q. Okay. Where can you remember 14:18:10 21 and shouting out deals, and that was 14:19:47 21 very shocking to me. 14:19:49 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33 25 That's not something I had normally saw it; hat 14:19:42 26 doing calls out and driving sales to 14:20:18 27 and shouting out deals, and that was 14:19:47 28 and shouting out deals, and that was 14:19:42 29 doing calls out and driving sales to 14:20:18 20 Q. Okay. 14:18:30 21 This one was that they were 14:20:18 22 Q. Huh. 14:20:20	4	•	4	
6 A. Conversations and some 14:17:48 7 educational materials around suspicious order 14:17:53 8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 A. Masters Drug and Masters 14:18:11 16 A. Masters Drug and Masters 14:18:17 17 Wholesale and KeySource. 14:18:18 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:30 24 Q. Okay. Huh. 14:20:20 25 Seen in the pharmaceutical industry. 14:19:44 26 And that they were selling on price 14:19:49 27 And that they were selling on price 14:19:49 28 and shouting out deals, and that was 14:19:47 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 21 "selling on price and shouting out deals," 14:19:52 21 what in what sort of setting do you mean 14:19:55 23 what in what sort of setting do you mean 14:19:55 24 A. They had someone at the front 14:19:58 25 A. They had someone at the front 14:19:58 26 would say, "Now we're selling acetaminophen 14:20:00 27 for two dollars a bottle from this company," 14:20:05 28 and shouting out deals, and that it is not how I normally saw it; that 14:20:08 29 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:13 21 site visits occur, if you can recall? 14:18:29 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 24 Q. Huh. 14:20:20	5		5	•
7 educational materials around suspicious order 14:17:53 8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:14 17 Wholesale and KeySource. 14:18:17 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:26 22 A. I can't. It was fairly early 14:18:30 24 Q. Okay. Hah. 14:20:20 25 Particular products based on pricing. 14:20:18 26 Q. Okay. 14:18:33 27 And that they were selling on price 14:19:45 28 and shouting out deals, and that was 14:19:47 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 21 Q. Okay. And when you say 14:19:51 22 I and shouting out deals, and that was 14:19:49 23 very shocking to me. 14:19:49 24 Q. Okay. And that they were selling on price 14:19:45 25 and shouting out deals, and that was 14:19:49 26 Q. Okay. And when you say 14:19:51 27 And that they were selling on price 14:19:45 28 and shouting out deals, and that was 14:19:49 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 21 They had someone at the front 14:19:55 28 and shouting out deals, and that was 14:19:49 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 21 They had someone at the front 14:19:51 21 This one was that they were 14:20:14 22 A. I can't. It was fairly early 14:18:29 23 particular products based on pricing. 14:20:18 24 Q. Huh. 14:20:20		`		
8 monitoring because I was not as familiar with 14:17:56 9 it as I needed to be. 14:17:58 10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:17 17 Wholesale and KeySource. 14:18:18 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:30 23 and shouting out deals, and that was 14:19:47 24 Q. Okay. and shouting out deals, and that was 14:19:49 25 very shocking to me. 14:19:49 26 Q. Okay. And when you say 14:19:51 27 Q. Okay. And when you say 14:19:51 28 and shouting out deals, and that was 14:19:49 29 very shocking to me. 14:19:49 20 Q. Okay. And when you say 14:19:51 21 deals in well shouting out deals, and that was 14:19:49 20 Q. Okay. And when you say 14:19:51 21 deals in what in what sort of setting do you mean 14:19:55 23 in my tenure 14:18:30 24 Q. Okay. And about deals, and that was 14:19:49 25 very shocking to me. 14:19:49 26 Q. Okay. And when you say 14:19:51 27 deals in well shouting out deals, and that was 14:19:49 28 and shouting out deals, and that was 14:19:49 29 very shocking to me. 14:19:51 20 Q. Okay. And when you say 14:19:51 21 deals in what in what sort of setting do you mean 14:19:55 28 and shouting out deals, and that was 14:19:49 29 very shocking to me. 14:19:54 20 Q. Okay. And when you say 14:19:51 21 deals in what in what sort of setting do you mean 14:19:55 21 deals in what in what sort of setting do you mean 14:19:55 22 deals in what in what sort of setting do you mean 14:19:55 23 and shouting out deals, and that was 14:19:51 24 Q. Okay. And when you say 14:19:51 25 Q. Okay. And when you say 14:19:52 26 This one was that they were 14:20:18 27 This one was that they were 14:20:19 28 Q. Okay. All	6	A. Conversations and some 14:17:48	6	-
9 it as I needed to be. 14:17:58 9 very shocking to me. 14:19:49 10 And I went with her to she 14:18:00 10 QUESTIONS BY MR. GOTTO: 14:19:51 11 was doing site visits to a couple of 14:18:06 11 Q. Okay. And when you say 14:19:51 12 facilities, and I went with her to site 14:18:08 12 "selling on price and shouting out deals," 14:19:52 13 visits. 14:18:10 13 what in what sort of setting do you mean 14:19:55 14 Q. Okay. Where can you remember 14:18:10 14 that? 14:19:57 15 going for site visits? 14:18:11 15 A. They had someone at the front 14:19:58 16 A. Masters Drug and Masters 14:18:14 16 would say, "Now we're selling acetaminophen 14:20:00 17 Wholesale and KeySource. 14:18:17 17 for two dollars a bottle from this company," 14:20:05 18 Q. Are those in Cincinnati? 14:18:18 18 and that is not how I normally saw it; that 14:20:08 19 A. Masters? Yes. 14:18:20 19 they typically would call the customer and 14:20:10 20 Q. Okay. And about when did those 14:18:22 20 ask them what they needed. 14:20:13 21 site visits occur, if you can recall? 14:18:29 22 doing calls out and driving sales to 14:20:15 22 A. I can't. It was fairly early 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20				seen in the pharmaceutical industry. 14:19:44
10 And I went with her to she 14:18:00 11 was doing site visits to a couple of 14:18:06 12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:14 17 Wholesale and KeySource. 14:18:17 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:20 21 site visits occur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:30 24 Q. Okay. And when you say 14:19:51 11 Q. Okay. And when you say 14:19:51 12 "selling on price and shouting out deals," 14:19:52 13 what in what sort of setting do you mean 14:19:55 14 that? 14:19:57 15 A. They had someone at the front 14:19:58 16 would say, "Now we're selling acetaminophen 14:20:00 17 Wholesale and KeySource. 14:18:18 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 24 Q. Huh. 14:20:20	7	educational materials around suspicious order 14:17:53	7	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45
11 was doing site visits to a couple of 14:18:06 14:18:06 11 Q. Okay. And when you say 14:19:51 12 facilities, and I went with her to site 14:18:10 14:18:10 12 "selling on price and shouting out deals," 14:19:52 13 visits. 14:18:10 13 what in what sort of setting do you mean 14:19:55 14 Q. Okay. Where can you remember 14:18:10 14 that? 14:19:57 15 going for site visits? 14:18:11 15 A. They had someone at the front 14:19:58 16 A. Masters Drug and Masters 14:18:14 16 would say, "Now we're selling acetaminophen 14:20:00 17 Wholesale and KeySource. 14:18:18 18 and that is not how I normally saw it; that 14:20:08 19 A. Masters? Yes. 14:18:20 19 they typically would call the customer and 14:20:10 20 Q. Okay. And about when did those 14:18:22 20 ask them what they needed. 14:20:13 21 site visits occur, if you can recall? 14:18:29 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56	7 8	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47
12 facilities, and I went with her to site 14:18:08 13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:14 17 Wholesale and KeySource. 14:18:17 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:26 22 A. I can't. It was fairly early 14:18:30 24 Q. Okay. 14:18:33 21 site visits occur. 14:18:33 22 and I went with her to site 14:18:08 12 "selling on price and shouting out deals," 14:19:52 13 what in what sort of setting do you mean 14:19:55 14 that? 14:19:55 15 A. They had someone at the front 14:19:58 16 would say, "Now we're selling acetaminophen 14:20:00 17 for two dollars a bottle from this company," 14:20:05 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 24 Q. Huh. 14:20:20	7 8 9	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58	7 8 9	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49
13 visits. 14:18:10 14 Q. Okay. Where can you remember 14:18:10 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:14 17 Wholesale and KeySource. 14:18:17 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:26 22 A. I can't. It was fairly early 14:18:30 24 Q. Okay. 14:18:33 13 what in what sort of setting do you mean 14:19:55 14 that? 14:19:57 15 A. They had someone at the front 14:19:58 16 would say, "Now we're selling acetaminophen 14:20:00 17 thory would say, "Now we're selling acetaminophen 14:20:05 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:13 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 particular products based on pricing. 14:20:18 24 Q. Huh. 14:20:20	7 8 9	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00	7 8 9	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51
Q. Okay. Where can you remember 14:18:10 14 that? 14:19:57 15 going for site visits? 14:18:11 16 A. Masters Drug and Masters 14:18:14 17 Wholesale and KeySource. 14:18:17 18 Q. Are those in Cincinnati? 14:18:18 19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:29 22 A. I can't. It was fairly early 14:18:29 24 Q. Okay. 14:18:33 14 that? 14:19:57 15 A. They had someone at the front 14:19:58 4. Would say, "Now we're selling acetaminophen 14:20:00 17 thory had someone at the front 14:19:58 4. They had someone at the front 14:20:00 4. They had someone at the front 14:19:58 4. They had someone at the front 14:19:19:18 4. They had someone at the front 14:19:19 4. They had someone at the front 14:19:19 4. They had someone at the following selling acetaminophen 14:20:00 5 and that is not how I normally saw it; that 14:20:08 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:11 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 particular product	7 8 9 10 11	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06	7 8 9 10 11	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51
going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:20 Q. Okay. And about when did those 14:18:22 15 A. They had someone at the front 14:19:58 16 would say, "Now we're selling acetaminophen 14:20:00 17 for two dollars a bottle from this company," 14:20:05 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:10 20 ask them what they needed. 21 This one was that they were 14:20:14 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Huh. 14:20:20	7 8 9 10 11 12	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08	7 8 9 10 11	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52
A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 15 would say, "Now we're selling acetaminophen 14:20:05 18 and that is not how I normally saw it; that 14:20:08 19 A. Masters? Yes. 14:18:20 19 they typically would call the customer and 14:20:10 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33 16 would say, "Now we're selling acetaminophen 14:20:00 17 for two dollars a bottle from this company," 14:20:08 18 and that is not how I normally saw it; that 14:20:10 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 particular products based on pricing. 14:20:18 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10	7 8 9 10 11 12	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55
Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 15 for two dollars a bottle from this company," 14:20:05 18 and that is not how I normally saw it; that 14:20:08 19 A. Masters? Yes. 14:18:20 19 they typically would call the customer and 14:20:10 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:26 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33 17 for two dollars a bottle from this company," 14:20:05 18 and that is not how I normally saw it; that 14:20:08 19 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 particular products based on pricing. 14:20:18 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10	7 8 9 10 11 12 13	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57
18 Q. Are those in Cincinnati? 14:18:18 18 and that is not how I normally saw it; that 14:20:08 19 A. Masters? Yes. 14:18:20 19 they typically would call the customer and 14:20:10 20 Q. Okay. And about when did those 14:18:22 20 ask them what they needed. 14:20:13 21 site visits occur, if you can recall? 14:18:26 21 This one was that they were 14:20:14 22 A. I can't. It was fairly early 14:18:29 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11	7 8 9 10 11 12 13 14 15	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58
19 A. Masters? Yes. 14:18:20 20 Q. Okay. And about when did those 14:18:22 21 site visits occur, if you can recall? 14:18:26 22 A. I can't. It was fairly early 14:18:29 23 in my tenure 14:18:30 24 Q. Okay. 14:18:33 29 they typically would call the customer and 14:20:10 20 ask them what they needed. 14:20:13 21 This one was that they were 14:20:14 22 doing calls out and driving sales to 14:20:15 23 particular products based on pricing. 14:20:18 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14	7 8 9 10 11 12 13 14 15 16	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00
20 Q. Okay. And about when did those 14:18:22 20 ask them what they needed. 14:20:13 21 site visits occur, if you can recall? 14:18:26 21 This one was that they were 14:20:14 22 A. I can't. It was fairly early 14:18:29 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15 16	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17	7 8 9 10 11 12 13 14 15 16	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05
21 site visits occur, if you can recall? 14:18:26 21 This one was that they were 14:20:14 22 A. I can't. It was fairly early 14:18:29 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15 16 17	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18	7 8 9 10 11 12 13 14 15 16 17	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08
22 A. I can't. It was fairly early 14:18:29 22 doing calls out and driving sales to 14:20:15 23 in my tenure 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15 16 17 18	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 A. Masters? Yes. 14:18:20	7 8 9 10 11 12 13 14 15 16 17 18	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10
23 in my tenure 14:18:30 23 particular products based on pricing. 14:20:18 24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15 16 17 18 19	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 A. Masters? Yes. 14:18:20 Q. Okay. And about when did those 14:18:22	7 8 9 10 11 12 13 14 15 16 17 18 19	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10 ask them what they needed. 14:20:13
24 Q. Okay. 14:18:33 24 Q. Huh. 14:20:20	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 A. Masters? Yes. 14:18:20 Q. Okay. And about when did those 14:18:22 site visits occur, if you can recall? 14:18:26	7 8 9 10 11 12 13 14 15 16 17 18 19 20	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10 ask them what they needed. 14:20:13 This one was that they were 14:20:14
	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 A. Masters? Yes. 14:18:20 Q. Okay. And about when did those 14:18:22 site visits occur, if you can recall? 14:18:29	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	seen in the pharmaceutical industry. And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10 ask them what they needed. 14:20:13 This one was that they were 14:20:15
This in your experience, that I 1/20/21	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 A. Masters? Yes. 14:18:20 Q. Okay. And about when did those 14:18:22 site visits occur, if you can recall? 14:18:29 in my tenure 14:18:30	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10 ask them what they needed. 14:20:13 This one was that they were 14:20:14 doing calls out and driving sales to 14:20:15 particular products based on pricing. 14:20:18
	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	educational materials around suspicious order 14:17:53 monitoring because I was not as familiar with 14:17:56 it as I needed to be. 14:17:58 And I went with her to she 14:18:00 was doing site visits to a couple of 14:18:06 facilities, and I went with her to site 14:18:08 visits. 14:18:10 Q. Okay. Where can you remember 14:18:10 going for site visits? 14:18:11 A. Masters Drug and Masters 14:18:14 Wholesale and KeySource. 14:18:17 Q. Are those in Cincinnati? 14:18:18 A. Masters? Yes. 14:18:20 Q. Okay. And about when did those 14:18:22 site visits occur, if you can recall? 14:18:29 in my tenure 14:18:30 Q. Okay. 14:18:33	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	seen in the pharmaceutical industry. 14:19:44 And that they were selling on price 14:19:45 and shouting out deals, and that was 14:19:47 very shocking to me. 14:19:49 QUESTIONS BY MR. GOTTO: 14:19:51 Q. Okay. And when you say 14:19:51 "selling on price and shouting out deals," 14:19:52 what in what sort of setting do you mean 14:19:55 that? 14:19:57 A. They had someone at the front 14:19:58 would say, "Now we're selling acetaminophen 14:20:00 for two dollars a bottle from this company," 14:20:05 and that is not how I normally saw it; that 14:20:08 they typically would call the customer and 14:20:10 ask them what they needed. 14:20:13 This one was that they were 14:20:14 doing calls out and driving sales to 14:20:15 particular products based on pricing. 14:20:18 Q. Huh. 14:20:20

		_	B 446
	Page 214		Page 216
1	was not something you were familiar with in 14:20:24	1	A. Yes. 14:23:09
2	the industry? 14:20:27	2	Q. Okay. And this indicates that 14:23:11
3	A. I had not seen it done that 14:20:27	3	committee met once per quarter. Is that 14:23:13
4	way, no. 14:20:29	4	consistent with your recollection? 14:23:17
5	Q. On the second page of the 14:20:29	5	A. I don't remember the frequency 14:23:18
6	exhibit, there's an e-mail from 14:20:44	6	of the meetings. 14:23:19
7	Ms. Muhlenkamp to Karen Harper, copying you, 14:20:46	7	Q. Okay. Do you remember the 14:23:21
8	saying, "We communicated the bullet to our 14:20:50	8	topics that would be discussed at those 14:23:22
9	sales team. We tried to word it carefully as 14:20:54	9	meetings? 14:23:26
10	to not overstep any actions you are taking." 14:20:56	10	A. I do remember one meeting, a 14:23:27
11	Do you know what actions 14:20:58	11	meeting with the committee, in discussing 14:23:30
12	Ms. Harper may have been taking that 14:21:00	12	chargeback reports and what's contained in 14:23:34
13	Ms. Muhlenkamp was being careful not to 14:21:04	13	them and how they might possibly be used to 14:23:37
14	overstep? 14:21:07	14	monitor what we found. You know, you could 14:23:39
15	A. Right. Our role in marketing 14:21:08	15	find multiple distributors in the chargeback 14:23:41
16	was not to be a compliance team. That was 14:21:10	16	report, and if you know what you're looking 14:23:44
17	not what we did. So we were very sensitive 14:21:13	17	for, you can possibly do that. 14:23:47
18	to that Karen had her job, she dealt with the 14:21:17	18	Q. Okay. Do you recall 14:23:49
19	DEA, she had to deal with the customers on 14:21:21	19	approximately when that meeting occurred? 14:23:50
20	these issues. So that's why I was a little 14:21:23 uncomfortable about us sending out 14:21:25	20	A. No, I don't. It would be after 14:23:52 we ran the report, obviously. 14:23:54
21	uncomfortable about us sending out 14:21:25 communication that Karen was not aware of, 14:21:26	21	1
22		22	Q. Okay. Do you recall 14:23:56
23	because she needed to be aware of everything 14:21:28 that was being said. 14:21:29	23	approximately how long a steering committee 14:24:01 meeting would typically last? 14:24:03
24	So that's that's where it 14:21:30	24	meeting would typically last? 14:24:03 A. No. 14:24:04
23	30 that's that's where it 14.21.30	23	A. INO. 14.24.04
	D 015		F 41
	Page 215		Page 217
1	is. We don't want we want to be careful 14:21:32	1	Page 217 Q. Were there materials provided 14:24:05
1 2	_	1 2	_
	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37		Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10
2	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39	2	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12
2 3	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40	2	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16
2 3 4	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44	2 3 4	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17
2 3 4 5	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46	2 3 4 5	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19
2 3 4 5 6 7 8	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12	2 3 4 5 6 7 8	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25
2 3 4 5 6 7 8	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12	2 3 4 5 6 7 8	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27
2 3 4 5 6 7 8 9	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12	2 3 4 5 6 7 8 9	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31
2 3 4 5 6 7 8 9 10	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19	2 3 4 5 6 7 8 9 10	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32
2 3 4 5 6 7 8 9 10 11	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21	2 3 4 5 6 7 8 9 10 11	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37
2 3 4 5 6 7 8 9 10 11 12 13	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28	2 3 4 5 6 7 8 9 10 11 12 13	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40
2 3 4 5 6 7 8 9 10 11 12 13	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33	2 3 4 5 6 7 8 9 10 11 12 13	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45
2 3 4 5 6 7 8 9 10 11 12 13 14 15	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47
2 3 4 5 6 7 8 9 10 11 12 13 14 15	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:35 document. 14:22:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:53
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 A. I'm not familiar with it, but I 14:22:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 A. I'm not familiar with it, but I 14:22:36 recognize it. 14:22:56	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55 just remember that. 14:24:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 A. I'm not familiar with it, but I 14:22:36 recognize it. 14:22:56 Q. Okay. You're shown as a member 14:22:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55 just remember that. 14:24:57 Q. Okay. And do you recall 14:24:58
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 recognize it. 14:22:56 Q. Okay. You're shown as a member 14:22:57 of the SOM steering committee, correct? 14:23:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55 just remember that. 14:24:57 Q. Okay. And do you recall 14:24:58 approximately when that occurred? 14:24:59
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 A. I'm not familiar with it, but I 14:22:36 recognize it. 14:22:56 Q. Okay. You're shown as a member 14:22:57 of the SOM steering committee, correct? 14:23:03 A. Correct. 14:23:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55 just remember that. 14:24:57 Q. Okay. And do you recall 14:24:58 approximately when that occurred? 14:24:59 A. It was sometime in 2011, 2010, 14:25:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 A. I'm not familiar with it, but I 14:22:36 recognize it. 14:22:56 Q. Okay. You're shown as a member 14:22:57 of the SOM steering committee, correct? 14:23:03 A. Correct. 14:23:04 Q. And were you a member of that 14:23:05	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55 just remember that. 14:24:57 Q. Okay. And do you recall 14:24:58 approximately when that occurred? 14:24:59 A. It was sometime in 2011, 2010, 14:25:01 2011 time frame. 14:25:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	is. We don't want we want to be careful 14:21:32 not to overstep our boundary as marketing 14:21:34 people. That's not what we do. 14:21:37 She drives compliance and tells 14:21:39 us what we need to do, and we follow her 14:21:40 direction. We don't provide the direction. 14:21:44 Q. Okay. You can set that aside. 14:21:46 (Mallinckrodt-Collier Exhibit 14:22:12 18 marked for identification.) 14:22:12 QUESTIONS BY MR. GOTTO: 14:22:12 Q. Exhibit 18 is a single-page 14:22:19 document, MNK-T1_0000496062, suspicious order 14:22:21 monitoring team charter, updated April 7th of 14:22:28 2011. 14:22:33 Take a look at that, if you 14:22:33 would, and let me know if you recognize that 14:22:35 document. 14:22:36 A. I'm not familiar with it, but I 14:22:36 recognize it. 14:22:56 Q. Okay. You're shown as a member 14:22:57 of the SOM steering committee, correct? 14:23:03 A. Correct. 14:23:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Were there materials provided 14:24:05 before the meeting for use at the meeting? 14:24:07 A. Not that I can recall. 14:24:10 Q. Do you recall if minutes were 14:24:12 maintained of the meetings of the committee? 14:24:16 A. I don't remember. 14:24:17 Q. Apart from the discussion about 14:24:19 chargeback data, any other particular 14:24:25 recollection of anything discussed at any of 14:24:27 the steering committee meetings? 14:24:31 A. I remember one meeting that was 14:24:32 vivid to me is that Karen Harper showed a 14:24:37 video of what they called the OxyContin 14:24:40 Express, and it was about a bunch of patients 14:24:45 outside a pharmacy or pain clinic, I can't 14:24:47 remember which it was, in Florida just 14:24:52 waiting to get drugs. And they were showing 14:24:53 they were from all around the country. So I 14:24:55 just remember that. 14:24:57 Q. Okay. And do you recall 14:24:58 approximately when that occurred? 14:24:59 A. It was sometime in 2011, 2010, 14:25:01

	Page 218		Page 220
1	that presentation? 14:25:12	1	of this page there are some subcommittees 14:27:20
2	A. Yes, that there was a serious 14:25:14	2	listed. 14:27:23
3	problem in Florida around pain clinics and 14:25:19	3	Were you a member of the 14:27:24
4	the abuse, and that they were getting 14:25:22	4	director order monitoring subcommittee? 14:27:25
5	dispensed product and taking it up I-95 and 14:25:25	5	A. I have no idea, because I don't 14:27:29
6	reselling it. 14:25:30	6	even know what that is. 14:27:35
7	Q. Do you recall any subsequent 14:25:31	7	Q. Yeah. 14:27:36
8	meetings where there was any update or 14:25:40	8	How about the 14:27:37
9	follow-up on that presentation to monitor how 14:25:45	9	A. Oh, that's probably direct 14:27:37
10	the situation was developing over time? 14:25:47	10	order monitoring. 14:27:40
11	MR. O'CONNOR: Object to form. 14:25:51	11	Q. I suspect so. 14:27:41
12	THE WITNESS: I can't remember 14:25:52	12	A. Yeah. 14:27:42
13	specifically what was discussed in 14:25:55	13	And indirect customer review. 14:27:44
14	future in the future or at any of 14:25:57	14	They might have included me in discussions or 14:27:45
15	the meetings. To be honest, it's 14:26:00	15	might have included me to ask me for data out 14:27:48
16	like it would be just another 14:26:02	16	of my team 14:27:50
17	meeting to me to go to. 14:26:03	17	Q. Uh-huh. 14:27:50
18	QUESTIONS BY MR. GOTTO: 14:26:05	18	A but I wasn't directing any 14:27:51
19	Q. Okay. Do you recall any 14:26:07	19	meetings or anything like this. 14:27:52
20	discussions of any proposed enhancements to 14:26:16	20	Q. Do you recall participating in 14:27:54
21	the suspicious order monitoring program that 14:26:20	21	any meetings of any of these subcommittees? 14:27:56
22	Mallinckrodt had in place? 14:26:22	22	A. I'm sure I did, but I don't 14:28:00
23	A. The only thing I remember is 14:26:24	23	remember the content. 14:28:02
24	that they were going to use different 14:26:26	24	Q. Okay. And do you remember 14:28:02
25	algorithms than what had been used in the 14:26:29	25	which of the subcommittees it would have been 14:28:05
	Page 219		Page 221
1	past. 14:26:34	1	that you would have participated in? 14:28:07
2	Q. Okay. Do you remember anything 14:26:34	2	A. It would have been anything 14:28:08
3	about the algorithms that had been used 14:26:35	3	involving the customer, like direct or the 14:28:12
4		~	m. or mig the editioner, like direct of the 17.20.12
	previously? 14:26:36	4	monitoring, indirect customer review and the 14:28:14
5	previously? 14:26:36 A. No, I didn't have anything to 14:26:36		-
5	1	4	monitoring, indirect customer review and the 14:28:14
	A. No, I didn't have anything to 14:26:36	4 5	monitoring, indirect customer review and the 14:28:14 customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18
6	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38	4 5 6	monitoring, indirect customer review and the 14:28:14 customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17
6 7	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39	4 5 6 7	monitoring, indirect customer review and the 14:28:14 customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18
6 7 8	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40	4 5 6 7 8	monitoring, indirect customer review and the 14:28:14 customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20
6 7 8 9	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44	4 5 6 7 8	monitoring, indirect customer review and the 14:28:14 customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21
6 7 8 9	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47	4 5 6 7 8 9	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47
6 7 8 9 10 11	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46	4 5 6 7 8 9 10	monitoring, indirect customer review and the 14:28:14 customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51
6 7 8 9 10 11 12	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53	4 5 6 7 8 9 10 11	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58
6 7 8 9 10 11 12 13	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53	4 5 6 7 8 9 10 11 12 13	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01
6 7 8 9 10 11 12 13	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53 Q. And do you know who had 14:26:56	4 5 6 7 8 9 10 11 12 13 14	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58
6 7 8 9 10 11 12 13 14 15	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53 Q. And do you know who had 14:26:56 ultimate responsibility for implementing the 14:27:00	4 5 6 7 8 9 10 11 12 13 14 15	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01
6 7 8 9 10 11 12 13 14 15	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53 Q. And do you know who had 14:26:56	4 5 6 7 8 9 10 11 12 13 14 15 16	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02
6 7 8 9 10 11 12 13 14 15 16 17	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53 Q. And do you know who had 14:26:56 ultimate responsibility for implementing the 14:27:00	4 5 6 7 8 9 10 11 12 13 14 15 16	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04
6 7 8 9 10 11 12 13 14 15 16 17	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:56 ultimate responsibility for implementing the 14:27:00 suspicious order monitoring program? 14:27:05 MR. O'CONNOR: Object to form. 14:27:07 THE WITNESS: Karen Harper was 14:27:08	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04 A. Okay. 14:29:05 Q. Do you recognize these e-mails? 14:29:31 A. Yes. 14:29:32
6 7 8 9 10 11 12 13 14 15 16 17 18	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:56 ultimate responsibility for implementing the 14:27:00 suspicious order monitoring program? 14:27:05 MR. O'CONNOR: Object to form. 14:27:07 THE WITNESS: Karen Harper was 14:27:08 my contact in compliance, so she's the 14:27:12	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04 A. Okay. 14:29:05 Q. Do you recognize these e-mails? 14:29:31 A. Yes. 14:29:32 Q. Okay. So the initial e-mail 14:29:34
6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:56 ultimate responsibility for implementing the 14:27:00 suspicious order monitoring program? 14:27:05 MR. O'CONNOR: Object to form. 14:27:07 THE WITNESS: Karen Harper was 14:27:08	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04 A. Okay. 14:29:05 Q. Do you recognize these e-mails? 14:29:31 A. Yes. 14:29:32 Q. Okay. So the initial e-mail 14:29:34 from Ms. Harper on August 7th, subject, 14:29:38
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53 Q. And do you know who had 14:26:56 ultimate responsibility for implementing the 14:27:00 suspicious order monitoring program? 14:27:05 MR. O'CONNOR: Object to form. 14:27:07 THE WITNESS: Karen Harper was 14:27:08 my contact in compliance, so she's the 14:27:12 one that I knew, and I knew Don 14:27:14 Lohman. 14:27:17	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04 A. Okay. 14:29:05 Q. Do you recognize these e-mails? 14:29:31 A. Yes. 14:29:32 Q. Okay. So the initial e-mail 14:29:34 from Ms. Harper on August 7th, subject, 14:29:38 Friday suspicious order monitoring meeting, 14:29:42
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:46 THE WITNESS: I just know it 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:56 ultimate responsibility for implementing the 14:27:00 suspicious order monitoring program? 14:27:05 MR. O'CONNOR: Object to form. 14:27:07 THE WITNESS: Karen Harper was 14:27:08 my contact in compliance, so she's the 14:27:12 one that I knew, and I knew Don 14:27:14	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04 A. Okay. 14:29:05 Q. Do you recognize these e-mails? 14:29:31 A. Yes. 14:29:32 Q. Okay. So the initial e-mail 14:29:34 from Ms. Harper on August 7th, subject, 14:29:38 Friday suspicious order monitoring meeting, 14:29:42 says to you that she "shared your frustration 14:29:46
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. No, I didn't have anything to 14:26:36 do with developing that. 14:26:38 Q. Okay. Anything any 14:26:39 description of the reasons for changing from 14:26:40 the prior algorithms to the subsequent 14:26:44 algorithms? 14:26:46 MR. O'CONNOR: Object to form. 14:26:47 was to enhance the information they 14:26:49 were receiving. 14:26:53 QUESTIONS BY MR. GOTTO: 14:26:53 Q. And do you know who had 14:26:56 ultimate responsibility for implementing the 14:27:00 suspicious order monitoring program? 14:27:05 MR. O'CONNOR: Object to form. 14:27:07 THE WITNESS: Karen Harper was 14:27:08 my contact in compliance, so she's the 14:27:12 one that I knew, and I knew Don 14:27:14 Lohman. 14:27:17	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	monitoring, indirect customer review and the customer checklist. 14:28:16 Q. Okay. You can set that aside. 14:28:17 A. Okay. 14:28:18 (Mallinckrodt-Collier Exhibit 14:28:20 19 marked for identification.) 14:28:21 QUESTIONS BY MR. GOTTO: 14:28:21 Q. We've marked as Exhibit 19 a 14:28:45 single-page e-mail thread, Bates 14:28:47 MNK-T1_0000262709. It appears to be an 14:28:51 e-mail exchange between you and Karen Harper. 14:28:58 Take a look at it, if you 14:29:01 would, please, and let me know if you 14:29:02 recognize it. 14:29:04 A. Okay. 14:29:05 Q. Do you recognize these e-mails? 14:29:31 A. Yes. 14:29:32 Q. Okay. So the initial e-mail 14:29:34 from Ms. Harper on August 7th, subject, 14:29:38 Friday suspicious order monitoring meeting, 14:29:42

	Page 222		Page 224
1	group could have been much more focused by 14:29:52	1	,
2	making sure only the right people were 14:29:54	2	to me. 14:31:49
3	brought to the table and having a published 14:29:57	3	The CARES Alliance was an 14:31:49
4	agenda that we adhered to." 14:29:58	4	initiative to be a responsible opioid 14:31:53
5	Do you remember the meeting 14:29:59	5	supplier in a marketplace. So we would talk 14:31:56
6	that Ms. Harper is referring to here? 14:30:00	6	about things like proper disposal. We 14:31:58
7	A. I don't recall this specific 14:30:02	7	supported opioid groups, you know, that were 14:32:01
8	meeting. I recall the tenor of the issue 14:30:03	8	helping either with abuse deterrence or 14:32:07
9	here. 14:30:08	9	things likes that. So that's what the CARES 14:32:11
10	Q. Okay. What do you recall of 14:30:08	10	Alliance was. 14:32:15
11	the issue? 14:30:10	11	And that is not what we were 14:32:15
12	A. We had another group that was 14:30:11	12	trying to accomplish. We were trying to 14:32:16
13	involved that was developing a CARES 14:30:15	13	understand what the DEA suspicious order 14:32:17
14	Alliance, a Covidien acting responsibly or 14:30:18	14	monitoring requirements were and if there 14:32:19
15	something like that, along the lines of pain 14:30:21	15	were materials that some of the team members, 14:32:21
16	management enacting responsibility, and I 14:30:24	16	not only in my group, from other groups like 14:32:23
17	remember they kept jumping in with things 14:30:28	17	Jeremy's, that they could provide. 14:32:25
18	thinking it was about CARES Alliance. 14:30:32	18	Q. Okay. Do you recall in any of 14:32:28
19	What we wanted to do was 14:30:33	19	the suspicious order monitoring steering 14:32:37
20	evaluate what we were supposed to be doing to 14:30:35	20	committee meetings that you attended any 14:32:38
21	be in compliance with the DEA and what 14:30:37	21	discussion of the extent to which 14:32:44
22	reports could we bring to the table so that 14:30:38	22	Mallinckrodt should be monitoring or 14:32:48
23	they knew so that Karen Harper's team 14:30:41	23	should be familiar with not only its 14:32:55
24	could know what information we had access to. 14:30:43	24	customer, but it's customers' customers? 14:32:57
25	Q. Okay. So this is in August 14:30:47	25	MR. O'CONNOR: Object to form. 14:33:00
	D 222		
	Page 223	,	Page 225
1	of 2010, which I think the analysis of the 14:30:53	1	THE WITNESS: I've heard that 14:33:00
2	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58	2	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02
2	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01	2	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03
2 3 4	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02	2 3 4	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04
2 3 4 5	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02	2 3 4 5	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05
2 3 4 5 6	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03	2 3 4 5 6	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08
2 3 4 5 6 7	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03	2 3 4 5 6 7	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09
2 3 4 5 6 7 8	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04	2 3 4 5 6 7 8	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12
2 3 4 5 6 7 8	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05	2 3 4 5 6 7 8	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15
2 3 4 5 6 7 8 9	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10	2 3 4 5 6 7 8 9	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19
2 3 4 5 6 7 8 9 10	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12	2 3 4 5 6 7 8 9 10	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21
2 3 4 5 6 7 8 9 10 11	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was - 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15	2 3 4 5 6 7 8 9 10 11	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23
2 3 4 5 6 7 8 9 10 11 12 13	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18	2 3 4 5 6 7 8 9 10 11 12 13	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27
2 3 4 5 6 7 8 9 10 11 12 13	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21	2 3 4 5 6 7 8 9 10 11 12 13	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:31
2 3 4 5 6 7 8 9 10 11 12 13 14	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23	2 3 4 5 6 7 8 9 10 11 12 13 14	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:31 customers? 14:33:34
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:31 customers? 14:33:34 A. That was discussed, yes. 14:33:34
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:05 your general recollection that there was - 14:31:10 that it was from your standpoint, the 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:36 information was discussed? 14:33:36
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31 CARES initiative, correct? 14:31:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:03 Q. Did you hear it in the context 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:35 information was discussed? 14:33:36 A. Chargeback data. How could we 14:33:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:12 intention was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31 CARES initiative, correct? 14:31:35 A. Correct. 14:31:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 Of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:36 A. Chargeback data. How could we 14:33:37 get chargeback data and find out what 14:33:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Florida doctor and pain clinic orders was 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:15 information was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31 CARES initiative, correct? 14:31:35 A. Correct. 14:31:36 Q. And explain to me again what 14:31:37	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:35 information was discussed? 14:33:36 A. Chargeback data. How could we 14:33:37 get chargeback data and find out what 14:33:39 customers are purchasing downstream from 14:33:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of 2010, which I think the analysis of the 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:15 information was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:35 A. Correct. 14:31:36 Q. And explain to me again what 14:31:37 the CARES initiative was? 14:31:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:35 information was discussed? 14:33:36 A. Chargeback data. How could we 14:33:37 get chargeback data and find out what 14:33:41 different wholesalers and distributors. 14:33:44
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:15 information was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31 CARES initiative, correct? 14:31:35 A. Correct. 14:31:36 Q. And explain to me again what 14:31:37 the CARES initiative was? 14:31:38 A. It was they were trying to 14:31:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:35 information was discussed? 14:33:36 A. Chargeback data. How could we 14:33:37 get chargeback data and find out what 14:33:41 different wholesalers and distributors. 14:33:44 Q. Okay. Anything apart from the 14:33:46
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Florida doctor and pain clinic orders was 14:30:53 Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:15 information was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31 CARES initiative, correct? 14:31:36 Q. And explain to me again what 14:31:37 the CARES initiative was? 14:31:38 A. It was they were trying to 14:31:40 develop an initiative and this goes back 14:31:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:35 information was discussed? 14:33:36 A. Chargeback data. How could we 14:33:37 get chargeback data and find out what 14:33:41 different wholesalers and distributors. 14:33:44 Q. Okay. Anything apart from the 14:33:46 chargeback data? 14:33:48
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Florida doctor and pain clinic orders was 14:30:58 shortly before this, correct? 14:31:01 A. Uh-huh. 14:31:02 MR. O'CONNOR: Objection. 14:31:02 Form. 14:31:03 THE WITNESS: Yes. 14:31:03 QUESTIONS BY MR. GOTTO: 14:31:04 Q. And so at this meeting, is it 14:31:05 your general recollection that there was 14:31:10 that it was from your standpoint, the 14:31:15 information was to discuss potential 14:31:15 information that could be brought to bear on 14:31:18 the suspicious order monitoring process? 14:31:21 A. Yes. 14:31:23 Q. Okay. And sounds like the 14:31:25 discussion got somehow side-railed by folks 14:31:28 who were there wanting to talk about the 14:31:31 CARES initiative, correct? 14:31:35 A. Correct. 14:31:36 Q. And explain to me again what 14:31:37 the CARES initiative was? 14:31:38 A. It was they were trying to 14:31:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	THE WITNESS: I've heard that 14:33:00 phrase before. 14:33:02 QUESTIONS BY MR. GOTTO: 14:33:04 of any of the SOM steering committee 14:33:05 meetings? 14:33:08 A. I'm not sure what context I 14:33:09 heard it in. I just remember hearing that 14:33:12 the DEA had the belief or the thought process 14:33:15 that we should know our customer's customer. 14:33:19 Q. Okay. Do you recall in the, 14:33:21 again, the SOM steering committee context, 14:33:23 any discussion of ways to obtain information 14:33:27 regarding Mallinckrodt's customers' 14:33:34 A. That was discussed, yes. 14:33:34 Q. Okay. And what sort of 14:33:35 information was discussed? 14:33:36 A. Chargeback data. How could we 14:33:37 get chargeback data and find out what 14:33:41 different wholesalers and distributors. 14:33:44 Q. Okay. Anything apart from the 14:33:46

1	D 44/	_	
1	Page 226		Page 228
	THE WITNESS: Not that I 14:33:50	1	the data sets that we get, and so she was 14:35:50
2	recall. Not from my group. There 14:33:52	2	looking specifically for something. Jeremy 14:35:52
3	were other groups that possibly had 14:33:54	3	could do that much easier than our group. 14:35:54
4	information, but not from my group. 14:33:55	4	Q. Okay. Okay. You can set that 14:35:57
5	QUESTIONS BY MR. GOTTO: 14:33:57	5	aside. 14:36:01
6	Q. Okay. All right. Back on 14:33:57	6	(Mallinckrodt-Collier Exhibit 14:36:03
7	Exhibit 19, your response to Ms. Harper, in 14:34:00	7	20 marked for identification.) 14:36:03
8	your first paragraph you say, "I truly hoped 14:34:05	8	QUESTIONS BY MR. GOTTO: 14:36:03
9	Carol could have brought more positive 14:34:07	9	Q. We have marked as Exhibit 20 a 14:36:27
10	feedback and seen the big picture." 14:34:09	10	multipage document beginning at Bates 14:36:30
11	Do you know who Carol is that 14:34:12	11	MNK-T1_0000496098. It appears to be a 2011 14:36:32
12	you're referring to in that sentence? 14:34:13	12	presentation concerning the suspicious order 14:36:40
13	A. No, I don't. 14:34:14	13	monitoring program. 14:36:43
14	Q. Okay. The next sentence you 14:34:15	14	If you could take a look at 14:36:44
15	say, "I also think Sherice is making this too 14:34:17	15	that and tell me if you're familiar with that 14:36:45
16	encompassing." 14:34:21	16	document. 14:36:48
17	Do you know who Sherice is? 14:34:22	17	Do you recognize that document? 14:40:26
18	A. Sherice was someone in Art 14:34:23	18	A. Yes, I do. 14:40:27
19	Morelli's group that was part of the 14:34:26	19	Q. And is it a presentation that 14:40:28
20	initiative for the CARES Alliance. 14:34:27	20	was made to the marketing group in 2011? 14:40:30
21	Q. Okay. And you went on to say, 14:34:29	21	A. Yes. 14:40:32
22	"If we go with her scope, we will monitor 14:34:30	22	Q. Do you recall the presentation? 14:40:32
23	hundreds of thousands of transactions and get 14:34:33	23	A. This is the one where I 14:40:33
24	nowhere." 14:34:35	24	recalled having the OxyContin Express video. 14:40:37
25	Do you recall what her scope 14:34:36	25	Q. Okay. Great. 14:40:40
	Page 227		Page 229
1	was that you're referring to there? 14:34:39	1	So on the on slide 5, 14:40:41
2	A. I don't remember that, but she 14:34:40	2	there's a reference here to the suspicious 14:40:48
3	was thinking really high level, I think 14:34:43	3	order monitoring subcommittee I'm sorry, 14:40:53
4	across the entire industry, and she just was 14:34:46	4	suspicious order monitoring steering 14:40:55
5	not focused in the meeting on what we were 14:34:52	5	committee that convenes once per month. 14:40:56
6	trying to accomplish. 14:34:54	6	I think in the prior document 14:41:00
7	Q. She was thinking across the 14:34:54	7	we just looked at indicated it was a 14:41:01
	industry in terms of order monitoring? 14:35:00	8	
8	•	"	quarterly meeting. 14:41:03
8	A. Yes. 14:35:01	9	quarterly meeting. 14:41:03 Do you recall that committee 14:41:04
	•		
9	A. Yes. 14:35:01	9	Do you recall that committee 14:41:04
9	A. Yes. 14:35:01 Q. Okay. 14:35:01	9	Do you recall that committee 14:41:04 meeting monthly? 14:41:07
9 10 11	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05	9 10 11	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07
9 10 11 12	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08	9 10 11 12	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08
9 10 11 12 13	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11	9 10 11 12 13	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08
9 10 11 12 13 14	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14	9 10 11 12 13 14	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11
9 10 11 12 13 14	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16	9 10 11 12 13 14 15	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13
9 10 11 12 13 14 15	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16	9 10 11 12 13 14 15	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15
9 10 11 12 13 14 15 16	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22	9 10 11 12 13 14 15 16 17	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16
9 10 11 12 13 14 15 16 17	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22 but he was very good at getting huge sets of 14:35:25 data and distilling it down into very strong 14:35:28	9 10 11 12 13 14 15 16 17	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16 Q. I see. Okay. 14:41:18 You were not a member of the 14:41:18
9 10 11 12 13 14 15 16 17 18	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22 but he was very good at getting huge sets of 14:35:25 data and distilling it down into very strong 14:35:28 content and material. So just taking a bunch 14:35:35	9 10 11 12 13 14 15 16 17 18	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16 Q. I see. Okay. 14:41:18 You were not a member of the 14:41:18 steering committee; is that correct? 14:41:19
9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22 but he was very good at getting huge sets of 14:35:25 data and distilling it down into very strong 14:35:28 content and material. So just taking a bunch 14:35:35 of data, eliminating the noise and making it 14:35:37	9 10 11 12 13 14 15 16 17 18 19	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16 Q. I see. Okay. 14:41:18 You were not a member of the 14:41:18 steering committee; is that correct? 14:41:19 A. I was a peripheral member. 14:41:20
9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22 but he was very good at getting huge sets of 14:35:25 data and distilling it down into very strong 14:35:28 content and material. So just taking a bunch 14:35:35 of data, eliminating the noise and making it 14:35:37 see what we need to see to it. 14:35:41	9 10 11 12 13 14 15 16 17 18 19 20 21	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16 Q. I see. Okay. 14:41:18 You were not a member of the 14:41:18 steering committee; is that correct? 14:41:19 A. I was a peripheral member. 14:41:20 Q. Okay. And on page I'm 14:41:21
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22 but he was very good at getting huge sets of 14:35:25 data and distilling it down into very strong 14:35:28 content and material. So just taking a bunch 14:35:35 of data, eliminating the noise and making it 14:35:37 see what we need to see to it. 14:35:41 Because as I keep saying, it's 14:35:42	9 10 11 12 13 14 15 16 17 18 19 20 21 22	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16 Q. I see. Okay. 14:41:18 You were not a member of the 14:41:18 steering committee; is that correct? 14:41:19 A. I was a peripheral member. 14:41:20 Q. Okay. And on page I'm 14:41:21 sorry, slide number slide number 13, 14:41:29
9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. 14:35:01 Q. Okay. 14:35:01 A. And involving other suppliers. 14:35:05 Q. Okay. The next paragraph you 14:35:08 say, "Jeremy is your best bet." 14:35:11 Who is Jeremy that you're 14:35:14 referring to there? 14:35:16 A. Jeremy worked in an analytical 14:35:16 team that mostly focused on brand products, 14:35:22 but he was very good at getting huge sets of 14:35:25 data and distilling it down into very strong 14:35:28 content and material. So just taking a bunch 14:35:35 of data, eliminating the noise and making it 14:35:37 see what we need to see to it. 14:35:41	9 10 11 12 13 14 15 16 17 18 19 20 21	Do you recall that committee 14:41:04 meeting monthly? 14:41:07 MR. O'CONNOR: Object to form. 14:41:07 THE WITNESS: The steering 14:41:08 committee, it said it meets once a 14:41:08 month. Quarterly was the other 14:41:11 members. There was a core group and 14:41:13 then peripheral members. 14:41:15 QUESTIONS BY MR. GOTTO: 14:41:16 Q. I see. Okay. 14:41:18 You were not a member of the 14:41:18 steering committee; is that correct? 14:41:19 A. I was a peripheral member. 14:41:20 Q. Okay. And on page I'm 14:41:21

	<u> </u>		<u>*</u>
	Page 230		Page 232
1	Do you see that? 14:41:41	1	You testified a little earlier 14:43:59
2	A. Yes. 14:41:41	2	recalling a meeting where there was 14:44:00
3	Q. And do you recall becoming 14:41:42	3	discussion about use of chargeback data as 14:44:02
4	familiar at this time with what the SOM 14:41:44	4	part of the SOM program. 14:44:04
5	program consisted of prior to June of 2010? 14:41:48	5	Do you know if that was if 14:44:06
6	A. Yes. 14:41:51	6	that discussion was in the context of 14:44:09
7	Q. Okay. And you see in the one, 14:41:52	7	selection of distributors to be audited, or 14:44:13
8	two, three, four, five, sixth bullet 14:42:01	8	was it for some other part of the SOM 14:44:15
9	there's I'm sorry, the fifth bullet, 14:42:06	9	program? 14:44:19 MR. O'CONNOR: Object to form. 14:44:19
10	"Customer accounts or orders that appear, 14:42:08 quote, peculiar, close quote, based on 14:42:09	10	MR. O'CONNOR: Object to form. 14:44:19 THE WITNESS: I'm not clear on 14:44:20
11		12	when that was discussed. Obviously, 14:44:22
12	customer checklist results, credit check, CSR 14:42:13		•
13	interaction or order entry system flags are 14:42:15	13	it was used with the information we 14:44:24 had was used, but I don't remember 14:44:27
15	reviewed by customer service customer 14:42:18 service manager." 14:42:19	15	
16	2	16	exactly what if this was what they 14:44:29 were intending to use. 14:44:32
17	Do you see that? 14:42:20 A. Yes. 14:42:21	17	MR. GOTTO: Okay. Okay. You 14:44:33
18	Q. Okay. And do you recall 14:42:22	18	can set that aside. Why don't we take 14:44:40
19	learning at this time that that was part of 14:42:24	19	a short break. 14:44:43
20	the SOM program? 14:42:26	20	VIDEOGRAPHER: We were going 14:44:44
21	A. Yes. 14:42:27	21	off the record at 2:44 p m. 14:44:45
22	Q. Okay. Two pages after that, on 14:42:28	22	(Off the record at 2:44 p m.) 14:44:47
23	slide 15 there's a slide concerning the DEA 14:42:36	23	VIDEOGRAPHER: We were back on 14:57:20
24	St. Louis conversation, July 20th of 2010. 14:42:42	24	the record at 2:57 p m. 14:57:21
25	Do you recall learning of this 14:42:50	25	(Mallinckrodt-Collier Exhibit 14:57:27
	· · · · · · · · · · · · · · · · · · ·		·
	Page 231		Page 233
	St. Louis conversation at this presentation? 14:42:53	1	21 marked for identification.) 14:57:28
2	A. Yes. 14:42:54	2	QUESTIONS BY MR. GOTTO: 14:57:28
3	Q. And the third entry on that 14:42:55	3	Q. We've marked as Exhibit 21 a 14:57:52
4	slide, "Mallinckrodt is viewed as the kingpin 14:42:57	4	letter dated November 10, 2010, beginning at 14:57:56
5	within the drug cartel." 14:43:00	5	Bates MNK-T1_0000484110, and it appears to be 14:57:58
6	Do you recall hearing that at 14:43:02	6	a letter from Karen Harper to KeySource 14:58:07
7	the time of this presentation? 14:43:04	7	Medical on which you were bcc'ed. 14:58:12
8	MR. O'CONNOR: Object to form. 14:43:04	8	If you'd take a look at that 14:58:15
9	THE WITNESS: Yes. 14:43:05	9	and tell me if you recognize that document. 14:58:17
10	QUESTIONS BY MR. GOTTO: 14:43:05	10	A. Okay. 14:58:19
11	Q. Did that surprise you? 14:43:07	11	Q. Do you recall are you 14:59:37
12	A. Yes, it did. 14:43:08	12	familiar with this letter? 14:59:39
13	Q. If you look on slide 17, is 14:43:10	13	A. Yes, I am. 14:59:40 O. Okay. And do you recall 14:59:41
14	that a still from the video that you were 14:43:19	14	
15	recalling seeing, the one outside the pain 14:43:21 clinic? 14:43:25	15	receiving a copy of it back in November 14:59:42 of 2010? 14:59:45
16		16	
17	A. Yes. 14:43:25	17	A. Yes. 14:59:45 O. Now, in this letter, Ms. Harper 14:59:45
18	Q. Okay. And if you turn to 14:43:25		
19	slide 20, SOM distributor audit next steps, 14:43:35	19	transmits various information regarding 14:59:52 KeySource orders into the state of Florida. 14:59:56
20	the first entry is "ongoing review of 14:43:45	20	Was the source of the 15:00:01
21	chargeback data to select other distributors 14:43:48 to be audited." 14:43:50		
22		22	information for Ms. Harper's letter, at least 15:00:04 in part, the multi-distributor analysis we 15:00:06
23	Do you see that? 14:43:51 A. Yes. 14:43:51	23	looked at earlier today? 15:00:09
25	Q. So this is March of 2011. 14:43:52	25	MR. O'CONNOR: Object to form. 15:00:10
2.5	Q. 50 mm is march of 2011. 14.43.32	23	171K. 0 CONTOK. Object to 101111. 15.00.10
		1	

	5 1		
	Page 234		Page 236
1	THE WITNESS: Yes. Yes. 15:00:11	1	8
2	QUESTIONS BY MR. GOTTO: 15:00:14	2	repeat pharmacies in there, and so we said, 15:03:28
3	Q. And in this letter, Ms. Harper 15:00:14	3	well, wait a minute, there's repeat 15:03:31
4	requested various information from KeySource. 15:00:18	4	pharmacies from different distributors. 15:03:33
5	Do you have any knowledge as to 15:00:20	5	Let's pull and see if we can bring this into 15:03:35
6	what KeySource's response to this letter was? 15:00:23	6	a better picture 15:03:38
7	A. No, I do not. 15:00:26	7	Q. I see. 15:03:40
8	Q. Okay. Did you or anyone on 15:00:28	8	A of what's going on. 15:03:41
9	your team, to your knowledge, conduct any 15:00:30	9	Q. Okay. So it may have grown out 15:03:42
10	subsequent analysis or inquiry with respect 15:00:32	10	of the original inquiry in terms of MD and 15:03:43
11	to ongoing orders from KeySource? 15:00:36	11	pain clinic purchasers in Florida? 15:03:47
12	A. I don't recall. 15:00:38	12	A. Yes. 15:03:50
13	Q. Do you know if the information 15:00:40	13	Q. Okay. And do you know if the 15:03:50
14	contained in this letter was ever provided to 15:00:42	14	information contained in the letters included 15:03:52
15	the DEA? 15:00:45	15	in Exhibit 22 was ever provided to the DEA? 15:03:54
16	A. I don't know. That would be 15:00:47	16	A. I didn't report to the DEA. I 15:03:57
17	Karen Harper's responsibility. 15:00:49	17	have no idea. 15:03:59
18	Q. Okay. All right. You can set 15:00:50	18	Q. Okay. You can set that aside. 15:04:01
19	that aside. 15:00:51	19	A. Okay. 15:04:03
20	(Mallinckrodt-Collier Exhibit 15:00:53	20	(Mallinckrodt-Collier Exhibit 15:04:04
21	22 marked for identification.) 15:00:53	21	23 marked for identification.) 15:04:04
22	QUESTIONS BY MR. GOTTO: 15:00:53	22	QUESTIONS BY MR. GOTTO: 15:04:04
23	Q. We've marked as Exhibit 22 a 15:01:29	23	Q. We've marked as Exhibit 23 a 15:04:48
24	series of letters, Bates MNK-T1_0000484145 15:01:32	24	single-page e-mail thread, Bates 15:04:50
25	through 156, from November 12th of 2010. 15:01:43	25	MNK-T1_0000558202. Take a moment and look at 15:04:53
	D 225		D 227
,	Page 235	1	Page 237
1	You're indicated as a bcc on the first 15:01:49 letter, and I don't know if you were bcc'ed 15:01:51	1	those e-mails, if you would, and tell me if 15:04:59 you recognize them. 15:05:02
3	on the balance of the letters in that 15:01:56	3	A. Yes. 15:05:27
4	package. 15:01:59]	
4		1 1	
5	•	4	Q. And the earlier e-mail in the 15:05:28
5	But if you could take a look at 15:02:00	5	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31
6	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02	5	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34
6 7	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04	5 6 7	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35
6 7 8	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05	5 6 7 8	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38
6 7 8 9	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44	5 6 7 8 9	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40
6 7 8 9	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45	5 6 7 8 9	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43
6 7 8 9 10 11	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47	5 6 7 8 9 10	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43
6 7 8 9 10 11	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47	5 6 7 8 9 10 11	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45
6 7 8 9 10 11 12	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50	5 6 7 8 9 10 11 12 13	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47
6 7 8 9 10 11 12 13 14	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56	5 6 7 8 9 10 11 12 13	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49
6 7 8 9 10 11 12 13 14 15	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58	5 6 7 8 9 10 11 12 13 14 15	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53
6 7 8 9 10 11 12 13 14 15	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59	5 6 7 8 9 10 11 12 13 14 15	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56
6 7 8 9 10 11 12 13 14 15 16	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01	5 6 7 8 9 10 11 12 13 14 15 16	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57
6 7 8 9 10 11 12 13 14 15 16 17	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04	5 6 7 8 9 10 11 12 13 14 15 16 17	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00
6 7 8 9 10 11 12 13 14 15 16 17 18	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05	5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01
6 7 8 9 10 11 12 13 14 15 16 17 18	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05 A. Yes. 15:03:06	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. And the earlier e-mail in the thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01 Q. Okay. And Ms. Digby indicates, 15:06:03
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05 A. Yes. 15:03:06 Q. And that analysis of multiple 15:03:07	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And the earlier e-mail in the thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01 Q. Okay. And Ms. Digby indicates, 15:06:03 here are "attached are the March monthly 15:06:06
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05 A. Yes. 15:03:06 Q. And that analysis of multiple 15:03:07 distributors that you and Ms. Muhlenkamp did, 15:03:10	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And the earlier e-mail in the 15:05:28 thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01 Q. Okay. And Ms. Digby indicates, 15:06:03 here are "attached are the March monthly 15:06:06 SOM reports." And there are three reports: 15:06:09
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05 A. Yes. 15:03:06 Q. And that analysis of multiple 15:03:07 distributors that you and Ms. Muhlenkamp did, 15:03:10 what triggered performing that analysis? 15:03:12	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. And the earlier e-mail in the thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01 Q. Okay. And Ms. Digby indicates, 15:06:03 here are "attached are the March monthly 15:06:06 SOM reports." And there are three reports: 15:06:09 a customer sourcing greater than two 15:06:11
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05 A. Yes. 15:03:06 Q. And that analysis of multiple 15:03:07 distributors that you and Ms. Muhlenkamp did, 15:03:10 what triggered performing that analysis? 15:03:12 A. I'm not sure if in the pulling 15:03:15	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. And the earlier e-mail in the thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01 Q. Okay. And Ms. Digby indicates, 15:06:03 here are "attached are the March monthly 15:06:06 SOM reports." And there are three reports: 15:06:09 a customer sourcing greater than two 15:06:11 distributors, a state concentration report, 15:06:15
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	But if you could take a look at 15:02:00 those letters and tell me if you recognize 15:02:02 them. 15:02:04 A. Yes. 15:02:05 Q. Do you recall receiving copies 15:02:44 of these letters back in November of 2010? 15:02:45 A. Yes, I do. 15:02:47 Q. Okay. And again, each of these 15:02:47 letters contains information regarding 15:02:50 Florida purchasers who were purchasing from 15:02:56 multiple distributors. 15:02:58 Do you understand that 15:02:59 information to be based on the 15:03:01 multi-distributor information we looked at a 15:03:04 little earlier today? 15:03:05 A. Yes. 15:03:06 Q. And that analysis of multiple 15:03:07 distributors that you and Ms. Muhlenkamp did, 15:03:10 what triggered performing that analysis? 15:03:12	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. And the earlier e-mail in the thread is from a Debbie Digby. 15:05:31 Who is that? 15:05:34 A. She was a senior financial 15:05:35 analyst. I'm not sure who she reported to or 15:05:38 what her role was. I did not interact with 15:05:40 her very often. 15:05:43 Q. Okay. And her e-mail went to 15:05:43 Ms. Harper, to Susan Moore. 15:05:45 Who was Susan Moore? 15:05:47 A. I do not remember. 15:05:49 Q. How about Pat Duft? 15:05:53 A. Pat was in logistics. 15:05:56 Q. Okay. And how about Carol 15:05:57 Svejkosky? 15:06:00 A. She was in customer service. 15:06:01 Q. Okay. And Ms. Digby indicates, 15:06:03 here are "attached are the March monthly 15:06:06 SOM reports." And there are three reports: 15:06:09 a customer sourcing greater than two 15:06:11

1	Page 238 to all products distributing. 15:06:20	1	Page 240 me if you recall them. 15:08:55
2	Do you recall that you would 15:06:22	2	
	receive this package of reports monthly? 15:06:25	3	•
3			Q. Do you recall these e-mails 15:09:29 from 2013? 15:09:30
4	_	4	
5	monthly, but apparently it was. 15:06:32 Q. Okay. Do you know what the 15:06:34	5	A. I don't recall them, but I 15:09:31 recognize them. 15:09:33
6	Q. Okay. Do you know what the 15:06:34 state concentration report, what information 15:06:37	6	Q. Okay. On the bottom of the 15:09:34
8	was contained on that? 15:06:39	8	first page, Mr. Longenecker's e-mail says, "I 15:09:37
			just met with Karen and Jennifer. Prior to 15:09:42
9	A. I do remember that was a report 15:06:40 that showed sales by state. I can't recall 15:06:42	9	removing the current allocation model, 15:09:45
10	if there were two different reports, and I 15:06:47	10	they're going to take some time to review the 15:09:47
11	can't recall if this would have been 15:06:50		algorithms for the SOM." 15:09:49
12		12	0
13	Mallinckrodt sales by state. 15:06:51	13	Do you recall what the what 15:09:51
14	Q. Okay. And the report by 15:06:54 distributor compared to all products 15:06:57	14	the interplay was between the SOM algorithms 15:09:55 and the allocation model? 15:09:58
15		15	
16	distributed, do you recall what information 15:07:00 was contained in that report? 15:07:02	16 17	MR. O'CONNOR: Object to form. 15:10:00 THE WITNESS: In the allocation 15:10:01
17			model, we would look at who had 15:10:03
18	A. I remember specifically that we 15:07:04 were looking at seeing if they were only 15:07:08	18	failure to supply and how much 15:10:06
19	purchasing oxycodone or were they purchasing 15:07:10	20	inventory we had available and when 15:10:08
20	all products. And if they were purchasing 15:07:12	21	the next production schedule would 15:10:09
21	just oxycodone, that was something we 15:07:17		
22		22	^^
23	evaluated and sent on to suspicious order 15:07:20 monitoring. 15:07:24		1
24	5	24	The algorithms that they were 15:10:13 doing for SOM was entirely different, 15:10:16
25	Q. Okay. And so in terms of your 15:07:24	25	doing for SOM was entirely different, 15:10:10
	Page 239		Page 241
1	personal involvement with the SOM process, 15:07:27	1	and they would stop orders or release 15:10:18
2	did you review these reports when you 15:07:30	2	orders through that process. That was 15:10:21
3	received them? 15:07:33	3	separate from what we were doing. 15:10:25
4	A. I looked at them, but I didn't 15:07:34	4	QUESTIONS BY MR. GOTTO: 15:10:26
	1 1 1 1 1 100 1 1 1 1 1 1 1 1 1 1 1 1 1		
5	make any direction on the SOM, so I probably 15:07:36	5	Q. Okay. And so Mr. Longenecker 15:10:26
5	didn't really dig into them too much. 15:07:40	5	goes on to say, "This should take about two 15:10:27
	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43		goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29
6	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45	6	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32
6	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48	6	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34
6 7 8	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51	6 7 8	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37
6 7 8 9	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52	6 7 8 9	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40
6 7 8 9	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53	6 7 8 9	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42
6 7 8 9 10 11	didn't really dig into them too much. 15:07:40 Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56	6 7 8 9 10 11	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45
6 7 8 9 10 11 12	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59	6 7 8 9 10 11 12	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46
6 7 8 9 10 11 12	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00	6 7 8 9 10 11 12	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46
6 7 8 9 10 11 12 13 14 15 16	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02	6 7 8 9 10 11 12 13	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:48
6 7 8 9 10 11 12 13 14 15	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05	6 7 8 9 10 11 12 13 14	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:51
6 7 8 9 10 11 12 13 14 15 16	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05	6 7 8 9 10 11 12 13 14 15 16	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:48 said that we would have gotten 15:10:51 information from Karen or Jen Buist in 15:10:52
6 7 8 9 10 11 12 13 14 15 16	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07	6 7 8 9 10 11 12 13 14 15 16	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:48 said that we would have gotten 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56
6 7 8 9 10 11 12 13 14 15 16 17	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07 (Mallinckrodt-Collier Exhibit 15:08:08	6 7 8 9 10 11 12 13 14 15 16 17	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56 certain customers to get product at 15:10:57
6 7 8 9 10 11 12 13 14 15 16 17 18	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07 (Mallinckrodt-Collier Exhibit 15:08:08 24 marked for identification.) 15:08:09	6 7 8 9 10 11 12 13 14 15 16 17 18	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:48 said that we would have gotten 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56 certain customers to get product at 15:10:57 all. 15:10:59
6 7 8 9 10 11 12 13 14 15 16 17 18 19	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07 (Mallinckrodt-Collier Exhibit 15:08:08 24 marked for identification.) 15:08:09 QUESTIONS BY MR. GOTTO: 15:08:09	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:48 said that we would have gotten 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56 certain customers to get product at 15:10:57 all. 15:10:59 QUESTIONS BY MR. GOTTO: 15:10:59
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07 (Mallinckrodt-Collier Exhibit 15:08:08 24 marked for identification.) 15:08:09 QUESTIONS BY MR. GOTTO: 15:08:09 Q. Exhibit 24 is a two-page e-mail 15:08:41	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:48 said that we would have gotten 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56 certain customers to get product at 15:10:57 all. 15:10:59 QUESTIONS BY MR. GOTTO: 15:10:59
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07 (Mallinckrodt-Collier Exhibit 15:08:09 QUESTIONS BY MR. GOTTO: 15:08:09 Q. Exhibit 24 is a two-page e-mail 15:08:41 thread starting at MNK-T1_0005905204. Take a 15:08:44	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:29 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:40 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56 certain customers to get product at 15:10:57 all. 15:10:59 QUESTIONS BY MR. GOTTO: 15:10:59 aside. 15:11:06
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	didn't really dig into them too much. Q. Okay. Do you recall ever 15:07:43 taking any action based on any information 15:07:45 that was contained in any of those reports? 15:07:48 A. No, that was outside the scope 15:07:51 of my responsibility. 15:07:52 Q. Okay. Do you ever recall 15:07:53 calling to anyone else's attention at 15:07:56 Mallinckrodt any information that was 15:07:59 contained in any of those reports? 15:08:00 A. I may have, but I don't recall 15:08:02 it. 15:08:05 Q. Okay. Okay. You can set that 15:08:05 aside. 15:08:07 (Mallinckrodt-Collier Exhibit 15:08:08 24 marked for identification.) 15:08:09 QUESTIONS BY MR. GOTTO: 15:08:09 Q. Exhibit 24 is a two-page e-mail 15:08:41	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	goes on to say, "This should take about two 15:10:27 weeks. They would like us to delay sending a 15:10:22 letter until they have completed this." 15:10:32 Do you know why the letter on 15:10:34 the allocation model or the allocation 15:10:37 yeah, the allocation model would be delayed 15:10:42 waiting for the SOM algorithms? 15:10:42 MR. O'CONNOR: Objection to 15:10:45 form. 15:10:46 THE WITNESS: It's likely 15:10:46 it's likely that they would have 15:10:51 information from Karen or Jen Buist in 15:10:52 compliance that they didn't want 15:10:56 certain customers to get product at 15:10:57 all. 15:10:59 QUESTIONS BY MR. GOTTO: 15:10:59

		_	
	Page 242		Page 244
1	25 marked for identification.) 15:11:07	1	And my question for you is: 15:13:47
2	QUESTIONS BY MR. GOTTO: 15:11:07	2	What programs are you referring to, and what 15:13:50
3	Q. Exhibit 25 is a multipage 15:11:32	3	type of behavior did you understand the DEA 15:13:52
4	e-mail thread beginning at MNK-T1_0004951225. 15:11:34	4	viewing them as driving? 15:13:55
5	Take a look at those and tell me if you 15:11:43	5	MR. O'CONNOR: Okay. And you 15:13:57
6	recognize these e-mails. 15:11:48	6	can answer the question. Just do not 15:13:59
7	The only one I have a question 15:11:49	7	discuss anything you said to or from 15:14:01
8	for you on is the very last one, the e-mail 15:11:50	8	Don. 15:14:03
9	from you to Jane Williams on October 23rd. 15:11:53	9	THE WITNESS: Then I cannot 15:14:03
10	A. Okay. 15:11:57	10	discuss that. 15:14:07
11	MR. O'CONNOR: Counsel, while 15:12:40	11	QUESTIONS BY MR. GOTTO: 15:14:09
12	reading this document, it looks like 15:12:41	12	Q. Okay. All right. You can put 15:14:10
13	the top two e-mails might be subject 15:12:42	13	that aside. 15:14:12
14	to a clawback. 15:12:45	14	(Mallinckrodt-Collier Exhibit 15:14:14
15	Are you planning to ask about 15:12:46	15	26 marked for identification.) 15:14:42
16	either of those top two e-mails? 15:12:48	16	MR. O'CONNOR: Counsel, just 15:14:42
17	MR. GOTTO: Do you mean the 15:12:48	17	for the record, we'll be making a 15:14:43
18	October 23rd? 15:12:49	18	clawback request and objecting on the 15:14:45
19	MR. O'CONNOR: Yes. From 15:12:50	19	basis of attorney-client privilege on 15:14:47
20	Ginger to Jane at 1:50. 15:12:52	20	the document. 15:14:48
21	MR. GOTTO: I was going to ask 15:12:56	21	MR. GOTTO: Okay. Very good. 15:14:48
22	about that one. 15:12:57	22	QUESTIONS BY MR. GOTTO: 15:14:49
23	MR. O'CONNOR: Okay. Yeah, we 15:12:57	23	Q. Exhibit 26 is a multipage 15:14:52
24	would assert privilege over the 15:13:00	24	document beginning with MNK-T1_0000384634. 15:14:54
25	references to the discussion she had 15:13:03	25	It's a printout of a spreadsheet. 15:15:03
	D 040		D 045
	Page 243		Page 245
1	with Don, who I believe is Don Lohman, 15:13:05	1	If you can take a look at that 15:15:04
2	who is counsel at Mallinckrodt. It 15:13:09	2	document and tell me if you're familiar with 15:15:06
	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11		document and tell me if you're familiar with 15:15:06 it. 15:15:08
2 3 4	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13	2 3 4	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08
2 3 4 5	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14	2 3 4 5	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18
2 3 4 5 6	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15	2 3 4 5	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18
2 3 4 5	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17	2 3 4 5	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20
2 3 4 5 6	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21	2 3 4 5	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the generic team. 15:15:20
2 3 4 5 6 7	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24	2 3 4 5 6 7	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24
2 3 4 5 6 7 8	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24	2 3 4 5 6 7 8	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27
2 3 4 5 6 7 8 9 10	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26	2 3 4 5 6 7 8 9 10	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29
2 3 4 5 6 7 8 9	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26	2 3 4 5 6 7 8 9 10 11	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29
2 3 4 5 6 7 8 9 10	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26	2 3 4 5 6 7 8 9 10	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30
2 3 4 5 6 7 8 9 10 11	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27	2 3 4 5 6 7 8 9 10 11	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34
2 3 4 5 6 7 8 9 10 11 12 13	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28	2 3 4 5 6 7 8 9 10 11 12 13	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39
2 3 4 5 6 7 8 9 10 11 12 13	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30	2 3 4 5 6 7 8 9 10 11 12 13	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30	2 3 4 5 6 7 8 9 10 11 12 13 14	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:30 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32 MR. O'CONNOR: And be sure to 15:13:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48 Are those the types of 15:15:49
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32 MR. O'CONNOR: And be sure to 15:13:32 let me chime in before you answer. 15:13:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48 Are those the types of 15:15:49 conventions that are listed on this exhibit? 15:15:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32 MR. O'CONNOR: And be sure to 15:13:32 let me chime in before you answer. 15:13:33 QUESTIONS BY MR. GOTTO: 15:13:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48 Are those the types of 15:15:49 conventions that are listed on this exhibit? 15:15:51 MR. O'CONNOR: Object to form. 15:15:53
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 Q. Have you been through the 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32 let me chime in before you answer. 15:13:33 QUESTIONS BY MR. GOTTO: 15:13:33 QUESTIONS BY MR. GOTTO: 15:13:33 QUESTIONS BY MR. GOTTO: 15:13:35 Q. Yeah. Here's the one question 15:13:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48 Are those the types of 15:15:49 conventions that are listed on this exhibit? 15:15:51 MR. O'CONNOR: Object to form. 15:15:53 THE WITNESS: Yes. 15:15:53
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	who is counsel at Mallinckrodt. It 15:13:09 appears this was inadvertently 15:13:11 produced. 15:13:13 MR. GOTTO: Okay. Well, I'll 15:13:14 ask her one question and see if it 15:13:15 if it is okay with you or if you have 15:13:17 a problem with it. 15:13:21 MR. O'CONNOR: Okay. 15:13:24 MR. GOTTO: After she's 15:13:24 once 15:13:26 QUESTIONS BY MR. GOTTO: 15:13:26 document? 15:13:27 A. I focused more up here. 15:13:28 Q. Okay. 15:13:30 A. So I'm familiar with what's 15:13:30 Q. Here's the one question. 15:13:32 let me chime in before you answer. 15:13:33 QUESTIONS BY MR. GOTTO: 15:13:35 I had on that October 23 e-mail. You make 15:13:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	document and tell me if you're familiar with 15:15:06 it. 15:15:08 A. Yes, I am. 15:15:08 Q. What is it? 15:15:18 A. This is a list of various trade 15:15:18 shows, conventions and conferences for the 15:15:20 generic team. 15:15:23 Q. Okay. And is this a list the 15:15:24 marketing department maintained from time to 15:15:27 time? 15:15:29 A. Marketing and sales, yes. 15:15:29 Q. Okay. And we talked a little 15:15:30 earlier today about conventions, and you 15:15:34 indicated that I think many of the 15:15:39 conventions are sort of industry-wide that 15:15:41 Mallinckrodt would attend or participate in 15:15:45 regularly. 15:15:48 Are those the types of 15:15:49 conventions that are listed on this exhibit? 15:15:51 MR. O'CONNOR: Object to form. 15:15:53 THE WITNESS: Yes. 15:15:53

	D 246	_	
1	Page 246 lower right-hand corner. 15:16:23	1	Page 248 audience. 15:19:03
	In column F on that page, there 15:16:37		
2		2	Q. Okay. You can set that aside. 15:19:05
3	are references to things like briefcase, 10 15:16:40	3	(Mallinckrodt-Collier Exhibit 15:19:07
4	by 30, et cetera. 15:16:42	4	28 marked for identification.) 15:19:08
5	Can you tell me what that 15:16:44	5	QUESTIONS BY MR. GOTTO: 15:19:08
6	column is describing? 15:16:45	6	Q. Exhibit 28 is a multipage 15:19:51
7	A. Those are displays. 15:16:46	7	e-mail thread beginning with 15:19:54
8	Q. The displays that would be used 15:16:48	8	MNK-T1_0005964786. Take a look at those 15:19:56
9	at the convention? 15:16:51	9	e-mails, if you would, and tell me if you 15:20:03
10	A. Yes. 15:16:52	10	recognize them. 15:20:05
11	Q. Okay. You can set that aside. 15:16:52	11	A. Okay. 15:20:06
12	(Mallinckrodt-Collier Exhibit 15:16:58	12	Q. Do you recognize those e-mails? 15:22:29
13	27 marked for identification.) 15:16:58	13	A. Yes, I do. 15:22:31
14	QUESTIONS BY MR. GOTTO: 15:16:58	14	Q. And if you turn to the second 15:22:31
15	Q. Exhibit 27 is a one-page 15:17:26	15	page, your e-mail at the bottom of that page 15:22:36
16	document produced in native format, 15:17:35	16	dated September 29th, it appears that you 15:22:38
17	MNK-T1_00006714382, and appears to be certain 15:17:38	17	were making adjustments to VIP tiers to 15:22:47
18	advertising expenditures. 15:17:48	18	remove oxy 30 milligrams; is that correct? 15:22:50
19	Can you tell me what the 15:17:50	19	A. Yes. 15:22:53
20	information on this document is? 15:17:52	20	Q. And what was the reason for 15:22:53
21	MR. O'CONNOR: Object to form. 15:17:56	21	that? 15:22:54
22	THE WITNESS: It relates to 15:17:56	22	A. Because the oxy 30 milligram we 15:22:54
23	materials that we would programs or 15:17:59	23	didn't want to appear to be promoting 15:22:57
24	advertising that we spend on 15:18:02	24	increasing value of volume on products, so we 15:23:00
25	particular products, our programs that 15:18:04	25	didn't want to provide incentives for that. 15:23:04
			<u> </u>
	Page 247		Page 249
1	we had. 15:18:08	1	And most of them, obviously, 15:23:08
2	QUESTIONS BY MR. GOTTO: 15:18:08	2	came some of them fell off with the 15:23:10
3	Q. Okay. And this is for the 15:18:08	3	Florida issues that were going on at the 15:23:12
4	years 2011 through 2015? 15:18:09	4	time. 15:23:15
5	A. Yes. 15:18:10	5	Q. When you say "fell off," what 15:23:15
6	Q. Okay. In terms of budgeting 15:18:12	6	do you mean? 15:23:17
7	for advertising expenses of these types, was 15:18:18	7	A. Many of their sales of some of 15:23:17
8			71. Waity of their sales of some of 15.25.17
1	this something that fell within your 15:18:21	8	our customers fell off, so the customers 15:23:19
9		8	•
9	this something that fell within your 15:18:21		our customers fell off, so the customers 15:23:19
	this something that fell within your 15:18:21 responsibility? 15:18:24	9	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21
10	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25	9	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24
10 11	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26	9 10 11	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27
10 11 12	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28	9 10 11 12	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29
10 11 12 13	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33	9 10 11 12 13	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32
10 11 12 13 14	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35	9 10 11 12 13 14	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34
10 11 12 13 14 15	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38	9 10 11 12 13 14	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43
10 11 12 13 14 15	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41	9 10 11 12 13 14 15	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45
10 11 12 13 14 15 16 17	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45	9 10 11 12 13 14 15 16	our customers fell off, so the customers weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47
10 11 12 13 14 15 16 17 18	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47	9 10 11 12 13 14 15 16 17 18	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:49
10 11 12 13 14 15 16 17 18 19	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47 more hospitals or if it was used in retail 15:18:48	9 10 11 12 13 14 15 16 17 18 19	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47 A. Steve Becker was the sales 15:23:49 representative. 15:23:53
10 11 12 13 14 15 16 17 18 19 20 21	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47 more hospitals or if it was used in retail 15:18:48 pharmacies and what the messaging was trying 15:18:51	9 10 11 12 13 14 15 16 17 18 19 20 21	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47 A. Steve Becker was the sales 15:23:49 representative. 15:23:53 Q. Okay. On the first page 15:23:53
10 11 12 13 14 15 16 17 18 19 20 21	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47 more hospitals or if it was used in retail 15:18:48 pharmacies and what the messaging was trying 15:18:51 to be about. You know, if the fentanyl patch 15:18:54	9 10 11 12 13 14 15 16 17 18 19 20 21	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47 A. Steve Becker was the sales 15:23:49 representative. 15:23:53 Q. Okay. On the first page 15:23:53 there's an October 6th e-mail from Jane 15:24:05
10 11 12 13 14 15 16 17 18 19 20 21 22 23	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47 more hospitals or if it was used in retail 15:18:48 pharmacies and what the messaging was trying 15:18:51 to be about. You know, if the fentanyl patch 15:18:54 size was a good size, we would try and 15:18:57	9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47 A. Steve Becker was the sales 15:23:49 representative. 15:23:53 Q. Okay. On the first page 15:23:53 there's an October 6th e-mail from Jane 15:24:05 Williams to you talking about a January 15:24:08
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47 more hospitals or if it was used in retail 15:18:48 pharmacies and what the messaging was trying 15:18:51 to be about. You know, if the fentanyl patch 15:18:54 size was a good size, we would try and 15:18:57 demonstrate that, or if we were launching a 15:18:59	9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47 A. Steve Becker was the sales 15:23:49 representative. 15:23:53 Q. Okay. On the first page 15:23:53 there's an October 6th e-mail from Jane 15:24:05 Williams to you talking about a January 15:24:08 target date for removal of oxy 15 and 30 from 15:24:12
10 11 12 13 14 15 16 17 18 19 20 21 22 23	this something that fell within your 15:18:21 responsibility? 15:18:24 A. Yes. 15:18:25 Q. Okay. And how did you go about 15:18:26 making the determination of what sorts of 15:18:28 journals or other publications were 15:18:33 appropriate ones to be spending money on 15:18:35 advertising in? 15:18:38 A. It depended on which magazines 15:18:38 or trade they were all trade journals, so 15:18:41 they went to pharmacists. And it depended on 15:18:45 specific to the product, if it was used in 15:18:47 more hospitals or if it was used in retail 15:18:48 pharmacies and what the messaging was trying 15:18:51 to be about. You know, if the fentanyl patch 15:18:54 size was a good size, we would try and 15:18:57	9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	our customers fell off, so the customers 15:23:19 weren't selling into the state of Florida. 15:23:21 So it we just advised them that the best 15:23:24 thing to do was just remove it from their 15:23:27 agreement so that they wouldn't have volume 15:23:29 incentive program for it. 15:23:32 Q. Okay. In the second paragraph 15:23:34 of your e-mail you say, "Sounds as if we 15:23:43 didn't have pushback from Steve's 15:23:45 perspective." 15:23:47 Who is Steve in that sentence? 15:23:47 A. Steve Becker was the sales 15:23:49 representative. 15:23:53 Q. Okay. On the first page 15:23:53 there's an October 6th e-mail from Jane 15:24:05 Williams to you talking about a January 15:24:08

	Page 250		Page 252
1	And then in the second 15:24:18	1	A. Yes. 15:26:14
2	paragraph she says, "It's also my 15:24:23	2	Q. Okay. And which was it? Was 15:26:14
3	recommendation that we consider a change in 15:24:26	3	it excluding all oxycodone or just 15 and 30; 15:26:17
4	strategy for customers requesting trade show 15:24:29	4	do you know? 15:26:20
5	buys on our products by providing a trade 15:24:31	5	MR. O'CONNOR: Object to form. 15:26:20
6	show allowance equal to what we might 15:24:33	6	THE WITNESS: I believe it 15:26:21
7	normally offer in discounted product costs or 15:24:36	7	became only the 15 and 30. We 15:26:23
8	possibly an educational giveaway to be 15:24:38	8	remained with the 5 milligram. 15:26:25
9	determined in order to keep this consistently 15:24:40	9	QUESTIONS BY MR. GOTTO: 15:26:29
10	managed." 15:24:43	10	Q. Okay. You can set that aside. 15:26:29
11	And then you respond, "This is 15:24:44	11	(Mallinckrodt-Collier Exhibit 15:26:30
12	the direction we discussed. I would like to 15:24:46	12	29 for identification.) 15:26:59
13	stop paying the trade show rebates and fees 15:24:48	13	QUESTIONS BY MR. GOTTO: 15:26:59
14	for our products when the contracts come 15:24:50	14	Q. Exhibit 29 is a two-page 15:26:59
15	due." 15:24:52	15	document beginning at Bates 15:27:01
16	Are the trade show rebates 15:24:52	16	MNK-T1_0001553297. It appears to be a mailer 15:27:08
17	related to the to the oxy 15 and oxy 30 15:24:55	17	concerning a CME presentation. 15:27:14
18	sales, or is that a separate issue? 15:25:00	18	Do you recognize this document? 15:27:22
19	MR. O'CONNOR: Objection to 15:25:01	19	A. No, I do not. 15:27:24
20	form. 15:25:02	20	Q. Do you recall having any 15:27:25
21	THE WITNESS: Are the trade 15:25:02	21	familiarity with any CME presentations 15:27:37
22	show rebates related to the oxy no. 15:25:04	22	concerning opioid rotation? 15:27:42
23	The customers gets trade show rebates, 15:25:06	23	A. Not the specific CE. We did 15:27:45
24	just a standard percentage of all 15:25:11	24	discuss doing continuing education. 15:27:51
25	sales. 15:25:12	25	Q. On this topic? 15:27:52
	Page 251		Page 253
1	QUESTIONS BY MR. GOTTO: 15:25:13	1	MR. O'CONNOR: Object to form. 15:27:53
2	Q. Okay. And that would were 15:25:13	2	THE WITNESS: I don't remember. 15:27:54
3	those rebates being suspended with respect to 15:25:15	3	QUESTIONS BY MR. GOTTO: 15:27:55
4	oxy 15 and 30 sales? 15:25:22	4	Q. Okay. Do you know what opioid 15:27:55
5	A. I wanted them suspended for all 15:25:23	5	rotation means in the context of this mailer? 15:27:57
6	products. 15:25:25	6	A. No, I do not. 15:28:00
7	Q. Okay. Did that happen? 15:25:25	7	Q. Okay. And down toward the 15:28:02
8	A. I believe we did. 15:25:27	8	bottom of the mailer it says, "This activity 15:28:04
9	Q. Okay. And what was the reason 15:25:28	9	is funded through an educational grant from 15:28:06
10	for that? 15:25:32	10	Mallinckrodt/Covidien." 15:28:11
11	A. I just didn't think that 15:25:33	11	Do you see that? 15:28:12
12	Mallinckrodt had value in offering an 15:25:34	12	A. Yes. 15:28:13
13	additional discount to some of these 15:25:36	13	Q. And educational grants of that 15:28:13
14	customers. They would just get additional 15:25:39	14	type, is that something that was handled by 15:28:17
15	rebate for doing nothing, basically. So we 15:25:42	15	the marketing department? 15:28:20
16	just didn't see that there was value in doing 15:25:47	16	A. Not in my group, because this 15:28:21
17	that. 15:25:49	17	is targeting physicians. We don't target 15:28:25
110		18	physicians at all. We don't even talk to 15:28:27
18	Q. Okay. And then in the top 15:25:49	-	
19	e-mail on the first page from Lisa Cardetti, 15:25:56	19	them. 15:28:29
	e-mail on the first page from Lisa Cardetti, 15:25:56 she says, "Originally we were going to 15:25:56		Q. Okay. So whatever educational 15:28:29
19	e-mail on the first page from Lisa Cardetti, 15:25:56 she says, "Originally we were going to 15:25:56 exclude all oxycodone. Just wanted to verify 15:26:01	19	Q. Okay. So whatever educational 15:28:29 grant underlay this presentation would have 15:28:33
19 20	e-mail on the first page from Lisa Cardetti, 15:25:56 she says, "Originally we were going to 15:25:56 exclude all oxycodone. Just wanted to verify 15:26:01 that we will only be excluding 15 and 30." 15:26:02	19 20 21 22	Q. Okay. So whatever educational 15:28:29 grant underlay this presentation would have 15:28:33 been something that someone else handled? 15:28:35
19 20 21	e-mail on the first page from Lisa Cardetti, 15:25:56 she says, "Originally we were going to 15:25:56 exclude all oxycodone. Just wanted to verify 15:26:01 that we will only be excluding 15 and 30." 15:26:02 Now, do you understand her 15:26:05	19 20 21 22 23	Q. Okay. So whatever educational 15:28:29 grant underlay this presentation would have 15:28:33 been something that someone else handled? 15:28:35 A. Correct. 15:28:37
19 20 21 22	e-mail on the first page from Lisa Cardetti, 15:25:56 she says, "Originally we were going to 15:25:56 exclude all oxycodone. Just wanted to verify 15:26:01 that we will only be excluding 15 and 30." 15:26:02 Now, do you understand her 15:26:05 there to be talking about excluding from the 15:26:08	19 20 21 22	Q. Okay. So whatever educational 15:28:29 grant underlay this presentation would have 15:28:33 been something that someone else handled? 15:28:35 A. Correct. 15:28:37 Q. Okay. All right. You can set 15:28:37
19 20 21 22 23	e-mail on the first page from Lisa Cardetti, 15:25:56 she says, "Originally we were going to 15:25:56 exclude all oxycodone. Just wanted to verify 15:26:01 that we will only be excluding 15 and 30." 15:26:02 Now, do you understand her 15:26:05	19 20 21 22 23	Q. Okay. So whatever educational 15:28:29 grant underlay this presentation would have 15:28:33 been something that someone else handled? 15:28:35 A. Correct. 15:28:37

	Page 254		Page 256
1	(Mallinckrodt-Collier Exhibits 15:28:55	1	Q. Okay. Do you remember what 15:31:40
2	30 and 31 marked for identification.) 15:28:56	2	division in Mallinckrodt he worked in? 15:31:42
3	QUESTIONS BY MR. GOTTO: 15:28:56	3	A. He wasn't brand or generic. He 15:31:44
4	Q. We've marked as Exhibit 30 a 15:29:23	4	actually both of us had to report our 15:31:47
5	single-page document, MNK-T1_0004673096, and 15:29:54	5	materials through him. I remember his first 15:31:49
6	as Exhibit 31, a single-page document bearing 15:30:01	6	name is Dennis. That's all I can remember. 15:31:53
7	the next succeeding Bates number. 15:30:06	7	Q. Okay. So there are available 15:31:55
8	Could you take a look at those 15:30:08	8	sales material materials that are listed 15:31:57
9	materials and tell me if you recognize them? 15:30:09	9	on the attachment, a sell sheet and a 15:32:01
10	A. I recognize this. 15:30:11	10	tri-fold sell sheet with "think Mallinckrodt" 15:32:07
11	Q. The attachment? 15:30:20	11	focus. 15:32:10
12	A. I do. 15:30:21	12	Do you know what those 15:32:10
13	Q. Okay. So in Exhibit 30, 15:30:21	13	materials are? 15:32:11
14	Mr. Vorderstrasse sends you an e-mail saying 15:30:26	14	A. The tri-fold sell sheet was 15:32:12
15	that "working on ideas for McKesson, who was 15:30:28	15	something that we were thinking of doing. 15:32:15
16	looking for information to show that we were 15:30:33	16	It's a folder. So if you go into brochure, 15:32:17
17	accepted in the market and to give them ideas 15:30:37	17	it's folded three times, and it opens up and 15:32:21
18	of selling techniques that have proven 15:30:38	18	it gives you information. So it was 15:32:23
19	successful." 15:30:42	19	something we were thinking of doing, and the 15:32:24
20	And then Exhibit 31 appears to 15:30:42	20	pharmacy said they couldn't use it because 15:32:26
21	be the attachment to the e-mail; is that 15:30:44	21	they didn't put anything on their shelves 15:32:28
22	right? 15:30:49	22	anymore, on their counters for patients to 15:32:30
23	A. Uh-huh. 15:30:49	23	pick up. 15:32:32
24	Q. And so Exhibit 31 has some 15:30:50	24	The sell sheet would be just a 15:32:32
25	information about Mallinckrodt historical 15:30:53	25	sell sheet explaining with a copy of the 15:32:34
	D 055		D 055
	Page 255		Page 257
1	market share and then "available sales 15:30:55	1	ad, the package insert, and all the 15:32:37
	111111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
2	materials, parens, we will likely need PARC, 15:30:59	2	information about the risks of the product. 15:32:39
3	P-A-R-C, approval to send examples." 15:31:02	3	And then it just showed, like I said, the 15:32:46
3 4	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06	3 4	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48
3 4 5	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07	3 4 5	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49
3 4 5 6	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10	3 4 5 6	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51
3 4 5 6 7	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13	3 4 5 6 7	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55
3 4 5 6 7 8	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13	3 4 5 6 7 8	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56
3 4 5 6 7 8	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15	3 4 5 6 7 8	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58
3 4 5 6 7 8 9	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15	3 4 5 6 7 8 9	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01
3 4 5 6 7 8 9 10	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15	3 4 5 6 7 8 9 10	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33
3 4 5 6 7 8 9 10 11	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16	3 4 5 6 7 8 9 10 11	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33
3 4 5 6 7 8 9 10 11 12	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18	3 4 5 6 7 8 9 10 11 12 13	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33
3 4 5 6 7 8 9 10 11 12 13 14	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19	3 4 5 6 7 8 9 10 11 12 13	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41
3 4 5 6 7 8 9 10 11 12 13 14	P-A-R-C, approval to send examples." What is PARC in this setting? A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. 15:31:19	3 4 5 6 7 8 9 10 11 12 13 14	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43
3 4 5 6 7 8 9 10 11 12 13 14 15 16	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. 15:31:19 Q. Who was on the committee; do 15:31:19	3 4 5 6 7 8 9 10 11 12 13 14 15	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49
3 4 5 6 7 8 9 10 11 12 13 14 15 16	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. 15:31:19 Q. Who was on the committee; do 15:31:19 you know? 15:31:21	3 4 5 6 7 8 9 10 11 12 13 14 15 16	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:51
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 Q. Okay. 15:31:19 Q. Who was on the committee; do 15:31:19 you know? 15:31:21 A. I didn't think I'd ever forget 15:31:21	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:51 A. Okay. 15:34:48
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	P-A-R-C, approval to send examples." What is PARC in this setting? A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 Q. Okay. 15:31:19 A for approval. 15:31:19 you know? 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. 15:31:26	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:51 A. Okay. 15:34:48 Q. Do you recognize those e-mails? 15:34:48
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	P-A-R-C, approval to send examples." What is PARC in this setting? A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. Q. Who was on the committee; do 15:31:19 you know? 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. 15:31:29	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:48 Q. Do you recognize those e-mails? 15:34:48 A. Yes, I do. 15:34:49
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	P-A-R-C, approval to send examples." What is PARC in this setting? A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 Q. Okay. 15:31:19 A for approval. Q. Who was on the committee; do 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. 15:31:29 A. The key gentleman. 15:31:30	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:48 Q. Do you recognize those e-mails? 15:34:48 A. Yes, I do. 15:34:49 Q. Okay. On the first page, the 15:34:50
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	P-A-R-C, approval to send examples." What is PARC in this setting? A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. Q. Who was on the committee; do 15:31:19 you know? 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. Q. Do you remember what his A. The key gentleman. Q. Do you remember what 15:31:34	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:48 Q. Do you recognize those e-mails? 15:34:48 A. Yes, I do. 15:34:49 Q. Okay. On the first page, the 15:34:50 bottom half, e-mail from you to Leah LaRue 15:34:53
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. 15:31:19 Q. Who was on the committee; do 15:31:19 you know? 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. 15:31:26 Q. Do you remember what his 15:31:30 Q. Do you remember what 15:31:34 his position was? 15:31:35	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:49 M. Okay. 15:34:48 Q. Do you recognize those e-mails? 15:34:48 A. Yes, I do. 15:34:49 Q. Okay. On the first page, the 15:34:50 bottom half, e-mail from you to Leah LaRue 15:34:53 and others. 15:34:58
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	P-A-R-C, approval to send examples." What is PARC in this setting? A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. A for approval. Q. Who was on the committee; do 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. 15:31:29 A. The key gentleman. Q. Do you remember what his position was? 15:31:35 A. He was the lead at PARC, and so 15:31:35	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:48 Q. Do you recognize those e-mails? 15:34:48 A. Yes, I do. 15:34:49 Q. Okay. On the first page, the 15:34:50 bottom half, e-mail from you to Leah LaRue 15:34:53 and others. 15:34:58 First of all, who was Leah 15:34:58
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	P-A-R-C, approval to send examples." 15:31:02 What is PARC in this setting? 15:31:06 A. Promotional material review 15:31:07 meeting. Promotional advertising review 15:31:10 committee. 15:31:13 Q. Okay. And that was a 15:31:13 Mallinckrodt committee? 15:31:15 A. Yes. 15:31:15 Q. Were you on the committee? 15:31:15 A. No, I submitted materials to 15:31:16 them 15:31:18 Q. Okay. 15:31:19 A for approval. 15:31:19 Q. Who was on the committee; do 15:31:19 you know? 15:31:21 A. I didn't think I'd ever forget 15:31:21 his name, but, no, I don't remember the name. 15:31:26 Q. Do you remember what his 15:31:30 Q. Do you remember what 15:31:34 his position was? 15:31:35	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	And then it just showed, like I said, the 15:32:46 size of our patch. 15:32:48 And then we were going to 15:32:49 enclose a sample patch that was inactive so 15:32:51 they could see the size of the patch, because 15:32:55 we felt that was our biggest advantage. 15:32:56 Q. Okay. Okay. All right. You 15:32:58 can set that aside. 15:33:01 (Mallinckrodt-Collier Exhibit 15:33:33 32 marked for identification.) 15:33:33 QUESTIONS BY MR. GOTTO: 15:33:33 Q. Exhibit 32 is a two-page e-mail 15:33:41 thread beginning at Bates MNK-T1_0000925331. 15:33:43 Please take a look at those e-mails and tell 15:33:49 me if you recognize them. 15:33:49 M. Okay. 15:34:48 Q. Do you recognize those e-mails? 15:34:48 A. Yes, I do. 15:34:49 Q. Okay. On the first page, the 15:34:50 bottom half, e-mail from you to Leah LaRue 15:34:53 and others. 15:34:58

	Page 258		Page 260
1	A. She was part of the CARES 15:35:01	1	Q. Okay. And do you recall if you 15:37:16
2	Alliance team. 15:35:05	2	were ever able to locate that poster again? 15:37:22
3	Q. And how about Dan Brague? 15:35:05	3	A. They never developed it again. 15:37:25
4	A. He was in brands. I don't 15:35:07	4	Q. Okay. You can set that aside. 15:37:26
5	remember what his role was. 15:35:11	5	(Mallinckrodt-Collier Exhibit 15:37:27
6	Q. Okay. Chris Wagner? 15:35:12	6	33 marked for identification.) 15:38:01
7	A. Not familiar with him. 15:35:13	7	QUESTIONS BY MR. GOTTO: 15:38:01
8	Q. Okay. In your e-mail you say, 15:35:15	8	Q. Exhibit 33 is a multipage 15:38:01
9	"For generics we need more educational and 15:35:22	9	e-mail thread beginning MNK-T1_0000660532. 15:38:03
10	communication materials for pharmacies, 15:35:24	10	Take a look at those, and tell me if you 15:38:09
11	including how to identify a patient that may 15:35:25	11	recognize those e-mails. 15:38:11
12	be at risk, how to handle a patient that 15:35:27	12	Do you recognize those e-mails? 15:39:16
13	comes in too soon for a refill," and then you 15:35:31	13	A. Yes. 15:39:19
14	have several other bullet items under that. 15:35:34	14	Q. And your e-mail on the bottom 15:39:19
15	How did you develop that list 15:35:36	15	part of the first page lists a series of 15:39:21
16	of information that you felt needed more 15:35:37	16	grants that had been funded the prior year, 15:39:24
17	education and communication materials for? 15:35:40	17	correct? 15:39:27
18	A. At trade shows we had asked 15:35:42	18	A. Correct. 15:39:27
19	customers what they thought was lacking and 15:35:46	19	Q. And the funding of these 15:39:27
20	what kind of information would they need from 15:35:48	20	grants, is that who was responsible for 15:39:30
21	a company like Mallinckrodt. 15:35:50	21	making the decision to fund grants of this 15:39:32
22	Q. Okay. At the end of your 15:35:51	22	type? 15:39:35
23	e-mail you say, "I am sure I will think of 15:35:58	23	A. That actually would have been 15:39:35
24	more once I dig into the SOM program more." 15:36:00	24	the president of our team. 15:39:37
25	So this is in you send the 15:36:03	25	Q. And Mr. Gunning? 15:39:38
_	D 250		D 2/1
	Page 259		Page 261
1	e-mail in February 2013. 15:36:08 Do you recall what digging into 15:36:12	1	A. Yes. 15:39:40
2	Do you recall what digging into 15:36:17		
		2	Q. Okay. 15:39:41
3	the SOM program you were doing at this time? 15:36:15	3	A. At this time it might have been 15:39:43
3 4	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18	3 4	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45
3 4 5	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19	3 4 5	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47
3 4 5 6	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23	3 4 5 6	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47
3 4 5 6 7	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26	3 4 5 6 7	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49
3 4 5 6 7 8	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28	3 4 5 6 7 8	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52
3 4 5 6 7 8	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31	3 4 5 6 7 8	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55
3 4 5 6 7 8 9	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36	3 4 5 6 7 8 9	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57
3 4 5 6 7 8 9 10	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39	3 4 5 6 7 8 9 10	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00
3 4 5 6 7 8 9 10 11	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41	3 4 5 6 7 8 9 10 11	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00
3 4 5 6 7 8 9 10 11 12 13	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43	3 4 5 6 7 8 9 10 11 12 13	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01
3 4 5 6 7 8 9 10 11 12 13	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:44	3 4 5 6 7 8 9 10 11 12 13 14	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:49 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01
3 4 5 6 7 8 9 10 11 12 13 14	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:44 Q. Okay. The last bullet item in 15:36:47	3 4 5 6 7 8 9 10 11 12 13 14	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02
3 4 5 6 7 8 9 10 11 12 13 14 15 16	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55	3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:03
3 4 5 6 7 8 9 10 11 12 13 14 15 16	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58	3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:03 A. Relationship to Mallinckrodt. 15:40:05
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:05 Their relationship to Mallinckrodt. 15:40:09
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:05 Their relationship to Mallinckrodt. 15:40:09 Q. And what sorts of when you 15:40:11
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:44 Q. Okay. The last bullet item in 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04 A. I do recall seeing that poster. 15:37:05	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:05 Their relationship to Mallinckrodt. 15:40:09 Q. And what sorts of when you 15:40:11 say "relationship to Mallinckrodt," what do 15:40:16
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04 A. I do recall seeing that poster. 15:37:05 Q. And in what context do you 15:37:07	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:05 Their relationship to Mallinckrodt. 15:40:09 Q. And what sorts of when you 15:40:11 say "relationship to Mallinckrodt," what do 15:40:16 you mean by that? 15:40:17
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:44 Q. Okay. The last bullet item in 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04 A. I do recall seeing that poster. 15:37:05 Q. And in what context do you 15:37:07 remember seeing it? 15:37:09	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:02 employ in making that determination? 15:40:03 A. Relationship to Mallinckrodt. 15:40:05 Their relationship to Mallinckrodt. 15:40:01 say "relationship to Mallinckrodt," what do 15:40:16 you mean by that? 15:40:17 A. For example, AATOD is a big 15:40:18
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04 A. I do recall seeing that poster. 15:37:07 remember seeing it? 15:37:09 A. There was a closet full of all 15:37:09	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed 15:39:45 away. 15:39:47 Q. Oh, I see. Okay. 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:05 Their relationship to Mallinckrodt. 15:40:05 Their relationship to Mallinckrodt. 15:40:09 Q. And what sorts of when you 15:40:11 say "relationship to Mallinckrodt," what do 15:40:16 you mean by that? 15:40:17 A. For example, AATOD is a big 15:40:18 organization about opioid dependence, and 15:40:25
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:44 Q. Okay. The last bullet item in 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04 A. I do recall seeing that poster. 15:37:05 Q. And in what context do you 15:37:07 remember seeing it? 15:37:09	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:52 you personally make recommendations as to 15:39:55 which grants you thought were worthwhile? 15:39:57 MR. O'CONNOR: Object to form. 15:40:00 THE WITNESS: Sometimes I did, 15:40:00 yes. 15:40:01 QUESTIONS BY MR. GOTTO: 15:40:01 Q. And what criteria did you 15:40:02 employ in making that determination? 15:40:05 Their relationship to Mallinckrodt. 15:40:05 Their relationship to Mallinckrodt. 15:40:11 say "relationship to Mallinckrodt," what do 15:40:16 you mean by that? 15:40:17 A. For example, AATOD is a big 15:40:18
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the SOM program you were doing at this time? 15:36:15 A. I don't recall. 15:36:18 Q. Do you recall if you did come 15:36:19 up with additional proposed items for 15:36:23 education for pharmacies? 15:36:26 A. I don't remember if we did. 15:36:28 Q. Okay. Do you recall if do 15:36:31 you recall participating in preparing any 15:36:36 educational and communication materials of 15:36:39 the type you describe in your e-mail? 15:36:41 A. The only thing I remember that 15:36:43 we did was information on safe disposal. 15:36:47 your e-mail you say, "There was a poster we 15:36:55 handed out at showing the most widely abused 15:36:58 drugs. It would be good to have that again." 15:37:01 Do you recall that poster? 15:37:04 A. I do recall seeing that poster. 15:37:07 remember seeing it? 15:37:09 A. There was a closet full of all 15:37:09	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. At this time it might have been 15:39:43 David Silver because Mr. Gunning had passed away. 15:39:47 Q. Oh, I see. Okay. 15:39:47 Did you have input into or 15:39:49 did you make recommendations as to grant 15:39:49 which grants you thought were worthwhile? 15:39: MR. O'CONNOR: Object to form. 15:40:00:00:00:00:00:00:00:00:00:00:00:00:

	Page 262		Page 264
1	be that relationship, that they were very 15:40:31	1	, ,
2	important in the industry for methadone 15:40:33	2	been in my area. 15:42:57
3	treatment, so you want to make sure that they 15:40:36	3	Q. Okay. Okay. So in terms of 15:42:58
4	continued doing work that they were doing. 15:40:38	4	grants that the marketing department made a 15:43:01
5	Q. Okay. Are there any other of 15:40:40	5	determination on, those would be reflected on 15:43:07
6	these organizations in particular that you 15:40:44	6	the the prior exhibit we just looked at? 15:43:08
7	can recall recommending Mallinckrodt make the 15:40:45	7	MR. O'CONNOR: Object to form. 15:43:10
8	grant? 15:40:48	8	THE WITNESS: Correct. 15:43:11
9	A. American Pharmacists 15:40:49	9	QUESTIONS BY MR. GOTTO: 15:43:11
10	Association. American Society Health System 15:41:01	10	Q. Okay. All right. You can set 15:43:12
11	Pharmacists Research and Education 15:41:03	11	that aside. 15:43:13
12	Foundation. And the two customer requests 15:41:05	12	(Mallinckrodt-Collier Exhibit 15:43:14
13	for Kroger and Cardinal would have come from 15:41:10	13	35 marked for identification.) 15:43:15
14	the sales team. 15:41:13	14	QUESTIONS BY MR. GOTTO: 15:43:15
15	Q. And in terms of the two 15:41:14	15	Q. Exhibit 35 is a two-page e-mail 15:43:51
16	pharmacists associations that you mentioned, 15:41:18	16	thread beginning at Bates MNK-T1_0000558153. 15:43:55
17	what was the reason for recommending those 15:41:20	17	Please take a look at that and let me know if 15:44:01
18	grants? 15:41:22	18	you recognize those e-mails. 15:44:03
19	A. They provide educational 15:41:22	19	A. Yes, I recognize it. 15:44:04
20	materials for pharmacies, and they help 15:41:24	20	Q. Okay. The bottom e-mail on the 15:44:10
21	provide programs and services to independent 15:41:30	21	first page from Debbie Digby is another 15:44:14
22	pharmacies which we don't have reach to. 15:41:32	22	e-mail transmitting monthly SOM reports 15:44:17
23	Q. Okay. You can set that aside. 15:41:35	23	similar to a document we looked at a little 15:44:21
24	(Mallinckrodt-Collier Exhibit 15:41:49	24	earlier this afternoon. 15:44:23
25	34 marked for identification.) 15:41:50	25	You recall? 15:44:27
	Page 263		Page 265
	_		8
1	OUESTIONS BY MR. GOTTO: 15:41:50	1	A. Yes. 15:44:27
1	QUESTIONS BY MR. GOTTO: 15:41:50 Q. I'll apologize in advance for 15:41:53	1 2	
	Q. I'll apologize in advance for 15:41:53		Q. And then the top e-mail is an 15:44:27
2	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54	2	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29
2	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57	2	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33
2 3 4	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58	2 3 4	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen."
2 3 4 5	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02	2 3 4 5	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35
2 3 4 5	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03	2 3 4 5	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37
2 3 4 5 6 7	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02	2 3 4 5 6 7	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37
2 3 4 5 6 7 8	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11	2 3 4 5 6 7 8	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44
2 3 4 5 6 7 8	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17	2 3 4 5 6 7 8	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50
2 3 4 5 6 7 8 9	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20	2 3 4 5 6 7 8 9	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53
2 3 4 5 6 7 8 9 10	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20	2 3 4 5 6 7 8 9 10	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53
2 3 4 5 6 7 8 9 10 11 12	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26	2 3 4 5 6 7 8 9 10 11	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58
2 3 4 5 6 7 8 9 10 11 12	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26	2 3 4 5 6 7 8 9 10 11 12 13	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:44:59
2 3 4 5 6 7 8 9 10 11 12 13	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29	2 3 4 5 6 7 8 9 10 11 12 13	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:44:59 doing that? 15:45:00
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:45:00 A. I guess so that to inform 15:45:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:44:59 doing that? 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:44:59 doing that? 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:12
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:44:59 doing that? 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38 contributions that Mallinckrodt made, or is 15:42:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07 Q. And why did you think that 15:45:12 would be something that she should be 15:45:21 informed of? 15:45:23
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38 contributions that Mallinckrodt made, or is 15:42:40 it some other compilation of grants and 15:42:43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07 Q. And why did you think that 15:45:12 would be something that she should be 15:45:21 informed of? 15:45:23
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38 contributions that Mallinckrodt made, or is 15:42:40 it some other compilation of grants and 15:42:43 contributions? 15:42:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:44:59 doing that? 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07 Q. And why did you think that 15:45:12 would be something that she should be 15:45:21 informed of? 15:45:23 A. I'm trying to understand what 15:45:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38 contributions that Mallinckrodt made, or is 15:42:40 it some other compilation of grants and 15:42:43 contributions? 15:42:45 A. I don't know if these are 15:42:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:45:90 doing that? 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07 Q. And why did you think that 15:45:12 would be something that she should be 15:45:21 informed of? 15:45:23 A. I'm trying to understand what 15:45:24 I'm even saying here. 15:45:26
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. I'll apologize in advance for 15:41:53 the small type on this document. 15:41:54 A. Oh, boy. 15:41:57 Q. Exhibit 34 is a multipage 15:41:58 well, actually it's a document that was 15:42:02 produced in native at MNK-T1_0000661003, and 15:42:03 it appears to be a list of grants. 15:42:11 And perhaps I can just ask you 15:42:14 a general question about the very first line 15:42:17 where it says, "GCC approved grants 15:42:20 January 14 to present." 15:42:25 Do you know what GCC means in 15:42:26 this setting? 15:42:28 A. No, I don't. 15:42:29 Q. Okay. Do you know if the 15:42:31 grants and contributions that are contained 15:42:35 in this document were grants and 15:42:38 contributions that Mallinckrodt made, or is 15:42:40 it some other compilation of grants and 15:42:43 contributions? 15:42:45 A. I don't know if these are 15:42:45 grants that specifically that Mallinckrodt 15:42:48	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. And then the top e-mail is an 15:44:27 e-mail from you to, well, a number of folks, 15:44:29 but in the body of the e-mail you say 15:44:33 "Karen." 15:44:35 I assume that means Karen 15:44:35 Harper? 15:44:37 A. I would assume so. 15:44:37 Q. Okay. And you indicate that 15:44:44 you took highest volume pharmacies ran by 15:44:50 distributor, et cetera, and compiled the data 15:44:53 that's in the table on the e-mail, correct? 15:44:55 A. Correct. 15:44:58 Q. And what was your reason for 15:45:00 A. I guess so that to inform 15:45:01 Karen of what the wholesalers' sales are. 15:45:07 Q. And why did you think that 15:45:12 would be something that she should be 15:45:21 informed of? 15:45:23 A. I'm trying to understand what 15:45:24 I'm even saying here. 15:45:26 Okay. Well, I guess in the 15:45:42

	Page 266	T	Page 268
1	Q. And monitoring it for what 15:45:50	1	notes? 15:48:17
2	purpose? 15:45:57	2	A. No, I did not. 15:48:17
3	A. To see if there's any high 15:45:57	3	Q. Do you know who did? 15:48:18
4	concentration by some of these smaller 15:46:00	4	A. This would have been someone in 15:48:19
5	distributors. 15:46:03	5	sales, possibly Jane. 15:48:21
6	Q. And high concentration meaning 15:46:03	6	Q. Okay. Did you have any input 15:48:23
7	what in this setting? 15:46:09	7	into what she put into the notes? 15:48:26
8	A. So, for example, if Masters 15:46:11	8	A. I don't recall putting anything 15:48:28
9	would have 15 percent share, that would be 15:46:12	9	in, adding any comments. 15:48:30
10	concerning because we have large volume 15:46:15	10	Q. Were these meetings held 15:48:32
11	customers on here. Or if KeySource was high. 15:46:17	11	regularly? 15:48:35
12	Q. And do you recall if you 15:46:22	12	A. Annually, yes. 15:48:35
13	performed this analysis on other occasions, 15:46:34	13	Q. And did you participate each 15:48:37
14	or was this a one-time thing that you did? 15:46:38	14	year? 15:48:39
15	MR. O'CONNOR: Object to form. 15:46:41	15	A. Yes, I did. 15:48:39
16	THE WITNESS: I'm not sure if 15:46:42	16	MR. GOTTO: Okay. All right. 15:48:46
17	it was done on a frequent basis. I 15:46:44	17	Why don't we go off the record. 15:48:47
18	I just said I just took this, so I 15:46:50	18	VIDEOGRAPHER: We're going off 15:48:49
19	assume that possibly from the data 15:46:52	19	the record at 3:48 p m. 15:48:50
20	that was provided by Debbie, I twisted 15:46:53	20	(Off the record at 3:48 p m.) 15:48:52
21	it a little bit further, you know, to 15:46:55	21	VIDEOGRAPHER: We are back on 15:53:10
22	look at the numbers in a different 15:46:57	22	the record at 3:52 p m. 15:53:11
23	way. 15:46:58	23	CROSS-EXAMINATION 15:53:12
24	QUESTIONS BY MR. GOTTO: 15:46:58	24	QUESTIONS BY MS. HERZFELD: 15:53:13
25	Q. Do you know if you had any 15:46:58	25	Q. Good afternoon, Ms. Collier. 15:53:14
	Page 267		D 260
	1 age 207		Page 269
1	_	1	Page 269 My name is Tricia Herzfeld. I'm an attorney 15:53:15
1 2	particular reason for performing that 15:46:59	1 2	My name is Tricia Herzfeld. I'm an attorney 15:53:15
	particular reason for performing that 15:46:59		_
2	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02	2	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17
2	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03	2	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19
2 3 4	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06	2 3 4	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20
2 3 4 5	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11	2 3 4 5	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21
2 3 4 5 6	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12	2 3 4 5 6	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21
2 3 4 5 6 7	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12	2 3 4 5 6 7	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22
2 3 4 5 6 7 8	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33	2 3 4 5 6 7 8	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22
2 3 4 5 6 7 8	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:36	2 3 4 5 6 7 8	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23
2 3 4 5 6 7 8 9	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:36 appears to be NACDS meeting notes from April 15:47:42	2 3 4 5 6 7 8 9	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24
2 3 4 5 6 7 8 9 10	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:36 appears to be NACDS meeting notes from April 15:47:42 of 2013. 15:47:48	2 3 4 5 6 7 8 9 10	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25
2 3 4 5 6 7 8 9 10 11	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:46 appears to be NACDS meeting notes from April 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49	2 3 4 5 6 7 8 9 10 11	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26
2 3 4 5 6 7 8 9 10 11 12 13	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:36 appears to be NACDS meeting notes from April 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:53	2 3 4 5 6 7 8 9 10 11 12 13	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27
2 3 4 5 6 7 8 9 10 11 12 13	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 appears to be NACDS meeting notes from April 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:53 A. Yes. 15:47:55	2 3 4 5 6 7 8 9 10 11 12 13	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:28
2 3 4 5 6 7 8 9 10 11 12 13 14 15	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:53 A. Yes. 15:47:55 Q. And what were they? 15:47:55	2 3 4 5 6 7 8 9 10 11 12 13 14	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:30
2 3 4 5 6 7 8 9 10 11 12 13 14 15	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:55 Q. And what were they? 15:47:55 A. They were National Association 15:47:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:28 we've made in every deposition we've 15:53:30 had thus far, so I won't repeat all 15:53:32
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	particular reason for performing that analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:55 Q. And what were they? 15:47:55 A. They were National Association 15:47:57 of Chain Drugstores, and it was meeting 15:47:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:28 we've made in every deposition we've 15:53:30 had thus far, so I won't repeat all 15:53:32 the specifics. 15:53:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:36 appears to be NACDS meeting notes from April 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:55 Q. And what were they? 15:47:55 A. They were National Association 15:47:57 of Chain Drugstores, and it was meeting 15:47:59 this particular meeting was with executives 15:48:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:30 had thus far, so I won't repeat all 15:53:32 the specifics. 15:53:35 MR. O'CONNOR: And we'll make 15:53:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:53 A. Yes. 15:47:55 Q. And what were they? 15:47:57 of Chain Drugstores, and it was meeting 15:47:59 this particular meeting was with executives 15:48:03 from the big wholesalers and big chains 15:48:05	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:28 we've made in every deposition we've 15:53:30 had thus far, so I won't repeat all 15:53:32 the specifics. 15:53:35 MR. O'CONNOR: And we'll make 15:53:35 our standard objection to your 15:53:36
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:55 Q. And what were they? 15:47:55 A. They were National Association 15:47:57 of Chain Drugstores, and it was meeting 15:47:59 this particular meeting was with executives 15:48:03 from the big wholesalers and big chains 15:48:05 and with the executives from the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:32 we've made in every deposition we've 15:53:30 had thus far, so I won't repeat all 15:53:35 MR. O'CONNOR: And we'll make 15:53:35 our standard objection to your 15:53:36 objection. 15:53:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:53 A. Yes. 15:47:55 Q. And what were they? 15:47:57 of Chain Drugstores, and it was meeting 15:47:59 this particular meeting was with executives 15:48:03 from the big wholesalers and big chains 15:48:09 manufacturers. 15:48:11	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:30 had thus far, so I won't repeat all 15:53:32 the specifics. 15:53:35 MR. O'CONNOR: And we'll make 15:53:35 our standard objection to your 15:53:36 objection. 15:53:37 MS. HERZFELD: Excellent. 15:53:38
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:53 A. Yes. 15:47:55 Q. And what were they? 15:47:57 of Chain Drugstores, and it was meeting 15:47:59 this particular meeting was with executives 15:48:03 from the big wholesalers and big chains 15:48:05 and with the executives from the 15:48:11 Q. Okay. And did you participate 15:48:11	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:32 we've made in every deposition we've 15:53:30 had thus far, so I won't repeat all 15:53:32 the specifics. 15:53:35 MR. O'CONNOR: And we'll make 15:53:35 our standard objection to your 15:53:36 objection. 15:53:37 MS. HERZFELD: Excellent. 15:53:38 Wonderful. Moving on. 15:53:39
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	particular reason for performing that 15:46:59 analysis in March of 2011? 15:47:02 A. I don't recall. 15:47:03 Q. Okay. You can put that aside. 15:47:06 (Mallinckrodt-Collier Exhibit 15:47:11 36 marked for identification.) 15:47:12 QUESTIONS BY MR. GOTTO: 15:47:12 Q. Exhibit 36 is a multipage 15:47:33 document beginning at MNK-T1_0000609142. It 15:47:42 of 2013. 15:47:48 Are you familiar with what the 15:47:49 NACDS meetings were? 15:47:55 Q. And what were they? 15:47:55 A. Yes. 15:47:55 A. They were National Association 15:47:59 this particular meeting was with executives 15:48:03 from the big wholesalers and big chains 15:48:05 and with the executives from the 15:48:09 manufacturers. 15:48:11 Q. Okay. And did you participate 15:48:11 in those meetings? 15:48:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	My name is Tricia Herzfeld. I'm an attorney 15:53:15 representing the plaintiffs in the Tennessee 15:53:17 state court litigation. 15:53:19 How are you doing this 15:53:20 afternoon? 15:53:21 A. Very good, thank you. 15:53:21 Q. Good. 15:53:22 Are you familiar at all with 15:53:22 the Tennessee litigation? 15:53:23 A. No, I'm not. 15:53:24 Q. Okay. 15:53:25 MS. HERZFELD: Well, before we 15:53:26 get on the record, I'm just going to 15:53:27 make our standard objection, which 15:53:28 we've made in every deposition we've 15:53:30 had thus far, so I won't repeat all 15:53:32 the specifics. 15:53:35 MR. O'CONNOR: And we'll make 15:53:35 our standard objection to your 15:53:36 objection. 15:53:37 MS. HERZFELD: Excellent. 15:53:38 Wonderful. Moving on. 15:53:39 QUESTIONS BY MS. HERZFELD: 15:53:41

	3 1		<u> </u>
	Page 270		Page 272
1	A. Yes, I have. 15:53:44	1	A. Yes. 15:55:07
2	Q. And for business or pleasure? 15:53:44	2	Q. Okay. And which cities did you 15:55:07
3	A. Both. 15:53:45	3	visit? 15:55:09
4	Q. Okay. When for business? 15:53:46	4	A. Memphis. 15:55:09
5	A. When for business? 15:53:47	5	Q. Oh, okay. 15:55:11
6	Q. Yes, ma'am. 15:53:50	6	Did you get to go to the Civil 15:55:13
7	A. I believe I was there for a 15:53:50	7	Rights Museum? 15:55:14
8	conference in Nashville, and doing business 15:53:52	8	A. No. 15:55:16
9	in Memphis with McKesson. 15:53:54	9	Q. Graceland? 15:55:16
10	Q. Okay. And when was the 15:53:59	10	A. Yes. 15:55:18
11	conference in Nashville? 15:54:00	11	Q. Did you like it? 15:55:18
12	A. I have no idea. 15:54:00	12	A. No. 15:55:19
13	Q. Okay. Do you know who you were 15:54:01	13	Q. Okay. It's a little different 15:55:19
14	working for when you attended the conference? 15:54:03	14	than people think. 15:55:21
15	A. Probably Baxter. 15:54:04	15	Okay. And does that pretty 15:55:22
16	Q. Okay. And when you said "in 15:54:08	16	much close out your visits to Tennessee, just 15:55:24
17	Memphis," was that for your time with 15:54:11	17	Memphis and Nashville? 15:55:27
18	McKesson? 15:54:12	18	A. Yes. 15:55:28
19	A. No. It was calling on 15:54:13	19	Q. Okay. Have you ever been to 15:55:29
20	McKesson. 15:54:15	20	the Appalachian region of Tennessee? 15:55:31
21	Q. Oh, calling on McKesson. 15:54:16	21	A. Possibly driven through it. 15:55:34
22	A. They have a warehouse there. 15:54:18	22	Q. Okay. 15:55:36
23	Q. Okay. 15:54:18	23	A. I'm not really sure where it 15:55:37
24	A. They had a warehouse there. 15:54:20	24	is. 15:55:39
25	Q. And who were you employed by 15:54:21	25	Q. Okay. You've heard of the 15:55:39
	Page 271		Page 273
1	when you were calling on McKesson? 15:54:23	1	Smoky Mountains? 15:55:42
2	A. Baxter. 15:54:24	2	A. Yes. 15:55:42
3	Q. Okay. In your capacity as an 15:54:25	3	Q. Okay. Do you know there's an 15:55:43
4	employee of Mallinckrodt, did you ever visit 15:54:27	4	area of Tennessee that's like up northeast of 15:55:44
5	Tennessee? 15:54:31	5	the Smoky Mountains? It's almost in 15:55:47
6	A. Yes. 15:54:31	6	Kentucky, West Virginia? 15:55:49
7	Q. Okay. And when was that? 15:54:32	7	A. Then I might have driven 15:55:51
8	A. I don't recall. 15:54:33	8	through it. 15:55:52
9	Q. Okay. And what were you doing 15:54:39	9	Q. Okay. Do you know where you 15:55:53
10	in Tennessee? 15:54:40	10	were going? 15:55:55
11	A. Visiting the McKesson 15:54:41	11	A. From New Jersey to St. Louis. 15:55:55
12	warehouse. 15:54:43	12	Q. Okay. Okay. I'm going to go 15:55:57
13	Q. Okay. So you visited the 15:54:43	13	through just a couple of e-mails with you 15:56:11
14	McKesson warehouse in Memphis during your job 15:54:45	14	quickly, hopefully. I don't think they've 15:56:13
15	at Baxter as well as your job at 15:54:49	15	been previously added as exhibits, so if they 15:56:17
16	Mallinckrodt; is that correct? 15:54:52	16	have, if somebody will stop me and hopefully 15:56:21
17	A. Correct. 15:54:52	17	we won't repeat it. 15:56:23
18	MR. O'CONNOR: Object to form. 15:54:52	18	If we could mark this one as 15:56:24
19	QUESTIONS BY MS. HERZFELD: 15:54:53	19	Exhibit are we on 29? 15:56:26
20	Q. Okay. Any other times that you 15:54:53	20	COURT REPORTER: 36. 15:56:32
21	visited Tennessee in your capacity as an 15:54:56	21	MS. HERZFELD: 36. 15:56:32
22	employee of Mallinckrodt? 15:54:58	22	MR. O'CONNOR: I think I have a 15:56:32
23	A. Not that I remember. 15:54:59	23	36 already. So 37. 15:56:32
24	Q. Okay. And you've gone 15:55:01	24	MS. HERZFELD: 37. Okay. 15:56:47
25	personally for vacation or something? 15:55:05	25	(Mallinckrodt-Collier Exhibit 15:56:47

	Page 274		Page 276
1	37 marked for identification.) 15:56:48	1	distributors, stating, "Have we ever asked 15:58:53
2	QUESTIONS BY MS. HERZFELD: 15:56:48	2	them to provide written protocol for how they 15:58:56
3	Q. Okay. If you'd take a moment 15:56:51	3	vet the customers that they sell to?" 15:58:58
4	and look at this e-mail, please. 15:56:52	4	Do you see where I'm at? 15:59:00
5	A. Okay. 15:56:53	5	A. Yes, I do. 15:59:02
6	MR. HIBEY: If there's a Bates 15:56:53	6	Q. And did I read that correctly? 15:59:02
7	number for the document, could you 15:56:53	7	A. Yes, you did. 15:59:04
8	please read it for us? 15:57:13	8	Q. Okay. And then, "Can we start 15:59:05
9	MS. HERZFELD: Sure. But it's 15:57:13	9	making it a requirement that they provide us 15:59:07
10	been produced in the Tennessee state 15:57:14	10	with written standard operating practices as 15:59:09
11	litigation, so I don't have a Bates 15:57:17	11	to how they confirm that an account is okay?" 15:59:12
12	number for the MDL. 15:57:18	12	Do you see that? 15:59:16
13	MR. HIBEY: Well, I guess I'd 15:57:20	13	A. Yes. 15:59:16
14	take that Bates number as well, just 15:57:21	14	Q. Okay. And then Karen Harper 15:59:16
15	some kind of identifier. 15:57:22	15	responds, "The question whether our customers 15:59:18
16	MS. HERZFELD: Sure. 15:57:25	16	monitor their customers was removed from the 15:59:22
17	Who is it on the phone? 15:57:25	17	questionnaire by the Mallinckrodt suspicious 15:59:24
18	MR. HIBEY: This is David Hibey 15:57:28	18	order monitoring team because there is no 15:59:25
19	from Arnold & Porter. 15:57:29	19	{sic} actual regulatory obligation to monitor 15:59:28
20	MS. HERZFELD: Okay. And 15:57:31	20	customers' customers." 15:59:32
21	you're representing whom? 15:57:31	21	Do you see where I'm at? 15:59:35
22	MR. HIBEY: Endo and Par. 15:57:33	22	A. Yes. 15:59:36
23	MS. HERZFELD: Okay. So the 15:57:35	23	Q. Okay. Was that your 15:59:37
24	Tennessee state litigation number is 15:57:36	24	understanding of the DEA requirements? 15:59:38
25	MNK_TNSTA05202063. And I have no idea 15:57:37	25	A. I did not know the DEA 15:59:39
		_	
	Page 275		Page 277
1	if this was produced in the MDL. 15:57:45	1	requirements. That's why we were requesting. 15:59:40
2	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55	2	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43
2	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56	2 3	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44
2 3 4	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57	2 3 4	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46
2 3 4 5	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57	2 3 4 5	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48
2 3 4 5 6	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59	2 3 4 5	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50
2 3 4 5 6 7	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00	2 3 4 5 6 7	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52
2 3 4 5 6 7 8	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01	2 3 4 5 6 7 8	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53
2 3 4 5 6 7 8	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:56 Q. Ma'am, you've had an opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the properties of the properties o	2 3 4 5 6 7 8	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54
2 3 4 5 6 7 8 9	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24	2 3 4 5 6 7 8 9	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57
2 3 4 5 6 7 8 9 10	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24	2 3 4 5 6 7 8 9 10	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58
2 3 4 5 6 7 8 9 10 11	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an opportunity to review it? 15:57:56 A. Yes. I'm still reviewing the properture it? 15:57:57 A. Yes. I'm still reviewing the properture it? 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished proviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this properture its properture its properture. 15:58:24 document? 15:58:25	2 3 4 5 6 7 8 9 10 11	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58
2 3 4 5 6 7 8 9 10 11 12 13	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25	2 3 4 5 6 7 8 9 10 11 12 13	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08
2 3 4 5 6 7 8 9 10 11 12 13 14	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26	2 3 4 5 6 7 8 9 10 11 12 13	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09
2 3 4 5 6 7 8 9 10 11 12 13 14	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:28	2 3 4 5 6 7 8 9 10 11 12 13 14 15	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:28 from Karen Harper? 15:58:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:28 from Karen Harper? 15:58:32 A. The top one is. The bottom one 15:58:33	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:32 A. The top one is. The bottom one 15:58:33 started with Kate Neely sending something to 15:58:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:09
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	if this was produced in the MDL. 15:57:45 QUESTIONS BY MS. HERZFELD: 15:57:55 Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:38 from Karen Harper? 15:58:32 A. The top one is. The bottom one 15:58:36 Karen Harper and me and copying me. 15:58:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:09 opportunity to read it? 16:01:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:28 from Karen Harper? 15:58:33 started with Kate Neely sending something to 15:58:36 Karen Harper and me and copying me. 15:58:39 Q. Okay. And then it looks like a 15:58:41	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:10 A. Yes, I have. 16:01:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:32 A. The top one is. The bottom one 15:58:33 started with Kate Neely sending something to 15:58:36 Karen Harper and me and copying me. 15:58:39 Q. Okay. And then it looks like a 15:58:44	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:10 A. Yes, I have. 16:01:11 Q. Okay. And what does this 16:01:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. 15:57:59 Q. That's okay. 15:58:00 Okay. Are you finished 15:58:01 reviewing it? 15:58:23 A. Yes, ma'am. 15:58:24 Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:32 A. The top one is. The bottom one 15:58:33 started with Kate Neely sending something to 15:58:39 Q. Okay. And then it looks like a 15:58:41 response on the top? 15:58:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:10 A. Yes, I have. 16:01:11 Q. Okay. And what does this 16:01:11 e-mail appear to be to you? 16:01:14
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? A. Yes. I'm still reviewing the 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. Q. That's okay. Okay. Are you finished 15:58:00 Okay. Are you finished 15:58:23 A. Yes, ma'am. Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:32 A. The top one is. The bottom one 15:58:33 started with Kate Neely sending something to 15:58:39 Q. Okay. And then it looks like a 15:58:44 A. Correct, from Karen. Q. Okay. Great. 15:58:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:10 A. Yes, I have. 16:01:11 Q. Okay. And what does this 16:01:11 e-mail appear to be to you? 16:01:14 A. This appears that we were 16:01:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. Q. That's okay. Okay. Are you finished 15:58:00 Okay. Are you finished 15:58:23 A. Yes, ma'am. Q. Okay. Do you recognize this 15:58:25 A. Yes, I do. 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:32 A. The top one is. The bottom one 15:58:33 started with Kate Neely sending something to 15:58:36 Karen Harper and me and copying me. Q. Okay. And then it looks like a 15:58:44 A. Correct, from Karen. 15:58:44 A. Correct, from Karen. Q. Okay. Great. 15:58:46 And so looking at this e-mail, 15:58:47	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:10 A. Yes, I have. 16:01:11 Q. Okay. And what does this 16:01:11 e-mail appear to be to you? 16:01:14 A. This appears that we were 16:01:16 requested to provide an average on 16:01:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	if this was produced in the MDL. QUESTIONS BY MS. HERZFELD: Q. Ma'am, you've had an 15:57:56 opportunity to review it? A. Yes. I'm still reviewing the 15:57:57 A. Yes. I'm still reviewing the 15:57:57 top. I'm sorry. Q. That's okay. Okay. Are you finished 15:58:00 Okay. Are you finished 15:58:23 A. Yes, ma'am. Q. Okay. Do you recognize this 15:58:24 document? 15:58:25 Q. Okay. Does it appear to be an 15:58:26 e-mail that was sent to you and Kate Neely 15:58:32 A. The top one is. The bottom one 15:58:33 started with Kate Neely sending something to 15:58:39 Q. Okay. And then it looks like a 15:58:44 A. Correct, from Karen. Q. Okay. Great. 15:58:45	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	requirements. That's why we were requesting. 15:59:40 Q. Okay. And were you part of the 15:59:43 decision to take that off the questionnaire? 15:59:44 A. No, I was not. 15:59:46 Q. Okay. And were you part of the 15:59:48 decision to not require distributors to 15:59:50 provide their written policies? 15:59:52 A. No, I was not. 15:59:53 Q. Okay. That was my only 15:59:54 questions on that document. Thank you, 15:59:57 ma'am. 15:59:58 A. Okay. 15:59:58 (Mallinckrodt-Collier Exhibit 16:00:08 38 marked for identification.) 16:00:09 MS. HERZFELD: For those on the 16:00:09 phone, this is MNK_TNSTA05202176. 16:00:27 QUESTIONS BY MS. HERZFELD: 16:00:34 Q. Okay. You've had an 16:01:10 A. Yes, I have. 16:01:11 Q. Okay. And what does this 16:01:11 e-mail appear to be to you? 16:01:14 A. This appears that we were 16:01:16

Page 278 2 2 2 2 2 2 2 2 2
2 Q. Okay. And it's an e-mail from 16:01:28 3 you to Michael Gamming; is that correct? 16:01:30 4 A. Correct. 16:01:31 5 Q. Okay. And it's dated 16:01:32 6 4/18/2011? 16:01:35 7 A. Correct. 16:01:35 8 Q. Okay. And do you have any 16:01:36 9 reason to think you didn't receive this 16:01:37 10 e-mail? 9 10 Gold Say. And do you have any 16:01:38 11 A. No, I have no reason. 16:01:38 12 Q. Okay. And so who is Michael 16:01:43 13 Gumning? 16:01:43 14 A. He was the president — or the 16:01:43 15 general manager of the generics division. 16:01:46 16 Q. Okay. And do you have any 16:01:48 17 specific memory of him requesting this 16:01:51 18 information from you? 16:01:53 19 A. No. 16:01:53 20 Q. Okay. And do you know my be 16:01:55 21 requested it from you? 16:01:55 22 A. I'm not sure that he did 16:01:58 23 request di from you? 16:01:55 24 Q. Okay. Might it have been a discussion 16:02:07 25 something that you just came up with to send? 16:02:07 26 q. Okay. Might it have been at a 16:02:07 27 proactively, or it could have been at a 16:02:09 28 request. 1 family have been at a 16:02:12 29 Q. Okay. Might it have been at a 16:02:17 20 Q. Okay. Might it have been at a 16:02:17 21 m. R. OrconNoR: Objection 16:02:21 22 and 1 decided—1 could have acted 16:02:17 23 proactively, or it could have been at a 16:02:19 24 Q. Okay. So looking at this 16:02:21 25 q. A. Correct. 16:02:19 26 and 1 decided—1 could have acted 16:02:21 27 q. Okay. So looking this 16:02:22 28 are might in the prior it of the process of the reason of the process o
3 you to Michael Gunning; is that correct? 16:01:30 4 A. Correct. 16:00:135 5 Q. Okay. And it's dated 16:01:35 6 4/18/2011? 16:01:35 7 A. Correct. 16:00:135 8 Q. Okay. And do you have any 16:01:36 9 reason to think you didn't receive this 16:01:37 10 c-mail? 16:01:38 11 A. No, I have no reason. 16:01:38 12 Q. Okay. And so who is Michael 16:01:40 13 Giunning? 16:01:43 14 A. He was the president—or the 16:01:43 15 general manager of the generics division. 16:01:46 16 Q. Okay. And do you have any 16:01:53 17 specific memory of him requesting this 16:01:51 18 information from you? 16:01:53 19 A. No. 16:01:53 20 Q. Okay. And do you know why he 16:01:55 21 requested it from you? 16:01:53 22 Q. Okay. And do you know why he 16:01:55 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:02 26 Q. Okay. Might it have been a discussion 16:02:05 27 and I decided—I could have acted 16:02:07 28 request. 16:02:21 29 very exercived a little bit earlier, it looks 16:02:13 30 Q. Okay. So looking at this 16:03:22 31 disconnetines you acted proactively and 16:02:15 32 or one of the control
4
5 Q. Okay. And it's dated 16:01:32 5 Q. Okay. So I'm going to back up 16:02:58 6 4/18/2011? 16:01:35 5 Q. Okay. And do you have any 16:01:36 7 2 2 2 2 3 2 3 2 3 2 3 3
6 4/18/2011?
7
Source Page 279
9 reason to think you didn't receive this 16:01:37 10 16:01:38 10 16:01:38 12 2 2 3 3 3 3 3 3 3
10
11
12 Q. Okay. And so who is Michael 16:01:40 13 Gunning? 16:01:43 14 A. He was the president or the 16:01:43 15 general manager of the generics division. 16:01:43 16 Q. Okay. And do you have any 16:01:48 17 specific memory of him requesting this 16:01:51 18 information from you? 16:01:53 19 A. No. 16:01:53 20 Q. Okay. And do you know why he 16:01:55 21 requested it from you? 16:01:56 22 A. I'm not sure that he did 16:01:58 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:03 26 and I decided I could have acted 16:02:07 27 and I decided I could have been at 16:02:09 28 and I decided I could have been at 16:02:12 30 proactively, or it could have been at 16:02:12 40 we've received a little bit earlier, it looks 16:02:13 51 crunched numbers in a way and would pass that 16:02:17 52 or Q. Okay. Self for its looks 16:02:13 53 crunched numbers in a way and would pass that 16:02:17 54 or to correct. 16:02:29 55 crunched numbers in a way and would pass that 16:02:17 56 or Creet. 16:02:29 10 A. Correct. 16:02:23 11 de-mail, it says, "Based on the report we get 16:02:23 12 dispensing unit? 16:03:16 15 dispensing unit? 16:03:16 16 MR. O'CONNOR: Objection to the 16:03:16 17 MR. O'CONNOR: Objection to the 16:03:16 18 owould think that it's tablets. It 16:03:21 19 on to someone; is that correct? 16:02:12 10 A. It might have been a discussion 16:02:13 16 we've received a little bit earlier, it looks 16:02:13 17 diversing from two or more distributors; is 16:03:35 18 dispensing units for the 15-milligram and 16:02:24 19 Q. Okay. And so when you're 16:03:25 10 vould think that it's tablets. It 16:03:16 11 would think that it's tablets. It 16:03:16 12 vould think that it's tablets. It 16:03:25 14 to the tablets or bottles, or what is a 16:03:25 15 vould think that it's tablets. It 16:03:26 16 vould think that it's tablets. It 16:03:25 16 vould think that it's tablets. It 16:03:25 16 vould think that it's tablets. It 16:03:25 16 vould think that it's tab
13 Guming? 16:01:43 14 A. He was the president—or the 16:01:43 15 general manager of the generics division. 16:01:46 16 Q. Okay. And do you have any 16:01:48 17 specific memory of him requesting this 16:01:51 18 information from you? 16:01:53 19 A. No. 16:01:53 19 A. No. 16:01:53 20 Q. Okay. And do you know why he 16:01:55 21 requested it from you? 16:01:56 22 A. I'm not sure that he did 16:01:58 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:02 26 and I decided — I could have acted 16:02:07 27 proactively, or it could have been at a 16:02:12 28 q. And from the testimony that 16:02:12 29 q. And from the testimony that 16:02:12 20 q. And from the testimony that 16:02:12 21 request. 16:02:01 22 and I decided — I could have acted 16:02:07 23 request. 16:02:12 24 and Rome thing that you just came up with to send? 16:02:07 25 request. 16:02:12 26 we've received a little bit earlier, it looks 16:02:13 27 request. 16:02:22 28 and Rome thing that you just came up with to send? 16:02:12 29 Q. Okay. And so when you're 16:03:23 20 Q. Okay. And so when you're 16:03:25 21 to the tablets. 16:03:27 22 and I decided — I could have acted 16:02:07 23 request. 16:02:12 24 Q. Okay. And from the testimony that 16:02:12 25 to the tablets. 16:03:35 26 we've received a little bit earlier, it looks 16:02:13 27 request. 16:02:21 28 q. Okay. And from the testimony that 16:02:12 29 Q. Okay. And from the testimony that 16:02:12 30 request. 16:02:22 31 Request. 16:02:22 31 request. 16:02:22 31 request. 16:02:22 32 and I decided — I could have acted 16:02:07 32 and I decided — I could have acted 16:02:07 33 request. 16:02:12 4
14 A. He was the president or the 16:01:43 15 general manager of the generics division. 16:01:46 16 Q. Okay. And do you have any 16:01:53 17 specific memory of him requesting this 16:01:51 18 information from you? 16:01:53 19 A. No. 16:01:53 10 Q. Okay. And do you know why he 16:01:55 20 Q. Okay. And do you know why he 16:01:55 21 requested it from you? 16:01:55 22 A. I'm not sure that he did 16:01:58 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:03 2 and I decided I could have acted 16:02:07 2 and I decided I could have been at 16:02:12 3 proactively, or it could have been at 16:02:12 4 we've received a little bit earlier, it looks 16:02:13 5 we've received a little bit earlier, it looks 16:02:17 9 on to someone; is that correct? 16:02:20 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection to the 16:03:16 12 mR. O'CONNOR: Objection to the 16:03:16 13 mR. O'CONNOR: Objection to the 16:03:16 14 mR. O'CONNOR: Objection to the 16:03:16 15 mR. O'CONNOR: Objection to the 16:03:16 16 mR. O'CONNOR: Objection to the 16:03:16 17 mR. O'CONNOR: Objection to the 16:03:16 18 to the tablets or bottles, or what is a 16:03:16 19 MR. O'CONNOR: Objection to the 16:03:16 19 mR. O'CONNOR: Objection to the 16:03:22 10 the tablets or bottles, or what is a 16:03:16 11 mR. O'CONNOR: Objection to the 16:03:23 12 later on. In looking at these 16:03:23 13 looking here, this looks like it could refer 16:03:23 14 vere received a little bit earlier, it looks 16:02:13 15 mR. O'CONNOR: Objection to the 16:03:14 16 verul think that it's tablets. It 16:03:24 17 dispensing unit? MR. O'CONNOR: Objection to the 16:01:55 18 to the tablets or bottles, or bleaction to the 16:03:16 19 mR. O'CONNOR: Objection to 16:01:53 19 or to come that earlier, it looks 16:02:17 20 Nay, and the test into would think that it's tablets. It 16:03:24 21 to the tablets or bottles, or bleacting the form. 16:03:25 22 later on. In looking at these 16:03:25 23 numbers, it looks like it's toxy 1
15 general manager of the generics division. 16:01:46 16:01:48 17 Specific memory of him requesting this 16:01:51 17 MR. O'CONNOR: Objection to the 16:03:16 18 information from you? 16:01:53 18 THE WITNESS: In this context 1 16:03:16 19 A. No. 16:01:53 19 THE WITNESS: In this context 1 16:03:16 19 THE WITNESS: In this context 1 16:03:16 19 THE WITNESS: In this context 1 16:03:16 16:03:21 16:03:21 16:03:22 16:03:23 16:03:23 16:03:23 16:03:23 16:03:23 16:03:23 16:03:23 16:03:24 16:03:25 16:03:35 16:03:36 16:03:35 16:03:36 16:03:35
16
17 specific memory of him requesting this 16:01:51 17 MR. O'CONNOR: Objection to the 16:03:16 18 information from you? 16:01:53 18 form. 16:03:16 19 THE WITNESS: In this context I 16:03:16 16:03:21 16:03:21 17 16:03:16 17 17 17 17 17 17 17
18
19 A. No. 16:01:53 20 Q. Okay. And do you know why he 16:01:55 21 requested it from you? 16:01:56 22 A. I'm not sure that he did 16:01:58 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:03 26 and I decided I could have acted 16:02:07 27 and I decided I could have been at a 16:02:07 28 q. And from the testimony that 16:02:12 29 and I decided I could have been at a 16:02:07 30 proactively, or it could have been at a 16:02:12 40 Q. Okay. Might it be tearlier, it looks 16:02:13 51 Q. And from the testimony that 16:02:12 52 where received a little bit earlier, it looks 16:02:13 53 request it. 16:02:12 54 Q. Okay. And so when you're 16:03:28 55 Q. And from the testimony that 16:02:12 56 we've received a little bit earlier, it looks 16:02:13 57 like sometimes you acted proactively and 16:02:15 58 request it. 16:02:20 59 and I decided I could have been at a 16:02:12 50 Q. Okay. And so looking at this, 16:03:36 50 Q. And from the testimony that 16:02:12 51 like sometimes you acted proactively and 16:02:12 52 like ron. In looking at these 16:03:28 53 proactively, or it could have been at a 16:02:09 54 proactively, or it could have been at a 16:02:12 55 like sometimes you acted proactively and 16:02:12 56 we've received a little bit earlier, it looks 16:02:13 57 Q. Okay. And so looking at this, 16:03:35 58 crunched numbers in a way and would pass that 16:02:17 59 on to someone; is that correct? 16:02:20 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:03:49 13 Q. Okay. So looking at this 16:02:23 14 de-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:25 16 the averages are the average pharmacy 16:02:25 17 dispensing units for the 15-milligram and 16:02:35 18 Objection 16:02:35 19 Do you see where it says that? 16:02:35 19 Do you see where it says that? 16:02:36 19 A. Yes. 16:03:02 10 A. Oxy 5 milligram. 16:04:02
20 Q. Okay. And do you know why he 16:01:55 21 requested it from you? 16:01:56 22 A. I'm not sure that he did 16:01:58 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:03 26 The page 279 27 A. It might have been a discussion 16:02:05 28 and I decided — I could have acted 16:02:07 29 and I decided — I could have acted 16:02:09 30 proactively, or it could have been at 16:02:12 40 Q. And from the testimony that 16:02:12 41 Guest 16:02:12 42 A. No, I do not. 16:03:27 43 proactively and 16:02:12 44 request. 16:02:12 45 Q. And from the testimony that 16:02:12 46 we've received a little bit earlier, it looks 16:02:13 47 like sometimes you acted proactively and 16:02:15 48 crunched numbers in a way and would pass that 16:02:17 49 on to someone; is that correct? 16:02:20 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:03:45 13 Q. Okay. So looking at this 16:02:22 14 that right? 16:03:49 15 for suspicious order monitoring, below are 16:02:22 16 the averages — are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 Ob you see where it says that? 16:02:35 19 Do you see where it says that? 16:02:35 10 A. Yes. 16:03:56 10 Consultation in the desired that are not included here? 16:03:22 10 A. Yes. 16:03:56 10 What other oxy sales would be 16:03:58 10 Do you see where it says that? 16:02:35 10 A. Yes. 16:04:00
21 requested it from you? 16:01:56 22 A. I'm not sure that he did 16:01:58 23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:03 26 The page 279 27 A. It might have been a discussion 16:02:05 28 and I decided I could have acted 16:02:07 29 and I decided I could have been at 16:02:07 20 and I decided I could have been at 16:02:07 20 and I decided I could have been at 16:02:09 21 are quest. 16:02:12 22 and I decided I could have been at 16:02:09 23 proactively, or it could have been at 16:02:09 24 request. 16:02:12 25 we've received a little bit earlier, it looks 16:02:13 26 we've received a little bit earlier, it looks 16:02:13 27 like sometimes you acted proactively and 16:02:15 28 crunched numbers in a way and would pass that 16:02:15 29 on to someone; is that correct? 16:02:29 20 Okay. And so when you're 16:03:36 21 like sometimes you acted proactively and 16:02:15 22 and I decided I could have been at 16:02:12 23 numbers, it looks like it could refer 16:03:27 24 to the tablets. 16:03:27 25 to the tablets. 16:03:27 26 QUESTIONS BY MS. HERZFELD: 16:03:20 27 Q. Okay. And so when you're 16:03:30 28 it looks like it is for, what 16:03:30 29 down, I de:03:30 20 Okay. And so looking it his, 16:03:31 20 Okay. And so looking at this, 16:03:37 20 Okay. And so looking at his, 16:03:37 21 diverties that correct? 16:02:20 22 down, I decided
A. I'm not sure that he did 16:01:58 22 later on. In looking at these 16:03:23 request it. 16:02:00 23 numbers, it looks like it could refer 16:03:25 to the tablets. 16:03:27 to the tablets. 16:03:27 Page 279 Page
23 request it. 16:02:00 24 Q. Okay. Might it have been 16:02:01 25 something that you just came up with to send? 16:02:03 Page 279 1 A. It might have been a discussion 16:02:05 2 and I decided I could have acted 16:02:07 3 proactively, or it could have been at a 16:02:09 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 5 we've received a little bit earlier, it looks 16:02:13 6 we've received a little bit earlier, it looks 16:02:15 7 like sometimes you acted proactively and 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:03:37 13 Q. Okay. So looking at this 16:02:22 14 A. Yes. 16:03:49 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:35 17 Do you see where it says that? 16:02:36 18 Do you see where it says that? 16:02:36 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:04:00 20 A. Oxy 5 milligram. 16:04:02
Q. Okay. Might it have been 16:02:01 24 to the tablets. 16:03:27
Page 279 1 A. It might have been a discussion 16:02:05 2 and I decided I could have acted 16:02:07 2 and I decided I could have been at a 16:02:09 3 proactively, or it could have been at a 16:02:12 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 5 Q. And from the testimony that 16:02:13 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:20 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:24 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:35 18 On willigram combined." 16:02:35 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:03:57 20 Okay. So loided at this 16:02:35 21 What other oxy sales would be 16:03:58 22 Okay. And it says, "I will ask 16:03:51 23 Owy sales." 16:03:58 24 in QUESTIONS BY MS. HERZFELD: 16:02:28 25 Okay. And it says, "I will ask 16:03:51 26 oxy sales." 16:03:49 27 Okay. And it says, "I will ask 16:03:51 28 What other oxy sales would be 16:03:58 29 Do you see where it says that? 16:02:36 20 A. Yes. 16:04:00 20 A. Oxy 5 milligram. 16:04:02
Page 279 1 A. It might have been a discussion 16:02:05 2 and I decided I could have acted 16:02:07 3 proactively, or it could have been at a 16:02:09 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:03:34 13 Q. Okay. So looking at this 16:02:22 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:35 17 Do you see where it says that? 16:02:35 18 Do you see where it says that? 16:02:37 2 Q. Okay. And so looking at his it is for, what 16:03:30 4 is it, a month? For a year? Do you know 16:03:34 5 what the time period is? 16:03:35 6 A. No, I do not. 16:03:36 6 A. No, I do not. 16:03:36 7 Q. Okay. And so looking at this, 16:03:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 Q. Okay. So looking at this 16:02:22 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:58 19 Do you see where it says that? 16:02:36 19 Do you see where it says that? 16:02:37 20 A. Oxy 5 milligram. 16:04:02
1 A. It might have been a discussion 16:02:05 2 and I decided I could have acted 16:02:07 3 proactively, or it could have been at a 16:02:09 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 5 We've received a little bit earlier, it looks 16:02:13 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:03:45 13 Q. Okay. So looking at this 16:02:23 14 A. Yes. 16:03:49 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:35 17 Qo you see where it says that? 16:02:36 18 Oby you see where it says that? 16:02:37 19 Do you see where it says that? 16:02:37 20 Q. Okay. And so looking at this 16:03:39 21 QUESTIONS BY MS. HERZFELD: 16:02:21 22 Q. Okay. And so when you're 16:03:30 23 looking here, this looks like it is for, what 16:03:30 24 is it, a month? For a year? Do you know 16:03:34 25 what the time period is? 16:03:36 26 A. No, I do not. 16:03:36 27 Q. Okay. And so looking at this, 16:03:37 28 it looks like it's oxy 15 and oxy 30, 16:03:37 29 according to your e-mail here; is that right? 16:03:42 20 QUESTIONS BY MS. HERZFELD: 16:02:21 21 Q. Okay. And it's for pharmacies 16:03:45 22 purchasing from two or more distributors; is 16:03:47 23 that right? 16:03:49 24 A. Yes. 16:03:49 25 Q. Okay. And it says, "I will ask 16:03:51 26 A. No, I do not. 16:03:36 27 Q. Okay. And it's for pharmacies 16:03:49 28 Q. Okay. And it's for pharmacies 16:03:49 29 A. Yes. 16:03:56 20 Q. Okay. And it says, "I will ask 16:03:51 20 Q. Okay. And it says, "I will ask 16:03:51 29 Q. Okay. And it says, "I will ask 16:03:51 20 Q. Okay. And it says, "I will ask 16:03:51 20 Q. Okay. And it says, "Based on the report to include all 16:03:54 20 Q. Okay. And it says, "Based on the report to include all 16:03:54 21 Oxy sales." 16:03:29 22 Q.
1 A. It might have been a discussion 16:02:05 2 and I decided I could have acted 16:02:07 3 proactively, or it could have been at a 16:02:09 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:03:36 13 looking here, this looks like it is for, what 16:03:30 4 is it, a month? For a year? Do you know 16:03:34 5 what the time period is? 16:03:35 6 A. No, I do not. 16:03:36 7 Q. Okay. And so looking at this, 16:03:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:42 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 What other oxy sales would be 16:03:58 19 Do you see where it says that? 16:02:37 10 Q. Oxy 5 milligram. 16:04:00 20 A. Yes. 16:04:00 20 A. Oxy 5 milligram. 16:04:02
2 and I decided I could have acted 16:02:07 3 proactively, or it could have been at a 16:02:09 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:23 13 looking here, this looks like it is for, what 16:03:30 4 is it, a month? For a year? Do you know 16:03:34 5 what the time period is? 16:03:35 6 A. No, I do not. 16:03:36 7 Q. Okay. And so looking at this, 16:03:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 Q. Okay. So looking at this 16:02:23 14 A. Yes. 16:03:49 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 30-milligram combined." 16:02:36 19 Do you see where it says that? 16:02:36 19 Do you see where it says that? 16:02:37 10 Q. Oxay. Smilligram. 16:04:02 10 A. Yes. 16:03:58 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
3 proactively, or it could have been at a 16:02:09 4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 looking here, this looks like it is for, what 16:03:30 4 is it, a month? For a year? Do you know 16:03:34 5 what the time period is? 16:03:35 6 A. No, I do not. 16:03:36 7 Q. Okay. And so looking at this, 16:03:37 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 9 according to your e-mail here; is that right? 16:03:42 11 Q. Okay. And it's for pharmacies 16:03:45 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 that right? 16:03:49 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 30-milligram combined." 16:02:35 19 Do you see where it says that? 16:02:36 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:04:00 20 A. Oxy 5 milligram. 16:04:02
4 request. 16:02:12 5 Q. And from the testimony that 16:02:12 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:29 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 is it, a month? For a year? Do you know 16:03:34 7 What the time period is? 16:03:35 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 that right? 16:03:49 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 30-milligram combined." 16:02:35 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:03:35 4 is it, a month? For a year? Do you know 16:03:34 A. No, I do not. 16:03:35 A. No, I do not. 16:03:35 A. No, I do not. 16:03:36 A. No, I do not. 16:03:36 A. No, I do not. 16:03:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 according to your e-mail here; is that right? 16:03:49 4 is it, a month? For a year? Do you know 16:03:35 A. No, I do not. 16:03:35 7 Q. Okay. And so looking at this, 16:03:39 according to your e-mail here; is that right? 16:03:49 4 it looks like it's oxy 15 and oxy 30, 16:03:39 according to your e-mail here; is that right? 16:03:49 4 it looks like it's oxy 15 and oxy 30, 16:03:39 according to your e-mail here; is that right? 16:03:49 4 it looks like it's oxy 15 and oxy 30, 16:03:39 according to your e-mail here; is that right? 16:03:49 4 it looks like it's oxy 15 and oxy 30, 16:03:49 4 it looks like it's oxy 16 and oxy 30, 16:03:49 4 it looks like it's oxy 16 and oxy 30, 16:03:49 4 it looks like it's oxy 16 a
5 Q. And from the testimony that 16:02:12 6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:35 17 dispensing units for the 15-milligram and 16:02:35 18 30-milligram combined." 16:02:36 19 Do you see where it says that? 16:02:37 20 What the time period is? 16:03:35 4. No, I do not. 16:03:36 4. No, I do not. 16:03:37 Q. Okay. And so looking at this, 16:03:37 Q. Okay. And so looking at this, 16:03:39 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 the averages are the average pharmacy 16:02:28 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 Do you see where it says that? 16:02:36 20 A. Oxy 5 milligram. 16:04:00
6 we've received a little bit earlier, it looks 16:02:13 7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 9 on to someone; is that correct? 16:02:20 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 30-milligram combined." 16:02:36 19 Do you see where it says that? 16:02:37 6 A. No, I do not. 16:03:36 7 Q. Okay. And so looking at this, 16:03:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 the averages are the average pharmacy 16:02:28 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 Do you see where it says that? 16:02:36 19 included that are not included here? 16:04:00 20 A. Yes. 16:02:37 20 A. Oxy 5 milligram. 16:04:02
7 like sometimes you acted proactively and 16:02:15 8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 30-milligram combined." 16:02:36 19 Do you see where it says that? 16:02:37 7 Q. Okay. And so looking at this, 16:03:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:44 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 the averages are the average pharmacy 16:02:28 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Yes. 16:02:37 20 A. Oxy 5 milligram. 16:04:02
8 crunched numbers in a way and would pass that 16:02:17 9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:28 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 Oyou see where it says that? 16:02:36 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:02:37 8 it looks like it's oxy 15 and oxy 30, 16:03:39 9 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
9 on to someone; is that correct? 16:02:19 10 A. Correct. 16:02:20 10 A. Yes. 16:03:44 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:26 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 30-milligram combined." 16:02:36 19 Do you see where it says that? 16:02:37 9 according to your e-mail here; is that right? 16:03:42 10 A. Yes. 16:03:44 11 Q. Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 Do you see where it says that? 16:02:36 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
10 A. Correct. 16:02:20 11 MR. O'CONNOR: Objection. 16:02:21 12 QUESTIONS BY MS. HERZFELD: 16:02:22 13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:26 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:35 18 30-milligram combined." 16:02:36 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:02:37 10 A. Yes. 16:03:44 21 purchasing from two or more distributors; is 16:03:47 22 purchasing from two or more distributors; is 16:03:47 23 that right? 16:03:49 24 A. Yes. 16:03:49 25 Q. Okay. And it says, "I will ask 16:03:51 26 if they can expand the report to include all 16:03:54 27 oxy sales." 16:03:56 28 What other oxy sales would be 16:03:58 29 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
MR. O'CONNOR: Objection. 16:02:21 QUESTIONS BY MS. HERZFELD: 16:02:22 Q. Okay. So looking at this 16:02:23 that right? 16:03:49 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:26 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 30-milligram combined." 16:02:35 19 Do you see where it says that? 16:02:36 10 Okay. And it's for pharmacies 16:03:45 12 purchasing from two or more distributors; is 16:03:47 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Yes. 16:02:37 20 A. Oxy 5 milligram. 16:04:02
QUESTIONS BY MS. HERZFELD: 16:02:22 Q. Okay. So looking at this 16:02:23 13 that right? 16:03:49 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:26 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 30-milligram combined." 16:02:35 19 Do you see where it says that? 16:02:37 12 purchasing from two or more distributors; is 16:03:47 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
13 Q. Okay. So looking at this 16:02:23 14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:26 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 30-milligram combined." 16:02:35 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:02:37 13 that right? 16:03:49 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
14 e-mail, it says, "Based on the report we get 16:02:24 15 for suspicious order monitoring, below are 16:02:26 16 the averages are the average pharmacy 16:02:28 17 dispensing units for the 15-milligram and 16:02:32 18 30-milligram combined." 16:02:35 19 Do you see where it says that? 16:02:36 20 A. Yes. 16:02:37 14 A. Yes. 16:03:49 15 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
for suspicious order monitoring, below are 16:02:26 the averages are the average pharmacy 16:02:28 dispensing units for the 15-milligram and 16:02:32 30-milligram combined." 16:02:35 Do you see where it says that? 16:02:36 Do you see where it says that? 16:02:37 20 A. Yes. 16:02:37 Q. Okay. And it says, "I will ask 16:03:51 16 if they can expand the report to include all 16:03:54 17 oxy sales." 16:03:56 18 What other oxy sales would be 16:03:58 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
the averages are the average pharmacy 16:02:28 the averages are the average pharmacy 16:02:28 dispensing units for the 15-milligram and 16:02:32 to average sum of the unit of the u
17 dispensing units for the 15-milligram and 16:02:32 17 oxy sales." 16:03:56 18 30-milligram combined." 16:02:35 18 What other oxy sales would be 16:03:58 19 Do you see where it says that? 16:02:36 19 included that are not included here? 16:04:00 20 A. Yes. 16:02:37 20 A. Oxy 5 milligram. 16:04:02
18 30-milligram combined." 16:02:35 18 What other oxy sales would be 16:03:58 19 Do you see where it says that? 16:02:36 19 included that are not included here? 16:04:00 20 A. Yes. 16:02:37 20 A. Oxy 5 milligram. 16:04:02
Do you see where it says that? 16:02:36 A. Yes. 16:02:37 19 included that are not included here? 16:04:00 20 A. Oxy 5 milligram. 16:04:02
20 A. Yes. 16:02:37 20 A. Oxy 5 milligram. 16:04:02
21 Q. Okay. And then kind of moving 16:02:38 21 Q. Okay. Is that what you're 16:04:04
22 forward, it says, "By any standard it appears 16:02:40 22 referring to that's excluded? 16:04:05
,,-,,,
23 5.000 tablets is too low." 16:02:42 23 A. Yes. 16:04:06
23 5,000 tablets is too low." 16:02:42 23 A. Yes. 16:04:06 24 What did you mean by that? 16:02:44 24 Q. Okay. "And so by any standard 16:04:07 25 A. When I'm looking at this, the 16:02:45 25 it appears that 5,000 tablets is too low." 16:04:11

	<i>5</i> 1		
	Page 282		Page 284
1	So do you know what the goal 16:04:14	1	Do you have any specific 16:05:36
2	was of this chart? 16:04:15	2	knowledge of communicating with him about 16:05:36
3	MR. O'CONNOR: Objection to 16:04:18	3	suspicious order monitoring target numbers? 16:05:38
4	form. 16:04:19	4	A. Well, this relates to a 16:05:39
5	THE WITNESS: I don't recall. 16:04:19	5	suspicious order monitoring report that we 16:05:44
6	QUESTIONS BY MS. HERZFELD: 16:04:20	6	received. 16:05:46
7	Q. Okay. And you said before I 16:04:20	7	Q. Okay. 16:05:46
8	think you said something about setting 16:04:21	8	A. And so it's referring to 16:05:46
9	standards. 16:04:23	9	dispensing units. 16:05:48
10	What did you mean by that? 16:04:23	10	Q. Okay. 16:05:49
11	A. Setting standards on it says 16:04:25	11	A. When I'm looking at sales, I'm 16:05:49
12	"by any standard." I don't know what 16:04:28	12	not looking at dispensing units. I'm usually 16:05:53
13	standard they were looking for, but it says 16:04:30	13	look at dollars 16:05:55
14	in here looking at if they're looking at 16:04:31	14	Q. Okay. 16:05:56
15	5,000 to make that a benchmark, that's below 16:04:34	15	A and units sold to 16:05:56
16	most of these numbers. 16:04:37	16	wholesalers 16:05:57
17	Q. Okay. And when you say 16:04:38	17	Q. Okay. 16:05:58 A and distributors. 16:05:58
18	"benchmark," I guess I'm trying to figure out 16:04:39 a benchmark for what. A benchmark for sales? 16:04:42	18	
19		19	Q. Okay. So based on that, you 16:06:00
20		20	think this is based on suspicious order 16:06:01 monitoring levels? 16:06:02
21	Q. Target sales? 16:04:46 A. I have no idea. I don't know 16:04:48	21	monitoring levels? 16:06:02 MR. O'CONNOR: Object to form. 16:06:05
23	if this is in relation to setting any the 16:04:49 suspicious order monitoring baseline to 16:04:52	23	THE WITNESS: I cannot say 16:06:07 definitively, yes, it is. That would 16:06:08
25	trigger part of their algorithms. Because 16:04:54	25	definitively, yes, it is. That would 16:06:08 be drawing a conclusion, and I don't 16:06:11
23	trigger part of their argorithms. Because 10.04.54	25	be drawing a conclusion, and I don't 10.00.11
	Page 283		Page 285
1	they were looking at changing how they were 16:04:56	1	know, and I don't recollect. 16:06:12
2	doing their algorithms, so it could have been 16:04:58	2	QUESTIONS BY MS. HERZFELD: 16:06:13
3	part of that. It could have been part of 16:04:59	3	Q. Okay. But if you had to guess, 16:06:14
4	sales. It could have been anything. 16:05:01	4	do you think that's what it is? 16:06:17
5	Q. Okay. And Michael Gunning, 16:05:02	5	MR. O'CONNOR: Objection to 16:06:18
6	what did you typically communicate with him 16:05:04	6	form. 16:06:19
7	about? Was it suspicious order monitoring or 16:05:06	7	THE WITNESS: I would think 16:06:20
8	sales? 16:05:08	8	that it might have something to do 16:06:21
9	A. Typically I would communicate 16:05:09	9	with that. 16:06:22
10	with him about forecast and employee issues. 16:05:11	10	QUESTIONS BY MS. HERZFELD: 16:06:23
11	Q. Forecast and employee issues. 16:05:15	11	Q. Okay. Very good. 16:06:23
12	Okay. 16:05:15	12	Looking at this, it says on 16:06:24
13	So when you say "forecast," 16:05:15	13	state average, right? California average, 16:06:30
14	that would be sales; is that right? 16:05:17	14	Florida average, Georgia average; is that 16:06:32
15	A. Yes. 16:05:18	15	right? 16:06:34
16	Q. Okay. So if you were sending 16:05:19	16	A. Yes. 16:06:34
17	something to Michael Gunning in your 16:05:21	17	Q. Okay. And do you know if those 16:06:35
18	position, and typically you dealt with him 16:05:24	18	are pharmacy-level oxy units per month? 16:06:36
19	about sales, it's likely that this chart here 16:05:26	19	MR. O'CONNOR: Objection to 16:06:39
20	would have to do with sales; is that right? 16:05:29	20	form. 16:06:41
21	MR. O'CONNOR: Objection. 16:05:31 Form. 16:05:32	21	THE WITNESS: There's no way to 16:06:41
22		22	tell without some context. 16:06:42 QUESTIONS BY MS. HERZFELD: 16:06:43
23	THE WITNESS: That's a reach. 16:05:32 QUESTIONS BY MS. HERZFELD: 16:05:34	23	QUESTIONS BY MS. HERZFELD: 16:06:43 Q. Okay. And it says, 16:06:43
25			
	O That's a reach Okay 16:05:34	2 5	"Tennessee's average here is 14 100 tablets": 16.06.44
	Q. That's a reach. Okay. 16:05:34	25	"Tennessee's average here is 14,100 tablets"; 16:06:44

	Page 286		Page 288
1	is that correct? 16:06:51	1	
2	A. Yes. 16:06:51	2	concentration, in that area, and so there's 16:08:10
3	Q. Okay. And could you tell from 16:06:51	3	more people coming to that pharmacy or that 16:08:12
4	that, from this chart, if Tennessee was 16:06:52	4	area because it's a higher population and it 16:08:14
5	considered high or low? 16:06:56	5	borders on other states. 16:08:16
6	MR. O'CONNOR: Objection to 16:06:57	6	Q. Okay. And so you've just given 16:08:17
7	form. 16:06:57	7	two different examples of information that 16:08:19
8	THE WITNESS: I cannot tell 16:06:58	8	you don't know when assessing the number of 16:08:22
9	that because I wouldn't know what the 16:06:58	9	oxy that are going to a particular area. 16:08:25
10	medical needs or the population was of 16:07:03	10	Why did you choose those two? 16:08:28
11	Tennessee 16:07:05	11	A. Those are the first two that 16:08:30
12	QUESTIONS BY MS. HERZFELD: 16:07:06	12	come to mind. 16:08:33
13	Q. Okay. 16:07:06	13	Q. Okay. And where did you 16:08:33
14	A so I wouldn't know that. 16:07:07	14	where did you develop that knowledge of 16:08:35
15	Q. And are those things that are 16:07:08	15	things you should look for in oxy 16:08:36
16	important for you to determine if someone's 16:07:09	16	prescriptions going to a specific area? 16:08:39
17	oxy numbers are high or low, is 16:07:11	17	MR. O'CONNOR: Objection to 16:08:40
18	population or what was the other thing you 16:07:16	18	form. 16:08:41
19	said? 16:07:17	19	THE WITNESS: I didn't develop 16:08:41
20	A. Or medical needs. 16:07:17	20	that knowledge. You asked me a 16:08:42
21	Q. Medical needs? 16:07:18	21	question, and I responded to your 16:08:44
22	MR. O'CONNOR: Objection. 16:07:18	22	question, so with what I would think 16:08:45
23	Form. 16:07:19	23	top of mind. 16:08:47
24	THE WITNESS: I wouldn't have 16:07:19	24	QUESTIONS BY MS. HERZFELD: 16:08:48
25	any way to know that, so I couldn't 16:07:20	25	Q. Okay. So you came up with that 16:08:48
	7.405		
	Page 287		Page 289
1	Page 287 use that in any decision-making 16:07:23	1	Page 289 information on your own. You didn't have 16:08:50
1 2	_	1 2	
	use that in any decision-making 16:07:23		information on your own. You didn't have 16:08:50
2	use that in any decision-making 16:07:23 anyway. 16:07:24	2	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52
2	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25	2	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55
2 3 4	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25	2 3 4	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57
2 3 4 5	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27	2 3 4 5	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57
2 3 4 5 6	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29	2 3 4 5 6	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58
2 3 4 5 6 7	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30	2 3 4 5 6 7	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58
2 3 4 5 6 7 8	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31	2 3 4 5 6 7 8	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58
2 3 4 5 6 7 8	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31	2 3 4 5 6 7 8	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:58
2 3 4 5 6 7 8 9	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35	2 3 4 5 6 7 8 9	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:58 Q. Okay. Do you recall ever being 16:08:59
2 3 4 5 6 7 8 9 10	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37	2 3 4 5 6 7 8 9 10	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:58 Q. Okay. Do you recall ever being 16:08:59 in a suspicious order monitoring team meeting 16:09:00
2 3 4 5 6 7 8 9 10 11 12	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38	2 3 4 5 6 7 8 9 10 11	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:58 Q. Okay. Do you recall ever being 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03
2 3 4 5 6 7 8 9 10 11 12 13	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39	2 3 4 5 6 7 8 9 10 11 12 13	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:58 Q. Okay. Do you recall ever being 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09
2 3 4 5 6 7 8 9 10 11 12 13 14	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43	2 3 4 5 6 7 8 9 10 11 12 13	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44	2 3 4 5 6 7 8 9 10 11 12 13 14	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:58 Q. Okay. Do you recall ever being 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 A. Oh. It wouldn't help because I 16:07:44	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 A. Oh. It wouldn't help because I 16:07:44 have no idea why the prescriptions are being 16:07:46	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:16 Q. Okay. 16:09:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 A. Oh. It wouldn't help because I 16:07:44 have no idea why the prescriptions are being 16:07:46 dispensed or being written for, so I cannot 16:07:49	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:16 Q. Okay. 16:09:17 A. I do remember that discussion. 16:09:17
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 A. Oh. It wouldn't help because I 16:07:44 have no idea why the prescriptions are being 16:07:46 dispensed or being written for, so I cannot 16:07:49 make a judgment on somebody's medical 16:07:51 condition that I do not know and that I have 16:07:54	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:17 Q. Okay. And what types of things 16:09:19 were discussed in relation to Florida? 16:09:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 A. Oh. It wouldn't help because I 16:07:44 have no idea why the prescriptions are being 16:07:46 dispensed or being written for, so I cannot 16:07:49 make a judgment on somebody's medical 16:07:51 condition that I do not know and that I have 16:07:54 not seen come into a pharmacy. I'm not there 16:07:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:17 Q. Okay. 16:09:17 A. I do remember that discussion. 16:09:17 Q. Okay. And what types of things 16:09:19 were discussed in relation to Florida? 16:09:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 have no idea why the prescriptions are being 16:07:46 dispensed or being written for, so I cannot 16:07:49 make a judgment on somebody's medical 16:07:51 condition that I do not know and that I have 16:07:55 physically in a pharmacy, so I have no idea 16:07:58	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:17 Q. Okay. 16:09:17 Q. Okay. And what types of things 16:09:19 were discussed in relation to Florida? 16:09:24 pain clinics and that they hadn't implemented 16:09:26
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 have no idea why the prescriptions are being 16:07:46 dispensed or being written for, so I cannot 16:07:49 make a judgment on somebody's medical 16:07:54 not seen come into a pharmacy. I'm not there 16:07:55 physically in a pharmacy, so I have no idea 16:07:58	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	information on your own. You didn't have that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:16 Q. Okay. 16:09:17 A. I do remember that discussion. 16:09:17 Q. Okay. And what types of things 16:09:19 were discussed in relation to Florida? 16:09:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	use that in any decision-making 16:07:23 anyway. 16:07:24 QUESTIONS BY MS. HERZFELD: 16:07:25 Q. Okay. But is that some is 16:07:25 that information you would like to know, the 16:07:27 population of a particular area? 16:07:29 MR. O'CONNOR: Objection to 16:07:30 form. 16:07:31 THE WITNESS: It wouldn't help, 16:07:31 so, no, I wouldn't need to know that. 16:07:35 QUESTIONS BY MS. HERZFELD: 16:07:37 Q. Okay. It wouldn't help what? 16:07:38 A. I'm sorry. It wouldn't help 16:07:39 why? 16:07:43 Q. Yes, ma'am. 16:07:44 A. Oh. It wouldn't help because I 16:07:44 have no idea why the prescriptions are being 16:07:46 dispensed or being written for, so I cannot 16:07:49 make a judgment on somebody's medical 16:07:51 condition that I do not know and that I have 16:07:55 physically in a pharmacy, so I have no idea 16:07:58 what's going on in that region. 16:07:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	information on your own. You didn't have 16:08:50 that in a discussion in like a suspicious 16:08:52 order monitoring team meeting or anyplace 16:08:55 else? 16:08:57 MR. O'CONNOR: Objection. 16:08:57 Form. 16:08:58 THE WITNESS: Not that I'm 16:08:58 aware of. 16:08:58 QUESTIONS BY MS. HERZFELD: 16:08:59 in a suspicious order monitoring team meeting 16:09:00 where factors relating to the volume of oxy 16:09:03 prescriptions going to a particular area were 16:09:09 discussed? 16:09:10 A. We had discussions about 16:09:11 Florida. 16:09:17 A. I do remember that discussion. 16:09:17 Q. Okay. And what types of things 16:09:21 A. That Florida had a problem with 16:09:24 pain clinics and that they hadn't implemented 16:09:26 any legislation to shut down the pain 16:09:30

	Page 290		Page 292
1	recall? 16:09:37	1	of things. 16:11:00
2	A. That's all that's all I 16:09:37	2	But did you mean did I do 16:11:00
3	remember. 16:09:39	3	anything at Mallinckrodt, go back to 16:11:02
4	Q. Okay. Do you recall ever being 16:09:39	4	Mallinckrodt and talk to them about the show 16:11:03
5	involved in a conversation with anyone during 16:09:42	5	that I saw? 16:11:04
6	your time at Mallinckrodt where anyone 16:09:43	6	Q. Did you do anything in response 16:11:05
7	mentioned that oxy from Florida were going to 16:09:45	7	to that? Did watching that show or learning 16:11:07
8	Tennessee? 16:09:47	8	that information, did that make you take any 16:11:10
9	MR. O'CONNOR: Objection to 16:09:48	9	steps in your personal or professional life? 16:11:13
10	form. 16:09:49	10	MR. O'CONNOR: Object to form. 16:11:17
11	THE WITNESS: I don't remember 16:09:50	11	THE WITNESS: In my personal or 16:11:20
12	specifically them saying any state. I 16:09:51	12	professional life? 16:11:22
13	do remember them saying they would 16:09:53	13	QUESTIONS BY MS. HERZFELD: 16:11:22
14	come up Highway 95. And I have no 16:09:55	14	Q. Yes, ma'am. 16:11:23
15	idea if that even goes through 16:09:57	15	A. I don't recall if it did. 16:11:23
16	Tennessee or not. 16:09:59	16	Q. Okay. So you thought it was 16:11:24
17	QUESTIONS BY MS. HERZFELD: 16:10:00	17	important to clarify that point, so I just 16:11:25
18	Q. Okay. Could it have been 16:10:00	18	want to 16:11:26
19	Highway 75? 16:10:01	19	A. Okay. 16:11:26
20	MR. O'CONNOR: Objection. 16:10:02	20	Q. I want to be clear, okay? 16:11:27
21	Form. 16:10:02	21	So let's kind of back up, and 16:11:28
22	THE WITNESS: I thought they 16:10:02	22	I'll try to make sure I'm understanding you. 16:11:30
23	said 95, but I don't remember. 16:10:04	23	A. Okay. 16:11:30
24	QUESTIONS BY MS. HERZFELD: 16:10:05	24	Q. So you said you'd seen a show 16:11:33
25	Q. And did you ever hear about a 16:10:05	25	that had talked about somewhere on coal 16:11:34
	D 201		P. 202
	Page 291		Page 293
1	particular problem with oxy in West Virginia 16:10:07	1	mining, problems with OxyContin or oxycodone 16:11:35
2	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10	2	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38
2	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13	2	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41
2 3 4	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14	2 3 4	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42
2 3 4 5	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14	2 3 4 5	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44
2 3 4 5 6	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15	2 3 4 5 6	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44
2 3 4 5 6 7	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17	2 3 4 5 6 7	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44
2 3 4 5 6 7 8	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18	2 3 4 5 6 7 8	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46
2 3 4 5 6 7 8	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19	2 3 4 5 6 7 8	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47
2 3 4 5 6 7 8 9	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20	2 3 4 5 6 7 8 9	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49
2 3 4 5 6 7 8 9 10	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21	2 3 4 5 6 7 8 9 10	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50
2 3 4 5 6 7 8 9 10 11 12	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25	2 3 4 5 6 7 8 9 10 11	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51
2 3 4 5 6 7 8 9 10 11 12 13	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25	2 3 4 5 6 7 8 9 10 11 12 13	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51
2 3 4 5 6 7 8 9 10 11 12 13	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26	2 3 4 5 6 7 8 9 10 11 12 13	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53
2 3 4 5 6 7 8 9 10 11 12 13 14	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:28	2 3 4 5 6 7 8 9 10 11 12 13 14	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55
2 3 4 5 6 7 8 9 10 11 12 13 14 15	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29	2 3 4 5 6 7 8 9 10 11 12 13	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57
2 3 4 5 6 7 8 9 10 11 12 13 14	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:28 A. Yes. 16:10:29 Q. Okay. And did you do anything 16:10:30	2 3 4 5 6 7 8 9 10 11 12 13 14	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59
2 3 4 5 6 7 8 9 10 11 12 13 14 15	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:50 Q. Okay. Do you remember it being 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:28 A. Yes. 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34 Q. Okay. Okay. Marking the next 16:10:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06 Q. Okay. Did you talk to anybody 16:12:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34 Q. Okay. Okay. Marking the next 16:10:36 document here. I'm not sure this one 16:10:51	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06 Q. Okay. Did you talk to anybody 16:12:07 at Mallinckrodt about that show you saw? 16:12:09
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34 Q. Okay. Okay. Marking the next 16:10:36 document here. I'm not sure this one 16:10:51 A. I think but wait a minute. 16:10:54	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06 Q. Okay. Did you talk to anybody 16:12:07 at Mallinckrodt about that show you saw? 16:12:09 A. No, I did not. 16:12:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34 Q. Okay. Okay. Marking the next 16:10:36 document here. I'm not sure this one 16:10:51	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06 Q. Okay. Did you talk to anybody 16:12:07 at Mallinckrodt about that show you saw? 16:12:09
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34 Q. Okay. Okay. Marking the next 16:10:36 document here. I'm not sure this one 16:10:51 A. I think but wait a minute. 16:10:54	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	mining, problems with OxyContin or oxycodone 16:11:35 in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06 Q. Okay. Did you talk to anybody 16:12:07 at Mallinckrodt about that show you saw? 16:12:09 A. No, I did not. 16:12:11
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	particular problem with oxy in West Virginia 16:10:07 or Appalachia region? 16:10:10 MR. O'CONNOR: Objection to 16:10:13 form. 16:10:14 THE WITNESS: I remember seeing 16:10:14 something about there was a problem in 16:10:15 the coal mining town. 16:10:17 QUESTIONS BY MS. HERZFELD: 16:10:18 Q. Okay. Do you remember where 16:10:19 you saw that? 16:10:20 A. On I believe it was a news 16:10:21 show. 16:10:25 Q. Okay. And do you think that 16:10:25 was during your time of employment at 16:10:26 Mallinckrodt? 16:10:28 A. Yes. 16:10:29 Q. Okay. And did you do anything 16:10:30 in response to learning that information? 16:10:32 A. No. 16:10:34 Q. Okay. Okay. Marking the next 16:10:51 A. I think but wait a minute. 16:10:54 I think I should clarify. What did you mean, 16:10:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	mining, problems with OxyContin or oxycodone in a coal mining area, in a coal mining town. 16:11:38 Am I right on that? 16:11:41 MR. O'CONNOR: Objection to the 16:11:42 form. 16:11:44 THE WITNESS: I don't remember 16:11:44 about it being any specific products. 16:11:44 I remember that there was a problem in 16:11:46 coal mining towns with drug abuse. 16:11:47 QUESTIONS BY MS. HERZFELD: 16:11:49 Q. Okay. Do you remember it being 16:11:50 opioid abuse? 16:11:51 A. I don't remember. 16:11:51 Q. Okay. And so based on that 16:11:53 show that you saw at the time that you were 16:11:55 employed at Mallinckrodt, did you take any 16:11:57 steps in your job at Mallinckrodt to focus on 16:11:59 coal mining areas? 16:12:04 A. No, I did not. 16:12:06 Q. Okay. Did you talk to anybody 16:12:07 at Mallinckrodt about that show you saw? 16:12:09 A. No, I did not. 16:12:11 Q. Did you send any e-mails? 16:12:11

	Page 294		Page 296
1	of your position in the suspicious order 16:12:15	1	8
2	monitoring team to monitor coal mining areas 16:12:18	2	A. Not that I recall. 16:14:12
3	for prescription abuse? 16:12:21	3	Q. Okay. Very good. Moving on. 16:14:13
4	MS. HERZFELD: Objection to 16:12:22	4	Okay. And I think before, we 16:14:18
5	form. 16:12:23	5	talked about you were involved in the 16:14:23
6	THE WITNESS: My role in the 16:12:23	6	indirect customer review subteam; is that 16:14:26
7	suspicious order monitoring team was 16:12:25	7	correct? 16:14:29
8	peripheral. I was not part of the 16:12:27	8	MR. O'CONNOR: Objection to 16:14:29
9	core team that established the policy 16:12:28	9	form. 16:14:30
10	or understood the government acts. 16:12:30	10	THE WITNESS: Yes. 16:14:30
11	QUESTIONS BY MS. HERZFELD: 16:12:33	11	QUESTIONS BY MS. HERZFELD: 16:14:31
12	Q. Okay. My question is: Did you 16:12:33	12	Q. Okay. And what did the 16:14:31
13	take any steps in your role as being even on 16:12:34	13	indirect customer review subteam do? 16:14:33
14	the periphery of the suspicious order 16:12:37	14	A. That was the team that which 16:14:36
15	monitoring team to monitor coal mining areas 16:12:39	15	we were providing additional information 16:14:40
16	for prescription abuse? 16:12:41	16	about chargebacks, if they wanted to know how 16:14:41
17	A. No. 16:12:43	17	were chargebacks run or generated. 16:14:44
18	Q. Okay. What about in your 16:12:44	18	Q. Okay. And you were providing 16:14:46
19	personal life? Did you send anybody an 16:12:46	19	that information to whom? 16:14:50
20	e-mail about, "Hey, I saw this show"? 16:12:48	20	A. To the suspicious order 16:14:52
21	A. No. 16:12:51	21	monitoring team. 16:14:55
22	Q. Okay. Did you have any 16:12:51	22	Q. And that would be the core 16:14:56
23	discussions with anybody about the show? 16:12:52	23	folks on that team? 16:14:58
24	A. Not that I recall. 16:12:54	24	A. Correct. 16:14:59
25	Q. Okay. Did you take any steps 16:12:55	25	Q. Okay. So you were kind of the 16:15:00
	Page 295		Page 297
1	because you saw that show? 16:12:57	1	number crunchers explaining things to the 16:15:01
1 2	because you saw that show? 16:12:57 A. Not that I recall. 16:12:58	1 2	number crunchers explaining things to the 16:15:01 team that was the core part of the suspicious 16:15:04
	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01		team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06
2	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03	2	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06
2	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06	2	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08
2 3 4	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08	2 3 4	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08
2 3 4 5	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10	2 3 4 5	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09
2 3 4 5 6	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10	2 3 4 5 6	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09
2 3 4 5 6 7 8	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20	2 3 4 5 6 7 8	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12
2 3 4 5 6 7 8 9	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20	2 3 4 5 6 7 8 9	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14
2 3 4 5 6 7 8 9 10	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:29 QUESTIONS BY MS. HERZFELD: 16:13:29	2 3 4 5 6 7 8 9 10	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15
2 3 4 5 6 7 8 9 10 11	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42	2 3 4 5 6 7 8 9 10 11	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29
2 3 4 5 6 7 8 9 10 11 12 13	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44	2 3 4 5 6 7 8 9 10 11 12 13	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29
2 3 4 5 6 7 8 9 10 11 12 13	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44	2 3 4 5 6 7 8 9 10 11 12 13	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47	2 3 4 5 6 7 8 9 10 11 12 13 14 15	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:42 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:53	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37 two different documents, but I will submit to 16:15:38
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Not that I recall. Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:53 are core members of the SOM team, this was 16:13:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:42 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:57 the meeting and they were this was the 16:13:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41 is an attachment to the e-mail. Okay? Just 16:15:42
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Not that I recall. 16:12:58 Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:42 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:57 the meeting and they were this was the 16:13:59 agenda for the meeting. 16:14:01	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41 is an attachment to the e-mail. Okay? Just 16:15:42 so everybody knows what I'm doing here. 16:15:44
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Not that I recall. Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:53 are core members of the SOM team, this was 16:13:57 the meeting and they were this was the 16:13:59 agenda for the meeting. 16:14:01 Q. Okay. And this would have been 16:14:02	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41 is an attachment to the e-mail. Okay? Just 16:15:42 so everybody knows what I'm doing here. 16:15:44 MS. HERZFELD: The e-mail is 16:15:55
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Not that I recall. Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:57 the meeting and they were this was the 16:13:59 agenda for the meeting. 16:14:01 Q. Okay. And this would have been 16:14:02 for the core team, not for people on the 16:14:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41 is an attachment to the e-mail. Okay? Just 16:15:42 so everybody knows what I'm doing here. 16:15:44 MS. HERZFELD: The e-mail is 16:15:55 MNK-T1_0007251678. 16:15:56
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Not that I recall. Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:29 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:57 the meeting and they were this was the 16:13:59 agenda for the meeting. 16:14:01 Q. Okay. And this would have been 16:14:02 for the core team, not for people on the 16:14:03	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41 is an attachment to the e-mail. Okay? Just 16:15:42 so everybody knows what I'm doing here. 16:15:44 MS. HERZFELD: The e-mail is 16:15:55 MNK-T1_0007251678. 16:15:56 And we're separately going to 16:16:14
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Not that I recall. Q. Okay. So we're moving on to 16:13:01 the next document here. This one may already 16:13:03 be an exhibit. I'm not 100 percent positive, 16:13:06 so I apologize if I'm doubling up. 16:13:08 (Mallinckrodt-Collier Exhibit 16:13:10 39 marked for identification.) 16:13:10 MS. HERZFELD: For those on the 16:13:20 phone, it's MNK_TNSTA05296154. 16:13:20 QUESTIONS BY MS. HERZFELD: 16:13:42 Q. Do you recognize this document, 16:13:42 ma'am? 16:13:44 A. No, I do not. 16:13:44 Q. Okay. What does it appear to 16:13:47 be? 16:13:53 A. It appears that the people that 16:13:53 are core members of the SOM team, this was 16:13:57 the meeting and they were this was the 16:13:59 agenda for the meeting. 16:14:01 Q. Okay. And this would have been 16:14:02 for the core team, not for people on the 16:14:03 periphery? 16:14:06	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	team that was the core part of the suspicious 16:15:04 order monitoring team? 16:15:06 MR. O'CONNOR: Objection to 16:15:06 form. 16:15:08 THE WITNESS: Correct. 16:15:08 QUESTIONS BY MS. HERZFELD: 16:15:09 Q. Okay. And do you know who else 16:15:09 was a member of the indirect customer review 16:15:12 subteam? 16:15:14 A. I don't recall. 16:15:15 Q. Okay. 16:15:29 (Mallinckrodt-Collier Exhibits 16:15:29 40 and 41 marked for identification.) 16:15:37 QUESTIONS BY MR. GOTTO: 16:15:37 Q. Okay. I'm going to hand you 16:15:37 two different documents, but I will submit to 16:15:38 you that one is an e-mail and the other one 16:15:41 is an attachment to the e-mail. Okay? Just 16:15:42 so everybody knows what I'm doing here. 16:15:44 MS. HERZFELD: The e-mail is 16:15:55 MNK-T1_0007251678. 16:15:56 And we're separately going to 16:16:14

	P. 2 00		D 200
	Page 298		Page 300
1	QUESTIONS BY MS. HERZFELD: 16:16:49 Q. Okay. If you'll take a look at 16:16:49	1 2	A. Yes. 16:18:31
2	Q. Okay. If you'll take a look at 16:16:49 the e-mail for me, please, ma'am, Exhibit 40. 16:16:51		Q. Okay. And if you'll turn with 16:18:31
3	This appears to be an e-mail 16:16:58		me then to the attachment, the one that ended 16:18:33
5	from Debbie Digby to Karen Harper, you and 16:16:59	4 5	Bates number 1679 on the top. 16:18:37
6	some other folks; is that correct? 16:17:03	6	Okay. Now looking at the top 16:18:40 of this it says, "Customer sourcing oxy 15 16:18:49
7	A. Correct. 16:17:05	7	and 30 from more than two distributors." 16:18:52
8	Q. Okay. And the subject is 16:17:06	8	Did I read that correctly? 16:18:55
9	"forward April indirect suspicious order 16:17:09	9	A. Yes. 16:18:57
10	monitoring reports." 16:17:11	10	Q. Right there. Yeah, and right 16:18:58
11	Did I read that correctly? 16:17:12		here at the top, if you look right there. 16:18:59
12	A. Yes. 16:17:13	12	A. It says, "Customer sourcing oxy 16:19:01
13	Q. Okay. And then the date it was 16:17:14	13	A. It says, Customer sourcing oxy 16.19.01 15, 30 from all distributors." 16:19:05
14	sent was May 31, 2011; is that right? 16:17:16	14	Q. Oh, you're right. It does. 16:19:06
15	A. Correct. 16:17:18		That is correct. 16:19:07
16	Q. Okay. And on I think we 16:17:19	16	Did you create this document? 16:19:08
17	already talked about who Debbie Digby was. 16:17:22	17	A. No, I did not. 16:19:09
18	Karen Harper has been discussed. 16:17:25	18	Q. Okay. And were you responsible 16:19:11
19	Who is Suzanne Pea? 16:17:27		for maintaining it? 16:19:12
20	A. I believe Suzanne Pea was 16:17:30	20	A. No, I was not. 16:19:13
21	involved in chargebacks. 16:17:37	21	Q. Okay. Did you use the 16:19:14
22	Q. Okay. Was there a specific 16:17:38	22	information that was contained within this 16:19:16
23	department for chargebacks? 16:17:39		document to assist you with your to assist 16:19:20
24	A. There was a contract admin 16:17:40		you with your job duties? 16:19:25
25	team. 16:17:42	25	A. No, I did not. 16:19:27
	10.17.12		A. 10,1 did not. 10.17.27
	Page 299		Page 301
	1 450 255		
1	Q. Okay. 16:17:42	1	Q. Okay. And why did you receive 16:19:28
1 2	Q. Okay. 16:17:42 A. Contract administration. 16:17:42		Q. Okay. And why did you receive 16:19:28 this information? 16:19:29
	Q. Okay. 16:17:42A. Contract administration. 16:17:42Q. And do you know who was part of 16:17:44	2 3	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30
2	Q. Okay. 16:17:42 A. Contract administration. 16:17:42	2 3	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33
2 3	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47	2 3 4 5	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34
2 3 4	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53	2 3 4 5	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36
2 3 4 5	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56	2 3 4 5	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38
2 3 4 5 6	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57	2 3 4 5 6	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36
2 3 4 5 6 7	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56	2 3 4 5 6	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39
2 3 4 5 6 7 8	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59	2 3 4 5 6 7 8 9	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41
2 3 4 5 6 7 8	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00	2 3 4 5 6 7 8 9 10	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45
2 3 4 5 6 7 8 9	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02	2 3 4 5 6 7 8 9	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46
2 3 4 5 6 7 8 9 10	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06	2 3 4 5 6 7 8 9 10	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47
2 3 4 5 6 7 8 9 10 11	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07	2 3 4 5 6 7 8 9 10 11	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:18	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55 information at some point. They would share 16:19:57
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:18 distributors; two, state concentration 16:18:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:57 that information with me. 16:19:58
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:18 distributors; two, state concentration 16:18:21 report; and three, summary report by 16:18:23	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55 information at some point. They would share 16:19:57 that information with me. 16:19:58 I also was part of the 16:19:59
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:18 distributors; two, state concentration 16:18:21	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55 information at some point. They would share 16:19:57 that information with me. 16:19:58 I also was part of the 16:19:59 peripheral that helped them understand 16:20:01
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:21 report; and three, summary report by 16:18:23 distributor compared to all products 16:18:25 distributed, one for oxy and one for hydro 16:18:25	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55 information at some point. They would share 16:19:57 that information with me. 16:19:59 peripheral that helped them understand 16:20:01 chargebacks, and so it may have been that 16:20:04
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:18 distributors; two, state concentration 16:18:21 report; and three, summary report by 16:18:23 distributor compared to all products 16:18:25 distributed, one for oxy and one for hydro 16:18:27 APAP. 16:18:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55 information at some point. They would share 16:19:57 that information with me. 16:19:58 I also was part of the 16:19:59 peripheral that helped them understand 16:20:01 chargebacks, and so it may have been that 16:20:04 they need me to have knowledge of this report 16:20:06
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. 16:17:42 A. Contract administration. 16:17:42 Q. And do you know who was part of 16:17:44 that team? 16:17:47 A. Carol actually was. I thought 16:17:47 she was customer service, but she was part of 16:17:53 the contract administration team. 16:17:56 Q. Okay. Do you recall anybody 16:17:57 else who was a member of that team? 16:17:58 A. No. 16:17:59 Q. Okay. And so here it looks 16:18:00 like "all attached are the April monthly SOM 16:18:02 reports." 16:18:06 SOM there stands for suspicious 16:18:07 order monitoring; is that right? 16:18:13 A. Yes. 16:18:13 Q. And then it looks like there's 16:18:13 customer service or I'm sorry. Number one 16:18:16 is customer sourcing of greater than two 16:18:21 report; and three, summary report by 16:18:23 distributor compared to all products 16:18:25 distributed, one for oxy and one for hydro 16:18:25	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Okay. And why did you receive 16:19:28 this information? 16:19:29 A. Just so I had general 16:19:30 knowledge. 16:19:33 Q. Okay. And why was it important 16:19:34 for you to have general knowledge? 16:19:36 MR. O'CONNOR: Objection to 16:19:38 form. 16:19:38 THE WITNESS: Most items that 16:19:39 affected the customers or the 16:19:41 products, I was part of the 16:19:45 information trail. 16:19:46 QUESTIONS BY MS. HERZFELD: 16:19:47 Q. Okay. And what do you mean, 16:19:47 "information trail"? 16:19:49 A. If there was any communication 16:19:49 about the customers or the products, so that 16:19:51 I wouldn't be blindsided, I would have that 16:19:55 information at some point. They would share 16:19:57 that information with me. 16:19:59 peripheral that helped them understand 16:20:01 chargebacks, and so it may have been that 16:20:04

	Page 302		Page 304
1	But I was at that point no 16:20:10	1	A. Not within my group, it was 16:21:32
2	longer involved in doing any assistance on 16:20:12	2	not. 16:21:35
3	this level. This was Debbie. 16:20:14	3	Q. Okay. But you're familiar with 16:21:35
4	Q. Okay. When you say "assistance 16:20:17	4	how to read chargeback data; is that correct, 16:21:36
5	on this level," what do you mean? 16:20:19	5	ma'am? 16:21:41
6	A. Running these types of reports. 16:20:20	6	A. It is not my expertise, but I 16:21:41
7	Q. Okay. Debbie was doing that? 16:20:22	7	am familiar with it, yes. 16:21:43
8	A. Yes. 16:20:23	8	Q. Okay. So if you'll switch with 16:21:44
9	Q. Okay. And what was Debbie's 16:20:23	9	me to the I'm sorry, there's no page 16:21:45
10	position? 16:20:25	10	numbers here. 16:21:47
11	A. She was a senior analyst. 16:20:25	11	A. You can give me the line number 16:21:49
12	Q. Okay. And so if you were 16:20:28	12	on the left. 16:21:51
13	forwarded these reports, would you read them 16:20:30	13	Q. 2352 is the very bottom. This 16:21:52
14	and crunch the numbers? 16:20:32	14	one, actually, believe it or not, says 16:22:00
15	MR. O'CONNOR: Objection to 16:20:34	15	page 1. Right here it says page 1. Yep, 16:22:02
16	form. 16:20:35	16	right there. 16:22:04
17	THE WITNESS: I have no idea 16:20:36	17	A. Here? Okay. 16:22:04
18	what I'd do with them, if I ever did 16:20:38	18	Q. Yep. 16:22:05
19	that. 16:20:41	19	Okay. Do you see where I'm at? 16:22:06
20	QUESTIONS BY MS. HERZFELD: 16:20:41	20	A. Yes. 16:22:07
21	Q. Okay. Do you know if someone 16:20:42	21	Q. Okay. So I will represent to 16:22:08
22	was responsible for looking at these reports 16:20:42	22	you that we've sorted this database that 16:22:11
23	to make a determination if an order appeared 16:20:44	23	we've received, this spreadsheet by 16:22:13
24	suspicious? 16:20:47	24	Tennessee, so I would let you know that this 16:22:15
25	A. That would be suspicious order 16:20:47	25	has been sorted by Tennessee. 16:22:17
23	A. That would be suspicious order 10.20.47	23	has been softed by Tellnessee. 10.22.17
	Page 303		Page 305
1	monitoring team. 16:20:52	1	Okay? 16:22:18
2	Q. Okay. And so nobody ever told 16:20:52	2	A. Okay. 16:22:19
3	you the purpose as to why you received this 16:20:54	3	Q. So looking at this, I just want 16:22:19
4	report? 16:20:56	4	to go through and look at some of the numbers 16:22:22
5	A. For information. 16:20:57	5	here for Tennessee to see if I can understand 16:22:24
6		1	here for reinfessee to see if reali understand 10.22.24
1	Q. Okay. And the information that 16:20:59	6	it. 16:22:27
7	Q. Okay. And the information that 16:20:59 I have says you're the custodian of this 16:21:01		
7 8	•	6	it. 16:22:27
	I have says you're the custodian of this 16:21:01	6 7	it. 16:22:27 If you could go with me, 16:22:28
8	I have says you're the custodian of this report. 16:21:01	6 7 8	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42
8	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03	6 7 8 9	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44
8 9 10	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04	6 7 8 9	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48
8 9 10 11	I have says you're the custodian of this 16:21:01 report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07	6 7 8 9 10 11	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51
8 9 10 11 12	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10	6 7 8 9 10 11 12	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50
8 9 10 11 12 13	I have says you're the custodian of this 16:21:01 report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07	6 7 8 9 10 11 12	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53
8 9 10 11 12 13	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17	6 7 8 9 10 11 12 13	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57
8 9 10 11 12 13 14 15	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20	6 7 8 9 10 11 12 13 14	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59
8 9 10 11 12 13 14 15 16	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21	6 7 8 9 10 11 12 13 14 15 16	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59
8 9 10 11 12 13 14 15 16 17	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21	6 7 8 9 10 11 12 13 14 15 16 17	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01
8 9 10 11 12 13 14 15 16 17 18	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21 earlier, that it was after Sunrise 16:21:24	6 7 8 9 10 11 12 13 14 15 16 17 18	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01 Do you know if that's meant to 16:23:06
8 9 10 11 12 13 14 15 16 17 18 19	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21 earlier, that it was after Sunrise 16:21:24 Medical. 16:21:26	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01 Do you know if that's meant to 16:23:06 be dollars or units? 16:23:08
8 9 10 11 12 13 14 15 16 17 18 19 20 21	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21 earlier, that it was after Sunrise 16:21:24 Medical. 16:21:26 QUESTIONS BY MS. HERZFELD: 16:21:26	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01 Do you know if that's meant to 16:23:06 be dollars or units? 16:23:09
8 9 10 11 12 13 14 15 16 17 18 19 20 21	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21 earlier, that it was after Sunrise 16:21:24 Medical. 16:21:26 QUESTIONS BY MS. HERZFELD: 16:21:26	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01 Do you know if that's meant to 16:23:06 be dollars or units? 16:23:08 A. That's dollars. Okay. 16:23:11
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21 earlier, that it was after Sunrise 16:21:24 Medical. 16:21:26 QUESTIONS BY MS. HERZFELD: 16:21:26 before Sunrise Medical; is that correct? 16:21:28	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01 Do you know if that's meant to 16:23:06 be dollars or units? 16:23:08 A. That's dollars. 16:23:09 Q. That's dollars. Okay. 16:23:11 And then it says, "DISP 16:23:12
8 9 10 11 12 13 14 15 16 17 18 19 20 21	I have says you're the custodian of this report. 16:21:03 Do you know why it's in your 16:21:03 custodian file? 16:21:04 A. I have no idea. I don't know 16:21:06 what they meant by that. 16:21:07 Q. Okay. Do you know when 16:21:10 Mallinckrodt began monitoring customers that 16:21:12 sourced from more than one distributor? 16:21:17 MR. O'CONNOR: Objection to the 16:21:20 form. 16:21:21 THE WITNESS: That was stated 16:21:21 earlier, that it was after Sunrise 16:21:24 Medical. 16:21:26 QUESTIONS BY MS. HERZFELD: 16:21:26	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	it. 16:22:27 If you could go with me, 16:22:28 please okay. So the first one on this 16:22:42 spreadsheet appears to be Lowe's Drug in 16:22:44 Maryville, Tennessee; is that correct? 16:22:48 A. Yes. 16:22:50 Q. Okay. And it has a ZIP code 16:22:51 there, and it says that it sold the apparent 16:22:53 customer name Cardinal Health. 16:22:57 Would that be the distributor? 16:22:58 A. Yes. 16:22:59 Q. Okay. And then it says, "gross 16:22:59 sales, 19,934.4." 16:23:01 Do you know if that's meant to 16:23:06 be dollars or units? 16:23:08 A. That's dollars. Okay. 16:23:11

		_	
	Page 306		Page 308
1	Do you know what the dispensing 16:23:19	1	Q. Okay. Did you ever hear of 16:25:02
2	units are here? 16:23:21	2	anybody talking about, "Hey, maybe we should 16:25:03
3	A. That would be tablets. 16:23:21	3	be looking at different population numbers 16:25:06
4	Q. Tablets. Okay. 16:23:22	4	for where pills are going"? 16:25:07
5	And do you happen to know the 16:23:24	5	MR. O'CONNOR: Objection. 16:25:08
6	population of Maryville, Tennessee? 16:23:26	6	THE WITNESS: Not that I'm 16:25:09
7	A. I have no clue. 16:23:28	7	aware of. 16:25:10
8	Q. Okay. And then looking at the 16:23:31	8	QUESTIONS BY MS. HERZFELD: 16:25:10
9	next one, Food City in Knoxville, Tennessee, 16:23:34	9	Q. Okay. At any point in your 16:25:10
10	DBS Trading, that's Masters Pharmaceuticals, 16:23:38	10	time at Mallinckrodt were you trained to 16:25:17
11	and then gross sales there at 8,068 and then 16:23:41	11	recognize various signs of diversion? 16:25:19
12	dispensing units 40,000; is that correct? 16:23:44	12	A. The only thing that we were 16:25:22
13	A. Correct. 16:23:47	13	made aware of is that if there were 16:25:24
14	Q. Okay. And so I guess I want to 16:23:48	14	unusually large orders or peculiar orders. 16:25:26
15	make sure I really understand the chargeback 16:23:50	15	Q. Okay. And how can you tell if 16:25:28
16	data. 16:23:52	16	something is an unusually large order, 16:25:30
17	Gross sales, is that how much 16:23:52	17	according to your training? 16:25:32
18	money Mallinckrodt gets after the chargeback? 16:23:56	18	A. From what I wouldn't have 16:25:34
19	A. That is the sale yes, after 16:24:00	19	visibility to the orders, so I wouldn't know 16:25:37
20	the chargeback, but not including any 16:24:04	20	if something was an unusually large order or 16:25:39
21	rebates, fees, discounts or allowances. 16:24:07	21	suspicious I say "peculiar" only because 16:25:43
22	Q. Okay. Okay. So then if you'll 16:24:10	22	we used the word "peculiar" today. But it 16:25:46
23	go with me the third one that is labeled 225, 16:24:13	23	would be if something was they were 16:25:49
24	Riggs Drugs in La Follette, Tennessee. 16:24:16	24	ordering too frequently, too often, compared 16:25:50
25	Cardinal Health, \$10,855.84, and 38,000 DISP 16:24:19	25	to what they usually did. They were ordering 16:25:52
	Page 307		Page 309
1	_	1	_
1 2	units, dispensing units. 16:24:27	1 2	too much. They were ordering not to the 16:25:54
	units, dispensing units. 16:24:27 Did I read that correctly? 16:24:29		too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58
2	units, dispensing units. 16:24:27 Did I read that correctly? 16:24:29 A. Yes. 16:24:30	2	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00
2 3	units, dispensing units. 16:24:27 Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31	2	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02
2 3 4 5	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33	2 3 4	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03
2 3 4	units, dispensing units. Did I read that correctly? A. Yes. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36	2 3 4 5	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04
2 3 4 5	units, dispensing units. Did I read that correctly? A. Yes. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36 Q. Okay. And do you know if 16:24:38	2 3 4 5 6	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03
2 3 4 5 6 7	units, dispensing units. Did I read that correctly? A. Yes. 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38	2 3 4 5 6 7	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05
2 3 4 5 6 7 8	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41	2 3 4 5 6 7 8	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15
2 3 4 5 6 7 8	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41	2 3 4 5 6 7 8	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17
2 3 4 5 6 7 8 9	units, dispensing units. Did I read that correctly? A. Yes. 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43	2 3 4 5 6 7 8 9	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17
2 3 4 5 6 7 8 9 10	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44	2 3 4 5 6 7 8 9 10	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20
2 3 4 5 6 7 8 9 10 11	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44	2 3 4 5 6 7 8 9 10 11	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22
2 3 4 5 6 7 8 9 10 11 12 13	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45	2 3 4 5 6 7 8 9 10 11 12 13	too much. They were ordering not to the 16:25:54 levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22
2 3 4 5 6 7 8 9 10 11 12 13	units, dispensing units. Did I read that correctly? A. Yes. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:50	2 3 4 5 6 7 8 9 10 11 12 13	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25
2 3 4 5 6 7 8 9 10 11 12 13 14 15	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: 16:24:50 Q. Okay. Was that anything that 16:24:50	2 3 4 5 6 7 8 9 10 11 12 13 14	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	units, dispensing units. Did I read that correctly? A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. QUESTIONS BY MS. HERZFELD: 16:24:50 Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order 16:24:52	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 Q. Okay. And I guess I would have 16:26:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order 16:24:52 monitoring team meeting when you were 16:24:56	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order 16:24:52 monitoring team meeting when you were 16:24:56 present? 16:24:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30 discussion of signs of diversion at the 16:26:32
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	units, dispensing units. Did I read that correctly? 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: 16:24:50 Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order 16:24:52 monitoring team meeting when you were present? 16:24:59 A. Not when I was 16:24:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30 discussion of signs of diversion at the 16:26:32 suspicious order monitoring team meetings. 16:26:35
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	units, dispensing units. Did I read that correctly? A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: 16:24:50 Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order monitoring team meeting when you were present? 16:24:59 A. Not when I was MR. O'CONNOR: Objection. 16:25:00	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30 discussion of signs of diversion at the 16:26:32 suspicious order monitoring team meetings. 16:26:35 Did that not occur? 16:26:36
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	units, dispensing units. Did I read that correctly? A. Yes. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order monitoring team meeting when you were present? 16:24:59 A. Not when I was MR. O'CONNOR: Objection. 16:25:00 Form. 16:25:01	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30 discussion of signs of diversion at the 16:26:32 suspicious order monitoring team meetings. 16:26:35 Did that not occur? 16:26:36 MR. O'CONNOR: Objection to 16:26:37
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	units, dispensing units. Did I read that correctly? A. Yes. 16:24:29 A. Yes. 16:24:30 Q. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? 16:24:33 A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the 16:24:38 population of these various locations? 16:24:41 MR. O'CONNOR: Objection to 16:24:43 form. 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order 16:24:52 monitoring team meeting when you were 16:24:56 present? 16:24:59 MR. O'CONNOR: Objection. 16:25:00 Form. 16:25:01 THE WITNESS: Oh, I'm sorry. 16:25:01	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30 discussion of signs of diversion at the 16:26:32 suspicious order monitoring team meetings. 16:26:35 Did that not occur? 16:26:36 MR. O'CONNOR: Objection to 16:26:37 form. 16:26:38
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	units, dispensing units. Did I read that correctly? A. Yes. Okay. Do you know what the 16:24:31 population is of La Follette, Tennessee? A. No. 16:24:36 Q. Okay. And do you know if 16:24:38 someone was responsible for looking at the MR. O'CONNOR: Objection to 16:24:41 MR. O'CONNOR: Objection to 16:24:44 THE WITNESS: I don't know 16:24:44 anybody that would do that, that would 16:24:45 have time to do that. 16:24:49 QUESTIONS BY MS. HERZFELD: Q. Okay. Was that anything that 16:24:50 was ever discussed in a suspicious order monitoring team meeting when you were present? 16:24:59 A. Not when I was MR. O'CONNOR: Objection. 16:25:00 Form. 16:25:01	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	too much. They were ordering not to the levels that they said they used to purchase. 16:25:58 Q. Okay. And that wasn't within 16:26:00 the purview of your responsibility to look 16:26:02 for those things? 16:26:03 A. Correct. 16:26:04 Q. Okay. Okay. Did they were 16:26:05 you taught while you were at Mallinckrodt of 16:26:13 any other potential signs of diversion other 16:26:15 than frequency, I think you said, and volume? 16:26:17 MR. O'CONNOR: Objection to 16:26:20 form. 16:26:21 THE WITNESS: It wasn't in my 16:26:22 job, so they didn't need to teach me 16:26:25 that. 16:26:28 QUESTIONS BY MS. HERZFELD: 16:26:29 expected perhaps there would have been some 16:26:30 discussion of signs of diversion at the 16:26:32 suspicious order monitoring team meetings. 16:26:35 Did that not occur? 16:26:36 MR. O'CONNOR: Objection to 16:26:37

discussion; otherwise, I wouldn't have 16:26:43 recalled two items. 16:26:45 QUESTIONS BY MS. HERZFELD: 16:26:45 Q. Okay. Do you recall anybody 16:26:46 talking about potential signs of diversion 16:26:47 being a percentage of cash sales? 16:26:50 A. No, I don't recall that. 16:26:53 Q. Okay. What about on a 16:26:56 Q. Okay. What about on a 16:26:59 10 concentration of pharmacies in a particular 16:26:59 11 area that are all high prescribing oxy 16:27:00 2 42 mar 3 QUESTIO 4 Q. OC 5 next exhib 6 MNK-T1 7 look at this 9 Q. Okay. What about on a 16:26:56 9 document? 10 A. No	Page 312 Idallinckrodt-Collier Exhibit 16:29:28 ked for identification.) 16:29:29 NS BY MS. HERZFELD: 16:29:29 Identify the Mark the 16:29:29 Identify the Mark the 16:29:30 NS BY MS. HERZFELD: 16:29:42 Identify the Mark the 16:29:42 Identify the Mark the 16:29:42 Identify the Mark the 16:29:56
discussion; otherwise, I wouldn't have 16:26:43 recalled two items. 16:26:45 QUESTIONS BY MS. HERZFELD: 16:26:45 Q. Okay. Do you recall anybody 16:26:46 talking about potential signs of diversion 16:26:47 being a percentage of cash sales? 16:26:50 A. No, I don't recall that. 16:26:53 Q. Okay. What about on a 16:26:56 Q. Okay. What about on a 16:26:59 10 concentration of pharmacies in a particular 16:26:59 11 area that are all high prescribing oxy 16:27:00 2 42 mar 3 QUESTIO 4 Q. Oc 5 next exhib 6 MNK-T1 7 look at this 9 document? 10 concentration of pharmacies in a particular 16:26:59 10 A. No	ked for identification.) 16:29:29 NS BY MS. HERZFELD: 16:29:29 kay. Okay. We'll mark the 16:29:29 it 42. This is Bates 16:29:30 0007251680. Okay. If you'll take a 16:29:42
3 recalled two items. 16:26:45 4 QUESTIONS BY MS. HERZFELD: 16:26:45 5 Q. Okay. Do you recall anybody 16:26:46 6 talking about potential signs of diversion 16:26:47 7 being a percentage of cash sales? 16:26:50 8 A. No, I don't recall that. 16:26:53 9 Q. Okay. What about on a 16:26:56 9 Q. Okay. What about on a 16:26:59 10 concentration of pharmacies in a particular 16:26:59 11 area that are all high prescribing oxy 16:27:00 11 Q. Ocay.	NS BY MS. HERZFELD: 16:29:29 bkay. Okay. We'll mark the 16:29:29 it 42. This is Bates 16:29:30 0007251680. Okay. If you'll take a 16:29:42
4 QUESTIONS BY MS. HERZFELD: 16:26:45 4 Q. CO 5 Q. Okay. Do you recall anybody 16:26:46 5 next exhib. 6 talking about potential signs of diversion 16:26:47 6 MNK-T1_ 7 being a percentage of cash sales? 16:26:50 7 look at this 8 A. No, I don't recall that. 16:26:53 8 Ok 9 Q. Okay. What about on a 16:26:56 9 document? 10 concentration of pharmacies in a particular 16:26:59 10 A. N 11 area that are all high prescribing oxy 16:27:00 11 Q. CO	okay. Okay. We'll mark the 16:29:29 it 42. This is Bates 16:29:30 0007251680. Okay. If you'll take a 16:29:42
5 Q. Okay. Do you recall anybody 16:26:46 5 next exhib. 6 talking about potential signs of diversion 16:26:47 6 MNK-T1_ 7 being a percentage of cash sales? 16:26:50 7 look at this 8 A. No, I don't recall that. 16:26:53 8 Ok 9 Q. Okay. What about on a 16:26:56 9 document? 10 concentration of pharmacies in a particular 16:26:59 10 A. N 11 area that are all high prescribing oxy 16:27:00 11 Q. C	it 42. This is Bates 16:29:30 0007251680. Okay. If you'll take a 16:29:42
6 talking about potential signs of diversion 16:26:47 7 being a percentage of cash sales? 16:26:50 8 A. No, I don't recall that. 16:26:53 9 Q. Okay. What about on a 16:26:56 10 concentration of pharmacies in a particular 16:26:59 11 area that are all high prescribing oxy 16:27:00 11 Q. Okay.	0007251680. Okay. If you'll take a 16:29:42
7 being a percentage of cash sales? 16:26:50 7 look at this 8 A. No, I don't recall that. 16:26:53 8 Ok 9 Q. Okay. What about on a 16:26:56 9 document? 10 concentration of pharmacies in a particular 16:26:59 10 A. N 11 area that are all high prescribing oxy 16:27:00 11 Q. C.	
8 A. No, I don't recall that. 16:26:53 8 Ok 9 Q. Okay. What about on a 16:26:56 9 document? 10 concentration of pharmacies in a particular 16:26:59 10 A. N 11 area that are all high prescribing oxy 16:27:00 11 Q. C	document for me please 16.70.36
9 Q. Okay. What about on a 16:26:56 9 document? 10 concentration of pharmacies in a particular 16:26:59 10 A. N 11 area that are all high prescribing oxy 16:27:00 11 Q. C	* *
10 concentration of pharmacies in a particular 16:26:59 10 A. N 11 area that are all high prescribing oxy 16:27:00 11 Q. C	tay. Do you recognize this 16:30:10
11 area that are all high prescribing oxy 16:27:00 11 Q. C	
	(o, I do not. 16:30:12
	okay. Do you think you've ever 16:30:13
12 pharmacies, did anybody ever discuss that? 16:27:05 12 seen it before	
	may have. 16:30:15
	okay. Do you know if you were 16:30:16
	n creating it? 16:30:18
	doubt that I was involved 16:30:19
the information about cash sales. 16:27:10 17 creating it.	
	okay. Do you think perhaps you 16:30:24
	nto the chart at all? 16:30:25
-	ossibly. Someone on my team 16:30:27
21 mean by "we"? 16:27:16 21 might have	
	okay. And this chart is 16:30:34
	rate concentration, oxy 15 and 30, 16:30:36
	"; is that correct? 16:30:39
25 Mallinckrodt may have that information? 16:27:21 25 A. Y	es. 16:30:40
Page 311	Page 313
1 A. I have no idea. 16:27:22 1 Q. C	kay. And so with this chart, 16:30:46
2 Q. Okay. 16:27:22 2 would this	show that Mallinckrodt was 16:30:49
A. I don't know how they would get 16:27:23	the percentage of each distributor 16:30:52
4 it. 16:27:24 4 shipments	going to the various states; is 16:30:55
5 Q. Okay. Okay. Going back to our 16:27:24 5 that right?	16:30:57
6 chart here. Okay. So I think the last one 16:27:31 6 M	R. O'CONNOR: Objection to 16:30:57
7 we talked about was the one in La Follette. 16:27:50 7 form.	16:30:58
8 That's Riggs. 16:27:53 8 Th	IE WITNESS: At this 16:30:58
9 And then at 334 we have 16:27:53 9 particu	lar on this particular 16:30:59
10 Ripptoe, Inc., in Morristown, Tennessee. And 16:27:56 10 report,	yes. 16:31:00
**	NS BY MS. HERZFELD: 16:31:01
	kay. And so included within 16:31:01
	on is, Mallinckrodt was monitoring 16:31:06
	tage of each distributor's 16:31:08
	going to Tennessee, at least in 16:31:11
	11, according to this chart; is 16:31:14
17 gross sales, \$10,855.84, and the units are 16:28:14 17 that correct	
	R. O'CONNOR: Objection to 16:31:16
19 A. Correct. 16:28:20 19 form.	16:31:19
	IE WITNESS: Correct. 16:31:20
21 population of Morristown, Tennessee, is? 16:28:22 21 QUESTIO	NS BY MS. HERZFELD: 16:31:21
-,	okay. And how was this 16:31:21
22 A. I have no idea. 16:28:25 22 Q. C	used by the indirect customer review 16:31:22
22 A. I have no idea. 16:28:25 22 Q. C	used by the indirect customer review 16:31:22

			2
	Page 314		Page 316
1	Q. Okay. Do you know if 16:31:30	1	Q. Okay. And so hydro APAP, is 16:34:11
2	Mallinckrodt was seeking to reduce the 16:31:35	2	that also hydrocodone? 16:34:14
3	concentration of oxycodone in Florida? 16:31:37	3	A. Yes. 16:34:15
4	A. Yes. 16:31:40	4	Q. Okay. And so looking at this 16:34:16
5	Q. Okay. Do you know if 16:31:42	5	chart, is this a chart that you would have 16:34:18
6	Mallinckrodt was seeking to reduce the 16:31:45	6	had input in creating or maintaining? 16:34:22
7	concentration of oxycodone in Tennessee? 16:31:47	7	A. I would not have created this. 16:34:25
8	A. I do not remember that being a 16:31:50	8	I might have had input, but I'm not sure I 16:34:28
9	topic of discussion. 16:31:53	9	did. 16:34:31
10	Q. Okay. Other than Florida, do 16:31:55	10	Q. Okay. 16:34:31
11	you recall any other states being a topic of 16:31:57	11	A. Because this was taken over by 16:34:32
12	discussion for the target of the reduction of 16:31:59	12	suspicious order monitoring. 16:34:34
13	oxycodone concentration by state? 16:32:03	13	Q. Okay. But you were employed by 16:34:35
14	A. I don't recall that. 16:32:04	14	Mallinckrodt in April of 2010; is that 16:34:37
15	Q. Okay. Okay. And in this 16:32:07	15	correct? 16:34:38
16	chart, do you know if population was 16:32:13	16	A. Yes, I was. 16:34:38
17	considered at all? 16:32:15	17	Q. Okay. And if you'll take a 16:34:39
18	MR. O'CONNOR: Objection to 16:32:17	18	look with me here, do you know if this chart 16:34:4
19	form. 16:32:19	19	is created using chargeback data? 16:34:48
20	THE WITNESS: Most likely not, 16:32:20	20	A. I would assume so 16:34:50
21	because we wouldn't know the 16:32:21	21	Q. Okay. 16:34:56
22	population. 16:32:23	22	A yes. 16:34:56
23	QUESTIONS BY MS. HERZFELD: 16:32:23	23	Q. And so looking at this chart 16:34:56
24	Q. You wouldn't know the 16:32:24	24	here, if you go down with me to the line for 16:34:59
25	population of a state? 16:32:24	25	Tennessee, which is 51? 16:35:03
	Page 315		Page 317
1	A. Yeah. At any given time, no. 16:32:25	1	A. Yes. 16:35:08
2	(Mallinckrodt-Collier Exhibit 16:32:36	2	Q. Okay. And then you see the 16:35:08
3	43 marked for identification.) 16:32:36	3	various percentages. I know it's kind of 16:35:09
4	QUESTIONS BY MS. HERZFELD: 16:32:36	4	hard to line up. 16:35:12
5	Q. Okay. The next one is 43. 16:32:37	5	What are the do you know 16:35:13
6	For those on the phone, it's 16:32:51	6	what the percentages are indicating? 16:35:14
7	MNK-T1 0007251681. 16:32:55	7	A. My I don't know. I'd have 16:35:18
8	The type is very small, so my 16:32:58	8	to look at this more carefully because I'm 16:35:23
9	apologies for that. 16:33:22	9	not sure. 16:35:26
	Okay. And so is this the 16:33:42		
10 11	what I've handed you, is this the the 16:33:43	10	Q. Okay. But the percentages are 16:35:27 indicating something regarding each one of 16:35:29
12	similar type of chart, a state concentration 16:33:46	12	these distributors; is that correct? 16:35:33
13	chart? 16:33:50	13	MR. O'CONNOR: Objection to 16:35:35
14	MR. O'CONNOR: Objection to 16:33:50	14	form. 16:35:36
15	form. 16:33:52	15	THE WITNESS: Yes. 16:35:37
	THE WITNESS: Yes. 16:33:53		QUESTIONS BY MS. HERZFELD: 16:35:39
16		16 17	
17 1Ω			Q. It's broken out by distributor; 16:35:40
18	· ·	18	is that right? 16:35:42
19	title here it says, "State concentration 16:33:55	19	A. Yes. 16:35:42
	hazadana A D A D - A maid 20110 d = 4= 11 17 22 50	20	Q. Okay. And so you have it 16:35:42
20	hydro APAP, April 2010 data." 16:33:58	0.1	harless down has state and see 1 2 1 1 1 2 2 2 4 4
21	Did I read that correctly? 16:34:02	21	broken down by state and you have it broken 16:35:44
21	Did I read that correctly? 16:34:02 A. Yes. 16:34:03	22	down by distributor in dealing with hydro 16:35:46
21 22 23	Did I read that correctly? 16:34:02 A. Yes. 16:34:03 Q. Okay. And hydro APAP is what? 16:34:03	22	down by distributor in dealing with hydro 16:35:46 APAP in April of 2010; is that correct? 16:35:51
21 22 23 24	Did I read that correctly? 16:34:02 A. Yes. 16:34:03 Q. Okay. And hydro APAP is what? 16:34:03 A. It's a Schedule II pain med 16:34:06	22 23 24	down by distributor in dealing with hydro 16:35:46 APAP in April of 2010; is that correct? 16:35:51 A. Correct. 16:35:52
21 22 23	Did I read that correctly? 16:34:02 A. Yes. 16:34:03 Q. Okay. And hydro APAP is what? 16:34:03	22	down by distributor in dealing with hydro 16:35:46 APAP in April of 2010; is that correct? 16:35:51

	<u> </u>		
	Page 318		Page 320
1	that right? 16:35:55	1	QUESTIONS BY MS. HERZFELD: 16:37:17
2	A. Yes. 16:35:55	2	Q. Okay. But I would like to have 16:37:17
3	Q. Okay. And so if you look with 16:35:55	3	your guess because I think it's probably more 16:37:18
4	me at Tennessee, I want you to go over to 16:35:57	4	educated than mine in this matter. I've 16:37:20
5	McKesson. If you look at Tennessee and 16:35:59	5	never seen these charts before. 16:37:22
6	McKesson in this itty-bitty little line, it 16:36:04	6	So can you guess what you think 16:37:23
7	says 10.7 percent. 16:36:08	7	that these I'm just trying to understand 16:37:25
8	Do you see where I'm at? 16:36:09	8	what it is. 16:37:27
9	A. I don't see a 10.7. I see 16:36:11	9	MR. O'CONNOR: Objection to 16:37:28
10	McKesson. 16:36:17	10	form. 16:37:29
11	Q. Okay. You see McKesson. 16:36:17	11	THE WITNESS: Okay. Give me a 16:37:30
12	A. Oh, I see it now. I'm sorry, I 16:36:18	12	minute. I'll calculate what these 16:37:33
13	was on the wrong line. 16:36:20	13	percentages add up to 16:37:34
14	Q. Do you see it? 16:36:21	14	QUESTIONS BY MS. HERZFELD: 16:37:36
15	A. Yes. 16:36:21	15	Q. Great. 16:37:37
16	Q. Okay. Do you know what that 16:36:22	16	A and I might be able to come 16:37:38
17	10.7 represents for McKesson? 16:36:23	17	up with something. 16:37:39
18	MR. BENSON: Object to form. 16:36:23	18	Q. I might be able to shortcut it 16:37:40
19	THE WITNESS: No, I do not, 16:36:24	19	for you a little bit. 16:37:41
20	because I don't know what those 16:36:25	20	If you look all the way at the 16:37:42
21	percentages represent. 16:36:28	21	bottom, it has a grand total. And it looks 16:37:45
22	MS. HERZFELD: I'm sorry, who 16:36:28	22	like the bottom of every one is totaled up to 16:37:49
23	objected? 16:36:30	23	100 percent. 16:37:52
24	MR. BENSON: (Hand gestures.) 16:36:30	24	Do you see? 16:37:52
25	MS. HERZFELD: Who are you? 16:36:31	25	A. Yes. Okay. 16:37:53
	P. 010		D 221
	Page 319		Page 321
1	MR. BENSON: Fred Benson for 16:36:33	1	Q. So if you look at McKesson and 16:37:54
2	McKesson. 16:36:33	2	you look at Tennessee, and if you add all 16:37:57
3	MS. HERZFELD: You're from 16:36:34	3	those up, it gets to a hundred percent. 16:38:02
4	McKesson. Okay. 16:36:35	4	So I'm looking at this and 16:38:04
5	But I don't think you 16:36:35	5	saying, is it that McKesson is 10.7 percent 16:38:07
6	cross-noticed this deposition, so I'm 16:36:36	6	of their sales of hydro APAP in April 2010 16:38:14
7	going to object to your objection. 16:36:38	7	were in Tennessee based on this chart? 16:38:21
8	Okay? You're not a party in our case. 16:36:40	8	MR. O'CONNOR: Object to form. 16:38:23
9	MR. BENSON: Fair enough. 16:36:43	9	THE WITNESS: That seems to be 16:38:24
10	QUESTIONS BY MS. HERZFELD: 16:36:44	10	the case. 16:38:29
11	Q. Okay. So 10.7. Do you know 16:36:44	11	QUESTIONS BY MS. HERZFELD: 16:38:31
12			Q. Okay. Thank you. 16:38:31
1-2	what that is in relation to McKesson, what 16:36:45	12	
13	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47	12	A. Uh-huh. 16:38:32
	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51		A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33
13	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53	13	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45
13 14	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53	13 14	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47
13 14 15	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53	13 14 15	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45
13 14 15 16	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53	13 14 15 16	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47
13 14 15 16 17	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03	13 14 15 16 17	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48
13 14 15 16 17 18	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03 of April 2010 going to the state of 16:37:06	13 14 15 16 17 18	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48 sales of Mallinckrodt products to the VA? 16:38:49
13 14 15 16 17 18	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03 of April 2010 going to the state of 16:37:06 Tennessee? 16:37:09	13 14 15 16 17 18 19	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48 sales of Mallinckrodt products to the VA? 16:38:49 MR. O'CONNOR: Objection to 16:38:51
13 14 15 16 17 18 19	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03 of April 2010 going to the state of 16:37:06 Tennessee? 16:37:09 MR. O'CONNOR: Objection to 16:37:09	13 14 15 16 17 18 19	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48 sales of Mallinckrodt products to the VA? 16:38:49 MR. O'CONNOR: Objection to 16:38:51 form. 16:38:51
13 14 15 16 17 18 19 20 21	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03 of April 2010 going to the state of 16:37:06 Tennessee? 16:37:09 MR. O'CONNOR: Objection to 16:37:09 form. 16:37:10	13 14 15 16 17 18 19 20 21	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48 sales of Mallinckrodt products to the VA? 16:38:49 MR. O'CONNOR: Objection to 16:38:51 form. 16:38:51 THE WITNESS: No, I don't 16:38:52
13 14 15 16 17 18 19 20 21 22	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03 of April 2010 going to the state of 16:37:06 Tennessee? 16:37:09 MR. O'CONNOR: Objection to 16:37:09 form. 16:37:10 THE WITNESS: That would ask me 16:37:10	13 14 15 16 17 18 19 20 21 22	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48 sales of Mallinckrodt products to the VA? 16:38:49 MR. O'CONNOR: Objection to 16:38:51 form. 16:38:51 THE WITNESS: No, I don't 16:38:52 recall. 16:38:55
13 14 15 16 17 18 19 20 21 22 23	what that is in relation to McKesson, what 16:36:45 that 10.7 represents? 16:36:47 A. No, because I don't know what 16:36:51 the percentages represent. 16:36:53 Q. Okay. Could it be that that's 16:36:53 10.7 percent of McKesson's hydrocodone APAP 16:37:03 of April 2010 going to the state of 16:37:06 Tennessee? 16:37:09 MR. O'CONNOR: Objection to 16:37:10 THE WITNESS: That would ask me 16:37:10 to guess, and I would make the 16:37:12	13 14 15 16 17 18 19 20 21 22 23	A. Uh-huh. 16:38:32 Q. Do you know anything 16:38:33 specifically or I'm going to back up. 16:38:45 Strike that. 16:38:47 Do you know anything about the 16:38:48 sales of Mallinckrodt products to the VA? 16:38:49 MR. O'CONNOR: Objection to 16:38:51 form. 16:38:51 THE WITNESS: No, I don't 16:38:52 recall. 16:38:55 QUESTIONS BY MS. HERZFELD: 16:38:55

	Page 322		Page 324
1	VA? 16:38:59	1	Q. Okay. And did you create this 16:42:12
2	A. No, I didn't have anything to 16:38:59	2	document? 16:42:14
3	do with sales. 16:39:02	3	A. I did not. 16:42:14
4	Q. Okay. And when I say "VA," I 16:39:03	4	Q. Okay. Did you have any input 16:42:16
5	mean Veterans Administration. 16:39:05	5	in this document? 16:42:18
6	Do you understand that? 16:39:06	6	A. I did not. 16:42:18
7	A. Yes, I understood that. 16:39:07	7	Q. Okay. This document is in your 16:42:20
8	Q. Do you know who would have been 16:39:08	8	custodian file. 16:42:22
9	the person in charge of selling Mallinckrodt 16:39:10	9	Have you seen this document 16:42:22
10	products to the VA? 16:39:14	10	before? 16:42:23
11	A. Yes. Rich McKendrick. 16:39:15	11	A. I do not remember seeing this. 16:42:24
12	Q. Okay. And do you know if Rich 16:39:19	12	Q. Okay. Well, you're listed as a 16:42:28
13	McKendrick is still employed by Mallinckrodt? 16:39:22	13	custodian for it, so do you know who would 16:42:29
14	A. No, he is not. 16:39:24	14	have been the person who created this 16:42:32
15	Q. Okay. Do you know where he 16:39:25	15	document? 16:42:33
16	if he is employed now? 16:39:27 A. I don't know. 16:39:28	16	A. I'm not sure where this came 16:42:34
17		17	from, so, no. 16:42:37
18	Q. Okay. Do you know if he 16:39:29 retired? 16:39:37	18	Q. Okay. Do you know if there was 16:42:38 routinely a list of top 150 pharmacies that 16:42:41
20	A. I don't know. 16:39:38	20	routinely a list of top 150 pharmacies that 16:42:41 was kept? 16:42:44
21	Q. Okay. Are you in touch with 16:39:39	21	A. No. 16:42:44
22	Mr. McKendrick? 16:39:43	22	Q. Okay. 16:42:46
23	A. Probably if I was, I would know 16:39:44	23	A. I don't know that either. 16:42:46
24	what he was doing. 16:39:46	24	Q. Okay. 16:42:48
25	Q. Okay. 16:39:47	25	A. If it was outside my area, I 16:42:48
	Q. Chay.		71. If it was outside my area, 1 10.12.10
	Page 323		Page 325
	1 450 323		1 age 323
1	A. No. 16:39:47	1	wouldn't know if somebody was doing this on a 16:42:51
1 2	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47	1 2	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52
	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24		wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54
2	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27	2 3 4	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55
2	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11	2 3 4 5	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58
2 3 4 5 6	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12	2 3 4 5 6	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00
2 3 4 5 6 7	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15	2 3 4 5 6 7	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01
2 3 4 5 6 7 8	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17	2 3 4 5 6 7 8	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02
2 3 4 5 6 7 8	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18	2 3 4 5 6 7 8	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04
2 3 4 5 6 7 8 9	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18	2 3 4 5 6 7 8 9	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06
2 3 4 5 6 7 8 9 10	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19	2 3 4 5 6 7 8 9 10	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10
2 3 4 5 6 7 8 9 10 11	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22	2 3 4 5 6 7 8 9 10 11	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10 necessarily generated by me? 16:43:11
2 3 4 5 6 7 8 9 10 11 12 13	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23	2 3 4 5 6 7 8 9 10 11 12 13	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12
2 3 4 5 6 7 8 9 10 11 12 13 14	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23	2 3 4 5 6 7 8 9 10 11 12 13	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25	2 3 4 5 6 7 8 9 10 11 12 13 14 15	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 Q. Okay. But you've potentially 16:43:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:23 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:25 sure if we have made this one an 16:41:26	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 Q. Okay. But you've potentially 16:43:13 seen this e-mail before or this list 16:43:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:25 sure if we have made this one an 16:41:26 exhibit or not yet. 44. 16:41:32	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 Q. Okay. But you've potentially 16:43:13 seen this e-mail before or this list 16:43:16 before? 16:43:18
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:26 exhibit or not yet. 44. 16:41:32 For those on the phone, this is 16:41:44	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 seen this e-mail before or this list 16:43:16 before? 16:43:18 A. Possibly. 16:43:18
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:26 exhibit or not yet. 44. 16:41:32 For those on the phone, this is 16:41:44 MNK_TNSTA05098003. 16:41:47	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 Q. Okay. But you've potentially 16:43:13 seen this e-mail before or this list 16:43:16 before? 16:43:18 A. Possibly. 16:43:18 MR. O'CONNOR: Objection. 16:43:19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:32 For those on the phone, this is 16:41:44 MNK_TNSTA05098003. 16:41:47 QUESTIONS BY MS. HERZFELD: 16:41:47	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 Q. Okay. But you've potentially 16:43:13 seen this e-mail before or this list 16:43:18 A. Possibly. 16:43:18 MR. O'CONNOR: Objection. 16:43:19 THE WITNESS: Possibly. 16:43:19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:32 For those on the phone, this is 16:41:44 MNK_TNSTA05098003. 16:41:47 QUESTIONS BY MS. HERZFELD: 16:41:47 Q. So the title of this document 16:42:02	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 seen this e-mail before or this list 16:43:18 A. Possibly. 16:43:18 MR. O'CONNOR: Objection. 16:43:19 THE WITNESS: Possibly. 16:43:19 QUESTIONS BY MS. HERZFELD: 16:43:19 QUESTIONS BY MS. HERZFELD: 16:43:19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:26 exhibit or not yet. 44. 16:41:32 For those on the phone, this is 16:41:44 MNK_TNSTA05098003. 16:41:47 Q. So the title of this document 16:42:02 is "Top 150 pharmacies, oxy 30-milligram 16:42:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 seen this e-mail before or this list 16:43:16 before? 16:43:18 A. Possibly. 16:43:18 MR. O'CONNOR: Objection. 16:43:19 THE WITNESS: Possibly. 16:43:19 QUESTIONS BY MS. HERZFELD: 16:43:20 Q. Okay. Do you know what this 16:43:20
2 3 4 5 6 7 8 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:32 For those on the phone, this is 16:41:44 MNK_TNSTA05098003. 16:41:47 Q. So the title of this document 16:42:04 only, 2009 to 2011 data combined." 16:42:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:06 THE WITNESS: But not 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 seen this e-mail before or this list 16:43:18 A. Possibly. 16:43:18 A. Possibly. 16:43:18 MR. O'CONNOR: Objection. 16:43:19 THE WITNESS: Possibly. 16:43:19 QUESTIONS BY MS. HERZFELD: 16:43:20 Q. Okay. Do you know what this 16:43:20 was used for in your capacity at 16:43:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No. 16:39:47 Q. Okay. Very good. Okay. 16:39:47 If you give me just one second, 16:40:24 I think I'm almost finished. 16:40:27 Were you involved at all in 16:41:11 creating a list of the 150 top pharmacies for 16:41:12 Mallinckrodt? 16:41:15 MR. O'CONNOR: Objection to 16:41:17 form. 16:41:18 THE WITNESS: I don't know what 16:41:18 you're talking about, so I'd need to 16:41:19 see what you're discussing. 16:41:22 (Mallinckrodt-Collier Exhibit 16:41:23 44 marked for identification.) 16:41:23 MS. HERZFELD: Okay. I'm not 16:41:25 sure if we have made this one an 16:41:26 exhibit or not yet. 44. 16:41:32 For those on the phone, this is 16:41:44 MNK_TNSTA05098003. 16:41:47 Q. So the title of this document 16:42:02 is "Top 150 pharmacies, oxy 30-milligram 16:42:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	wouldn't know if somebody was doing this on a 16:42:51 regular basis. 16:42:52 And what does it mean that it's 16:42:54 in my custodian? 16:42:55 MS. HERZFELD: There maybe I 16:42:58 should have your lawyer explain that 16:43:00 to you. 16:43:01 MR. O'CONNOR: It simply means 16:43:02 that it was identified as being in 16:43:04 your e-mail or electronic files. 16:43:10 necessarily generated by me? 16:43:11 MR. O'CONNOR: Exactly right. 16:43:12 QUESTIONS BY MS. HERZFELD: 16:43:13 seen this e-mail before or this list 16:43:16 before? 16:43:18 A. Possibly. 16:43:18 MR. O'CONNOR: Objection. 16:43:19 THE WITNESS: Possibly. 16:43:19 QUESTIONS BY MS. HERZFELD: 16:43:20 Q. Okay. Do you know what this 16:43:20

1	Page 326 so I would not remember what it was used for. 16:43:26	1	Page 328 THE WITNESS: Maybe not state 16:46:12
2	Q. Okay. Are you disputing that 16:43:36	2	by state. The data were pulled. That 16:46:13
3	you've ever received this document? 16:43:37	3	does not mean that that's what we were 16:46:15
4	A. No. 16:43:38	4	reviewing. 16:46:17
5	Q. Okay. 16:43:40	5	QUESTIONS BY MS. HERZFELD: 16:46:18
6	A. I just don't recall it. 16:43:40	6	Q. Okay. I don't think I 16:46:18
7	Q. Okay. Okay. Exhibit 45. 16:43:43	7	understand your answer. 16:46:20
8	(Mallinckrodt-Collier Exhibit 16:44:10	8	I'll back up. 16:46:20
9	45 marked for identification.) 16:44:10	9	A. Okay. Can you ask the question 16:46:21
10	QUESTIONS BY MS. HERZFELD: 16:44:10	10	a different way then? 16:46:22
11	Q. Okay. If you'll look at the 16:45:00	11	Q. Sure. 16:46:24
12	first page, do you recognize this document? 16:45:01	12	Okay. So looking at this, it's 16:46:24
13	A. I recognize it as being an 16:45:03	13	oxy it says attachments are sales by 16:46:26
14	e-mail from Lisa Cardetti to me, yes. 16:45:08	14	state, August 30, 2011; is that right? 16:46:32
15	Q. Okay. And is it dated 16:45:11	15	A. Yes. 16:46:34
16	August 30, 2011? 16:45:13	16	Q. Okay. And then, "Ginger, as 16:46:35
17	A. Yes. 16:45:13	17	requested, I've looked at the past six months 16:46:39
18	Q. Okay. And in the e-mail it 16:45:14	18	compared to the prior six months of oxy sales 16:46:40
19	says, "Ginger, as requested, I've looked at 16:45:16	19	by state." 16:46:43
20	past six months compared to the prior six 16:45:19	20	Did I state that correctly? 16:46:46
21	months of oxy sales by state." 16:45:21	21	A. Yes. 16:46:47
22	Did I read that correctly? 16:45:22	22	Q. Okay. And so looking at these 16:46:48
23	A. Yes. 16:45:23	23	charts, it was looking at oxy sales by state; 16:46:49
24	Q. Do you recall asking Lisa to do 16:45:23	24	is that right? 16:46:52
25	this project? 16:45:27	25	A. Yes. 16:46:52
	1 0		
	Page 327		Page 329
1	A. I don't recall asking her to do 16:45:28	1	Q. Okay. 16:46:54
2	it, no. 16:45:31	2	A. That's what's in the chart. 16:46:54
3	Q. Okay. But she's clearly 16:45:32	3	Q. Okay. And the charts seem to 16:46:55
4	responding to something, right? 16:45:33	4	measure prior six months, past six months, 16:46:59
5	A. Right. 16:45:34	5	and then column F says percentage change. 16:47:01
6	MR. O'CONNOR: Objection. 16:45:35	6	I'm on the page ahead of you. 16:47:04
7	QUESTIONS BY MS. HERZFELD: 16:45:36	7	This one right here. 16:47:06
8	Q. And so looking at that, it 16:45:36	8	A. Yes. 16:47:08
9			
	looks like if you look at the charts that 16:45:38	9	Q. And so my question is actually 16:47:12
	are attached here, the next couple, there are 16:45:40	10	pretty simple. So as of the date this e-mail 16:47:14
11	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45	10 11	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18
11 12	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47	10 11 12	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22
11 12 13	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47	10 11 12 13	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25
11 12 13 14	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48	10 11 12 13 14	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26
11 12 13 14	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51	10 11 12 13 14 15	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26
11 12 13 14 15	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53	10 11 12 13 14 15	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29
11 12 13 14 15 16	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56	10 11 12 13 14 15 16	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31
11 12 13 14 15 16 17	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56	10 11 12 13 14 15 16 17	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33
11 12 13 14 15 16 17 18	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56 Q. Okay. And so at least as of 16:45:58	10 11 12 13 14 15 16 17 18	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33 at many states. She was looking at 16:47:35
11 12 13 14 15 16 17 18 19	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56 Q. Okay. And so at least as of 16:45:58 the date of this e-mail, during this time, 16:46:01	10 11 12 13 14 15 16 17 18 19	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33 at many states. She was looking at 16:47:35 Ohio, California, New York and 16:47:37
11 12 13 14 15 16 17 18 19 20 21	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56 Q. Okay. And so at least as of 16:45:58 the date of this e-mail, during this time, 16:46:01 Mallinckrodt was looking at the percentage 16:46:06	10 11 12 13 14 15 16 17 18 19 20	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33 at many states. She was looking at 16:47:35 Ohio, California, New York and 16:47:37 Florida, which were flagged for SLM. 16:47:40
11 12 13 14 15 16 17 18 19 20 21 22	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56 Q. Okay. And so at least as of 16:45:58 the date of this e-mail, during this time, 16:46:01 Mallinckrodt was looking at the percentage 16:46:06 change of oxy sales state by state; is that 16:46:08	10 11 12 13 14 15 16 17 18 19 20 21	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33 at many states. She was looking at 16:47:35 Ohio, California, New York and 16:47:37 Florida, which were flagged for SLM. 16:47:40 QUESTIONS BY MS. HERZFELD: 16:47:41
11 12 13 14 15 16 17 18 19 20 21 22 23	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56 Q. Okay. And so at least as of 16:45:58 the date of this e-mail, during this time, 16:46:01 Mallinckrodt was looking at the percentage 16:46:06 change of oxy sales state by state; is that 16:46:08 right? 16:46:11	10 11 12 13 14 15 16 17 18 19 20 21 22 23	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33 at many states. She was looking at 16:47:35 Ohio, California, New York and 16:47:37 Florida, which were flagged for SLM. 16:47:40 QUESTIONS BY MS. HERZFELD: 16:47:41 Q. Okay. So then I will back up. 16:47:42
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	are attached here, the next couple, there are 16:45:40 various charts that are broken down by state; 16:45:45 is that correct? 16:45:47 A. Yes. 16:45:47 Q. Okay. And it has to do with 16:45:48 prior six months and the past six months and 16:45:51 the percentage of change for oxy sales; is 16:45:53 that right? 16:45:56 A. Yes. 16:45:56 Q. Okay. And so at least as of 16:45:58 the date of this e-mail, during this time, 16:46:01 Mallinckrodt was looking at the percentage 16:46:06 change of oxy sales state by state; is that 16:46:08	10 11 12 13 14 15 16 17 18 19 20 21	pretty simple. So as of the date this e-mail 16:47:14 was sent, August 30, 2011, Mallinckrodt 16:47:18 monitored oxy sales by state? 16:47:22 MR. O'CONNOR: Objection to 16:47:25 form. 16:47:26 THE WITNESS: We pulled data by 16:47:26 state. I wouldn't say we necessarily 16:47:29 monitored it because Lisa if she 16:47:31 referred to this, she wasn't looking 16:47:33 at many states. She was looking at 16:47:35 Ohio, California, New York and 16:47:37 Florida, which were flagged for SLM. 16:47:40 QUESTIONS BY MS. HERZFELD: 16:47:41

	Page 330		Page 332
1	Q. So as of August 2011 when these 16:47:44	1	form. 16:49:08
2	charts were sent to you from Lisa, 16:47:47	2	MS. HERZFELD: Okay. I'm going 16:49:09
3	Mallinckrodt had the capability of monitoring 16:47:53	3	to back up one more time. 16:49:10
4	oxy sales by state? 16:47:55	4	MR. O'CONNOR: Do you want to 16:49:11
5	MR. O'CONNOR: Objection to 16:47:56	5	just try that question again? It was 16:49:12
6	form. 16:47:57	6	because you stopped in the middle. 16:49:14
7	MS. HERZFELD: What's the 16:47:58	7	MS. HERZFELD: You're objecting 16:49:16
8	objection? 16:47:59	8	because I stopped in the middle? 16:49:16
9	MR. O'CONNOR: Vague. What 16:48:00	9	MR. O'CONNOR: Because it 16:49:18
10	monitoring means, the capability. 16:48:02	10	became unclear what the question was. 16:49:20
11	QUESTIONS BY MS. HERZFELD: 16:48:07	11	MS. HERZFELD: Okay. We'll be 16:49:22
12	Q. Do you understand what 16:48:08	12	really clear this time. 16:49:23
13	"capability" means, ma'am? 16:48:09	13	QUESTIONS BY MS. HERZFELD: 16:49:24
14	A. The ability. 16:48:10	14	Q. As of the date that this e-mail 16:49:25
15	Q. Okay. And do you understand 16:48:10	15	was sent to you, August 30, 2011, 16:49:28
16	what "monitoring" means? 16:48:11	16	Mallinckrodt was capable of tracking oxy 16:49:34
17	A. Well, it could mean any number 16:48:12	17	sales by state; is that correct? 16:49:37
18	of things. In the context of suspicious 16:48:15	18	A. Mallinckrodt was capable of 16:49:40
19	order monitoring? Or were we monitoring 16:48:18	19	running a report by state, yes. 16:49:42
20	those sales? Which we were not. 16:48:19	20	Q. Okay. Do you not understand 16:49:45
21	Q. Okay. But my question wasn't 16:48:22	21	what I mean when I say "tracking"? 16:49:47
22	"were you." That was my question before. 16:48:24	22	A. Tracking, to me, would indicate 16:49:49
23	You said you only knew you were 16:48:26	23	it could be any number of things of what you 16:49:51
24	monitoring some, right? 16:48:28	24	were asking. 16:49:53
25	So my question now is: Did you 16:48:29	25	Q. Okay. So you don't understand 16:49:54
	Page 331		Page 333
	_		8
1	have did Mallinckrodt have the 16:48:31	1	
1 2	capability which we've determined you 16:48:32	1 2	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58
	capability which we've determined you 16:48:32 understand what capability means. 16:48:33		the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01
2	capability which we've determined you 16:48:32 understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35	2	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01
2 3	capability which we've determined you 16:48:32 understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36	2	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03
2 3 4 5 6	capability which we've determined you 16:48:32 understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39	2 3 4 5	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04
2 3 4 5 6 7	capability which we've determined you 16:48:32 understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43	2 3 4 5 6 7	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06
2 3 4 5 6 7 8	capability which we've determined you 16:48:32 understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44	2 3 4 5 6 7 8	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07
2 3 4 5 6 7 8	capability which we've determined you 16:48:32 understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44	2 3 4 5 6 7 8	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10
2 3 4 5 6 7 8 9	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45	2 3 4 5 6 7 8 9	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12
2 3 4 5 6 7 8 9 10	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45	2 3 4 5 6 7 8 9 10	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12
2 3 4 5 6 7 8 9 10 11	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47	2 3 4 5 6 7 8 9 10 11	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14
2 3 4 5 6 7 8 9 10 11 12 13	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49	2 3 4 5 6 7 8 9 10 11 12 13	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15
2 3 4 5 6 7 8 9 10 11 12 13 14	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50	2 3 4 5 6 7 8 9 10 11 12 13	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16
2 3 4 5 6 7 8 9 10 11 12 13 14 15	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51	2 3 4 5 6 7 8 9 10 11 12 13 14 15	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17
2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15	capability which we've determined you understand what capability means. Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 Q. I'm going to ask it in smaller 16:48:53	2 3 4 5 6 7 8 9 10 11 12 13 14 15	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 Q. I'm going to ask it in smaller 16:48:53 parts so we don't get a compound objection. 16:48:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 Q. I'm going to ask it in smaller 16:48:53 parts so we don't get a compound objection. 16:48:55 Okay? 16:48:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22 could have been pulled every month if 16:50:24
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 parts so we don't get a compound objection. 16:48:55 Okay? 16:48:57 Looking at this chart, 16:48:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22 could have been pulled every month if 16:50:24 Mallinckrodt wanted to pull it as of August 16:50:26
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 Q. I'm going to ask it in smaller 16:48:53 parts so we don't get a compound objection. 16:48:55 Okay? 16:48:57	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22 could have been pulled every month if 16:50:24 Mallinckrodt wanted to pull it as of August 16:50:26
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 Q. I'm going to ask it in smaller 16:48:53 parts so we don't get a compound objection. 16:48:55 Okay? 16:48:57 Looking at this chart, 16:48:57 Mallinckrodt, here, according to this chart, 16:48:59	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22 could have been pulled every month if 16:50:24 Mallinckrodt wanted to pull it as of August 16:50:26 2011; is that correct? 16:50:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 parts so we don't get a compound objection. 16:48:55 Okay? 16:48:57 Looking at this chart, 16:48:57 Mallinckrodt, here, according to this chart, 16:48:59 was monitoring sales I won't say 16:49:01	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22 could have been pulled every month if 16:50:24 Mallinckrodt wanted to pull it as of August 16:50:26 2011; is that correct? 16:50:29 A. Yes. 16:50:29
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	capability which we've determined you understand what capability means. 16:48:33 Did Mallinckrodt have the 16:48:35 capability of monitoring let's use a 16:48:36 different word tracking sales of oxy by 16:48:39 state? 16:48:43 MR. O'CONNOR: Objection to 16:48:44 form. 16:48:44 MS. HERZFELD: What is the 16:48:45 objection? 16:48:45 MR. O'CONNOR: Compound. 16:48:47 Vague. 16:48:49 MS. HERZFELD: Okay. We'll 16:48:50 back up and ask it again. 16:48:51 QUESTIONS BY MS. HERZFELD: 16:48:53 parts so we don't get a compound objection. 16:48:55 Okay? 16:48:57 Looking at this chart, 16:48:57 Mallinckrodt, here, according to this chart, 16:48:59 was monitoring sales I won't say 16:49:01 monitoring tracking sales by state; is 16:49:04	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the term "monitoring" because it can mean a 16:49:56 lot of things, and tracking seems like it 16:49:58 means a lot of things. 16:50:01 So I just want to know: 16:50:01 According to this chart, there's 50 states on 16:50:03 this chart, correct? 16:50:04 A. Correct. 16:50:06 Q. And also the Virgin Islands, it 16:50:07 appears, and Puerto Rico, right? 16:50:10 A. Yes. 16:50:12 Q. So looking at this, the data is 16:50:12 broken down by state; is that correct? 16:50:14 A. Correct. 16:50:15 Q. Okay. And the percentage 16:50:16 change of oxy sales is broken down per state; 16:50:17 is that correct? 16:50:21 A. Yes. 16:50:21 Q. Okay. And this information 16:50:22 could have been pulled every month if 16:50:24 Mallinckrodt wanted to pull it as of August 16:50:26 2011; is that correct? 16:50:29 A. Yes. 16:50:29 MS. HERZFELD: Okay. Take a 16:50:33

	<u> </u>		
	Page 334		Page 336
1	the record at 4:50 p m. 16:50:35	1	form. 17:00:07
2	(Off the record at 4:50 p.m.) 16:50:37	2	THE WITNESS: I don't remember 17:00:07
3	VIDEOGRAPHER: We are back on 16:58:30	3	what CDIG stood for. I thought that 17:00:09
4	the record at 4:58 p m. 16:58:31	4	was an acronym for sales reporting. 17:00:13
5	REDIRECT EXAMINATION 16:58:36	5	QUESTIONS BY MR. GOTTO: 17:00:15
6	QUESTIONS BY MR. GOTTO: 16:58:37	6	Q. Okay. So you're not familiar 17:00:15
7	Q. Ms. Collier, just a few 16:58:38	7	with CDIG as a function at Mallinckrodt? 17:00:16
8	follow-up questions. 16:58:38	8	A. No, I don't remember. And I 17:00:18
9	If you could look back at 16:58:39	9	know that there was CDIG was used in some 17:00:20
10	Exhibit 45, the document you were just 16:58:40	10	of the memos, but I don't know what it stood 17:00:25
11	looking at with Ms. Herzfeld. 16:58:44	11	for. 17:00:27
12	A. Oh, yes. 16:58:47	12	Q. Okay. Okay. I just have a 17:00:27
13	Q. The e-mail. 16:58:48	13	couple more questions for you on some 17:00:29
14	My question the final 16:58:49	14	documents. 17:00:31
15	sentence of the first paragraph says, "The 16:58:53	15	(Mallinckrodt-Collier Exhibit 17:00:40
16	other states that are increasing are 16:58:54	16	46 marked for identification.) 17:00:40
17	highlighted, Ohio, California and New York, 16:58:55	17	QUESTIONS BY MR. GOTTO: 17:00:40
18	which are the same states that SOM 16:58:56	18	Q. Exhibit 46 is a multipage 17:00:58
19	highlighted." 16:58:59	19	e-mail thread beginning at Bates 17:01:00
20	Do you know what Ms. Cardetti 16:59:00 meant when she said those were the same 16:59:02	20	MNK-T1_0000368477, and it's a several-page 17:01:06 document. 17:01:10
21		21	
22	states that SOM highlighted? 16:59:04 A. I'm not clear, but it's 16:59:05	23	My only question for you 17:01:10 concerns your e-mail to Ms. Lundergan on 17:01:11
24	possible that there was a discussion during 16:59:08	24	February 9th, the very top e-mail on the 17:01:15
25	an SOM meeting about those particular states. 16:59:09	25	second page. 17:01:23
23	an sow meeting about those particular states. 10.37.07	23	second page.
	Page 335		Page 337
1	Q. Okay. Was Ms. Cardetti part of 16:59:13	1	A. Okay. 17:01:59
2	the SOM committee or any subcommittee? 16:59:18	2	Q. In your e-mail well, first, 17:02:00
1			
3	A. She was part of pulling data 16:59:19	3	the e-mail thread concerns resuming shipments 17:02:04
3 4	for the meetings, for some of the meetings 16:59:24	3 4	to KeySource, correct? 17:02:07
	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27		to KeySource, correct? 17:02:07 A. Correct. 17:02:08
4	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29	4	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09
4 5	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34	4 5 6 7	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09 of 2011. 17:02:12
4 5 6 7 8	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34	4 5 6	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09 of 2011. 17:02:12 On February 8th, Ms. Lundergan 17:02:12
4 5 6 7 8	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36	4 5 6 7 8	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09 of 2011. 17:02:12 On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20
4 5 6 7 8 9	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37	4 5 6 7 8 9	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09 of 2011. 17:02:12 On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22
4 5 6 7 8 9 10	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39	4 5 6 7 8 9 10	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09 of 2011. 17:02:12 On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25
4 5 6 7 8 9 10 11	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40	4 5 6 7 8 9 10 11	to KeySource, correct? 17:02:07 A. Correct. 17:02:08 Q. And this is in February 17:02:09 of 2011. 17:02:12 On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26
4 5 6 7 8 9 10 11 12 13	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45	4 5 6 7 8 9 10 11 12 13	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28
4 5 6 7 8 9 10 11 12 13	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45	4 5 6 7 8 9 10 11 12 13 14	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." 17:02:32
4 5 6 7 8 9 10 11 12 13 14	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46	4 5 6 7 8 9 10 11 12 13 14 15	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." 17:02:34
4 5 6 7 8 9 10 11 12 13 14 15	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47	4 5 6 7 8 9 10 11 12 13 14 15	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." 17:02:34 you said, "we are cutting off the suspicious 17:02:38
4 5 6 7 8 9 10 11 12 13 14 15 16	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47	4 5 6 7 8 9 10 11 12 13 14 15 16	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:38 pharmacies"? 17:02:39
4 5 6 7 8 9 10 11 12 13 14 15 16 17	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 Q. Okay. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:29 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:52	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, and you say, "Yes, Karen Harper said we can 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:42
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:52 chargeback contract admin team, and so she 16:59:55	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:45
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:55 would have known about chargebacks. 16:59:58	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." 17:02:32 What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:45 uncomfortable with them buying from multiple 17:02:48
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:55 would have known about chargebacks. 16:59:58 Q. Okay. Do you recall there 16:59:59	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	to KeySource, correct? A. Correct. 17:02:08 Q. And this is in February 17:02:12 On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:42 more than one distributor, and we were 17:02:48 distributors, and so we wouldn't allow 17:02:50
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:55 would have known about chargebacks. 16:59:59 being a time when the SOM function was moved 17:00:00	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:42 more than one distributor, and we were 17:02:45 uncomfortable with them buying from multiple 17:02:50 chargebacks anymore. 17:02:52
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:52 chargeback contract admin team, and so she 16:59:55 would have known about chargebacks. 16:59:59 being a time when the SOM function was moved 17:00:00 to a group known as CDIG? 17:00:02	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." 17:02:32 What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:42 more than one distributor, and we were 17:02:45 uncomfortable with them buying from multiple 17:02:50 chargebacks anymore. 17:02:52
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	for the meetings, for some of the meetings 16:59:24 early on. She was the one that helped with 16:59:27 some of the analytics 16:59:39 Q. Okay. 16:59:34 A along with Kate Neely. 16:59:34 Q. Okay. And you've testified 16:59:36 about an indirect purchaser subcommittee of 16:59:37 the SOM committee. 16:59:39 Who else was on that 16:59:40 subcommittee; can you recall? 16:59:45 A. I don't remember. 16:59:45 Q. You don't remember anyone at 16:59:46 all? 16:59:47 A. No, I don't remember who was in 16:59:47 that. It would have been people like the 16:59:49 Carol that was mentioned because she was in a 16:59:55 would have known about chargebacks. 16:59:59 being a time when the SOM function was moved 17:00:00	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	to KeySource, correct? A. Correct. Q. And this is in February 17:02:09 of 2011. On February 8th, Ms. Lundergan 17:02:12 asks you if you agree with the resumption, 17:02:20 and you say, "Yes, Karen Harper said we can 17:02:22 ship all of our approved distributors because 17:02:25 they performed the audits, and the 17:02:26 distributors complied with our requests. We 17:02:28 are cutting off the suspicious pharmacies." What did you mean by that when 17:02:34 you said, "we are cutting off the suspicious 17:02:39 A. That probably refers to where 17:02:40 we had pharmacies that were ordering from 17:02:42 more than one distributor, and we were 17:02:45 uncomfortable with them buying from multiple 17:02:50 chargebacks anymore. 17:02:52

mechanism for the wholesaler/distributor to 17.02:56	1. mechanism for the wholesaler/distributor to 17:02:56 2 get their money back. 17:02:58 3 Q. Okay. And when you said "they 17:02:59 4 performed the audits and the distributors 17:03:04 5 complicid with our requests," who is the 17:03:04 5 complicid with our requests," who is the 17:03:06 5 complicid with our requests," who is the 17:03:09 5 miles of "they" you're referring to in that sentence? 17:03:09 5 Markard Harper and the SOM team 17:03:10 5 Do you recognize this document? 17:06:21 70:06:24 A. Karen Harper and the SOM team 17:03:13 3 saide. 17:03:16 17:03:18 17:06:28 Markard Harper and the SOM team 17:03:18 12 QUESTIONS BY MR. GOTTO: 17:03:18 12 QUESTIONS BY MR. GOTTO: 17:04:07 17:04:07 17:06:000273249, and it appears to be a 17:04:07 17:04:07 17:06:000273249, and it appears to be a 17:04:04 17:06:04 17:0	-11	ignity confidencial - bublect to	0 1	dicher confidenciality keview
2 get their money back 17-02/58 3 Q. Okay. And when you said "they 17-02/59 4 performed the audits and the distributors 17-03/64 5 compiled with our requests," who is the 17-03-06 6 "they" you're referring to in that seatence? 17-03-09 5 T-06-19 7-06-19	2 get their money back 17-02-58 3		_		Page 340
2	3				_
2 performed the audits and the distributors 17.03.04	4 performed the audits and the distributors 17-03-04 5 compilied with our requests, who is the 17-03-06 6		,		
5 cumplied with our requests," who is the 17-03-06 6 "dhey" you're referring to in that sentence? 17-03-09	5	3		3	<u> •</u>
6 "they" you're referring to in that sentence? 17:03:09 7 A. Karen Harper and the SOM team. 17:03:10 8 Q. Okay, Okay. Okay. Oxue on put that 17:03:13 9 aside. 17:03:16 10 (Mallinckrodt-Collier Exhibit 17:03:17 11 47 marked for identification.) 17:03:18 12 QUISTIONS BY MR. GOTTO: 17:03:18 12 QUISTIONS BY MR. GOTTO: 17:03:18 13 MNK-T1, 0000273249, and it appears to be a 17:04:05 14 document beginning at Bates 17:03:58 15 MNK-T1, 0000273249, and it appears to be a 17:04:05 16 spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:07 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:17 20 A. I recognize the content, yes. 17:04:21 21 Q. Okay. Is a document that 17:04:22 22 you had involvement in preparing? 17:04:27 23 A. Not that I recollect. 17:04:29 24 Q. Okay. Okay. Oxay on on your team? 17:04:35 2 Q. Okay. Oxay. Oxay on on your team? 17:04:35 2 Q. Okay. Oxay. Oxay on on your team? 17:04:35 2 Q. Okay. Oxay. Oxay on spone on my team? 17:04:37 4 A. Just to understand, this might 17:04:37 5 have been part of removing it from their VIP 17:04:48 7 wholesalers were purchasing. 17:04:51 10 mans," in this context? 17:05:12 11 mans," in this context? 17:05:22 12 (Oxay. Oxay. 17:05:22 13 aside. 17:05:23 14 Content of the content, yes. 17:05:51 15 mans," in this context? 17:05:18 16 C. Oxay. Oxay. Oxay. Oxay. Oxay. 17:05:22 17:05:18 18 A. Oxay. 17:05:23 19 (Oxay. Oxay. Oxay	6	4			e e :
7	7	5		5	
8 Q. Okay. Okay. You can put that 17:03:13 9 aside. 17:03:16 9 uside. 17:03:16 10 (Mallinckrodt-Collier Exhibit 17:03:17 11 47 marked for identification.) 17:03:18 12 QUESTIONS PWR. GOTTO: 17:03:18 13 Q. Exhibit 48 (sic) is a multipage 17:03:58 14 document beginning at Bates 17:03:58 15 MNK-T1_0000273249, and it appears to be a 17:04:05 16 spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:17 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 20 A. I recognize the content, vs. 17:04:17 21 Q. Okay. Is it a document that 17:04:24 22 you had involvement in preparing? 17:04:24 23 A. Nor that 1 recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:36 25 A. Someone on my team might have 17:04:33 26 Q. Okay. Or anyone on your team? 17:04:36 27 Q. Okay. Do you know the purpose 17:04:36 28 rogards and understand, this might 17:04:42 29 that hat you or someone on your team 17:05:05 10 mare, in this context? 17:04:18 11 A. It appears it would be. 17:06:43 12 Into the reason for the compilation of this 17:06:41 13 into the reason for the compilation of this 17:06:41 14 date? In not sure why we were 17:06:41 15 running this data on a regular basis, but it 17:06:49 16 was to understand who was selling most of our 17:06:51 17:06:10 Time this data on a regular basis, but it 17:06:49 17:07:04:17 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 20 A. Nor that 1 recollect. 17:04:29 21 Q. Okay. On anyone on your team? 17:04:24 22 you had involvement in preparing? 17:04:24 23 A. Someone on my team might have 17:04:35 24 Q. Okay. Okay. On anyone on your team? 17:04:36 25 A. Just to understand, this might 17:04:36 26 Q. Okay. Okay. Okay. Okay. 17:05:10 27 A. Just to understand what cach of the 17:04:45 28 programs and understand what cach of the 17:04:45 29 programs and understand what cach of the 17:04:45 20 programs and understand what cach of the 17:04:45 21 profits page, sold via parent/customer lane. 17:05:10 22 A.	8	6	"they" you're referring to in that sentence? 17:03:09	6	A. I recognize the content, yes. 17:06:22
9 data that you or someone on your team 17:06:30 (Mallinekrodt-Collier Exhibit 17:03:17 12 47 marked for identification.) 17:03:18 12 QUESTIONS BY MR. GOTTO: 17:03:18 13 Q. Exhibit 48 (sic) is a multipage 17:03:52 14 document beginning at Bates 17:03:58 15 MNK-T1_000273:249, and it appears to be a 17:04:07 16 spreadshect that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:10 18 January 2011 time frame. 17:04:11 19 Do you recognize this document? 17:04:12 10 Q. Okay. Is it a document that 17:04:24 22 you had involvement in preparing? 17:04:24 23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:33 26 done this. 17:04:35 27 Q. Okay. Do you know the purpose 17:04:36 28 of compiling this data back in early 2011: 17:04:37 29 Late the collect of the col	9	7	A. Karen Harper and the SOM team. 17:03:10	7	Q. Okay. And again, similar to 17:06:24
Mallinckrodt-Collier Exhibit 17:03:17 10 participated in compiling? 17:06:33 17:06:34 17:06:35 12 QUESTIONS BY MR. GOTTO: 17:03:18 12 QUESTIONS BY MR. GOTTO: 17:03:52 13 document beginning at Bates 17:03:58 14 data? 17:06:43 17:06:41 17:06:43 15 MNK-T1 (2000273249, and it appears to be a 17:04:05 15 Spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:10 17 concerning oxy 15 and 30 gross sales in 17:04:17 17 Do you recognize this document? 17:04:18 17 Do you recognize this document? 17:04:18 17 Do you recognize the content, yes 17:04:21 19 Do you recognize the content, yes 17:04:22 20 Qokay. Is in a document that 17:04:27 22 you had involvement in preparing? 17:04:27 23 A. Not that I recollect. 17:04:29 24 Qo Qokay. Or anyone on your team? 17:04:35 24 Qo Qokay. Or anyone on your team? 17:04:35 25 A. Someone on my team might have 17:04:36 26 A. Just to understand, this might 17:04:42 45 programs and understand what each of the 17:04:43 7 wholesalers were purchasing. 17:04:36 7 programs and understand what each of the 17:04:43 17:05:10 17:05:11 18 programs and understand what each of the 17:04:43 17:05:10 18 programs and understand what each of the 17:04:43 17:05:10 19 programs and understand what each of the 17:04:43 17:05:10 19 programs and understand what each of the 17:04:43 17:05:10 19 programs and understand what each of the 17:04:35 17:05:10 19 programs and understand what each of the 17:04:36 17:05:10 19 programs and understand what each of the 17:05:10 19 programs and understand what each of the 17:04:36 17:05:30 17:05:31 18 programs and understand what each of the 17:05:10 19 programs and understand what each of the 17:05:10 19 programs and understand what each of the 17:05:10 19 programs and understand what each of the 17:	10	8	Q. Okay. Okay. You can put that 17:03:13	8	the Exhibit 47 we just looked at, is this 17:06:26
12 47 marked for identification. 17:03:18 12 Q. UESTIONS BY MR, GOTTO: 17:03:18 13 Q. Exhibit 48 (sic) is a multipage 17:03:52 14 document beginning at Bates 17:03:58 15 MNK-TL_0000273249, and it appears to be a 17:04:05 15 spreadsheet that compiles information 17:04:10 17:06:41 data? 17:06:43 17:06:44 17:06:45 17:06:41 data? 17:06:43 17:06:44 17:06:49 17:06:54 17:06:5	12 47 marked for identification. 17-03:18 12 Q. Okay. And again, any insight 17-06:34 13 Q. Exhibit 48 (sic) is a multipage 17-03:58 17-03:58 17-06:41 14 document beginning at Bates 17-03:58 17-06:45 17-06:41 15 MNK-TI	9	aside. 17:03:16	9	data that you or someone on your team 17:06:30
12 QUESTIONS BY MR. GOTTO: 17:03:18 12 Q. Okay. And again, any insight 17:06:36 17:06:49 17:06	12 QUESTIONS BY MR. GOTTO: 17:03:18 17:06:36 Q. Exhibit 48 {sic} is a multipage 17:03:52 13 into the reason for the compilation of this 17:06:41 17:06:43 17:06:43 17:06:43 17:06:43 17:06:43 17:06:43 17:06:43 17:06:43 17:06:44 17:06:44 17:06:44 17:06:44 17:06:45 17:06:45 17:06:45 17:06:45 17:06:45 17:06:45 17:06:49 17:06:59 17:06:49 17:06:59 17:06:49	10	(Mallinckrodt-Collier Exhibit 17:03:17	10	participated in compiling? 17:06:33
13 Q. Exhibit 48 (sic) is a multipage 17:03:52 13 into the reason for the compilation of this 17:06:41 17:06:43 17:06:43 17:06:44 17:06:44 17:06:45 18 MNK-T1_0000273249, and it appears to be a 17:04:07 17 17:06:10 17:06:40 17:06:40 17:06:40 17:06:41 17:06:49 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:41 17:06:49 17:06:41 17:06:41 17:06:49 17:06:41 17:06:41 17:06:41 17:06:41 17:07:02 17:07:02 17:07:02 17:07:02 17:07:02 17:07:02 17:07:02 17:07:02 17:07:02 17:07:03 17:07:03 17:07:04 17:07:02 17:07:03 17:07:03 17:07:03 17:07:03 17:07:03 17:07:03 17:07:03 17:07:03 17:07:04 17:07:04 17:07:05 17:07:04 17:07:05 17:07:05 17:07:05 17:07:05 17:07:05 17:07:05 17:07:05 17:07:05 17:07:05 17:07	13 Q. Exhibit 48 {sic} is a multipage 17:03:52 13 into the reason for the compilation of this 17:06:41 17:06:43 17:06:43 17:06:43 17:06:44 17:06:44 17:06:44 17:06:44 17:06:45 17:06:54 17:0	11	47 marked for identification.) 17:03:18	11	A. It appears it would be. 17:06:34
13 Q. Exhibit 48 (sic) is a multipage 17:03:52 13 into the reason for the compilation of this 17:06:41 data 17:06:43 data 17:06:43 data 17:06:43 data 17:06:44 data 17:06:44 data 17:06:45 data 17:06:47 data 17:06:47 data 17:06:41 data 17:06:49 data	13 Q. Exhibit 48 {sic} is a multipage 17:03:52 13 into the reason for the compilation of this 17:06:41 17:06:43 17:06:43 17:06:43 17:06:44 17:06:44 17:06:44 17:06:44 17:06:45 17:06:54 17:0	12	QUESTIONS BY MR. GOTTO: 17:03:18	12	Q. Okay. And again, any insight 17:06:36
14 document beginning at Bates 17:03:58 15 MKK-TI 0000273249, and it appears to be a 17:04:07 15 15 spreadsheet that compiles information 17:04:07 16 17:06:54 17:06:54 17:06:54 17:06:54 17:06:54 17:06:54 17:06:54 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 19 Do you recognize this document that 17:04:24 19 Do you recognize the content, yes. 17:04:28 19 MR. GOTTO: Okay, I have no 17:07:02 17:07:04 17:04:29 17:04:27 19 MR. GOTTO: Okay, I have no 17:07:02 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:05 17:07:05 10 17:07:05 1	14 document beginning at Bates 17:03:58 15 MNK-TI (0000273249, and it appears to be a 17:04:05 15 es preadsheet that compiles information 17:04:07 17 17:06:44 17:06:49 17 17:06:49 18 18 19 19 19 19 19 1	13		13	
15 MNK-T1_0000273249, and it appears to be a 17:04:05 16 spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:17 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 19 Do you recognize the content, yes. 17:04:21 20 A. I recognize the content, yes. 17:04:21 21 Q. Okay. 18 document that 17:04:24 22 you had involvement in preparing? 17:04:27 23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team 17:04:31 25 A. I'm not sure why we were 17:06:44 17:06:54 18 product. 17:06:54 18 product. 17:06:54 19 MR. GOTTO: Okay. I have no 17:07:02 19 further questions. Thank you for your 17:07:04 20 Q. Okay. Or anyone on your team 17:04:32 21 done this. 17:04:35 22 Q. Okay. Do you know the purpose 17:04:35 3 done this. 17:04:35 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:45 9 first page, sold via parent/customer name, 17:05:02 10 was to understand who was selling most of our 17:07:02 17:07:02 time. 17:07:04 17:07:03 17:07:04 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:45 9 first page, sold via parent/customer name, 17:05:05 10 name," in this context? 17:05:16 12 A. That's our customer that we 17:05:16 13 sold to, so it pulls the someone pulled 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:32 17:05:18 A. Okay. 17:05:32 19 Q. Okay. Okay. So to correct, the prior 17:05:55 10 Q. Okay. So to correct, the prior 17:05:55 20 Q. Okay. So to correct, the prior 17:0	15 MNK-TI_0000273249, and it appears to be a 17:04:07 16 spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:10 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 20 A. I recognize the content, yes. 17:04:21 21 Q. Okay. Is it a document that 17:04:24 22 you had involvement in preparing? 17:04:27 23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:32 26 Q. Okay. Or anyone on your team? 17:04:31 27 done this. 17:04:35 28 Q. Okay. Do you know the purpose 17:04:36 3 of compiling this data back in early 2011? 17:04:42 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:45 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:10 10 anime," in this context? 17:05:18 11 anime," in this context? 17:05:23 12 A. Okay. Okay. You can set that 17:05:12 13 sold to, so it pulls the someone pulled 17:05:32 14 Q. Okay. Okay. You can set that 17:05:32 15 A. I'm not sure why we were 17:06:54 17:06:54 was to understand who was selling most of our 17:06:55 18 January 2011 time frame. 17:06:02 17:07:02 time frame. 17:07:02 18 product. 17:06:54 18 product. 17:06:54 18 product. 17:06:54 18 product. 17:07:02 19 (Mallinekrodt-Collier Exhibit 17:04:37 17:04:27 22 20 Als more purchasing 17:04:37 21 time (understand who was selling most of our 17:05:32 22 Q. Okay. Okay. You can set that 17:05:32 23 A. Okay.	14		14	•
16 spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:10 17:04:10 18 January 2011 time frame. 17:04:17 18 January 2011 time frame. 17:04:18 19 Do you recognize this document? 17:04:21 20 A. I recognize the content, yes. 17:04:21 20 A. I recognize the content, yes. 17:04:21 20 further questions. Thank you for your 17:07:02 17:07:02 21 Q. Okay. Is it a document that 17:04:27 22 you had involvement in preparing? 17:04:27 22 you had involvement in preparing? 17:04:37 23 A. Not that I recollect. 17:04:39 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:33 27 MR. GOTTO: All right. 17:07:07 28 MR. GOTTO: All right. 17:07:07 29 MR. GOTTO: All right. 17:07:07 20 MR. GOTTO: All right. 17:07:07 20 MR. GOTTO: All right. 17:07:07 21 MR. GOTTO: All right. 17:07:07 22 MR. GOTTO: All right. 17:07:07 23 MR. GOTTO: All right. 17:07:07 24 MR. GOTTO: All right. 17:07:07 25 MR. GOTTO: All right. 17:07:07 25 MR. GOTTO: All right. 17:07:07 26 MR. GOTTO: All right. 17:07:07 26 MR. GOTTO: All right. 17:07:07 27 MR. GOTTO: All right. 17:07:07 27 MR. GOTTO: All right. 17:07:07 28 MR. GOTTO: All right. 17:07:07 29 MR. GOTTO: All right. 17:07:07 20 20 MR. GOTTO: All right. 17:07:07 20 21 MR. GOTTO: All right. 17:07:07 20 21 MR. GOTTO: All right. 17:07:07 21 22 MR. GOTTO: All right. 17:07:07 21 22 MR. GOTTO: All right. 17:07:07 21 22 23 24 MR. GOTTO: All right. 17:07:07 22 23 24 MR. GOTTO: All right. 17:07:07 22 23 24 MR. GOTTO: All right. 17:07:07 24 24 25 MR. GOTTO: All right. 17:07:07 25 25 25 26 27 27 27 27 27 27 27	16 spreadsheet that compiles information 17:04:07 17 concerning oxy 15 and 30 gross sales in 17:04:10 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 20 A. I recognize the content, yes. 17:04:21 21 Q. Okay. Is it a document that 17:04:24 22 you had involvement in preparing? 17:04:27 23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:31 26 Q. Okay. Do you know the purpose 17:04:33 27 Q. Okay. Do you know the purpose 17:04:35 28 Q. Okay. Do you know the purpose 17:04:35 29 Q. Okay. Do you know the purpose 17:04:35 30 of compiling this data back in early 2011? 17:04:42 51 have been part of removing it from their VIP 17:04:45 52 programs and understand, this might 17:04:45 53 programs and understand what each of the 17:04:45 54 programs and understand what each of the 17:04:50 55 programs and understand what each of the 17:05:11 56 Q. Okay. And the column A on the 17:05:12 57 A. That's our customer that we 17:05:11 58 Q. Okay. Okay. Vou can set that 17:05:12 59 G. Okay. Okay. You can set that 17:05:13 50 Q. Okay. Okay. You can set that 17:05:32 50 Q. Okay. Okay. You can set that 17:05:32 51 QUESTIONS BY MR. GOTTO: 17:05:32 52 Q. Okay. Okay. You can set that 17:05:56 53 Q. Okay. Okay. So to correct, the prior 17:05:56 54 Q. Okay. Okay. So to correct, the prior 17:05:57 55 december of the prior 17:05:56 56 Q. Okay. Okay. So to correct, the prior 17:05:57 57 Q. Okay. Okay. So to correct, the prior 17:05:57 58 Q. Okay. Okay. So to correct, the prior 17:05:55 58 Q. Okay. Okay. So to correct, the prior 17:05:55 59 Q. Okay. Okay. So to correct, the prior 17:05:55 50 Q. Okay. Okay. So to correct, the prior 17:05:55 50 Q. Okay. Okay. So to correct, the prior 17:05:55 51 drough. SERBING AND			15	
17 concerning oxy 15 and 30 gross sales in 17:04:10 17:06:51 18 January 2011 time frame. 17:04:17 18 17:06:52 19 Do you recognize this document? 17:04:18 19 MR, GOTTO: Okay. I have no 17:07:02 further questions. Thank you for your 17:07:02 further questions. Thank you for your 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:05 10 17:07:07	17 concerning oxy 15 and 30 gross sales in 17:04:10 18 January 2011 time frame. 17:04:17 19 Do you recognize this document? 17:04:18 19 MR. GOTTO: Okay. I have no 17:07:02 17:07:02 17:07:04 18 17:07:04 17:07:02 19 MR. GOTTO: Okay. I have no 17:07:02 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:04 17:07:05 17:07:05 17:07:06 17:07:06 17:07:07 17:07				•
18 January 2011 time frame. 17:04:17 18 Do you recognize this document? 17:04:18 19 MR. GOTTO: Okay. I have no 17:07:02 17:07:02 20 Okay. Okay. Is it a document that 17:04:24 21 22 you had involvement in preparing? 17:04:27 22 you had involvement in preparing? 17:04:27 22 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:33 27:07:07 MR. GOTTO: All right. 17:07:07 MR. GOTTO:	18 January 2011 time frame. 17:04:17 18 product. 17:06:54				-
19	19				C
20	20 A. I recognize the content, yes. 17:04:21 21 Q. Okay. Is it a document that 17:04:24 22 you had involvement in preparing? 17:04:27 23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:33 26 Q. Okay. Do you know the purpose 17:04:35 27 Q. Okay. Do you know the purpose 17:04:35 28 Q. Okay. Do you know the purpose 17:04:36 30 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:45 6 programs and understand what each of the 17:04:45 6 programs and understand what each of the 17:04:45 6 programs and understand what each of 17:05:10 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:10 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:14 14 the chargeback data by who it was shipped 17:05:14 15 through. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 Q. Okay. So to correct, the prior 17:05:56 21 Q. Okay. So to correct, the prior 17:05:56 22 Q. Okay. So to correct, the prior 17:05:56 23 document was Exhibit 47. 17:05:56 24 This is Exhibit 48, which was a 17:05:57 25 furnity requestions. Thank you 17:07:02 26 time. 17:04:27 27 MR. O'CONNOR: I have no 17:07:07 28 MR. GOTTO: All right. 17:07:07 29 MR. GOTTO: All right. 17:07:07 20 furnity requestions. 17:07:07 20 furnity requestions. 17:07:04 21 THE WITNESS: Okay. Thank you. 17:07:04 22 questions. 17:04:30 23 MR. O'CONNOR: I have no 17:07:07 24 The WiTNESS: Okay. Thank you. 17:07:07 25 MR. GOTTO: Thouse 17:07:07 26 MR. GOTTO: All right. 17:07:07 27 the record at 5:07 pm. 17:07:07 28 the record at 5:07 pm. 17:07:01 29 furnity requestions. 17:07:05 20 furnity requestions. 17:04:33 21 furnity requestions. 17:07:04 22 furnity requestions. 17:04:33 24 furnity requestions. 17:04:35 25 MR. O'CONNOR: I have no		•		1
21	21		· · · · · · · · · · · · · · · · · · ·		•
22 you had involvement in preparing? 17:04:27 22 THE WITNESS: Okay. Thank you. 17:07:04 23 A. Not that I recollect. 17:04:29 23 MR. O'CONNOR: I have no 17:07:06 questions. 17:07:07 The work of the record at 5:07 pm. 17:07:07 The work of the record at 5:07 pm. 17:07:07 The work of the record at 5:07 pm. 17:07:10 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:01 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:11 The work of the record at 5:07 pm. 17:07:01 The work of the record at 5:07 pm. 17:07:01 The work of	22 you had involvement in preparing? 17:04:27 22 THE WITNESS: Okay. Thank you. 17:07:06 23 A. Not that I recollect. 17:04:29 24 MR. O'CONNOR: I have no 17:07:06 25 A. Someone on my team might have 17:04:33 25 MR. GOTTO: All right. 17:07:07				
23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:33 26 A. Someone on my team might have 17:04:33 27 Page 339 28 Page 341 29 Q. Okay. Do you know the purpose 17:04:36 20 Q. Okay. Do you know the purpose 17:04:36 21 done this. 17:04:35 22 Q. Okay. Do you know the purpose 17:04:36 23 of compiling this data back in early 2011? 17:04:37 25 have been part of removing it from their VIP 17:04:45 26 programs and understand, this might 17:04:42 27 have been part of removing it from their VIP 17:04:45 28 Q. Okay. And the column A on the 17:04:50 29 what does that phrase mean, "parent/customer 17:05:02 20 what does that phrase mean, "parent/customer 17:05:05 21 name," in this context? 17:05:10 22 A. That's our customer that we 17:05:11 23 sold to, so it pulls the someone pulled 17:05:14 24 the chargeback data by who it was shipped 17:05:16 25 through. 17:05:23 26 Q. Okay. Okay. You can set that 17:05:32 27 QUESTIONS BY MR. GOTTO: 17:05:55 28 Q. Okay. So to correct, the prior 17:05:56 29 Q. Okay. So to correct, the prior 17:05:56 20 Q. Okay. So to correct, the prior 17:05:56 21 This is Exhibit 48, which was a 17:05:57 24 MR. GOTTO: All right. 17:07:07 25 MR. GOTTO: All right. 17:07:07 26 WR. GOTTO: All right. 17:07:07 27 WR. GOTTO: All right. 17:07:07 28 VIDEOGRAPHER: We are going off 17:07:08 29 the record at 5:07 p.m. 17:07:10 20 (Deposition concluded at 5:07 p.m.) 17:07:11 20 This is Exhibit 48, which was a 17:05:57 20 A. This is Exhibit 48, which was a 17:05:57	23 A. Not that I recollect. 17:04:29 24 Q. Okay. Or anyone on your team? 17:04:31 25 A. Someone on my team might have 17:04:33 26 Page 339 27 Q. Okay. Do you know the purpose 17:04:36 28 Q. Okay. Do you know the purpose 17:04:36 30 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:45 6 programs and understand what each of the 17:04:45 6 programs and understand what each of the 17:04:45 6 programs and understand what each of the 17:04:50 8 Q. Okay. And the column A on the 17:05:02 10 what does that phrase mean, "parent/customer name, 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:32 17 aside. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinekrodt-Collier Exhibit 17:05:32 20 Q. Okay. So to correct, the prior 17:05:56 21 Okay. So to correct, the prior 17:05:56 22 Q. Okay. So to correct, the prior 17:05:56 23 document was Exhibit 47. 17:05:56 24 This is Exhibit 48, which was a 17:05:57 24 MR. GOTTO: All right. 17:07:07 MR. GOTTO: All right. 17:07:07 MR. GOTTO: All right. 17:07:07 This is Exhibit 48, which was a 17:04:31 24 questions. 17:07:07 MR. GOTTO: All right. 17:07:07 This is Exhibit 48, which was a 17:05:31		•		
Q. Okay. Or anyone on your team? 17:04:31 24 questions. 17:07:07	Q. Okay. Or anyone on your team? 17:04:31				•
Page 339 done this. 17:04:35 Q. Okay. Do you know the purpose 17:04:36 a of compiling this data back in early 2011? 17:04:37 A. Just to understand, this might 17:04:42 bave been part of removing it from their VIP 17:04:45 programs and understand what each of the 17:04:48 wholesalers were purchasing. 17:04:50 man," in this context? 17:05:10 man," in this context? 17:05:11 A. That's our customer that we 17:05:11 the chargeback data by who it was shipped 17:05:14 the chargeback data by who it was shipped 17:05:23 (Mallinckrodt-Collier Exhibit 17:05:32 Q. Okay. So to correct, the prior 17:05:55 10 11 12 Q. Okay. So to correct, the prior 17:05:32 Q. Okay. So to correct, the prior 17:05:56 17:05:56 24 MR. GOTTO: All right. 17:07:07 Page 341 VIDEOGRAPHER: We are going off 17:07:08 the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m.) 17:07:11 17:07:11 18 VIDEOGRAPHER: We are going off 17:07:08 the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:11 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m.) 17:07:11 Experimental the record at 5:07 p.m. 17:07:01 Experimental the record at 5:07 p.m. 17:0	25 A. Someone on my team might have 17:04:33 25 MR. GOTTO: All right. 17:07:07 Page 339 1 done this. 17:04:35 12 Q. Okay. Do you know the purpose 17:04:36 22 This is Exhibit 48, which was a 17:05:57 24				
Page 339 1 done this. 17:04:35 2 Q. Okay. Do you know the purpose 17:04:36 3 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:10 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:32 17 aside. 17:05:23 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 Q. Okay. So to correct, the prior 17:05:56 21 QUESTIONS BY MR. GOTTO: 17:05:56 22 document was Exhibit 47. 17:05:56 23 document was Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57	Page 339 1 done this. 17:04:35 2 Q. Okay. Do you know the purpose 17:04:36 3 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:32 17 aside. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 QUESTIONS BY MR. GOTTO: 17:05:55 21 document was Exhibit 47. 17:05:56 22 Q. Okay. So to correct, the prior 17:05:57 24 This is Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57 10 VIDEOGRAPHER: We are going off 17:07:00 1 the record at 5:07 p.m. 17:07:10 1 the record at 5:07 p.m. 17:07:11 10 the record at 5:07 p.m. 17:07:11 11 VIDEOGRAPHER: We are going off 17:07:10 12 the record at 5:07 p.m. 17:07:11 14 the record at 5:07 p.m. 17:07:11 15 the record at 5:07 p.m. 17:07:11 16 (Deposition concluded at 5:07 p.m.) 17:07:11 17:07:11 18 (Deposition concluded at 5:07 p.m.) 17:07:11 18 the record at 5:07 p.m. 17:07:10 19 (Deposition concluded at 5:07 p.m.) 17:07:11 18 (Deposition concluded at 5:07 p.m.) 17:07:11 19 (Deposition concluded at 5:07 p.m.) 17:07:11 10 the record at 5:07 p.m. 17:07:10 10 the record at 5:07 p.m.) 17:07:11 11 the record at 5:07 p.m.) 17:07:10 12 the record at 5:07 p.m.) 17:07:11 12 the record at 5:07 p.m.) 17:07:11 13 (Deposition concluded at 5:07 p.m.) 17:07:11 14 the record at 5:07 p.m.) 17:07:11 15 the record at 5:07 p.m.) 17:07:11 16 the record at 5:07 p.m.) 17:07:10 17:07:11 18 the record at 5:07 p.m.) 17:07:10 19				1
1 done this. 17:04:35	1 done this. 17:04:35 1 VIDEOGRAPHER: We are going off 17:07:0 2 Q. Okay. Do you know the purpose 17:04:36 2 the record at 5:07 p m. 17:07:10 3 of compiling this data back in early 2011? 17:04:37 3 (Deposition concluded at 5:07 p.m.) 17:07:11 4 A. Just to understand, this might 17:04:42 4 5 have been part of removing it from their VIP 17:04:45 5 6 programs and understand what each of the 17:04:48 6 7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 19 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 10 QUESTIONS BY MR. GOTTO: 17:05:32 21 20 Q. Okay. So to correct, the prior 17:05:56 23 21 Question concluded at 5:07 p.m. 17:07:11 (Deposition concluded at 5:07 p.m.) 17:07:11 17:07:11 17:04:45 4 4 4 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 18 A. Okay. And the each of their I7:04:55 10 11 19 three cord at 5:07 p.m. 17:07:11 17:07:11 19 three cord at 5:07 p.m. 17:07:11 17:07:11 19 three cord at 5:07 p.m. 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:10 17:07:10 17:07:10 17:07:10 17:07:10 11 17:07:10 11 11 11 11 11 11 11	25	A. Someone on my team might have 17:04:33	25	MR. GOTTO: All right. 17:07:07
1 done this. 17:04:35	1 done this. 17:04:35 1 VIDEOGRAPHER: We are going off 17:07:0 2 Q. Okay. Do you know the purpose 17:04:36 2 the record at 5:07 p m. 17:07:10 3 of compiling this data back in early 2011? 17:04:37 3 (Deposition concluded at 5:07 p.m.) 17:07:11 4 A. Just to understand, this might 17:04:42 4 5 have been part of removing it from their VIP 17:04:45 5 6 programs and understand what each of the 17:04:48 6 7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 19 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 10 QUESTIONS BY MR. GOTTO: 17:05:32 21 20 Q. Okay. So to correct, the prior 17:05:56 23 21 Question concluded at 5:07 p.m. 17:07:11 (Deposition concluded at 5:07 p.m.) 17:07:11 17:07:11 17:04:45 4 4 4 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 18 A. Okay. And the each of their I7:04:55 10 11 19 three cord at 5:07 p.m. 17:07:11 17:07:11 19 three cord at 5:07 p.m. 17:07:11 17:07:11 19 three cord at 5:07 p.m. 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:11 17:07:10 17:07:10 17:07:10 17:07:10 17:07:10 11 17:07:10 11 11 11 11 11 11 11		Page 339		Page 341
2 Q. Okay. Do you know the purpose 17:04:36 3 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:32 17 aside. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:56 23 document was Exhibit 47. 17:05:56 24 This is Exhibit 48, which was a 17:05:57 24 the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11 3 (Deposition concluded at 5:07 p.m.) 17:07:11 4	Q. Okay. Do you know the purpose 17:04:36 3 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:45 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:02 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:14 13 sold to, so it pulls the someone pulled 17:05:14 15 through. 17:05:18 16 Q. Okay. Okay. You can set that 17:05:29 17 aside. 17:05:23 18 A. Okay. 17:05:23 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:52 22 Q. Okay. So to correct, the prior 17:05:56 23 This is Exhibit 48, which was a 17:05:57 24 the record at 5:07 p.m. 17:07:10 (Deposition concluded at 5:07 p.m.) 17:07:11	1	_	1	
3 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:32 17 aside. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:55 21 QUESTIONS BY MR. GOTTO: 17:05:56 22 document was Exhibit 47. 17:05:56 23 This is Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57	3 of compiling this data back in early 2011? 17:04:37 4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:23 16 Q. Okay. Okay. You can set that 17:05:19 17 aside. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:51 20 Q. Okay. So to correct, the prior 17:05:51 21 document was Exhibit 47. 17:05:56 22 document was Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57	2		2	
4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 6 wholesalers were purchasing. 17:04:50 7 Wholesalers were purchasing. 17:04:51 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:14 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:18 16 Q. Okay. Okay. You can set that 17:05:19 17 aside. 17:05:32 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 document was Exhibit 47. 17:05:56 23 This is Exhibit 48, which was a 17:05:57 24 This is Exhibit 48, which was a 17:05:57	4 A. Just to understand, this might 17:04:42 5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:18 16 Q. Okay. Okay. You can set that 17:05:19 17 aside. 17:05:23 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 document was Exhibit 47. 17:05:56 23 This is Exhibit 48, which was a 17:05:57 24	3		3	÷
5 have been part of removing it from their VIP 17:04:45 6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:18 16 Q. Okay. Okay. You can set that 17:05:19 17 aside. 17:05:23 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:51 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 Q. Okay. So to correct, the prior 17:05:56 23 document was Exhibit 47. 17:05:56 24 This is Exhibit 48, which was a 17:05:57 24	5 have been part of removing it from their VIP 17:04:45 5 6 programs and understand what each of the 17:04:48 6 7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:32 17 18 A. Okay. 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 22 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24				
6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 aside. 17:05:23 17 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 20 QUESTIONS BY MR. GOTTO: 17:05:51 22 20 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	6 programs and understand what each of the 17:04:48 7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 19 QUESTIONS BY MR. GOTTO: 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 3 document was Exhibit 47. 17:05:56 23 17:05:56 23 17:05:56 25 17:05:57 24		_		
7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:32 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	7 wholesalers were purchasing. 17:04:50 7 8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 22 Q. Okay. So to correct, the prior 17:05:56 23 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24		-		
8 Q. Okay. And the column A on the 17:04:51 8 9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 22 Q. Okay. So to correct, the prior 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	8 Q. Okay. And the column A on the 17:04:51 9 first page, sold via parent/customer name, 17:05:02 10 what does that phrase mean, "parent/customer 17:05:05 11 name," in this context? 17:05:10 12 A. That's our customer that we 17:05:11 13 sold to, so it pulls the someone pulled 17:05:14 14 the chargeback data by who it was shipped 17:05:16 15 through. 17:05:18 16 Q. Okay. Okay. You can set that 17:05:19 17 aside. 17:05:23 18 A. Okay. 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 (Mallinckrodt-Collier Exhibit 17:05:32 20 48 marked for identification.) 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 Q. Okay. So to correct, the prior 17:05:56 23 document was Exhibit 47. 17:05:56 24 This is Exhibit 48, which was a 17:05:57 24				
9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:56 23 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	9 first page, sold via parent/customer name, 17:05:02 9 10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:51 22 22 Q. Okay. So to correct, the prior 17:05:56 23 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24				
10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 21 21 QUESTIONS BY MR. GOTTO: 17:05:32 22 22 Q. Okay. So to correct, the prior 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	10 what does that phrase mean, "parent/customer 17:05:05 10 11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24		•		
11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	11 name," in this context? 17:05:10 11 12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:56 23 23 document was Exhibit 47. 17:05:57 24		* • • • • • • • • • • • • • • • • • • •		
12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	12 A. That's our customer that we 17:05:11 12 13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:56 23 23 document was Exhibit 47. 17:05:57 24		· •		
13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	13 sold to, so it pulls the someone pulled 17:05:14 13 14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24				
14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	14 the chargeback data by who it was shipped 17:05:16 14 15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	12		12	
15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	15 through. 17:05:18 15 16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	13	*	13	
16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	16 Q. Okay. Okay. You can set that 17:05:19 16 17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	14		14	
17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	17 aside. 17:05:23 17 18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	15	through. 17:05:18	15	
18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	18 A. Okay. 17:05:32 18 19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	16	Q. Okay. Okay. You can set that 17:05:19	16	
19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	17	aside. 17:05:23	17	
19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	19 (Mallinckrodt-Collier Exhibit 17:05:32 19 20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	18	A. Okay. 17:05:32	18	
20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	20 48 marked for identification.) 17:05:32 20 21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	19	•	19	
21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	21 QUESTIONS BY MR. GOTTO: 17:05:32 21 22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	20	`	20	
22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	22 Q. Okay. So to correct, the prior 17:05:51 22 23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24		,		
23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24	23 document was Exhibit 47. 17:05:56 23 24 This is Exhibit 48, which was a 17:05:57 24				
This is Exhibit 48, which was a 17:05:57	24 This is Exhibit 48, which was a 17:05:57				
		エノス	accument was Lamon T/. 1/.UJ.JU	ر ت ا	
25 document produced native under Rates 17.06.01 25	2.5 document produced native under Dates 17.00.01 2.5			2/	
2.5 document produced native under Dates 1/:00:01 25		24	This is Exhibit 48, which was a 17:05:57		

	Page 342		Page 344
1	_	1	ACKNOWLEDGMENT OF DEPONENT
2	CERTIFICATE	2	ACKNOWLEDGMENT OF DEPONENT
3	I, CARRIE A. CAMPBELL, Registered	3	
4	I, CARRIE A. CAMPBELL, Registered Diplomate Reporter, Certified Realtime Reporter and Certified Shorthand Reporter, do hereby certify that prior to the commencement	4	I do
-	hereby certify that prior to the commencement		I,, do hereby certify that I have read the foregoing
5	of the examination, Ginger Collier was duly	5	pages and that the same is a correct
6	of the examination, Ginger Collier was duly sworn by me to testify to the truth, the whole truth and nothing but the truth. I DO FURTHER CERTIFY that the		transcription of the answers given by me to
7	I DO FURTHER CERTIFY that the	6	the questions therein propounded, except for
	foregoing is a verbatim transcript of the		the corrections or changes in form or
8	testimony as taken stenographically by and	7	substance, if any, noted in the attached
9	before me at the time, place and on the date hereinbefore set forth, to the best of my		Errata Sheet.
10	ability.	8	
10	I DO FURTHER CERTIFY that I am	9	
11	neither a relative nor employee nor attorney	10	
12	neither a relative nor employee nor attorney nor counsel of any of the parties to this action, and that I am neither a relative nor	12	
12	employee of such attorney or counsel and	12	Ginger Collier DATE
13	employee of such attorney or counsel, and that I am not financially interested in the	13	diliger Comer DATE
14	action.	14	
15		15	Subscribed and sworn to before me this
16		16	
17	CARRIE A. CAMPBELL,	17	day of, 20 My commission expires:
- '	NCRA Registered Diplomate Reporter	18	
18	NCRA Registered Diplomate Reporter Certified Realtime Reporter	19	Notary Public
19	Notary Public Dated: January 14, 2019	20	
20	Dated: January 14, 2017	21	
21		22	
23		23	
24		24	
25		23	
	Page 343		Page 345
1	_	1	Page 345
1 2	Page 343 INSTRUCTIONS TO WITNESS	1	
2	INSTRUCTIONS TO WITNESS	1 2	Page 345 ERRATA
2 3	INSTRUCTIONS TO WITNESS Please read your deposition over	2	ERRATA
2 3 4	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections.	2	
2 3 4 5	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the	2	ERRATA
2 3 4 5 6	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any	2 3 4 5	ERRATA
2 3 4 5	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made.	2 3 4 5 6	ERRATA
2 3 4 5 6	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any	2 3 4 5 6 7	ERRATA
2 3 4 5 6 7	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made.	2 3 4 5 6 7 8	ERRATA
2 3 4 5 6 7 8	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing	2 3 4 5 6 7 8 9	ERRATA
2 3 4 5 6 7 8	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on	2 3 4 5 6 7 8 9	ERRATA
2 3 4 5 6 7 8 9	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to	2 3 4 5 6 7 8 9 10	ERRATA
2 3 4 5 6 7 8 9 10 11	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition.	2 3 4 5 6 7 8 9	ERRATA
2 3 4 5 6 7 8 9 10 11 12	INSTRUCTIONS TO WITNESS Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return	2 3 4 5 6 7 8 9 10	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing	2 3 4 5 6 7 8 9 10 11 12	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt	2 3 4 5 6 7 8 9 10 11 12 13	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you	2 3 4 5 6 7 8 9 10 11 12 13	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may	2 3 4 5 6 7 8 9 10 11 12 13 14	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	ERRATA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made. After doing so, please sign the errata sheet and date it. You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	ERRATA

	Page 346		
LAWYER'S NOTE	S		
PAGE LINE			
TAGE LINE			
	1		